

CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;
 AAB64273 Length: 28 February 4, 2005 13:32 Type: P Check: 381
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTSDXSKQLEEEAVRLFIETFLKN 28
 |-----|
 1 match found in sequence:
 aab64274 ; Exendin agonist, SEQ ID NO:94.
 (from "seq5ags.pep")
 TOIG of: aab64274 check: 657 from: 1 to: 28
 ID AAB64274 standard; peptide; 28 AA.
 XX
 AC AAB64274;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:94.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extensins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 87; Page 73; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM

CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;
 AAB64274 Length: 28 February 4, 2005 13:32 Type: P Check: 657
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTSDLSKQLEEEAVRLXIEFLKN 28
 |-----|
 1 match found in sequence:
 aab64275 ; Exendin agonist, SEQ ID NO:95.
 (from "seq5ags.pep")
 TOIG of: aab64275 check: 1045 from: 1 to: 28
 ID AAB64275 standard; peptide; 28 AA.
 XX
 AC AAB64275;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:95.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extensins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 88; Page 73; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM

CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 28 AA;
 SQ
 AAB64271 Length: 28 February 4, 2005 13:32 Type: P Check: 701 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGTFSTDLSSKQMBEAEVRLFIWLKN 28
 1 -----|
 1 match found in sequence:
 aab64272 ; Extendin agonist, SEQ ID NO:92.
 (from "seq5ags.pep")
 TOIG of: aab64272 check: 649 from: 1 to: 28
 ID AAB64272 standard; peptide; 28 AA.
 AC AAB64272;
 XX
 XX 27-MAR-2001 (first entry)
 DT
 XX
 XX Extendin agonist, SEQ ID NO:92.
 DE
 XX
 XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 XX Heloderma suspectum.
 OS Synthetic.
 OS
 XX WO200073331-A2.
 PN
 XX 07-DEC-2000.
 PD
 XX 23-MAY-2000; 2000WO-US014231.
 PF
 XX 01-JUN-1999; 99US-00323867.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX
 XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PT
 XX
 XX Example 85; Page 72; 133pp; English.
 PS
 XX
 XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.

CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 28 AA;
 SQ
 AAB64272 Length: 28 February 4, 2005 13:32 Type: P Check: 649 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGTFSTLSKQMBEAEVRLFIWLKN 28
 1 -----|
 1 match found in sequence:
 aab64273 ; Extendin agonist, SEQ ID NO:93.
 (from "seq5ags.pep")
 TOIG of: aab64273 check: 381 from: 1 to: 28
 ID AAB64273 standard; peptide; 28 AA.
 AC AAB64273;
 XX
 XX 27-MAR-2001 (first entry)
 DT
 XX
 XX Extendin agonist, SEQ ID NO:93.
 DE
 XX
 XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 XX Heloderma suspectum.
 OS Synthetic.
 OS
 XX WO200073331-A2.
 PN
 XX 07-DEC-2000.
 PD
 XX 23-MAY-2000; 2000WO-US014231.
 PF
 XX 01-JUN-1999; 99US-00323867.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX
 XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PT
 XX
 XX Example 86; Page 72; 133pp; English.
 PS
 XX
 XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.

CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;
 AAB64269 Length: 28 February 4, 2005 13:32 Type: P Check: 369 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEGETYSDLSKQLEEEAVRLFIEFLKN 28
 1 -----|
 1 match found in sequence:
 aab64270 ; Extendin agonist, SEQ ID NO:90.
 (from "seq5ags.pep")
 TOIG of: aab64270 check: 693 from: 1 to: 28
 ID AAB64270 standard; peptide; 28 AA.
 XX
 AC AAB64270;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:90.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 83; Page 71; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the

CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;
 AAB64270 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEGETYSDLSKQLEEEAVRLFIEFLKN 28
 1 -----|
 1 match found in sequence:
 aab64271 ; Extendin agonist, SEQ ID NO:91.
 (from "seq5ags.pep")
 TOIG of: aab64271 check: 701 from: 1 to: 28
 ID AAB64271 standard; peptide; 28 AA.
 XX
 AC AAB64271;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:91.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 84; Page 71; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit

CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 35 AA;
 AAB64267 Length: 35 February 4, 2005 13:32 Type: P Check: 7463 ..
 Found using 'seq5' (mohamed337.key)

1 RRGDTFTDLSKQMBEEAVRLFIEWLKNGG 28
 1
 -----|
 1 match found in sequence:
 aab64268 ; Extendin agonist, SEQ ID NO:88.
 (from "seq5ags.pep")
 TOIG of: aab64268 check: 4886 from: 1 to: 30

ID AAB64268 standard; peptide; 30 AA.
 XX
 AC AAB64268;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:88.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 WPI; 2001-137634/14.
 XX
 DR Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 81; Page 70; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional

CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 30 AA;
 AAB64268 Length: 30 February 4, 2005 13:32 Type: P Check: 4886 ..
 Found using 'seq5' (mohamed337.key)

1 RRGDTFTDLSKQMBEEAVRLFIEWLKNGG 28
 1
 -----|
 1 match found in sequence:
 aab64269 ; Extendin agonist, SEQ ID NO:89.
 (from "seq5ags.pep")
 TOIG of: aab64269 check: 369 from: 1 to: 28

ID AAB64269 standard; peptide; 28 AA.
 XX
 AC AAB64269;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:89.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 WPI; 2001-137634/14.
 XX
 DR Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 82; Page 70; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do

```
AAB64265 Length: 37 February 4, 2005 13:32 Type: P Check: 4125 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMBEEAVRLFIWLNKGXSGXGX 28
1 -----
1 match found in sequence:
aab64266; Exendin agonist, SEQ ID NO:86.
(from "seq5ags.pep")
TOIG of: aab64266 check: 869 from: 1 to: 36

ID AAB64266 standard; peptide; 36 AA.
XX
AC AAB64266;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:86.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 79; Page 69; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
```

```
SQ Sequence 36 AA;
AAB64266 Length: 36 February 4, 2005 13:32 Type: P Check: 869 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMBEEAVRLFIWLNKGXSGXGX 28
1 -----
1 match found in sequence:
aab64267; Exendin agonist, SEQ ID NO:87.
(from "seq5ags.pep")
TOIG of: aab64267 check: 7463 from: 1 to: 35

ID AAB64267 standard; peptide; 35 AA.
XX
AC AAB64267;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:87.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 80; Page 69; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
```

```
1 HEGTFTSLSKQMBEEAVRLFIEWLKNKGSSGAPP
1
-----|-----|-----|
1 HEGTFTSLSKQMBEEAVRLFIEWLKNKGSSGAA
28

1 match found in sequence:
aab64264 ; Exendin agonist, SEQ ID NO:84.
(from "seq5ags.pep")
TOIG of: aab64264 check: 1733 from: 1 to: 37

ID AAB64264 standard; peptide; 37 AA.
XX
AC AAB64264;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:84.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
DR Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 77; Page 68; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 37 AA;

AAB64264 Length: 37 February 4, 2005 13:32 Type: P Check: 1733
Found using 'seq5' (mohamed337.key)
```

1 match found in sequence:
aab64262 ; Exendin agonist, SEQ ID NO:82.
(from "seq5ags.pep")
TOIG of: aab64262 check: 7221 from: 1 to: 38

ID AAB64262 standard; peptide; 38 AA.

XX AC AAB64262;

XX DT 27-MAR-2001 (first entry)

XX DE Exendin agonist, SEQ ID NO:82.

XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.

XX OS Heloderma suspectum.

XX OS Synthetic.

XX PN WO200073331-A2.

XX PD 07-DEC-2000.

XX PF 23-MAY-2000; 2000WO-US014231.

XX PR 01-JUN-1999; 99US-00323867.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Hiles R, Prickett KS;

XX DR WPI; 2001-137634/14.

XX PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX PS Example 75; Page 67; 133pp; English.

XX PS The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4

XX SQ Sequence 38 AA;

AAB64262 Length: 38 February 4, 2005 13:32 Type: P Check: 7221 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTDLKQMEAEVRLFIWLNKGGPSSGAXXX

28

1 match found in sequence:
aab64263 ; Exendin agonist, SEQ ID NO:83.
(from "seq5ags.pep")
TOIG of: aab64263 check: 2828 from: 1 to: 37

ID AAB64263 standard; peptide; 37 AA.

XX AC AAB64263;

XX DT 27-MAR-2001 (first entry)

XX DE Exendin agonist, SEQ ID NO:83.

XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.

XX OS Heloderma suspectum.

XX OS Synthetic.

XX PN WO200073331-A2.

XX PD 07-DEC-2000.

XX PF 23-MAY-2000; 2000WO-US014231.

XX PR 01-JUN-1999; 99US-00323867.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Hiles R, Prickett KS;

XX DR WPI; 2001-137634/14.

XX PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX PS Example 76; Page 67; 133pp; English.

XX PS The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4

XX SQ Sequence 37 AA;

AAB64263 Length: 37 February 4, 2005 13:32 Type: P Check: 2828 ..
Found using 'seq5' (mohamed337.key)

1

Fri Feb 4 14:12:17 2005

(from "seq5ags.pep")
TOIG of: aab64261 check: 7221 from: 1 to: 38
AAB64261 standard; peptide; 38 AA.
AAB64261;
27-MAR-2001 (first entry)
Extendin agonist, SEQ ID NO:81.
Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
pregnancy complication; neonatal abnormality; blood glucose modulator;
insulinotropic; anorectic; extendin-4.
Heloderma suspectum.
Synthetic.
WO200073331-A2.
07-DEC-2000.
23-MAY-2000; 2000WO-US014231.
01-JUN-1999; 99US-00323867.
(AMYL-) AMYLIN PHARM INC.
Hiles R, Prickett KS;
WPI; 2001-137634/14.
Use of extendins or extendin agonists for lowering or reducing blood
glucose levels and treating gestational diabetes mellitus in a subject,
especially in a human.
Example 74; Page 66; 133pp; English.
The invention relates to the use of an extendin (AAB64181-B64182) or an
extendin agonist (AAB64185-B64368) for treating gestational diabetes
mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
combination of increased insulin resistance and a diminished ability to
increase insulin secretion. In contrast, in a normal pregnancy, both
insulin resistance and insulin secretion increase. GDM pregnancies are
associated with complications in both the mother and the foetus. Women
with GDM have increased rates of Caesarian delivery, hypertensive
disorders such as pre-eclampsia, and urinary tract infections. GDM
results in an elevated rate of foetal abnormalities such as neural tube
defects, and is associated with an increased risk of neonatal morbidities
such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
Extendins are peptides from the salivary secretions of the Gila monster
(extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
homology with several members of the glucagon-like peptide family,
particularly GLP-1, and have similar insulinotropic effects. Unlike the
GDM, extendins and extendin agonists do not cross the placenta and thus do
not cause severe prolonged hypoglycaemia in the newborn. They have a
potent and prolonged effect on blood glucose, and, unlike conventional
insulin therapy, should not cause weight gain, as they inhibit gastric
emptying and reduce appetite. The present sequence represents a extendin
agonist of the invention which is based upon the sequence of extendin-4

(from "seq5ags.pep")
TOIG of: aab64261 check: 7221 from: 1 to: 38
AAB64261 standard; peptide; 38 AA.
AAB64261;
27-MAR-2001 (first entry)
Extendin agonist, SEQ ID NO:80.
Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
pregnancy complication; neonatal abnormality; blood glucose modulator;
insulinotropic; anorectic; extendin-4.
Heloderma suspectum.
Synthetic.
WO200073331-A2.
07-DEC-2000.
23-MAY-2000; 2000WO-US014231.
01-JUN-1999; 99US-00323867.
(AMYL-) AMYLIN PHARM INC.
Hiles R, Prickett KS;
WPI; 2001-137634/14.
Use of extendins or extendin agonists for lowering or reducing blood
glucose levels and treating gestational diabetes mellitus in a subject,
especially in a human.
Example 73; Page 66; 133pp; English.
The invention relates to the use of an extendin (AAB64181-B64182) or an
extendin agonist (AAB64185-B64368) for treating gestational diabetes
mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
combination of increased insulin resistance and a diminished ability to
increase insulin secretion. In contrast, in a normal pregnancy, both
insulin resistance and insulin secretion increase. GDM pregnancies are
associated with complications in both the mother and the foetus. Women
with GDM have increased rates of Caesarian delivery, hypertensive
disorders such as pre-eclampsia, and urinary tract infections. GDM
results in an elevated rate of foetal abnormalities such as neural tube
defects, and is associated with an increased risk of neonatal morbidities
such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
Extendins are peptides from the salivary secretions of the Gila monster
(extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
homology with several members of the glucagon-like peptide family,
particularly GLP-1, and have similar insulinotropic effects. Unlike the
GDM, extendins and extendin agonists do not cross the placenta and thus do
not cause severe prolonged hypoglycaemia in the newborn. They have a
potent and prolonged effect on blood glucose, and, unlike conventional
insulin therapy, should not cause weight gain, as they inhibit gastric
emptying and reduce appetite. The present sequence represents a extendin
agonist of the invention which is based upon the sequence of extendin-4

Sequence 38 AA;
AAB64261 Length: 38 February 4, 2005 13:32 Type: P Check: 7221 ..
Found using 'seq5' (mohamed337.key)

Sequence 29 AA;
AAB64260 Length: 29 February 4, 2005 13:32 Type: P Check: 2320 ..
Found using 'seq5' (mohamed337.key)

1 HGEGTFTSDLSKQEEAEVRLFIETLKNKGPPSSGAXXX
28

1 match found in sequence:
aab64261 ; Extendin agonist, SEQ ID NO:81.


```

XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX XX 23-MAY-2000; 2000WO-US014231.
XX PF 01-JUN-1999; 99US-00323867.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX XX Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 67; Page 63; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the fetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 32 AA;
AAB64254 Length: 32 February 4, 2005 13:32 Type: P Check: 25 ..
Found using 'seq5' (mohamed337.key)
1 HGGGTFTSLSKQMEAEVRLFIELKNGGPS
1 28
-----
1 match found in sequence:
aab64255 ; Extendin agonist, SEQ ID NO:75.
(from "seq5ags.pep")
TOIG of: aab64255 check: 9586 from: 1 to: 32
ID AAB64255 standard; peptide; 32 AA.
XX AC AAB64255;
XX XX
XX DT 27-MAR-2001 (first entry)
XX XX
XX DE Extendin agonist, SEQ ID NO:75.
XX XX
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;

```

```

KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulintropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX XX 23-MAY-2000; 2000WO-US014231.
XX PF 01-JUN-1999; 99US-00323867.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX XX Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 68; Page 64; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the fetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 32 AA;
AAB64255 Length: 32 February 4, 2005 13:32 Type: P Check: 9586 ..
Found using 'seq5' (mohamed337.key)
1 HGGGTFTSLSKQMEAEVRLFIELKNGGPS
1 28
-----
1 match found in sequence:
aab64256 ; Extendin agonist, SEQ ID NO:76.
(from "seq5ags.pep")
TOIG of: aab64256 check: 7369 from: 1 to: 31
ID AAB64256 standard; peptide; 31 AA.
XX AC AAB64256;
XX XX
XX DT 27-MAR-2001 (first entry)
XX XX
XX DE Extendin agonist, SEQ ID NO:76.

```

```
PN WO200073331-A2.
XX
XX
XX 07-DEC-2000.
PD
PF 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 65; Page 62; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 33 AA;
SQ
AAB64252 Length: 33 February 4, 2005 13:32 Type: P Check: 2764 ..
Found using 'seq5' (mohamed337.key)
1 HGGGTFTSDLSKQWEAEVRLFTIEWLKNKGPPS
1 28
-----
1 match found in sequence:
aab64253 ; Extendin agonist, SEQ ID NO:73.
(from "seq5ags.pep")
TOIG of: aab64253 check: 2325 from: 1 to: 33
ID AAB64253 standard; peptide; 33 AA.
XX
XX AAB64253;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:73.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS

OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
PD
PF 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 66; Page 63; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 33 AA;
SQ
AAB64253 Length: 33 February 4, 2005 13:32 Type: P Check: 2325 ..
Found using 'seq5' (mohamed337.key)
1 HGGGTFTSDLSKQWEAEVRLFTIEWLKNKGPPS
1 28
-----
1 match found in sequence:
aab64254 ; Extendin agonist, SEQ ID NO:74.
(from "seq5ags.pep")
TOIG of: aab64254 check: 25 from: 1 to: 32
ID AAB64254 standard; peptide; 32 AA.
XX
XX AAB64254;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:74.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX
```

```

PP 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 63; Page 61; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 34 AA;
XX
AAB64250 Length: 34 February 4, 2005 13:32 Type: P Check: 5178
Found using 'seq5' (mohamed337.key)

1 HGEFTFTDLSKQMBEEAVRLFIWLNKGPPSSG
1 |-----|
1 HGEFTFTDLSKQMBEEAVRLFIWLNKGPPSSG
28

-----
1 match found in sequence:
aab64251; Extendin agonist, SEQ ID NO:71.
(from "seq5ags.pep")
TOIG of: aab64251 check: 4739 from: 1 to: 34

ID AAB64251 standard; peptide; 34 AA.
XX
XX AAB64251;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:71.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX
XX Synthetic.
XX
XX WO200073331-A2.
XX

```

```

PD 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 64; Page 62; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 34 AA;
XX
AAB64251 Length: 34 February 4, 2005 13:32 Type: P Check: 4739
Found using 'seq5' (mohamed337.key)

1 HGEFTFTDLSKQMBEEAVRLFIWLNKGPPSSG
1 |-----|
1 HGEFTFTDLSKQMBEEAVRLFIWLNKGPPSSG
28

-----
1 match found in sequence:
aab64252; Extendin agonist, SEQ ID NO:72.
(from "seq5ags.pep")
TOIG of: aab64252 check: 2764 from: 1 to: 33

ID AAB64252 standard; peptide; 33 AA.
XX
XX AAB64252;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:72.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX
XX Synthetic.
XX

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 61; Page 60; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 35 AA;
AAB64248 Length: 35 February 4, 2005 13:32 Type: P Check: 7453
Found using 'seq5' (mohamed337.key)
1 HGEGFTSDLSKQMBEEAVRLFIEFLKNGGPSSGA
1 28
-----
1 match found in sequence:
aab64249 ; Extendin agonist, SEQ ID NO:69.
(from "seq5ags.pep")
TOIG of: aab64249 check: 7014 from: 1 to: 35
ID AAB64249 standard; peptide; 35 AA.
XX
AC AAB64249;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:69.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX

```

```

PR 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 62; Page 61; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 35 AA;
AAB64249 Length: 35 February 4, 2005 13:32 Type: P Check: 7014
Found using 'seq5' (mohamed337.key)
1 HGEGFTSDLSKQMBEEAVRLFIEFLKNGGPSSGA
1 28
-----
1 match found in sequence:
aab64250 ; Extendin agonist, SEQ ID NO:70.
(from "seq5ags.pep")
TOIG of: aab64250 check: 5178 from: 1 to: 34
ID AAB64250 standard; peptide; 34 AA.
XX
AC AAB64250;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:70.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX

```

```
DR WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 59; Page 59; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 36 AA;
AAB64246 Length: 36 February 4, 2005 13:32 Type: P Check: 333
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQMEEEAVRLFIETLKNKGPPSSGAP
1
-----|-----|
1 match found in sequence:
aab64247; Extendin agonist, SEQ ID NO:67.
(from "seq5ags.pep")
TOIG of: aab64247 check: 9894 from: 1 to: 36
ID AAB64247 standard; peptide; 36 AA.
XX
AC AAB64247;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:67.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
```

```
PI Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 60; Page 60; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 36 AA;
AAB64247 Length: 36 February 4, 2005 13:32 Type: P Check: 9894
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQLEEEAVRLFIETLKNKGPPSSGAP
1
-----|-----|
1 match found in sequence:
aab64248; Extendin agonist, SEQ ID NO:68.
(from "seq5ags.pep")
TOIG of: aab64248 check: 7453 from: 1 to: 35
ID AAB64248 standard; peptide; 35 AA.
XX
AC AAB64248;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:68.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
```

PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 58; Page 59; 133pp; English.
PS
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family.
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 37 AA;
SQ
AAB64245 Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQLEEAARVLFIEFLKNGPSSGAPP
1 28

1 match found in sequence:
aab64246 ; Extendin agonist, SEQ ID NO:66.
(from "seq5ags.pep")
TOIG of: aab64246 check: 333 from: 1 to: 36
ID AAB64246 standard; peptide; 36 AA.
XX
XX AAB64246;
AC
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:66.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS
OS Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR
XX

PT especially in a human.
XX
XX Example 57; Page 58; 133pp; English.
PS
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family.
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 37 AA;
SQ
AAB64244 Length: 37 February 4, 2005 13:32 Type: P Check: 3293 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQLEEAARVLFIEFLKNGPSSGAPP
1 28

1 match found in sequence:
aab64245 ; Extendin agonist, SEQ ID NO:65.
(from "seq5ags.pep")
TOIG of: aab64245 check: 2854 from: 1 to: 37
ID AAB64245 standard; peptide; 37 AA.
XX
XX AAB64245;
AC
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:65.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS
OS Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR
XX

CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 38 AA;
 AAB64242 Length: 38 February 4, 2005 13:32 Type: P Check: 6333 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTTSLSKQMEEEAVRLFIEFLKNGSPSSGAPPP
 1

 1 match found in sequence:
 aab64243 ; Extendin agonist, SEQ ID NO:63.
 (from "seq5ags.pep")
 TOIG of: aab64243 check: 5894 from: 1 to: 38
 ID AAB64243 standard; peptide; 38 AA.
 XX
 AC AAB64243;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:63.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PP 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 DR Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX

PS Example 56; Page 58; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 38 AA;
 AAB64243 Length: 38 February 4, 2005 13:32 Type: P Check: 5894 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTTSLSKQMEEEAVRLFIEFLKNGSPSSGAPPP
 1

 1 match found in sequence:
 aab64244 ; Extendin agonist, SEQ ID NO:64.
 (from "seq5ags.pep")
 TOIG of: aab64244 check: 3293 from: 1 to: 37
 ID AAB64244 standard; peptide; 37 AA.
 XX
 AC AAB64244;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:64.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PP 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 DR Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX

CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family.
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 XX
 SQ Sequence 28 AA;

AAB64240 Length: 28 February 4, 2005 13:32 Type: P Check: 9991 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGTFTSDLSKQLEEAARLFTIEFLAN 28

 1 match found in sequence:
 aab64241 ; Exendin agonist, SEQ ID NO:61.
 (from "seq5ags.pep")
 TOIG of: aab64241 check: 9897 from: 1 to: 28

ID AAB64241 standard; peptide; 28 AA.
 XX
 AC AAB64241;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 XX Exendin agonist, SEQ ID NO:61.
 XX
 XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 XX 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Hiles R, Prickett KS;
 XX WPI; 2001-137634/14.
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 54; Page 57; 133pp; English.
 XX
 XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes

CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family.
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 XX
 SQ Sequence 28 AA;

AAB64241 Length: 28 February 4, 2005 13:32 Type: P Check: 9897 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGTFTSDLSKQLEEAARLFTIEFLKA 28

 1 match found in sequence:
 aab64242 ; Exendin agonist, SEQ ID NO:62.
 (from "seq5ags.pep")
 TOIG of: aab64242 check: 6333 from: 1 to: 38

ID AAB64242 standard; peptide; 38 AA.
 XX
 AC AAB64242;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 XX Exendin agonist, SEQ ID NO:62.
 XX
 XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 XX 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Hiles R, Prickett KS;
 XX WPI; 2001-137634/14.
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 55; Page 57; 133pp; English.
 XX
 XX

disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Extensins are peptides from the salivary secretions of the Gila monster (extensin-4) and the Mexican beaded lizard (extensin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulinotropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, extensins and extensin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a extensin agonist of the invention which is based upon the sequence of extensin-4

XX Sequence 28 AA;

AAB64238 Length: 28 February 4, 2005 13:32 Type: P Check: 136 ..
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLPIEAKN 28
1 |-----|

1 match found in sequence:
aab64239 ; Extensin agonist, SEQ ID NO:59.
(from "seq5ags.pep")
TOIG of: aab64239 check: 9975 from: 1 to: 28

ID AAB64239 standard; peptide; 28 AA.
XX
AC AAB64239;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extensin agonist, SEQ ID NO:59.
XX
KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extensin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of extensins or extensin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 52; Page 56; 133pp; English.
XX
CC The invention relates to the use of an extensin (AAB64181-B64182) or an
CC extensin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are

associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Extensins are peptides from the salivary secretions of the Gila monster (extensin-4) and the Mexican beaded lizard (extensin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulinotropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, extensins and extensin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a extensin agonist of the invention which is based upon the sequence of extensin-4

XX Sequence 28 AA;

AAB64239 Length: 28 February 4, 2005 13:32 Type: P Check: 9975 ..
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLPIEAKN 28
1 |-----|

1 match found in sequence:
aab64240 ; Extensin agonist, SEQ ID NO:60.
(from "seq5ags.pep")
TOIG of: aab64240 check: 9991 from: 1 to: 28

ID AAB64240 standard; peptide; 28 AA.
XX
AC AAB64240;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extensin agonist, SEQ ID NO:60.
XX
KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extensin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of extensins or extensin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 53; Page 56; 133pp; English.
XX
CC The invention relates to the use of an extensin (AAB64181-B64182) or an
CC extensin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to

CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family.
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64236 Length: 28 February 4, 2005 13:32 Type: P Check: 30 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTFTDLSKQLEEEAVRAFIETFLKN 28

 1 match found in sequence:
 aab64237 ; Exendin agonist, SEQ ID NO:57.
 (from "seq5ags.pep")
 TOIG of: aab64237 check: 165 from: 1 to: 28
 ID AAB64237 standard; peptide; 28 AA.

XX
 AC AAB64237;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:57.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extensins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 50; Page 55; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube

CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64237 Length: 28 February 4, 2005 13:32 Type: P Check: 165 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTFTDLSKQLEEEAVRLFIAPLKN 28

 1 match found in sequence:
 aab64238 ; Exendin agonist, SEQ ID NO:58.
 (from "seq5ags.pep")
 TOIG of: aab64238 check: 136 from: 1 to: 28
 ID AAB64238 standard; peptide; 28 AA.

XX
 AC AAB64238;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:58.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extensins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 51; Page 55; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive

CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX Sequence 28 AA;
 SQ Sequence 28 AA;
 AAB64234 Length: 28 February 4, 2005 13:32 Type: P Check: 9862 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTSDLSKQLEEEAARLFIEFLKN 28
 1 HGEFTFTSDLSKQLEEEAARLFIEFLKN 28

 1 match found in sequence:
 aab64235 ; Exendin agonist, SEQ ID NO:55.
 (from "seq5ags.pep")
 TOIG of: aab64235 check: 9921 from: 1 to: 28
 ID AAB64235 standard; peptide; 28 AA.
 XX AC AAB64235;
 AC AAB64235;
 XX AC AAB64235;
 DT 27-MAR-2001 (first entry)
 XX DT 27-MAR-2001 (first entry)
 DE Exendin agonist, SEQ ID NO:55.
 XX DE Exendin agonist, SEQ ID NO:55.
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX KW insulinotropic; anorectic; exendin-4.
 OS Heloderma suspectum.
 OS Synthetic.
 XX OS Heloderma suspectum.
 XX OS Synthetic.
 PN WO200073331-A2.
 XX PN WO200073331-A2.
 PD 07-DEC-2000.
 XX PD 07-DEC-2000.
 PF 23-MAY-2000; 2000WO-US014231.
 XX PF 23-MAY-2000; 2000WO-US014231.
 PR 01-JUN-1999; 99US-00323867.
 XX PR 01-JUN-1999; 99US-00323867.
 PA (AMYL-) AMYLIN PHARM INC.
 XX PA (AMYL-) AMYLIN PHARM INC.
 PI Hiles R, Prickett KS;
 XX PI Hiles R, Prickett KS;
 DR WPI; 2001-137634/14.
 XX DR WPI; 2001-137634/14.
 PT Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX PT Use of exendins or exendin agonists for lowering or reducing blood
 PS Example 48; Page 54; 133pp; English.
 XX PS Example 48; Page 54; 133pp; English.
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster

CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX Sequence 28 AA;
 SQ Sequence 28 AA;
 AAB64235 Length: 28 February 4, 2005 13:32 Type: P Check: 9921 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTSDLSKQLEEEAARLFIEFLKN 28
 1 HGEFTFTSDLSKQLEEEAARLFIEFLKN 28

 1 match found in sequence:
 aab64236 ; Exendin agonist, SEQ ID NO:56.
 (from "seq5ags.pep")
 TOIG of: aab64236 check: 30 from: 1 to: 28
 ID AAB64236 standard; peptide; 28 AA.
 XX AC AAB64236;
 AC AAB64236;
 XX AC AAB64236;
 DT 27-MAR-2001 (first entry)
 XX DT 27-MAR-2001 (first entry)
 DE Exendin agonist, SEQ ID NO:56.
 XX DE Exendin agonist, SEQ ID NO:56.
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX KW insulinotropic; anorectic; exendin-4.
 OS Heloderma suspectum.
 OS Synthetic.
 XX OS Heloderma suspectum.
 XX OS Synthetic.
 PN WO200073331-A2.
 XX PN WO200073331-A2.
 PD 07-DEC-2000.
 XX PD 07-DEC-2000.
 PF 23-MAY-2000; 2000WO-US014231.
 XX PF 23-MAY-2000; 2000WO-US014231.
 PR 01-JUN-1999; 99US-00323867.
 XX PR 01-JUN-1999; 99US-00323867.
 PA (AMYL-) AMYLIN PHARM INC.
 XX PA (AMYL-) AMYLIN PHARM INC.
 PI Hiles R, Prickett KS;
 XX PI Hiles R, Prickett KS;
 DR WPI; 2001-137634/14.
 XX DR WPI; 2001-137634/14.
 PT Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX PT Use of exendins or exendin agonists for lowering or reducing blood
 PS Example 49; Page 54; 133pp; English.
 XX PS Example 49; Page 54; 133pp; English.
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster

CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;
 AAB64232 Length: 28 February 4, 2005 13:32 Type: P Check: 197 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGTFTSDLSKQLEAAVRLFIETFLKN 28

 1 match found in sequence:
 aab64233 ; Extendin agonist, SEQ ID NO:53.
 (from "seq5ags.pep")
 TOIG of: aab64233 Check: 193 from: 1 to: 28

ID AAB64233 standard; peptide; 28 AA.
 AC AAB64233;
 XX
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:53.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 XX WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 PF 01-JUN-1999; 99US-00323867.
 XX
 PR (AMYL-) AMYLIN PHARM INC.
 XX
 PA Hiles R, Prickett KS;
 XX
 PI WPI; 2001-137634/14.
 XX
 DR
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 46; Page 53; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for

CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;
 AAB64233 Length: 28 February 4, 2005 13:32 Type: P Check: 193 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGTFTSDLSKQLEAAVRLFIETFLKN 28

 1 match found in sequence:
 aab64234 ; Extendin agonist, SEQ ID NO:54.
 (from "seq5ags.pep")
 TOIG of: aab64234 Check: 9862 from: 1 to: 28

ID AAB64234 standard; peptide; 28 AA.
 XX
 AC AAB64234;
 XX
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:54.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 XX WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 PF 01-JUN-1999; 99US-00323867.
 XX
 PR (AMYL-) AMYLIN PHARM INC.
 XX
 PA Hiles R, Prickett KS;
 XX
 PI WPI; 2001-137634/14.
 XX
 DR
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 47; Page 53; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,

```

XX      Sequence 28 AA;
SQ      Length: 28 February 4, 2005 13:32 Type: P Check: 107
Found using 'seq5' (mohamed337.key)

1      |-----|
      HEGTFTSDLSKQAEAEVRLFIETFLKN
      1
-----
1 match found in sequence:
aab64231; Exendin agonist, SEQ ID NO:51.
(from "seq5ags.pep")
TOIG of: aab64231 check: 201 from: 1 to: 28

ID AAB64231 standard; peptide; 28 AA.
XX
AC AAB64231;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:51.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PP 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
PS Example 44; Page 52; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric

```

```

CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ      Sequence 28 AA;
AAB64231 Length: 28 February 4, 2005 13:32 Type: P Check: 201
Found using 'seq5' (mohamed337.key)

1      |-----|
      HEGTFTSDLSKQAEAEVRLFIETFLKN
      1
-----
1 match found in sequence:
aab64232; Exendin agonist, SEQ ID NO:52.
(from "seq5ags.pep")
TOIG of: aab64232 check: 197 from: 1 to: 28

ID AAB64232 standard; peptide; 28 AA.
XX
AC AAB64232;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:52.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PP 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
PS Example 45; Page 52; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a

```

Fri Feb 4 14:12:17 2005

Found using 'seq5' (mohamed337.key)

```
1  HGGCTFTSDLSAQLEEEAVRLFIEFLKN 28
    |-----|
    1
```

1 match found in sequence:
aab64229 ; Exendin agonist, SEQ ID NO:49.

(from "seq5ags pep")
TOIG of: aab64229 check: 53 from: 1 to: 28

ID AAB64229 standard; peptide; 28 AA.

XX AAB64229;

DT 27-MAR-2001 (first entry)

XX Exendin agonist, SEQ ID NO:49.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO2000073331-A2.

XX PD 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX Example 42; Page 51; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4

XX Sequence 28 AA;

CC

AAB64229 Length: 28 February 4, 2005 13:32 Type: P Check: 53
Found using 'seq5' (mohamed337.key)

```
1  HGGCTFTSDLSAQLEEEAVRLFIEFLKN 28
    |-----|
    1
```

1 match found in sequence:
aab64230 ; Exendin agonist, SEQ ID NO:50.

(from "seq5ags pep")
TOIG of: aab64230 check: 107 from: 1 to: 28

ID AAB64230 standard; peptide; 28 AA.

XX AAB64230;

DT 27-MAR-2001 (first entry)

XX Exendin agonist, SEQ ID NO:50.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO2000073331-A2.

XX PD 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX Example 43; Page 51; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4

```
1
-----
1 match found in sequence:
aab64227 : Exendin agonist, SEQ ID NO:47.
(from "seq5ags.pep")
TOIG of: aab64227 check: 63 from: 1 to: 28

ID AAB64227 standard; peptide; 28 AA.
XX
AC AAB64227;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:47.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 40; Page 50; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64227 Length: 28 February 4, 2005 13:32 Type: P Check: 63
Found using 'seq5' (mohamed337.key)
```

```
1
-----
1 match found in sequence:
aab64228 : Exendin agonist, SEQ ID NO:48.
(from "seq5ags.pep")
TOIG of: aab64228 check: 141 from: 1 to: 28

ID AAB64228 standard; peptide; 28 AA.
XX
AC AAB64228;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:48.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 41; Page 50; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64228 Length: 28 February 4, 2005 13:32 Type: P Check: 141
```

```

aab64225 ; Exendin agonist, SEQ ID NO:45.
(from "seq5ags.pep")
TOIG of: aab64225 Check: 117 from: 1 to: 28

ID AAB64225 standard; peptide; 28 AA.
XX
XX AAB64225;
XX AC
XX AAB64226;
DT 27-MAR-2001 (first entry)
XX
XX
DE Exendin agonist, SEQ ID NO:45.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
PD
XX 23-MAY-2000; 2000WO-US014231.
XX PF
XX 01-JUN-1999; 99US-00323867.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Hiles R, Prickett KS;
XX PI
XX WPI; 2001-137634/14.
XX DR
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 38; Page 49; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
SQ

AAB64225 Length: 28 February 4, 2005 13:32 Type: P Check: 117
Found using 'seq5' (mohamed337.key)

|-----|
1 HGGTFTADLSKQLEEAARVLFIEFLKN 28

```

```

-----
1 match found in sequence:
aab64226 ; Exendin agonist, SEQ ID NO:46.
(from "seq5ags.pep")
TOIG of: aab64226 Check: 151 from: 1 to: 28

ID AAB64226 standard; peptide; 28 AA.
XX
XX AAB64226;
XX AC
XX AAB64226;
DT 27-MAR-2001 (first entry)
XX
XX
DE Exendin agonist, SEQ ID NO:46.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
PD
XX 23-MAY-2000; 2000WO-US014231.
XX PF
XX 01-JUN-1999; 99US-00323867.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Hiles R, Prickett KS;
XX PI
XX WPI; 2001-137634/14.
XX DR
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 39; Page 49; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
SQ

AAB64226 Length: 28 February 4, 2005 13:32 Type: P Check: 151
Found using 'seq5' (mohamed337.key)

|-----|
1 HGGTFTADLSKQLEEAARVLFIEFLKN

```



```

ID AAB64223 standard; peptide; 28 AA.
XX
AC AAB64223;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:43.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 36; Page 48; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64223 Length: 28 February 4, 2005 13:32 Type: P Check: 166 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTATSDLSKQLEEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aab64224; Exendin agonist, SEQ ID NO:44.
(from 'seq5ags.pep')

```

```

TOIG of: aab64224 check: 231 from: 1 to: 28
ID AAB64224 standard; peptide; 28 AA.
XX
AC AAB64224;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:44.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 37; Page 48; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64224 Length: 28 February 4, 2005 13:32 Type: P Check: 231 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTATSDLSKQLEEEAVRLFIEFLKN 28

-----
1 match found in sequence:

```

AC AAB64222;
 XX 27-MAR-2001 (first entry)
 XX
 XX Extendin agonist, SEQ ID NO:42.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 XX Heloderma suspectum.
 OS
 OS Synthetic.
 XX
 XX WO200073331-A2.
 XX
 XX 07-DEC-2000.
 PD
 XX 23-MAY-2000; 2000WO-US014231.
 PD
 XX 01-JUN-1999; 99US-00323867.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX
 XX Use of extendin or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PT
 XX Example 35; Page 47; 133pp; English.
 PS
 XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities,
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 XX SQ Sequence 28 AA;
 AAB64222 Length: 28 February 4, 2005 13:32 Type: P Check: 249 ..
 Found using 'seq5' (mohamed337.key)
 1 -----|
 1 HAEGFTTSDLKQLEEEAVRLFIEFLKN 28

 1 match found in sequence:
 aab64223 ; Extendin agonist, SEQ ID NO:43.
 (from "seq5ags.pep")
 TOIC of: aab64223 check: 166 from: 1 to: 28

```

KW insulintropic; anorectic; extendin-4.
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 30; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 39 AA;
XX
AAB64219 Length: 39 February 4, 2005 13:32 Type: P Check: 7221
Found using 'seq5' (mohamed337.key)
1
1 HGEFTSDLSKQLEEEAVRLPIEFILKNGASSGAAAS
28
-----
1 match found in sequence:
aab64220 ; Extendin-4 (1-28)-amide, SEQ ID NO:40.
(from "seq5ags.pep")
TOIG of: aab64220 check: 700 from: 1 to: 28
ID AAB64220 standard; peptide; 28 AA.
XX
XX AAB64220;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin-4 (1-28)-amide, SEQ ID NO:40.
XX

```

```

KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulintropic; anorectic; extendin-4.
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Claim 13; Page 13; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a
XX specifically claimed extendin agonist, which is based upon the sequence of
XX extendin-4
XX
XX Sequence 28 AA;
XX
AAB64220 Length: 28 February 4, 2005 13:32 Type: P Check: 700
Found using 'seq5' (mohamed337.key)
1
1 HGEFTSDLSKQLEEEAVRLPIEFILKNG
28
-----
1 match found in sequence:
aab64221 ; [Leu 14, Phe 25] - extendin-4 (1-28) amide, SEQ ID NO:41.
(from "seq5ags.pep")
TOIG of: aab64221 check: 261 from: 1 to: 28
ID AAB64221 standard; peptide; 28 AA.
XX
XX AAB64221;
XX
XX 27-MAR-2001 (first entry)
XX
XX

```

```

XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 28; Fig 1B; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 39 AA;

AAB64217 Length: 39 February 4, 2005 13:32 Type: P Check: 7660 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEGFTSDLSKQMBEEAVRLPIEWLKNKGSSGAAAS
  28

-----
1 match found in sequence:
aab64218 ; Exendin agonist, SEQ ID NO:38.
(from "seq5ags.pep")
TOIG of: aab64218 check: 8125 from: 1 to: 39

ID AAB64218 standard; peptide; 39 AA.
XX AC AAB64218;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:38.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.

OS Heloderma suspectum.
OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 29; Fig 1B; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 39 AA;

AAB64218 Length: 39 February 4, 2005 13:32 Type: P Check: 8125 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEGFTSDLSKQMBEEAVRLPIEWLKNKGSSGAAAS
  28

-----
1 match found in sequence:
aab64219 ; Exendin agonist, SEQ ID NO:39.
(from "seq5ags.pep")
TOIG of: aab64219 check: 7221 from: 1 to: 39

ID AAB64219 standard; peptide; 39 AA.
XX AC AAB64219;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:39.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.

```

```

XX PF 23-MAY-2000; 2000WO-US014231.
XX XX
XX PR 01-JUN-1999; 99US-00323867.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX XX
XX DR WPI; 2001-137634/14.
XX XX
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 26; Fig 1B; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the fetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 39 AA;

AAB64215 Length: 39 February 4, 2005 13:32 Type: P Check: 487
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEFTTSLSKQLEEEAVRLPIEFKNGXSGAXXXS
    28

-----
1 match found in sequence:
aab64216 ; Extendin agonist, SEQ ID NO:36.
(from "seq5ags.pep")
TOIG of: aab64216 check: 487 from: 1 to: 39

ID AAB64216 standard; peptide; 39 AA.
XX XX
XX AC AAB64216;
XX XX
XX DT 27-MAR-2001 (first entry)
XX XX
XX DE Extendin agonist, SEQ ID NO:36.
XX XX
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX XX
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.

```

```

XX 07-DEC-2000.
XX PD
XX PF 23-MAY-2000; 2000WO-US014231.
XX XX
XX PR 01-JUN-1999; 99US-00323867.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX XX
XX DR WPI; 2001-137634/14.
XX XX
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 27; Fig 1B; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the fetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 39 AA;

AAB64216 Length: 39 February 4, 2005 13:32 Type: P Check: 487
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEFTTSLSKQLEEEAVRLPIEFKNGXSGAXXXS
    28

-----
1 match found in sequence:
aab64217 ; Extendin agonist, SEQ ID NO:37.
(from "seq5ags.pep")
TOIG of: aab64217 check: 7660 from: 1 to: 39

ID AAB64217 standard; peptide; 39 AA.
XX XX
XX AC AAB64217;
XX XX
XX DT 27-MAR-2001 (first entry)
XX XX
XX DE Extendin agonist, SEQ ID NO:37.
XX XX
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX XX
XX OS Heloderma suspectum.
XX OS Synthetic.

```

```

XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 24; Fig 1B; 133pp; English.
XX PS
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 39 AA;

AAB64213 Length: 39 February 4, 2005 13:32 Type: P Check: 926
Found using 'seq5' (mohamed337.key)

1 HGGFTSDLSKQMEEEAVRLPIEWLKNKGXSSGAXXXS
1 -----|-----
1 HGGFTSDLSKQMEEEAVRLPIEWLKNKGXSSGAXXXS
28

-----
1 match found in sequence:
aab64214 : Exendin agonist, SEQ ID NO:34.
(from "seq5ags.pep")
TOIG of: aab64214 check: 678 from: 1 to: 39

ID AAB64214 standard; peptide; 39 AA.
XX AC
XX AC AAB64214;
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Exendin agonist, SEQ ID NO:34.
XX DE
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN W0200073331-A2.
XX XX
XX PD 07-DEC-2000.
XX PF
XX PF 23-MAY-2000; 2000WO-US014231.

```

```

XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 25; Fig 1B; 133pp; English.
XX PS
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 39 AA;

AAB64214 Length: 39 February 4, 2005 13:32 Type: P Check: 678
Found using 'seq5' (mohamed337.key)

1 HGGFTSDLSKQMEEEAVRLPIEWLKNKGPPSSGAXXXS
1 -----|-----
1 HGGFTSDLSKQMEEEAVRLPIEWLKNKGPPSSGAXXXS
28

-----
1 match found in sequence:
aab64215 : Exendin agonist, SEQ ID NO:35.
(from "seq5ags.pep")
TOIG of: aab64215 check: 487 from: 1 to: 39

ID AAB64215 standard; peptide; 39 AA.
XX AC
XX AC AAB64215;
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Exendin agonist, SEQ ID NO:35.
XX DE
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN W0200073331-A2.
XX XX
XX PD 07-DEC-2000.
XX PF

```

```

XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 22; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 39 AA;
XX
AAB64211 Length: 39 February 4, 2005 13:32 Type: P Check: 926
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQMBEEAVRLPIEWLKNKGXSGAXXXS
1
-----|-----|
1 match found in sequence:
aab64212 ; Exendin agonist, SEQ ID NO:32.
(from "seq5ags.pep")
TOIG of: aab64212 check: 678 from: 1 to: 39
ID AAB64212 standard; peptide; 39 AA.
XX
XX AAB64212;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:32.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
XX Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.

```

```

XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 23; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 39 AA;
XX
AAB64212 Length: 39 February 4, 2005 13:32 Type: P Check: 678
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQMBEEAVRLPIEWLKNKGXSGAXXXS
1
-----|-----|
1 match found in sequence:
aab64213 ; Exendin agonist, SEQ ID NO:33.
(from "seq5ags.pep")
TOIG of: aab64213 check: 926 from: 1 to: 39
ID AAB64213 standard; peptide; 39 AA.
XX
XX AAB64213;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:33.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
XX Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.

```

```

PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 20; Fig 1B; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC .agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 39 AA;
AAB64209 Length: 39 February 4, 2005 13:32 Type: P Check: 9766 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQMEEEAVRLPIDWLKNGPSSGAPPPS
1 1
-----|-----|
1 match found in sequence:
aab64210; Extendin agonist, SEQ ID NO:30.
(from "seq5ags.pep")
TOIG of: aab64210 check: 9365 from: 1 to: 39
ID AAB64210 standard; peptide; 39 AA.
XX
XX AAB64210;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:30.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
KW
XX
XX Heloderma suspectum.
OS
XX Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR

```

```

XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 21; Fig 1B; 133pp; English.
PS
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC .agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 39 AA;
AAB64210 Length: 39 February 4, 2005 13:32 Type: P Check: 9365 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQMEEEAVRLPIEFLKNGPSSGAPPPS
1 1
-----|-----|
1 match found in sequence:
aab64211; Extendin agonist, SEQ ID NO:31.
(from "seq5ags.pep")
TOIG of: aab64211 check: 926 from: 1 to: 39
ID AAB64211 standard; peptide; 39 AA.
XX
XX AAB64211;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:31.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
KW
XX
XX Heloderma suspectum.
OS
XX Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX

```


XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the fetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 39 AA;
 SQ
 AAB64207 Length: 39 February 4, 2005 13:32 Type: P Check: 135
 Found using 'seq5' (mohamed337.key)
 1 HGEFTSDLSKQMEAEVRLPXELKNGSPSSGAPPPS
 1

 1 match found in sequence:
 aab64208 ; Extendin agonist, SEQ ID NO:28.
 (from "seq5ags.pep")
 TOIG of: aab64208 check: 9696 from: 1 to: 39
 ID AAB64208 standard; peptide; 39 AA.
 XX
 AC AAB64208;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:28.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 19; Fig 1B; 133pp; English.
 XX
 PS The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the fetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 39 AA;
 SQ
 AAB64208 Length: 39 February 4, 2005 13:32 Type: P Check: 9696
 Found using 'seq5' (mohamed337.key)
 1 HGEFTSDLSKQLEAEVRLPXELKNGSPSSGAPPPS
 1

 1 match found in sequence:
 aab64209 ; Extendin agonist, SEQ ID NO:29.
 (from "seq5ags.pep")
 TOIG of: aab64209 check: 9766 from: 1 to: 39
 ID AAB64209 standard; peptide; 39 AA.
 XX
 AC AAB64209;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:29.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 XX
 SQ Sequence 39 AA;

AAB64205 Length: 39 February 4, 2005 13:32 Type: P Check: 9790 ..
 Found using 'seq5' (mohamed337.key)

1 HGEGTFTSLSKQMBEAVRLPIELKNGSPSSGAPPPS
 28

1 match found in sequence:
 aab64206 ; Exendin agonist, SEQ ID NO:26.
 (from "seq5ags.pep")
 TOIG of: aab64206 check: 9351 from: 1 to: 39

ID AAB64206 standard; peptide; 39 AA.

AC AAB64206;

DT 27-MAR-2001 (first entry)

DE Exendin agonist, SEQ ID NO:26.

KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

PN WO200073331-A2.

XX 07-DEC-2000.

PF 23-MAY-2000; 2000WO-US014231.

PR 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

PA Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extensins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 17; Fig 1B; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an

CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 XX
 SQ Sequence 39 AA;

AAB64206 Length: 39 February 4, 2005 13:32 Type: P Check: 9351 ..
 Found using 'seq5' (mohamed337.key)

1 HGEGTFTSLSKQMBEAVRLPIELKNGSPSSGAPPPS
 28

1 match found in sequence:
 aab64207 ; Exendin agonist, SEQ ID NO:27.
 (from "seq5ags.pep")
 TOIG of: aab64207 check: 135 from: 1 to: 39

ID AAB64207 standard; peptide; 39 AA.

AC AAB64207;

DT 27-MAR-2001 (first entry)

DE Exendin agonist, SEQ ID NO:27.

KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

PN WO200073331-A2.

XX 07-DEC-2000.

PF 23-MAY-2000; 2000WO-US014231.

PR 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

PA Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extensins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 18; Fig 1B; 133pp; English.

CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 XX Sequence 39 AA;
 SQ

AAB64201 Length: 39 February 4, 2005 13:32 Type: P Check: 9471 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDXSKOLEBEEAVRLPIEFLLKNGPSSGAPPPS
 1
 -----|-----|
 28

 1 match found in sequence:
 aab64202 : Exendin agonist, SEQ ID NO:22.
 (from "seq5ags.pep")
 TOIG of: aab64202 check: 9944 from: 1 to: 39

ID AAB64202 standard; peptide; 39 AA.

XX AAB64202;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:22.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 OS WO200073331-A2.
 PN
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 XX 01-JUN-1999; 99US-00323867.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX
 PI Hiles R, Prickett KS;
 PI WPI; 2001-137634/14.
 DR
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 13; Fig 1A; 133pp; English.
 XX
 XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections.. GDM

CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 XX Sequence 39 AA;
 SQ

AAB64202 Length: 39 February 4, 2005 13:32 Type: P Check: 9944 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQBEAEVRLPIEWLKNKGPPSSGAPPPS
 1
 -----|-----|
 28

 1 match found in sequence:
 aab64203 : Exendin agonist, SEQ ID NO:23.
 (from "seq5ags.pep")
 TOIG of: aab64203 check: 9519 from: 1 to: 39

ID AAB64203 standard; peptide; 39 AA.

XX AAB64203;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:23.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 OS WO200073331-A2.
 PN
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 XX 01-JUN-1999; 99US-00323867.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX
 PI Hiles R, Prickett KS;
 PI WPI; 2001-137634/14.
 DR
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 14; Fig 1B; 133pp; English.
 XX
 XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women

CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 CC
 XX Sequence 39 AA;
 SQ

AAB64199 Length: 39 February 4, 2005 13:32 Type: P Check: 9799 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTTSELKQMBEEAVRLPIELWLNKGPGSSGAPPPS
 -----|-----
 28

 1 match found in sequence:
 aab64200 ; Extendin agonist, SEQ ID NO:20.
 (from "seq5ags.pep")
 TOIG of: aab64200 check: 9910 from: 1 to: 39

ID AAB64200 standard; peptide; 39 AA.

XX AAB64200;
 AC
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:20.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX

OS Heloderma suspectum.
 OS Synthetic.

PN WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

PS Example 11; Fig 1A; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.

CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 CC
 XX Sequence 39 AA;
 SQ

AAB64200 Length: 39 February 4, 2005 13:32 Type: P Check: 9910 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTTSDXSQMBEEAVRLPIELWLNKGPGSSGAPPPS
 -----|-----
 28

 1 match found in sequence:
 aab64201 ; Extendin agonist, SEQ ID NO:21.
 (from "seq5ags.pep")
 TOIG of: aab64201 check: 9471 from: 1 to: 39

ID AAB64201 standard; peptide; 39 AA.

XX AAB64201;

XX 27-MAR-2001 (first entry)

XX Extendin agonist, SEQ ID NO:21.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

OS Heloderma suspectum.
 OS Synthetic.

PN WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

PS Example 12; Fig 1A; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities

CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 39 AA;

AAB64197 Length: 39 February 4, 2005 13:32 Type: P Check: 9791 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTFTDLSKQMEEEAVRLPIEWLKNKGSPSSGAPPPS 28

 1 match found in sequence:
 aab64198 ; Extendin agonist, SEQ ID NO:18.
 (from "seq5ags.pep")
 TOIG of: aab64198 check: 9798 from: 1 to: 39

ID AAB64198 standard; peptide; 39 AA.

XX AAB64198;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:18.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 XX pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 XX Heloderma suspectum.
 OS Synthetic.
 OS
 XX WO200073331-A2.
 PN
 XX 07-DEC-2000.
 PD
 XX 23-MAY-2000; 2000WO-US014231.
 PF
 XX 01-JUN-1999; 99US-00323867.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PS

Example 9; Fig 1A; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the

CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 39 AA;

AAB64198 Length: 39 February 4, 2005 13:32 Type: P Check: 9798 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTFTDLSKQMEEEAVRLPIEWLKNKGSPSSGAPPPS 28

 1 match found in sequence:
 aab64199 ; Extendin agonist, SEQ ID NO:19.
 (from "seq5ags.pep")
 TOIG of: aab64199 check: 9799 from: 1 to: 39

ID AAB64199 standard; peptide; 39 AA.

XX AAB64199;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:19.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 XX pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 XX Heloderma suspectum.
 OS Synthetic.
 OS
 XX WO200073331-A2.
 PN
 XX 07-DEC-2000.
 PD
 XX 23-MAY-2000; 2000WO-US014231.
 PF
 XX 01-JUN-1999; 99US-00323867.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PS

Example 10; Fig 1A; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit

CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 39 AA;
 SQ Sequence 39 AA;
 AAB64195 Length: 39 February 4, 2005 13:32 Type: P Check: 9898 ..
 Found using 'seq5', (mohamed337.key)

1 HGEGXTSLSKQMEEEAVRLPIEWLKNKGPPSSGAPPPS
 28

1 match found in sequence:
 aab64196 ; Extendin agonist, SEQ ID NO:16.
 (from "seq5ags.pep")
 TOIG of: aab64196 check: 9783 from: 1 to: 39

ID AAB64196 standard; peptide; 39 AA.

XX AAB64196;

XX 27-MAR-2001 (first entry)

XX Extendin agonist, SEQ ID NO:16.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 7; Fig 1A; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional

CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 39 AA;
 SQ Sequence 39 AA;
 AAB64196 Length: 39 February 4, 2005 13:32 Type: P Check: 9783 ..
 Found using 'seq5', (mohamed337.key)

1 HGEGTFSSDLKQMEEEAVRLPIEWLKNKGPPSSGAPPPS
 28

1 match found in sequence:
 aab64197 ; Extendin agonist, SEQ ID NO:17.
 (from "seq5ags.pep")
 TOIG of: aab64197 check: 9791 from: 1 to: 39

ID AAB64197 standard; peptide; 39 AA.

XX AAB64197;

XX 27-MAR-2001 (first entry)

XX Extendin agonist, SEQ ID NO:17.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 8; Fig 1A; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional

AAB64193 Length: 39 February 4, 2005 13:32 Type: P Check: 24 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEERAVRLPIEWLKNKGPPSSGAPPPY
-----|
1 28

1 match found in sequence:
aab64194 ; Exendin agonist, SEQ ID NO:14.
(from "seq5ags.pep")
TOIG of: aab64194 Check: 9787 from: 1 to: 39

ID AAB64194 standard; peptide; 39 AA.
XX
AC AAB64194;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:14.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
PI WPI; 2001-137634/14.
DR
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX
XX Example 5; Fig 1A; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family.
XX particularly GIP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin-4
XX agonist of the invention which is based upon the sequence of exendin-4
XX

SQ Sequence 39 AA;

AAB64194 Length: 39 February 4, 2005 13:32 Type: P Check: 9787 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEERAVRLPIEWLKNKGPPSSGAPPPS
-----|
1 28

1 match found in sequence:
aab64195 ; Exendin agonist, SEQ ID NO:15.
(from "seq5ags.pep")
TOIG of: aab64195 Check: 9898 from: 1 to: 39

ID AAB64195 standard; peptide; 39 AA.
XX
AC AAB64195;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:15.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
PI WPI; 2001-137634/14.
DR
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX
XX Example 6; Fig 1A; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GIP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX


```
1  HGEFTTSDLSKQMEEEAVRLPIEFLKNGPSSGAPPPS
1  28
-----|
1  YGEGTFTSDLSKQMEEEAVRLPIEFLKNGPSSGAPPPS
1  28
-----|
1 match found in sequence:
aab64192 ; Exendin agonist, SEQ ID NO:12.
(from "seq5ags.pep")
TOIG of: aab64192 check: 9807 from: 1 to: 39

ID AAB64192 standard; peptide; 39 AA.
XX
AC AAB64192;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:12.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 3; Fig 1A; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 39 AA;

AAB64192 Length: 39 February 4, 2005 13:32 Type: P Check: 9807
Found using 'seq5' (mohamed337.key)
```

Fri Feb 4 14:12:17 2005

```

1 match found in sequence:
aab64190 ; Exendin agonist, SEQ ID NO:10.
(from "seq5ags.pep")
TOIG of: aab64190 check: 9776 from: 1 to: 39

ID AAB64190 standard; peptide; 39 AA.
XX
AC AAB64190;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:10.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 2; Fig 1A; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 39 AA;
AAB64190 Length: 39 February 4, 2005 13:32 Type: P Check: 9776
Found using 'seq5' (mohamed337.key)

1 HEGGTTSLSKQLEEEAVRLFIEWLKNGPSSGAPPPS
-----|
1

```

```

ID AAB64188 standard; peptide; 39 AA.
AC AAB64188;
XX
DT 27-MAR-2001 (first entry)
XX
DE [Leu 14, Phe 25]-exendin-4 amide, SEQ ID NO:9.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Claim 13; Page 13; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a
CC specifically claimed exendin agonist, which is based upon the sequence of
CC exendin-4
XX
SQ Sequence 39 AA;
AAB64188 Length: 39 February 4, 2005 13:32 Type: P Check: 9131
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQLEEAVALRPIEFLKNGPSSGAPPPS
1
-----
1 match found in sequence:
aab64189 ; Exendin agonist, SEQ ID NO:9.
-----

```

```

(from "seq5ags.pep")
TOIG of: aab64189 check: 9351 from: 1 to: 39
ID AAB64189 standard; peptide; 39 AA.
XX
AC AAB64189;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:9.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 1; Fig 1A; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 39 AA;
AAB64189 Length: 39 February 4, 2005 13:32 Type: P Check: 9351
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQLEEAVALRPIEFLKNGPSSGAPPPS
1
-----

```

```

XX DE Extentin-4 (1-30)-amide, SEQ ID NO:7.
XX KW Extentin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extentin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extentin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Claim 13; Page 13; 133pp; English.
XX CC The invention relates to the use of an extentin (AAB64181-B64182) or an
XX CC extentin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extentin-4) and the Mexican beaded lizard (extentin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extentin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a
XX CC specifically claimed extentin agonist, which is based upon the sequence of
XX CC extentin-4
XX SQ Sequence 30 AA;

AAB64186 Length: 30 February 4, 2005 13:32 Type: P Check: 4889 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEFTFTDLSKQMEEEAVRLFIWLNKNG
    28

-----
1 match found in sequence:
aab64187 ; [Leu 14, Ala 22, Phe 25]- extentin-4 (1-28) amide, SEQ ID NO:8.
(from "seq5ags.pep")
TOIG of: aab64187 check: 151 from: 1 to: 28

ID AAB64187 standard; peptide; 28 AA.
XX

```

```

AC AAB64187;
XX 27-MAR-2001 (first entry)
XX [Leu 14, Ala 22, Phe 25]- extentin-4 (1-28) amide, SEQ ID NO:8.
XX Extentin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extentin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extentin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Disclosure; Page 13; 133pp; English.
XX CC The invention relates to the use of an extentin (AAB64181-B64182) or an
XX CC extentin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extentin-4) and the Mexican beaded lizard (extentin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extentin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a
XX CC agonist of the invention which is based upon the sequence of extentin-4
XX SQ Sequence 28 AA;

AAB64187 Length: 28 February 4, 2005 13:32 Type: P Check: 151 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEFTFTDLSKQLEEEAVRLAIEFLKN
    28

-----
1 match found in sequence:
aab64188 ; [Leu 14, Phe 25]- extentin-4 amide, SEQ ID NO:9.
(from "seq5ags.pep")
TOIG of: aab64188 check: 9131 from: 1 to: 39

```

KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; Gila monster.

OS Heloderma suspectum.

PN WO200073331-A2.

PD 07-DEC-2000.

PF 23-MAY-2000; 2000WO-US014231.

PR 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

PI Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

DR Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Claim 12; Page 11; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents extendin-4
 CC from the Gila monster, which is specifically claimed for use in the
 CC invention

XX Sequence 39 AA;

AAB64182 Length: 39 February 4, 2005 13:32 Type: P Check: 9570

Found using 'seq5' (mohamed337.key)

```

1  |-----|
  |HGEFTSDLSKQMEEEAVRLFIEMLNKGSPSSGAPPPS
  |28
  |-----|

```

1 match found in sequence:
 aab64185 ; Extendin-4 (1-30), SEQ ID NO:6.
 (from "seq5ags.pep")
 TOIG of: aab64185 check: 4889 from: 1 to: 30

ID AAB64185 standard; peptide; 30 AA.

XX AAB64185;

XX 27-MAR-2001 (first entry)

DT Extendin-4 (1-30), SEQ ID NO:6.

DE

XX

KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

OS Heloderma suspectum.

PN WO200073331-A2.

PD 07-DEC-2000.

PF 23-MAY-2000; 2000WO-US014231.

PR 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

PI Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

DR Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Claim 13; Page 13; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a
 CC specifically claimed extendin agonist, which is based upon the sequence of
 CC extendin-4

XX Sequence 30 AA;

AAB64185 Length: 30 February 4, 2005 13:32 Type: P Check: 4889

Found using 'seq5' (mohamed337.key)

```

1  |-----|
  |HGEFTSDLSKQMEEEAVRLFIEMLNKG
  |28
  |-----|

```

1 match found in sequence:
 aab64186 ; Extendin-4 (1-30)-amide, SEQ ID NO:7.
 (from "seq5ags.pep")
 TOIG of: aab64186 check: 4889 from: 1 to: 30

ID AAB64186 standard; peptide; 30 AA.

XX AAB64186;

XX 27-MAR-2001 (first entry)

DT

XX DE Gila monster venom GLP-1 analogue, extendin 4.
XX KW Extendin 4; Gila monster venom; GLP-1 analogue; glucagon-like peptide-1;
KW type II diabetes; non-insulin dependent diabetes mellitus; NIDDM;
KW beta-cell function; secretory capacity; impaired glucose tolerance; IGT;
KW beta-cell stimulatory test; diagnostic test; insulinotropic.
XX OS Heloderma suspectum.
XX PN WO200077039-A2.
XX PD 21-DEC-2000.
XX PF 14-JUN-2000; 2000WO-US016428.
XX PR 15-JUN-1999; 99US-00333415.
XX PA (BION-) BIONEBRASKA INC.
XX PI Holst JJ, Vilsboll T;
XX PS WPI; 2001-102518/11.
XX CC Evaluating beta-cell secretory capacity and responsiveness to glucose,
PT useful for diagnosing impaired glucose tolerance and diabetes, comprises
PT employing glucagon-like-peptide-1 as a diagnostic test to determine beta-
PT cell function.
XX PS Disclosure; Page 13; 42pp; English.
XX CC The invention relates to a new method for evaluating beta-cell secretory
CC capacity in an individual, or responsiveness of a beta-cell to glucose,
CC comprising the administration of glucose and glucagon-like peptide-1 (GLP
CC -1) or its biologically active analogues. The response in the individual to
CC is then measured against the standard response of a healthy individual to
CC determine if the individual has impaired beta-cell function. The method
CC is useful for detecting impaired beta-cell function in an individual, and
CC is particularly useful for diagnosing impaired glucose tolerance (IGT)
CC and non-insulin-dependent (type II) diabetes. The method is a rapid test
CC of beta-cell function, which is a marker for impaired glucose tolerance.
CC Unlike prior methods, the method is reliable and without significant
CC adverse side effects and/or patient pain and discomfort. The method also
CC provides information about insulin secretory capacity, and is easy and
CC reproducible. The present sequence represents a Gila monster venom GLP-1
CC analogue peptide referred to in the disclosure of the invention
XX SQ Sequence 39 AA;
AAB60254 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS 28

1 match found in sequence:
aab64181; Mexican beaded lizard extendin-3, SEQ ID NO:1.
(from "seq5ags.pep")
TOIG of: aab64181 check: 9591 from: 1 to: 39
ID AAB64181 standard; peptide; 39 AA.
XX AC AAB64181;
XX DT 27-MAR-2001 (first entry)
XX DE Mexican beaded lizard extendin-3, SEQ ID NO:1.
XX KW Extendin-3; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; Mexican beaded lizard.

XX OS Heloderma horridum.
XX PN WO200077331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PS WPI; 2001-137634/14.
XX CC Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX PS Claim 11; Page 10-11; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents extendin-3
CC from the Mexican beaded lizard which is specifically claimed for use in
CC the invention
XX SQ Sequence 39 AA;
AAB64181 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 HSDGFTFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS 28

1 match found in sequence:
aab64182; Gila monster extendin-4, SEQ ID NO:2.
(from "seq5ags.pep")
TOIG of: aab64182 check: 9570 from: 1 to: 39
ID AAB64182 standard; peptide; 39 AA.
XX AC AAB64182;
XX DT 27-MAR-2001 (first entry)
XX DE Gila monster extendin-4, SEQ ID NO:2.
XX KW Extendin-4; gestational diabetes mellitus; GDM; insulin resistance;

```

XX KW Insulinotropic peptide; insulin production; GLP-1 derivative;
XX KW glucagon-like peptide 1; extendin derivative; reactive group;
XX KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
XX KW insulin resistance; nervous system disorder; sedative; anxiolytic;
XX KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 40
XX FT /note= "side chain is linked to a maleimidopropionic acid
XX FT (MPA) moiety, optionally via two ABEA (2-(2-
XX FT amino)ethoxy)ethoxy acetic acid) linking groups"
XX PN WO20069911-A1.
XX PD 23-NOV-2000.
XX PF 17-MAY-2000; 2000WO-US013563.
XX PR 17-MAY-1999; 99US-0134406P.
XX PR 15-OCT-1999; 99US-0159783P.
XX PA (CONJ-) CONJUCHEM INC.
XX PI Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
XX PI St Pierre S;
XX WPI; 2001-025008/03.
XX DR Novel modified insulinotropic peptides for treating diabetes, nervous
XX PT system disorders and for post surgery treatment, has reactive groups
XX PT which react with amino, hydroxy or thiol groups on blood components.
XX PS Claim 19; Page 69; 96pp; English.
XX CC The invention relates to modified insulinotropic peptides (ITPs), or
XX CC derivatives thereof which comprise a reactive group which reacts with
XX CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
XX CC serum albumin) to form a stable covalent bond. The insulinotropic
XX CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
XX CC -1) or extendin and contain a reactive group such as a maleimido group or
XX CC a succinimidyl group. The peptides of the invention act by stimulating
XX CC the synthesis or expression of insulin. A composition comprising a
XX CC peptide of the invention is useful for treating diabetes, particularly
XX CC type II (maturity onset) diabetes. It is also useful as a sedative; for
XX CC the treatment of nervous system disorders including anxiety, psychosis,
XX CC seizures, panic attacks, hysteria and sleep disorders; to induce an
XX CC anxiolytic effect on the central nervous system (CNS); to activate the
XX CC CNS for the treatment of disorders such as depression, memory loss and
XX CC narcolepsy; and as a treatment for insulin resistance, particularly that
XX CC which occurs after certain types of surgery. The conjugation of a peptide
XX CC of the invention to a blood component via the reactive group provides
XX CC increased stability in the presence of peptidases. The peptides of the
XX CC invention therefore have a longer in vivo half-life as they are less
XX CC susceptible to proteolytic degradation. The present sequence represents
XX CC an insulinotropic peptide of the invention
XX SQ Sequence 40 AA;
AAB48823 Length: 40 February 4, 2005 13:32 Type: P Check: 2591 ..
Found using 'seq5' (mohamed337.key)
1 HSDGFTSLSKQMBEEAVRLFIEWLKNGPSSGAPPSK
1
-----
1 match found in sequence:
aab60252 ; Gila monster venom GLP-1 analogue, extendin 3.
(from "seq5ags.pep")
TOIG of: aab60252 check: 9591 from: 1 to: 39

```

```

ID AAB60252 standard; peptide; 39 AA.
XX AC AAB60252;
XX DT 28-MAR-2001 (first entry)
XX DE Gila monster venom GLP-1 analogue, extendin 3.
XX KW Extendin 3; Gila monster venom; GLP-1 analogue; glucagon-like peptide-1;
XX KW type II diabetes; non-insulin dependent diabetes mellitus; NIDDM;
XX KW beta-cell function; secretory capacity; impaired glucose tolerance; IGT;
XX KW beta-cell stimulatory test; diagnostic test; insulinotropic.
XX OS Heloderma suspectum.
XX PN WO200077039-A2.
XX PD 21-DEC-2000.
XX PF 14-JUN-2000; 2000WO-US016428.
XX PR 15-JUN-1999; 99US-00333415.
XX PA (BION-) BIONBRASKA INC.
XX PI Holst JJ, Vilsboll T;
XX WPI; 2001-102518/11.
XX PT Evaluating beta-cell secretory capacity and responsiveness to glucose,
XX PT useful for diagnosing impaired glucose tolerance and diabetes, comprises
XX PT employing glucagon-like-peptide-1 as a diagnostic test to determine beta-
XX PT cell function.
XX PS Disclosure; Page 13; 42pp; English.
XX CC The invention relates to a new method for evaluating beta-cell secretory
XX CC capacity in an individual, or responsiveness of a beta-cell to glucose,
XX CC comprising the administration of glucose and glucagon-like peptide-1 (GLP
XX CC -1) or its biologically active analogues. The response in the individual
XX CC is then measured against the standard response of a healthy individual to
XX CC determine if the individual has impaired beta-cell function. The method
XX CC is useful for detecting impaired beta-cell function in an individual, and
XX CC is particularly useful for diagnosing impaired glucose tolerance (IGT)
XX CC and non-insulin-dependent (type II) diabetes. The method is a rapid test
XX CC of beta-cell function, which is a marker for impaired glucose tolerance.
XX CC Unlike prior methods, the method is reliable and without significant
XX CC adverse side effects and/or patient pain and discomfort. The method also
XX CC provides information about insulin secretory capacity, and is easy and
XX CC reproducible. The present sequence represents a Gila monster venom GLP-1
XX CC analogue peptide referred to in the disclosure of the invention
XX SQ Sequence 39 AA;
AAB60252 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 HSDGFTSLSKQMBEEAVRLFIEWLKNGPSSGAPPS
1
-----
1 match found in sequence:
aab60254 ; Gila monster venom GLP-1 analogue, extendin 4.
(from "seq5ags.pep")
TOIG of: aab60254 check: 9570 from: 1 to: 39
ID AAB60254 standard; peptide; 39 AA.
XX AC AAB60254;
XX DT 28-MAR-2001 (first entry)

```

```

XX PD 23-NOV-2000.
XX PF 17-MAY-2000; 2000WO-US013563.
XX PR 17-MAY-1999; 99US-0134406P.
XX PR 15-OCT-1999; 99US-0159783P.
XX PA (CONJ-) CONJUCHEM INC.
XX PI Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
XX PI St Pierre S;
XX DR WPI; 2001-025008/03.
XX PT Novel modified insulinotropic peptides for treating diabetes, nervous
XX PT system disorders and for post surgery treatment, has reactive groups
XX PT which react with amino, hydroxy or thiol groups on blood components.
XX PS Claim 5; Page 91; 96pp; English.
XX CC The invention relates to modified insulinotropic peptides (ITPs), or
XX CC derivatives thereof which comprise a reactive group which reacts with
XX CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
XX CC serum albumin) to form a stable covalent bond. The insulinotropic
XX CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
XX CC -1) or exendin and contain a reactive group such as a maleimido group or
XX CC a succinimidyl group. The peptides of the invention act by stimulating
XX CC the synthesis or expression of insulin. A composition comprising a
XX CC peptide of the invention is useful for treating diabetes, particularly
XX CC type II (maturity onset) diabetes. It is also useful as a sedative; for
XX CC the treatment of nervous system disorders including anxiety, psychosis,
XX CC seizures, panic attacks, hysteria and sleep disorders; to induce an
XX CC anxiolytic effect on the central nervous system (CNS); to activate the
XX CC CNS for the treatment of disorders such as depression, memory loss and
XX CC narcolepsy; and as a treatment for insulin resistance, particularly that
XX CC which occurs after certain types of surgery. The conjugation of a peptide
XX CC of the invention to a blood component via the reactive group provides
XX CC increased stability in the presence of peptidases. The peptides of the
XX CC invention therefore have a longer in vivo half-life as they are less
XX CC susceptible to proteolytic degradation. The present sequence represents
XX CC an insulinotropic peptide of the invention
XX SQ Sequence 40 AA;
AAB48807 Length: 40 February 4, 2005 13:32 Type: P Check: 2570 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSLSKQMEAEVRLFIWLKNGPSSGAPPPSK
1 28
-----
1 match found in sequence:
aab48822 ; Exendin-4(1-39)Lys40.
(from "seq5ags.pep")
TOIG of: aab48822 check: 2570 from: 1 to: 40
ID AAB48822 standard; peptide; 40 AA.
XX AC AAB48822;
XX AC AAB48823;
XX DT 09-MAR-2001 (first entry)
XX DE Exendin-4(1-39)Lys40.
XX KW Insulinotropic peptide; insulin production; GLP-1 derivative;
XX KW glucagon-like peptide 1; exendin derivative; reactive group;
XX KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
XX KW insulin resistance; nervous system disorder; sedative; anxiolytic;
XX KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.
XX OS Synthetic.

```

```

XX FH Key Location/Qualifiers
XX FT Modified-site 40
XX FT /note= "Side chain is linked to a maleimidopropionic acid
XX FT (MPA) moiety, optionally via two AEEA ([2-(2-
XX FT amino)ethoxy]ethoxy acetic acid) linking groups"
XX PN WO200069911-A1.
XX XX 23-NOV-2000.
XX XX 17-MAY-2000; 2000WO-US013563.
XX PF 17-MAY-1999; 99US-0134406P.
XX PR 15-OCT-1999; 99US-0159783P.
XX XX (CONJ-) CONJUCHEM INC.
XX PA Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
XX PI St Pierre S;
XX PI WPI; 2001-025008/03.
XX DR Novel modified insulinotropic peptides for treating diabetes, nervous
XX PT system disorders and for post surgery treatment, has reactive groups
XX PT which react with amino, hydroxy or thiol groups on blood components.
XX PS Claim 19; Page 62; 96pp; English.
XX CC The invention relates to modified insulinotropic peptides (ITPs), or
XX CC derivatives thereof which comprise a reactive group which reacts with
XX CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
XX CC serum albumin) to form a stable covalent bond. The insulinotropic
XX CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
XX CC -1) or exendin and contain a reactive group such as a maleimido group or
XX CC a succinimidyl group. The peptides of the invention act by stimulating
XX CC the synthesis or expression of insulin. A composition comprising a
XX CC peptide of the invention is useful for treating diabetes, particularly
XX CC type II (maturity onset) diabetes. It is also useful as a sedative; for
XX CC the treatment of nervous system disorders including anxiety, psychosis,
XX CC seizures, panic attacks, hysteria and sleep disorders; to induce an
XX CC anxiolytic effect on the central nervous system (CNS); to activate the
XX CC CNS for the treatment of disorders such as depression, memory loss and
XX CC narcolepsy; and as a treatment for insulin resistance, particularly that
XX CC which occurs after certain types of surgery. The conjugation of a peptide
XX CC of the invention to a blood component via the reactive group provides
XX CC increased stability in the presence of peptidases. The peptides of the
XX CC invention therefore have a longer in vivo half-life as they are less
XX CC susceptible to proteolytic degradation. The present sequence represents
XX CC an insulinotropic peptide of the invention
XX SQ Sequence 40 AA;
AAB48822 Length: 40 February 4, 2005 13:32 Type: P Check: 2570 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSLSKQMEAEVRLFIWLKNGPSSGAPPPSK
1 28
-----
1 match found in sequence:
aab48823 ; Exendin-3(1-39)Lys40.
(from "seq5ags.pep")
TOIG of: aab48823 check: 2591 from: 1 to: 40
ID AAB48823 standard; peptide; 40 AA.
XX AC AAB48823;
XX AC AAB48823;
XX DT 09-MAR-2001 (first entry)
XX DE Exendin-3(1-39)Lys40.

```



```
XX 17-MAY-1999; 99US-0134406P.
PR 15-OCT-1999; 99US-0159783P.
XX
XX (CONJ-) CONJUCHEM INC.
XX
XX Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
XX St Pierre S;
XX
XX WPI; 2001-025008/03.
XX
XX Novel modified insulinotropic peptides for treating diabetes, nervous
XX system disorders and for post surgery treatment, has reactive groups
XX PT which react with amino, hydroxy or thiol groups on blood components.
XX
XX Disclosure; Page 89; 96pp; English.
XX
XX The invention relates to modified insulinotropic peptides (ITPs), or
XX derivatives thereof which comprise a reactive group which reacts with
XX amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
XX serum albumin) to form a stable covalent bond. The insulinotropic
XX peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
XX -1) or exendin and contain a reactive group such as a maleimido group or
XX a succinimidyl group. The peptides of the invention act by stimulating
XX the synthesis or expression of insulin. A composition comprising a
XX peptide of the invention is useful for treating diabetes, particularly
XX type II (maturity onset) diabetes. It is also useful as a sedative; for
XX the treatment of nervous system disorders including anxiety, psychosis,
XX anxiolytic effect on the central nervous system (CNS); to activate the
XX CNS for the treatment of disorders such as depression, memory loss and
XX narcolepsy; and as a treatment for insulin resistance, particularly that
XX which occurs after certain types of surgery. The conjugation of a peptide
XX of the invention to a blood component via the reactive group provides
XX increased stability in the presence of peptidases. The peptides of the
XX invention therefore have a longer in vivo half-life as they are less
XX susceptible to proteolytic degradation. The present sequence represents
XX an insulinotropic peptide referred to in the disclosure of the invention
XX
XX Sequence 39 AA;
XX
AAB48801 Length: 39 February 4, 2005 13:32 Type: P Check: 9570
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQMBEAVRLFIEWLKNGPSSGAPPPS
1 -----|-----|
1 HGEFTFTDLSKQMBEAVRLFIEWLKNGGY
1 -----|-----|
1 match found in sequence:
aab48803 ; Exendin-4(1-30)Tyr31, SEQ ID NO:14.
(from "seq5ags.pep")
TOIG of: aab48803 check: 7648 from: 1 to: 31
ID AAB48803 standard; peptide; 31 AA.
XX
XX AAB48803;
XX
XX 09-MAR-2001 (first entry)
XX
XX Exendin-4(1-30)Tyr31, SEQ ID NO:14.
XX
XX Insulinotropic peptide; insulin production; GLP-1 derivative;
XX glucagon-like peptide 1; exendin derivative; reactive group;
XX peptidase stabilisation; blood protein; conjugation; type II diabetes;
XX insulin resistance; nervous system disorder; sedative; anxiolytic;
XX antidiabetic; neuroprotective; tranquiliser; anticonvulsant.
XX
XX Synthetic.
XX
XX WO200069911-A1.
XX
XX 23-NOV-2000.
XX
17-MAY-2000; 2000WO-US013563.
17-MAY-1999; 99US-0134406P.
15-OCT-1999; 99US-0159783P.
(CONJ-) CONJUCHEM INC.
Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
St Pierre S;
WPI; 2001-025008/03.
Novel modified insulinotropic peptides for treating diabetes, nervous
system disorders and for post surgery treatment, has reactive groups
which react with amino, hydroxy or thiol groups on blood components.
Claim 4; Page 90; 96pp; English.
The invention relates to modified insulinotropic peptides (ITPs), or
derivatives thereof which comprise a reactive group which reacts with
amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
serum albumin) to form a stable covalent bond. The insulinotropic
peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
-1) or exendin and contain a reactive group such as a maleimido group or
a succinimidyl group. The peptides of the invention act by stimulating
the synthesis or expression of insulin. A composition comprising a
peptide of the invention is useful for treating diabetes, particularly
type II (maturity onset) diabetes. It is also useful as a sedative; for
the treatment of nervous system disorders including anxiety, psychosis,
seizures, panic attacks, hysteria and sleep disorders; to induce an
anxiolytic effect on the central nervous system (CNS); to activate the
CNS for the treatment of disorders such as depression, memory loss and
narcolepsy; and as a treatment for insulin resistance, particularly that
which occurs after certain types of surgery. The conjugation of a peptide
of the invention to a blood component via the reactive group provides
increased stability in the presence of peptidases. The peptides of the
invention therefore have a longer in vivo half-life as they are less
susceptible to proteolytic degradation. The present sequence represents
an insulinotropic peptide of the invention
Sequence 31 AA;
AAB48803 Length: 31 February 4, 2005 13:32 Type: P Check: 7648
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQMBEAVRLFIEWLKNGGY
1 -----|-----|
1 match found in sequence:
aab48807 ; Exendin-derived insulinotropic peptide, SEQ ID NO:18.
(from "seq5ags.pep")
TOIG of: aab48807 check: 2570 from: 1 to: 40
ID AAB48807 standard; peptide; 40 AA.
XX
XX AAB48807;
XX
XX 09-MAR-2001 (first entry)
XX
XX Exendin-derived insulinotropic peptide, SEQ ID NO:18.
XX
XX Insulinotropic peptide; insulin production; GLP-1 derivative;
XX glucagon-like peptide 1; exendin derivative; reactive group;
XX peptidase stabilisation; blood protein; conjugation; type II diabetes;
XX insulin resistance; nervous system disorder; sedative; anxiolytic;
XX antidiabetic; neuroprotective; tranquiliser; anticonvulsant.
XX
XX Synthetic.
XX
XX WO200069911-A1.
XX
XX 23-NOV-2000.
```

XX PF 27-APR-2000; 2000WO-US011251.
 XX PR 30-APR-1999; 99US-00302596.
 XX PA (BION-) BIONEERASKA INC.
 XX PI Coolidge TR, Ehlers MRW;
 XX PT WPI; 2001-040881/05.
 XX DR Metabolic intervention with GLP-1 improves function of ischemic and
 XX PT reperfusion tissue.
 XX PS Disclosure; Page 13; 22pp; English.
 XX CC The present invention describes metabolic intervention with GLP-1 which
 CC improves the function of ischaemic and reperfusion tissue. The method for
 CC amelioration of organ tissue caused by reperfusion of blood flow
 CC following a period of ischaemia comprises administering a composition
 CC including a compound which binds to a receptor for glucagon-like peptide-
 CC 1 (GLP-1), in a carrier. Also described are: (1) a method of metabolic
 CC intervention with GLP-1 to improve the function of ischaemic and
 CC reperfusion tissue, the method comprising administering a composition
 CC comprising GLP-1 in a carrier; and (2) a composition for use in the
 CC metabolic intervention with GLP-1 as above. The method is useful after
 CC surgical procedures selected from cardiac surgical procedures, organ
 CC transplants, traumatic limb amputation and reattachment, a ischaemic
 CC reperfusion event concurrent with gut infarct and myocardial infarct and
 CC improves the function of ischaemic and reperfusion tissues. The method is
 CC devoid of side effects associated with current procedures. Antigenic and
 CC immune stimulating properties are not adversely affected. The present
 CC sequence represents a Gila monster venom peptide which is homologous to
 CC GLP-1, and is given in the exemplification of the present invention
 XX SQ Sequence 39 AA;
 AAB36434 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 28
 1 match found in sequence:
 aab48800 ; Exendin-3, SEQ ID NO:11.
 (from "seq5ags.pep")
 TOIG of: aab48800 check: 9591 from: 1 to: 39
 ID AAB48800 standard; peptide; 39 AA.
 XX AC AAB48800;
 XX DT 09-MAR-2001 (first entry)
 XX DE Exendin-3, SEQ ID NO:11.
 XX KW Insulinotropic peptide; insulin production; GLP-1 derivative;
 KW glucagon-like peptide 1; exendin derivative; reactive group;
 KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
 KW insulin resistance; nervous system disorder; sedative; anxiolytic;
 KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.
 XX OS Unidentified.
 XX PN WO200069911-A1.
 XX PD 23-NOV-2000.
 XX PF 17-MAY-2000; 2000WO-US013563.
 XX PR 17-MAY-1999; 99US-0134406P.

PR 15-OCT-1999; 99US-0159783P.
 XX PA (CONJ-) CONJUCHEM INC.
 XX PI Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
 XX PT St Pierre S;
 XX DR WPI; 2001-025008/03.
 XX PT Novel modified insulinotropic peptides for treating diabetes, nervous
 XX PT system disorders and for post surgery treatment, has reactive groups
 XX PT which react with amino, hydroxy or thiol groups on blood components.
 XX PS Claim 4; Page 88-89; 96pp; English.
 XX CC The invention relates to modified insulinotropic peptides (ITPs), or
 CC derivatives thereof which comprise a reactive group which reacts with
 CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
 CC serum albumin) to form a stable covalent bond. The insulinotropic
 CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
 CC -1) or exendin and contain a reactive group such as a maleimido group or
 CC a succinimidyl group. The peptides of the invention act by stimulating
 CC the synthesis or expression of insulin. A composition comprising a
 CC peptide of the invention is useful for treating diabetes, particularly
 CC type II (maturity onset) diabetes. It is also useful as a sedative; for
 CC the treatment of nervous system disorders including anxiety, psychosis,
 CC seizures, panic attacks, hysteria and sleep disorders; to induce an
 CC anxiolytic effect on the central nervous system (CNS); to activate the
 CC CNS for the treatment of disorders such as depression, memory loss and
 CC narcolepsy; and as a treatment for insulin resistance, particularly that
 CC which occurs after certain types of surgery. The conjugation of a peptide
 CC of the invention to a blood component via the reactive group provides
 CC increased stability in the presence of peptidases. The peptides of the
 CC invention therefore have a longer in vivo half-life as they are less
 CC susceptible to proteolytic degradation. The present sequence represents
 CC an insulinotropic peptide of the invention
 XX SQ Sequence 39 AA;
 AAB48800 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)
 1 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 28
 1 match found in sequence:
 aab48801 ; Exendin-4, SEQ ID NO:12.
 (from "seq5ags.pep")
 TOIG of: aab48801 check: 9570 from: 1 to: 39
 ID AAB48801 standard; peptide; 39 AA.
 XX AC AAB48801;
 XX DT 09-MAR-2001 (first entry)
 XX DE Exendin-4, SEQ ID NO:12.
 XX KW Insulinotropic peptide; insulin production; GLP-1 derivative;
 KW glucagon-like peptide 1; exendin derivative; reactive group;
 KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
 KW insulin resistance; nervous system disorder; sedative; anxiolytic;
 KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.
 XX OS Unidentified.
 XX PN WO200069911-A1.
 XX PD 23-NOV-2000.
 XX PF 17-MAY-2000; 2000WO-US013563.

```

PF 01-MAY-2000; 2000WO-US011652.
XX
PR 30-APR-1999; 99US-00303016.
XX
PA (BION-) BIONEERASKA INC.
XX
PI Coolidge TR, Ehlers MRW;
XX
DR WPI; 2001-015911/02.
XX
PT A method for amelioration of brain tissue injury comprises administering
PT a composition including a compound which binds to a receptor for glucagon
PT -like peptide-1.
XX
PS Disclosure; Page 8; 19pp; English.
XX
CC The present invention describes a method for the amelioration of brain
CC tissue injury caused by reperfusion of blood flow comprising
CC administering a composition including a compound which binds to a
CC receptor for glucagon-like peptide-1 (GLP-1), in a pharmaceutical
CC carrier. The method is used for amelioration of brain tissue injury
CC caused by reperfusion of blood flow following a period of ischaemia. GLP-
CC 1 is used for metabolic intervention to improve the function of ischaemic
CC and reperused brain cells. It treats patients after an acute stroke or
CC haemorrhage and tissue damage arising from a medical procedure that is a
CC surgical event causing ischaemia of brain tissue or a medical procedure
CC involving a reperfusion event. GLP-1 is an ideal alternative to insulin
CC for the treatment of stroke as it stimulates endogenous insulin secretion
CC in the presence of normo- to hyperglycaemia but not during hypoglycaemia,
CC thus protecting against the development of severe hypoglycaemia. The
CC treatment optimises insulin secretion, increases brain anabolism,
CC enhancing insulin effectiveness by suppressing glucagon and maintains
CC euglycaemia or mild hypoglycaemia with no risk of severe hypoglycaemia.
CC The present sequence represents a Gila monster venom peptide which is
CC homologous to GLP-1, and is given in the exemplification of the present
CC invention
XX
SQ Sequence 39 AA;

AAB36421 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
  1
-----|-----|
1 match found in sequence:
aab36432 ; Gila monster venom extendin 3 peptide SEQ ID NO:7.
(from "seq5ags.pep")
TOIG of: aab36432 check: 9591 from: 1 to: 39

ID AAB36432 standard; peptide; 39 AA.
XX
AC AAB36432;
XX
DT 28-FEB-2001 (first entry)
XX
DE Gila monster venom extendin 3 peptide SEQ ID NO:7.
XX
KW Glucagon-like peptide-1; GLP-1; GLP-2; metabolic intervention; ischaemia;
KW reperfusion; surgical procedure; cardiac surgical procedure;
KW organ transplant; traumatic limb amputation; limb reattachment;
KW ischaemic reperfusion; gut infarct; myocardial infarct.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39 /note= "amidated"
XX
PN WO200066138-A2.
XX
PD 09-NOV-2000.

PD 09-NOV-2000.
XX
PR 27-APR-2000; 2000WO-US011251.
XX
PR 30-APR-1999; 99US-00302596.
XX
PA (BION-) BIONEERASKA INC.
XX
PI Coolidge TR, Ehlers MRW;
XX
DR WPI; 2001-040881/05.
XX
PT Metabolic intervention with GLP-1 improves function of ischemic and
PT reperused tissue.
XX
PS Disclosure; Page 13; 22pp; English.
XX
CC The present invention describes metabolic intervention with GLP-1 which
CC improves the function of ischaemic and reperused tissue. The method for
CC amelioration of organ tissue caused by reperfusion of blood flow
CC following a period of ischaemia comprises administering a composition
CC including a compound which binds to a receptor for glucagon-like peptide-
CC 1 (GLP-1), in a carrier. Also described are: (1) a method of metabolic
CC intervention with GLP-1 to improve the function of ischaemic and
CC reperused tissue, the method comprising administering a composition
CC comprising GLP-1 in a carrier; and (2) a composition for use in the
CC metabolic intervention with GLP-1 as above. The method is useful after
CC surgical procedures selected from cardiac surgical procedures, organ
CC transplants, traumatic limb amputation and reattachment, a ischaemic
CC reperfusion event concurrent with gut infarct and myocardial infarct and
CC improves the function of ischaemic and reperused tissues. The method is
CC devoid of side effects associated with current procedures. Antigenic and
CC immune stimulating properties are not adversely affected. The present
CC sequence represents a Gila monster venom peptide which is homologous to
CC GLP-1, and is given in the exemplification of the present invention
XX
SQ Sequence 39 AA;

AAB36432 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)

1 HSDGTFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
  1
-----|-----|
1 match found in sequence:
aab36434 ; Gila monster venom extendin 4 peptide SEQ ID NO:9.
(from "seq5ags.pep")
TOIG of: aab36434 check: 9570 from: 1 to: 39

ID AAB36434 standard; peptide; 39 AA.
XX
AC AAB36434;
XX
DT 28-FEB-2001 (first entry)
XX
DE Gila monster venom extendin 4 peptide SEQ ID NO:9.
XX
KW Glucagon-like peptide-1; GLP-1; GLP-2; metabolic intervention; ischaemia;
KW reperfusion; surgical procedure; cardiac surgical procedure;
KW organ transplant; traumatic limb amputation; limb reattachment;
KW ischaemic reperfusion; gut infarct; myocardial infarct.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39 /note= "amidated"
XX
PN WO200066138-A2.
XX
PD 09-NOV-2000.

```

```

OS Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI
XX WPI; 2000-514584/46.
XX DR
XX
XX New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PT
XX Example 44; Fig 15; 281pp; English.
XX PS
XX This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC
XX Sequence 39 AA;
XX SQ
AAB11313 Length: 39 February 4, 2005 13:32 Type: P Check: 7001 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGASSGAAAAA
1 28
-----|
1 match found in sequence:
aab36419; Gila monster venom exendin 3 peptide SEQ ID NO:7.
(from "seq5ags.pep")
TOIG of: aab36419 check: 9591 from: 1 to: 39
ID AAB36419 standard; peptide; 39 AA.
XX AC
XX AAB36419;
XX AC
XX 28-FEB-2001 (first entry)
XX DT
XX Gila monster venom exendin 3 peptide SEQ ID NO:7.
XX DE
XX Glucagon-like peptide-1; GLP-1; GLP-2; vasotropic; cerebroprotective;
XX KW brain tissue injury; reperfusion; blood flow; ischaemia; acute stroke;
XX KW metabolic intervention; haemorrhage; tissue damage; medical procedure;
XX KW surgical; insulin; hyperglycaemia; hypoglycaemia; brain anabolism;
XX KW euglycaemia.
XX KW
XX Heloderma suspectum.
XX OS
XX Key Location/Qualifiers
XX FH Modified-site 39
XX FT /note= "amidated"
XX FT
XX WO200066142-A2.
XX PN
XX 09-NOV-2000.
XX PD
XX 01-MAY-2000; 2000WO-US011652.
XX PF
XX 30-APR-1999; 99US-00303016.
XX PR

```

```

XX PA (BION-) BIONEERASKA INC.
XX PI Coolidge TR, Ehlers MRW;
XX PI
XX WPI; 2001-015911/02.
XX DR
XX
XX A method for amelioration of brain tissue injury comprises administering
XX PT a composition including a compound which binds to a receptor for glucagon
XX PT -like peptide-1.
XX PT
XX Disclosure; Page 8; 19pp; English.
XX PS
XX The present invention describes a method for the amelioration of brain
XX CC tissue injury caused by reperfusion of blood flow comprising
XX CC administering a composition including a compound which binds to a
XX CC receptor for glucagon-like peptide-1 (GLP-1), in a pharmaceutical
XX CC carrier. The method is used for amelioration of brain tissue injury
XX CC caused by reperfusion of blood flow following a period of ischaemia. GLP-
XX CC 1 is used for metabolic intervention to improve the function of ischaemic
XX CC and reperfusion brain cells. It treats patients after an acute stroke or
XX CC haemorrhage and tissue damage arising from a medical procedure that is a
XX CC surgical event causing ischaemia of brain tissue or a medical procedure
XX CC involving a reperfusion event. GLP-1 is an ideal alternative to insulin
XX CC for the treatment of stroke as it stimulates endogenous insulin secretion
XX CC in the presence of normo- to hyperglycaemia but not during hypoglycaemia,
XX CC thus protecting against the development of severe hypoglycaemia. The
XX CC treatment optimises insulin secretion, increases brain anabolism,
XX CC enhancing insulin effectiveness by suppressing glucagon and maintaining
XX CC euglycaemia or mild hypoglycaemia with no risk of severe hypoglycaemia.
XX CC The present sequence represents a Gila monster venom peptide which is
XX CC homologous to GLP-1, and is given in the exemplification of the present
XX CC invention
XX CC
XX Sequence 39 AA;
XX SQ
AAB36419 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 HSDGTFTSDLSKQMEEEAVRLFIEFLKNGSPSSGAPPPS
1 28
-----|
1 match found in sequence:
aab36421; Gila monster venom exendin 4 peptide SEQ ID NO:9.
(from "seq5ags.pep")
TOIG of: aab36421 check: 9570 from: 1 to: 39
ID AAB36421 standard; peptide; 39 AA.
XX AC
XX AAB36421;
XX AC
XX 28-FEB-2001 (first entry)
XX DT
XX Gila monster venom exendin 4 peptide SEQ ID NO:9.
XX DE
XX Glucagon-like peptide-1; GLP-1; GLP-2; vasotropic; cerebroprotective;
XX KW brain tissue injury; reperfusion; blood flow; ischaemia; acute stroke;
XX KW metabolic intervention; haemorrhage; tissue damage; medical procedure;
XX KW surgical; insulin; hyperglycaemia; hypoglycaemia; brain anabolism;
XX KW euglycaemia.
XX KW
XX Heloderma suspectum.
XX OS
XX Key Location/Qualifiers
XX FH Modified-site 39
XX FT /note= "amidated"
XX FT
XX WO200066142-A2.
XX PN
XX 09-NOV-2000.
XX PD
XX 01-MAY-2000; 2000WO-US011652.
XX PF
XX 30-APR-1999; 99US-00303016.
XX PR

```

CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11310 Length: 39 February 4, 2005 13:32 Type: P Check: 9131 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQLEEEAVRLFIEFLKNGSPSSGAPPPS
28

1 match found in sequence:
aabl1311; extendin agonist peptide SEQ ID NO 37.
(from "seq5ags.pep")
TOIG of: aabl1311 check: 7440 from: 1 to: 39

ID AAB11311 standard; peptide; 39 AA.

XX AC AAB11311;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 37.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 42; Fig 15; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake

XX SQ Sequence 39 AA;

AAB11311 Length: 39 February 4, 2005 13:32 Type: P Check: 7440 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEFLKNGSGSSGAAAS
28

1 match found in sequence:
aabl1312; extendin agonist peptide SEQ ID NO 38.
(from "seq5ags.pep")
TOIG of: aabl1312 check: 7905 from: 1 to: 39

ID AAB11312 standard; peptide; 39 AA.

XX AC AAB11312;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 38.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 43; Fig 15; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake

XX SQ Sequence 39 AA;

AAB11312 Length: 39 February 4, 2005 13:32 Type: P Check: 7905 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEFLKNGSPSSGAAAS
28

1 match found in sequence:
aabl1313; extendin agonist peptide SEQ ID NO 39.
(from "seq5ags.pep")
TOIG of: aabl1313 check: 7001 from: 1 to: 39

ID AAB11313 standard; peptide; 39 AA.

XX AC AAB11313;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 39.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

```
DT 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 34.
DE
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 39; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 39 AA;
XX
AAB11308 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTDLSKQMEEEAVRLFIEFLKNGGPPSGAPPPS
1
-----|
1 match found in sequence:
aabl1309 ; extendin agonist peptide SEQ ID NO 35.
(from "seq5ags.pep")
TOIG of: aabl1309 check: 9131 from: 1 to: 39
ID AAB11309 standard; peptide; 39 AA.
XX
XX AC AAB11309;
XX
XX 20-FEB-2001 (first entry)
DE extendin agonist peptide SEQ ID NO 35.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
```

```
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 40; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 39 AA;
XX
AAB11309 Length: 39 February 4, 2005 13:32 Type: P Check: 9131 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTDLSKQMEEEAVRLFIEFLKNGGPPSGAPPPS
1
-----|
1 match found in sequence:
aabl1310 ; extendin agonist peptide SEQ ID NO 36.
(from "seq5ags.pep")
TOIG of: aabl1310 check: 9131 from: 1 to: 39
ID AAB11310 standard; peptide; 39 AA.
XX
XX AC AAB11310;
XX
XX 20-FEB-2001 (first entry)
DE extendin agonist peptide SEQ ID NO 36.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 41; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
```

```

PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 36; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11305 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
  1 28
-----
1 match found in sequence:
aabl1306 ; exendin agonist peptide SEQ ID NO 32.
(from "seq5ags.pep")
TOIG of: aabl1306 check: 9570 from: 1 to: 39

ID AAB11306 standard; peptide; 39 AA.
XX
AC AAB11306;
XX
DT 20-FEB-2001 (first entry)
XX
DE exendin agonist peptide SEQ ID NO 32.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 37; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11306 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
  1 28
-----
1 match found in sequence:
aabl1306 ; exendin agonist peptide SEQ ID NO 32.
(from "seq5ags.pep")
TOIG of: aabl1306 check: 9570 from: 1 to: 39

ID AAB11306 standard; peptide; 39 AA.
XX
AC AAB11306;
XX
DT 20-FEB-2001 (first entry)
XX
DE exendin agonist peptide SEQ ID NO 32.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 37; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11306 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
  1 28
-----
1 match found in sequence:
aabl1308 ; exendin agonist peptide SEQ ID NO 34.
(from "seq5ags.pep")
TOIG of: aabl1308 check: 9570 from: 1 to: 39

ID AAB11308 standard; peptide; 39 AA.
XX
AC AAB11308;
XX

```

```

Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
  1 28
-----
1 match found in sequence:
aabl1307 ; exendin agonist peptide SEQ ID NO 33.
(from "seq5ags.pep")
TOIG of: aabl1307 check: 9570 from: 1 to: 39

ID AAB11307 standard; peptide; 39 AA.
XX
AC AAB11307;
XX
DT 20-FEB-2001 (first entry)
XX
DE exendin agonist peptide SEQ ID NO 33.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 38; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11307 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
  1 28
-----
1 match found in sequence:
aabl1308 ; exendin agonist peptide SEQ ID NO 34.
(from "seq5ags.pep")
TOIG of: aabl1308 check: 9570 from: 1 to: 39

ID AAB11308 standard; peptide; 39 AA.
XX
AC AAB11308;
XX

```

```

(from "seq5ags.pep")
TOIG of: aab11303 check: 9546 from: 1 to: 39

ID AAB11303 standard; peptide; 39 AA.
XX
AC AAB11303;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 29.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
DR
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 34; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 39 AA;
SQ

AAB11303 Length: 39 February 4, 2005 13:32 Type: P Check: 9546 ..
Found using 'seq5' (mohamed337.key)

1 HGGGTFTSLSKQMBEAEVRLFDLWLNKGPGSSGAPPPS
  1 28
-----
1 match found in sequence:
aabil1304; extendin agonist peptide SEQ ID NO 30.
(from "seq5ags.pep")
TOIG of: aabil1304 check: 9145 from: 1 to: 39

ID AAB11304 standard; peptide; 39 AA.
XX
AC AAB11304;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 30.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
DR
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 34; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 39 AA;
SQ

AAB11303 Length: 39 February 4, 2005 13:32 Type: P Check: 9546 ..
Found using 'seq5' (mohamed337.key)

1 HGGGTFTSLSKQMBEAEVRLFDLWLNKGPGSSGAPPPS
  1 28
-----
1 match found in sequence:
aabil1304; extendin agonist peptide SEQ ID NO 30.
(from "seq5ags.pep")
TOIG of: aabil1304 check: 9145 from: 1 to: 39

ID AAB11304 standard; peptide; 39 AA.
XX
AC AAB11304;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 30.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
DR
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 35; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 39 AA;
SQ

AAB11304 Length: 39 February 4, 2005 13:32 Type: P Check: 9145 ..
Found using 'seq5' (mohamed337.key)

1 HGGGTFTSLSKQMBEAEVRLFDLWLNKGPGSSGAPPPS
  1 28
-----
1 match found in sequence:
aabil1305; extendin agonist peptide SEQ ID NO 31.
(from "seq5ags.pep")
TOIG of: aabil1305 check: 9570 from: 1 to: 39

ID AAB11305 standard; peptide; 39 AA.
XX
AC AAB11305;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 31.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
DR
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 35; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 39 AA;
SQ

```



```
PA (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 31; Fig 15; 281pp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX Sequence 39 AA;
AAB11300 Length: 39 February 4, 2005 13:32 Type: P Check: 9430 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLFVEFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aabl1301 ; extendin agonist peptide SEQ ID NO 27.
(from "seq5ags.pep")
TOIG of: aabl1301 check: 9915 from: 1 to: 39
ID AABL1301 standard; peptide; 39 AA.
XX AC AABL1301;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 27.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 32; Fig 15; 281pp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX Sequence 39 AA;
AAB11302 Length: 39 February 4, 2005 13:32 Type: P Check: 9476 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLFVEFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aabl1302 ; extendin agonist peptide SEQ ID NO 28.
(from "seq5ags.pep")
TOIG of: aabl1302 check: 9476 from: 1 to: 39
ID AABL1302 standard; peptide; 39 AA.
XX AC AABL1302;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 28.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 33; Fig 15; 281pp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX Sequence 39 AA;
AAB11303 Length: 39 February 4, 2005 13:32 Type: P Check: 9476 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLFVEFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aabl1303 ; extendin agonist peptide SEQ ID NO 29.
```

```
1 1 HEGTFTSLSKQEEAVRLFIEWLKNGGSPSGAPPPS
    1 28
-----
1 match found in sequence:
aabl1297 ; extendin agonist peptide SEQ ID NO 23.
(from "seq5ags.pep")
TOIG of: aabl1297 check: 9061 from: 1 to: 39

ID ABL1297 standard; peptide; 39 AA.
XX AC
XX AAB11297;
XX AC
XX 20-FEB-2001 (first entry)
XX DT
XX DE extendin agonist peptide SEQ ID NO 23.
XX DE
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX OS
XX PN WO200041546-A2.
XX PD
XX 20-JUL-2000.
XX XX
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX XX
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX XX
XX PS Example 30; Fig 15; 281pp; English.
XX XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX XX
XX SQ Sequence 39 AA;

AABL1299 Length: 39 February 4, 2005 13:32 Type: P Check: 9869 ..
Found using 'seq5' (mohamed337.key)

1 1 HEGTFTSLSKQEEAVRLFIEWLKNGGSPSGAPPPS
    1 28
-----
1 match found in sequence:
aabl1300 ; extendin agonist peptide SEQ ID NO 26.
(from "seq5ags.pep")
TOIG of: aabl1300 check: 9430 from: 1 to: 39

ID AABL1300 standard; peptide; 39 AA.
XX AC
XX AABL1300;
XX AC
XX 20-FEB-2001 (first entry)
XX DT
XX DE extendin agonist peptide SEQ ID NO 26.
XX DE
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX OS
XX PN WO200041546-A2.
XX XX
XX 20-JUL-2000.
XX PD
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX XX
```

```

PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 25; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX SQ Sequence 39 AA;
XX

AAB11294 Length: 39 February 4, 2005 13:32 Type: P Check: 9520 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEFTSDGSKQLEBEAVRLFIEFLKNGSPSSGAPPPS
  1 28

-----
1 match found in sequence:
aab11295 ; extendin agonist peptide SEQ ID NO 21.
(from "seq5ags.pep")
TOIG of: aab11295 check: 9081 from: 1 to: 39

ID AAB11295 standard; peptide; 39 AA.
XX
XX AC AAB11295;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 21.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX FN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 25; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 39 AA;
XX

AAB11295 Length: 39 February 4, 2005 13:32 Type: P Check: 9520 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEFTSDGSKQLEBEAVRLFIEFLKNGSPSSGAPPPS
  1 28

-----
1 match found in sequence:
aab11295 ; extendin agonist peptide SEQ ID NO 21.
(from "seq5ags.pep")
TOIG of: aab11295 check: 9081 from: 1 to: 39

ID AAB11295 standard; peptide; 39 AA.
XX
XX AC AAB11295;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 21.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX FN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 25; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 39 AA;
XX

AAB11296 Length: 39 February 4, 2005 13:32 Type: P Check: 9486 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEFTSDGSKQLEBEAVRLFIEFLKNGSPSSGAPPPS
  1 28

-----
1 match found in sequence:
aab11296 ; extendin agonist peptide SEQ ID NO 22.
(from "seq5ags.pep")
TOIG of: aab11296 check: 9486 from: 1 to: 39

ID AAB11296 standard; peptide; 39 AA.
XX
XX AC AAB11296;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 22.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX FN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 27; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 39 AA;
XX

AAB11296 Length: 39 February 4, 2005 13:32 Type: P Check: 9486 ..
Found using 'seq5' (mohamed337.key)

```

```

PS Example 26; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 39 AA;
XX

AAB11295 Length: 39 February 4, 2005 13:32 Type: P Check: 9081 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEFTSDGSKQLEBEAVRLFIEFLKNGSPSSGAPPPS
  1 28

-----
1 match found in sequence:
aab11296 ; extendin agonist peptide SEQ ID NO 22.
(from "seq5ags.pep")
TOIG of: aab11296 check: 9486 from: 1 to: 39

ID AAB11296 standard; peptide; 39 AA.
XX
XX AC AAB11296;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 22.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX FN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 27; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 39 AA;
XX

AAB11296 Length: 39 February 4, 2005 13:32 Type: P Check: 9486 ..
Found using 'seq5' (mohamed337.key)

```

```
CC or reducing food intake
XX
SQ Sequence 39 AA;
AAB11291 Length: 39 February 4, 2005 13:32 Type: P Check: 9571 ..
Found using 'seq5' (mohamed337.key)

|-----|
1 HEGTFTDLSKQMEEEAVRLFIEWLKNGGSPSGAPPPS
28
1 match found in sequence:
aab11292 ; extendin agonist peptide SEQ ID NO 18.
(from "seq5ags.pep")
TOIG of: aab11292 check: 9578 from: 1 to: 39

ID AAB11292 standard; peptide; 39 AA.
XX
AC AAB11292;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 18.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX OS
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PP
XX PR 14-JAN-1999; 99US-0116380P.
XX PT 10-JAN-2000; 2000US-0175365P.
XX PS (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 23; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11293 Length: 39 February 4, 2005 13:32 Type: P Check: 9579 ..
Found using 'seq5' (mohamed337.key)

|-----|
1 HEGTFTDLSKQMEEEAVRLFIEWLKNGGSPSGAPPPS
28
1 match found in sequence:
aab11294 ; extendin agonist peptide SEQ ID NO 20.
(from "seq5ags.pep")
TOIG of: aab11294 check: 9520 from: 1 to: 39

ID AAB11294 standard; peptide; 39 AA.
XX
AC AAB11294;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 20.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX OS
XX PN WO200041546-A2.
XX
```

KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PW WO2000041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 20; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;
AAB11289 Length: 39 February 4, 2005 13:32 Type: P Check: 9678 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTXSDLSKQMEEA VRLFI EWLNKGSPSSGAPPPS
1 28

1 match found in sequence:
aabl1290 ; exendin agonist peptide SEQ ID NO 16.
(from "seq5ags.pep")
TOIG of: aabl1290 check: 9563 from: 1 to: 39
ID AAB11290 standard; peptide; 39 AA.
XX
AC AAB11290;
XX
DT 20-FEB-2001 (first entry)
XX
DE exendin agonist peptide SEQ ID NO 16.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PW WO2000041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 20; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;
AAB11289 Length: 39 February 4, 2005 13:32 Type: P Check: 9678 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTXSDLSKQMEEA VRLFI EWLNKGSPSSGAPPPS
1 28

1 match found in sequence:
aabl1290 ; exendin agonist peptide SEQ ID NO 16.
(from "seq5ags.pep")
TOIG of: aabl1290 check: 9563 from: 1 to: 39
ID AAB11290 standard; peptide; 39 AA.
XX
AC AAB11290;
XX
DT 20-FEB-2001 (first entry)
XX
DE exendin agonist peptide SEQ ID NO 16.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PW WO2000041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX

PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 21; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;
AAB11290 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSDLSKQMEEA VRLFI EWLNKGSPSSGAPPPS
1 28

1 match found in sequence:
aabl1291 ; exendin agonist peptide SEQ ID NO 17.
(from "seq5ags.pep")
TOIG of: aabl1291 check: 9571 from: 1 to: 39
ID AAB11291 standard; peptide; 39 AA.
XX
AC AAB11291;
XX
DT 20-FEB-2001 (first entry)
XX
DE exendin agonist peptide SEQ ID NO 17.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PW WO2000041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 22; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying

```

CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 39 AA;
SQ
AAB11286 Length: 39 February 4, 2005 13:32 Type: P Check: 9587 ..
Found using 'seq5' (mohamed337.key)

1 YGEGFTSLSKQMEEAVALRFLFWLKNKGSPSSGAPPPS
  28
-----
1 match found in sequence:
aabl1287 ; extendin agonist peptide SEQ ID NO 13.
(from "seq5ags.pep")
TOIG of: aabl1287 check: 9804 from: 1 to: 39

ID AAB11287 standard; peptide; 39 AA.
XX
XX AAB11287;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 13.
DE
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX
XX WO200041546-A2.
PN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX
XX 10-JAN-2000; 2000US-0175365P.
PS
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX
XX WPI; 2000-514584/46.
DR
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
PS
XX
XX Example 18; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 39 AA;
SQ
AAB11287 Length: 39 February 4, 2005 13:32 Type: P Check: 9804 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTSLSKQMEEAVALRFLFWLKNKGSPSSGAPPPY
  28
-----
1 match found in sequence:
aabl1287 ; extendin agonist peptide SEQ ID NO 13.
(from "seq5ags.pep")
TOIG of: aabl1287 check: 9804 from: 1 to: 39

ID AAB11287 standard; peptide; 39 AA.
XX
XX AAB11287;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 13.
DE
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX
XX WO200041546-A2.
PN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX
XX 10-JAN-2000; 2000US-0175365P.
PS
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX
XX WPI; 2000-514584/46.
DR
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
PS
XX
XX Example 18; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 39 AA;
SQ
AAB11288 Length: 39 February 4, 2005 13:32 Type: P Check: 9567 ..
Found using 'seq5' (mohamed337.key)

1 HGDGFTSLSKQMEEAVALRFLFWLKNKGSPSSGAPPPS
  28
-----
1 match found in sequence:
aabl1289 ; extendin agonist peptide SEQ ID NO 15.
(from "seq5ags.pep")
TOIG of: aabl1289 check: 9678 from: 1 to: 39

ID AAB11289 standard; peptide; 39 AA.
XX
XX AAB11289;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 15.
DE
XX

```

```

1 28
-----
1 match found in sequence:
aabl1288 ; extendin agonist peptide SEQ ID NO 14.
(from "seq5ags.pep")
TOIG of: aabl1288 check: 9567 from: 1 to: 39

ID AAB11288 standard; peptide; 39 AA.
XX
XX AAB11288;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 14.
DE
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX
XX WO200041546-A2.
PN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX
XX 10-JAN-2000; 2000US-0175365P.
PS
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX
XX WPI; 2000-514584/46.
DR
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
PS
XX
XX Example 19; Fig 15; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 39 AA;
SQ
AAB11288 Length: 39 February 4, 2005 13:32 Type: P Check: 9567 ..
Found using 'seq5' (mohamed337.key)

1 HGDGFTSLSKQMEEAVALRFLFWLKNKGSPSSGAPPPS
  28
-----
1 match found in sequence:
aabl1289 ; extendin agonist peptide SEQ ID NO 15.
(from "seq5ags.pep")
TOIG of: aabl1289 check: 9678 from: 1 to: 39

ID AAB11289 standard; peptide; 39 AA.
XX
XX AAB11289;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 15.
DE
XX

```

```

XX AC AAB11284;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 10.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 15; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11284 Length: 39 February 4, 2005 13:32 Type: P Check: 9556 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSLSKQLEEEAVRLFIEFLKNGSPSSGAPPPS
1 28
-----
1 match found in sequence:
aab11285; extendin agonist peptide SEQ ID NO 11.
(from "seq5ags.pep")
TOIG of: aab11285 check: 9145 from: 1 to: 39
ID AAB11285 standard; peptide; 39 AA.
XX AC AAB11285;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 11.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 17; Fig 15; 281pp; English.

```

```

PF 14-JAN-2000; 2000WO-US000902.
XX AC AAB11286;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 12.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 16; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11285 Length: 39 February 4, 2005 13:32 Type: P Check: 9145 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSLSKQLEEEAVRLFIEFLKNGSPSSGAPPPS
1 28
-----
1 match found in sequence:
aab11286; extendin agonist peptide SEQ ID NO 12.
(from "seq5ags.pep")
TOIG of: aab11286 check: 9587 from: 1 to: 39
ID AAB11286 standard; peptide; 39 AA.
XX AC AAB11286;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 12.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 17; Fig 15; 281pp; English.

```

DR WPI; 2000-514584/46.
 XX
 PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 PS Example 197; Page 242; 281pp; English.
 XX
 CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 39 AA;
 AAB11280 Length: 39 February 4, 2005 13:32 Type: P Check: 9112 ..
 Found using 'seq5' (mohamed337.key)
 1 AGAGTTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1

 1 match found in sequence:
 aab11281; H. horridum extendin 3 peptide SEQ ID NO 1.
 (from "seq5ags.pep")
 TOIG of: aab11281 check: 9591 from: 1 to: 39
 ID AAB11281 standard; peptide; 39 AA.
 XX
 AC AAB11281;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE H. horridum extendin 3 peptide SEQ ID NO 1.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Heloderma horridum.
 XX
 PN WO200041546-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, L'italien JJ, Kolterman O;
 XX
 DR WPI; 2000-514584/46.
 XX
 PF 14-JAN-2000; 2000WO-US000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, L'italien JJ, Kolterman O;
 XX
 DR WPI; 2000-514584/46.
 XX
 PF New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 PS Example 1; Fig 1; 281pp; English.
 XX
 CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX

SQ Sequence 39 AA;

AAB11281 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1

 28

1 match found in sequence:
 aab11282; H. suspectum extendin 4 peptide SEQ ID NO 2.
 (from "seq5ags.pep")
 TOIG of: aab11282 check: 9570 from: 1 to: 39

ID AAB11282 standard; peptide; 39 AA.

XX

AC AAB11282;

XX

DT 20-FEB-2001 (first entry)

XX

DE H. suspectum extendin 4 peptide SEQ ID NO 2.

XX

KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX

OS Heloderma suspectum.

XX

PN WO200041546-A2.

XX

PD 20-JUL-2000.

XX

PF 14-JAN-2000; 2000WO-US000902.

XX

PR 14-JAN-1999; 99US-0116380P.

PR

10-JAN-2000; 2000US-0175365P.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Young A, L'italien JJ, Kolterman O;

XX

DR WPI; 2000-514584/46.

XX

PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX

PS Example 2; Fig 2; 281pp; English.

XX

CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX

SQ Sequence 39 AA;

AAB11282 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

1 HCEGFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1

 28

1 match found in sequence:
 aab11284; extendin agonist peptide SEQ ID NO 10.
 (from "seq5ags.pep")
 TOIG of: aab11284 check: 9556 from: 1 to: 39

ID AAB11284 standard; peptide; 39 AA.

1 match found in sequence:
aabl1278 ; extendin agonist peptide SEQ ID NO 186.
(from "seq5ags.pep")
TOIG of: aabl1278 check: 4862 from: 1 to: 30

ID AABL1278 standard; peptide; 30 AA.
XX
AC AABL1278;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 186.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
FN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PP 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
DR New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 195; Page 240; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 30 AA;

AABL1278 Length: 30 February 4, 2005 13:32 Type: P Check: 4862 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGDATFTSDLSKQMEEAARLFIWLNKGG 28

1 match found in sequence:
aabl1279 ; extendin agonist peptide SEQ ID NO 187.
(from "seq5ags.pep")
TOIG of: aabl1279 check: 9563 from: 1 to: 39

ID AABL1279 standard; peptide; 39 AA.
XX
AC AABL1279;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 187.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.

XX Synthetic.
OS WO200041546-A2.
PN 20-JUL-2000.
XX
PD 14-JAN-2000; 2000WO-US000902.
XX
PP 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
DR New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 196; Page 241; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AABL1279 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGEFTTSDLSKQMEEAARLFIWLNKGGPSSGAPPS 28

1 match found in sequence:
aabl1280 ; extendin agonist peptide SEQ ID NO 188.
(from "seq5ags.pep")
TOIG of: aabl1280 check: 9112 from: 1 to: 39

ID AABL1280 standard; peptide; 39 AA.
XX
AC AABL1280;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 188.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
FN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PP 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX


```
AAB11272 Length: 29 February 4, 2005 13:32 Type: P Check: 2313 ..
Found using 'seq5' (mohamed337.key)

1 AGEGFTSDLSKQLEEEAVRLFIEFLKNG
  1
-----
1 match found in sequence:
aabl1273 ; extendin agonist peptide SEQ ID NO 181.
(from "seq5ags.pep")
TOIG of: aabl1273 check: 6321 from: 1 to: 38

ID AAB11273 standard; peptide; 38 AA.
XX
AC AAB11273;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 181.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 190; Page 236; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 38 AA;

AAB11273 Length: 38 February 4, 2005 13:32 Type: P Check: 6321 ..
Found using 'seq5' (mohamed337.key)

1 HGAGFTSDLSKQMBEEAVRLFIEWLKNGPSSGAPPP
  1
-----
1 match found in sequence:
aabl1274 ; extendin agonist peptide SEQ ID NO 182.
(from "seq5ags.pep")
TOIG of: aabl1274 check: 6309 from: 1 to: 38

ID AAB11274 standard; peptide; 38 AA.
XX
AC AAB11274;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 183.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 190; Page 236; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 38 AA;

AAB11274 Length: 38 February 4, 2005 13:32 Type: P Check: 6309 ..
Found using 'seq5' (mohamed337.key)

1 HGEATFTSDLSKQMBEEAVRLFIEWLKNGPSSGAPPP
  1
-----
1 match found in sequence:
aabl1275 ; extendin agonist peptide SEQ ID NO 183.
(from "seq5ags.pep")
TOIG of: aabl1275 check: 4098 from: 1 to: 37

ID AAB11275 standard; peptide; 37 AA.
XX
AC AAB11275;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 183.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 191; Page 237; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 38 AA;
```

```
XX WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 187; Page 234; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX SQ Sequence 31 AA;

AAB11270 Length: 31 February 4, 2005 13:32 Type: P Check: 7345 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEATFTSLSKQMEEEAVRLFIEFLKNGG
    28

-----
1 match found in sequence:
aabl1271 ; exendin agonist peptide SEQ ID NO 179.
(from "seq5ags.pep")
TOIG of: aabl1271 check: 4423 from: 1 to: 30

ID AAB11271 standard; peptide; 30 AA.
XX
XX AC AAB11271;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 179.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 189; Page 236; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 29 AA;

AAB11271 Length: 30 February 4, 2005 13:32 Type: P Check: 4423 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEATFTSLSKQMEEEAVRLFIEFLKNGG
    28

-----
1 match found in sequence:
aabl1272 ; exendin agonist peptide SEQ ID NO 180.
(from "seq5ags.pep")
TOIG of: aabl1272 check: 2313 from: 1 to: 29

ID AAB11272 standard; peptide; 29 AA.
XX
XX AC AAB11272;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 180.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 189; Page 236; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 29 AA;
```

CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 33 AA;

AAB11267 Length: 33 February 4, 2005 13:32 Type: P Check: 3230 ..
 Found using 'seq5' (mohamed337.key)

1 HGGFTSALSQMBEAVRLFIEFLKNGGPS
 28

 1 match found in sequence:
 aab11268 ; extendin agonist peptide SEQ ID NO 176.
 (from "seq5ags.pep")
 TOIG of: aab11268 check: 18 from: 1 to: 32

ID AAB11268 standard; peptide; 32 AA.

XX
 AC AAB11268;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 176.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.

XX
 XX WO200041546-A2.
 XX
 PD 20-JUL-2000.

XX
 PF 14-JAN-2000; 2000WO-US000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PA Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX
 PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 185; Page 233; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 32 AA;

AAB11268 Length: 32 February 4, 2005 13:32 Type: P Check: 18 ..
 Found using 'seq5' (mohamed337.key)

1 AGEFTTSLSQMBEAVRLFIEFLKNGGPS
 28

 1 match found in sequence:

aab11269 ; extendin agonist peptide SEQ ID NO 177.
 (from "seq5ags.pep")
 TOIG of: aab11269 check: 9574 from: 1 to: 32

ID AAB11269 standard; peptide; 32 AA.

XX
 AC AAB11269;

XX
 DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 177.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX
 PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 186; Page 233; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 32 AA;

AAB11269 Length: 32 February 4, 2005 13:32 Type: P Check: 9574 ..
 Found using 'seq5' (mohamed337.key)

1 HGGFTSLSQMBEAVRLFIEFLKNGGPS
 28

 1 match found in sequence:

aab11270 ; extendin agonist peptide SEQ ID NO 178.
 (from "seq5ags.pep")
 TOIG of: aab11270 check: 7345 from: 1 to: 31

ID AAB11270 standard; peptide; 31 AA.

XX
 AC AAB11270;

XX
 DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 178.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

```
XX DE extendin agonist peptide SEQ ID NO 173.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX SQ Sequence 35 AA;
XX AAB11265 Length: 35 February 4, 2005 13:32 Type: P Check: 7002 ..
XX Found using 'seq5' (mohamed337.key)
1 HGAGTFTSLSKQLEEEAVRLFIEFLKNGPSSGA
  1 -----|-----|
  28
-----|-----|
1 match found in sequence:
aabl1266 ; extendin agonist peptide SEQ ID NO 174.
(from "seq5ags.pep")
TOIG of: aabl1266 check: 5154 from: 1 to: 34
ID AAB11266 standard; peptide; 34 AA.
XX AC AAB11266;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 174.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
```

```
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 183; Page 231; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 34 AA;
XX AAB11266 Length: 34 February 4, 2005 13:32 Type: P Check: 5154 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEATFTSLSKQLEEEAVRLFIEFLKNGPSSG
  1 -----|-----|
  28
-----|-----|
1 match found in sequence:
aabl1267 ; extendin agonist peptide SEQ ID NO 175.
(from "seq5ags.pep")
TOIG of: aabl1267 check: 3230 from: 1 to: 33
ID AAB11267 standard; peptide; 33 AA.
XX AC AAB11267;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 175.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 184; Page 232; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
```

```

XX PS Example 179; Page 228; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 36 AA;
XX SQ

AAB11262 Length: 36 February 4, 2005 13:32 Type: P Check: 306 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSALSKQEEAEVRLFIWLNKGGPSSGA
  1 28
-----
1 match found in sequence:
aabl1263; extendin agonist peptide SEQ ID NO 171.
(from "seq5ags.pep")
TOIG of: aabl1263 check: 9777 from: 1 to: 36

ID AAB11263 standard; peptide; 36 AA.
XX AC
XX AC AAB11263;
XX DT
XX DT 20-FEB-2001 (first entry)
XX DE
XX DE extendin agonist peptide SEQ ID NO 171.
XX KW
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS
XX OS Synthetic.
XX PN
XX PN WO200041546-A2.
XX PD
XX PD 20-JUL-2000.
XX PF
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI
XX PI Young A, L'italien JJ, Kolterman O;
XX DR
XX DR WPI; 2000-514584/46.
XX CC
XX CC New formulations comprising an extendin or extendin agonist peptide used
XX CC for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX PS Example 180; Page 229; 281pp; English.
XX CC
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 36 AA;
XX SQ

AAB11263 Length: 36 February 4, 2005 13:32 Type: P Check: 9777 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSALSKQEEAEVRLFIWLNKGGPSSGA
  1 28
-----
1 match found in sequence:
aabl1263; extendin agonist peptide SEQ ID NO 171.
(from "seq5ags.pep")
TOIG of: aabl1263 check: 9777 from: 1 to: 36

ID AAB11263 standard; peptide; 36 AA.
XX AC
XX AC AAB11263;
XX DT
XX DT 20-FEB-2001 (first entry)
XX DE
XX DE extendin agonist peptide SEQ ID NO 171.
XX KW
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS
XX OS Synthetic.
XX PN
XX PN WO200041546-A2.
XX PD
XX PD 20-JUL-2000.
XX PF
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI
XX PI Young A, L'italien JJ, Kolterman O;
XX DR
XX DR WPI; 2000-514584/46.
XX CC
XX CC New formulations comprising an extendin or extendin agonist peptide used
XX CC for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX PS Example 180; Page 229; 281pp; English.
XX CC
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 36 AA;
XX SQ

AAB11263 Length: 36 February 4, 2005 13:32 Type: P Check: 9777 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSALSKQEEAEVRLFIWLNKGGPSSGA
  1 28
-----
1 match found in sequence:
aabl1263; extendin agonist peptide SEQ ID NO 171.
(from "seq5ags.pep")
TOIG of: aabl1263 check: 7002 from: 1 to: 35

ID AAB11265 standard; peptide; 35 AA.
XX AC
XX AC AAB11265;
XX DT
XX DT 20-FEB-2001 (first entry)

```

```

1 AEGTFTSDASKQLEEEAEVRLFIWLNKGGPSSGA
  1 28
-----
1 match found in sequence:
aabl1264; extendin agonist peptide SEQ ID NO 172.
(from "seq5ags.pep")
TOIG of: aabl1264 check: 7446 from: 1 to: 35

ID AAB11264 standard; peptide; 35 AA.
XX AC
XX AC AAB11264;
XX DT
XX DT 20-FEB-2001 (first entry)
XX DE
XX DE extendin agonist peptide SEQ ID NO 172.
XX KW
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS
XX OS Synthetic.
XX PN
XX PN WO200041546-A2.
XX PD
XX PD 20-JUL-2000.
XX PF
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI
XX PI Young A, L'italien JJ, Kolterman O;
XX DR
XX DR WPI; 2000-514584/46.
XX CC
XX CC New formulations comprising an extendin or extendin agonist peptide used
XX CC for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX PS Example 181; Page 229-230; 281pp; English.
XX CC
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 35 AA;
XX SQ

AAB11264 Length: 35 February 4, 2005 13:32 Type: P Check: 7446 ..
Found using 'seq5' (mohamed337.key)

1 AEGTFTSDLSKQEEAEVRLFIWLNKGGPSSGA
  1 28
-----
1 match found in sequence:
aabl1265; extendin agonist peptide SEQ ID NO 173.
(from "seq5ags.pep")
TOIG of: aabl1265 check: 7002 from: 1 to: 35

ID AAB11265 standard; peptide; 35 AA.
XX AC
XX AC AAB11265;
XX DT
XX DT 20-FEB-2001 (first entry)

```

```

TOIG of: aab11260 check: 5882 from: 1 to: 38
ID AAB11260 standard; peptide; 38 AA.
XX
AC AAB11260;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 168.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 177; Page 226-227; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
which would benefit from agents that delay and/or slow gastric emptying
or reducing food intake
XX
SQ Sequence 38 AA;
AAB11260 Length: 38 February 4, 2005 13:32 Type: P Check: 5882 ..
Found using 'seq5' (mohamed337.key)
1 HGAGTFTSLSKQLEEEAVRLFTEFLKNGGPGSGAPPP
1
-----|-----|
1 match found in sequence:
aab11261; extendin agonist peptide SEQ ID NO 169.
(from "seq5ags.pep")
TOIG of: aab11261 check: 3269 from: 1 to: 37
ID AAB11261 standard; peptide; 37 AA.
XX
AC AAB11261;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 169.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 177; Page 226-227; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
which would benefit from agents that delay and/or slow gastric emptying
or reducing food intake
XX
SQ Sequence 37 AA;
AAB11261 Length: 37 February 4, 2005 13:32 Type: P Check: 3269 ..
Found using 'seq5' (mohamed337.key)
1 HGAGTFTSLSKQLEEEAVRLFTEFLKNGGPGSGAPP
1
-----|-----|
1 match found in sequence:
aab11262; extendin agonist peptide SEQ ID NO 170.
(from "seq5ags.pep")
TOIG of: aab11262 check: 306 from: 1 to: 36
ID AAB11262 standard; peptide; 36 AA.
XX
AC AAB11262;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 170.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.

```


XX Young A, L'italien JJ, Kolterman O;
 XX WPI; 2000-514584/46.
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 174; Page 224; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 28 AA;
 SQ
 AAB11257 Length: 28 February 4, 2005 13:32 Type: P Check: 326 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDLSKQMEEEAVRLFIEFLKA 28
 1 match found in sequence:
 aab11258 ; extendin agonist peptide SEQ ID NO 166.
 (from "seq5ags.pep")
 TOIG of: aab11258 check: 9887 from: 1 to: 28
 ID AAB11258 standard; peptide; 28 AA.
 XX
 AC AAB11258;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 166.
 XX
 XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.
 XX
 PN WO200041546-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 XX
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, L'italien JJ, Kolterman O;
 XX
 WPI; 2000-514584/46.
 XX
 PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 175; Page 225; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders

CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 28 AA;
 SQ
 AAB11258 Length: 28 February 4, 2005 13:32 Type: P Check: 9887 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDLSKQLEEEAVRLFIEFLKA 28
 1 match found in sequence:
 aab11259 ; extendin agonist peptide SEQ ID NO 167.
 (from "seq5ags.pep")
 TOIG of: aab11259 check: 6326 from: 1 to: 38
 ID AAB11259 standard; peptide; 38 AA.
 XX
 AC AAB11259;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 167.
 XX
 XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.
 XX
 PN WO200041546-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 XX
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, L'italien JJ, Kolterman O;
 XX
 WPI; 2000-514584/46.
 XX
 PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 176; Page 226; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 38 AA;
 SQ
 AAB11259 Length: 38 February 4, 2005 13:32 Type: P Check: 6326 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDLSKQMEEEAVRLFIEWLKNGSPSGAPPP 28
 1 match found in sequence:
 aab11260 ; extendin agonist peptide SEQ ID NO 168.
 (from "seq5ags.pep")

XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
XX
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 169; Page 220; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
SQ
AAB11252 Length: 28 February 4, 2005 13:32 Type: P Check: 126 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTDLSKQEEAVRLFIEWAKN 28

1 match found in sequence:
aabl1253; exendin agonist peptide SEQ ID NO 161.
(from "seq5ags.pep")
TOIG of: aabl1253 check: 404 from: 1 to: 28
ID AAB11253 standard; peptide; 28 AA.
XX
XX AAB11253;
AC
XX 20-FEB-2001 (first entry)
DT
XX exendin agonist peptide SEQ ID NO 161.
DE
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO200041546-A2.
PN
XX 20-JUL-2000.
PD
XX 14-JAN-2000; 2000WO-US000902.
PF
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 170; Page 221; 281pp; English.
PS

XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
SQ
AAB11253 Length: 28 February 4, 2005 13:32 Type: P Check: 404 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTDLSKQEEAVRLFIEWAKN 28

1 match found in sequence:
aabl1254; exendin agonist peptide SEQ ID NO 162.
(from "seq5ags.pep")
TOIG of: aabl1254 check: 9965 from: 1 to: 28
ID AAB11254 standard; peptide; 28 AA.
XX
XX AAB11254;
AC
XX 20-FEB-2001 (first entry)
DT
XX exendin agonist peptide SEQ ID NO 162.
DE
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO200041546-A2.
PN
XX 20-JUL-2000.
PD
XX 14-JAN-2000; 2000WO-US000902.
PF
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 171; Page 222; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
SQ
AAB11254 Length: 28 February 4, 2005 13:32 Type: P Check: 9965 ..
Found using 'seq5' (mohamed337.key)


```
XX      SQ      Sequence 28 AA;
AAB11249 Length: 28 February 4, 2005 13:32 Type: P Check: 666
Found using 'seq5' (mohamed337.key)

1      |-----|
      1 AGDGTFTSLSKQMEEEAVRLFIDFLKN 28
      -----
1 match found in sequence:
aabl1250 ; extendin agonist peptide SEQ ID NO 158.
(from "seq5ags.pep")
TOIG of: aabl1250 check: 227 from: 1 to: 28

ID AAB11250 standard; peptide; 28 AA.
XX
AC AAB11250;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 158.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 167; Page 219; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ      Sequence 28 AA;
AAB11250 Length: 28 February 4, 2005 13:32 Type: P Check: 227
Found using 'seq5' (mohamed337.key)

1      |-----|
      1 AGDGTFTSLSKQLEEEAVRLFIDFLKN 28
      -----
1 match found in sequence:
aabl1251 ; extendin agonist peptide SEQ ID NO 159.
(from "seq5ags.pep")
TOIG of: aabl1251 check: 140 from: 1 to: 28
```

```
ID AAB11251 standard; peptide; 28 AA.
XX
AC AAB11251;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 159.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 168; Page 220; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ      Sequence 28 AA;
AAB11251 Length: 28 February 4, 2005 13:32 Type: P Check: 140
Found using 'seq5' (mohamed337.key)

1      |-----|
      1 AGDGTFTSLSKQMEEEAVRLFIEALKN 28
      -----
1 match found in sequence:
aabl1252 ; extendin agonist peptide SEQ ID NO 160.
(from "seq5ags.pep")
TOIG of: aabl1252 check: 126 from: 1 to: 28

ID AAB11252 standard; peptide; 28 AA.
XX
AC AAB11252;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 160.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
```

KW plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 164; Page 217; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX
XX SQ Sequence 28 AA;

AAB11247 Length: 28 February 4, 2005 13:32 Type: P Check: 644 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEBEAVRLFGWELKN 28
|-----|
1

1 match found in sequence:
aabl1248 ; extendin agonist peptide SEQ ID NO 156.
(from "seq5ags.pep")
TOIG of: aabl1248 check: 205 from: 1 to: 28

ID AAB11248 standard; peptide; 28 AA.
XX
XX AC AAB11248;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 156.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 164; Page 217; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX
XX SQ Sequence 28 AA;

AAB11247 Length: 28 February 4, 2005 13:32 Type: P Check: 644 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEBEAVRLFGWELKN 28
|-----|
1

1 match found in sequence:
aabl1248 ; extendin agonist peptide SEQ ID NO 156.
(from "seq5ags.pep")
TOIG of: aabl1248 check: 205 from: 1 to: 28

ID AAB11248 standard; peptide; 28 AA.
XX
XX AC AAB11248;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 156.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 165; Page 217; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX
XX SQ Sequence 28 AA;

AAB11248 Length: 28 February 4, 2005 13:32 Type: P Check: 205 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEBEAVRLFGWELKN 28
|-----|
1

1 match found in sequence:
aabl1249 ; extendin agonist peptide SEQ ID NO 157.
(from "seq5ags.pep")
TOIG of: aabl1249 check: 666 from: 1 to: 28

ID AAB11249 standard; peptide; 28 AA.
XX
XX AC AAB11249;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 157.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 166; Page 218; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11244 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGDGTFTSLSKQLEEEAVRLAIEFLKN 28

1 match found in sequence:
aabl1245 ; extendin agonist peptide SEQ ID NO 153.
(from "seq5ags.pep")
TOIG of: aabl1245 check: 989 from: 1 to: 28

ID AAB11245 standard; peptide; 28 AA.

XX AAB11245;

XX 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 153.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO2000041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 162; Page 215; 281pp; English.

CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11245 Length: 28 February 4, 2005 13:32 Type: P Check: 989 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGDGTFTSLSKQMEAEVRLFVFLKN 28

1 match found in sequence:
aabl1246 ; extendin agonist peptide SEQ ID NO 154.
(from "seq5ags.pep")
TOIG of: aabl1246 check: 550 from: 1 to: 28

ID AAB11246 standard; peptide; 28 AA.

XX AAB11246;

XX 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 154.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO2000041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 163; Page 216; 281pp; English.

CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11246 Length: 28 February 4, 2005 13:32 Type: P Check: 550 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGDGTFTSLSKQLEEEAVRLFVFLKN 28

1 match found in sequence:
aabl1247 ; extendin agonist peptide SEQ ID NO 155.
(from "seq5ags.pep")
TOIG of: aabl1247 check: 644 from: 1 to: 28

ID AAB11247 standard; peptide; 28 AA.

XX AAB11247;

XX 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 155.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;

AC AAB11242;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 150.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
DR New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 159; Page 213; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;
AAB11242 Length: 28 February 4, 2005 13:32 Type: P Check: 20 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRAFIETFLKN 28
1

1 match found in sequence:
aab11243 : extendin agonist peptide SEQ ID NO 151.
(from "seq5ags.pep")
TOIG of: aab11243 check: 580 from: 1 to: 28
ID AAB11243 standard; peptide; 28 AA.
XX
AC AAB11243;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 151.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX

XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
DR
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 160; Page 213; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;
AAB11243 Length: 28 February 4, 2005 13:32 Type: P Check: 580 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRAFIETFLKN 28
1

1 match found in sequence:
aab11244 : extendin agonist peptide SEQ ID NO 152.
(from "seq5ags.pep")
TOIG of: aab11244 check: 141 from: 1 to: 28
ID AAB11244 standard; peptide; 28 AA.
XX
AC AAB11244;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 152.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
DR
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 161; Page 214; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or

```

XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 156; Page 210; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11239 Length: 28 February 4, 2005 13:32 Type: P Check: 350 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVALFIEFLKN 28
-----
1 match found in sequence:
aabl1240 ; extendin agonist peptide SEQ ID NO 148.
(from "seq5ags.pep")
TOIG of: aabl1240 check: 9911 from: 1 to: 28

ID AAB11240 standard; peptide; 28 AA.
XX
AC AAB11240;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 148.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 157; Page 211; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11240 Length: 28 February 4, 2005 13:32 Type: P Check: 459 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVALFIEFLKN 28
-----
1 match found in sequence:
aabl1242 ; extendin agonist peptide SEQ ID NO 150.
(from "seq5ags.pep")
TOIG of: aabl1242 check: 20 from: 1 to: 28

ID AAB11242 standard; peptide; 28 AA.
XX

```

```

AAB11240 Length: 28 February 4, 2005 13:32 Type: P Check: 9911 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVALFIEFLKN 28
-----
1 match found in sequence:
aabl1241 ; extendin agonist peptide SEQ ID NO 149.
(from "seq5ags.pep")
TOIG of: aabl1241 check: 459 from: 1 to: 28

ID AAB11241 standard; peptide; 28 AA.
XX
AC AAB11241;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 149.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 158; Page 212; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11241 Length: 28 February 4, 2005 13:32 Type: P Check: 459 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVALFIEFLKN 28
-----
1 match found in sequence:
aabl1242 ; extendin agonist peptide SEQ ID NO 150.
(from "seq5ags.pep")
TOIG of: aabl1242 check: 20 from: 1 to: 28

ID AAB11242 standard; peptide; 28 AA.
XX

```



```
1 match found in sequence:
aab11237 ; extendin agonist peptide SEQ ID NO 145.
(from "seq5ags.pep")
TOIG of: aab11237 check: 291 from: 1 to: 28

ID AAB11237 standard; peptide; 28 AA.
XX
AC AAB11237;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 145.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 154; Page 209; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11237 Length: 28 February 4, 2005 13:32 Type: P Check: 291 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMEEEAARLFIEWLKN 28
|-----|
1 match found in sequence:
aab11237 ; extendin agonist peptide SEQ ID NO 146.
(from "seq5ags.pep")
TOIG of: aab11237 check: 9852 from: 1 to: 28

ID AAB11238 standard; peptide; 28 AA.
XX
XX AAB11238;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 146.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 154; Page 209; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11237 Length: 28 February 4, 2005 13:32 Type: P Check: 291 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMEEEAARLFIEWLKN 28
|-----|
1 match found in sequence:
aab11239 ; extendin agonist peptide SEQ ID NO 147.
(from "seq5ags.pep")
TOIG of: aab11239 check: 350 from: 1 to: 28

ID AAB11239 standard; peptide; 28 AA.
XX
XX AAB11239;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 147.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
```


Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMAEAVRLFIEWLK 28
1

1 match found in sequence:
aabl1232 ; extendin agonist peptide SEQ ID NO 140.
(from "seq5ags.pep")
TOIG of: aabl1232 check: 191 from: 1 to: 28

ID AAB11232 standard; peptide; 28 AA.

XX

AC

XX

DT 20-FEB-2001 (first entry)

XX

DE extendin agonist peptide SEQ ID NO 140.

XX

KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;

KW plasma glucose; gastric emptying; food intake.

XX

OS Synthetic.

XX

PN WO200041546-A2.

XX

PD 20-JUL-2000.

XX

PF 14-JAN-2000; 2000WO-US000902.

XX

PR 14-JAN-1999; 99US-0116380P.

XX

PR 10-JAN-2000; 2000US-0175365P.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Young A, L'italien JJ, Kolterman O;

XX

DR WPI; 2000-514584/46.

XX

PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX

PS Example 149; Page 205; 281pp; English.

XX

CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake

XX

SQ Sequence 28 AA;

AAB11232 Length: 28 February 4, 2005 13:32 Type: P Check: 191

Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMAEAVRLFIEWLK 28
1

1 match found in sequence:
aabl1233 ; extendin agonist peptide SEQ ID NO 141.
(from "seq5ags.pep")
TOIG of: aabl1233 check: 626 from: 1 to: 28

ID AAB11233 standard; peptide; 28 AA.

XX

AC

XX

DT 20-FEB-2001 (first entry)

XX

DE

XX

XX extendin agonist peptide SEQ ID NO 141.

KW

XX

KW

XX

XX

OS

XX

XX

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11226 Length: 28 February 4, 2005 13:32 Type: P Check: 43 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKALBEEAVRLFIEFLKN 28
 -----|

1 match found in sequence:
 aab11227; extendin agonist peptide SEQ ID NO 135.
 (from "seq5ags.pep")
 TOIG of: aab11227 check: 522 from: 1 to: 28

ID AAB11227 standard; peptide; 28 AA.

XX AAB11227;
 AC
 XX
 DT 20-FEB-2001 (first entry)
 XX

extendin agonist peptide SEQ ID NO 135.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 144; Page. 201; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11227 Length: 28 February 4, 2005 13:32 Type: P Check: 522 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKALBEEAVRLFIEFLKN 28
 -----|

1 match found in sequence:
 aab11228; extendin agonist peptide SEQ ID NO 136.

(from "seq5ags.pep")
 TOIG of: aab11228 check: 97 from: 1 to: 28

ID AAB11228 standard; peptide; 28 AA.

XX AAB11228;

XX 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 136.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 145; Page 202; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11228 Length: 28 February 4, 2005 13:32 Type: P Check: 97 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKALBEEAVRLFIEFLKN 28
 -----|

1 match found in sequence:
 aab11229; extendin agonist peptide SEQ ID NO 137.
 (from "seq5ags.pep")
 TOIG of: aab11229 check: 606 from: 1 to: 28

ID AAB11229 standard; peptide; 28 AA.

XX AAB11229;

XX 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 137.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

DE extendin agonist peptide SEQ ID NO 132.
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 141; Page 199; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 28 AA;
SQ
AAB11224 Length: 28 February 4, 2005 13:32 Type: P Check: 131 ..
Found using 'seqs' (mohamed337.key)
1 AGDGTFTSDLSAQLEEAVALRFLFIEWLNK 28
-----|
1 match found in sequence:
aabl1225 ; extendin agonist peptide SEQ ID NO 133.
(from "seq5ags.pep")
TOIG of: aabl1225 check: 482 from: 1 to: 28
ID AAB11225 standard; peptide; 28 AA.
XX
XX AC AAB11225;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 133.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 141; Page 199; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 28 AA;
SQ
AAB11225 Length: 28 February 4, 2005 13:32 Type: P Check: 482 ..
Found using 'seqs' (mohamed337.key)
1 AGDGTFTSDLSKAMEEAAVRLFIWLNK 28
-----|
1 match found in sequence:
aabl1226 ; extendin agonist peptide SEQ ID NO 134.
(from "seq5ags.pep")
TOIG of: aabl1226 check: 43 from: 1 to: 28
ID AAB11226 standard; peptide; 28 AA.
XX
XX AC AAB11226;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 134.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 143; Page 200; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which

PA (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 142; Page 200; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
CC
XX Sequence 28 AA;
SQ
AAB11225 Length: 28 February 4, 2005 13:32 Type: P Check: 482 ..
Found using 'seqs' (mohamed337.key)
1 AGDGTFTSDLSKAMEEAAVRLFIWLNK 28
-----|
1 match found in sequence:
aabl1226 ; extendin agonist peptide SEQ ID NO 134.
(from "seq5ags.pep")
TOIG of: aabl1226 check: 43 from: 1 to: 28
ID AAB11226 standard; peptide; 28 AA.
XX
XX AC AAB11226;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 134.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 143; Page 200; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which

```

PS Example 138; Page 197; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11221 Length: 28 February 4, 2005 13:32 Type: P Check: 492 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSLAKQMEEEAVRLFIEFLKN 28
  -----
  1 match found in sequence:
  aab11222 ; extendin agonist peptide SEQ ID NO 130.
  (from "seq5ags.pep")
  TOIG of: aab11222 check: 53 from: 1 to: 28

ID AAB11222 standard; peptide; 28 AA.
XX
AC AAB11222;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 130.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 140; Page 198; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11223 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSLAKQMEEEAVRLFIEFLKN 28
  -----
  1 match found in sequence:
  aab11224 ; extendin agonist peptide SEQ ID NO 132.
  (from "seq5ags.pep")
  TOIG of: aab11224 check: 131 from: 1 to: 28

ID AAB11224 standard; peptide; 28 AA.
XX
AC AAB11224;
XX
DT 20-FEB-2001 (first entry)
XX

```

```

ID AAB11219 standard; peptide; 28 AA.
AC AAB11219;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 127.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
FN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
FA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
WPI; 2000-514584/46.
XX
XX
New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
Example 136; Page 195; 281pp; English.
XX
XX
This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
which would benefit from agents that delay and/or slow gastric emptying
or reducing food intake
XX
XX
Sequence 28 AA;
XX
AAB11219 Length: 28 February 4, 2005 13:32 Type: P Check: 640 ..
Found using 'seq5' (mohamed337.key)
XX
XX
1 AGDGTFTSDGSKQMEEEAVRLFIEWLKN 28
|-----|
1 match found in sequence:
aabl1220; extendin agonist peptide SEQ ID NO 128.
(from "seq5ags.pep")
TOIG of: aabl1220 check: 201 from: 1 to: 28
ID AAB11220 standard; peptide; 28 AA.
XX
XX
AC AAB11220;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 128.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
FN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
FA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
WPI; 2000-514584/46.
XX
XX
New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
Example 136; Page 195; 281pp; English.
XX
XX
This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
which would benefit from agents that delay and/or slow gastric emptying
or reducing food intake
XX
XX
Sequence 28 AA;
XX
AAB11219 Length: 28 February 4, 2005 13:32 Type: P Check: 640 ..
Found using 'seq5' (mohamed337.key)
XX
XX
1 AGDGTFTSDGSKQMEEEAVRLFIEWLKN 28
|-----|
1 match found in sequence:
aabl1220; extendin agonist peptide SEQ ID NO 128.
(from "seq5ags.pep")
TOIG of: aabl1220 check: 201 from: 1 to: 28
ID AAB11220 standard; peptide; 28 AA.
XX
XX
AC AAB11220;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 128.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
FN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
FA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
WPI; 2000-514584/46.
XX
XX
New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
Example 136; Page 195; 281pp; English.
XX
XX
This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
which would benefit from agents that delay and/or slow gastric emptying
or reducing food intake
XX
XX
Sequence 28 AA;
XX
AAB11219 Length: 28 February 4, 2005 13:32 Type: P Check: 640 ..
Found using 'seq5' (mohamed337.key)
XX
XX
1 AGDGTFTSDGSKQMEEEAVRLFIEWLKN 28
|-----|
1 match found in sequence:
aabl1220; extendin agonist peptide SEQ ID NO 128.
(from "seq5ags.pep")
TOIG of: aabl1220 check: 201 from: 1 to: 28
ID AAB11220 standard; peptide; 28 AA.
XX
XX
AC AAB11221;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 129.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
FN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
FA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
WPI; 2000-514584/46.
XX
XX
New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
Example 137; Page 196; 281pp; English.
XX
XX
This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
which would benefit from agents that delay and/or slow gastric emptying
or reducing food intake
XX
XX
Sequence 28 AA;
XX
AAB11220 Length: 28 February 4, 2005 13:32 Type: P Check: 201 ..
Found using 'seq5' (mohamed337.key)
XX
XX
1 AGDGTFTSDGSKQMEEEAVRLFIEWLKN 28
|-----|
1 match found in sequence:
aabl1221; extendin agonist peptide SEQ ID NO 129.
(from "seq5ags.pep")
TOIG of: aabl1221 check: 492 from: 1 to: 28
ID AAB11221 standard; peptide; 28 AA.
XX
XX
AC AAB11221;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 129.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
FN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
FA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
WPI; 2000-514584/46.
XX
XX
New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.

```


PI Young A, L'italien JJ, Kolterman O;
 XX WPI; 2000-514584/46.
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 133; Page 193; 281pp; English.
 XX
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 XX Sequence 28 AA;
 SQ
 AAB11216 Length: 28 February 4, 2005 13:32 Type: P Check: 260 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSELSKQLEEEAVRLFIEFLKN 28
 |-----|
 1

 1 match found in sequence:
 aab11217; extendin agonist peptide SEQ ID NO 125.
 (from "seq5ags.pep")
 TOIG of: aab11217 check: 580 from: 1 to: 28
 ID AAB11217 standard; peptide; 28 AA.
 XX
 XX AAB11217;
 AC
 XX 20-FEB-2001 (first entry)
 DT
 XX extendin agonist peptide SEQ ID NO 125.
 DE
 XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 KW
 XX Synthetic.
 OS
 XX WO200041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI
 XX WPI; 2000-514584/46.
 DR
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PT
 XX Example 134; Page 193; 281pp; English.
 PS
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying

CC or reducing food intake
 XX
 XX Sequence 28 AA;
 SQ
 AAB11217 Length: 28 February 4, 2005 13:32 Type: P Check: 580 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDASKQMEEEAVRLFIEFLKN 28
 |-----|
 1

 1 match found in sequence:
 aab11218; extendin agonist peptide SEQ ID NO 126.
 (from "seq5ags.pep")
 TOIG of: aab11218 check: 141 from: 1 to: 28
 ID AAB11218 standard; peptide; 28 AA.
 XX
 XX AAB11218;
 AC
 XX 20-FEB-2001 (first entry)
 DT
 XX extendin agonist peptide SEQ ID NO 126.
 DE
 XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 KW
 XX Synthetic.
 OS
 XX WO200041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI
 XX WPI; 2000-514584/46.
 DR
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PT
 XX Example 135; Page 194; 281pp; English.
 PS
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 XX Sequence 28 AA;
 SQ
 AAB11218 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDASKQLEEEAVRLFIEFLKN 28
 |-----|
 1

 1 match found in sequence:
 aab11219; extendin agonist peptide SEQ ID NO 127.
 (from "seq5ags.pep")
 TOIG of: aab11219 check: 640 from: 1 to: 28

```
-----
1
1 match found in sequence:
aabl1214 ; extendin agonist peptide SEQ ID NO 122.
(from "seq5ags.pep")
TOIG of: aabl1214 check: 224 from: 1 to: 28

ID AAB11214 standard; peptide; 28 AA.
XX
AC AAB11214;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 122.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 131; Page 191; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11215 Length: 28 February 4, 2005 13:32 Type: P Check: 699
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQEEEAARLFIWLNK 28
1
-----
1 match found in sequence:
aabl1215 ; extendin agonist peptide SEQ ID NO 123.
(from "seq5ags.pep")
TOIG of: aabl1215 check: 699 from: 1 to: 28

ID AAB11215 standard; peptide; 28 AA.
XX
AC AAB11215;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 123.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 131; Page 191; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11216 Length: 28 February 4, 2005 13:32 Type: P Check: 224
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQEEEAARLFIWLNK 28
1
-----
1 match found in sequence:
aabl1216 ; extendin agonist peptide SEQ ID NO 124.
(from "seq5ags.pep")
TOIG of: aabl1216 check: 260 from: 1 to: 28

ID AAB11216 standard; peptide; 28 AA.
XX
AC AAB11216;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 124.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
```



```

SQ Sequence 28 AA;
AAB11208 Length: 28 February 4, 2005 13:32 Type: P Check: 221 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 AGDGTATSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1209; extendin agonist peptide SEQ ID NO 117.
(from "seq5ags.pep")
TOIG of: aabl1209 check: 683 from: 1 to: 28

ID AAB11209 standard; peptide; 28 AA.
XX AC AAB11209;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 117.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX WI WI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 126; Page 187; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 28 AA;
AAB11209 Length: 28 February 4, 2005 13:32 Type: P Check: 683 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 AGDGTATSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1210; extendin agonist peptide SEQ ID NO 118.
(from "seq5ags.pep")
TOIG of: aabl1210 check: 244 from: 1 to: 28

ID AAB11210 standard; peptide; 28 AA.
XX AC AAB11210;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 119.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX WI WI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 127; Page 188; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 28 AA;
AAB11210 Length: 28 February 4, 2005 13:32 Type: P Check: 244 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 AGDGTATSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1211; extendin agonist peptide SEQ ID NO 119.
(from "seq5ags.pep")
TOIG of: aabl1211 check: 546 from: 1 to: 28

ID AAB11211 standard; peptide; 28 AA.
XX AC AAB11211;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 119.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX WI WI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 126; Page 187; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 28 AA;
AAB11209 Length: 28 February 4, 2005 13:32 Type: P Check: 683 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 AGDGTATSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1210; extendin agonist peptide SEQ ID NO 118.
(from "seq5ags.pep")
TOIG of: aabl1210 check: 244 from: 1 to: 28

ID AAB11210 standard; peptide; 28 AA.
```

```
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 123; Page 185; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 28 AA;
AAB11206 Length: 28 February 4, 2005 13:32 Type: P Check: 156
Found using 'seq5' (mohamed337.key)
1 AGDGTATSDLSKQMEERAVRLFIEWLKN 28
1
-----
1 match found in sequence:
aabl1207; exendin agonist peptide SEQ ID NO 115.
(from "seq5ags.pep")
TOIG of: aabl1207 check: 660 from: 1 to: 28
ID AAB11207 standard; peptide; 28 AA.
XX AC AAB11207;
XX DT 20-FEB-2001 (first entry)
XX DE exendin agonist peptide SEQ ID NO 115.
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX XX WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 123; Page 185; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 28 AA;
AAB11207 Length: 28 February 4, 2005 13:32 Type: P Check: 660
Found using 'seq5' (mohamed337.key)
1 AGDGTATSDLSKQMEERAVRLFIEWLKN 28
1
-----
1 match found in sequence:
aabl1207; exendin agonist peptide SEQ ID NO 116.
(from "seq5ags.pep")
TOIG of: aabl1207 check: 660 from: 1 to: 28
ID AAB11208 standard; peptide; 28 AA.
XX AC AAB11208;
XX DT 20-FEB-2001 (first entry)
XX DE exendin agonist peptide SEQ ID NO 116.
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX XX WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 125; Page 186-187; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
```

```
DR WPI; 2000-514584/46.
XX New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 124; Page 186; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 28 AA;
AAB11207 Length: 28 February 4, 2005 13:32 Type: P Check: 660
Found using 'seq5' (mohamed337.key)
1 AGDGTATSDLSKQMEERAVRLFIEWLKN 28
1
-----
1 match found in sequence:
aabl1208; exendin agonist peptide SEQ ID NO 116.
(from "seq5ags.pep")
TOIG of: aabl1208 check: 221 from: 1 to: 28
ID AAB11208 standard; peptide; 28 AA.
XX AC AAB11208;
XX DT 20-FEB-2001 (first entry)
XX DE exendin agonist peptide SEQ ID NO 116.
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX XX WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 125; Page 186-187; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
```

CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX
 SQ Sequence 28 AA;

AAB11203 Length: 28 February 4, 2005 13:32 Type: P Check: 590 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDLSKQEEAEVRLFIWLKN 28

1 match found in sequence:
 aab11204 ; extendin agonist peptide SEQ ID NO 112.
 (from "seq5ags.pep")
 TOIG of: aab11204 check: 251 from: 1 to: 28

ID AAB11204 standard; peptide; 28 AA.

XX AC AAB11204;

XX DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 112.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US0000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 121; Page 183; 281pp; English.

CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX
 SQ Sequence 28 AA;

AAB11204 Length: 28 February 4, 2005 13:32 Type: P Check: 251 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDLSKQEEAEVRLFIWLKN 28

 1 match found in sequence:
 aab11205 ; extendin agonist peptide SEQ ID NO 113.
 (from "seq5ags.pep")
 TOIG of: aab11205 check: 595 from: 1 to: 28

ID AAB11205 standard; peptide; 28 AA.

XX AC AAB11205;

XX DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 113.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US0000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 122; Page 184; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX
 SQ Sequence 28 AA;

AAB11205 Length: 28 February 4, 2005 13:32 Type: P Check: 595 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDLSKQEEAEVRLFIWLKN 28

1 match found in sequence:
 aab11206 ; extendin agonist peptide SEQ ID NO 114.
 (from "seq5ags.pep")
 TOIG of: aab11206 check: 156 from: 1 to: 28

ID AAB11206 standard; peptide; 28 AA.

XX AC AAB11206;

XX DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 114.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

```
XX 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 109.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 118; Page 181; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX Sequence 28 AA;
XX
AAB11201 Length: 28 February 4, 2005 13:32 Type: P Check: 681
Found using 'seq5' (mohamed337.key)
1 -----|
1 AAGTFTSLSKQMEEEAVRLFIETLKN 28
1
-----|
1 match found in sequence:
aabl1202; extendin agonist peptide SEQ ID NO 110.
(from "seq5ags.pep")
TOIG of: aabl1202 check: 242 from: 1 to: 28
ID AAB11202 standard; peptide; 28 AA.
XX
XX AAB11202;
XX
XX 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 110.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 118; Page 181; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX Sequence 28 AA;
XX
AAB11201 Length: 28 February 4, 2005 13:32 Type: P Check: 681
Found using 'seq5' (mohamed337.key)
1 -----|
1 AAGTFTSLSKQMEEEAVRLFIETLKN 28
1
-----|
1 match found in sequence:
aabl1202; extendin agonist peptide SEQ ID NO 110.
(from "seq5ags.pep")
TOIG of: aabl1202 check: 242 from: 1 to: 28
ID AAB11202 standard; peptide; 28 AA.
XX
XX AAB11202;
XX
XX 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 110.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
```

```
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 119; Page 182; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX Sequence 28 AA;
XX
AAB11202 Length: 28 February 4, 2005 13:32 Type: P Check: 242
Found using 'seq5' (mohamed337.key)
1 -----|
1 AAGTFTSLSKQLEEEAVRLFIETLKN 28
1
-----|
1 match found in sequence:
aabl1203; extendin agonist peptide SEQ ID NO 111.
(from "seq5ags.pep")
TOIG of: aabl1203 check: 590 from: 1 to: 28
ID AAB11203 standard; peptide; 28 AA.
XX
XX AAB11203;
XX
XX 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 111.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 120; Page 183; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
```

PT New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 115; Page 179; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB1198 Length: 28 February 4, 2005 13:32 Type: P Check: 676 ..
Found using 'seqs' (mohamed337.key)

1 HGEATFTSLSKQMEEEAVRLFIEWLKN 28
|-----|

1 match found in sequence:
aabl1199 ; exendin agonist peptide SEQ ID NO 107.
(from "seq5ags.pep")
TOIG of: aabl1199 check: 673 from: 1 to: 28

ID AAB1199 standard; peptide; 28 AA.

XX AAB11199;

DT 20-FEB-2001 (first entry)

XX exendin agonist peptide SEQ ID NO 107.

XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO2000041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 116; Page 180; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB1199 Length: 28 February 4, 2005 13:32 Type: P Check: 673 ..
Found using 'seqs' (mohamed337.key)

1 HGEGTFTSLSKQMEEEAVRLFIEWLKN 28
|-----|

1 match found in sequence:
aabl1200 ; exendin agonist peptide SEQ ID NO 108.
(from "seq5ags.pep")
TOIG of: aabl1200 check: 590 from: 1 to: 28

ID AAB11200 standard; peptide; 28 AA.

XX AAB11200;

DT 20-FEB-2001 (first entry)

XX exendin agonist peptide SEQ ID NO 108.

XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO2000041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 117; Page 180; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB1200 Length: 28 February 4, 2005 13:32 Type: P Check: 590 ..
Found using 'seqs' (mohamed337.key)

1 HGEGTFTSLSKQMEEEAVRLFIEWLKN 28
|-----|

1 match found in sequence:
aabl1201 ; exendin agonist peptide SEQ ID NO 109.
(from "seq5ags.pep")
TOIG of: aabl1201 check: 681 from: 1 to: 28

ID AAB11201 standard; peptide; 28 AA.

XX AAB11201;

Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.

```

XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 110; Page 175; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes, and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11193 Length: 28 February 4, 2005 13:32 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGAGTFTSLSKQLEEEAVRLFIETFLKN 28
  -----
  1 match found in sequence:
aabl1194 ; extendin agonist peptide SEQ ID NO 102.
(from "seq5ags.pep")
TOIG of: aabl1194 check: 237 from: 1 to: 28

ID AAB11194 standard; peptide; 28 AA.
XX
XX AAB11194;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 102.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX Plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 111; Page 176; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the

```

```

CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11194 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGAGTFTSLSKQLEEEAVRLFIETFLKN 28
  -----
  1 match found in sequence:
aabl1195 ; extendin agonist peptide SEQ ID NO 103.
(from "seq5ags.pep")
TOIG of: aabl1195 check: 234 from: 1 to: 28

ID AAB11195 standard; peptide; 28 AA.
XX
XX AAB11195;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 103.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX Plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 112; Page 176; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11195 Length: 28 February 4, 2005 13:32 Type: P Check: 234 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGAGTFTSLSKQLEEEAVRLFIETFLKN 28
  -----
  1 match found in sequence:

```

```

FH Key Location/Qualifiers
FT Modified-site 6
FT FT /note= "Naphthylalanine"
FT Modified-site 28
FT FT /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 82; Page 86; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
XX AAE08433 Length: 28 February 4, 2005 13:32 Type: P Check: 369 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTYSDLSKQLEEEAVRLFIEPLKN 28
-----
1 match found in sequence:
aae08434 ; Extendin agonist peptide #79.
(from "seq5ags.pep")
TOIG of: aae08434 check: 693 from: 1 to: 28
-----
ID AAE08434 standard; peptide; 28 AA.
XX AC AAE08434;
XX 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #79.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 82; Page 86; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
XX AAE08433 Length: 28 February 4, 2005 13:32 Type: P Check: 369 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTYSDLSKQLEEEAVRLFIEPLKN 28
-----
1 match found in sequence:
aae08434 ; Extendin agonist peptide #79.
(from "seq5ags.pep")
TOIG of: aae08434 check: 693 from: 1 to: 28
-----
ID AAE08434 standard; peptide; 28 AA.
XX AC AAE08434;
XX 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #79.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
```

```

XX (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 83; Page 87; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
XX AAE08434 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTFSDLSKQEEAEVRLFIEWLKN 28
-----
1 match found in sequence:
aae08435 ; Extendin agonist peptide #80.
(from "seq5ags.pep")
TOIG of: aae08435 check: 701 from: 1 to: 28
-----
ID AAE08435 standard; peptide; 28 AA.
XX AC AAE08435;
XX 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #80.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 84; Page 87; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
```

AAE08430 Length: 36 February 4, 2005 13:32 Type: P Check: 869 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEEEAVRLFIEWLKNGXSSGAX
1 28

1 match found in sequence:

aae08431 ; Exendin agonist peptide #76.
(from "seq5ags.pep")
TOIG of: aae08431 check: 7463 from: 1 to: 35

ID AAE08431 standard; peptide; 35 AA.

XX AC AAE08431;

DT 01-NOV-2001 (first entry)

DE Exendin agonist peptide #76.

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers
FT Modified-site 35
FT /note= "C-terminal amide"

XX PN WO200151078-A1.

XX XX 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

XX PS Example 80; Page 85; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX SQ Sequence 35 AA;

AAE08431 Length: 35 February 4, 2005 13:32 Type: P Check: 7463 ..
Found using 'seq5' (mohamed337.key)

1 RGGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGA
1 28

1 match found in sequence:

aae08432 ; Exendin agonist peptide #77.
(from "seq5ags.pep")
TOIG of: aae08432 check: 4886 from: 1 to: 30

ID AAE08432 standard; peptide; 30 AA.

XX AC AAE08432;

DT 01-NOV-2001 (first entry)

DE Exendin agonist peptide #77.

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"

XX PN WO200151078-A1.

XX XX 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

XX PS Example 81; Page 86; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX SQ Sequence 30 AA;

AAE08432 Length: 30 February 4, 2005 13:32 Type: P Check: 4886 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEEEAVRLFIEWLKNGG
1 28

1 match found in sequence:

aae08433 ; Exendin agonist peptide #78.
(from "seq5ags.pep")
TOIG of: aae08433 check: 369 from: 1 to: 28

ID AAE08433 standard; peptide; 28 AA.

XX AC AAE08433;

DT 01-NOV-2001 (first entry)

DE Exendin agonist peptide #78.

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

PI Kolterman OG, Young AA;
 XX WPI; 2001-514422/56.
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidemia.
 XX
 XX Example 77; Page 83; 161pp; English.
 XX
 XX The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin
 XX
 XX Sequence 37 AA;
 SQ
 AAE08428 Length: 37 February 4, 2005 13:32 Type: P Check: 1733 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSLSKQMBEEAVRLFIEWLKGSGSAAA
 1
 -----|-----|
 1 match found in sequence:
 aae08429 ; Exendin agonist peptide #74.
 (from "seq5ags.pep")
 TOIG of: aae08429 check: 4125 from: 1 to: 37
 ID AAE08429 standard; peptide; 37 AA.
 XX
 XX AAE08429;
 AC
 XX 01-NOV-2001 (first entry)
 DT
 XX Exendin agonist peptide #74.
 DE
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 KW
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 31
 FT /note= "Homoproline"
 FT Modified-site 36
 FT /note= "Homoproline"
 FT Modified-site 37
 FT /note= "Homoproline; C-terminal amide"
 FT
 XX WO200151078-A1.
 PN
 XX 19-JUL-2001.
 PD
 XX 09-JAN-2001; 2001WO-US000719.
 PF
 XX 10-JAN-2000; 2000US-0175365P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Kolterman OG, Young AA;
 PI
 XX WPI; 2001-514422/56.
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidemia.
 PT
 XX Example 78; Page 84; 161pp; English.
 PS
 XX

CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin
 XX
 XX Sequence 37 AA;
 SQ
 AAE08429 Length: 37 February 4, 2005 13:32 Type: P Check: 4125 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSLSKQMBEEAVRLFIEWLKGXSGAXX
 1
 -----|-----|
 1 match found in sequence:
 aae08430 ; Exendin agonist peptide #75.
 (from "seq5ags.pep")
 TOIG of: aae08430 check: 869 from: 1 to: 36
 ID AAE08430 standard; peptide; 36 AA.
 XX
 XX AAE08430;
 AC
 XX 01-NOV-2001 (first entry)
 DT
 XX Exendin agonist peptide #75.
 DE
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 KW
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 31
 FT /note= "Homoproline"
 FT Modified-site 36
 FT /note= "Homoproline; C-terminal amide"
 FT
 XX WO200151078-A1.
 PN
 XX 19-JUL-2001.
 PD
 XX 09-JAN-2001; 2001WO-US000719.
 PF
 XX 10-JAN-2000; 2000US-0175365P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Kolterman OG, Young AA;
 PI
 XX WPI; 2001-514422/56.
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidemia.
 PT
 XX Example 79; Page 84; 161pp; English.
 PS
 XX The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin
 XX
 XX Sequence 36 AA;
 SQ

OS	Synthetic.
XX	
XX	Key Location/Qualifiers
FH	Modified-site 36
FT	/note= "Thioprolin"
FT	Modified-site 37
FT	/note= "Thioprolin"
FT	Modified-site 38
FT	/note= "Thioproline; C-terminal amide"
XX	
XX	WO200151078-A1.
XX	
XX	PD 19-JUL-2001.
XX	
XX	PP 09-JAN-2001; 2001WO-US000719.
XX	
XX	PR 10-JAN-2000; 2000US-0175365P.
XX	
XX	(AMYL-) AMYLIN PHARM INC.
XX	
XX	Kolterman OG, Young AA;
XX	
XX	PI WPI; 2001-514422/56.
XX	
XX	DR Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.
XX	
XX	PS Example 76; Page 82; 16lpp; English.
XX	
CC	The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin
XX	
XX	SQ Sequence 38 AA;
XX	
XX	AAE08426 Length: 38 February 4, 2005 13:32 Type: P Check: 7221 ..
XX	Found using 'seq5' (mohamed337.key)
1	----- HGEGTFTSLKQMEEAVRLFIEWLKNKGSPSGAXX 1 28

1	match found in sequence: aae08427 ; Extendin agonist peptide #72. (from "seq5ags.pep") TOIG of: aae08427 check: 2828 from: 1 to: 37
ID	AAE08427 standard; peptide; 37 AA.
XX	
AC	AAE08427;
XX	
DT	01-NOV-2001 (first entry)
XX	
DE	Extendin agonist peptide #72.
XX	
XX	Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic; diuretic; coronary heart disease; dyslipidaemia.
KW	
XX	
OS	Synthetic.
XX	
XX	FH Key Location/Qualifiers
FT	Modified-site 31
FT	/note= "N-Methyl-alanine"
XX	
XX	WT 01-NOV-2001 (first entry)
XX	
DE	Extendin agonist peptide #72.
XX	
XX	Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic; diuretic; coronary heart disease; dyslipidaemia.
KW	
XX	
OS	Synthetic.
XX	
XX	FH Key Location/Qualifiers
FT	Modified-site 31
FT	/note= "N-Methyl-alanine"
XX	
FT	Modified-site 37
FT	/note= "C-terminal amide"
XX	
XX	WO200151078-A1.
XX	
XX	PD 19-JUL-2001.
XX	
XX	PP 09-JAN-2001; 2001WO-US000719.
XX	
XX	PR 10-JAN-2000; 2000US-0175365P.
XX	
XX	(AMYL-) AMYLIN PHARM INC.
XX	
XX	Kolterman OG, Young AA;
XX	
XX	PI WPI; 2001-514422/56.
XX	
XX	DR Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.
XX	
XX	PS Example 75; Page 82; 16lpp; English.
XX	
CC	The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin
XX	
XX	SQ Sequence 37 AA;
XX	
XX	AAE08427 Length: 37 February 4, 2005 13:32 Type: P Check: 2828 ..
XX	Found using 'seq5' (mohamed337.key)
1	----- HGEGTFTSLKQMEEAVRLFIEWLKNKGSSGAPP 1 28

1	match found in sequence: aae08428 ; Extendin agonist peptide #73. (from "seq5ags.pep") TOIG of: aae08428 check: 1733 from: 1 to: 37
ID	AAE08428 standard; peptide; 37 AA.
XX	
AC	AAE08428;
XX	
DT	01-NOV-2001 (first entry)
XX	
DE	Extendin agonist peptide #73.
XX	
XX	Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic; diuretic; coronary heart disease; dyslipidaemia.
KW	
XX	
OS	Synthetic.
XX	
XX	FH Key Location/Qualifiers
FT	Modified-site 31
FT	/note= "N-Methyl-alanine"
XX	
XX	WT 01-NOV-2001 (first entry)
XX	
DE	Extendin agonist peptide #73.
XX	
XX	Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic; diuretic; coronary heart disease; dyslipidaemia.
KW	
XX	
OS	Synthetic.
XX	
XX	FH Key Location/Qualifiers
FT	Modified-site 31
FT	/note= "N-Methyl-alanine"
XX	
FT	Modified-site 37
FT	/note= "C-terminal amide"
XX	
XX	WO200151078-A1.
XX	
XX	PD 19-JUL-2001.
XX	
XX	PP 09-JAN-2001; 2001WO-US000719.
XX	
XX	PR 10-JAN-2000; 2000US-0175365P.
XX	
XX	(AMYL-) AMYLIN PHARM INC.
XX	
XX	Kolterman OG, Young AA;
XX	
XX	PI WPI; 2001-514422/56.
XX	
XX	DR Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.
XX	
XX	PS Example 76; Page 82; 16lpp; English.
XX	
CC	The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin
XX	
XX	SQ Sequence 37 AA;
XX	
XX	AAE08427 Length: 37 February 4, 2005 13:32 Type: P Check: 2828 ..
XX	Found using 'seq5' (mohamed337.key)
1	----- HGEGTFTSLKQMEEAVRLFIEWLKNKGSSGAPP 1 28

1	match found in sequence: aae08428 ; Extendin agonist peptide #73. (from "seq5ags.pep") TOIG of: aae08

PA (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 70; Page 79; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 31 AA;
SQ
AAE08421 Length: 31 February 4, 2005 13:32 Type: P Check: 6930 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEFTTSDLSKQLEEAVALFIEFLKNGP 28

1 match found in sequence:
aae08422 ; Extendin agonist peptide #67.
(from "seq5ags.pep")
TOIG of: aae08422 check: 4450 from: 1 to: 30

ID AAE08422 standard; peptide; 30 AA.
XX
XX AAE08422;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #67.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 71; Page 79; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 30 AA;
SQ
AAE08422 Length: 30 February 4, 2005 13:32 Type: P Check: 4450 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEFTTSDLSKQLEEAVALFIEFLKNGG 28

1 match found in sequence:
aae08423 ; Extendin agonist peptide #68.
(from "seq5ags.pep")
TOIG of: aae08423 check: 2759 from: 1 to: 29

ID AAE08423 standard; peptide; 29 AA.
XX
XX AAE08423;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #68.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 29
FT /note= "C-terminal amide"
FT
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 72; Page 80; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 29 AA;
SQ
AAE08423 Length: 29 February 4, 2005 13:32 Type: P Check: 2759 ..
Found using 'seq5' (mohamed337.key)
1 |-----|


```
ID AAE08419 standard; peptide; 32 AA.
XX
AC AAE08419;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #64.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 32
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PP 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
PD Example 68; Page 77; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 32 AA;
AAE08419 Length: 32 February 4, 2005 13:32 Type: P Check: 9586 ..
Found using 'seq5' (mohamed337.key)
1 HGRGTFSTLSKQLEEEAVRLFIEFLKNGGPS
28
-----
1 match found in sequence:
aae08420 ; Exendin agonist peptide #65.
(from "seq5ags.pep")
TOIG of: aae08420 check: 7369 from: 1 to: 31
ID AAE08420 standard; peptide; 31 AA.
XX
AC AAE08420;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #65.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 31
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PP 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
PD Example 68; Page 77; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 32 AA;
AAE08419 Length: 32 February 4, 2005 13:32 Type: P Check: 9586 ..
Found using 'seq5' (mohamed337.key)
1 HGRGTFSTLSKQLEEEAVRLFIEFLKNGGPS
28
-----
1 match found in sequence:
aae08420 ; Exendin agonist peptide #65.
(from "seq5ags.pep")
TOIG of: aae08420 check: 7369 from: 1 to: 31
ID AAE08420 standard; peptide; 31 AA.
XX
AC AAE08420;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #65.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
```

```
XX
FH Key Location/Qualifiers
FT Modified-site 31
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PP 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
PD Example 69; Page 78; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 31 AA;
AAE08420 Length: 31 February 4, 2005 13:32 Type: P Check: 7369 ..
Found using 'seq5' (mohamed337.key)
1 HGRGTFSTLSKQMBEEAVRLFIEWLKNGGP
28
-----
1 match found in sequence:
aae08421 ; Exendin agonist peptide #66.
(from "seq5ags.pep")
TOIG of: aae08421 check: 6930 from: 1 to: 31
ID AAE08421 standard; peptide; 31 AA.
XX
AC AAE08421;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #66.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 31
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PP 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
```

```
XX PS Example 65; Page 76; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 33 AA;
AAE08416 Length: 33 February 4, 2005 13:32 Type: P Check: 2764 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRLFIETLKNKGPPS
1 28
-----
1 match found in sequence:
aae08417 ; Extendin agonist peptide #62.
(from "seq5ags.pep")
TOIG of: aae08417 check: 2325 from: 1 to: 33
ID AAE08417 standard; peptide; 33 AA.
XX AC AAE08417;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #62.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 33 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PT WPI; 2001-514422/56.
XX PS Use of extendin and extendin agonist compounds for modulating triglyceride
XX PS levels, and treating heart disease and dyslipidaemia.
XX PS Example 66; Page 76; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 33 AA;
```

```
AAE08417 Length: 33 February 4, 2005 13:32 Type: P Check: 2325 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRLFIETLKNKGPPS
1 28
-----
1 match found in sequence:
aae08418 ; Extendin agonist peptide #63.
(from "seq5ags.pep")
TOIG of: aae08418 check: 25 from: 1 to: 32
ID AAE08418 standard; peptide; 32 AA.
XX AC AAE08418;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #63.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 32 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PT WPI; 2001-514422/56.
XX PS Use of extendin and extendin agonist compounds for modulating triglyceride
XX PS levels, and treating heart disease and dyslipidaemia.
XX PS Example 67; Page 77; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 32 AA;
AAE08418 Length: 32 February 4, 2005 13:32 Type: P Check: 25 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRLFIETLKNKGPPS
1 28
-----
1 match found in sequence:
aae08419 ; Extendin agonist peptide #64.
(from "seq5ags.pep")
TOIG of: aae08419 check: 9586 from: 1 to: 32
```

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX Key Location/Qualifiers
FH Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.
XX Example 63; Page 75; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 34 AA;
AAE08414 Length: 34 February 4, 2005 13:32 Type: P Check: 5178 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSLSKQMEBEAVRLFIEWLKNGPSSG 28

1 match found in sequence:
aae08415; Extendin agonist peptide #60.
(from "seq5ags.pep")
TOIG of: aae08415 check: 4739 from: 1 to: 34
ID AAE08415 standard; peptide; 34 AA.
XX
XX AAE08415;
XX
XX 01-NOV-2001 (first entry)
XX Extendin agonist peptide #60.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX Key Location/Qualifiers
FH Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.
XX Example 64; Page 75; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 34 AA;
AAE08415 Length: 34 February 4, 2005 13:32 Type: P Check: 4739 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSLSKQMEBEAVRLFIEWLKNGPSSG 28

1 match found in sequence:
aae08416; Extendin agonist peptide #61.
(from "seq5ags.pep")
TOIG of: aae08416 check: 2764 from: 1 to: 33
ID AAE08416 standard; peptide; 33 AA.
XX
XX AAE08416;
XX
XX 01-NOV-2001 (first entry)
XX Extendin agonist peptide #61.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX Key Location/Qualifiers
FH Modified-site 33
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.

CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 36 AA;

AAE08411 Length: 36 February 4, 2005 13:32 Type: P Check: 9894 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGGGTFSTLSKQLEEEAVRLFIETFLKNGGPSSGAP
28

1 match found in sequence:
aae08412 ; Extendin agonist peptide #57.
(from "seq5ags.pep")
TOIG of: aae08412 check: 7453 from: 1 to: 35

ID AAE08412 standard; peptide; 35 AA.
XX
AC AAE08412;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #57.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 35 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX Example 61; Page 73; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin

XX Sequence 35 AA;

AAE08412 Length: 35 February 4, 2005 13:32 Type: P Check: 7453 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGGGTFSTLSKQLEEEAVRLFIETFLKNGGPSSGA
28

1 match found in sequence:
aae08413 ; Extendin agonist peptide #58.
(from "seq5ags.pep")
TOIG of: aae08413 check: 7014 from: 1 to: 35

ID AAE08413 standard; peptide; 35 AA.

XX
AC AAE08413;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #58.

XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 35 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.

XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX Example 62; Page 74; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin

XX Sequence 35 AA;

AAE08413 Length: 35 February 4, 2005 13:32 Type: P Check: 7014 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGGGTFSTLSKQLEEEAVRLFIETFLKNGGPSSGA
28

1 match found in sequence:
aae08414 ; Extendin agonist peptide #59.
(from "seq5ags.pep")
TOIG of: aae08414 check: 5178 from: 1 to: 34

ID AAE08414 standard; peptide; 34 AA.

XX
AC AAE08414;
XX
DT 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #59.

FT XX /note= "C-terminal amide"
PN WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT Example 58; Page 72; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX Sequence 37 AA;
SQ
AAE08409 Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTTSLSKQLEEEAVRLFIEFLKNGPSSGAPP
28

1 match found in sequence:
aae08410 ; Exendin agonist peptide #55.
(from "seq5ags.pep")
TOIG of: aae08410 check: 333 from: 1 to: 36
ID AAE08410 standard; peptide; 36 AA.
XX
AC AAE08410;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #55.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 36
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
DE Exendin agonist peptide #55.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 36
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
DE Exendin agonist; 2001WO-US000719.
XX
KW 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
PI

XX WPI; 2001-514422/56.
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 59; Page 72; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX Sequence 36 AA;
SQ
AAE08410 Length: 36 February 4, 2005 13:32 Type: P Check: 333 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTTSLSKQLEEEAVRLFIEFLKNGPSSGAPP
28

1 match found in sequence:
aae08411 ; Exendin agonist peptide #56.
(from "seq5ags.pep")
TOIG of: aae08411 check: 9894 from: 1 to: 36
ID AAE08411 standard; peptide; 36 AA.
XX
AC AAE08411;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #56.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 36
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
DE 09-JAN-2001; 2001WO-US000719.
XX
KW 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
PI
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 60; Page 73; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC


```

PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 53; Page 69; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
XX
AAE08404 Length: 28 February 4, 2005 13:32 Type: P Check: 9991 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQLEEAVALRFTIEFLAN 28
-----
1 match found in sequence:
aae08405; Extendin agonist peptide #50.
(from "seq5ags.pep")
TOIG of: aae08405 check: 9897 from: 1 to: 28

ID AAE08405 standard; peptide; 28 AA.
XX
XX AC AAE08405;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #50.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 54; Page 69; 161pp; English.
XX

```

```

CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
XX
AAE08405 Length: 28 February 4, 2005 13:32 Type: P Check: 9897 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQLEEAVALRFTIEFLKA 28
-----
1 match found in sequence:
aae08406; Extendin agonist peptide #51.
(from "seq5ags.pep")
TOIG of: aae08406 check: 6333 from: 1 to: 38

ID AAE08406 standard; peptide; 38 AA.
XX
XX AC AAE08406;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #51.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 38
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 55; Page 70; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 38 AA;
XX
AAE08406 Length: 38 February 4, 2005 13:32 Type: P Check: 6333 ..
Found using 'seq5' (mohamed337.key)

```

```

XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200151078-A1.
XX XX
XX PD 19-JUL-2001.
XX XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX XX
XX PI Kolterman OG, Young AA;
XX XX
XX DR WPI; 2001-514422/56.
XX XX
XX FT Use of extendin and extendin agonist compounds for modulating triglyceride
XX FT levels, and treating heart disease and dyslipidemia.
XX FT
XX PS Example 52; Page 68; 161pp; English.
XX XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC triglyceride agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX XX
XX SQ Sequence 28 AA;
XX XX
AAE08403 Length: 28 February 4, 2005 13:32 Type: P Check: 9975 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEFTFTSDLSKQLEEA VRLFIETPAKN 28

-----
1 match found in sequence:
aae08404 ; Extendin agonist peptide #49.
(from "seq5ags.pep")
TOIG of: aae08404 check: 9991 from: 1 to: 28

ID AAE08404 standard; peptide; 28 AA.
XX XX
AC AAE08404;
XX XX
DT 01-NOV-2001 (first entry)
XX XX
DE Extendin agonist peptide #49.
XX XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX XX
OS Synthetic.
XX XX
FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200151078-A1.
XX XX
XX PD 19-JUL-2001.
XX XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX XX

```


PT Use of exendin and exendin agonist compounds for modulating triglyceride
 XX PT levels, and treating heart disease and dyslipidaemia.
 PS Example 48; Page 66; 161pp; English.
 XX CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin
 XX Sequence 28 AA;
 SQ
 AAE08399 Length: 28 February 4, 2005 13:32 Type: P Check: 9921 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSDLSKQLEEEAVLFIEFLKN 28
 1

 1 match found in sequence:
 aae08400 ; Exendin agonist peptide #45.
 (from "seq5ags.pep")
 TOIG of: aae08400 check: 30 from: 1 to: 28
 ID AAE08400 standard; peptide; 28 AA.
 XX AC AAE08400;
 XX DT 01-NOV-2001 (first entry)
 XX DE Exendin agonist peptide #45.
 XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 XX KW diuretic; coronary heart disease; dyslipidaemia.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"
 FT WO200151078-A1.
 XX PN 19-JUL-2001.
 XX PD
 XX PF 09-JAN-2001; 2001WO-US000719.
 XX PR 10-JAN-2000; 2000US-0175365P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Kolterman OG, Young AA;
 XX PI WPI; 2001-514422/56.
 XX DR
 XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
 XX PT levels, and treating heart disease and dyslipidaemia.
 XX PS Example 49; Page 66; 161pp; English.
 XX CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin

XX Sequence 28 AA;
 SQ
 AAE08400 Length: 28 February 4, 2005 13:32 Type: P Check: 30 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSDLSKQLEEEAVRFIEFLKN 28
 1

 1 match found in sequence:
 aae08401 ; Exendin agonist peptide #46.
 (from "seq5ags.pep")
 TOIG of: aae08401 check: 165 from: 1 to: 28
 ID AAE08401 standard; peptide; 28 AA.
 XX AC AAE08401;
 XX DT 01-NOV-2001 (first entry)
 XX DE Exendin agonist peptide #46.
 XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 XX KW diuretic; coronary heart disease; dyslipidaemia.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"
 FT WO200151078-A1.
 XX PN 19-JUL-2001.
 XX PD
 XX PF 09-JAN-2001; 2001WO-US000719.
 XX PR 10-JAN-2000; 2000US-0175365P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Kolterman OG, Young AA;
 XX PI WPI; 2001-514422/56.
 XX DR
 XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
 XX PT levels, and treating heart disease and dyslipidaemia.
 XX PS Example 50; Page 67; 161pp; English.
 XX CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin
 XX Sequence 28 AA;
 SQ
 AAE08401 Length: 28 February 4, 2005 13:32 Type: P Check: 165 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSDLSKQLEEEAVRLFIAFLKN 28
 1

 1 match found in sequence:
 aae08402 ; Exendin agonist peptide #47.

```

XX DE      Exendin agonist peptide #42.
XX KW      Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW      diuretic; coronary heart disease; dyslipidaemia.
XX OS      Synthetic.
XX FH      Key      Location/Qualifiers
XX FT      Modified-site 28
XX FT      /note= "C-terminal amide"
XX PN      WO200151078-A1.
XX XX      19-JUL-2001.
XX XX      09-JAN-2001; 2001WO-US000719.
XX PF      10-JAN-2000; 2000US-0175365P.
XX XX      (AMYL-) AMYLIN PHARM INC.
XX PA      Kolterman OG, Young AA;
XX PI      WPI; 2001-514422/56.
XX XX      Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT      levels, and treating heart disease and dyslipidemia.
XX PS      Example 46; Page 65; 161pp; English.
XX CC      The patent discloses a method for modulating plasma or postprandial
XX CC      triglyceride and other lipid levels by administering exendin or an
XX CC      exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC      suppress the secretion of glucagon. Exendin and its agonists have a
XX CC      significant effect on the reduction of blood serum triglyceride
XX CC      concentrations. They are used to treat coronary heart disease and
XX CC      dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC      present peptide sequence is an agonist of exendin
XX SQ      Sequence 28 AA;
XX
AAE08397 Length: 28 February 4, 2005 13:32 Type: P Check: 193 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGGGTFTSLSKQLSEAAVLFIEFLKN 28
-----
1 match found in sequence:
aae08398 ; Exendin agonist peptide #43.
(from "seq5ags.pep")
TOIG of: aae08398 check: 9862 from: 1 to: 28

ID AAE08398 standard; peptide; 28 AA.
XX AC      AAE08398;
XX DT      01-NOV-2001 (first entry)
XX DE      Exendin agonist peptide #43.
XX KW      Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW      diuretic; coronary heart disease; dyslipidaemia.
XX OS      Synthetic.
XX FH      Key      Location/Qualifiers
XX FT      Modified-site 28
XX FT      /note= "C-terminal amide"
XX PN      WO200151078-A1.
XX XX      19-JUL-2001.
XX XX      09-JAN-2001; 2001WO-US000719.
XX PF      10-JAN-2000; 2000US-0175365P.
XX XX      (AMYL-) AMYLIN PHARM INC.
XX PA      Kolterman OG, Young AA;
XX PI      WPI; 2001-514422/56.
XX XX      Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT      levels, and treating heart disease and dyslipidemia.
XX PS      Example 46; Page 65; 161pp; English.
XX CC      The patent discloses a method for modulating plasma or postprandial
XX CC      triglyceride and other lipid levels by administering exendin or an
XX CC      exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC      suppress the secretion of glucagon. Exendin and its agonists have a
XX CC      significant effect on the reduction of blood serum triglyceride
XX CC      concentrations. They are used to treat coronary heart disease and
XX CC      dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC      present peptide sequence is an agonist of exendin
XX SQ      Sequence 28 AA;
XX
AAE08399 Length: 28 February 4, 2005 13:32 Type: P Check: 193 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGGGTFTSLSKQLSEAAVLFIEFLKN 28
-----
1 match found in sequence:
aae08399 ; Exendin agonist peptide #44.
(from "seq5ags.pep")
TOIG of: aae08399 check: 9921 from: 1 to: 28

ID AAE08399 standard; peptide; 28 AA.
XX AC      AAE08399;
XX DT      01-NOV-2001 (first entry)
XX DE      Exendin agonist peptide #44.
XX KW      Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW      diuretic; coronary heart disease; dyslipidaemia.
XX OS      Synthetic.
XX FH      Key      Location/Qualifiers
XX FT      Modified-site 28
XX FT      /note= "C-terminal amide"
XX PN      WO200151078-A1.
XX XX      19-JUL-2001.
XX XX      09-JAN-2001; 2001WO-US000719.
XX PF      10-JAN-2000; 2000US-0175365P.
XX XX      (AMYL-) AMYLIN PHARM INC.
XX PA      Kolterman OG, Young AA;
XX PI      WPI; 2001-514422/56.
XX XX

```

```

XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 47; Page 65; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX SQ      Sequence 28 AA;
XX
AAE08398 Length: 28 February 4, 2005 13:32 Type: P Check: 9862 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGGGTFTSLSKQLSEAAVLFIEFLKN 28
-----
1 match found in sequence:
aae08399 ; Exendin agonist peptide #44.
(from "seq5ags.pep")
TOIG of: aae08399 check: 9921 from: 1 to: 28

ID AAE08399 standard; peptide; 28 AA.
XX AC      AAE08399;
XX DT      01-NOV-2001 (first entry)
XX DE      Exendin agonist peptide #44.
XX KW      Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW      diuretic; coronary heart disease; dyslipidaemia.
XX OS      Synthetic.
XX FH      Key      Location/Qualifiers
XX FT      Modified-site 28
XX FT      /note= "C-terminal amide"
XX PN      WO200151078-A1.
XX XX      19-JUL-2001.
XX XX      09-JAN-2001; 2001WO-US000719.
XX PF      10-JAN-2000; 2000US-0175365P.
XX XX      (AMYL-) AMYLIN PHARM INC.
XX PA      Kolterman OG, Young AA;
XX PI      WPI; 2001-514422/56.
XX XX

```

CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX Sequence 28 AA;
SQ

AAE08394 Length: 28 February 4, 2005 13:32 Type: P Check: 107 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTTSDLSKQAEAEAVRLFIEFLKN 28
1

1 match found in sequence:
aae08395 ; Exendin agonist peptide #40.
(from "seq5ags.pep")
TOIG of: aae08395 check: 201 from: 1 to: 28

ID AAE08395 standard; peptide; 28 AA.

XX AAE08395;

AC AAE08395;

XX 01-NOV-2001 (first entry)

DE Exendin agonist peptide #40.

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.

XX Example 44; Page 64; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 28 AA;

AAE08395 Length: 28 February 4, 2005 13:32 Type: P Check: 201 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTTSDLSKQAEAEAVRLFIEFLKN

1 28

1 match found in sequence:
aae08396 ; Exendin agonist peptide #41.
(from "seq5ags.pep")
TOIG of: aae08396 check: 197 from: 1 to: 28

ID AAE08396 standard; peptide; 28 AA.

XX AAE08396;

AC AAE08396;

XX 01-NOV-2001 (first entry)

DE Exendin agonist peptide #41.

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.

XX Example 45; Page 64; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 28 AA;

AAE08396 Length: 28 February 4, 2005 13:32 Type: P Check: 197 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTTSDLSKQAEAEAVRLFIEFLKN 28
1

1 match found in sequence:
aae08397 ; Exendin agonist peptide #42.
(from "seq5ags.pep")
TOIG of: aae08397 check: 193 from: 1 to: 28

ID AAE08397 standard; peptide; 28 AA.

XX AAE08397;

XX 01-NOV-2001 (first entry)

```

FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 41; Page 62; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
XX
XX AAE08392 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX |-----|
XX 1 HGEFTFTSDLSAQLEEAARLFIIEFLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aae08393 ; Extendin agonist peptide #38.
XX (from "seq5ags.pep")
XX TOIG of: aae08393 check: 53 from: 1 to: 28
XX
XX ID AAE08393 standard; peptide; 28 AA.
XX AC AAE08393;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #38.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28
XX /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 41; Page 62; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
XX
XX AAE08392 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX |-----|
XX 1 HGEFTFTSDLSAQLEEAARLFIIEFLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aae08393 ; Extendin agonist peptide #38.
XX (from "seq5ags.pep")
XX TOIG of: aae08393 check: 53 from: 1 to: 28
XX
XX ID AAE08393 standard; peptide; 28 AA.
XX AC AAE08393;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #38.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28
XX /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.

```

```

XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 42; Page 62; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
XX
XX AAE08393 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX |-----|
XX 1 HGEFTFTSDLSAQLEEAARLFIIEFLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aae08394 ; Extendin agonist peptide #39.
XX (from "seq5ags.pep")
XX TOIG of: aae08394 check: 107 from: 1 to: 28
XX
XX ID AAE08394 standard; peptide; 28 AA.
XX AC AAE08394;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #39.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28
XX /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 43; Page 63; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They

```

AAE08389 Length: 28 February 4, 2005 13:32 Type: P Check: 117 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTTADLSKQLEEEAVRLPIEFLKN 28

1 match found in sequence:
aae08390 ; Exendin agonist peptide #35.
(from "seq5ags.pep")
TOIG of: aae08390 check: 151 from: 1 to: 28

ID AAE08390 standard; peptide; 28 AA.

XX AC AAE08390;

DT 01-NOV-2001 (first entry)

DE Exendin agonist peptide #35.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers
FT Modified-site 28
PT /note= "C-terminal amide"

XX WO200151078-A1.

PN 19-JUL-2001.

PP 09-JAN-2001; 2001WO-US000719.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.

XX Example 39; Page 61; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 28 AA;

AAE08390 Length: 28 February 4, 2005 13:32 Type: P Check: 151 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTTADLSKQLEEEAVRLPIEFLKN 28

1 match found in sequence:
aae08391 ; Exendin agonist peptide #36.
(from "seq5ags.pep")
TOIG of: aae08391 check: 63 from: 1 to: 28

ID AAE08391 standard; peptide; 28 AA.

XX AC AAE08391;

DT 01-NOV-2001 (first entry)

DE Exendin agonist peptide #36.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers
FT Modified-site 28
PT /note= "C-terminal amide"

XX WO200151078-A1.

PN 19-JUL-2001.

PP 09-JAN-2001; 2001WO-US000719.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.

XX Example 40; Page 61; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 28 AA;

AAE08391 Length: 28 February 4, 2005 13:32 Type: P Check: 63 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTTADLSKQLEEEAVRLPIEFLKN 28

1 match found in sequence:
aae08392 ; Exendin agonist peptide #37.
(from "seq5ags.pep")
TOIG of: aae08392 check: 141 from: 1 to: 28

ID AAE08392 standard; peptide; 28 AA.

XX AC AAE08392;

DT 01-NOV-2001 (first entry)

DE Exendin agonist peptide #37.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

```
PF 09-JAN-2001; 2001WO-US0000719.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
PS Example 36; Page 59; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ
AAE08387 Length: 28 February 4, 2005 13:32 Type: P Check: 166 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGATSDLSKQLEEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aac08388 ; Extendin agonist peptide #33.
(from "seq5ags.pep")
TOIG of: aae08388 check: 231 from: 1 to: 28
ID AAE08388 standard; peptide; 28 AA.
XX
XX AAE08388;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Extendin agonist peptide #33.
DE
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 38; Page 60; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ
AAE08388 Length: 28 February 4, 2005 13:32 Type: P Check: 231 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGATSDLSKQLEEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aac08389 ; Extendin agonist peptide #34.
(from "seq5ags.pep")
TOIG of: aae08389 check: 117 from: 1 to: 28
ID AAE08389 standard; peptide; 28 AA.
XX
XX AAE08389;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Extendin agonist peptide #34.
DE
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 38; Page 60; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ
```

```
aae08385 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28
TOIG of: aae08385) check: 261 from: 1 to: 28

ID AAE08385 standard; peptide; 28 AA.
XX
AC AAE08385;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #2.
XX
KW Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;
KW coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Claim 13; Page 58; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is Heloderma suspectum modified extendin-4 amide
CC (residues 1-28) which is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08385 Length: 28 February 4, 2005 13:32 Type: P Check: 261 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGEFTSDLSKQLEEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aae08386 ; Extendin agonist peptide #31.
(from "seq5ags.pep")
TOIG of: aae08386 check: 249 from: 1 to: 28

ID AAE08386 standard; peptide; 28 AA.
XX
AC AAE08386;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #31.
XX

-----
1 match found in sequence:
aae08386 ; Extendin agonist peptide #31.
(from "seq5ags.pep")
TOIG of: aae08386 check: 249 from: 1 to: 28

ID AAE08386 standard; peptide; 28 AA.
XX
AC AAE08386;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #31.
XX
```

```
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 35; Page 58; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08386 Length: 28 February 4, 2005 13:32 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HAEGFTSDLSKQLEEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aae08387 ; Extendin agonist peptide #32.
(from "seq5ags.pep")
TOIG of: aae08387 check: 166 from: 1 to: 28

ID AAE08387 standard; peptide; 28 AA.
XX
AC AAE08387;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #32.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
```

CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX Sequence 39 AA;

AAE08382 Length: 39 February 4, 2005 13:32 Type: P Check: 7905 ..
Found using 'seq5' (mohamed337.key)

1 HEGFTSLSKQMEBEAVRLFIEFLKNGSPSSGAAAS
1 28

1 match found in sequence:

aae08383 ; Exendin agonist peptide #30.
(from "seq5ags.pep")
TOIG of: aae08383 check: 7001 from: 1 to: 39

ID AAE08383 standard; peptide; 39 AA.

XX AAE08383;

XX 01-NOV-2001 (first entry)

XX Exendin agonist peptide #30.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX	Key	Location/Qualifiers
FT	Modified-site	31 /note= "N-Methyl-alanine"
FT	Modified-site	36 /note= "N-Methyl-alanine"
FT	Modified-site	37 /note= "N-Methyl-alanine"
FT	Modified-site	38 /note= "N-Methyl-alanine"
FT	Modified-site	39 /note= "N-Methyl-alanine"
FT	Modified-site	/note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
FT levels, and treating heart disease and dyslipidemia.

XX Example 30; Page; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX Sequence 39 AA;
SQ

AAE08383 Length: 39 February 4, 2005 13:32 Type: P Check: 7001 ..
Found using 'seq5' (mohamed337.key)

1 HEGFTSLSKQLEEEAVRLFIEFLKNGSGSAAAS
1 28

1 match found in sequence:

aae08384 ; Heloderma suspectum exendin-4 amide peptide (residues 1-28).
(from "seq5ags.pep")
TOIG of: aae08384 check: 700 from: 1 to: 28

ID AAE08384 standard; peptide; 28 AA.

XX AAE08384;

XX 01-NOV-2001 (first entry)

XX Heloderma suspectum exendin-4 amide peptide (residues 1-28).

XX Exendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;
KW coronary heart disease; dyslipidaemia.

XX Heloderma suspectum.

XX	Key	Location/Qualifiers
FT	Modified-site	28 /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
FT levels, and treating heart disease and dyslipidemia.

XX Claim 13; Page 57; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is an agonist of exendin, exendin-4 amide (residues 1-
CC 28) from Heloderma suspectum

XX Sequence 28 AA;

AAE08384 Length: 28 February 4, 2005 13:32 Type: P Check: 700 ..
Found using 'seq5' (mohamed337.key)

1 HEGFTSLSKQMEBEAVRLFIEFLKNG
1 28

1 match found in sequence:

XX The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC present peptide sequence is an agonist of extendin. Note: The present
 CC sequence is not shown in the specification but is derived from SEQ ID
 CC NO:3 shown in page 17 of the specification
 XX
 SQ Sequence 39 AA;

AAE08380 Length: 39 February 4, 2005 13:32 Type: P Check: 267 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSLSKQLEEEAVRLFIEFLKNGXSGAXXXS
 1 28

 1 match found in sequence:
 aae08381; Extendin agonist peptide #28.
 (from "seq5ags.pep")
 TOIG of: aae08381 check: 7440 from: 1 to: 39

ID AAE08381 standard; peptide; 39 AA.
 XX
 AC AAE08381;
 XX
 DT 01-NOV-2001 (first entry)
 XX
 DE Extendin agonist peptide #28.
 XX
 XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 OS Synthetic.

Key	Location/Qualifiers
FT Modified-site 31	/note= "N-Methyl-alanine"
FT Modified-site 36	/note= "N-Methyl-alanine"
FT Modified-site 37	/note= "N-Methyl-alanine"
FT Modified-site 38	/note= "N-Methyl-alanine"
FT Modified-site 39	/note= "N-Methyl-alanine"
FT Modified-site	/note= "C-terminal amide"

WO200151078-A1.
 19-JUL-2001.

09-JAN-2001; 2001WO-US000719.

10-JAN-2000; 2000US-0175365P.

(AMYL-) AMYLIN PHARM INC.

Kolterman OG, Young AA;

WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidemia.

PS Example 28; Page; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC present peptide sequence is an agonist of extendin. Note: The present
 CC sequence is not shown in the specification but is derived from SEQ ID
 CC NO:3 shown in page 17 of the specification
 XX
 SQ Sequence 39 AA;

AAE08381 Length: 39 February 4, 2005 13:32 Type: P Check: 7440 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSLSKQLEEEAVRLFIEFLKNGXSGAXXAS
 1 28

 1 match found in sequence:
 aae08382; Extendin agonist peptide #29.
 (from "seq5ags.pep")
 TOIG of: aae08382 check: 7905 from: 1 to: 39

ID AAE08382 standard; peptide; 39 AA.

XX

AC AAE08382;

XX 01-NOV-2001 (first entry)

XX Extendin agonist peptide #29.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

Key	Location/Qualifiers
FT Modified-site 36	/note= "N-Methyl-alanine"
FT Modified-site 37	/note= "N-Methyl-alanine"
FT Modified-site 38	/note= "N-Methyl-alanine"
FT Modified-site 39	/note= "N-Methyl-alanine"
FT Modified-site	/note= "C-terminal amide"

WO200151078-A1.

19-JUL-2001.

09-JAN-2001; 2001WO-US000719.

10-JAN-2000; 2000US-0175365P.

(AMYL-) AMYLIN PHARM INC.

Kolterman OG, Young AA;

WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidemia.

PS Example 29; Page; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

DR WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PS
XX Example 25; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
XX NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;
AAE08378 Length: 39 February 4, 2005 13:32 Type: P Check: 458 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGETFTDLSKQMBEAVRLFIEWLKNGGPFSSGAXXXS
28

1 match found in sequence:
aae08379; Exendin agonist peptide #26.
(from "seq5ags.pep")
TOIG of: aae08379 check: 267 from: 1 to: 39
ID AAE08379 standard; peptide; 39 AA.
XX
XX AAE08379;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #26.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
KW
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 31
FT /note= "Thioprolin"
FT Modified-site 36
FT /note= "Thioprolin"
FT Modified-site 37
FT /note= "Thioprolin"
FT Modified-site 38
FT /note= "Thioprolin"
FT Modified-site 39
FT /note= "C-terminal amide"
FT
FT
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PS

PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 26; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
XX NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;
AAE08379 Length: 39 February 4, 2005 13:32 Type: P Check: 267 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGETFTDLSKQMBEAVRLFIEWLKNGGXSXGAXXXS
28

1 match found in sequence:
aae08380; Exendin agonist peptide #27.
(from "seq5ags.pep")
TOIG of: aae08380 check: 267 from: 1 to: 39
ID AAE08380 standard; peptide; 39 AA.
XX
XX AAE08380;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #27.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
KW
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 31
FT /note= "Homoprolin"
FT Modified-site 36
FT /note= "Homoprolin"
FT Modified-site 37
FT /note= "Homoprolin"
FT Modified-site 38
FT /note= "Homoprolin"
FT Modified-site 39
FT /note= "C-terminal amide"
FT
FT
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 27; Page; 161pp; English.
PS

PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 23; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;
AAE08376 Length: 39 February 4, 2005 13:32 Type: P Check: 458 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEFTSLSKQMEEEAVRLFIEWLKNGGPGSGAXXXS
28

1 match found in sequence:
aae08377; Extendin agonist peptide #24.
(from "seq5ags.pep")
TOIG of: aae08377 check: 706 from: 1 to: 39
ID AAE08377 standard; peptide; 39 AA.
XX
AC AAE08377;
XX
XX 01-NOV-2001 (first entry)
DT
DE Extendin agonist peptide #24.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "Homoproline"
FT Modified-site 36 /note= "Homoproline"
FT Modified-site 37 /note= "Homoproline"
FT Modified-site 38 /note= "Homoproline"
FT Modified-site 39 /note= "Homoproline"
FT Modified-site 39 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX 10-JAN-2000; 2000US-0175365P.
XX

XX (AMYL-) AMYLIN PHARM INC..
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 24; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;
AAE08377 Length: 39 February 4, 2005 13:32 Type: P Check: 706 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEFTSLSKQMEEEAVRLFIEWLKNGGSGAXXXS
28

1 match found in sequence:
aae08378; Extendin agonist peptide #25.
(from "seq5ags.pep")
TOIG of: aae08378 check: 458 from: 1 to: 39
ID AAE08378 standard; peptide; 39 AA.
XX
AC AAE08378;
XX
XX 01-NOV-2001 (first entry)
DT
DE Extendin agonist peptide #25.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 36 /note= "Homoproline"
FT Modified-site 37 /note= "Homoproline"
FT Modified-site 38 /note= "Homoproline"
FT Modified-site 39 /note= "Homoproline"
FT Modified-site 39 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX

AC	AAE08373;
XX	
DT	01-NOV-2001 (first entry)
XX	
DE	Extendin agonist peptide #20.
XX	
KW	Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW	diuretic; coronary heart disease; dyslipidaemia.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	Modified-site 39
FT	/note= "C-terminal amide"
XX	
PN	WO200151078-A1.
XX	
PD	19-JUL-2001.
XX	
PF	09-JAN-2001; 2001WO-US000719.
XX	
PR	10-JAN-2000; 2000US-0175365P.
XX	
PA	(AMYL-) AMYLIN PHARM INC.
XX	
PI	Kolterman OG, Young AA;
XX	
DR	WPI; 2001-514422/56.
XX	
PT	Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.
XX	
PS	Example 20; Page; 161pp; English.
XX	
CC	The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin. Note: The present sequence is not shown in the specification but is derived from SEQ ID NO:3 shown in page 17 of the specification
XX	
SQ	Sequence 39 AA;
XX	
AAE08373	Length: 39 February 4, 2005 13:32 Type: P Check: 9546 ..
Found using 'seq5'	(mohamed337.key)
1	HGEGTTSDLSKQLEEEAVRLFDLXNGGPSSGAPPPS ----- 1 28

1 match found in sequence:	
aae08374 ; Extendin agonist peptide #21.	
(from "seq5ags.psp")	
TOIG of: aae08374 check: 9145 from: 1 to: 39	
ID	AAE08374 standard; peptide; 39 AA.
XX	
AC	AAE08374;
XX	
DT	01-NOV-2001 (first entry)
XX	
DE	Extendin agonist peptide #21.
XX	
KW	Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW	diuretic; coronary heart disease; dyslipidaemia.
XX	
OS	Synthetic.
XX	

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX Sequence 39 AA;
SQ AAE08369 Length: 39 February 4, 2005 13:32 Type: P Check: 9869 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSLSKQMEEEAVRLFVEWLKNGPSSGAPPPS
28
-----|-----
1 match found in sequence:
aae08370 ; Extendin agonist peptide #17.
(from "seq5ags.pep")
TOIG of: aae08370 check: 9430 from: 1 to: 39

ID AAE08370 standard; peptide; 39 AA.
XX
AC AAE08370;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #17.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT Modified-site 39 /note= "C-terminal amide"
FT
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 17; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX Sequence 39 AA;
SQ AAE08370 Length: 39 February 4, 2005 13:32 Type: P Check: 9430 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSLSKQMEEEAVRLFVEWLKNGPSSGAPPPS
28
-----|-----
1 match found in sequence:
aae08371 ; Extendin agonist peptide #18.
(from "seq5ags.pep")
TOIG of: aae08371 check: 9915 from: 1 to: 39

ID AAE08371 standard; peptide; 39 AA.
XX
AC AAE08371;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #18.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 23
FT Modified-site 39 /note= "Tertiary-butylglycine"
FT Modified-site 39 /note= "C-terminal amide"
FT
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 18; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX Sequence 39 AA;
SQ AAE08371 Length: 39 February 4, 2005 13:32 Type: P Check: 9915 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSLSKQMEEEAVRLFVEWLKNGPSSGAPPPS
28
-----|-----
1 match found in sequence:
aae08371 ; Extendin agonist peptide #18.
(from "seq5ags.pep")
TOIG of: aae08371 check: 9915 from: 1 to: 39

ID AAE08371 standard; peptide; 39 AA.
XX
AC AAE08371;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #18.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 23
FT Modified-site 39 /note= "Tertiary-butylglycine"
FT Modified-site 39 /note= "C-terminal amide"
FT
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 18; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

1 HGEFTTSLSKQMEEEAVRLFVEWLKNGPSSGAPPPS
28
-----|-----


```
ID AAE08365 standard; peptide; 39 AA.
XX AC AAE08365;
XX OS
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Exendin agonist peptide #12.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 10 Location/Qualifiers
XX FT Modified-site 39 /note= "Pentylglycine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX OS
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 12; Page; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin. Note: The present
XX CC sequence is not shown in the specification but is derived from SEQ ID
XX CC NO:3 shown in page 17 of the specification
XX SQ Sequence 39 AA;
AAE08365 Length: 39 February 4, 2005 13:32 Type: P Check: 9251 ..
Found using 'seq5' (mohamed337.key)
1 HGGGFTSDSKQLEEEAVRLFIEFLKNGGPPSGAPPPS
28
-----
1 match found in sequence:
aae08366 ; Exendin agonist peptide #13.
(from "seq5ags.pep")
TOIG of: aae08366 check: 9724 from: 1 to: 39
ID AAE08366 standard; peptide; 39 AA.
XX AC AAE08366;
XX OS
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Exendin agonist peptide #13.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 10 Location/Qualifiers
XX FT Modified-site 39 /note= "Pentylglycine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX OS
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 13; Page; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin. Note: The present
XX CC sequence is not shown in the specification but is derived from SEQ ID
XX CC NO:3 shown in page 17 of the specification
XX SQ Sequence 39 AA;
AAE08366 Length: 39 February 4, 2005 13:32 Type: P Check: 9251 ..
Found using 'seq5' (mohamed337.key)
1 HGGGFTSDSKQLEEEAVRLFIEFLKNGGPPSGAPPPS
28
-----
1 match found in sequence:
aae08367 ; Exendin agonist peptide #14.
(from "seq5ags.pep")
TOIG of: aae08367 check: 9299 from: 1 to: 39
ID AAE08367 standard; peptide; 39 AA.
XX AC AAE08367;
XX OS
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Exendin agonist peptide #14.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 10 Location/Qualifiers
XX FT Modified-site 39 /note= "Pentylglycine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX OS
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 13; Page; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin. Note: The present
XX CC sequence is not shown in the specification but is derived from SEQ ID
XX CC NO:3 shown in page 17 of the specification
XX SQ Sequence 39 AA;
AAE08366 Length: 39 February 4, 2005 13:32 Type: P Check: 9724 ..
Found using 'seq5' (mohamed337.key)
1 HGGGFTSDSKQLEEEAVRLFIEFLKNGGPPSGAPPPS
28
-----
1 match found in sequence:
aae08367 ; Exendin agonist peptide #14.
(from "seq5ags.pep")
TOIG of: aae08367 check: 9299 from: 1 to: 39
```



```

CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08362 Length: 39 February 4, 2005 13:32 Type: P Check: 9617 ..
Found using 'seq5' (mohamed337.key)

1 HEGGTTTDLKQMEERAVRLFIEWLKNKGPPSSGAPPT
  1
-----
1 match found in sequence:
aae08363 ; Extendin agonist peptide #10.
(from "seq5ags.pep")
TOIG of: aae08363 check: 9579 from: 1 to: 39

ID AAE08363 standard; peptide; 39 AA.
XX
AC AAE08363;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #10.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 10; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08363 Length: 39 February 4, 2005 13:32 Type: P Check: 9579 ..
Found using 'seq5' (mohamed337.key)

1 HEGGTTTDLKQMEERAVRLFIEWLKNKGPPSSGAPPT
  1
-----
1 match found in sequence:
aae08363 ; Extendin agonist peptide #10.
(from "seq5ags.pep")
TOIG of: aae08363 check: 9579 from: 1 to: 39

ID AAE08363 standard; peptide; 39 AA.
XX
AC AAE08363;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #10.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 10; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08364 Length: 39 February 4, 2005 13:32 Type: P Check: 9690 ..
Found using 'seq5' (mohamed337.key)

1 HEGGTTTDLKQMEERAVRLFIEWLKNKGPPSSGAPPT
  1
-----
1 match found in sequence:
aae08364 ; Extendin agonist peptide #11.
(from "seq5ags.pep")
TOIG of: aae08364 check: 9690 from: 1 to: 39

ID AAE08364 standard; peptide; 39 AA.
XX
AC AAE08364;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #11.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 10
FT Modified-site /note= "Pentyglycine"
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 11; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08364 Length: 39 February 4, 2005 13:32 Type: P Check: 9690 ..
Found using 'seq5' (mohamed337.key)

1 HEGGTTTDLKQMEERAVRLFIEWLKNKGPPSSGAPPT
  1
-----
1 match found in sequence:
aae08365 ; Extendin agonist peptide #12.
(from "seq5ags.pep")
TOIG of: aae08365 check: 9251 from: 1 to: 39

```

PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 7; Page; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
SQ
AAE08360 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSSDLSKQMEEEAVRLFIEWLKNCGPSSGAPPPS
28

1 match found in sequence:
aae08361 ; Exendin agonist peptide #8.
(from "seq5ags.pep")
TOIG of: aae08361 check: 9610 from: 1 to: 39
ID AAE08361 standard; peptide; 39 AA.
XX
XX AAE08361;
AC
XX 01-NOV-2001 (first entry)
DT
XX Exendin agonist peptide #8.
DE
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
KW
XX Synthetic.
OS
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT
XX WO200151078-A1.
PN
XX 19-JUL-2001.
PD
XX 09-JAN-2001; 2001WO-US000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 7; Page; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
SQ
AAE08360 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSSDLSKQMEEEAVRLFIEWLKNCGPSSGAPPPS
28

1 match found in sequence:
aae08361 ; Exendin agonist peptide #8.
(from "seq5ags.pep")
TOIG of: aae08361 check: 9610 from: 1 to: 39
ID AAE08361 standard; peptide; 39 AA.
XX
XX AAE08361;
AC
XX 01-NOV-2001 (first entry)
DT
XX Exendin agonist peptide #8.
DE
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
KW
XX Synthetic.
OS
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT
XX WO200151078-A1.
PN
XX 19-JUL-2001.
PD
XX 09-JAN-2001; 2001WO-US000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX

XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 8; Page; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
SQ
AAE08361 Length: 39 February 4, 2005 13:32 Type: P Check: 9610 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSSDLSKQMEEEAVRLFIEWLKNCGPSSGAPPP
28

1 match found in sequence:
aae08362 ; Exendin agonist peptide #9.
(from "seq5ags.pep")
TOIG of: aae08362 check: 9617 from: 1 to: 39
ID AAE08362 standard; peptide; 39 AA.
XX
XX AAE08362;
AC
XX 01-NOV-2001 (first entry)
DT
XX Exendin agonist peptide #9.
DE
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
KW
XX Synthetic.
OS
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT
XX WO200151078-A1.
PN
XX 19-JUL-2001.
PD
XX 09-JAN-2001; 2001WO-US000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 9; Page; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
SQ

```

ID  AAE08358 standard; peptide; 39 AA.
XX
AC  AAE08358;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #5.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 39
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US0000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
DR  WPI; 2001-514422/56.
XX
PT  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidaemia.
XX
PS  Example 5; Page; 16lpp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin. Note: The present
CC  sequence is not shown in the specification but is derived from SEQ ID
CC  NO:3 shown in page 17 of the specification
XX
SQ  Sequence 39 AA;

AAE08358 Length: 39 February 4, 2005 13:32 Type: P Check: 9567 ..
Found using 'seq5' (mohamed337.key)

1  |-----|
  1  HGGTFTSLSKQMBEEAVRLFIEWLKGPGSSGAPPPS
    28

-----
1 match found in sequence:
aae08358 ; Exendin agonist peptide #6.
(from "seq5ags.pep")
TOIG of: aae08358 check: 9678 from: 1 to: 39

ID  AAE08359 standard; peptide; 39 AA.
XX
AC  AAE08359;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #6.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 39
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US0000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
DR  WPI; 2001-514422/56.
XX
PT  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidaemia.
XX
PS  Example 5; Page; 16lpp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin. Note: The present
CC  sequence is not shown in the specification but is derived from SEQ ID
CC  NO:3 shown in page 17 of the specification
XX
SQ  Sequence 39 AA;

AAE08359 Length: 39 February 4, 2005 13:32 Type: P Check: 9567 ..
Found using 'seq5' (mohamed337.key)

1  |-----|
  1  HGGTFTSLSKQMBEEAVRLFIEWLKGPGSSGAPPPS
    28

-----
1 match found in sequence:
aae08359 ; Exendin agonist peptide #6.
(from "seq5ags.pep")
TOIG of: aae08359 check: 9678 from: 1 to: 39

ID  AAE08359 standard; peptide; 39 AA.
XX
AC  AAE08359;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #6.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.

```

```

XX  Synthetic.
XX
XX  Key Location/Qualifiers
XX  Modified-site 6
XX  /note= "Naphthylalanine"
XX  Modified-site 39
XX  /note= "C-terminal amide"
XX
XX  WO200151078-A1.
XX
XX  19-JUL-2001.
XX
XX  09-JAN-2001; 2001WO-US0000719.
XX
XX  10-JAN-2000; 2000US-0175365P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Kolterman OG, Young AA;
XX
XX  WPI; 2001-514422/56.
XX
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
XX  levels, and treating heart disease and dyslipidaemia.
XX
XX  Example 6; Page; 16lpp; English.
XX
XX  The patent discloses a method for modulating plasma or postprandial
XX  triglyceride and other lipid levels by administering exendin or an
XX  exendin agonist. Exendins have inotropic and diuretic effects. They
XX  suppress the secretion of glucagon. Exendin and its agonists have a
XX  significant effect on the reduction of blood serum triglyceride
XX  concentrations. They are used to treat coronary heart disease and
XX  dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX  present peptide sequence is an agonist of exendin. Note: The present
XX  sequence is not shown in the specification but is derived from SEQ ID
XX  NO:3 shown in page 17 of the specification
XX
XX  Sequence 39 AA;

AAE08359 Length: 39 February 4, 2005 13:32 Type: P Check: 9678 ..
Found using 'seq5' (mohamed337.key)

1  |-----|
  1  HGGTFTSLSKQMBEEAVRLFIEWLKGPGSSGAPPPS
    28

-----
1 match found in sequence:
aae08360 ; Exendin agonist peptide #7.
(from "seq5ags.pep")
TOIG of: aae08360 check: 9563 from: 1 to: 39

ID  AAE08360 standard; peptide; 39 AA.
XX
XX  AAE08360;
XX
XX  01-NOV-2001 (first entry)
XX
XX  Exendin agonist peptide #7.
XX
XX  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX  diuretic; coronary heart disease; dyslipidaemia.
XX
XX  Synthetic.
XX
XX  Key Location/Qualifiers
XX  Modified-site 39
XX  /note= "C-terminal amide"
XX
XX  WO200151078-A1.
XX

```

CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin. Note: The present
 CC sequence is not shown in the specification but is derived from SEQ ID
 CC NO:3 shown in page 17 of the specification
 XX
 XX Sequence 39 AA;
 SQ
 AAE08355 Length: 39 February 4, 2005 13:32 Type: P Check: 9145 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGTTSDLSKQMEEEAVRLFIWLNKGPGSSGAPPPS
 1

 1 match found in sequence:
 aae08356 ; Exendin agonist peptide #3.
 (from "seq5ags.pep")
 TOIG of: aae08356 check: 9587 from: 1 to: 39
 ID AAE08356 standard; peptide; 39 AA.
 XX
 AC AAE08356;
 XX
 DT 01-NOV-2001 (first entry)
 DE Exendin agonist peptide #3.
 XX
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX WO200151078-A1.
 XX 19-JUL-2001.
 XX 09-JAN-2001; 2001WO-US000719.
 XX 10-JAN-2000; 2000US-0175365P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Kolterman OG, Young AA;
 XX WPI; 2001-514422/56.
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride
 XX levels, and treating heart disease and dyslipidaemia.
 XX Example 3b; Page; 161pp; English.
 XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin. Note: The present
 CC sequence is not shown in the specification but is derived from SEQ ID
 CC NO:3 shown in page 17 of the specification
 XX
 XX Sequence 39 AA;
 SQ
 AAE08356 Length: 39 February 4, 2005 13:32 Type: P Check: 9587 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGTTSDLSKQMEEEAVRLFIWLNKGPGSSGAPPPS
 1

 1 match found in sequence:
 aae08355 ; Exendin agonist peptide #3.
 (from "seq5ags.pep")
 TOIG of: aae08355 check: 9145 from: 1 to: 39
 ID AAE08355 standard; peptide; 39 AA.
 XX
 AC AAE08355;
 XX
 DT 01-NOV-2001 (first entry)
 DE Exendin agonist peptide #3.
 XX
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX WO200151078-A1.
 XX 19-JUL-2001.
 XX 09-JAN-2001; 2001WO-US000719.
 XX 10-JAN-2000; 2000US-0175365P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Kolterman OG, Young AA;
 XX WPI; 2001-514422/56.
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride
 XX levels, and treating heart disease and dyslipidaemia.
 XX Example 3b; Page; 161pp; English.
 XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin. Note: The present
 CC sequence is not shown in the specification but is derived from SEQ ID
 CC NO:3 shown in page 17 of the specification
 XX
 XX Sequence 39 AA;
 SQ

Found using 'seq5' (mohamed337.key)
 1 YGEGTFTSDLSKQMEEEAVRLFIWLNKGPGSSGAPPPS
 1

 1 match found in sequence:
 aae08357 ; Exendin agonist peptide #4.
 (from "seq5ags.pep")
 TOIG of: aae08357 check: 9804 from: 1 to: 39
 ID AAE08357 standard; peptide; 39 AA.
 XX
 AC AAE08357;
 XX
 DT 01-NOV-2001 (first entry)
 DE Exendin agonist peptide #4.
 XX
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX WO200151078-A1.
 XX 19-JUL-2001.
 XX 09-JAN-2001; 2001WO-US000719.
 XX 10-JAN-2000; 2000US-0175365P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Kolterman OG, Young AA;
 XX WPI; 2001-514422/56.
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride
 XX levels, and treating heart disease and dyslipidaemia.
 XX Example 4; Page; 161pp; English.
 XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering exendin or an
 CC exendin agonist. Exendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Exendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of exendin. Note: The present
 CC sequence is not shown in the specification but is derived from SEQ ID
 CC NO:3 shown in page 17 of the specification
 XX
 XX Sequence 39 AA;
 SQ
 AAE08357 Length: 39 February 4, 2005 13:32 Type: P Check: 9804 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGTTSDLSKQMEEEAVRLFIWLNKGPGSSGAPPPY
 1

 1 match found in sequence:
 aae08358 ; Exendin agonist peptide #5.
 (from "seq5ags.pep")
 TOIG of: aae08358 check: 9567 from: 1 to: 39


```
1
-----
1 match found in sequence:
aae08351 ; Heloderma suspectum modified extendin-4 peptide (residues 1-30) amide.
(from "seq5ags.pep")
TOIG of: aae08351 check: 4889 from: 1 to: 30

ID AAE08351 standard; peptide; 30 AA.
XX
AC AAE08351;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectum extendin-4 peptide (residues 1-30) amide.
XX
KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
PS WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Claim 13; Page 56; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is an agonist of extendin, extendin-4 amide (residues 1-
CC 30) from Heloderma suspectum
XX
SQ Sequence 30 AA;

AAE08351 Length: 30 February 4, 2005 13:32 Type: P Check: 4889
Found using 'seq5' (mohamed337.key)

1 HEGTFTDLSKQMEEEAVRLFIWLNKG
28
-----
1 match found in sequence:
aae08352 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28)
(from "seq5ags.pep")
TOIG of: aae08352 check: 151 from: 1 to: 28

ID AAE08352 standard; peptide; 28 AA.
XX
AC AAE08352;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectum modified extendin-4 peptide.
XX
KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT /note= "C-terminal amide"
XX
```

```
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #1.
XX
KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
PS WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Disclosure; Page 14; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is Heloderma suspectum modified extendin-4 amide
CC (residues 1-28) which is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08352 Length: 28 February 4, 2005 13:32 Type: P Check: 151
Found using 'seq5' (mohamed337.key)

1 HEGTFTDLSKQMEEEAVRLAIEFLKN
28
-----
1 match found in sequence:
aae08353 ; Heloderma suspectum modified extendin-4 peptide.
(from "seq5ags.pep")
TOIG of: aae08353 check: 9131 from: 1 to: 39

ID AAE08353 standard; peptide; 39 AA.
XX
AC AAE08353;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectum modified extendin-4 peptide.
XX
KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT /note= "C-terminal amide"
XX
```

```

PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX Disclosure; Page 10; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is exendin-3 peptide from Heloderma horridum
XX
XX Sequence 39 AA;
SQ
AAE08345 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 HSDGFTTSLSKQMEERAVRLFIEWLKNGSPSSGAPPPS
28
-----
1 match found in sequence:
aae08346 ; Heloderma suspectum exendin-4 peptide.
(from "seq5ags.pep")
TOIG of: aae08346 check: 9570 from: 1 to: 39
ID AAE08346 standard; peptide; 39 AA.
XX
XX AC AAE08346;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Heloderma suspectum exendin-4 peptide.
XX
XX KW Exendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.
XX
XX OS Heloderma suspectum.
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX OS WPI; 2001-514422/56.
XX
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX OS WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX Disclosure; Page 10; 161pp; English.
XX

```

```

CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is exendin-4 peptide from Heloderma suspectum
XX
XX Sequence 39 AA;
SQ
AAE08346 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTTSLSKQMEERAVRLFIEWLKNGSPSSGAPPPS
28
-----
1 match found in sequence:
aae08350 ; Heloderma suspectum exendin-4 peptide (residues 1-30).
(from "seq5ags.pep")
TOIG of: aae08350 check: 4889 from: 1 to: 30
ID AAE08350 standard; peptide; 30 AA.
XX
XX AC AAE08350;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Heloderma suspectum exendin-4 peptide (residues 1-30).
XX
XX KW Exendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.
XX
XX OS Heloderma suspectum.
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX OS WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX Claim 13; Page 14; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is an agonist of exendin, exendin-4 (residues 1-30) from
CC Heloderma suspectum
XX
XX Sequence 30 AA;
SQ
AAE08350 Length: 30 February 4, 2005 13:32 Type: P Check: 4889 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTTSLSKQMEERAVRLFIEWLKNG

```

XX Key Location/Qualifiers
 FH Modified-site 39
 FT /note= "C-terminal amide"

PN US6284725-B1.

PD 04-SEP-2001.

PF 30-APR-1999; 99US-00302596.

PR 08-OCT-1998; 98US-0103498P.

PA (BION-) BIONEERASKA INC.

PI Coolidge TR, Ehlers MRW;

PS WPI; 2001-040881/05.

XX Metabolic intervention with GLP-1 improves function of ischemic and
 reperfused tissue.

XX Disclosure; Col 7-10; 10pp; English.

XX The invention is directed towards the amelioration of organ tissue injury
 caused by reperfusion of blood flow after ischemia. The method involves
 administering a composition containing a compound which binds to a
 receptor for glucagon-like peptide-1 (GLP-1) in a carrier. GLP-1
 effectively enhances peripheral glucose uptake without inducing dangerous
 hypoglycemia. GLP-1 strongly suppresses glucagon secretion, independent
 of its insulinotropic action and powerfully reduces plasma free fatty
 acid (FFA) level having major toxic mechanism during myocardial ischemia,
 substantially more than can be accomplished with insulin. The method is
 without side effects normally attendant with therapies presently
 available. GLP-1 suppresses paracrine by intra-islet release of insulin
 or somatostatin. GLP-1 is unique in its capacity to simultaneously
 stimulate insulin secretion and inhibit glucagon release. The present
 sequence represents a gila monster venom extendin 3 peptide fragment,
 homologous to a mammalian GLP-1 peptide fragment

XX Sequence 39 AA;

AAB85925 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGTTSDLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
 1 28

1 match found in sequence:
 aab85927; Gila monster venom extendin 4 peptide fragment.
 (from "seq5ags.pep")
 TOIG of: aab85927 check: 9570 from: 1 to: 39

ID AAB85927 standard; peptide; 39 AA.

XX AAB85927;

AC AAB85927;

XX 30-NOV-2001 (first entry)

DE Gila monster venom extendin 4 peptide fragment.
 XX GLP-1; organ tissue; injury; reperfusion; ischemia; glucose; extendin;
 KW glucagon-like peptide-1; vasotropic; antiarrhythmic; antidiabetic;
 KW gila monster; venom.

XX Heloderma suspectum.

XX Key Location/Qualifiers

FH Modified-site 39

FT /note= "C-terminal amide"

XX

PN US6284725-B1.

PD 04-SEP-2001.

PF 30-APR-1999; 99US-00302596.

PR 08-OCT-1998; 98US-0103498P.

PA (BION-) BIONEERASKA INC.

PI Coolidge TR, Ehlers MRW;

PS WPI; 2001-040881/05.

XX Metabolic intervention with GLP-1 improves function of ischemic and
 reperfused tissue.

XX Disclosure; Col 7-10; 10pp; English.

XX The invention is directed towards the amelioration of organ tissue injury
 caused by reperfusion of blood flow after ischemia. The method involves
 administering a composition containing a compound which binds to a
 receptor for glucagon-like peptide-1 (GLP-1) in a carrier. GLP-1
 effectively enhances peripheral glucose uptake without inducing dangerous
 hypoglycemia. GLP-1 strongly suppresses glucagon secretion, independent
 of its insulinotropic action and powerfully reduces plasma free fatty
 acid (FFA) level having major toxic mechanism during myocardial ischemia,
 substantially more than can be accomplished with insulin. The method is
 without side effects normally attendant with therapies presently
 available. GLP-1 suppresses paracrine by intra-islet release of insulin
 or somatostatin. GLP-1 is unique in its capacity to simultaneously
 stimulate insulin secretion and inhibit glucagon release. The present
 sequence represents a gila monster venom extendin 4 peptide fragment,
 homologous to a mammalian GLP-1 peptide fragment

XX Sequence 39 AA;

AAB85927 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

1 HEGGTTSDLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
 1 28

1 match found in sequence:
 aae08345; Heloderma horridum extendin-3 peptide.
 (from "seq5ags.pep")
 TOIG of: aae08345 check: 9591 from: 1 to: 39

ID AAE08345 standard; peptide; 39 AA.

XX AAE08345;

AC AAE08345;

XX 01-NOV-2001 (first entry)

DE Heloderma horridum extendin-3 peptide.

XX Extendin-3; antilipemic; cardiant; triglyceride; inotropic; diuretic;

XX coronary heart disease; dyslipidaemia.

XX Heloderma horridum.

XX Key Location/Qualifiers

FH Modified-site 39

FT /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX


```

XX Novel peptide agonist of glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
XX Claim 23; Page 67; 83pp; English.
XX
XX The present sequence is peptide X, a component of a novel peptide
CC conjugate. X is an extendin at least 90 & homologous to extendin-4, a
CC variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
CC at position 40 having a lipophilic substituent, a glucagon-like peptide
CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
CC C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
CC conjugate with the proviso that X is not extendin-4 or extendin-3. The
CC peptide conjugate is useful in the manufacture of a pharmaceutical
CC composition for use in treatment of type 1 or type 2 diabetes, insulin
CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
CC disorders and gastric disease. It is useful for treating disease states
CC associated with elevated blood glucose levels elicited by hormones known
CC to increase blood glucose levels, such as catechol amines including
CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
CC regulation of gastric emptying, for stimulating insulin release, for
CC lowering plasma lipid level, and for reducing mortality and morbidity
CC after myocardial infarction
XX
SQ Sequence 37 AA;
AAAB69989 Length: 37 February 4, 2005 13:32 Type: P Check: 3404
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGGGTFTSLSKQMBEEAVRLFIEWLKNQGPSSGAPS
    28
-----
1 match found in sequence:
aAB69990 ; des Pro36-des Pro37-des Pro 38-extendin-4(1-39)-NH2.
  (from "seq5ags.pep")
TOIG of: aAB69990 check: 441 from: 1 to: 36
ID AAB69990 standard; peptide; 36 AA.
XX
AC AAB69990;
XX
XX 02-MAY-2001 (first entry)
XX
XX des Pro36-des Pro37-des Pro 38-extendin-4(1-39)-NH2.
XX
XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
KW antinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
XX WO200104156-A1.
XX
XX 18-JAN-2001.
XX
XX 12-JUL-2000; 2000WO-DK000393.
XX

```

```

PR 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
PA (ZEAL-) ZEALAND PHARM AS.
XX
PI Larsen BD, Mikkelsen JD, Neve S;
XX
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
XX Claim 23; Page 67; 83pp; English.
XX
XX The present sequence is peptide X, a component of a novel peptide
CC conjugate. X is an extendin at least 90 & homologous to extendin-4, a
CC variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
CC at position 40 having a lipophilic substituent, a glucagon-like peptide
CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
CC C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
CC conjugate with the proviso that X is not extendin-4 or extendin-3. The
CC peptide conjugate is useful in the manufacture of a pharmaceutical
CC composition for use in treatment of type 1 or type 2 diabetes, insulin
CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
CC disorders and gastric disease. It is useful for treating disease states
CC associated with elevated blood glucose levels elicited by hormones known
CC to increase blood glucose levels, such as catechol amines including
CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
CC regulation of gastric emptying, for stimulating insulin release, for
CC lowering plasma lipid level, and for reducing mortality and morbidity
CC after myocardial infarction
XX
SQ Sequence 36 AA;
AAAB69990 Length: 36 February 4, 2005 13:32 Type: P Check: 441
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGGGTFTSLSKQMBEEAVRLFIEWLKNQGPSSGAS
    28
-----
1 match found in sequence:
aAB85925 ; Gila monster venom extendin 3 peptide fragment.
  (from "seq5ags.pep")
TOIG of: aAB85925 check: 9591 from: 1 to: 39
ID AAB85925 standard; peptide; 39 AA.
XX
AC AAB85925;
XX
XX 30-NOV-2001 (first entry)
XX
XX Gila monster venom extendin 3 peptide fragment.
DE
XX GLP-1; organ tissue; injury; reperfusion; ischemia; glucose; extendin;
KW glucagon-like peptide-1; vasotropic; antiarrhythmic; antidiabetic;
KW gila monster; venom.
XX
OS Heloderma suspectum.
XX

```

CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 SQ Sequence 48 AA;

AAB69983 Length: 48 February 4, 2005 13:32 Type: P Check: 8664 ..
 Found using 'seq5' (mohamed337.key)

1 NEEEEHGGTFTSDLSKQMEEEAVRLFIEWLKGPGSSGASKKKKKK
 7
 34

 1 match found in sequence:
 aab69984 ; des Pro36, Pro37, Pro38-extendin-4(1-39)-(Lys)6-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69984 check: 8216 from: 1 to: 42

ID AAB69984 standard; peptide; 42 AA.
 XX
 AC AAB69984;
 XX
 XX 02-MAY-2001 (first entry)
 DT
 DE des Pro36, Pro37, Pro38-extendin-4(1-39)-(Lys)6-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 XX WO200104156-A1.
 PN
 XX 18-JAN-2001.
 PD
 XX 12-JUL-2000; 2000WO-DK000393.
 PF
 XX 12-JUL-1999; 99US-0143591P.
 PR
 PR 09-AUG-1999; 99EP-00610043.
 XX
 XX (ZEAL-) ZEALAND PHARM AS.
 PA
 XX Larsen BD, Mikkelsen JD, Neve S;
 XX
 XX WPI; 2001-159381/16.
 XX
 XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 PT
 XX
 XX Claim 22; Page 67; 83pp; English.
 PS
 XX The present sequence is a peptide conjugate comprising a peptide (X)

CC which is an extendin at least 90 % homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 SQ Sequence 42 AA;

AAB69984 Length: 42 February 4, 2005 13:32 Type: P Check: 8216 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEEEAVRLFIEWLKGPGSSGASKKKKKK
 1
 28

 1 match found in sequence:
 aab69989 ; des Pro36-des Pro37-extendin-4(1-39)-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69989 check: 3404 from: 1 to: 37

ID AAB69989 standard; peptide; 37 AA.
 XX
 AC AAB69989;
 XX
 XX 02-MAY-2001 (first entry)
 DT
 DE des Pro36-des Pro37-extendin-4(1-39)-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 XX WO200104156-A1.
 PN
 XX 18-JAN-2001.
 PD
 XX 12-JUL-2000; 2000WO-DK000393.
 PF
 XX 12-JUL-1999; 99US-0143591P.
 PR
 PR 09-AUG-1999; 99EP-00610043.
 XX
 XX (ZEAL-) ZEALAND PHARM AS.
 PA
 XX Larsen BD, Mikkelsen JD, Neve S;
 XX
 XX WPI; 2001-159381/16.

CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction

XX Sequence 42 AA;

AAB69981 Length: 42 February 4, 2005 13:32 Type: P Check: 8189 ..
 Found using 'seq5' (mohamed337.key)

1 NEEEEEHGGTFTSDLSKQMEEEAVRLFIEWLKNGGPPSGAS
 34

 1 match found in sequence:
 aab69982; (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39)-(Lys)6-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69982 check: 8781 from: 1 to: 48

ID AAB69982 standard; peptide; 48 AA.

XX AAB69982;

AC AAB69983;

XX 02-MAY-2001 (first entry)

DT (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39)-(Lys)6-NH2.

DE Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

OS WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an exendin at least 90 % homologous to exendin-4, a variant of
 CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic

CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not exendin-4 or
 CC exendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction

XX Sequence 48 AA;

AAB69982 Length: 48 February 4, 2005 13:32 Type: P Check: 8781 ..

Found using 'seq5' (mohamed337.key)

1 KKKKKKHGGTFTSDLSKQMEEEAVRLFIEWLKNGGPPSGASKKKKKK
 34

 1 match found in sequence:

aab69983; Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39)-(Lys)6-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69983 check: 8664 from: 1 to: 48

ID AAB69983 standard; peptide; 48 AA.

XX AAB69983;

XX 02-MAY-2001 (first entry)

XX Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39)-(Lys)6-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an exendin at least 90 % homologous to exendin-4, a variant of
 CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-

aab69980 ; (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.

(from "seq5ags.pep")

TOIG of: aab69980 check: 8306 from: 1 to: 42

ID AAB69980 standard; peptide; 42 AA.

XX AAB69980;

XX 02-MAY-2001 (first entry)

XX (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
XX antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
CC which is an exendin at least 90 % homologous to exendin-4, a variant of
CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
CC isobutyric acid for Ala at position 8 and/or having a lipophilic
CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
CC R2, together with the carbon atom to which they are bound, form a
CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
CC of the peptide conjugate with the proviso that X is not exendin-4 or
CC exendin-3. The peptide conjugate for use in the manufacture of a
CC pharmaceutical composition for use in treatment of type 1 or type 2
CC diabetes, insulin resistance syndrome, obesity, eating disorder,
CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
CC treating disease states associated with elevated blood glucose levels
CC elicited by hormones known to increase blood glucose levels, such as
CC catechol amines including adrenalin, glucocorticoids, growth hormone and
CC glucagon. It is useful in regulation of gastric emptying, for stimulating
CC insulin release, for lowering plasma lipid level, and for reducing
CC mortality and morbidity after myocardial infarction

XX Sequence 42 AA;

XX AAB69980 Length: 42 February 4, 2005 13:32 Type: P Check: 8306 ..

Found using 'seq5' (mohamed337.key)

1 KKKKKHGGTFTSDLSQWEEBVRLEFIEWLKNKGPPSSGAS
7
34

1 match found in sequence:

aab69981 ; Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.

(from "seq5ags.pep")

TOIG of: aab69981 check: 8189 from: 1 to: 42

ID AAB69981 standard; peptide; 42 AA.

XX AAB69981;

XX 02-MAY-2001 (first entry)

XX Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
XX antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
CC which is an exendin at least 90 % homologous to exendin-4, a variant of
CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
CC isobutyric acid for Ala at position 8 and/or having a lipophilic
CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
CC R2, together with the carbon atom to which they are bound, form a
CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
CC of the peptide conjugate with the proviso that X is not exendin-4 or
CC exendin-3. The peptide conjugate for use in the manufacture of a
CC pharmaceutical composition for use in treatment of type 1 or type 2
CC diabetes, insulin resistance syndrome, obesity, eating disorder,
CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
CC treating disease states associated with elevated blood glucose levels
CC elicited by hormones known to increase blood glucose levels, such as
CC catechol amines including adrenalin, glucocorticoids, growth hormone and
CC glucagon. It is useful in regulation of gastric emptying, for stimulating
CC insulin release, for lowering plasma lipid level, and for reducing
CC mortality and morbidity after myocardial infarction

DR WPI; 2001-159381/16.
 XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 XX
 XX Claim 24; Page 67; 83pp; English.
 XX
 CC The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an extendin at least 90 % homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 XX Sequence 45 AA;
 AAB69968 Length: 45 February 4, 2005 13:32 Type: P Check: 8695 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HGGGTTSDLSKQMBEEAVRLFIEWLKNGPSSGAPPSPKKKKK
 28

 1 match found in sequence:
 aab69969 ; des Pro36-extendin-4(1-39) - (Lys) 6-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69969 check: 5122 from: 1 to: 44
 ID AAB69969 standard; peptide; 44 AA.
 XX
 AC AAB69969;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE des Pro36-extendin-4(1-39) - (Lys) 6-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 XX WO200104156-A1.
 XX
 XX 18-JAN-2001.
 PD
 XX 12-JUL-2000; 2000WO-DK000393.

XX
 PR 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX
 PA (ZEL-) ZEALAND PHARM AS.
 XX
 XX Larsen BD, Mikkelsen JD, Neve S;
 XX WPI; 2001-159381/16.
 XX
 PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 XX
 XX Claim 27; Page 68; 83pp; English.
 XX
 CC The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an extendin at least 90 % homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 XX Sequence 44 AA;
 AAB69969 Length: 44 February 4, 2005 13:32 Type: P Check: 5122 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HGGGTTSDLSKQMBEEAVRLFIEWLKNGPSSGAPPSPKKKKK
 28

 1 match found in sequence:
 aab69971 ; Extendin-4(1-39).
 (from "seq5ags.pep")
 TOIG of: aab69971 check: 9570 from: 1 to: 39
 ID AAB69971 standard; peptide; 39 AA.
 XX
 AC AAB69971;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 XX Extendin-4(1-39).
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenyl-
 CC methyl, where C1-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
 CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
 CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
 CC conjugate with the proviso that X is not extendin-4 or extendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 CC
 CC Sequence 39 AA;

AAB69966 Length: 39 February 4, 2005 13:32 Type: P Check: 9897
 Found using 'seq5' (mohamed337.key)

1 HGGTFTDLSKQMBEEAVRLFIEWLKNGGPPSSGPPPSK
 28

1 match found in sequence:

aab69967; des Pro36-(Lys40(palmitoyl)extendin-4(1-39)-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69967 check: 9372 from: 1 to: 39

ID AAB69967 standard; peptide; 39 AA.

XX AAB69967;

AC 02-MAY-2001 (first entry)

DT des Pro36-(Lys40(palmitoyl)extendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

OS WO200104156-A1.

PN 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 23; Page 67; 83pp; English.

XX

CC The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an extendin at least 90 % homologous to extendin-4, a
 CC variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
 CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenyl-
 CC methyl, where C1-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
 CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
 CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
 CC conjugate with the proviso that X is not extendin-4 or extendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 CC
 CC Sequence 39 AA;

AAB69967 Length: 39 February 4, 2005 13:32 Type: P Check: 9372

Found using 'seq5' (mohamed337.key)

1 HGGTFTDLSKQMBEEAVRLFIEWLKNGGPPSSGPPPSK
 28

1 match found in sequence:

aab69968; Extendin-4(1-39)-(Lys)6-NH2.
 (from "seq5ags.pep")

TOIG of: aab69968 check: 8695 from: 1 to: 45

ID AAB69968 standard; peptide; 45 AA.

XX AAB69968;

AC 02-MAY-2001 (first entry)

DT Extendin-4(1-39)-(Lys)6-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

OS WO200104156-A1.

PN 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 XX
 SQ Sequence 38 AA;

AAB69964 Length: 38 February 4, 2005 13:32 Type: P Check: 6768 ..

Found using 'seq5' (mohamed337.key)

```
1  |-----|
  HGGTFTDLSKQMEEEAVRLFIEWLKNGSPSSAPPPS
  1 28
```

1 match found in sequence:
 aab69965 ; des Gly34-(Lys40 (palmitoyl)exendin-4(1-39)-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69965 check: 9693 from: 1 to: 39

ID AAB69965 standard; peptide; 39 AA.

XX AAB69965;

AC (first entry)

DT 02-MAY-2001

DE des Gly34-(Lys40 (palmitoyl)exendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 FT and eating disorders.

XX Claim 23; Page 67; 83pp; English.

XX The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
 CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
 CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(=O)-, R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenyl-
 CC methyl, where C1-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
 CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,

CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
 CC conjugate with the proviso that X is not exendin-4 or exendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 XX
 SQ Sequence 39 AA;

AAB69965 Length: 39 February 4, 2005 13:32 Type: P Check: 9693 ..
 Found using 'seq5' (mohamed337.key)

```
1  |-----|
  HGGTFTDLSKQMEEEAVRLFIEWLKNGSPSSAPPPSK
  1 28
```

1 match found in sequence:
 aab69966 ; des Ala35-(Lys40 (palmitoyl)exendin-4(1-39)-NH2.
 (from "seq5ags.pep")

TOIG of: aab69966 check: 9897 from: 1 to: 39

ID AAB69966 standard; peptide; 39 AA.

XX AAB69966;

XX 02-MAY-2001 (first entry)

XX des Ala35-(Lys40 (palmitoyl)exendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 FT and eating disorders.

XX Claim 23; Page 67; 83pp; English.

XX The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
 CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,

1 match found in sequence:
 aab69963 ; des Ala35-exendin-4(1-39)-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69963 check: 6972 from: 1 to: 38

ID AAB69963 standard; peptide; 38 AA.
 AC AAB69963;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE des Ala35-exendin-4(1-39)-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 XX WO200104156-A1.
 FN
 PD 18-JAN-2001.
 XX
 XX 12-JUL-2000; 2000WO-DK000393.
 PF
 XX 12-JUL-1999; 99US-0143591P.
 PR
 PR 09-AUG-1999; 99EP-00610043.
 XX
 XX (ZEAL-) ZEALAND PHARM AS.
 PA
 XX Larsen BD, Mikkelsen JD, Neve S;
 PI
 XX WPI; 2001-159381/16.
 DR
 XX

Novel peptide agonist of Glucagon-like peptide, useful for decreasing the level of blood glucose and for treating diseases like diabetes, obesity and eating disorders.

Claim 23; Page 67; 83pp; English.

The present sequence is peptide X, a component of a novel peptide conjugate. X is an exendin at least 90 % homologous to exendin-4, a variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent. X is covalently bound to Z, a peptide sequence of 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenylmethyl, where C1-6-alkyl is optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not exendin-4 or exendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

Sequence 38 AA;

AAB69963 Length: 38 February 4, 2005 13:32 Type: P Check: 6972
 Found using 'seq5' (mohamed337.key)

1 HGGGFTSDLSKQMEEA VRLFIWLKNGSPSSGPPPS
 1 28

1 match found in sequence:
 aab69964 ; des Gly34-exendin-4(1-39)-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69964 check: 6768 from: 1 to: 38

ID AAB69964 standard; peptide; 38 AA.
 XX
 AC AAB69964;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE des Gly34-exendin-4(1-39)-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 XX WO200104156-A1.
 FN
 PD 18-JAN-2001.
 XX
 XX 12-JUL-2000; 2000WO-DK000393.
 PF
 XX 12-JUL-1999; 99US-0143591P.
 PR
 PR 09-AUG-1999; 99EP-00610043.
 XX
 XX (ZEAL-) ZEALAND PHARM AS.
 PA
 XX Larsen BD, Mikkelsen JD, Neve S;
 PI
 XX WPI; 2001-159381/16.
 DR

Novel peptide agonist of Glucagon-like peptide, useful for decreasing the level of blood glucose and for treating diseases like diabetes, obesity and eating disorders.

Claim 23; Page 67; 83pp; English.

The present sequence is peptide X, a component of a novel peptide conjugate. X is an exendin at least 90 % homologous to exendin-4, a variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent. X is covalently bound to Z, a peptide sequence of 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenylmethyl, where C1-6-alkyl is optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not exendin-4 or exendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

KW metabolic disorder; gastric disease; myocardial infarction.
 XX Synthetic.
 XX WO200104156-A1.
 PN 18-JAN-2001.
 XX 12-JUL-2000; 2000WO-DK000393.
 XX 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX (ZEAL-) ZEALAND PHARM AS.
 PA Larsen BD, Mikkelsen JD, Neve S;
 PI WPI; 2001-159381/16.
 XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 XX Claim 22; Page 66; 83pp; English.
 XX The present sequence is a peptide conjugate comprising a peptide (X)
 XX which is an extendin at least 90 % homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-,
 CC C(R1)(R2)-C(O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
 CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cycloheptyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX Sequence 47 AA;
 SQ AAB69959 Length: 47 February 4, 2005 13:32 Type: P Check: 5670 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 HGBGFTSDLSKQMEBAVRLFIWLNKGPPSGAPPSPKKKKKKK
 28
 1

 1 match found in sequence:
 aab69962 ; des Pro36-extendin-4 (1-39) -NH2.
 (from "seq5ags.pep")
 TOIG of: aab69962 check: 6447 from: 1 to: 38
 ID AAB69962 standard; peptide; 38 AA.
 XX
 AC AAB69962;

XX 02-MAY-2001 (first entry)
 XX des Pro36-extendin-4 (1-39) -NH2.
 DE
 XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX Synthetic.
 OS WO200104156-A1.
 XX 18-JAN-2001.
 XX 12-JUL-2000; 2000WO-DK000393.
 PF 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX (ZEAL-) ZEALAND PHARM AS.
 PA Larsen BD, Mikkelsen JD, Neve S;
 XX WPI; 2001-159381/16.
 DR Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 XX level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 PT Claim 23; Page 67; 83pp; English.
 XX The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an extendin at least 90 % homologous to extendin-4, a
 CC variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
 CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
 CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
 CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cycloheptyl, cyclohexyl,
 CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid or its salt, or the C-terminal amide of the
 CC peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 XX Sequence 38 AA;
 SQ AAB69962 Length: 38 February 4, 2005 13:32 Type: P Check: 6447 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 HGBGFTSDLSKQMEBAVRLFIWLNKGPPSGAPPSSGAPPS
 28
 1

```

XX WI; 2001-159381/16.
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
XX level of blood glucose and for treating diseases like diabetes, obesity
XX and eating disorders.
XX Claim 22; Page 66; 83pp; English.
XX
XX The present sequence is a peptide conjugate comprising a peptide (X)
XX which is an extendin at least 90 % homologous to extendin-4, a variant of
XX extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
XX 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
XX 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
XX isobutyric acid for Ala at position 8 and/or having a lipophilic
XX substituent, and Z, a peptide sequence of 4-20 amino acids covalently
XX bound to the variant. Each amino acid in Z is selected from A, L, S, T,
XX Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
XX C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
XX phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
XX sulfono, and carboxy, and phenyl and phenylmethyl are optionally
XX substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
XX halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
XX R2, together with the carbon atom to which they are bound, form a
XX cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
XX acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
XX of the peptide conjugate with the proviso that X is not extendin-4 or
XX extendin-3. The peptide conjugate is useful in the manufacture of a
XX pharmaceutical composition for use in treatment of type 1 or type 2
XX diabetes, insulin resistance syndrome, obesity, eating disorder,
XX hyperglycaemia, metabolic disorders and gastric disease. It is useful for
XX treating disease states associated with elevated blood glucose levels
XX elicited by hormones known to increase blood glucose levels, such as
XX catechol amines including adrenalin, glucocorticoids, growth hormone and
XX glucagon. It is useful in regulation of gastric emptying, for stimulating
XX insulin release, for lowering plasma lipid level, and for reducing
XX mortality and morbidity after myocardial infarction
XX
XX Sequence 46 AA;
AAB69957 Length: 46 February 4, 2005 13:32 Type: P Check: 2472
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGTFTSDLSKQMEEEAVRLFTLEWLNKGPSGPPSPKSKKKKKKK
28
-----
1 match found in sequence:
aab69958 ; des Pro36-(Lys40 (palmitoyl) extendin-4 (1-39) - (Lys)7-NH2.
(from "seq5ags.pep")
TOIG of: aab69958 check: 1947 from: 1 to: 46
ID AAB69958 standard; peptide; 46 AA.
XX
XX AAB69958;
XX
XX 02-MAY-2001 (first entry)
XX
XX des Pro36-(Lys40 (palmitoyl) extendin-4 (1-39) - (Lys)7-NH2.
XX
XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
XX antiinflammatory; peptide conjugate; diabetes; obesity;
XX insulin resistance syndrome; eating disorder; hyperglycaemia;
XX metabolic disorder; gastric disease; myocardial infarction.
XX
XX Synthetic.
XX
XX WO200104156-A1.
XX
XX 18-JAN-2001.
XX

```

```

PF 12-JUL-2000; 2000WO-DK000393.
XX
XX 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX
XX (ZEAL-) ZEALAND PHARM AS.
XX
XX Larsen BD, Mikkelsen JD, Neve S;
XX
XX WI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
XX level of blood glucose and for treating diseases like diabetes, obesity
XX and eating disorders.
XX Claim 22; Page 66; 83pp; English.
XX
XX The present sequence is a peptide conjugate comprising a peptide (X)
XX which is an extendin at least 90 % homologous to extendin-4, a variant of
XX extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
XX 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
XX 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
XX isobutyric acid for Ala at position 8 and/or having a lipophilic
XX substituent, and Z, a peptide sequence of 4-20 amino acids covalently
XX bound to the variant. Each amino acid in Z is selected from A, L, S, T,
XX Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
XX C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
XX phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
XX sulfono, and carboxy, and phenyl and phenylmethyl are optionally
XX substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
XX halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
XX R2, together with the carbon atom to which they are bound, form a
XX cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
XX acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
XX of the peptide conjugate with the proviso that X is not extendin-4 or
XX extendin-3. The peptide conjugate is useful in the manufacture of a
XX pharmaceutical composition for use in treatment of type 1 or type 2
XX diabetes, insulin resistance syndrome, obesity, eating disorder,
XX hyperglycaemia, metabolic disorders and gastric disease. It is useful for
XX treating disease states associated with elevated blood glucose levels
XX elicited by hormones known to increase blood glucose levels, such as
XX catechol amines including adrenalin, glucocorticoids, growth hormone and
XX glucagon. It is useful in regulation of gastric emptying, for stimulating
XX insulin release, for lowering plasma lipid level, and for reducing
XX mortality and morbidity after myocardial infarction
XX
XX Sequence 46 AA;
AAB69958 Length: 46 February 4, 2005 13:32 Type: P Check: 1947
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGTFTSDLSKQMEEEAVRLFTLEWLNKGPSGPPSPKSKKKKKKK
28
-----
1 match found in sequence:
aab69959 ; Lys40 (palmitoyl) extendin-4 (1-39) - (Lys)7-NH2.
(from "seq5ags.pep")
TOIG of: aab69959 check: 5670 from: 1 to: 47
ID AAB69959 standard; peptide; 47 AA.
XX
XX AAB69959;
XX
XX 02-MAY-2001 (first entry)
XX
XX Lys40 (palmitoyl) extendin-4 (1-39) - (Lys)7-NH2.
XX
XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
XX antiinflammatory; peptide conjugate; diabetes; obesity;
XX insulin resistance syndrome; eating disorder; hyperglycaemia;
XX

```

CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkenyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 CC
 CC
 CC Sequence 46 AA;

AAB69955 Length: 46 February 4, 2005 13:32 Type: P Check: 1833 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGGTFTSLSKQMBEEAVRLFIEWLKNGSPSSGAPPPKKKKKKK
 28

 1 match found in sequence:
 aab69956 ; Des Gly34-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.
 (from "seq5ags.pep")

TOIG of: aab69956 check: 2268 from: 1 to: 46

ID AAB69956 standard; peptide; 46 AA.
 XX
 AC AAB69956;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE des Gly34-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.

XX WO200104156-A1.
 XX
 XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an extendin at least 90 % homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 CC
 CC
 CC Sequence 46 AA;

AAB69956 Length: 46 February 4, 2005 13:32 Type: P Check: 2268 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGGTFTSLSKQMBEEAVRLFIEWLKNGSPSSAPPPKKKKKKK
 28

 1 match found in sequence:
 aab69957 ; des Ala35-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.
 (from "seq5ags.pep")

TOIG of: aab69957 check: 2472 from: 1 to: 46

ID AAB69957 standard; peptide; 46 AA.

XX AAB69957;

XX 02-MAY-2001 (first entry)

XX des Ala35-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction

XX Sequence 44 AA;

AA69953 Length: 44 February 4, 2005 13:32 Type: P Check: 5647 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTSLSKQMEAEVRLFIWLKNGGPPSGPPSPKKKKK
 28

1 match found in sequence:
 aab69954 ; des Gly34-exendin-4(1-39)-(Lys)6-NH2.
 (from "seq5ags.pep")
 TOIG of: aab69954 check: 5443 from: 1 to: 44

ID AAB69954 standard; peptide; 44 AA.

XX AAB69954;

AC AAB69954;

XX 02-MAY-2001 (first entry)

XX des Gly34-exendin-4(1-39)-(Lys)6-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an exendin at least 90 % homologous to exendin-4, a variant of
 CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and

CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not exendin-4 or
 CC exendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction

XX Sequence 44 AA;

AA69954 Length: 44 February 4, 2005 13:32 Type: P Check: 5443 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTSLSKQMEAEVRLFIWLKNGGPPSGPPSPKKKKK
 28

1 match found in sequence:
 aab69955 ; des Ser39-(Lys40 (palmitoyl)exendin-4(1-39)-(Lys)7-NH2.
 (from "seq5ags.pep")

TOIG of: aab69955 check: 1833 from: 1 to: 46

ID AAB69955 standard; peptide; 46 AA.

XX AAB69955;

AC AAB69955;

XX 02-MAY-2001 (first entry)

XX des Ser39-(Lys40 (palmitoyl)exendin-4(1-39)-(Lys)7-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an exendin at least 90 % homologous to exendin-4, a variant of
 CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently

1 match found in sequence:
aab69952 ; des Ala35-exendin-4 (1-39) - (Lys)6-NH2.
(from "seq5ags.pep")
TOIG of: aab69952 check: 5122 from: 1 to: 44

ID AAB69952 standard; peptide; 44 AA.
XX
AC AAB69952;
XX
DT 02-MAY-2001 (first entry)
DE
DE des Ala35-exendin-4 (1-39) - (Lys)6-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
XX
XX WO200104156-A1.
XX
XX 18-JAN-2001.
XX
XX 12-JUL-2000; 2000WO-DK000393.
XX
XX 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX
XX (ZEAL-) ZEALAND PHARM AS.
XX
XX Larsen BD, Mikkelsen JD, Neve S;
XX
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
XX Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X) which is an extendin at least 90 % homologous to extendin-4, a variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

Sequence 44 AA;
XX
XX

1 match found in sequence:
aab69953 ; des Ala35-exendin-4 (1-39) - (Lys)6-NH2.
(from "seq5ags.pep")
TOIG of: aab69953 check: 5647 from: 1 to: 44

ID AAB69953 standard; peptide; 44 AA.
XX
AC AAB69953;
XX
DT 02-MAY-2001 (first entry)
DE
DE des Ala35-exendin-4 (1-39) - (Lys)6-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
XX
XX WO200104156-A1.
XX
XX 18-JAN-2001.
XX
XX 12-JUL-2000; 2000WO-DK000393.
XX
XX 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX
XX (ZEAL-) ZEALAND PHARM AS.
XX
XX Larsen BD, Mikkelsen JD, Neve S;
XX
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
XX Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X) which is an extendin at least 90 % homologous to extendin-4, a variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

Sequence 44 AA;
XX
XX


```

KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
OS Heloderma suspectum.
OS Synthetic.
PN WO200073331-A2.
PD 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX Example 181; Page 120; 133pp; English.
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
SQ Sequence 30 AA;

AAB64366 Length: 30 February 4, 2005 13:32 Type: P Check: 4862 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  | HGDATFTSDLSKQMBEEAVRLFIWLNKG 28
  | 1

-----
1 match found in sequence:
aab64367; Exendin agonist, SEQ ID NO:187.
  (from "seq5ags.pep")
TOIG of: aab64367 check: 9563 from: 1 to: 39

ID AAB64367 standard; peptide; 39 AA.
XX
XX AAB64367;
XX
XX 27-MAR-2001 (first entry)
XX

```

```

DE Extendin agonist, SEQ ID NO:187.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX Example 182; Page 121; 133pp; English.
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
SQ Sequence 39 AA;

AAB64367 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  | AGEFTFTSDLSKQMBEEAVRLFIWLNKG 28
  | 1

-----
1 match found in sequence:
aab64368; Exendin agonist, SEQ ID NO:188.
  (from "seq5ags.pep")
TOIG of: aab64368 check: 9112 from: 1 to: 39

ID AAB64368 standard; peptide; 39 AA.
XX
XX AAB64368;
XX

```



```

OS Heloderma suspectum.
OS Synthetic.
PN WO200073331-A2.
PD 07-DEC-2000.
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 179; Page 119; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 36 AA;

AAB64364 Length: 36 February 4, 2005 13:32 Type: P Check: 862 ..
Found using 'seq5' (mohamed337.key)

1 AGEFTFTSLSKQMEEEAVRLFIEWLKGXSGXG
  1
  28
-----
1 match found in sequence:
aab64365 ; Extendin agonist, SEQ ID NO:185.
(from "seq5ags.pep")
TOIG of: aab64365 check: 7441 from: 1 to: 35

ID AAB64365 standard; peptide; 35 AA.
XX
AC AAB64365;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:185.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;

insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
PD 07-DEC-2000.
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 180; Page 120; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 35 AA;

AAB64365 Length: 35 February 4, 2005 13:32 Type: P Check: 7441 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSLSKQMEEEAVRLFIEWLKGXGSSGA
  1
  28
-----
1 match found in sequence:
aab64366 ; Extendin agonist, SEQ ID NO:186.
(from "seq5ags.pep")
TOIG of: aab64366 check: 4862 from: 1 to: 30

ID AAB64366 standard; peptide; 30 AA.
XX
AC AAB64366;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:186.
XX

```

```

XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 177; Page 118; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX CC
XX SQ Sequence 38 AA;
AAB64362 Length: 38 February 4, 2005 13:32 Type: P Check: 7197 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEATFTSLSKQMBEAVRLFIEWLKNGSPSSGAXXX
28
-----
1 match found in sequence:
aab64363; Extendin agonist, SEQ ID NO:183.
(from "seq5ags.pep")
TOIG of: aab64363 check: 1694 from: 1 to: 37
ID AAB64363 standard; peptide; 37 AA.
XX
XX AAB64363;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Extendin agonist, SEQ ID NO:183.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX OS Synthetic.
XX
XX PD WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 178; Page 119; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX CC
XX SQ Sequence 37 AA;
AAB64363 Length: 37 February 4, 2005 13:32 Type: P Check: 1694 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGAFTFTSLSKQMBEAVRLFIEWLKNGSGAGAA
28
-----
1 match found in sequence:
aab64364; Extendin agonist, SEQ ID NO:184.
(from "seq5ags.pep")
TOIG of: aab64364 check: 862 from: 1 to: 36
ID AAB64364 standard; peptide; 36 AA.
XX
XX AAB64364;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Extendin agonist, SEQ ID NO:184.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX
XX

```

```

XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX Example 175; Page 117; 133pp; English.
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX Sequence 29 AA;
XX
AAB64360 Length: 29 February 4, 2005 13:32 Type: P Check: 2313 ..
Found using 'seqs' (mohamed337.key)
1 AGEGTFTDLSKQLEEEAVRLFTEFLKNG
1 |-----|
1 1 AGEGTFTDLSKQLEEEAVRLFTEFLKNG
1 28
-----
1 match found in sequence:
aab64361 ; Extendin agonist, SEQ ID NO:181.
(from "seq5ags.pep")
TOIG of: aab64361 check: 7457 from: 1 to: 38
ID AAB64361 standard; peptide; 38 AA.
XX
AC AAB64361;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:181.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
OS
PN WO200073331-A2.
XX
PD 07-DEC-2000.

```

```

XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX Example 176; Page 118; 133pp; English.
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX Sequence 38 AA;
XX
AAB64361 Length: 38 February 4, 2005 13:32 Type: P Check: 7457 ..
Found using 'seqs' (mohamed337.key)
1 HGAGTFTDLSKQMEEEAVRLFIEWLKNGKSSGAXXX
1 |-----|
1 1 HGAGTFTDLSKQMEEEAVRLFIEWLKNGKSSGAXXX
1 28
-----
1 match found in sequence:
aab64362 ; Extendin agonist, SEQ ID NO:182.
(from "seq5ags.pep")
TOIG of: aab64362 check: 7197 from: 1 to: 38
ID AAB64362 standard; peptide; 38 AA.
XX
AC AAB64362;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:182.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
OS
PN WO200073331-A2.

```

```

XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 173; Page 116; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 31 AA;
XX
AAB64358 Length: 31 February 4, 2005 13:32 Type: P Check: 7345 ..
Found using 'seq5' (mohamed337.key)
1 HGEATFTSLSKQMBEAVRLFIEWLKNGGP
1 28
-----|-----
1 match found in sequence:
aab64359 ; Extendin agonist, SEQ ID NO:179.
(from "seq5ags.pep")
TOIG of: aab64359 check: 4423 from: 1 to: 30
ID AAB64359 standard; peptide; 30 AA.
XX
XX AAB64359;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:179.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX

```

```

XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 174; Page 117; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 30 AA;
XX
AAB64359 Length: 30 February 4, 2005 13:32 Type: P Check: 4423 ..
Found using 'seq5' (mohamed337.key)
1 HGEATFTSLSKQMBEAVRLFIEWLKNGG
1 28
-----|-----
1 match found in sequence:
aab64360 ; Extendin agonist, SEQ ID NO:180.
(from "seq5ags.pep")
TOIG of: aab64360 check: 2313 from: 1 to: 29
ID AAB64360 standard; peptide; 29 AA.
XX
XX AAB64360;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:180.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX

```

```

XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 171; Page 115; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 32 AA;
AAB64356 Length: 32 February 4, 2005 13:32 Type: P Check: 18
Found using 'seq5' (mohamed337.key)
1 AGEGTFTDLSKQMEEEAVRLFIEFLKNGGGS
1 |-----|
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGGGS
1 |-----|
1 match found in sequence:
aab64357 ; Extendin agonist, SEQ ID NO:177.
(from "seq5ags.pep")
TOIG of: aab64357 check: 9574 from: 1 to: 32
ID AAB64357 standard; peptide; 32 AA.
XX AC AAB64357;
XX DT 27-MAR-2001 (first entry)
XX DE Extendin agonist, SEQ ID NO:177.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;

```

```

XX WPI; 2001-137634/14.
XX DR Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 172; Page 116; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 32 AA;
AAB64357 Length: 32 February 4, 2005 13:32 Type: P Check: 9574
Found using 'seq5' (mohamed337.key)
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGGGS
1 |-----|
1 match found in sequence:
aab64358 ; Extendin agonist, SEQ ID NO:178.
(from "seq5ags.pep")
TOIG of: aab64358 check: 7345 from: 1 to: 31
ID AAB64358 standard; peptide; 31 AA.
XX AC AAB64358;
XX DT 27-MAR-2001 (first entry)
XX DE Extendin agonist, SEQ ID NO:178.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.

```

```

XX PS Example 169; Page 114; 133pp; English.
XX PS
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 34 AA;
SQ
AAB64354 Length: 34 February 4, 2005 13:32 Type: P Check: 5154 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEATFTSLSKQMEAEAVRLFIEWLKNGGPSSG
28
-----
1 match found in sequence:
aab64355 ; Extendin agonist, SEQ ID NO:175.
(from "seq5ags.pep")
TOIG of: aab64355 check: 2737 from: 1 to: 33
ID AAB64355 standard; peptide; 33 AA.
XX AC
XX AAB64355;
XX DT 27-MAR-2001 (first entry)
XX DE Extendin agonist, SEQ ID NO:175.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood

```

```

PT PT Glucose levels and treating gestational diabetes mellitus in a subject,
XX XX especially in a human.
XX PS Example 170; Page 115; 133pp; English.
XX PS
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 33 AA;
SQ
AAB64355 Length: 33 February 4, 2005 13:32 Type: P Check: 2737 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGTFTSLSKQMEAEAVRLFIEWLKNGGPSS
28
-----
1 match found in sequence:
aab64356 ; Extendin agonist, SEQ ID NO:176.
(from "seq5ags.pep")
TOIG of: aab64356 check: 18 from: 1 to: 32
ID AAB64356 standard; peptide; 32 AA.
XX AC
XX AAB64356;
XX DT 27-MAR-2001 (first entry)
XX DE Extendin agonist, SEQ ID NO:176.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT

```

```

CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 35 AA;
AAB64352 Length: 35 February 4, 2005 13:32 Type: P Check: 7446 ..
Found using 'seq5' (mohamed337.key)
1 -----|-----|
  AEGGTFSTLSKQMEAEAVRLFIEFLKNGPSSGA
  1 28
-----
1 match found in sequence:
aab64353 ; Extendin agonist, SEQ ID NO:173.
(from "seq5ags.pep")
TOIG of: aab64353 check: 7002 from: 1 to: 35
ID AAB64353 standard; peptide; 35 AA.
XX
AC AAB64353;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:173.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
XX
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
PS Example 168; Page 114; 133pp; English.

```

```

XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 35 AA;
AAB64353 Length: 35 February 4, 2005 13:32 Type: P Check: 7002 ..
Found using 'seq5' (mohamed337.key)
1 -----|-----|
  HGAGTFTSLSKQLEAEAVRLFIEFLKNGPSSGA
  1 28
-----
1 match found in sequence:
aab64354 ; Extendin agonist, SEQ ID NO:174.
(from "seq5ags.pep")
TOIG of: aab64354 check: 5154 from: 1 to: 34
ID AAB64354 standard; peptide; 34 AA.
XX
AC AAB64354;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:174.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
XX
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

```

combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalcaemia, hypomagnasaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Exendins are peptides from the salivary secretions of the Gila monster (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulinotropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, exendins and exendin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a exendin agonist of the invention which is based upon the sequence of exendin-4

SQ Sequence 36 AA;
AAB4351 Length: 36 February 4, 2005 13:32 Type: P Check: 9777 ...
Found using 'seq5' (mohamed337.key)

```

1 Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGEFTTSDASKQLEEEAVRLFIEFLKNGCPSSGAP
1 28

```

```

-----
1 match found in sequence:
aab64352 ; Exendin agonist, SEQ ID NO:172.
(from "seq5ags.pep")
TOIG of: aab64352 check: 7446 from: 1 to: 35

```

ID AAB64352 standard; peptide; 35 AA.

DT 27-MAR-2001 (first entry) XX

Exendin agonist. SEO TD NO

Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

OS Synthetic.

PN WO200073331-A2.

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

XX	6
XX	7
XX	8
XX	9
XX	10
XX	11
XX	12
XX	13
XX	14
XX	15
XX	16
XX	17
XX	18
XX	19
XX	20
XX	21
XX	22
XX	23
XX	24
XX	25
XX	26
XX	27
XX	28
XX	29
XX	30
XX	31
XX	32
XX	33
XX	34
XX	35
XX	36
XX	37
XX	38
XX	39
XX	40
XX	41
XX	42
XX	43
XX	44
XX	45
XX	46
XX	47
XX	48
XX	49
XX	50
XX	51
XX	52
XX	53
XX	54
XX	55
XX	56
XX	57
XX	58
XX	59
XX	60
XX	61
XX	62
XX	63
XX	64
XX	65
XX	66
XX	67
XX	68
XX	69
XX	70
XX	71
XX	72
XX	73
XX	74
XX	75
XX	76
XX	77
XX	78
XX	79
XX	80
XX	81
XX	82
XX	83
XX	84
XX	85
XX	86
XX	87
XX	88
XX	89
XX	90
XX	91
XX	92
XX	93
XX	94
XX	95
XX	96
XX	97
XX	98
XX	99
XX	100

PA (AMYL-) AMYLIN PHARM INC.

PI Hiles R, Prickett KS;

DK
XX
WFI; 2001-137034/14.

DR WPI; 2001-137634/14.

PT glucose levels and treating gestational
PT especially in a human.

100

PS Example 167; Page 113; 133pp; English
XX
CC The invention relates to the use of an

CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC Sequence 38 AA;
 CC
 CC AAB64348 Length: 38 February 4, 2005 13:32 Type: P Check: 5882 ..
 CC Found using 'seq5' (mohamed337.key)
 CC
 CC 1 HGAGTFTSDLSKQLEEAVERLFTIEFLKNGSPSSGAPP
 CC 28
 CC
 CC -----
 CC 1 match found in sequence:
 CC aab64349 ; Exendin agonist, SEQ ID NO:169.
 CC (from "seq5ags.pep")
 CC TOIG of: aab64349 check: 3269 from: 1 to: 37
 CC
 CC ID AAB64349 standard; peptide; 37 AA.
 CC XX
 CC AC AAB64349;
 CC XX
 CC DT 27-MAR-2001 (first entry)
 CC XX
 CC DE Exendin agonist, SEQ ID NO:169.
 CC XX
 CC KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 CC pregnancy complication; neonatal abnormality; blood glucose modulator;
 CC insulinotropic; anorectic; exendin-4.
 CC KW
 CC XX Heloderma suspectum.
 CC OS Synthetic.
 CC OS
 CC PN WO200073331-A2.
 CC XX
 CC PD 07-DEC-2000.
 CC XX
 CC PF 23-MAY-2000; 2000WO-US014231.
 CC XX
 CC PR 01-JUN-1999; 99US-00323867.
 CC XX
 CC PA (AMYL-) AMYLIN PHARM INC.
 CC XX
 CC PI Hiles R, Prickett KS;
 CC XX
 CC DR WPI; 2001-137634/14.
 CC XX
 CC PT Use of exendins or exendin agonists for lowering or reducing blood
 CC glucose levels and treating gestational diabetes mellitus in a subject,
 CC especially in a human.
 CC PT
 CC XX Example 164; Page 112; 133pp; English.
 CC PS
 CC XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women

CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC Sequence 37 AA;
 CC
 CC AAB64349 Length: 37 February 4, 2005 13:32 Type: P Check: 3269 ..
 CC Found using 'seq5' (mohamed337.key)
 CC
 CC 1 HGATFTSDLSKQMEERAVRLFTIEFLKNGSPSSGAPP
 CC 28
 CC
 CC -----
 CC 1 match found in sequence:
 CC aab64350 ; Exendin agonist, SEQ ID NO:170.
 CC (from "seq5ags.pep")
 CC TOIG of: aab64350 check: 306 from: 1 to: 36
 CC
 CC ID AAB64350 standard; peptide; 36 AA.
 CC XX
 CC AC AAB64350;
 CC XX
 CC DT 27-MAR-2001 (first entry)
 CC XX
 CC DE Exendin agonist, SEQ ID NO:170.
 CC XX
 CC KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 CC pregnancy complication; neonatal abnormality; blood glucose modulator;
 CC insulinotropic; anorectic; exendin-4.
 CC KW
 CC XX Heloderma suspectum.
 CC OS Synthetic.
 CC OS
 CC PN WO200073331-A2.
 CC XX
 CC PD 07-DEC-2000.
 CC XX
 CC PF 23-MAY-2000; 2000WO-US014231.
 CC XX
 CC PR 01-JUN-1999; 99US-00323867.
 CC XX
 CC PA (AMYL-) AMYLIN PHARM INC.
 CC XX
 CC PI Hiles R, Prickett KS;
 CC XX
 CC DR WPI; 2001-137634/14.
 CC XX
 CC PT Use of exendins or exendin agonists for lowering or reducing blood
 CC glucose levels and treating gestational diabetes mellitus in a subject,
 CC especially in a human.
 CC PT
 CC XX Example 165; Page 112; 133pp; English.
 CC PS
 CC XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women

CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64346 Length: 28 February 4, 2005 13:32 Type: P Check: 9887 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTDLSKQLEEEAVRLFIEFLKA 28
 |-----|

1 match found in sequence:
 aab64347 ; Exendin agonist, SEQ ID NO:167.
 (from "seq5ags.pep")

TOIG of: aab64347 check: 6326 from: 1 to: 38

ID AAB64347 standard; peptide; 38 AA.

XX AAB64347;

AC 27-MAR-2001 (first entry)

DT Exendin agonist, SEQ ID NO:167.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

OS WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 162; Page 111; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities

CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX

SQ Sequence 38 AA;

AAB64347 Length: 38 February 4, 2005 13:32 Type: P Check: 6326 ..
 Found using 'seq5' (mohamed337.key)

1 AGEGTFTDLSKQLEEEAVRLFIEWLKNGGPPSGAPPP 28
 |-----|

1 match found in sequence:
 aab64348 ; Exendin agonist, SEQ ID NO:168.
 (from "seq5ags.pep")

TOIG of: aab64348 check: 5882 from: 1 to: 38

ID AAB64348 standard; peptide; 38 AA.

XX AAB64348;

XX 27-MAR-2001 (first entry)

XX Exendin agonist, SEQ ID NO:168.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

OS WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 163; Page 111; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM

The invention relates to the use of an extendin (AA864181-B64182) or an extendin agonist (AA864185-B64368) for treating gestational diabetes mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Extendins are peptides from the salivary secretions of the Gila monster (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit

CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4

XX SQ Sequence 28 AA;

AAB64342 Length: 28 February 4, 2005 13:32 Type: P Check: 9965 ..

Found using 'seq5' (mohamed337.key)

```
1 AGDGTFTSDLSKQLEEEAVRLFIEFAKN
  1 |-----|
  28
```

1 match found in sequence:

aab64343 ; Extendin agonist, SEQ ID NO:163.

(from "seq5ags.pep")

TOIG of: aab64343 check: 420 from: 1 to: 28

ID AAB64343 standard; peptide; 28 AA.

XX AC AAB64343;

XX DT 27-MAR-2001 (first entry)

XX DE Extendin agonist, SEQ ID NO:163.

XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX OS Heloderma suspectum.

XX OS Synthetic.

XX PN WO200073331-A2.

XX PD 07-DEC-2000.

XX PF 23-MAY-2000; 2000WO-US014231.

XX PR 01-JUN-1999; 99US-00323867.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Hiles R, Prickett KS;

XX DR WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

PS Example 158; Page 109; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do

CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4

XX SQ Sequence 28 AA;

AAB64343 Length: 28 February 4, 2005 13:32 Type: P Check: 420 ..

Found using 'seq5' (mohamed337.key)

```
1 AGDGTFTSDLSKQMEEEAVRLFIEWLAN
  1 |-----|
  28
```

1 match found in sequence:

aab64344 ; Extendin agonist, SEQ ID NO:164.

(from "seq5ags.pep")

TOIG of: aab64344 check: 9981 from: 1 to: 28

ID AAB64344 standard; peptide; 28 AA.

XX AC AAB64344;

XX DT 27-MAR-2001 (first entry)

XX DE Extendin agonist, SEQ ID NO:164.

XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX OS Heloderma suspectum.

XX OS Synthetic.

XX PN WO200073331-A2.

XX PD 07-DEC-2000.

XX PF 23-MAY-2000; 2000WO-US014231.

XX PR 01-JUN-1999; 99US-00323867.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Hiles R, Prickett KS;

XX DR WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

PS Example 159; Page 109; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the

```

SQ      Sequence 28 AA;
AAB64340 Length: 28 February 4, 2005 13:32 Type: P Check: 126
Found using 'seq5' (mohamed337.key)

1      |-----|
      AGDGTFTSLSKQLEEEAVRLFIEAKN      28
      |-----|
1 match found in sequence:
aab64341; Exendin agonist, SEQ ID NO:161.
(from "seq5ags.pep")
TOIG of: aab64341 check: 404 from: 1 to: 28

ID AAB64341 standard; peptide; 28 AA.
XX
AC AAB64341;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:161.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
DR Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 156; Page 108; 133pp; English.
XX
PS The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin

```

```

CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
AAB64341 Length: 28 February 4, 2005 13:32 Type: P Check: 404
Found using 'seq5' (mohamed337.key)

1      |-----|
      AGDGTFTSLSKQMEEEAVRLFIEWAKN      28
      |-----|
1 match found in sequence:
aab64342; Exendin agonist, SEQ ID NO:162.
(from "seq5ags.pep")
TOIG of: aab64342 check: 9965 from: 1 to: 28

ID AAB64342 standard; peptide; 28 AA.
XX
AC AAB64342;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:162.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
DR Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 157; Page 108; 133pp; English.
XX
PS The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin

```

Fri Feb 4 14:12:17 2005

AAB64339 Length: 28 February 4, 2005 13:32 Type: P Check: 140 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEEEAVRLFIDFLKN 28
1

1 match found in sequence:
aab64339 ; Exendin agonist, SEQ ID NO:159.
(from "seq5ags.pep")
TOIG of: aab64339 check: 140 from: 1 to: 28

ID AAB64339 standard; peptide; 28 AA.

AC AAB64339;

DT 27-MAR-2001 (first entry)

DE Exendin agonist, SEQ ID NO:159.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX Example 154; Page 107; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4

XX Sequence 28 AA;

XX SQ

1 AGDGTFTSDLSKQLEEEAVRLFTEALKN 28
1

1 match found in sequence:
aab64340 ; Exendin agonist, SEQ ID NO:160.
(from "seq5ags.pep")
TOIG of: aab64340 check: 126 from: 1 to: 28

ID AAB64340 standard; peptide; 28 AA.

XX AAB64340;

DT 27-MAR-2001 (first entry)

DE Exendin agonist, SEQ ID NO:160.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX Example 155; Page 107; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4

XX

```

1 -----
1 match found in sequence:
aab64337 ; Exendin agonist, SEQ ID NO:157.
(from "seq5ags.pep")
TOIG of: aab64337 Check: 666 from: 1 to: 28

ID AAB64337 standard; peptide; 28 AA.
XX
XX AAB64337;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Exendin agonist, SEQ ID NO:157.
DE
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS
XX Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 152; Page 106; 133pp; English.
PS
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
SQ

AAB64337 Length: 28 February 4, 2005 13:32 Type: P Check: 666
Found using 'seq5' (mohamed337.key)
|-----|

```

```

AAB64338 Length: 28 February 4, 2005 13:32 Type: P Check: 227
Found using 'seq5' (mohamed337.key)

```

Fri Feb 4 14:12:17 2005

(from "seq5ags.pep")
TOIG of: aab64335 check: 1035 from: 1 to: 28
ID AAB64335 standard; peptide; 28 AA.

XX AC AAB64335;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:155.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX XX Use of exendins or exendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 150; Page 105; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX

SQ Sequence 28 AA;
AAB64335 Length: 28 February 4, 2005 13:32 Type: P Check: 1035
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMBEAEVRLFXEWLKN 28
-----|-----|
1 AGDGTFTSLSKQMBEAEVRLFXEFLKN 28

1 match found in sequence:
aab64336 : Exendin agonist, SEQ ID NO:156.
(from "seq5ags.pep")
TOIG of: aab64336 check: 596 from: 1 to: 28

ID AAB64336 standard; peptide; 28 AA.
XX AC AAB64336;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:156.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX XX Use of exendins or exendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.

Example 151; Page 105; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX

SQ Sequence 28 AA;
AAB64336 Length: 28 February 4, 2005 13:32 Type: P Check: 596
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMBEAEVRLFXEFLKN 28
-----|-----|
1 AGDGTFTSLSKQMBEAEVRLFXEFLKN 28


```

XX AAB64333;
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:153.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 148; Page 104; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
SQ
AAB64333 Length: 28 February 4, 2005 13:32 Type: P Check: 989
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSDLSKQMEEEAVRLFWELKN 28
  |-----|

1 match found in sequence:
aab64334 ; Extendin agonist, SEQ ID NO:154.
(from "seq5ags.pep")
TOIG of: aab64334 check: 550 from: 1 to: 28

```

```

ID AAB64334 standard; peptide; 28 AA.
XX
XX AAB64334;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:154.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 149; Page 104; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
SQ
AAB64334 Length: 28 February 4, 2005 13:32 Type: P Check: 550
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSDLSKQLEEEAVRLFVEFLKN 28
  |-----|

1 match found in sequence:
aab64335 ; Extendin agonist, SEQ ID NO:155.

```

XX DE Extensin agonist, SEQ ID NO:151.
XX DE Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 146; Page 103; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64331 Length: 28 February 4, 2005 13:32 Type: P Check: 1086 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEEAARLXIEWLKN 28

1 match found in sequence:
aab64332 ; Extensin agonist, SEQ ID NO:152.
(from "seq5agr.pep")
TOIG of: aab64332 check: 647 from: 1 to: 28
ID AAB64332 standard; peptide; 28 AA.
XX AAB64332;
AC

XX DT 27-MAR-2001 (first entry)
XX DE Extensin agonist, SEQ ID NO:152.
XX KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 147; Page 103; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64332 Length: 28 February 4, 2005 13:32 Type: P Check: 647 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEEAARLXIEFLKN 28

1 match found in sequence:
aab64333 ; Extensin agonist, SEQ ID NO:153.
(from "seq5agr.pep")
TOIG of: aab64333 check: 989 from: 1 to: 28
ID AAB64333 standard; peptide; 28 AA.

```

KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
OS Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX Use of exendins or exendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX Example 144; Page 102; 133pp; English.
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
AAB64329 Length: 28 February 4, 2005 13:32 Type: P Check: 459
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEEEAVRAPIEWLKN
1
-----
1 match found in sequence:
aab64330 ; Exendin agonist, SEQ ID NO:150.
(from "seq5ags.pep")
TOIG of: aab64330 check: 20 from: 1 to: 28
ID AAB64330 standard; peptide; 28 AA.
XX
XX AAB64330;
XX
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:150.

```

```

XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
OS Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX Use of exendins or exendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX Example 145; Page 102; 133pp; English.
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
AAB64330 Length: 28 February 4, 2005 13:32 Type: P Check: 20
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEAIVRAPIEFILKN
1
-----
1 match found in sequence:
aab64331 ; Exendin agonist, SEQ ID NO:151.
(from "seq5ags.pep")
TOIG of: aab64331 check: 1086 from: 1 to: 28
ID AAB64331 standard; peptide; 28 AA.
XX
XX AAB64331;
XX
XX 27-MAR-2001 (first entry)
XX
XX

```

OS Synthetic.
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
PI Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
DR
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 142; Page 101; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64327 Length: 28 February 4, 2005 13:32 Type: P Check: 350 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEEEAVALFIEWLKN 28

1 match found in sequence:
aab64328 ; Extendin agonist, SEQ ID NO:148.
(from "seq5ags.pep")
TOIG of: aab64328 check: 9911 from: 1 to: 28
ID AAB64328 standard; peptide; 28 AA.
XX
AC AAB64328;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:148.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
PI Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
DR
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 143; Page 101; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64328 Length: 28 February 4, 2005 13:32 Type: P Check: 9911 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEEEAVALFIEWLKN 28

1 match found in sequence:
aab64329 ; Extendin agonist, SEQ ID NO:149.
(from "seq5ags.pep")
TOIG of: aab64329 check: 459 from: 1 to: 28
ID AAB64329 standard; peptide; 28 AA.
XX
AC AAB64329;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:149.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;

```

PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
DR
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 140; Page 100; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64325 Length: 28 February 4, 2005 13:32 Type: P Check: 291 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEEEAARLFIEFLKN 28
|-----|
1 aab64326 found in sequence:
  aab64326 ; Exendin agonist, SEQ ID NO:146.
  (from "seq5ags.pep")
  TOIG of: aab64326 check: 9852 from: 1 to: 28

ID AAB64326 standard; peptide; 28 AA.
XX
AC AAB64326;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:146.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.

-----
1 match found in sequence:
  aab64327 ; Exendin agonist, SEQ ID NO:147.
  (from "seq5ags.pep")
  TOIG of: aab64327 check: 350 from: 1 to: 28

ID AAB64327 standard; peptide; 28 AA.
XX
AC AAB64327;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:147.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.

```

```

PR 01-JUN-1999; 99US-00323867.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 138; Page 99; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
XX
AAB64323 Length: 28 February 4, 2005 13:32 Type: P Check: 622 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSDLSKQWEEAAVRLFIETLKN 28
-----
1 match found in sequence:
aab64324 ; Exendin agonist, SEQ ID NO:144.
(from "seq5ags.pep")
TOIG of: aab64324 check: 183 from: 1 to: 28
ID AAB64324 standard; peptide; 28 AA.
XX
XX AC AAB64324;
XX
XX DT 27-MAR-2001 (first entry)
XX
XX DE Exendin agonist, SEQ ID NO:144.
XX
XX EX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX
XX OS Heloderma suspectum.
XX
XX OS Synthetic.
XX
XX PN WO200073331-A2.
XX
XX PD 07-DEC-2000.
XX
XX

```

```

PF 23-MAY-2000; 2000WO-US014231.
XX
XX PR 01-JUN-1999; 99US-00323867.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 139; Page 99; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
XX
AAB64324 Length: 28 February 4, 2005 13:32 Type: P Check: 183 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSDLSKQWEEAAVRLFIETLKN 28
-----
1 match found in sequence:
aab64325 ; Exendin agonist, SEQ ID NO:145.
(from "seq5ags.pep")
TOIG of: aab64325 check: 291 from: 1 to: 28
ID AAB64325 standard; peptide; 28 AA.
XX
XX AC AAB64325;
XX
XX DT 27-MAR-2001 (first entry)
XX
XX DE Exendin agonist, SEQ ID NO:145.
XX
XX EX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX
XX OS Heloderma suspectum.
XX
XX OS Synthetic.
XX
XX PN WO200073331-A2.
XX
XX PD

```

```

PI Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 136; Page 98; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
SQ
AAB64321 Length: 28 February 4, 2005 13:32 Type: P Check: 626
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSLSKQMEAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aab64322; Extendin agonist, SEQ ID NO:142.
(from "seq5ags.pep")
TOIG of: aab64322 check: 187 from: 1 to: 28
ID AAB64322 standard; peptide; 28 AA.
XX
XX AAB64322;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:142.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 137; Page 98; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
SQ
AAB64322 Length: 28 February 4, 2005 13:32 Type: P Check: 187
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSLSKQLEAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aab64323; Extendin agonist, SEQ ID NO:143.
(from "seq5ags.pep")
TOIG of: aab64323 check: 622 from: 1 to: 28
ID AAB64323 standard; peptide; 28 AA.
XX
XX AAB64323;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:143.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
XX Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX

```

PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 134; Page 97; 133pp; English.

XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 28 AA;

AAB64319 Length: 28 February 4, 2005 13:32 Type: P Check: 630 ..
 Found using 'seq5' (mohamed337.key)

```

1 |-----|
  1 AGDGTFTSDLSKQMAEEAVRLFIETLKN 28

```

1 match found in sequence:
 aab64320 ; Extendin agonist, SEQ ID NO:140.
 (from "seq5ags.pep")
 TOIG of: aab64320 check: 191 from: 1 to: 28

ID AAB64320 standard; peptide; 28 AA.
 XX AAB64320;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE
 XX
 DE Extendin agonist, SEQ ID NO:140.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.
 OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX

DR WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 135; Page 97; 133pp; English.

XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 28 AA;

AAB64320 Length: 28 February 4, 2005 13:32 Type: P Check: 191 ..

Found using 'seq5' (mohamed337.key)

```

1 |-----|
  1 AGDGTFTSDLSKQMAEEAVRLFIETLKN 28

```

1 match found in sequence:
 aab64321 ; Extendin agonist, SEQ ID NO:141.
 (from "seq5ags.pep")
 TOIG of: aab64321 check: 626 from: 1 to: 28

ID AAB64321 standard; peptide; 28 AA.

XX AAB64321;

XX 27-MAR-2001 (first entry)

XX Extendin agonist, SEQ ID NO:141.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.
 OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and extensin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extensin
 CC agonist of the invention which is based upon the sequence of extensin-4
 XX
 SQ Sequence 28 AA;

AAB64313 Length: 28 February 4, 2005 13:32 Type: P Check: 482 ..
 Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTFTSLSKAMEEAVRLFIEFLKN 28

```

 1 match found in sequence:
 aab64314 ; Extensin agonist, SEQ ID NO:134.
 (from "seq5ags.pep")
 TOIG of: aab64314 check: 43 from: 1 to: 28

ID AAB64314 standard; peptide; 28 AA.

```

XX AC AAB64314;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DE Extensin agonist, SEQ ID NO:134.
XX DE
XX KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extensin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PP 23-MAY-2000; 2000WO-US014231.
XX PP
XX PR 01-JUN-1999; 99US-00323867.
XX PR
XX PA (AMYL-) AMYLIN PHARM INC.
XX PA
XX PI Hiles R, Prickett KS;
XX PI
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extensins or extensin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 129; Page 94; 133pp; English.
XX PS
XX CC The invention relates to the use of an extensin (AAB64181-B64182) or an
XX CC extensin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to

```

CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and extensin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extensin
 CC agonist of the invention which is based upon the sequence of extensin-4
 XX
 SQ Sequence 28 AA;

AAB64314 Length: 28 February 4, 2005 13:32 Type: P Check: 43 ..
 Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTFTSLSKALBEEAVRLFIEFLKN 28

```

 1 match found in sequence:
 aab64315 ; Extensin agonist, SEQ ID NO:135.
 (from "seq5ags.pep")
 TOIG of: aab64315 check: 522 from: 1 to: 28

ID AAB64315 standard; peptide; 28 AA.

```

XX AC AAB64315;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DE Extensin agonist, SEQ ID NO:135.
XX DE
XX KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extensin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PP 23-MAY-2000; 2000WO-US014231.
XX PP
XX PR 01-JUN-1999; 99US-00323867.
XX PR
XX PA (AMYL-) AMYLIN PHARM INC.
XX PA
XX PI Hiles R, Prickett KS;
XX PI
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extensins or extensin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 130; Page 95; 133pp; English.
XX PS
XX CC The invention relates to the use of an extensin (AAB64181-B64182) or an
XX CC extensin agonist (AAB64185-B64368) for treating gestational diabetes

```

CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC
 CC Sequence 28 AA;
 CC
 CC AAB64311 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
 CC Found using 'seq5' (mohamed337.key)
 CC
 CC 1 |-----|
 CC AGDGTFTSDLSAQMBEAVRLFIEWLKN 28
 CC
 CC -----
 CC 1 match found in sequence:
 CC aab64312; Exendin agonist, SEQ ID NO:132.
 CC (from "seq5ags.pep")
 CC TOIG of: aab64312 check: 131 from: 1 to: 28
 CC
 CC ID AAB64312 standard; peptide; 28 AA.
 CC XX
 CC AC AAB64312;
 CC XX
 CC DT 27-MAR-2001 (first entry)
 CC XX
 CC DE Exendin agonist, SEQ ID NO:132.
 CC XX
 CC KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 CC KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 CC KW insulinotropic; anorectic; exendin-4.
 CC XX
 CC OS Heloderma suspectum.
 CC OS Synthetic.
 CC XX
 CC PN WO200073331-A2.
 CC XX
 CC PD 07-DEC-2000.
 CC XX
 CC PF 23-MAY-2000; 2000WO-US014231.
 CC XX
 CC PR 01-JUN-1999; 99US-00323867.
 CC XX
 CC PA (AMYL-) AMYLIN PHARM INC.
 CC XX
 CC PI Hiles R, Prickett KS;
 CC XX
 CC DR WPI; 2001-137634/14.
 CC XX
 CC XX Use of exendins or exendin agonists for lowering or reducing blood
 CC PT glucose levels and treating gestational diabetes mellitus in a subject,
 CC PT especially in a human.
 CC XX
 CC PS Example 127; Page 93; 133pp; English.
 CC XX
 CC CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC CC combination of increased insulin resistance and a diminished ability to
 CC CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC CC associated with complications in both the mother and the foetus. Women
 CC CC with GDM have increased rates of Caesarian delivery, hypertensive

CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC
 CC Sequence 28 AA;
 CC
 CC AAB64312 Length: 28 February 4, 2005 13:32 Type: P Check: 131 ..
 CC Found using 'seq5' (mohamed337.key)
 CC
 CC 1 |-----|
 CC AGDGTFTSDLSAQMBEAVRLFIEFLKN 28
 CC
 CC -----
 CC 1 match found in sequence:
 CC aab64313; Exendin agonist, SEQ ID NO:133.
 CC (from "seq5ags.pep")
 CC TOIG of: aab64313 check: 482 from: 1 to: 28
 CC
 CC ID AAB64313 standard; peptide; 28 AA.
 CC XX
 CC AC AAB64313;
 CC XX
 CC DT 27-MAR-2001 (first entry)
 CC XX
 CC DE Exendin agonist, SEQ ID NO:133.
 CC XX
 CC KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 CC KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 CC KW insulinotropic; anorectic; exendin-4.
 CC XX
 CC OS Heloderma suspectum.
 CC OS Synthetic.
 CC XX
 CC PN WO200073331-A2.
 CC XX
 CC PD 07-DEC-2000.
 CC XX
 CC PF 23-MAY-2000; 2000WO-US014231.
 CC XX
 CC PR 01-JUN-1999; 99US-00323867.
 CC XX
 CC PA (AMYL-) AMYLIN PHARM INC.
 CC XX
 CC PI Hiles R, Prickett KS;
 CC XX
 CC DR WPI; 2001-137634/14.
 CC XX
 CC XX Use of exendins or exendin agonists for lowering or reducing blood
 CC PT glucose levels and treating gestational diabetes mellitus in a subject,
 CC PT especially in a human.
 CC XX
 CC PS Example 128; Page 94; 133pp; English.
 CC XX
 CC CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC CC combination of increased insulin resistance and a diminished ability to
 CC CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC CC associated with complications in both the mother and the foetus. Women
 CC CC with GDM have increased rates of Caesarian delivery, hypertensive

CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64309 Length: 28 February 4, 2005 13:32 Type: P Check: 492 ..
 Found using 'seq5' (mohamed337.key)

```

1 |-----|
  1 AGDGTFTSLAKQMBEEAVRLFIEWLKN 28
  |-----|
  1 match found in sequence:
  aab64310 ; Exendin agonist, SEQ ID NO:130.
  (from "seq5ags.pep")
  TOIG of: aab64310 check: 53 from: 1 to: 28

ID AAB64310 standard; peptide; 28 AA.
XX
AC AAB64310;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:130.
XX
EX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 125; Page 92; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,

```

CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64310 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..
 Found using 'seq5' (mohamed337.key)

```

1 |-----|
  1 AGDGTFTSLAKQLEEEAVRLFIFELKN 28
  |-----|
  1 match found in sequence:
  aab64311 ; Exendin agonist, SEQ ID NO:131.
  (from "seq5ags.pep")
  TOIG of: aab64311 check: 570 from: 1 to: 28

ID AAB64311 standard; peptide; 28 AA.
XX
AC AAB64311;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:131.
XX
EX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 126; Page 93; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube

```

CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 CC
 XX
 SQ Sequence 28 AA;

AAB64306 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
 Found using 'seq5' (mohamed337.key)

```

1  |-----|
  1 AGDGTFTSDASKQLEEEAVRLFIEFLKN 28

```

 1 match found in sequence:
 aab64307 ; Extendin agonist, SEQ ID NO:127.
 (from "seq5ags.pep")
 TOIG of: aab64307 check: 810 from: 1 to: 28

ID AAB64307 standard; peptide; 28 AA.

XX AAB64307;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:127.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

OS Heloderma suspectum.

OS Synthetic.

PN WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 XX glucose levels and treating gestational diabetes mellitus in a subject,
 XX especially in a human.

XX Example 122; Page 91; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,

CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 CC
 XX
 SQ Sequence 28 AA;

AAB64307 Length: 28 February 4, 2005 13:32 Type: P Check: 810 ..
 Found using 'seq5' (mohamed337.key)

```

1  |-----|
  1 AGDGTFTSDXSKQMEEEAVRLFIEWLKN 28

```

 1 match found in sequence:
 aab64309 ; Extendin agonist, SEQ ID NO:129.
 (from "seq5ags.pep")
 TOIG of: aab64309 check: 492 from: 1 to: 28

ID AAB64309 standard; peptide; 28 AA.

XX AAB64309;

XX 27-MAR-2001 (first entry)

XX Extendin agonist, SEQ ID NO:129.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

OS Heloderma suspectum.

OS Synthetic.

PN WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood
 XX glucose levels and treating gestational diabetes mellitus in a subject,
 XX especially in a human.

XX Example 124; Page 92; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,

The invention relates to the use of an extendin (AAB64181-B64182) or an extendin agonist (AAB64185-B64368) for treating gestational diabetes mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalcaemia, hyponaesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Extendins are peptides from the salivary secretions of the Gila monster (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GIP-1, and have similar insulinotropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, extendins and extendin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a

AAB64302 Length: 28 February 4, 2005 13:32 Type: P Check: 224 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSALSQLEBEAVRLFIEFLKN 28
1

1 match found in sequence:

aab64303; Exendin agonist, SEQ ID NO:123.
(from 'seq5ags.pep')
TOIG of: aab64303 check: 699 from: 1 to: 28

ID AAB64303 standard; peptide; 28 AA.

XX AAB64303;

XX 27-MAR-2001 (first entry)

XX Exendin agonist, SEQ ID NO:123.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

XX Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.

XX Example 118; Page 89; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4

XX

SQ Sequence 28 AA;

AAB64303 Length: 28 February 4, 2005 13:32 Type: P Check: 699 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSQMBEAVRLFIEWLKN 28
1

1 match found in sequence:

aab64304; Exendin agonist, SEQ ID NO:124.
(from 'seq5ags.pep')
TOIG of: aab64304 check: 260 from: 1 to: 28

ID AAB64304 standard; peptide; 28 AA.

XX AAB64304;

XX 27-MAR-2001 (first entry)

XX Exendin agonist, SEQ ID NO:124.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; exendin-4.

XX Heloderma suspectum.

XX Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.

XX Example 119; Page 89; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4


```
1 AGDGTFTADLSKQLEEEAVRLFIEFLKN 28
-----|-----
1 match found in sequence:
aab64301; Exendin agonist, SEQ ID NO:121.
(from "seq5ags.pep")
TOIG of: aab64301 check: 663 from: 1 to: 28

ID AAB64301 standard; peptide; 28 AA.
XX AC AAB64301;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:121.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX DR Use of exendins or exendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 116; Page 88; 133pp; English.
XX CC The invention relates to the use of an exendin (AAB64181-B64182) or an
XX CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Exendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC GDM, exendins and exendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a exendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX CC
XX CC Sequence 28 AA;
XX SQ

1 match found in sequence:
aab64301; Exendin agonist, SEQ ID NO:121.
(from "seq5ags.pep")
TOIG of: aab64301 check: 663 from: 1 to: 28

ID AAB64301 standard; peptide; 28 AA.
XX AC AAB64301;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:121.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX DR Use of exendins or exendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 116; Page 88; 133pp; English.
XX CC The invention relates to the use of an exendin (AAB64181-B64182) or an
XX CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Exendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC GDM, exendins and exendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a exendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX CC
XX CC Sequence 28 AA;
XX SQ

AAB64301 Length: 28 February 4, 2005 13:32 Type: P Check: 663
```

```

-----
1 match found in sequence:
aab64299 ; Exendin agonist, SEQ ID NO:119.
(from "seq5ags.pep")
TOIG of: aab64299 check: 546 from: 1 to: 28

ID AAB64299 standard; peptide; 28 AA.
XX
AC AAB64299;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:119.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 114; Page 87; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64299 Length: 28 February 4, 2005 13:32 Type: P Check: 546
Found using 'seq5' (mohamed337.key)

-----
1 match found in sequence:
aab64300 ; Exendin agonist, SEQ ID NO:120.
(from "seq5ags.pep")
TOIG of: aab64300 check: 107 from: 1 to: 28

ID AAB64300 standard; peptide; 28 AA.
XX
AC AAB64300;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:120.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 115; Page 87; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;

AAB64300 Length: 28 February 4, 2005 13:32 Type: P Check: 107
Found using 'seq5' (mohamed337.key)

```

```
TOIG of: aab64297 check: 683 from: 1 to: 28
ID AAB64297 standard; peptide; 28 AA.
XX
AC AAB64297;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:117.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 112; Page 86; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;
AAB64297 Length: 28 February 4, 2005 13:32 Type: P Check: 683
Found using 'seq5' (mohamed337.key)
1
AGDGTFFSDLKQLEEEAVRLFIEFLKN
1
-----|
1 AGDGTFFSDLKQLEEEAVRLFIEFLKN
1
-----|
1 match found in sequence:
```

```
aab64298 ; Exendin agonist, SEQ ID NO:118.
(from "seq5ags.pep")
TOIG of: aab64298 check: 244 from: 1 to: 28
ID AAB64298 standard; peptide; 28 AA.
XX
AC AAB64298;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:118.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 113; Page 86; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 28 AA;
AAB64298 Length: 28 February 4, 2005 13:32 Type: P Check: 244
Found using 'seq5' (mohamed337.key)
1
AGDGTFFSDLKQLEEEAVRLFIEFLKN
1
-----|
1 AGDGTFFSDLKQLEEEAVRLFIEFLKN
1
-----|
1 match found in sequence:
```

```

AC AAB64295;
XX
XX 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:115.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 110; Page 85; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;

```

AAB64295 Length: 28 February 4, 2005 13:32 Type: P Check: 798 ..
Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTXTSLSKQMEAEVRLFIWLNK
  28

```

1 match found in sequence:
aab64296; Exendin agonist, SEQ ID NO:116.
(from "seq5ags.pep")
TOIG of: aab64296 check: 359 from: 1 to: 28

```

ID AAB64296 standard; peptide; 28 AA.
XX
XX AAB64296;
XX
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:116.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 111; Page 85; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;

```

Sequence 28 AA;

AAB64296 Length: 28 February 4, 2005 13:32 Type: P Check: 359 ..
Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTXTSLSKQLEAEVRLFIPLKN
  28

```

1 match found in sequence:
aab64297; Exendin agonist, SEQ ID NO:117.
(from "seq5ags.pep")

```

DE  Exendin agonist, SEQ ID NO:113.
XX
KW  Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
KW  insulinotropic; anorectic; exendin-4.
XX
OS  Heloderma suspectum.
OS  Synthetic.
XX
PN  WO200073331-A2.
XX
PD  07-DEC-2000.
XX
XX
PF  23-MAY-2000; 2000WO-US014231.
XX
PR  01-JUN-1999; 99US-00323867.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Hiles R, Prickett KS;
XX
DR  WPI; 2001-137634/14.
XX
PT  Use of exendins or exendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX
PS  Example 108; Page 84; 133pp; English.
XX
CC  The invention relates to the use of an exendin (AAB64181-B64182) or an
CC  exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Exendins are peptides from the salivary secretions of the Gila monster
CC  (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, exendins and exendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a exendin
CC  agonist of the invention which is based upon the sequence of exendin-4
XX
SQ  Sequence 28 AA;
AAB64293 Length: 28 February 4, 2005 13:32 Type: P Check: 595
Found using 'seq5' (mohamed337.key)
1  |-----|
  1  AGDGAFSTLSKQMEAEAVRLFIETLKN 28
-----
1 match found in sequence:
aab64294 ; Exendin agonist, SEQ ID NO:114.
(from "seq5ags.pep")
TOIG of: aab64294 check: 156 from: 1 to: 28
ID  AAB64294 standard; peptide; 28 AA.
XX
AC  AAB64294;
XX

```

```

DT  27-MAR-2001 (first entry)
XX
XX  Exendin agonist, SEQ ID NO:114.
XX
KW  Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
KW  insulinotropic; anorectic; exendin-4.
XX
OS  Heloderma suspectum.
OS  Synthetic.
XX
PN  WO200073331-A2.
XX
PD  07-DEC-2000.
XX
XX
PF  23-MAY-2000; 2000WO-US014231.
XX
PR  01-JUN-1999; 99US-00323867.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Hiles R, Prickett KS;
XX
DR  WPI; 2001-137634/14.
XX
PT  Use of exendins or exendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX
PS  Example 109; Page 84; 133pp; English.
XX
CC  The invention relates to the use of an exendin (AAB64181-B64182) or an
CC  exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Exendins are peptides from the salivary secretions of the Gila monster
CC  (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, exendins and exendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a exendin
CC  agonist of the invention which is based upon the sequence of exendin-4
XX
SQ  Sequence 28 AA;
AAB64294 Length: 28 February 4, 2005 13:32 Type: P Check: 156
Found using 'seq5' (mohamed337.key)
1  |-----|
  1  AGDGAFSTLSKQLEAEAVRLFIEFLKN 28
-----
1 match found in sequence:
aab64295 ; Exendin agonist, SEQ ID NO:115.
(from "seq5ags.pep")
TOIG of: aab64295 check: 798 from: 1 to: 28
ID  AAB64295 standard; peptide; 28 AA.
XX

```

KW insulinotropic; anorectic; exendin-4.
 XX Heloderma suspectum.
 OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 106; Page 83; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4

XX Sequence 28 AA;

XX AAB64291 Length: 28 February 4, 2005 13:32 Type: P Check: 690 ..

Found using 'seqs' (mohamed337.key)

```

1  |-----|
  1  AGDGTFTSDLSKQWEEAEVRLFIETLKN 28

```

 1 match found in sequence:
 aab64292 : Exendin agonist, SEQ ID NO:112.
 (from "seq5ags.pep")
 TOIG of: aab64292 check: 251 from: 1 to: 28

ID AAB64292 standard; peptide; 28 AA.

XX AAB64292;

XX 27-MAR-2001 (first entry)

XX Exendin agonist, SEQ ID NO:112.

XX

KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 XX insulinotropic; anorectic; exendin-4.

OS Heloderma suspectum.

XX Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 107; Page 83; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4

XX Sequence 28 AA;

XX AAB64292 Length: 28 February 4, 2005 13:32 Type: P Check: 251 ..

Found using 'seqs' (mohamed337.key)

```

1  |-----|
  1  AGDGTFTSDLSKQWEEAEVRLFIETLKN 28

```

 1 match found in sequence:
 aab64293 : Exendin agonist, SEQ ID NO:113.
 (from "seq5ags.pep")
 TOIG of: aab64293 check: 595 from: 1 to: 28

ID AAB64293 standard; peptide; 28 AA.

XX AAB64293;

XX 27-MAR-2001 (first entry)

XX

```

XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 104; Page 82; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
XX
AAB64289 Length: 28 February 4, 2005 13:32 Type: P Check: 681
Found using 'seq5' (mohamed337.key)
1 AAGCTFTSDLSKQMEEEAVRLFIETLKN
1 |-----|
1 1 AAGCTFTSDLSKQMEEEAVRLFIETLKN
1 28
-----
1 match found in sequence:
aab64290 ; Extendin agonist, SEQ ID NO:110.
(from "seq5ags.pep")
TOIG of: aab64290 check: 242 from: 1 to: 28
ID AAB64290 standard; peptide; 28 AA.
XX
XX AAB64290;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:110.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulinotropic; anorectic; extendin-4.
XX

```

```

OS Heloderma suspectum.
OS Synthetic.
XX
XX PN WO200073331-A2.
XX
XX PD 07-DEC-2000.
XX
XX PF 23-MAY-2000; 2000WO-US014231.
XX
XX PR 01-JUN-1999; 99US-00323867.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Hiles R, Prickett KS;
XX
XX DR WPI; 2001-137634/14.
XX
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX PS Example 105; Page 82; 133pp; English.
XX
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
XX
AAB64290 Length: 28 February 4, 2005 13:32 Type: P Check: 242
Found using 'seq5' (mohamed337.key)
1 AAGCTFTSDLSKQMEEEAVRLFIETLKN
1 |-----|
1 1 AAGCTFTSDLSKQMEEEAVRLFIETLKN
1 28
-----
1 match found in sequence:
aab64291 ; Extendin agonist, SEQ ID NO:111.
(from "seq5ags.pep")
TOIG of: aab64291 check: 690 from: 1 to: 28
ID AAB64291 standard; peptide; 28 AA.
XX
XX AAB64291;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:111.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX

```

```
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS
XX PS Example 102; Page 81; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64287 Length: 28 February 4, 2005 13:32 Type: P Check: 673
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGFTTSALSQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
aab64288 ; Extendin agonist, SEQ ID NO:108.
(from "seq5ags.pep")
TOIG of: aab64288 check: 590 from: 1 to: 28
ID AAB64288 standard; peptide; 28 AA.
XX AC AAB64288;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:108.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX KW
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.

XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS
XX PS Example 103; Page 81; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64288 Length: 28 February 4, 2005 13:32 Type: P Check: 590
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGFTTSASKQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
aab64289 ; Extendin agonist, SEQ ID NO:109.
(from "seq5ags.pep")
TOIG of: aab64289 check: 681 from: 1 to: 28
ID AAB64289 standard; peptide; 28 AA.
XX AC AAB64289;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:109.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX KW
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
```



```
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 100; Page 80; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64285 Length: 28 February 4, 2005 13:32 Type: P Check: 688
Found using 'seq5' (mohamed337.key)
1 HGAGTFTDLSKQMEEEAVRLFIEWLKN
1 |-----|
1 HGEATFTDLSKQMEEEAVRLFIEWLKN
1 28
-----
1 match found in sequence:
aab64286 ; Extendin agonist, SEQ ID NO:106.
(from "seq5ags.pep")
TOIG of: aab64286 check: 676 from: 1 to: 28
ID AAB64286 standard; peptide; 28 AA.
XX AC AAB64286;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:106.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX XX
XX OS Heloderma suspectum.
XX OS Synthetic.
XX XX
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PF 23-MAY-2000; 2000WO-US014231.
```

```
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 101; Page 80; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64286 Length: 28 February 4, 2005 13:32 Type: P Check: 676
Found using 'seq5' (mohamed337.key)
1 HGAGTFTDLSKQMEEEAVRLFIEWLKN
1 |-----|
1 HGEATFTDLSKQMEEEAVRLFIEWLKN
1 28
-----
1 match found in sequence:
aab64287 ; Extendin agonist, SEQ ID NO:107.
(from "seq5ags.pep")
TOIG of: aab64287 check: 673 from: 1 to: 28
ID AAB64287 standard; peptide; 28 AA.
XX AC AAB64287;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:107.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX XX
XX OS Heloderma suspectum.
XX OS Synthetic.
XX XX
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
```

```
XX DR WPI; 2001-137634/14.
XX PT
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS
XX PS Example 98; Page 79; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ
XX SQ Sequence 28 AA;
AAB64283 Length: 28 February 4, 2005 13:32 Type: P Check: 234 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSALSKQLEEBEAVRLFLEFN 28
1 -----|
1 match found in sequence:
aab64284 ; Extendin agonist, SEQ ID NO:104.
(from "seq5ags.pep")
TOIG of: aab64284 check: 693 from: 1 to: 28
ID AAB64284 standard; peptide; 28 AA.
XX AC
XX AC AAB64284;
XX DT
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Extendin agonist, SEQ ID NO:104.
XX KW
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN
XX PN WO200073331-A2.
XX PD
XX PD 07-DEC-2000.
XX PF
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR
XX PR 01-JUN-1999; 99US-00323867.
XX PR (AMYL-) AMYLIN PHARM INC.
```

```
XX PI
XX PI Hiles R, Prickett KS;
XX DR
XX DR WPI; 2001-137634/14.
XX PT
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS
XX PS Example 99; Page 79; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ
XX SQ Sequence 28 AA;
AAB64284 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
Found using 'seq5' (mohamed337.key)
1 AGEGFTTSDLSKQMEEBEAVRLFLEWLN 28
1 -----|
1 match found in sequence:
aab64285 ; Extendin agonist, SEQ ID NO:105.
(from "seq5ags.pep")
TOIG of: aab64285 check: 688 from: 1 to: 28
ID AAB64285 standard; peptide; 28 AA.
XX AC
XX AC AAB64285;
XX DT
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Extendin agonist, SEQ ID NO:105.
XX KW
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN
XX PN WO200073331-A2.
XX PD
XX PD 07-DEC-2000.
XX PF
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR
XX PR 01-JUN-1999; 99US-00323867.
```

```

PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX
XX  Example 96; Page 78; 133pp; English.
XX
CC  The invention relates to the use of an extendin (AAB64181-B64182) or an
CC  extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Extendins are peptides from the salivary secretions of the Gila monster
CC  (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, extendins and extendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a extendin
CC  agonist of the invention which is based upon the sequence of extendin-4
XX
XX  Sequence 28 AA;
SQ
AAB64281 Length: 28 February 4, 2005 13:32 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  HGAGFTSLSKQLBEEAVRLFIEFLKN 28
1  |-----|
1  match found in sequence:
aab64282 ; Extendin agonist, SEQ ID NO:102.
(from "seq5ags.pep")
TOIG of: aab64282 check: 237 from: 1 to: 28

ID  AAB64282 standard; peptide; 28 AA.
XX
XX  AAB64282;
AC
XX
XX  27-MAR-2001 (first entry)
DT
XX
XX  Extendin agonist, SEQ ID NO:102.
DE
XX
XX  Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
KW  insulinotropic; anorectic; extendin-4.
XX
XX  Heloderma suspectum.
OS
XX  Synthetic.
XX
XX  WO200073331-A2.
PN
XX
XX  07-DEC-2000.
PD
XX
XX  23-MAY-2000; 2000WO-US014231.
PF
XX
XX  01-JUN-1999; 99US-00323867.
PR
XX
XX  (AMYL-) AMYLIN PHARM INC.
PA
XX  Hiles R, Prickett KS;
PI
XX  WPI; 2001-137634/14.
DR

```

```

XX  Use of extendins or extendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX
XX  Example 97; Page 78; 133pp; English.
XX
CC  The invention relates to the use of an extendin (AAB64181-B64182) or an
CC  extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Extendins are peptides from the salivary secretions of the Gila monster
CC  (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, extendins and extendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a extendin
CC  agonist of the invention which is based upon the sequence of extendin-4
XX
XX  Sequence 28 AA;
SQ
AAB64282 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  HGEATFTSLSKQLBEEAVRLFIEFLKN 28
1  |-----|
1  match found in sequence:
aab64283 ; Extendin agonist, SEQ ID NO:103.
(from "seq5ags.pep")
TOIG of: aab64283 check: 234 from: 1 to: 28

ID  AAB64283 standard; peptide; 28 AA.
XX
XX  AAB64283;
AC
XX
XX  27-MAR-2001 (first entry)
DT
XX
XX  Extendin agonist, SEQ ID NO:103.
DE
XX
XX  Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
KW  insulinotropic; anorectic; extendin-4.
XX
XX  Heloderma suspectum.
OS
XX  Synthetic.
XX
XX  WO200073331-A2.
PN
XX
XX  07-DEC-2000.
PD
XX
XX  23-MAY-2000; 2000WO-US014231.
PF
XX
XX  01-JUN-1999; 99US-00323867.
PR
XX
XX  (AMYL-) AMYLIN PHARM INC.
PA
XX  Hiles R, Prickett KS;
PI
XX  WPI; 2001-137634/14.
DR

```

```

XX Example 95; Page 77; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
XX
AAB64280 Length: 28 February 4, 2005 13:32 Type: P Check: 254 ..
Found using 'seq5' (mohamed337.key)
1
1 -----
1 AAGGTFTSDLSKQLREEAVRLFIEFLKN
1 28
-----
1 1 match found in sequence:
aab64281; Extendin agonist, SEQ ID NO:101.
(from "seq5ags.pep")
TOIG of: aab64281 check: 249 from: 1 to: 28

ID AAB64281 standard; peptide; 28 AA.
AC AAB64281;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:101.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
OS
XX WO2000073331-A2.
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT

```

CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC SQ Sequence 33 AA;

AAB64277 Length: 33 February 4, 2005 13:32 Type: P Check: 2215 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDASKQLEEEAVRLFTEFLKNGPSS
 28

 1 match found in sequence:
 aab64278 ; Exendin agonist, SEQ ID NO:98.
 (from "seq5ags.pep")
 TOIG of: aab64278 check: 2649 from: 1 to: 29

ID AAB64278 standard; peptide; 29 AA.

XX AAB64278;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:98.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 XX 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 91; Page 75; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an

CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC SQ Sequence 29 AA;

AAB64278 Length: 29 February 4, 2005 13:32 Type: P Check: 2649 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDASKQMEEEAVRLFIEWLKNG
 28

 1 match found in sequence:
 aab64279 ; Exendin agonist, SEQ ID NO:99.
 (from "seq5ags.pep")
 TOIG of: aab64279 check: 4015 from: 1 to: 37

ID AAB64279 standard; peptide; 37 AA.

XX AAB64279;
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:99.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 XX 23-MAY-2000; 2000WO-US014231.
 XX
 XX 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Hiles R, Prickett KS;
 PI
 XX WPI; 2001-137634/14.
 DR
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 92; Page 75; 133pp; English.
 PS

CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX
SQ Sequence 28 AA;
AAB64275 Length: 28 February 4, 2005 13:32 Type: P Check: 1045 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQMEEAARLFXEWLKN 28
|-----|
1

1 match found in sequence:
aab64276 ; Exendin agonist, SEQ ID NO:96.
(from "seq5ags.pep")
TOIG of: aab64276 check: 237 from: 1 to: 28
ID AAB64276 standard; peptide; 28 AA.
XX
AC AAB64276;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:96.
XX
XW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XW pregnancy complication; neonatal abnormality; blood glucose modulator;
XW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 89; Page 74; 133pp; English.
XX
XW The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both

CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX
SQ Sequence 28 AA;
AAB64276 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQLEEAARLFDLKN 28
|-----|
1

1 match found in sequence:
aab64277 ; Exendin agonist, SEQ ID NO:97.
(from "seq5ags.pep")
TOIG of: aab64277 check: 2215 from: 1 to: 33
ID AAB64277 standard; peptide; 33 AA.
XX
AC AAB64277;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:97.
XX
XW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XW pregnancy complication; neonatal abnormality; blood glucose modulator;
XW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 90; Page 74; 133pp; English.
XX
XW The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both

```

1 1 AGDGTFTSDLSAQMEEEAVRLFIEWLKN 28
    1
-----
1 match found in sequence:
aay17567 ; Exendin agonist peptide #33.
(from "seq5ags.pep")
TOIG of: aay17567 check: 131 from: 1 to: 28

ID AAY17567 standard; peptide; 28 AA.
XX
AC AAY17567;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #33.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17567 Length: 28 February 4, 2005 13:32 Type: P Check: 131 ..
Found using 'seq5' (mohamed337.key)

1 1 AGDGTFTSDLSAQMEEEAVRLFIEWLKN 28
    1
-----
1 match found in sequence:
aay17567 ; Exendin agonist peptide #33.
(from "seq5ags.pep")
TOIG of: aay17567 check: 43 from: 1 to: 28

ID AAY17567 standard; peptide; 28 AA.
XX
AC AAY17567;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #33.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17567 Length: 28 February 4, 2005 13:32 Type: P Check: 482 ..
Found using 'seq5' (mohamed337.key)

1 1 AGDGTFTSDLSKAMEEEAVRLFIEWLKN 28
    1
-----
1 match found in sequence:
aay17569 ; Exendin agonist peptide #35.
(from "seq5ags.pep")
TOIG of: aay17569 check: 43 from: 1 to: 28

ID AAY17569 standard; peptide; 28 AA.
XX
AC AAY17569;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #35.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX

```

```

XX WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 28 AA;

AAY17564 Length: 28 February 4, 2005 13:32 Type: P Check: 492 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDIAKQLEEAVERLFIETFLN 28
1 |-----|
1 match found in sequence:
aay17565 ; Exendin agonist peptide #31.
(from "seqsags.pep")
TOIG of: aay17565 check: 53 from: 1 to: 28

ID AAY17565 standard; peptide; 28 AA.
XX
XX AC AAY17565;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #31.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 28 AA;

AAY17566 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDIAKQLEEAVERLFIETFLN 28
1 |-----|
1 match found in sequence:
aay17566 ; Exendin agonist peptide #32.
(from "seqsags.pep")
TOIG of: aay17566 check: 570 from: 1 to: 28

ID AAY17566 standard; peptide; 28 AA.
XX
XX AC AAY17566;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #32.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 28 AA;

AAY17566 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
Found using 'seq5' (mohamed337.key)

```

```

PT diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 28 AA;

AAY17565 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDIAKQLEEAVERLFIETFLN 28
1 |-----|
1 match found in sequence:
aay17566 ; Exendin agonist peptide #32.
(from "seqsags.pep")
TOIG of: aay17566 check: 570 from: 1 to: 28

ID AAY17566 standard; peptide; 28 AA.
XX
XX AC AAY17566;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #32.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 28 AA;

AAY17566 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
Found using 'seq5' (mohamed337.key)

```


CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)

SQ Sequence 28 AA;

AAV17561 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDASKQLEEEAVRLFIEFLKN 28

 1 match found in sequence:

aay17562 ; Exendin agonist peptide #28.
 (from "seq5ags.pep")

TOIG of: aay17562 check: 640 from: 1 to: 28

ID AAY17562 standard; peptide; 28 AA.

XX AC AAY17562;

DT 09-AUG-1999 (first entry)

DE Exendin agonist peptide #28.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925728-A1.

PN 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.

XX 14-NOV-1997; 97US-0066029P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beley NRA, Prickett KS;

XX WPI; 1999-347456/29.

XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)

XX Sequence 28 AA;

AAV17562 Length: 28 February 4, 2005 13:32 Type: P Check: 640 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDGSKQMEEEAVRLFIEWLKN 28

 1 match found in sequence:

aay17563 ; Exendin agonist peptide #29.
 (from "seq5ags.pep")

TOIG of: aay17563 check: 201 from: 1 to: 28

ID AAY17563 standard; peptide; 28 AA.

XX AC AAY17563;

DT 09-AUG-1999 (first entry)

XX Exendin agonist peptide #29.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925728-A1.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.

XX 14-NOV-1997; 97US-0066029P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beley NRA, Prickett KS;

XX WPI; 1999-347456/29.

XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)

XX Sequence 28 AA;

AAV17563 Length: 28 February 4, 2005 13:32 Type: P Check: 201 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDGSKQLEEEAVRLFIEFLKN 28

 1 match found in sequence:

aay17564 ; Exendin agonist peptide #30.
 (from "seq5ags.pep")

TOIG of: aay17564 check: 492 from: 1 to: 28

ID AAY17564 standard; peptide; 28 AA.

XX AC AAY17564;

DT 09-AUG-1999 (first entry)

XX Exendin agonist peptide #30.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

```

XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 28 AA;

AAY17559 Length: 28 February 4, 2005 13:32 Type: P Check: 260 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSELSKQLEEAARLFIPLKN 28

-----
1 match found in sequence:
aay17560 ; Exendin agonist peptide #26.
(from "seqSags.pep")
TOIG of: aay17560 check: 580 from: 1 to: 28

ID AAY17560 standard; peptide; 28 AA.
XX AC AAY17560;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #26.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 28 AA;

AAY17559 Length: 28 February 4, 2005 13:32 Type: P Check: 260 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSELSKQLEEAARLFIPLKN 28

-----
1 match found in sequence:
aay17560 ; Exendin agonist peptide #26.
(from "seqSags.pep")
TOIG of: aay17560 check: 580 from: 1 to: 28

ID AAY17560 standard; peptide; 28 AA.
XX AC AAY17560;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #26.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 28 AA;

AAY17560 Length: 28 February 4, 2005 13:32 Type: P Check: 580 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSDASKQMEEAARLFIPLKN 28

-----
1 match found in sequence:
aay17561 ; Exendin agonist peptide #27.
(from "seqSags.pep")
TOIG of: aay17561 check: 141 from: 1 to: 28

ID AAY17561 standard; peptide; 28 AA.
XX AC AAY17561;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #27.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC

```

```

PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;
AAY17556 Length: 28 February 4, 2005 13:32 Type: P Check: 663 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSALSQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17557 ; Extendin agonist peptide #23.
(from "seq5ags.pep")
TOIG of: aay17557 check: 224 from: 1 to: 28

ID AAY17557 standard; peptide; 28 AA.
XX
AC AAY17557;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #23.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
PT WPI; 1999-347456/29.
XX
PS Peptide agonists of extendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
SQ Claim 28; Fig 4; 144pp; English.
CC
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;
AAY17557 Length: 28 February 4, 2005 13:32 Type: P Check: 224 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSALSQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17557 ; Extendin agonist peptide #23.
(from "seq5ags.pep")
TOIG of: aay17557 check: 224 from: 1 to: 28

ID AAY17557 standard; peptide; 28 AA.
XX
AC AAY17557;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #23.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
PT WPI; 1999-347456/29.
XX
PS Peptide agonists of extendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
SQ Claim 28; Fig 4; 144pp; English.
CC
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;
AAY17557 Length: 28 February 4, 2005 13:32 Type: P Check: 224 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSALSQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17557 ; Extendin agonist peptide #23.
(from "seq5ags.pep")
TOIG of: aay17557 check: 224 from: 1 to: 28

ID AAY17557 standard; peptide; 28 AA.
XX
AC AAY17557;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #23.

```

```

1 AGDGTFTSALSQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17558 ; Extendin agonist peptide #24.
(from "seq5ags.pep")
TOIG of: aay17558 check: 699 from: 1 to: 28

ID AAY17558 standard; peptide; 28 AA.
XX
AC AAY17558;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #24.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
PT WPI; 1999-347456/29.
XX
PS Peptide agonists of extendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
SQ Claim 28; Fig 4; 144pp; English.
CC
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;
AAY17558 Length: 28 February 4, 2005 13:32 Type: P Check: 699 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSALSQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17559 ; Extendin agonist peptide #25.
(from "seq5ags.pep")
TOIG of: aay17559 check: 260 from: 1 to: 28

ID AAY17559 standard; peptide; 28 AA.
XX
AC AAY17559;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #25.

```

```

ID AAY17554 standard; peptide; 28 AA.
XX
AC AAY17554;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #20.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17554 Length: 28 February 4, 2005 13:32 Type: P Check: 546 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTADLSKQLEEEAVRLFIEFLKN
    28

-----
1 match found in sequence:
aay17555 ; Extendin agonist peptide #21.
(from "seq5ags.pep")
TOIG of: aay17555 check: 107 from: 1 to: 28

ID AAY17555 standard; peptide; 28 AA.
XX
AC AAY17555;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #21.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17554 Length: 28 February 4, 2005 13:32 Type: P Check: 546 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTADLSKQLEEEAVRLFIEFLKN
    28

-----
1 match found in sequence:
aay17555 ; Extendin agonist peptide #21.
(from "seq5ags.pep")
TOIG of: aay17555 check: 107 from: 1 to: 28

ID AAY17555 standard; peptide; 28 AA.
XX
AC AAY17555;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #21.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.

```

```

XX 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17555 Length: 28 February 4, 2005 13:32 Type: P Check: 107 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTADLSKQLEEEAVRLFIEFLKN
    28

-----
1 match found in sequence:
aay17556 ; Extendin agonist peptide #22.
(from "seq5ags.pep")
TOIG of: aay17556 check: 663 from: 1 to: 28

ID AAY17556 standard; peptide; 28 AA.
XX
AC AAY17556;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #22.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17555 Length: 28 February 4, 2005 13:32 Type: P Check: 107 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTADLSKQLEEEAVRLFIEFLKN
    28

-----
1 match found in sequence:
aay17556 ; Extendin agonist peptide #22.
(from "seq5ags.pep")
TOIG of: aay17556 check: 663 from: 1 to: 28

ID AAY17556 standard; peptide; 28 AA.
XX
AC AAY17556;
XX
DT 09-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #22.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

```

```

PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycaemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17551 Length: 28 February 4, 2005 13:32 Type: P Check: 359 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17552 ; Exendin agonist peptide #18.
(from "seq5ags.pep")
TOIG of: aay17552 check: 683 from: 1 to: 28

ID AAY17552 standard; peptide; 28 AA.
XX
AC AAY17552;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #18.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycaemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX

```

```

XX Sequence 28 AA;
SQ
AAY17552 Length: 28 February 4, 2005 13:32 Type: P Check: 683 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17553 ; Exendin agonist peptide #19.
(from "seq5ags.pep")
TOIG of: aay17553 check: 244 from: 1 to: 28

ID AAY17553 standard; peptide; 28 AA.
XX
AC AAY17553;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #19.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycaemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17553 Length: 28 February 4, 2005 13:32 Type: P Check: 244 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay17554 ; Exendin agonist peptide #20.
(from "seq5ags.pep")
TOIG of: aay17554 check: 546 from: 1 to: 28

```

```

-----
1 match found in sequence:
aay17549 ; Exendin agonist peptide #15.
  (from "seq5ags.pep")
TOIG of: aay17549 check: 156 from: 1 to: 28

ID AAY17549 standard; peptide; 28 AA.
XX
AC AAY17549;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #15.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17550 Length: 28 February 4, 2005 13:32 Type: P Check: 798 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTXTSDLSKQMEBAVRLFIEWLN 28
  |-----|

-----
1 match found in sequence:
aay17551 ; Exendin agonist peptide #17.
  (from "seq5ags.pep")
TOIG of: aay17551 check: 359 from: 1 to: 28

ID AAY17551 standard; peptide; 28 AA.
XX
AC AAY17551;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #17.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX

```

```

XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 28 AA;

AAY17546 Length: 28 February 4, 2005 13:32 Type: P Check: 690
Found using 'seq5' (mohamed337.key)

1 |-----|
  | AGDGTFTSDLSKQMEEEAVRLFIEFLKN 28
  |
-----
1 match found in sequence:
aay17547; Exendin agonist peptide #13.
(from "seq5ags.pep")
TOIG of: aay17547 check: 251 from: 1 to: 28

ID AAY17547 standard; peptide; 28 AA.
XX AC AAY17547;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #13.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX PI diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX PI hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.

```

```

CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 28 AA;

AAY17547 Length: 28 February 4, 2005 13:32 Type: P Check: 251
Found using 'seq5' (mohamed337.key)

1 |-----|
  | AGDGTFTSDLSKQMEEEAVRLFIEFLKN 28
  |
-----
1 match found in sequence:
aay17548; Exendin agonist peptide #14.
(from "seq5ags.pep")
TOIG of: aay17548 check: 595 from: 1 to: 28

ID AAY17548 standard; peptide; 28 AA.
XX AC AAY17548;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #14.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 28 AA;

AAY17548 Length: 28 February 4, 2005 13:32 Type: P Check: 595
Found using 'seq5' (mohamed337.key)

1 |-----|
  | AGDGTFTSDLSKQMEEEAVRLFIEFLKN 28
  |
-----
1 match found in sequence:
aay17549; Exendin agonist peptide #15.
(from "seq5ags.pep")
TOIG of: aay17549 check: 595 from: 1 to: 28

ID AAY17549 standard; peptide; 28 AA.
XX AC AAY17549;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #15.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.

```

AAV17543 Length: 28 February 4, 2005 13:32 Type: P Check: 590 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTSDASKQMBEEAVRLFIEWLKN 28
1

1 match found in sequence:
aay17544 ; Exendin agonist peptide #10.
(from "seq5ags.pep")
TOIG of: aay17544 check: 681 from: 1 to: 28

ID AAY17544 standard; peptide; 28 AA.
XX
AC AAY17544;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #10.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.

CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;
XX
AAV17544 Length: 28 February 4, 2005 13:32 Type: P Check: 681 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
AAGFTSDLSKQMBEEAVRLFIEWLKN 28
1

1 match found in sequence:
aay17545 ; Exendin agonist peptide #11.
(from "seq5ags.pep")
TOIG of: aay17545 check: 242 from: 1 to: 28

ID AAY17545 standard; peptide; 28 AA.
XX

AC AAY17545;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #11.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.

CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAV17545 Length: 28 February 4, 2005 13:32 Type: P Check: 242 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AAGFTSDLSKQMBEEAVRLFIEWLKN 28
1

1 match found in sequence:
aay17546 ; Exendin agonist peptide #12.
(from "seq5ags.pep")
TOIG of: aay17546 check: 690 from: 1 to: 28

ID AAY17546 standard; peptide; 28 AA.
XX
AC AAY17546;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #12.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
FN WO9925728-A1.
XX
PD 27-MAY-1999.


```

XX Synthetic.
OS Heloderma sp.
XX WO9925728-A1.
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
XX AAY17541 Length: 28 February 4, 2005 13:32 Type: P Check: 676 ..
XX Found using 'seq5' (mohamed337.key)
XX
1 |-----|
1 HGEATFTSDLSKQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
aay17542; Exendin agonist peptide #8.
(from "seq5ags.pep")
TOIG of: aay17542 check: 673 from: 1 to: 28

ID AAY17542 standard; peptide; 28 AA.
XX
XX AC AAY17542;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #8.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX SQ Sequence 28 AA;

```

```

DR WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
XX AAY17542 Length: 28 February 4, 2005 13:32 Type: P Check: 673 ..
XX Found using 'seq5' (mohamed337.key)
XX
1 |-----|
1 HGEATFTSALSQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
aay17543; Exendin agonist peptide #9.
(from "seq5ags.pep")
TOIG of: aay17543 check: 590 from: 1 to: 28

ID AAY17543 standard; peptide; 28 AA.
XX
XX AC AAY17543;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #9.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
XX SQ Sequence 28 AA;

```

CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX
 SQ Sequence 28 AA;

AAV17538 Length: 28 February 4, 2005 13:32 Type: P Check: 234 ..
 Found using 'seq5' (mohamed337.key)

1 HEGGFTSALSKQLEEEAVRLFIEWLKN
 1 28

 1 match found in sequence:
 aay17539 ; Exendin agonist peptide #5.
 (from "seq5ags.pep")
 TOIG of: aay17539 check: 693 from: 1 to: 28

ID AAV17539 standard; peptide; 28 AA.
 XX
 AC AAV17539;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #5.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.
 OS Heloderma sp.
 OS
 PN WO9925728-A1.
 XX
 XX 27-MAY-1999.

PD 13-NOV-1998; 98WO-US024273.
 XX
 PF 14-NOV-1997; 97US-0066029P.
 XX
 PR (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;
 PI
 XX WPI; 1999-347456/29.
 DR

XX Peptide agonists of exendin - delay stomach emptying, for treating
 XX diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

XX AAV17535 to AAV17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX

SQ Sequence 28 AA;

AAV17539 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
 Found using 'seq5' (mohamed337.key)

1 AGEGFTSALSKQLEEEAVRLFIEWLKN
 1 28

1 match found in sequence:
 aay17540 ; Exendin agonist peptide #6.
 (from "seq5ags.pep")
 TOIG of: aay17540 check: 688 from: 1 to: 28

ID AAV17540 standard; peptide; 28 AA.

XX
 AC AAV17540;

XX 09-AUG-1999 (first entry)

XX Exendin agonist peptide #6.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925728-A1.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.

XX 14-NOV-1997; 97US-0066029P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-347456/29.

XX Peptide agonists of exendin - delay stomach emptying, for treating
 XX diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

XX AAV17535 to AAV17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX

SQ Sequence 28 AA;

AAV17540 Length: 28 February 4, 2005 13:32 Type: P Check: 688 ..
 Found using 'seq5' (mohamed337.key)

1 HEGGFTSALSKQLEEEAVRLFIEWLKN
 1 28

 1 match found in sequence:
 aay17541 ; Exendin agonist peptide #7.
 (from "seq5ags.pep")
 TOIG of: aay17541 check: 676 from: 1 to: 28

ID AAV17541 standard; peptide; 28 AA.

XX
 AC AAV17541;

XX 09-AUG-1999 (first entry)

XX Exendin agonist peptide #7.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

```

XX 14-NOV-1997; 97US-0066029P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels).
XX
XX Sequence 28 AA;
XX
XX AAY17537 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
XX Found using 'seq5' (mohamed337.key)
XX
1 |-----|
1 HGEATFTSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay17538 ; Exendin agonist peptide #4.
(from "seq5aqs.pep")
TOIG of: aay17538 check: 234 from: 1 to: 28
-----
ID AAY17538 standard; peptide; 28 AA.
XX
XX AAY17538;
XX
XX 09-AUG-1999 (first entry)
XX
XX Exendin agonist peptide #4.
XX
XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard

```

```

-----|-----|
1  HSDGTFSDLSKQMEEEAVRLFIETWLNKGSPSSGAPPPS 28
1  -----|-----|
1  match found in sequence:
aay03718 ; Amino acid sequence of exendin-4.
(from "seq5ags.pep")
TOIG of: aay03718 check: 9570 from: 1 to: 39

ID AAY03718 standard; peptide; 39 AA.
XX
AC AAY03718;
XX
DT 08-JUN-1999 (first entry)
XX
DE Amino acid sequence of exendin-4.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological; generic.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT /note= "C-terminal amide"
XX
XX WO9907404-A1.
XX
XX 18-FEB-1999.
XX
XX 06-AUG-1998; 98WO-US016387.
XX
XX 08-AUG-1997; 97US-0055404P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-180403/15.
XX
XX New exendin agonists - useful in the treatment of Type I and II diabetes.
XX
XX Disclosure; Fig 3; 70pp; English.
XX
XX The invention relates to exendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The peptides are of the formula Xaa1-Xaa2-
XX Xaa3-Gly-Thr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Ser-Tyr-Gln-Xaa9-Glu-Glu-Xaa10-Ala-
XX Val-Arg-Leu-Xaa10- Xaa11- Xaa12- Xaa13-Leu-Tyr-Asn-Gly-Gly Xaa14-Ser-Ser-
XX Gly-Ala- Xaa15-Xaa16- Xaa17- Xaa18-Z; wherein: Xaa1 is His, Arg or Tyr;
XX Xaa2 is Ser, Gly, Ala, or Thr; Xaa3 is Asp or Glu; Xaa4 is Phe, Tyr, or
XX naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or
XX Glu; Xaa8 is Leu, Ile, Val, pentylglycine, or Met; Xaa9 is Leu, Ile,
XX pentylglycine, Val, or Met; Xaa10 is Phe, Tyr, or naphthylalanine; Xaa11
XX is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met; Xaa12 is Glu
XX or Asp; Xaa13 is Trp, Phe, Tyr, or naphthylalanine; Xaa14, Xaa15, Xaa16,
XX and Xaa17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-
XX alkylglycine, N-alkylpentylglycine, or N-alkylalanine; Xaa18 is Ser, Thr,
XX or Tyr; and Z is -OH or -NH2 with the proviso that the sequence is not
XX the amino acid sequences shown in the present sequence and AAY03717. The
XX specification claims for a second peptide of the above formula where Xaa1
XX is His, Arg, Tyr or 4-imidazopropionyl. The exendin agonists are used to
XX treat Type I and II diabetes, disorders which would be benefited by
XX agents which lower plasma glucose levels, and disorders which would be
XX benefited by agents useful in delaying and/or slowing gastric emptying.
XX Delayed gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. The present sequence represents the amino acid
XX sequence of exendin-4
XX
XX Sequence 39 AA;
XX
AAY03718 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..

Found using 'seq5' (mohamed337.key)
-----|-----|
1  HGEFTFSDLSKQMEEEAVRLFIETWLNKGSPSSGAPPPS 28
1  -----|-----|
1  match found in sequence:
aay17535 ; Exendin agonist peptide #1.
(from "seq5ags.pep")
TOIG of: aay17535 check: 254 from: 1 to: 28

ID AAY17535 standard; peptide; 28 AA.
XX
AC AAY17535;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #1.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17535 Length: 28 February 4, 2005 13:32 Type: P Check: 254 ..
Found using 'seq5' (mohamed337.key)
-----|-----|
1  AGEFTFSDLSKQLEEEAVRLFIETWLNKGSPSSGAPPPS 28
1  -----|-----|
1  match found in sequence:
aay17536 ; Exendin agonist peptide #2.
(from "seq5ags.pep")
TOIG of: aay17536 check: 249 from: 1 to: 28

ID AAY17536 standard; peptide; 28 AA.
XX
AC AAY17536;
XX
XX

```

TOIG of: aaw70288 check: 973 from: 1 to: 87

ID AAW70288 standard; protein; 87 AA.
 XX AAW70288;
 XX
 DT 06-NOV-1998 (first entry)
 XX Heloderma suspectum proexendin peptide.
 DE
 XX Heloderma suspectum proexendin; exendin N-terminal peptide; ENTp;
 KW exendin 4 peptide; exendin 3 gene; Heloderma horridum; metabolic disease;
 KW drug screening; endocrine tumour; organ failure; cell metabolism;
 KW diabetes; reptilian venom peptide.
 XX
 OS Heloderma suspectum.

Key	Location/Qualifiers
Peptide	1..47
FT	/note= "ENTp"
Peptide	1..23
FT	/note= "Signal peptide"
Cleavage-site	46..47
FT	/note= "Dipeptidyl peptidase cleavage site"
Peptide	48..87
FT	/note= "Exendin 4"

XX WO9835033-A1.
 XX
 XX 13-AUG-1998.
 XX
 XX 04-FEB-1998; 98WO-CA000071.
 XX
 XX 05-FEB-1997; 97US-0037412P.
 XX 07-FEB-1997; 97GB-00002582.
 XX
 XX (ONEO-) 1149336 ONTARIO INC.
 XX

PI Drucker DJ;

XX WPI; 1998-447230/38.
 XX N-PSDB; AAV33163.

XX New nucleic acid encoding proexendin - used to diagnose and treat, e.g.
 PT endocrine tumours, also to treat poisoning by reptile venom.

XX Claim 3; Fig 2; 26pp; English.

XX The Heloderma suspectum proexendin peptide is encoded by its cDNA which
 CC was isolated from a H. suspectum salivary gland cDNA library. The
 CC proexendin protein comprises of a novel exendin N-terminal peptide (ENTP).
 CC linked to the N-terminus of the exendin 4 peptide by a consensus
 CC dipeptidyl peptidase cleavage site. The proexendin cDNA can be used to
 CC clone or identify related sequences (e.g. the exendin 3 gene of Heloderma
 CC horridum, mutant alleles and proexendin gene regulatory defects
 CC associated with metabolic disease) and species homologues (e.g. for
 CC developing animal models for drug screening). The proexendin peptide can
 CC be used to raise antibodies. Anti-proexendin antibodies are claimed to be
 CC useful for diagnosing conditions associated with altered levels of
 CC proexendin (e.g. endocrine tumours and organ failure), for identifying
 CC other regulators of cell metabolism, in drug screens and for treating
 CC metabolic diseases (e.g. diabetes) and for neutralising, or detecting,
 CC reptilian venom peptides

XX Sequence 87 AA;

AAW70288 Length: 87 February 4, 2005 13:31 Type: P Check: 973 ..
 Found using 'seq5' (mohamed337.key)

1

MKIIILWCVGLFLATLFPISWQMPVESGLSSDSASSESPASKIKRGEGCTFTSDLSKQ
 48

61 -----
 MESEAVRLPIEWLKNCGPSSGAPPPSG
 75

 1 match found in sequence:
 aay03717; Amino acid sequence of exendin-3.
 (from "seq5ags.pep")
 TOIG of: aay03717 check: 9591 from: 1 to: 39

ID AAY03717 standard; peptide; 39 AA.
 XX
 AC AAY03717;
 XX
 DT 08-JUN-1999 (first entry)
 XX
 DE Amino acid sequence of exendin-3.
 XX
 KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
 KW diagnostic; gastro-intestinal; radiological; generic.

Key	Location/Qualifiers
Modified-site	39
FT	/note= "C-terminal amide"

XX WO9907404-A1.

XX 18-FEB-1999.

XX 06-AUG-1998; 98WO-US016387.

XX 08-AUG-1997; 97US-0055404P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-180403/15.

XX New exendin agonists - useful in the treatment of Type I and II diabetes.

XX Disclosure; Fig 2; 70pp; English.

XX The invention relates to exendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The peptides are of the formula Xaa1-Xaa2-
 CC Xaa3-Gly-Thr-Xaa4-Xaa5-Xaa6-Xaa7-Lys-Gln-Xaa8-Glu-Gly-Xaa9-Glu-Xaa10-
 CC Val-Arg-Leu-Xaa10-Xaa11-Xaa12-Xaa13-Leu-Lys-Aan-Gly-Xaa14-Ser-Ser-
 CC Gly-Ala-Xaa15-Xaa16-Xaa17-Xaa18-2; wherein: Xaa1 is His, Arg or Tyr;
 CC Xaa2 is Ser, Gly, Ala, or Thr; Xaa3 is Asp or Glu; Xaa4 is Phe, Tyr, or
 CC naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or
 CC Glu; Xaa8 is Leu, Ile, Val, pentylglycine, or Met; Xaa9 is Leu, Ile,
 CC pentylglycine, Val, or Met; Xaa10 is Phe, Tyr, or naphthylalanine; Xaa11
 CC is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met; Xaa12 is Glu
 CC or Asp; Xaa13 is Trp, Phe, Tyr, or naphthylalanine; Xaa14, Xaa15, Xaa16,
 CC and Xaa17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioroline, N-
 CC alkylglycine, N-alkylpentylglycine, or N-alkylalanine; Xaa18 is Ser, Thr,
 CC or Tyr; and 2 is -OH or -NH2 with the proviso that the sequence is not
 CC the amino acid sequences shown in the present sequence and AAY03718. The
 CC specification claims for a second peptide of the above formula where Xaa1
 CC is His, Arg, Tyr or 4-imidazopropionyl. The exendin agonists are used to
 CC treat Type I and II diabetes, disorders which would be benefited by
 CC agents which lower plasma glucose levels, and disorders which would be
 CC benefited by agents useful in delaying and/or slowing gastric emptying.
 CC Delayed gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. The present sequence represents the amino acid
 CC sequence of exendin-3

XX Sequence 39 AA;

AAW03717 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)

```

AAW61773 Length: 39 February 4, 2005 13:31 Type: P Check: 9131 ..
Found using 'seq5', (mohamed337.key)

1 -----
1 HEGTFTSDLSKQLEEEAVRLFIEFLKNGGSPGGAPPS
28
1 -----
1 match found in sequence:
aaw61774 ; Leu(14), Phe(25)-exendin-4 (1-28) amide, for reducing food intake.
(from "seq5ags.pep")
TOIG of: aaw61774 check: 261 from: 1 to: 28

ID AAW61774 standard; peptide; 28 AA.
XX
AC AAW61774;
XX
DT 29-MAR-1999 (first entry)
XX
DE Leu(14), Phe(25)-exendin-4 (1-28) amide, for reducing food intake.
XX
KW Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
KW insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT Modified-site 28 /note= "the C-terminal is in amide form"
FT
XX WO9830231-A1.
XX
XX 16-JUL-1998.
XX
XX 07-JAN-1998; 98WO-US000449.
XX
XX 07-JAN-1997; 97US-0034905P.
XX 08-AUG-1997; 97US-0055404P.
XX 14-NOV-1997; 97US-0065442P.
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
XX for treatment of e.g. obesity, type II diabetes, eating disorders and
XX insulin resistance.
XX
XX Claim 18, 26; Page 12; 214pp; English.
XX
XX The invention relates to a new method for treating disorders that are
XX alleviated by reducing food intake, in particular obesity, type II
XX diabetes, eating disorders, insulin resistance syndrome, elevated plasma
XX glucose levels, or the risk of cardiac disease. The method comprises
XX administering an exendin or an exendin agonist. The treatment reduces
XX appetite and lowers plasma lipid levels. It inhibits food consumption as
XX effectively as amylin or cholecystokinin but has a much longer-lasting
XX action (still effective after 6 hours in a mouse model). The present
XX sequence is that of an exendin-4 variant which is one of the preferred
XX compounds for use in the method
XX
XX Sequence 28 AA;
XX
AAW61774 Length: 28 February 4, 2005 13:31 Type: P Check: 261 ..
Found using 'seq5', (mohamed337.key)

1 -----
1 HEGTFTSDLSKQLEEEAVRLFIEFLKN
28
1 -----
1 match found in sequence:
aaw70288 ; Heloderma suspectum proexendin peptide.
(from "seq5ags.pep")

```

```

1 -----
1 match found in sequence:
aaw61775 ; Leu(14), Ala(22), Phe(25)-exendin-4 (1-28) amide.
(from "seq5ags.pep")
TOIG of: aaw61775 check: 151 from: 1 to: 28

ID AAW61775 standard; peptide; 28 AA.
XX
AC AAW61775;
XX
DT 29-MAR-1999 (first entry)
XX
DE Leu(14), Ala(22), Phe(25)-exendin-4 (1-28) amide.
XX
KW Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
KW insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT Modified-site 28 /note= "the C-terminal is in amide form"
FT
XX WO9830231-A1.
XX
XX 16-JUL-1998.
XX
XX 07-JAN-1998; 98WO-US000449.
XX
XX 07-JAN-1997; 97US-0034905P.
XX 08-AUG-1997; 97US-0055404P.
XX 14-NOV-1997; 97US-0065442P.
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
XX for treatment of e.g. obesity, type II diabetes, eating disorders and
XX insulin resistance.
XX
XX Claim 18, 26; Page 12; 214pp; English.
XX
XX The invention relates to a new method for treating disorders that are
XX alleviated by reducing food intake, in particular obesity, type II
XX diabetes, eating disorders, insulin resistance syndrome, elevated plasma
XX glucose levels, or the risk of cardiac disease. The method comprises
XX administering an exendin or an exendin agonist. The treatment reduces
XX appetite and lowers plasma lipid levels. It inhibits food consumption as
XX effectively as amylin or cholecystokinin but has a much longer-lasting
XX action (still effective after 6 hours in a mouse model). The present
XX sequence is that of an exendin-4 variant which is one of the preferred
XX compounds for use in the method
XX
XX Sequence 28 AA;
XX
AAW61775 Length: 28 February 4, 2005 13:31 Type: P Check: 151 ..
Found using 'seq5', (mohamed337.key)

1 -----
1 HEGTFTSDLSKQLEEEAVRLFIEFLKN
28
1 -----
1 match found in sequence:
aaw70288 ; Heloderma suspectum proexendin peptide.
(from "seq5ags.pep")

```

XX The invention relates to a new method for treating disorders that are
 CC alleviated by reducing food intake, in particular obesity, type II
 CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
 CC glucose levels, or the risk of cardiac disease. The method comprises
 CC administering an extendin or an extendin agonist. The treatment reduces
 CC appetite and lowers plasma lipid levels. It inhibits food consumption as
 CC effectively as amylin or cholecystokinin but has a much longer-lasting
 CC action (still effective after 6 hours in a mouse model). The present
 CC sequence is that of extendin-4 (1-30) or its amide which is one of the
 CC preferred compounds for use in the method
 XX
 SQ Sequence 30 AA;

AAW61771 Length: 30 February 4, 2005 13:31 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQWEEAVRLFIEWLKN 28
 1 -----|

 1 match found in sequence:
 aaw61772 ; Extendin-4 (1-28) amide for use in treating disorders related to foo
 (from "seq5ags.pep")
 TOIG of: aaw61772 check: 700 from: 1 to: 28

ID AAW61772 standard; peptide; 28 AA.
 XX
 AC AAW61772;
 XX
 DT 29-MAR-1999 (first entry)
 XX
 DE Extendin-4 (1-28) amide for use in treating disorders related to food.
 XX
 KW Extendin; obesity; type II diabetes; eating disorders; cardiac disease;
 KW insulin resistance syndrome; elevated plasma glucose level; agonist.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28 /note= "the C-terminal is in amide form"
 FT
 XX WO9830231-A1.
 XX
 PD 16-JUL-1998.
 XX
 PF 07-JAN-1998; 98WO-US000449.
 XX
 PR 07-JAN-1997; 97US-0034905P.
 PR 08-AUG-1997; 97US-0055404P.
 PR 14-NOV-1997; 97US-0065442P.
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS, Bhavsar S;
 XX
 DR WPI; 1998-398796/34.
 XX
 XX Reducing food intake by administering extendin(s) or their analogue(s) -
 PT for treatment of e.g. obesity, type II diabetes, eating disorders and
 PT insulin resistance.
 XX
 PS Claim 18, 26; Page 12; 214pp; English.
 XX
 CC The invention relates to a new method for treating disorders that are
 CC alleviated by reducing food intake, in particular obesity, type II
 CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
 CC glucose levels, or the risk of cardiac disease. The method comprises
 CC administering an extendin or an extendin agonist. The treatment reduces
 CC appetite and lowers plasma lipid levels. It inhibits food consumption as
 CC effectively as amylin or cholecystokinin but has a much longer-lasting
 CC action (still effective after 6 hours in a mouse model). The present
 CC sequence is that of extendin-4 (1-30) or its amide which is one of the
 CC preferred compounds for use in the method

CC effectively as amylin or cholecystokinin but has a much longer-lasting
 CC action (still effective after 6 hours in a mouse model). The present
 CC sequence is that of extendin-4 (1-28) amide which is one of the preferred
 CC compounds for use in the method
 XX
 SQ Sequence 28 AA;

AAW61772 Length: 28 February 4, 2005 13:31 Type: P Check: 700 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQWEEAVRLFIEWLKN 28
 1 -----|

 1 match found in sequence:
 aaw61773 ; Leu(14), Phe(25)-extendin-4 amide, for reducing food intake.
 (from "seq5ags.pep")
 TOIG of: aaw61773 check: 9131 from: 1 to: 39

ID AAW61773 standard; peptide; 39 AA.
 XX
 AC AAW61773;
 XX
 DT 29-MAR-1999 (first entry)
 XX
 DE Leu(14), Phe(25)-extendin-4 amide, for reducing food intake.
 XX
 KW Extendin; obesity; type II diabetes; eating disorders; cardiac disease;
 KW insulin resistance syndrome; elevated plasma glucose level; agonist.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39 /note= "the C-terminal is in amide form"
 FT
 XX WO9830231-A1.
 XX
 PD 16-JUL-1998.
 XX
 PF 07-JAN-1998; 98WO-US000449.
 XX
 PR 07-JAN-1997; 97US-0034905P.
 PR 08-AUG-1997; 97US-0055404P.
 PR 14-NOV-1997; 97US-0065442P.
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS, Bhavsar S;
 XX
 DR WPI; 1998-398796/34.
 XX
 XX Reducing food intake by administering extendin(s) or their analogue(s) -
 PT for treatment of e.g. obesity, type II diabetes, eating disorders and
 PT insulin resistance.
 XX
 PS Claim 18, 26; Page 12; 214pp; English.
 XX
 CC The invention relates to a new method for treating disorders that are
 CC alleviated by reducing food intake, in particular obesity, type II
 CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
 CC glucose levels, or the risk of cardiac disease. The method comprises
 CC administering an extendin or an extendin agonist. The treatment reduces
 CC appetite and lowers plasma lipid levels. It inhibits food consumption as
 CC effectively as amylin or cholecystokinin but has a much longer-lasting
 CC action (still effective after 6 hours in a mouse model). The present
 CC sequence is that of an extendin-4 variant which is one of the preferred
 CC compounds for use in the method
 XX
 SQ Sequence 39 AA;

```
PF 07-JAN-1998; 98WO-US000449.
XX
XX 07-JAN-1997; 97US-0034905P.
PR 08-AUG-1997; 97US-0055404P.
PR 14-NOV-1997; 97US-0065442P.
PR 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Beesley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 16, 24; Page 8; 214pp; English.
XX
XX The invention relates to a new method for treating disorders that are
CC alleviated by reducing food intake, in particular obesity, type II
CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
CC glucose levels, or the risk of cardiac disease. The method comprises
CC administering an exendin or an exendin agonist. The treatment reduces
CC appetite and lowers plasma lipid levels. It inhibits food consumption as
CC effectively as amylin or cholecystokinin but has a much longer-lasting
CC action (still effective after 6 hours in a mouse model). The present
CC sequence is that of exendin-3 which is one of the preferred compounds for
CC use in the method
XX
XX SQ Sequence 39 AA;
AAW61769 Length: 39 February 4, 2005 13:31 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSDLSKQMEEAARLFIWLNKNGPSSGAPPPS
28
-----
1 match found in sequence:
aaw61770 ; Exendin-4, for use in treating disorders related to food intake.
(from "seq5ags.pep")
TOIG of: aaw61770 check: 9570 from: 1 to: 39
ID AAW61770 standard; peptide; 39 AA.
XX
XX AC AAW61770;
XX
XX DT 29-MAR-1999 (first entry)
XX
XX DE Exendin-4, for use in treating disorders related to food intake.
XX
XX KW Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
XX insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
XX OS Heloderma suspectum.
XX
XX PH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "optionally the C-terminal is in amide form"
XX
XX PN WO9830231-A1.
XX
XX PD 16-JUL-1998.
XX
XX PF 07-JAN-1998; 98WO-US000449.
XX
XX XX 07-JAN-1997; 97US-0034905P.
XX PR 08-AUG-1997; 97US-0055404P.
XX PR 14-NOV-1997; 97US-0065442P.
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beesley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 17, 25; Page 8; 214pp; English.
XX
XX The invention relates to a new method for treating disorders that are
CC alleviated by reducing food intake, in particular obesity, type II
CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
CC glucose levels, or the risk of cardiac disease. The method comprises
CC administering an exendin or an exendin agonist. The treatment reduces
CC appetite and lowers plasma lipid levels. It inhibits food consumption as
CC effectively as amylin or cholecystokinin but has a much longer-lasting
CC action (still effective after 6 hours in a mouse model). The present
CC sequence is that of exendin-4 which is one of the preferred compounds for
CC use in the method
XX
XX SQ Sequence 39 AA;
AAW61770 Length: 39 February 4, 2005 13:31 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSDLSKQMEEAARLFIWLNKNGPSSGAPPPS
28
-----
1 match found in sequence:
aaw61771 ; Exendin-4 (1-30) for use in treating disorders related to food intake.
(from "seq5ags.pep")
TOIG of: aaw61771 check: 4889 from: 1 to: 30
ID AAW61771 standard; peptide; 30 AA.
XX
XX AC AAW61771;
XX
XX DT 29-MAR-1999 (first entry)
XX
XX DE Exendin-4 (1-30) for use in treating disorders related to food intake.
XX
XX KW Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
XX insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
XX OS Heloderma suspectum.
XX
XX PH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "optionally the C-terminal is in amide form"
XX
XX PN WO9830231-A1.
XX
XX PD 16-JUL-1998.
XX
XX PF 07-JAN-1998; 98WO-US000449.
XX
XX XX 07-JAN-1997; 97US-0034905P.
XX PR 08-AUG-1997; 97US-0055404P.
XX PR 14-NOV-1997; 97US-0065442P.
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beesley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 18, 26; Page 11; 214pp; English.
XX
XX PS
```



```

KW Gila monster venom; extendin-3.
XX OS Heloderma horridum.
XX FH
XX FT
XX FT
XX FT
XX FT
XX Key Location/Qualifiers
XX Modified-site 39
XX /note= "amidated"
XX
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX
XX 08-AUG-1997; 97WO-US014199.
XX
XX 08-AUG-1996; 96US-00694954.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX
XX Claim 20 and 21; Fig 1; 70pp; English.
XX
XX AAW47549 describes a generic extendin agonist, provided that it does have
XX the formula of either extendin-3 (AAW47608) or extendin-4 (AAW47609).
XX Extendin agonists, which reduce gastric motility and delay gastric
XX emptying, can be used to treat spasm (where associated with acute
XX diverticulitis or disorders of the biliary tract or sphincter of Oddi),
XX postprandial dumping syndrome and hyperglycaemia (particularly associated
XX with type 2 diabetes), type 1 diabetes, impaired glucose tolerance, toxin
XX ingestion (an extendin agonist is administered to prevent stomach contents
XX passing into the intestines, then the stomach pumped) and obesity. They
XX can also be administered to subjects undergoing gastrointestinal
XX diagnostic investigation, particularly radiological or by magnetic
XX resonance imaging. Extendins, components of Gila monster venom, have some
XX agonists and have been suggested (US5424286) for treatment of diabetes
XX and prevention of hyperglycaemia
XX
XX Sequence 39 AA;
XX
AAW47608 Length: 39 February 4, 2005 13:31 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGTFSTDSLKQMEERAVRLFIEWLKNKGPPSGAPPPS
28
-----
1 match found in sequence:
aaw47609 ; Gila monster extendin-4.
(from "seq5ags.pep")
TOIG of: aaw47609 check: 9570 from: 1 to: 39
ID AAW47609 standard; peptide; 39 AA.
XX AC AAW47609;
XX DT 03-JUL-1998 (first entry)
XX DE Gila monster extendin-4.
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom; extendin-4.
XX OS Heloderma suspectum.

```

```

XX FH
XX FT
XX FT
XX FT
XX FT
XX Key Location/Qualifiers
XX Modified-site 39
XX /note= "amidated"
XX
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX
XX 08-AUG-1997; 97WO-US014199.
XX
XX 08-AUG-1996; 96US-00694954.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX
XX Claim 20 and 21; Fig 1; 70pp; English.
XX
XX AAW47549 describes a generic extendin agonist, provided that it does have
XX the formula of either extendin-3 (AAW47608) or extendin-4 (AAW47609).
XX Extendin agonists, which reduce gastric motility and delay gastric
XX emptying, can be used to treat spasm (where associated with acute
XX diverticulitis or disorders of the biliary tract or sphincter of Oddi),
XX postprandial dumping syndrome and hyperglycaemia (particularly associated
XX with type 2 diabetes), type 1 diabetes, impaired glucose tolerance, toxin
XX ingestion (an extendin agonist is administered to prevent stomach contents
XX passing into the intestines, then the stomach pumped) and obesity. They
XX can also be administered to subjects undergoing gastrointestinal
XX diagnostic investigation, particularly radiological or by magnetic
XX resonance imaging. Extendins, components of Gila monster venom, have some
XX agonists and have been suggested (US5424286) for treatment of diabetes
XX and prevention of hyperglycaemia
XX
XX Sequence 39 AA;
XX
AAW47609 Length: 39 February 4, 2005 13:31 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGBGTFSTDSLKQMEERAVRLFIEWLKNKGPPSGAPPPS
28
-----
1 match found in sequence:
aaw61769 ; Extendin-3, for use in treating disorders related to food intake.
(from "seq5ags.pep")
TOIG of: aaw61769 check: 9591 from: 1 to: 39
ID AAW61769 standard; peptide; 39 AA.
XX AC AAW61769;
XX DT 29-MAR-1999 (first entry)
XX DE Extendin-3, for use in treating disorders related to food intake.
XX
XX Extendin; obesity; type II diabetes; eating disorders; cardiac disease;
XX insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
XX Heloderma horridum.
XX WO9830231-A1.
XX
XX 16-JUL-1998.
XX

```

```

AC AAW39417;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide derivative #60.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goetze R, Goetze B;
PI
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 30; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39417 Length: 30 February 4, 2005 13:32 Type: P Check: 5371 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HSDGFTSDLSKQAEAEAVRLFVWLKNGR 28

-----
1 match found in sequence:
aaw39420 ; H. horridum extendin-3 peptide derivative #63.
(from "seq5ags.pep")
TOIG of: aaw39420 check: 5394 from: 1 to: 30

ID AAW39420 standard; peptide; 30 AA.
XX
XX AAW39420;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide derivative #63.
DE

```

```

XX
KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 14
FT /label= Nle
FT /note= "Norleucine"
FT
FT Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goetze R, Goetze B;
PI
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 31; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39420 Length: 30 February 4, 2005 13:31 Type: P Check: 5394 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HSDGFTSDLSKQAEAEAVRLFVWLKNGR 28

-----
1 match found in sequence:
aaw47608 ; Gila monster extendin-3.
(from "seq5ags.pep")
TOIG of: aaw47608 check: 9591 from: 1 to: 39

ID AAW47608 standard; peptide; 39 AA.
XX
XX AAW47608;
XX
XX 03-JUL-1998 (first entry)
DT
XX
XX Gila monster extendin-3.
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW

```

```

1 |-----|
  KSDGTFSDLSKQAEAAVRLFIWLNKGR
  1 28

-----
1 match found in sequence:
aaw39415 ; H. horridum exendin-3 peptide derivative #58.
(from "seq5ags.pep")
TOIG of: aaw39415 check: 4732 from: 1 to: 30

ID AAW39415 standard; peptide; 30 AA.
XX
AC AAW39415;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
DE H. horridum exendin-3 peptide derivative #58.
XX
KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN W09746584-A1.
XX
PD 11-DEC-1997.
XX
PP 05-JUN-1997; 97WO-EP002930.
XX
PR 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
PI Hoffmann E, Goeke R, Goeke B;
XX
DR WPI; 1998-042119/04.
XX
PT Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
PS Claim 2; Page 30; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;
AAW39415 Length: 30 February 4, 2005 13:31 Type: P Check: 4732
Found using 'seq5' (mohamed337.key)

1 |-----|
  HSDGTFSDLSKQAEAAVRLFIWLNKGR
  1 28

-----
1 match found in sequence:
aaw39417 ; H. horridum exendin-3 peptide derivative #60.
(from "seq5ags.pep")
TOIG of: aaw39417 check: 5371 from: 1 to: 30

ID AAW39417 standard; peptide; 30 AA.
XX

```

CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39410 Length: 30 February 4, 2005 13:31 Type: P Check: 4864 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGTFSDLSKQAEAEAVRLFIEWLKNGR
 28

 1 match found in sequence:
 aaw39411; H. horridum extendin-3 peptide derivative #54.
 (from "seq5ags.pep")
 TOIG of: aaw39411 check: 5012 from: 1 to: 30

ID AAW39411 standard; peptide; 30 AA.

XX AAW39411;

AC AAW39411;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum extendin-3 peptide derivative #54.

XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 30; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39411 Length: 30 February 4, 2005 13:31 Type: P Check: 5012 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGTFSDLSKQAEAEAVRLFIEWLKNGR
 28

 1 match found in sequence:
 aaw39412; H. horridum extendin-3 peptide derivative #55.
 (from "seq5ags.pep")
 TOIG of: aaw39412 check: 5007 from: 1 to: 30

ID AAW39412 standard; peptide; 30 AA.

XX AAW39412;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum extendin-3 peptide derivative #55.

XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 30; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39412 Length: 30 February 4, 2005 13:31 Type: P Check: 5007 ..
 Found using 'seq5' (mohamed337.key)

PT Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 30; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39408 Length: 30 February 4, 2005 13:32 Type: P Check: 4874 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 | HSDGFTTSDLSAQAEERAVRLFIEWLNKR
 1 28

 1 match found in sequence:

aaw39409 ; H. horridum exendin-3 peptide derivative #52.
 (from "seq5agg.pep")

TOIG of: aaw39409 check: 4931 from: 1 to: 30

ID AAW39409 standard; peptide; 30 AA.

XX AC AAW39409;

XX DT 25-MAR-2003 (revised)

XX DT 05-JUN-1998 (first entry)

XX DE H. horridum exendin-3 peptide derivative #52.

XX EX Endin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

XX FT Modified-site 30 /note= "C-terminal amide"

XX PN WO9746584-A1.

XX PD 11-DEC-1997.

XX PF 05-JUN-1997; 97WO-EP002930.

XX PR 05-JUN-1996; 96DE-01022502.

XX PR 13-SEP-1996; 96DE-01037230.

XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX PI Hoffmann E, Goeke R, Goeke B;

XX DR WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 30; 150pp; English.

XX

CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39409 Length: 30 February 4, 2005 13:31 Type: P Check: 4931 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 | HSGTFTTSDLSAQAEERAVRLFIEWLNKR
 1 28

 1 match found in sequence:

aaw39410 ; H. horridum exendin-3 peptide derivative #53.
 (from "seq5agg.pep")

TOIG of: aaw39410 check: 4864 from: 1 to: 30

ID AAW39410 standard; peptide; 30 AA.

XX AC AAW39410;

XX DT 25-MAR-2003 (revised)

XX DT 05-JUN-1998 (first entry)

XX DE H. horridum exendin-3 peptide derivative #53.

XX EX Endin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

XX FT Modified-site 30 /note= "C-terminal amide"

XX PN WO9746584-A1.

XX PD 11-DEC-1997.

XX PF 05-JUN-1997; 97WO-EP002930.

XX PR 05-JUN-1996; 96DE-01022502.

XX PR 13-SEP-1996; 96DE-01037230.

XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX PI Hoffmann E, Goeke R, Goeke B;

XX DR WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 30; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,

```

XX PP 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX DR
XX
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;
AAW39406 Length: 30 February 4, 2005 13:31 Type: P Check: 5081 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSLSKQAEAEAVRLFIEWLNKGR 28
-----
1 match found in sequence:
aaw39407 ; H. horridum exendin-3 peptide derivative #50.
(from "seq5ags.pep")
TOIG of: aaw39407 check: 4962 from: 1 to: 30
ID AAW39407 standard; peptide; 30 AA.
XX AC AAW39407;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-3 peptide derivative #50.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX

```

```

PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;
AAW39407 Length: 30 February 4, 2005 13:31 Type: P Check: 4962 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSDASKQAEAEAVRLFIEWLNKGR 28
-----
1 match found in sequence:
aaw39408 ; H. horridum exendin-3 peptide derivative #51.
(from "seq5ags.pep")
TOIG of: aaw39408 check: 4874 from: 1 to: 30
ID AAW39408 standard; peptide; 30 AA.
XX AC AAW39408;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-3 peptide derivative #51.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX

```

```

KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEP ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 30; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known extendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39402 Length: 30 February 4, 2005 13:32 Type: P Check: 5065
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGTFSSDLKQAEBAVRLFIWLNKGR 28
-----
1 match found in sequence:
aaw39404 ; H. horridum extendin-3 peptide derivative #47.
(from "seq5ags.pep")
TOIG of: aaw39404 check: 5080 from: 1 to: 30

ID AAW39404 standard; peptide; 30 AA.
XX
XX AC AAW39404;
XX
XX 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide derivative #47.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.

```

```

FT Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEP ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 30; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known extendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39404 Length: 30 February 4, 2005 13:31 Type: P Check: 5080
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGTFTTDLKQAEBAVRLFIWLNKGR 28
-----
1 match found in sequence:
aaw39406 ; H. horridum extendin-3 peptide derivative #49.
(from "seq5ags.pep")
TOIG of: aaw39406 check: 5081 from: 1 to: 30

ID AAW39406 standard; peptide; 30 AA.
XX
XX AC AAW39406;
XX
XX 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide derivative #49.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.

```

```
(from "seq5ags.pep")
TOIG of: aaw39400 check: 5186 from: 1 to: 30

ID AAW39400 standard; peptide; 30 AA.
XX AC AAW39400;
XX AC
XX AC
XX AC
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-3 peptide derivative #43.
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX KW Heloderma horridum.
XX OS
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN W09746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX PI WPI; 1998-042119/04.
XX DR
XX FT Truncated versions of extendin peptide(s) for treating diabetes - increase
XX FT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX FT do not induce hypoglycaemia.
XX PS Claim 2; Page 29; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known extendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39400 Length: 30 February 4, 2005 13:32 Type: P Check: 5186
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HSDGTYTSDLSKQAEAEAVRLFIEWLNKR
28

-----
1 match found in sequence:
aaw39401 ; H. horridum extendin-3 peptide derivative #44.
(from "seq5ags.pep")
TOIG of: aaw39401 check: 5090 from: 1 to: 30

ID AAW39401 standard; peptide; 30 AA.
XX AC AAW39401;
XX AC
XX AC
XX AC
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-3 peptide derivative #45.
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX KW Heloderma horridum.
XX OS
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN W09746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX PI WPI; 1998-042119/04.
XX DR
XX FT Truncated versions of extendin peptide(s) for treating diabetes - increase
XX FT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX FT do not induce hypoglycaemia.
XX PS Claim 2; Page 29; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known extendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39401 Length: 30 February 4, 2005 13:31 Type: P Check: 5090
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HSDGTYTSDLSKQAEAEAVRLFIEWLNKR
28

-----
1 match found in sequence:
aaw39402 ; H. horridum extendin-3 peptide derivative #45.
(from "seq5ags.pep")
TOIG of: aaw39402 check: 5065 from: 1 to: 30

ID AAW39402 standard; peptide; 30 AA.
XX AC AAW39402;
XX AC
XX AC
XX AC
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-3 peptide derivative #45.
XX AC AAW39401;
```


SQ Sequence 30 AA;
AAW39393 Length: 30 February 4, 2005 13:31 Type: P Check: 5396 ..
Found using 'seq5', (mohamed337.key)

1 |-----|
1 HSDGFTSDLSKQAEAEAVRLFIEWLNKR 28

1 match found in sequence:
aaw39397; H. horridum exendin-3 peptide derivative #40.
(from "seq5ags.pep")
TOIG of: aaw39397 check: 5063 from: 1 to: 30

ID AAW39397 standard; peptide; 30 AA.
XX AC AAW39397;
XX AC AAW39397;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-3 peptide derivative #40.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase secretion and biosynthesis of insulin, but reduce those of glucagon, and do not induce hypoglycaemia.
XX Claim 2; Page 29; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX SQ Sequence 30 AA;
AAW39397 Length: 30 February 4, 2005 13:32 Type: P Check: 5063 ..
Found using 'seq5', (mohamed337.key)

1 HSDGFTSDLSKQAEAEAVRLFIEWLNKR 28

1 match found in sequence:
aaw39398; H. horridum exendin-3 peptide derivative #41.
(from "seq5ags.pep")
TOIG of: aaw39398 check: 4977 from: 1 to: 30

ID AAW39398 standard; peptide; 30 AA.
XX AC AAW39398;
XX AC AAW39398;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-3 peptide derivative #41.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase secretion and biosynthesis of insulin, but reduce those of glucagon, and do not induce hypoglycaemia.
XX Claim 2; Page 29; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX SQ Sequence 30 AA;
AAW39398 Length: 30 February 4, 2005 13:31 Type: P Check: 4977 ..
Found using 'seq5', (mohamed337.key)

1 |-----|
1 HSDGFTSDLSKQAEAEAVRLFIEWLNKR 28

1 match found in sequence:
aaw39400; H. horridum exendin-3 peptide derivative #43.

CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39378 Length: 30 February 4, 2005 13:31 Type: P Check: 5358 ..
 Found using 'seq5' (mohamed337.key)

1 HADGTFSDLSKQXEEAVRLFIEWLKNGR
 1 28

1 match found in sequence:
 aaw39383 ; H. horridum extendin-3 peptide derivative #26.
 (from "seq5ags.pep")
 TOIG of: aaw39383 check: 5370 from: 1 to: 30

ID AAW39383 standard; peptide; 30 AA.
 XX
 AC AAW39383;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum extendin-3 peptide derivative #26.
 XX
 KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 OS Heloderma horridum.
 XX

Key Location/Qualifiers
 FT Modified-site 14
 FT /label= Nle
 FT /note= "Norleucine"
 FT Modified-site 30
 FT /note= "C-terminal amide"

XX WO9746584-A1.
 XX
 PD 11-DEC-1997.
 XX
 PF 05-JUN-1997; 97WO-EP002930.
 XX
 PR 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX
 PA (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX
 PI Hoffmann E, Goeke R, Goeke B;
 XX
 DR WPI; 1998-042119/04.
 XX

Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 28; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more

CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39383 Length: 30 February 4, 2005 13:31 Type: P Check: 5370 ..
 Found using 'seq5' (mohamed337.key)

1 HGDGTFSDLSKQXEEAVRLFIEWLKNGR
 1 28

1 match found in sequence:
 aaw39393 ; H. horridum extendin-3 peptide derivative #36.
 (from "seq5ags.pep")
 TOIG of: aaw39393 check: 5396 from: 1 to: 30

ID AAW39393 standard; peptide; 30 AA.
 XX
 AC AAW39393;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum extendin-3 peptide derivative #36.
 XX
 KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 OS Heloderma horridum.
 XX

Key Location/Qualifiers
 FT Modified-site 14
 FT /label= Nle
 FT /note= "Norleucine"
 FT Modified-site 30
 FT /note= "C-terminal amide"

XX WO9746584-A1.
 XX
 PD 11-DEC-1997.
 XX
 PF 05-JUN-1997; 97WO-EP002930.
 XX
 PR 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX
 PA (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX
 PI Hoffmann E, Goeke R, Goeke B;
 XX
 DR WPI; 1998-042119/04.
 XX

Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 29; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX

CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39370 Length: 30 February 4, 2005 13:31 Type: P Check: 5394 ..
 Found using 'seq5' (mohamed337.key)

```

1 1-----|
   HSDGTFSDLSKQEEAEVRLFIWLNKGR
   28

```

 1 match found in sequence:
 aaw39371; H. horridum exendin-3 peptide derivative #14.
 (from "seq5ags.pep")

TOIG of: aaw39371 check: 5072 from: 1 to: 30

ID AAW39371 standard; peptide; 30 AA.

XX AAW39371;

AC AAW39371;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-3 peptide derivative #14.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

KW Heloderma horridum.

OS Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 14

FT /label= Nle

FT /note= "Norleucine"

FT Modified-site 30

FT /note= "C-terminal amide"

FT WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase

PT secretion and biosynthesis of insulin, but reduce those of glucagon, and

PT do not induce hypoglycaemia.

XX Claim 2; Page 28; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method for the

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis

CC and secretion of insulin, but have the opposite effect on glucagon, and

CC

CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39371 Length: 30 February 4, 2005 13:32 Type: P Check: 5072 ..
 Found using 'seq5' (mohamed337.key)

```

1 1-----|
   HSDGTFSDLSKQEEAEVRLFIWLNKGR
   28

```

 1 match found in sequence:
 aaw39378; H. horridum exendin-3 peptide derivative #21.
 (from "seq5ags.pep")

TOIG of: aaw39378 check: 5358 from: 1 to: 30

ID AAW39378 standard; peptide; 30 AA.

XX AAW39378;

AC AAW39378;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-3 peptide derivative #21.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

KW Heloderma horridum.

OS Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 14

FT /label= Nle

FT /note= "Norleucine"

FT Modified-site 30

FT /note= "C-terminal amide"

FT WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase

PT secretion and biosynthesis of insulin, but reduce those of glucagon, and

PT do not induce hypoglycaemia.

XX Claim 2; Page 28; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method for the

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis

CC and secretion of insulin, but have the opposite effect on glucagon, and

CC independent of this activity can increase peripheral glucose utilisation.

CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,

CC so they will not induce hypoglycaemia. Compared with glucagon-like

CC

PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 27; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39368 Length: 30 February 4, 2005 13:31 Type: P Check: 5240 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HSDGTFSTDSLKQEEAVRLFIEWLKNGR 28

 1 match found in sequence:
 aaw39369 ; H. horridum exendin-3 peptide derivative #12.
 (from "seq5ags.pep")
 TOIG of: aaw39369 check: 5604 from: 1 to: 30

ID AAW39369 standard; peptide; 30 AA.
 XX
 AC AAW39369;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum exendin-3 peptide derivative #12.
 XX
 KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX
 OS Heloderma horridum.

Key	Location/Qualifiers
Modified-site 14	/label= Nle
Modified-site 30	/note= "Norleucine"
Modified-site 30	/note= "C-terminal amide"

WO9746584-A1.
 11-DEC-1997.
 05-JUN-1997; 97WO-EP002930.
 05-JUN-1996; 96DE-01022502.
 13-SEP-1996; 96DE-01037230.
 (BOEF) BOEHRINGER MANNHEIM GMBH.
 Hoffmann E, Goeke R, Goeke B;
 WPI; 1998-042119/04.

Truncated versions of exendin peptide(s) for treating diabetes - increase
 secretion and biosynthesis of insulin, but reduce those of glucagon, and
 do not induce hypoglycaemia.

XX

PS Claim 2; Page 27; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39369 Length: 30 February 4, 2005 13:31 Type: P Check: 5604 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HSDGTFSTDSLKQEEAVRLFIEWLKNGY 28

 1 match found in sequence:
 aaw39370 ; H. horridum exendin-3 peptide derivative #13.
 (from "seq5ags.pep")
 TOIG of: aaw39370 check: 5394 from: 1 to: 30

ID AAW39370 standard; peptide; 30 AA.
 XX
 AC AAW39370;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum exendin-3 peptide derivative #13.
 XX
 KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX
 OS Heloderma horridum.

Key	Location/Qualifiers
Modified-site 14	/label= Nle
Modified-site 30	/note= "Norleucine"
Modified-site 30	/note= "C-terminal OH group"

WO9746584-A1.
 11-DEC-1997.
 05-JUN-1997; 97WO-EP002930.
 05-JUN-1996; 96DE-01022502.
 13-SEP-1996; 96DE-01037230.
 (BOEF) BOEHRINGER MANNHEIM GMBH.
 Hoffmann E, Goeke R, Goeke B;
 WPI; 1998-042119/04.

Truncated versions of exendin peptide(s) for treating diabetes - increase
 secretion and biosynthesis of insulin, but reduce those of glucagon, and
 do not induce hypoglycaemia.

PS Claim 2; Page 28; 150pp; English.
 XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

Truncated versions of exendin peptide(s) for treating diabetes - increase

```

KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
OS
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 27; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39364 Length: 30 February 4, 2005 13:31 Type: P Check: 4765 ..
Found using 'seq5' (mohamed337.key)
1
1 HGEFTTSLSKQAEAEAVRLFIEWAKNGR
28
-----
1 match found in sequence:
aaw39365; H. horridum exendin-4 peptide derivative #53.
(from "seq5ags.pep")
TOIG of: aaw39365 check: 4781 from: 1 to: 30
ID AAW39365 standard; peptide; 30 AA.
XX
AC AAW39365;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #53.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 27; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39365 Length: 30 February 4, 2005 13:31 Type: P Check: 4781 ..
Found using 'seq5' (mohamed337.key)
1
1 HGEFTTSLSKQAEAEAVRLFIEWLANGR
28
-----
1 match found in sequence:
aaw39366; H. horridum exendin-4 peptide derivative #54.
(from "seq5ags.pep")
TOIG of: aaw39366 check: 4877 from: 1 to: 30
ID AAW39366 standard; peptide; 30 AA.
XX
AC AAW39366;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #54.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX

```

```

TOIG of: aaw39361 check: 5350 from: 1 to: 30
ID AAW39361 standard; peptide; 30 AA.
XX AC AAW39361;
XX
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #49.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW Glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX PN WO9746584-A1.
XX
XX PD 11-DEC-1997.
XX
XX PF 05-JUN-1997; 97WO-EP002930.
XX
XX PR 05-JUN-1996; 96DE-01022502.
XX
XX PR 13-SEP-1996; 96DE-01037230.
XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX PI Hoffmann E, Goeke R, Goeke B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX PS Claim 2; Page 27; 150pp; English.
XX
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX SQ Sequence 30 AA;
XX
AAW39361 Length: 30 February 4, 2005 13:31 Type: P Check: 5350 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGGTFTSLSKQAEBAVRLFVEWLNKGR
    28

-----
1 match found in sequence:
aaw39363 ; H. horridum extendin-4 peptide derivative #51.
(from "seq5ags.pep")
TOIG of: aaw39363 check: 4501 from: 1 to: 30

ID AAW39363 standard; peptide; 30 AA.
XX AC AAW39363;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #52.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW Glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX PN WO9746584-A1.
XX
XX PD 11-DEC-1997.
XX
XX PF 05-JUN-1997; 97WO-EP002930.
XX
XX PR 05-JUN-1996; 96DE-01022502.
XX
XX PR 13-SEP-1996; 96DE-01037230.
XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX PI Hoffmann E, Goeke R, Goeke B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX PS Claim 2; Page 27; 150pp; English.
XX
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX SQ Sequence 30 AA;
XX
AAW39363 Length: 30 February 4, 2005 13:31 Type: P Check: 4501 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGGTFTSLSKQAEBAVRLFVEWLNKGR
    28

-----
1 match found in sequence:
aaw39364 ; H. horridum extendin-4 peptide derivative #52.
(from "seq5ags.pep")
TOIG of: aaw39364 check: 4765 from: 1 to: 30

ID AAW39364 standard; peptide; 30 AA.
XX AC AAW39364;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #52.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW Glucagon reduction; hypoglycaemia; glucose; treatment.

```

AAW39356 Length: 30 February 4, 2005 13:31 Type: P Check: 4986
Found using 'seq5' (mohamed337.key)

1 KEGTFTSDLSKQAEAAVRLFIWLNKGR
28

1 match found in sequence:
aaw39359 ; H. horridum extendin-4 peptide derivative #48.
(from "seq5ags.pep")
TOIG of: aaw39359 check: 4711 from: 1 to: 30

ID AAW39359 standard; peptide; 30 AA.
XX AC AAW39359;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #48.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX WO9746584-A1.
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
PI WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 27; 150pp; English.
XX

Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Extendin-3 and extendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known extendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39359 Length: 30 February 4, 2005 13:31 Type: P Check: 4711
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQAEAAVRLFIWLNKGR

1 28

1 match found in sequence:
aaw39360 ; H. horridum extendin-3 peptide derivative #10.
(from "seq5ags.pep")
TOIG of: aaw39360 check: 5490 from: 1 to: 30

ID AAW39360 standard; peptide; 30 AA.
XX AC AAW39360;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide derivative #10.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX WO9746584-A1.
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
PI WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 27; 150pp; English.
XX

Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Extendin-3 and extendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known extendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39360 Length: 30 February 4, 2005 13:31 Type: P Check: 5490
Found using 'seq5' (mohamed337.key)

1 HSDGTFTSDLSKQAEAAVRLFIWLNKGR
28

1 match found in sequence:
aaw39361 ; H. horridum extendin-4 peptide derivative #49.
(from "seq5ags.pep")

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX Sequence 30 AA;

AAW39353 Length: 30 February 4, 2005 13:32 Type: P Check: 4843 ..
 Found using 'seq5' (mohamed337.key)

1 HCGTFTSDLSKQAAEEAVRLFIEWLKNGR
 1
 -----|-----
 28

 1 match found in sequence:
 aaw39354 ; H. horridum exendin-4 peptide derivative #44.
 (from "seq5ags.pep")
 TOIG of: aaw39354 check: 4991 from: 1 to: 30

ID AAW39354 standard; peptide; 30 AA.

XX AAW39354;

AC AAW39354;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-4 peptide derivative #44.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT WO9746584-Al.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEP) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goetze R, Goetze B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 27; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective

CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX Sequence 30 AA;

AAW39354 Length: 30 February 4, 2005 13:31 Type: P Check: 4991 ..
 Found using 'seq5' (mohamed337.key)

1 HCGTFTSDLSKQAAEEAVRLFIEWLKNGR
 1
 -----|-----
 28

 1 match found in sequence:
 aaw39356 ; H. horridum exendin-4 peptide derivative #45.
 (from "seq5ags.pep")
 TOIG of: aaw39356 check: 4986 from: 1 to: 30

ID AAW39356 standard; peptide; 30 AA.

XX AAW39356;

AC AAW39356;

DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-4 peptide derivative #45.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT WO9746584-Al.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEP) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goetze R, Goetze B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

PS Claim 2; Page 27; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

```

PI Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 26; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39351 Length: 30 February 4, 2005 13:31 Type: P Check: 4853 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEGETFTSLDAQAQEEAEVRLFIWLNKGR
  28

-----
1 match found in sequence:
aaw39352 ; H. horridum exendin-4 peptide derivative #42.
(from "seq5aggs.pep")
TOIG of: aaw39352 check: 4931 from: 1 to: 30

ID AAW39352 standard; peptide; 30 AA.
XX
XX AAW39352;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #42.
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 26; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39352 Length: 30 February 4, 2005 13:31 Type: P Check: 4931 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGEGETFTSLDAQAQEEAEVRLFIWLNKGR
  28

-----
1 match found in sequence:
aaw39353 ; H. horridum exendin-4 peptide derivative #43.
(from "seq5aggs.pep")
TOIG of: aaw39353 check: 4843 from: 1 to: 30

ID AAW39353 standard; peptide; 30 AA.
XX
XX AAW39353;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #43.
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 26; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the

```



```

DT 05-JUN-1998 (first entry)
XX H. horridum extendin-4 peptide derivative #35.
DE
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
PR
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
PI WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 26; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39345 Length: 30 February 4, 2005 13:31 Type: P Check: 5044 ..
Found using 'seq5' (mohamed337.key)

1 HEGGTFTDLSKQAEAEAVRLFIEWLKNGR
1 28

-----
1 match found in sequence:
aaw39347 ; H. horridum extendin-4 peptide derivative #37.
(from "seq5ags.pep")
TOIG of: aaw39347 check: 5059 from: 1 to: 30

ID AAW39347 standard; peptide; 30 AA.
XX
XX AAW39347;
AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #37.
DE
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX

```

```

XX OS Heloderma horridum.
XX
XX FH Key Location/Qualifiers
FT Modified-site 30
XX /note= "C-terminal amide"
XX
XX PN WO9746584-A1.
XX
XX PD 11-DEC-1997.
XX
XX PF 05-JUN-1997; 97WO-EP002930.
XX
XX PR 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX PI Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX PS Claim 2; Page 26; 150pp; English.
XX
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX SQ Sequence 30 AA;
AAW39347 Length: 30 February 4, 2005 13:31 Type: P Check: 5059 ..
Found using 'seq5' (mohamed337.key)

1 HEGGTFTDLSKQAEAEAVRLFIEWLKNGR
1 28

-----
1 match found in sequence:
aaw39349 ; H. horridum extendin-4 peptide derivative #39.
(from "seq5ags.pep")
TOIG of: aaw39349 check: 5060 from: 1 to: 30

ID AAW39349 standard; peptide; 30 AA.
XX
XX AAW39349;
AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #39.
DE
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX OS Heloderma horridum.
XX
XX FH Key Location/Qualifiers
FT Modified-site 30
XX /note= "C-terminal amide"
FT

```

```

-----
1 match found in sequence:
aaw39343 ; H. horridum exendin-4 peptide derivative #33.
(from "seq5ags.pep")
TOIG of: aaw39343 check: 5165 from: 1 to: 30

ID AAW39343 standard; peptide; 30 AA.
XX AC AAW39343;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #33.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PP 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX PI WPI; 1998-042119/04.
XX DR
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS Claim 2; Page 26; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39344 Length: 30 February 4, 2005 13:31 Type: P Check: 5069 ..
Found using 'seq5' (mohamed337.key)

1 HGGGTITSDLKQAEAEAVRLFIEWLKNGR
1 28

-----
1 match found in sequence:
aaw39345 ; H. horridum exendin-4 peptide derivative #35.
(from "seq5ags.pep")
TOIG of: aaw39345 check: 5044 from: 1 to: 30

ID AAW39345 standard; peptide; 30 AA.
XX AC AAW39345;
XX DT 25-MAR-2003 (revised)

```

Fri Feb 4 14:12:17 2005

CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;

AAW39339 Length: 30 February 4, 2005 13:31 Type: P Check: 5359 ..
Found using 'seq5' (mohamed337.key)

1 ASDGFTSDLSKQAEAEAVRLFIEWLNKR 28
1

1 match found in sequence:

aaw39340 ; H. horridum extendin-4 peptide derivative #30.
(from "seq5agb.pap")
TOIG of: aaw39340 check: 5039 from: 1 to: 30

ID AAW39340 standard; peptide; 30 AA.

XX AAW39340;

AC AAW39341;

DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum extendin-4 peptide derivative #30.

XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
KW Heloderma horridum.

OS Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.

XX Claim 2; Page 26; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4

CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.

CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)

XX Sequence 30 AA;

AAW39341 Length: 30 February 4, 2005 13:31 Type: P Check: 4956 ..
Found using 'seq5' (mohamed337.key)

1 HGEAFTSDLSKQAEAEAVRLFIEWLNKR 28
1

Sequence 30 AA;

AAW39341 Length: 30 February 4, 2005 13:31 Type: P Check: 4956 ..
Found using 'seq5' (mohamed337.key)

1 HGEAFTSDLSKQAEAEAVRLFIEWLNKR 28
1

Sequence 30 AA;

AAW39340 Length: 30 February 4, 2005 13:31 Type: P Check: 5039 ..
Found using 'seq5' (mohamed337.key)

1 HGEAFTSDLSKQAEAEAVRLFIEWLNKR 28
1

Sequence 30 AA;

AAW39340 Length: 30 February 4, 2005 13:31 Type: P Check: 5039 ..
Found using 'seq5' (mohamed337.key)

XX PS Claim 2; Page 25; 150pp; English.

XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)

XX SQ Sequence 30 AA;

AAW39337 Length: 30 February 4, 2005 13:31 Type: P Check: 4522 ..
Found using 'seq5' (mohamed337.key)

1 HSDGFTSDLSKQAEAEAVRLFIEVLKNGR 28
|-----|
1 HSDGFTSDLSKQAEAEAVRLFIEVLKNGR 28

1 match found in sequence:
aaw39338 ; H. horridum exendin-3 peptide derivative #7.
(from "seq5ags.pep")
TOIG of: aaw39338 check: 5075 from: 1 to: 30

ID AAW39338 standard; peptide; 30 AA.

XX AC AAW39338;

XX DT 25-MAR-2003 (revised)

XX DT 05-JUN-1998 (first entry)

XX DE H. horridum exendin-3 peptide derivative #7.

XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

XX KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

XX FT Modified-site 30

XX FT /note= "C-terminal amide"

XX PN W09746584-A1.

XX PD 11-DEC-1997.

XX PF 05-JUN-1997; 97WO-EP002930.

XX PR 05-JUN-1996; 96DE-01022502.

XX PR 13-SEP-1996; 96DE-01037230.

XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX PI Hoffmann E, Goeke R, Goeke B;

XX DR WPI; 1998-042119/04.

XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase secretion and biosynthesis of insulin, but reduce those of glucagon, and do not induce hypoglycaemia.

XX PS Claim 2; Page 26; 150pp; English.

XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis

CC and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)

XX SQ Sequence 30 AA;

AAW39338 Length: 30 February 4, 2005 13:31 Type: P Check: 5075 ..
Found using 'seq5' (mohamed337.key)

1 HSEGTFTSDLSKQAEAEAVRLFIEVLKNGR 28
|-----|
1 HSEGTFTSDLSKQAEAEAVRLFIEVLKNGR 28

1 match found in sequence:
aaw39339 ; H. horridum exendin-3 peptide derivative #8.
(from "seq5ags.pep")
TOIG of: aaw39339 check: 5359 from: 1 to: 30

ID AAW39339 standard; peptide; 30 AA.

XX AC AAW39339;

XX DT 25-MAR-2003 (revised)

XX DT 05-JUN-1998 (first entry)

XX DE H. horridum exendin-3 peptide derivative #8.

XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

XX KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

XX FT Modified-site 30

XX FT /note= "C-terminal amide"

XX PN W09746584-A1.

XX PD 11-DEC-1997.

XX PF 05-JUN-1997; 97WO-EP002930.

XX PR 05-JUN-1996; 96DE-01022502.

XX PR 13-SEP-1996; 96DE-01037230.

XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX PI Hoffmann E, Goeke R, Goeke B;

XX DR WPI; 1998-042119/04.

XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase secretion and biosynthesis of insulin, but reduce those of glucagon, and do not induce hypoglycaemia.

XX PS Claim 2; Page 26; 150pp; English.

XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation. Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a

PA (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX Hoffmann E, Goeke R, Goeke B;
 PI
 XX WPI; 1998-042119/04.
 XX
 PT Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 XX
 PS Claim 2; Page 25; 150pp; English.
 XX
 CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39331 Length: 30 February 4, 2005 13:31 Type: P Check: 5397 ..
 Found using 'seq5' (mohamed337.key)

1 HSEGTFTSDLSKQXEEAVRLFIWLNKGR
 1 |-----|
 28

 1 match found in sequence:
 aaw39332 ; H. horridum exendin-4 peptide derivative #26.
 (from "seq5ags.pep")
 TOIG of: aaw39332 check: 5399 from: 1 to: 30
 ID AAW39332 standard; peptide; 30 AA.
 XX
 AC AAW39332;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 XX H. horridum exendin-4 peptide derivative #26.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW Heloderma horridum.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 14
 FT /label= Nle
 FT /note= "norleucine"
 FT Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 XX 13-SEP-1996; 96DE-01037230.
 XX
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA Hoffmann E, Goeke R, Goeke B;
 PI

XX WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 XX
 PS Claim 2; Page 25; 150pp; English.
 XX
 CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39332 Length: 30 February 4, 2005 13:31 Type: P Check: 5399 ..
 Found using 'seq5' (mohamed337.key)

1 HTSGTFTSDLSKQXEEAVRLFIWLNKGR
 1 |-----|
 28

 1 match found in sequence:
 aaw39337 ; H. horridum exendin-3 peptide derivative #6.
 (from "seq5ags.pep")
 TOIG of: aaw39337 check: 4522 from: 1 to: 30
 ID AAW39337 standard; peptide; 30 AA.
 XX
 AC AAW39337;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 XX H. horridum exendin-3 peptide derivative #6.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW Heloderma horridum.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 XX 13-SEP-1996; 96DE-01037230.
 XX
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA Hoffmann E, Goeke R, Goeke B;
 PI WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT


```

XX 05-JUN-1997; 97WO-EF002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39316 Length: 30 February 4, 2005 13:31 Type: P Check: 4786 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTTSDLSKQABEAVRLFTEWAKNGR 28
-----
1 match found in sequence:
aaw39317; H. horridum exendin-4 peptide derivative #11.
(from "seq5ags.pep")
TOIG of: aaw39317 check: 5361 from: 1 to: 30

ID AAW39317 standard; peptide; 30 AA.
XX
AC AAW39317;
XX
XX 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #11.
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 14 /label= Nle
XX /note= "norleucine"
XX Modified-site 30
XX /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EF002930.
XX
XX
XX
XX

```

```

PR 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39317 Length: 30 February 4, 2005 13:31 Type: P Check: 5361 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HARGTFTSDLSKQABEAVRLFTEWAKNGR 28
-----
1 match found in sequence:
aaw39331; H. horridum exendin-4 peptide derivative #25.
(from "seq5ags.pep")
TOIG of: aaw39331 check: 5397 from: 1 to: 30

ID AAW39331 standard; peptide; 30 AA.
XX
AC AAW39331;
XX
XX 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #25.
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 14 /label= Nle
XX /note= "norleucine"
XX Modified-site 30
XX /note= "C-terminal amide"
XX
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EF002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX
XX

```

KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX Heloderma horridum.
 OS
 XX
 XX
 XX Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX
 XX Hoffmann E, Goeke R, Goeke B;
 PI
 XX WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX
 PS Claim 2; Page 24; 150pp; English.
 XX
 XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;
 AAW39314 Length: 30 February 4, 2005 13:31 Type: P Check: 4898 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HSDGFTTSLSKQAEAEVRLFIWLNAR 28

 1 match found in sequence:
 aaw39315 ; H. horridum exendin-3 peptide derivative #3.
 (from "seq5ags.pep")
 TOIG of: aaw39315 check: 4802 from: 1 to: 30
 ID AAW39315 standard; peptide; 30 AA.
 XX
 AC AAW39315;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 DT
 XX H. horridum exendin-3 peptide derivative #3.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW
 XX Heloderma horridum.
 OS
 XX
 XX Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX
 XX Hoffmann E, Goeke R, Goeke B;
 PI
 XX WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX
 PS Claim 2; Page 24; 150pp; English.
 XX
 XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;
 AAW39315 Length: 30 February 4, 2005 13:31 Type: P Check: 4802 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HSDGFTTSLSKQAEAEVRLFIWLNAR 28

 1 match found in sequence:
 aaw39316 ; H. horridum exendin-3 peptide derivative #4.
 (from "seq5ags.pep")
 TOIG of: aaw39316 check: 4786 from: 1 to: 30
 ID AAW39316 standard; peptide; 30 AA.
 XX
 AC AAW39316;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 DT
 XX H. horridum exendin-3 peptide derivative #4.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW
 XX Heloderma horridum.
 OS
 XX
 XX Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX

FT Modified-site 30
 FT /note= "C-terminal amide"
 XX
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX
 XX Hoffmann E, Goeke R, Goeke B;
 PI
 XX WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX
 PS Claim 2; Page 24; 150pp; English.
 XX
 XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;
 AAW39315 Length: 30 February 4, 2005 13:31 Type: P Check: 4802 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HSDGFTTSLSKQAEAEVRLFIWLNAR 28

 1 match found in sequence:
 aaw39316 ; H. horridum exendin-3 peptide derivative #4.
 (from "seq5ags.pep")
 TOIG of: aaw39316 check: 4786 from: 1 to: 30
 ID AAW39316 standard; peptide; 30 AA.
 XX
 AC AAW39316;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 DT
 XX H. horridum exendin-3 peptide derivative #4.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW
 XX Heloderma horridum.
 OS
 XX
 XX Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX
 XX WO9746584-A1.
 XX
 XX 11-DEC-1997.
 XX

```

ID AAW39311 standard; peptide; 30 AA.
XX
AC AAW39311,
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #8.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT Modified-site 30 /note= "C-terminal OH group"
FT
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF.) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39311 Length: 30 February 4, 2005 13:31 Type: P Check: 5051 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGRGFTSDLSKQABEAVRLFIEWLKNKR
  1 28

-----
1 match found in sequence:
aaw39312 ; H. horridum extendin-4 peptide derivative #8.
(from "seq5ags.pep")
TOIG of: aaw39312 check: 5163 from: 1 to: 30

ID AAW39312 standard; peptide; 30 AA.
XX
AC AAW39312;
XX
XX 25-MAR-2003 (revised)
DT
XX
XX H. horridum extendin-3 peptide derivative #2.
XX

```

```

DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-4 peptide derivative #9.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX OS Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Modified-site 1 /note= "N-terminal acetylated"
FT Modified-site 30
FT Modified-site 30 /note= "C-terminal OH group"
FT
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF.) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39312 Length: 30 February 4, 2005 13:31 Type: P Check: 5163 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  HGRGFTSDLSKQIBEEAVRLFIEWLKNKR
  1 28

-----
1 match found in sequence:
aaw39314 ; H. horridum extendin-3 peptide derivative #2.
(from "seq5ags.pep")
TOIG of: aaw39314 check: 4898 from: 1 to: 30

ID AAW39314 standard; peptide; 30 AA.
XX
AC AAW39314;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide derivative #2.
XX

```

AAW39308 Length: 30 February 4, 2005 13:31 Type: P Check: 4988 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGGGTFTSDLSKQMEEEAVRAFIWLKAGR
28

1 match found in sequence:

aaw39309 ; H. horridum extendin-4 peptide derivative #6.
(from "seq5ags.pep")
TOIG of: aaw39309 check: 4855 from: 1 to: 30

ID AAW39309 standard; peptide; 30 AA.

XX AC AAW39309;
XX AC
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-4 peptide derivative #6.
XX DE
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT

XX PN W09746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX PS Claim 2; Page 22; 150pp; English.
XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.

XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known extendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39309 Length: 30 February 4, 2005 13:31 Type: P Check: 4855 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGGGTFTSDLSKQMEEEAVRAFIWLKAGR
28

1 match found in sequence:
aaw39310 ; H. horridum extendin-4 peptide derivative #7.
(from "seq5ags.pep")
TOIG of: aaw39310 check: 4624 from: 1 to: 30

ID AAW39310 standard; peptide; 30 AA.

XX AC AAW39310;
XX AC
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-4 peptide derivative #7.
XX DE
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT

XX PN W09746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX PS Claim 2; Page 23; 150pp; English.
XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.

XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known extendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39310 Length: 30 February 4, 2005 13:31 Type: P Check: 4624 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGGGTFTSDLSKQMEEEAVRAFIWLKAGR
28

1 match found in sequence:
aaw39311 ; H. horridum extendin-4 peptide derivative #8.
(from "seq5ags.pep")
TOIG of: aaw39311 check: 5051 from: 1 to: 30

CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39305 Length: 30 February 4, 2005 13:31 Type: P Check: 5394
 Found using 'seq5' (mohamed337.key)

1 |-----|
 HSDGTFSTDLKQXEEAVRLFIEWLKNGR 28

 1 match found in sequence:
 aaw39306 ; H. horridum exendin-4 peptide derivative #3.
 (from "seq5ags.pep")
 TOIG of: aaw39306 check: 5373 from: 1 to: 30

ID AAW39306 standard; peptide; 30 AA.

XX AAW39306;

XX AC

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-4 peptide derivative #3.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX W09746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 21; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a

CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39306 Length: 30 February 4, 2005 13:31 Type: P Check: 5373
 Found using 'seq5' (mohamed337.key)

1 |-----|
 HGBGTFTSLSKQXEEAVRLFIEWLKNGR 28

 1 match found in sequence:
 aaw39308 ; H. horridum exendin-4 peptide derivative #5.
 (from "seq5ags.pep")
 TOIG of: aaw39308 check: 4988 from: 1 to: 30

ID AAW39308 standard; peptide; 30 AA.

XX AAW39308;

XX AC

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-4 peptide derivative #5.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX W09746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 22; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

XX Claim 2; Page 19; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method for the

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis

CC and secretion of insulin, but have the opposite effect on glucagon, and

CC independent of this activity can increase peripheral glucose utilisation.

CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,

CC so they will not induce hypoglycaemia. Compared with glucagon-like

CC peptide 1 (GLP1) and the known exendins, they are more active (effective

CC at lower doses), more stable to degradation and metabolism and have a

CC longer lasting effect. Truncated forms of this peptide can be made more

CC economically than full length versions. (Updated on 25-MAR-2003 to

CC correct PR field.)

XX

SQ Sequence 30 AA;

AAW39303 Length: 30 February 4, 2005 13:31 Type: P Check: 5373 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSLSKQXEEAVRLFIEWLKNGR 28

-----|-----|

1 match found in sequence:

aaw39304; H. horridum exendin-4 peptide derivative #2.

(from "seq5ags.pep")

TOIG of: aaw39304 check: 5583 from: 1 to: 30

ID AAW39304 standard; peptide; 30 AA.

XX

AC AAW39304;

XX

DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX

DE H. horridum exendin-4 peptide derivative #2.

XX

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

XX

OS Heloderma horridum.

XX

Key	Location/Qualifiers
Modified-site 14	/label= Nle
Modified-site 30	/note= "Norleucine"
Modified-site 30	/note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX

PR 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX

PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX

PI Hoffmann E, Goeke R, Goeke B;

XX

DR WPI; 1998-042119/04.

XX

XX Truncated versions of exendin peptide(s) for treating diabetes - increase

PT secretion and biosynthesis of insulin, but reduce those of glucagon, and

PT do not induce hypoglycaemia.

XX

XX Claim 2; Page 20; 150pp; English.

XX

CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method for the

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis

CC and secretion of insulin, but have the opposite effect on glucagon, and

CC independent of this activity can increase peripheral glucose utilisation.

CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,

CC so they will not induce hypoglycaemia. Compared with glucagon-like

CC peptide 1 (GLP1) and the known exendins, they are more active (effective

CC at lower doses), more stable to degradation and metabolism and have a

CC longer lasting effect. Truncated forms of this peptide can be made more

CC economically than full length versions. (Updated on 25-MAR-2003 to

CC correct PR field.)

XX

SQ Sequence 30 AA;

AAW39304 Length: 30 February 4, 2005 13:31 Type: P Check: 5583 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSLSKQXEEAVRLFIEWLKNGY 28

-----|-----|

1 match found in sequence:

aaw39305; H. horridum exendin-3 peptide derivative #1.

(from "seq5ags.pep")

TOIG of: aaw39305 check: 5394 from: 1 to: 30

ID AAW39305 standard; peptide; 30 AA.

XX

AC AAW39305;

XX

DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX

DE H. horridum exendin-3 peptide derivative #1.

XX

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW Glucagon reduction; hypoglycaemia; glucose; treatment.

XX

OS Heloderma horridum.

XX

Key	Location/Qualifiers
Modified-site 14	/label= Nle
Modified-site 30	/note= "Norleucine"
Modified-site 30	/note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX

PR 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX

PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX

PI Hoffmann E, Goeke R, Goeke B;

XX

DR WPI; 1998-042119/04.

XX

XX Truncated versions of exendin peptide(s) for treating diabetes - increase

PT secretion and biosynthesis of insulin, but reduce those of glucagon, and

PT do not induce hypoglycaemia.

XX

XX Claim 2; Page 20; 150pp; English.

XX

CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

CC isolated from Heloderma horridum which are used in a novel method for the

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis

```

PR 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 1; Page 3; 150pp; English.
XX
XX This peptide is a fragment of exendin-3 isolated from Heloderma horridum.
XX This peptide and its salts, esters and derivatives can be used to treat
XX diabetes mellitus. They stimulate biosynthesis and secretion of insulin,
XX but have the opposite effect on glucagon, and independent of this
XX activity can increase peripheral glucose utilisation. Exendin-3 and
XX exendin-4 are only active when blood sugar levels are high, so they will
XX not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1)
XX and the known exendins, they are more active (effective at lower doses),
XX more stable to degradation and metabolism and have a longer lasting
XX effect. Truncated forms of this peptide can be made more economically
XX than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39301 Length: 30 February 4, 2005 13:31 Type: P Check: 5420 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSDLSKQMEBAVRLFIWLNKGX
28
-----
1 match found in sequence:
aaw39302 ; H. horridum exendin-4 peptide.
(from "seq5ags.pep")
TOIG of: aaw39302 check: 5399 from: 1 to: 30

ID AAW39302 standard; peptide; 30 AA.
XX AC AAW39302;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 30 /note= "This residue can be any amino acid except Gly"
XX
XX W09746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930..
XX
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.

```

```

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 1; Page 4; 150pp; English.
XX
XX This peptide is a fragment of exendin-4 isolated from Heloderma horridum.
XX This peptide and its salts, esters and derivatives can be used to treat
XX diabetes mellitus. They stimulate biosynthesis and secretion of insulin,
XX but have the opposite effect on glucagon, and independent of this
XX activity can increase peripheral glucose utilisation. Exendin-3 and
XX exendin-4 are only active when blood sugar levels are high, so they will
XX not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1)
XX and the known exendins, they are more active (effective at lower doses),
XX more stable to degradation and metabolism and have a longer lasting
XX effect. Truncated forms of this peptide can be made more economically
XX than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39302 Length: 30 February 4, 2005 13:31 Type: P Check: 5399 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSGGFTSDLSKQMEBAVRLFIWLNKGX
28
-----
1 match found in sequence:
aaw39303 ; H. horridum exendin-4 peptide derivative #1.
(from "seq5ags.pep")
TOIG of: aaw39303 check: 5373 from: 1 to: 30

ID AAW39303 standard; peptide; 30 AA.
XX AC AAW39303;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #1.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX
XX Key Location/Qualifiers
XX Modified-site 14 /label= Nle
XX FT /note= "Norleucine"
XX Modified-site 30
XX FT /note= "C-terminal amide"
XX
XX W09746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930..
XX
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.

```

```

PF 14-MAR-2001; 2001WO-EP002882.
XX
PR
XX
XX 14-MAR-2000; 2000US-0189091P.
XX
PA (GOEK/) GOEKE B.
PA (SCHI/) SCHIRRA J.
XX
XX Goeke B, Schirra J;
XX
XX WPI; 2001-596887/67.
XX
XX Inhibiting antro-duodenal motility, useful to prevent or treat
PT gastrointestinal disorders such as irritable bowel syndrome and non-
PT infectious diarrhea, comprises administering glucagon-like peptide.
XX
PS Disclosure; Page 13; 43pp; English.
XX
CC The invention relates to a method of inhibiting antro-duodenal motility
CC in a patient, comprising administering a glucagon-like peptide (GLP-1)
CC molecule. The method is used to premedicate or in endoscopic procedures
CC or to treat or prevent non-infectious acute and chronic diarrhoea, post-
CC operative dumping syndrome, irritable bowel syndrome or symptoms
CC associated with narcotics withdrawal. Unlike prior art treatment with
CC glucagon, the invention is not contraindicated in persons with diabetes,
CC does not incur the risks of side effects such as nausea, and is not
CC expensive. The present sequence represents mammalian glucagon-like
CC peptide-1, (GLP-1) homologue, extendin 4 as described in the method of the
CC invention
XX
SQ Sequence 39 AA;
AAU07380 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSGGTFSTDSLKQMEEEAVRLFIEWLKNKGPPPS
28
-----
1 match found in sequence:
aau08763 ; Human extendin degenerate peptide fragment.
(from "seq5ags.pep")
TOIG of: aau08763 check: 7617 from: 1 to: 31
ID AAU08763 standard; peptide; 31 AA.
XX
AC AAU08763;
XX
XX 16-JAN-2002 (first entry)
XX
XX Human extendin degenerate peptide fragment.
XX
XX Human; glucagon-like peptide 1; GLP-1; serum lipid; triglyceride; plasma;
KW low density lipoprotein; high density lipoprotein; cholesterol; stroke;
KW fatty acid; plasma; apolipoprotein; dyslipidaemia; fatty acid; artery;
KW cerebrovascular disease; cardiovascular disease; aneurysm; surgery;
KW bypass graft stenosis; diabetes mellitus; anticoagulative treatment;
KW coronary thrombosis; antilipemic; cardiant; cerebroprotective; extendin;
KW antidiabetic; antiarteriosclerotic; vasotropic; nootropic; antianginal.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH Key 31
FT Misc-difference 31 /label= Pro, Tyr
FT
XX WO200166135-A1.
XX
XX 13-SEP-2001.
XX
XX 08-MAR-2001; 2001WO-DK000150.
XX
XX 08-MAR-2000; 2000DK-00000375.
XX
PR

```

```

XX (NOVO ) NOVO NORDISK AS.
XX
XX Knudsen LB, Selmer J, Sturis J, Larsen PJ;
XX
XX WPI; 2001-602602/68.
XX
XX Use of glucagon-like peptide-1 agonist for manufacturing a medicament for
PT lowering total serum lipids e.g. low density lipoproteins and
PT cholesterol.
XX
XX Disclosure; Page 40; 52pp; English.
XX
XX The invention relates to a medicament for lowering serum lipids,
CC comprising a glucagon-like peptide 1 (GLP-1) agonist. The GLP-1 agonist
CC is used for lowering total serum lipids such as low density lipoproteins
CC particularly small, dense lipoproteins, triglycerides, cholesterol and
CC non-esterified fatty acids, for increasing high density lipoproteins, for
CC lowering plasma levels of lipoprotein, for inhibiting generation of
CC apolipoprotein, for treating dyslipidaemia in humans and also for
CC lowering fatty acids, such as free fatty acids and non-esterified fatty
CC acids. The medicament is also useful for treating cerebrovascular
CC diseases and cardiovascular diseases such as stroke, cerebral
CC haemorrhage, coronary heart disease, coronary artery disease, diabetic
CC vasculopathy, atherosclerosis, peripheral atherosclerosis,
CC arteriosclerosis, myocardial infarction, ischaemic heart disease,
CC restenosis, peripheral artery disease, angina pectoris, intermittent
CC claudication, aneurysms of aorta and other large arteries, bypass graft
CC stenosis and diabetes mellitus. The peptides may also be used in
CC anticoagulative treatment e.g. following a coronary thrombosis or after
CC surgery. This sequence represents a fragment of a degenerate extendin
CC polypeptide, a GLP-1 agonist
XX
SQ Sequence 31 AA;
AAU08763 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSGGTFSTDSLKQMEEEAVRLFIEWLKNKGX
28
-----
1 match found in sequence:
aaw39301 ; H. horridum extendin-3 peptide.
(from "seq5ags.pep")
TOIG of: aaw39301 check: 5420 from: 1 to: 30
ID AAW39301 standard; peptide; 30 AA.
XX
AC AAW39301;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum extendin-3 peptide.
XX
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Key 30
FT Modified-site 30 /note= "This residue can be any amino acid except Gly"
FT
XX WO9746584-A1.
XX
XX 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
PR

```


XX Exendin; glucagon-like peptide-1; GLP-1; crystallisation;
 KW diabetes mellitus; hyperglycaemia; therapeutic.
 XX Synthetic.

XX Key Location/Qualifiers
 FH Misc-difference 31 /label= Pro, Tyr
 FT
 XX WO200157084-A1.
 PN
 XX 09-AUG-2001.
 PD
 XX
 XX 31-JAN-2001; 2001WO-DK000067.
 PF
 XX 31-JAN-2000; 2000DK-00000156.
 PR
 XX (NOVO) NOVO NORDISK AS.
 PA
 XX Arentsen AC;
 PI
 XX WPI; 2001-514598/56.
 DR
 XX

XX Producing crystals of glucagon-like peptide-1 analog for preparing
 PT pharmaceutical composition, by preparing aqueous solution comprising the
 PT analog, salt and organic solvent, and isolating crystals after formation.
 PT
 XX Disclosure; Page 18; 33pp; English.
 PS
 XX The invention relates to a method of producing crystals of a glucagon-
 CC like peptide-1 (GLP-1) analogue or producing a GLP-1 analogue or a GLP-1
 CC analogue attached to a lipophilic substituent, which involves preparing
 CC an aqueous solution comprising a GLP-1 analogue, a salt, and an organic
 CC solvent, and isolating the crystals after formation. The method is useful
 CC for producing crystals of a GLP-1 or for producing a GLP-1 analogue
 CC attached to a lipophilic substituent. These are useful for preparing a
 CC pharmaceutical product in the manufacturing process for preparing GLP-1
 CC analogue, and for preparing a mono-acylated GLP-1 analogue. The
 CC implementation of a crystallisation step in the manufacturing process for
 CC the preparation of a GLP-1 analogue results in removal of coloured
 CC compounds from the fermentation broth, reduction of yeast host cell
 CC proteins, such as Saccharomyces cerevisiae proteins as well as removal of
 CC water, and low loss of the GLP-1 analogue from the mother liquor. The
 CC present sequence represents the amino acid sequence of exendin
 CC polypeptide fragment #1, a GLP-1 analogue used to treat diabetes mellitus
 CC types I or II and prevention of hyperglycaemia
 XX

XX Sequence 31 AA;
 AAU07291 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGTFTSDLSKQMEBEAVRLFTIEWLKNKGX
 28

 1 match found in sequence:
 aau07378 ; Glucagon-like peptide-1 (GLP-1) homologue, exendin 3.
 (from "seq5ags.pep")
 TOIG of: aau07378 check: 9591 from: 1 to: 39

ID AAU07378 standard; peptide; 39 AA.
 XX
 XX AAU07378;
 AC
 XX 18-DEC-2001 (first entry)
 DT
 XX Glucagon-like peptide-1 (GLP-1) homologue, exendin 3.
 DE
 XX Antidiarrhoeic; antiinflammatory; antiaddictive; premedication;
 KW

KW antro-duodenal motility; glucagon-like peptide-1; GLP-1; endoscopy;
 KW diarrhoea; post-operative dumping syndrome; irritable bowel syndrome;
 KW narcotics withdrawal; exendin 3.
 XX Homo sapiens.

XX WO200168112-A2.
 PN
 XX 20-SEP-2001.
 PD
 XX 14-MAR-2001; 2001WO-EP002882.
 PF
 XX 14-MAR-2000; 2000US-0189091P.
 PR
 XX (GOEK/) GOEKE B.
 PA (SCHI/) SCHIRRA J.
 PI
 XX Goeke B, Schirra J;
 XX WPI; 2001-596887/67.
 DR

XX Inhibiting antro-duodenal motility, useful to prevent or treat
 PT gastrointestinal disorders such as irritable bowel syndrome and non-
 PT infectious diarrhea, comprises administering glucagon-like peptide.
 PT
 XX Disclosure; Page 13; 43pp; English.
 PS
 XX The invention relates to a method of inhibiting antro-duodenal motility
 CC in a patient, comprising administering a glucagon-like peptide (GLP-1)
 CC molecule. The method is used to premedicate or in endoscopic procedures
 CC or to treat or prevent non-infectious acute and chronic diarrhoea, post-
 CC operative dumping syndrome, irritable bowel syndrome or symptoms
 CC associated with narcotics withdrawal. Unlike prior art treatment with
 CC glucagon, the invention is not contraindicated in persons with diabetes,
 CC does not incur the risks of side effects such as nausea, and is not
 CC expensive. The present sequence represents mammalian glucagon-like
 CC peptide-1, (GLP-1) homologue, exendin 3 as described in the method of the
 CC invention
 XX

XX Sequence 39 AA;
 AAU07378 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)
 1 HSDGTFSDLSKQMEBEAVRLFTIEWLKNKGPPSSGAPPPS
 28

 1 match found in sequence:
 aau07380 ; Glucagon-like peptide-1 (GLP-1) homologue, exendin 4.
 (from "seq5ags.pep")
 TOIG of: aau07380 check: 9570 from: 1 to: 39

ID AAU07380 standard; peptide; 39 AA.
 XX
 XX AAU07380;
 AC
 XX 18-DEC-2001 (first entry)
 DT
 XX Glucagon-like peptide-1 (GLP-1) homologue, exendin 4.
 DE
 XX Antidiarrhoeic; antiinflammatory; antiaddictive; premedication;
 KW antro-duodenal motility; glucagon-like peptide-1; GLP-1; endoscopy;
 KW diarrhoea; post-operative dumping syndrome; irritable bowel syndrome;
 KW narcotics withdrawal; exendin 4.
 XX Homo sapiens.
 OS
 XX WO200168112-A2.
 PN
 XX 20-SEP-2001.
 PD
 XX

```

PT treating diabetes mellitus and preventing hyperglycaemia.
XX Claim 5; Col 13-14; 17pp; English.
XX
CC AAR80545 is Heloderma horridum extendin-3. It is an insulinotropic
CC peptide, and can therefore be used in the treatment of diabetes mellitus
CC (types I or II), and for the prevention of hyperglycaemia. It normalises
CC hyperglycaemia through glucose-dependent and insulin-(in)dependent
CC mechanisms
XX
SQ Sequence 39 AA;
AAR80545 Length: 39 February 4, 2005 13:31 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSDLSKQMEBEAVRLFIEWLKNKGPPSSGAPPPS
28
-----
1 match found in sequence:
aar80546 ; Heloderma suspectum extendin-4.
(from "seq5ags.pep")
TOIG of: aar80546 check: 9570 from: 1 to: 39
ID AAR80546 standard; peptide; 39 AA.
XX
AC AAR80546;
XX
DT 27-FEB-1996 (first entry)
XX
DE Heloderma suspectum extendin-4.
XX
KW Extendin-4; diabetes mellitus; hyperglycaemia; insulinotropic peptide.
XX
OS Heloderma suspectum.
XX
PN US5424286-A.
XX
PD 13-JUN-1995.
XX
PF 24-MAY-1993; 93US-00066480.
XX
PR 24-MAY-1993; 93US-00066480.
XX
PA (ENGJ/) ENG J.
XX
PI Eng J;
XX
PI 1995-262627/34.
XX
DR WPI; 1995-262627/34.
XX
PT Stimulating/inhibiting insulin release with extendin polypeptide(s) - for
PT treating diabetes mellitus and preventing hyperglycaemia.
XX
PS Claim 6; Col 13-14; 17pp; English.
XX
CC AAR80546 is Heloderma suspectum extendin-4. It is an insulinotropic
CC peptide, and can therefore be used in the treatment of diabetes mellitus
CC (types I or II), and for the prevention of hyperglycaemia. It normalises
CC hyperglycaemia through glucose-dependent and insulin-(in)dependent
CC mechanisms
XX
SQ Sequence 39 AA;
AAR80546 Length: 39 February 4, 2005 13:31 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSGTFTSDLSKQMEBEAVRLFIEWLKNKGPPSSGAPPPS
28
-----
1 match found in sequence:

```

```

aau05785 ; Insulin release stimulating polypeptide, extendin.
(from "seq5ags.pep")
TOIG of: aau05785 check: 7617 from: 1 to: 31
ID AAU05785 standard; peptide; 31 AA.
XX
AC AAU05785;
XX
DT 24-OCT-2001 (first entry)
XX
DE Insulin release stimulating polypeptide, extendin.
XX
KW Insulin release; extendin; GLP-1; diabetes type I; diabetes type II;
KW obesity; gastric ulcers; gastric acid secretion; apoptosis; antidiabetic;
KW anorectic; antiulcer.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 31 /label= Pro, Tyr
FT FT
XX WO200151071-A2.
XX PD 19-JUL-2001.
XX
XX 11-JAN-2001; 2001WO-DK000015.
XX PR 11-JAN-2000; 2000DK-00000030.
XX
XX (NOVO ) NOVO NORDISK AS.
XX
XX Anderson K, Agerso H;
XX WPI; 2001-502577/55.
XX
XX New pulmonary liquid or dry formulation comprises a GLP-1 compound to
XX which a lipophilic substituent is attached, optionally via a spacer,
XX useful in a pulmonary delivery device.
XX
XX Disclosure; Page 6; 30pp; English.
XX
XX The invention relates to a new pulmonary liquid or dry formulation
XX comprises a GLP-1 compound to which a lipophilic substituent is attached,
XX optionally via a spacer. The formulation is useful in a pulmonary
XX delivery device. The formulation is useful for reducing blood glucose
XX levels, treating diabetes type I, diabetes type II, obesity and gastric
XX ulcers, and inhibiting gastric acid secretion and apoptosis of beta-
XX cells. The present sequence is an extendin peptide, derivatives of which
XX can be used as a spacer peptide with GLP-1
XX
SQ Sequence 31 AA;
AAR05785 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSGTFTSDLSKQMEBEAVRLFIEWLKNKGX
28
-----
1 match found in sequence:
aau07291 ; Extendin polypeptide fragment #1.
(from "seq5ags.pep")
TOIG of: aau07291 check: 7617 from: 1 to: 31
ID AAU07291 standard; peptide; 31 AA.
XX
AC AAU07291;
XX
DT 24-OCT-2001 (first entry)
XX
DE Extendin polypeptide fragment #1.

```

Found using 'seq5' (mohamed337.key)

1 |-----|
HGEFTFTDLSKQMEAEAVRLFIEWLKNQGPSSGAPPPS
28

1 match found in sequence:

aar80543 ; Heloderma suspectum extendin-4 residues 1-31 (Extendin-4(1-31)).
(from "seq5ags.pep")

TOIG of: aar80543 check: 7369 from: 1 to: 31

ID AAR80543 standard; peptide; 31 AA.

XX AC

XX AAR80543;

XX DT 27-FEB-1996 (first entry)

XX DE Heloderma suspectum extendin-4 residues 1-31 (Extendin-4(1-31)).

XX KW Extendin-4; residues 1-31; Extendin-4(1-31); diabetes mellitus;

XX OS hyperglycaemia; insulinotropic peptide.

XX OS Heloderma suspectum.

XX PN US5424286-A.

XX PD 13-JUN-1995.

XX PF 24-MAY-1993; 93US-00066480.

XX PR 24-MAY-1993; 93US-00066480.

XX PA (ENGJ/) ENG J.

XX PI Eng J;

XX DR WPI; 1995-262627/34.

XX ST Stimulating/inhibiting insulin release with extendin polypeptide(s) - for

XX PT treating diabetes mellitus and preventing hyperglycaemia.

XX PS Claim 1; Col 13-14; 17pp; English.

XX CC AAR80543 is the Heloderma suspectum extendin-4 residues 1-31. It is an

XX CC insulinotropic peptide, and can therefore be used in the treatment of

XX CC diabetes mellitus (types I or II), and for the prevention of

XX CC hyperglycaemia. It normalises hyperglycaemia through glucose-dependent

XX CC and insulin-(in)dependent mechanisms

XX SQ Sequence 31 AA;

AAR80543 Length: 31 February 4, 2005 13:31 Type: P Check: 7369 ..

Found using 'seq5' (mohamed337.key)

1 |-----|

HGEFTFTDLSKQMEAEAVRLFIEWLKNQGP

28

1 match found in sequence:

aar80544 ; Heloderma suspectum extendin-4 residues 1-31-Tyr31.
(from "seq5ags.pep")

TOIG of: aar80544 check: 7648 from: 1 to: 31

ID AAR80544 standard; peptide; 31 AA.

XX AC

XX AAR80544;

XX DT 27-FEB-1996 (first entry)

XX DE Heloderma suspectum extendin-4 residues 1-31-Tyr31.

XX ST Stimulating/inhibiting insulin release with extendin polypeptide(s) - for

XX PT treating diabetes mellitus and preventing hyperglycaemia.

XX PS Claim 1; Col 13-14; 17pp; English.

XX CC AAR80543 is the Heloderma suspectum extendin-4 residues 1-31. It is an

XX CC insulinotropic peptide, and can therefore be used in the treatment of

XX CC diabetes mellitus (types I or II), and for the prevention of

XX CC hyperglycaemia. It normalises hyperglycaemia through glucose-dependent

XX CC and insulin-(in)dependent mechanisms

XX SQ Sequence 31 AA;

AAR80543 Length: 31 February 4, 2005 13:31 Type: P Check: 7369 ..

Found using 'seq5' (mohamed337.key)

1 |-----|

HGEFTFTDLSKQMEAEAVRLFIEWLKNQGP

28

1 match found in sequence:

aar80544 ; Heloderma suspectum extendin-4 residues 1-31-Tyr31.
(from "seq5ags.pep")

TOIG of: aar80544 check: 7648 from: 1 to: 31

ID AAR80544 standard; peptide; 31 AA.

XX AC

XX AAR80544;

XX DT 27-FEB-1996 (first entry)

XX DE Heloderma suspectum extendin-4 residues 1-31-Tyr31.

XX ST Stimulating/inhibiting insulin release with extendin polypeptide(s) - for

XX PT treating diabetes mellitus and preventing hyperglycaemia.

KW Extendin-4; residues 1-31; Y-31-Extendin-4(1-31); diabetes mellitus;

XX hyperglycaemia; Tyr31; insulinotropic peptide.

XX Heloderma suspectum.

XX PN US5424286-A.

XX PD 13-JUN-1995.

XX PF 24-MAY-1993; 93US-00066480.

XX PR 24-MAY-1993; 93US-00066480.

XX PA (ENGJ/) ENG J.

XX PI Eng J;

XX DR WPI; 1995-262627/34.

XX ST Stimulating/inhibiting insulin release with extendin polypeptide(s) - for

XX PT treating diabetes mellitus and preventing hyperglycaemia.

XX PS Claim 2; Col 13-14; 17pp; English.

XX CC AAR80544 is the Heloderma suspectum extendin-4 residues 1-31, where the

XX CC native Pro31 has been replaced with a Tyr residue. It is an

XX CC insulinotropic peptide, and can therefore be used in the treatment of

XX CC diabetes mellitus (types I or II), and for the prevention of

XX CC hyperglycaemia. It normalises hyperglycaemia through glucose-dependent

XX CC and insulin-(in)dependent mechanisms

XX SQ Sequence 31 AA;

AAR80544 Length: 31 February 4, 2005 13:31 Type: P Check: 7648 ..

Found using 'seq5' (mohamed337.key)

1 |-----|

HGEFTFTDLSKQMEAEAVRLFIEWLKNQGY

28

1 match found in sequence:

aar80545 ; Heloderma horridum extendin-3.
(from "seq5ags.pep")

TOIG of: aar80545 check: 9591 from: 1 to: 39

ID AAR80545 standard; peptide; 39 AA.

XX AC

XX AAR80545;

XX DT 27-FEB-1996 (first entry)

XX DE Heloderma horridum extendin-3.

XX KW Extendin-3; diabetes mellitus; hyperglycaemia; insulinotropic peptide.

XX OS Heloderma horridum.

XX PN US5424286-A.

XX PD 13-JUN-1995.

XX PF 24-MAY-1993; 93US-00066480.

XX PR 24-MAY-1993; 93US-00066480.

XX PA (ENGJ/) ENG J.

XX PI Eng J;

XX DR WPI; 1995-262627/34.

XX ST Stimulating/inhibiting insulin release with extendin polypeptide(s) - for

XX PT treating diabetes mellitus and preventing hyperglycaemia.

PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
PT immunoglobulin.

XX Example 6; Page 90; 200pp; English.

XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC -terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is human GLP/exendin peptide analogue

XX Sequence 39 AA;

AAE30938 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEBEAVRLFIWLKNGGPFSSGAPPPS
28

1 match found in sequence:

aag62439 ; Exendin polypeptide #1.
(from "seq5ags.pep")
TOIG of: aag62439 check: 7617 from: 1 to: 31

ID AAG62439 standard; peptide; 31 AA.

XX AAG62439;

XX 04-SEP-2001 (first entry)

XX Exendin polypeptide #1.

XX Beta cell degeneration; GLP-1; glucagon-like peptide-1; agonist;
KW antiapoptotic; cytostatic; immunosuppressive; neuroprotective; nootropic;
KW anti-HIV; antiparkinsonian; cerebroprotective; antidiabetic; stroke;
KW type 2 diabetes; cancer; immunological disorder; multiple sclerosis;
KW acquired immunodeficiency syndrome; AIDS; neurodegenerative disorder;
KW Alzheimer's disease; Parkinson's disease; exendin.

XX Unidentified.

XX Key Location/Qualifiers
FH Misc-difference 31
FT /label= Pro, Tyr

XX WO200135988-A1.

XX 25-MAY-2001.

XX 10-NOV-2000; 2000WO-DK000625.

XX 12-NOV-1999; 99DK-00001628.

XX 22-FEB-2000; 2000DK-00000270.

XX (NOVO) NOVO NORDISK AS.

XX Knudsen LB, Godtfredsen CF, Petersen JS, Carr RD;

XX WPI; 2001-329208/34.

XX Treating beta cell degeneration in subjects, particularly humans,
PT involves administering GLP-1 agonists.

XX Disclosure; Page 41; 59pp; English.

XX

CC This invention relates to a method of treating beta cell degeneration
CC through the administration of a GLP-1 (glucagon-like peptide-1) agonist.
CC Use of the method results in antiapoptotic; cytostatic; immunosuppressive
CC ; neuroprotective; nootropic; anti-HIV (human immunodeficiency virus);
CC cloniparkinsonian; cerebroprotective; and antidiabetic activity. The
CC claims refer to the use of a specific GLP-1 analogue Arg34, Lys26(N-
CC epsilon-(gamma-Glu(N-alpha-hexadecanoyl))-GLP-1 (7-37)). The method is
CC used for the treatment of beta cell degeneration, particularly apoptosis
CC of beta cells. The GLP-1 agonist is used to modulate, inhibit, decrease
CC or prevent beta cell degeneration, loss of beta cell function, beta cell
CC dysfunction and/or death of beta cells, such as necrosis or apoptosis of
CC beta cells, in subjects, preferably mammals, especially humans. The
CC apoptosis is associated with type 2 diabetes, cancer, immunological
CC disorders, multiple sclerosis, acquired immunodeficiency syndrome (AIDS),
CC and neurodegenerative disorders such as Alzheimer's disease, stroke and
CC Parkinson's disease. The present sequence represents an exendin
CC polypeptide, an GLP-1 agonist which can be used in the method of the
CC invention

XX Sequence 31 AA;

AAG62439 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEBEAVRLFIWLKNGGX
28

1 match found in sequence:

aag70462 ; Exendin-4.
(from "seq5ags.pep")
TOIG of: aag70462 check: 9570 from: 1 to: 39

ID AAG70462 standard; peptide; 39 AA.

XX AAG70462;

XX 13-JUL-2001 (first entry)

XX Exendin-4.

XX Exendin-1; pituitary adenylate cyclase activating peptide; PACAP;
KW antidiabetic; antiasthmatic; hypotensive; cardiast; antiulcer;
KW respiratory disease; diabetes; glucose intolerance; asthma;
KW male fertility; cardiovascular disease; ulcer; gene therapy;
KW PACAP receptor 3; R3; agonist.

XX Unidentified.

XX WO200123420-A2.

XX 05-APR-2001.

XX 27-SEP-2000; 2000WO-US026638.

XX 28-SEP-1999; 99US-00407832.

XX 15-JUN-2000; 2000US-00595280.

XX (FARB) BAYER CORP.

XX Pan C, Tsutsumi M, Shanafelt AB;

XX WPI; 2001-367200/38.

XX Novel pituitary adenylate cyclase activating peptide receptor 3 agonist
PT useful for treating type 2 diabetes, asthma, hypertension, ulcers and
PT cardiovascular diseases.

XX Disclosure; Page 6; 62pp; English.

XX The present sequence is provided in a specification relating to pituitary

```

XX PF 29-NOV-2001; 2001WO-US043165.
XX XX
XX PR 07-DEC-2000; 2000US-0251954P.
XX XX
XX PA (ELIL ) LILLY & CO ELI.
XX PI Glaesner W, Micanovic R, Tschang SR;
XX XX
XX DR WPI; 2003-018534/01.
XX XX
XX PT Novel heterologous fusion protein, useful for treating non-insulin
XX PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX PT 1 compound fused to human albumin or to the Fc portion of an
XX PT immunoglobulin.
XX PS Example 6; Page 85; 200pp; English.
XX CC The invention relates to a heterologous fusion protein comprising a first
XX CC polypeptide fused to a second polypeptide, where the polypeptides has a N
XX CC -terminus and a C-terminus and the first polypeptide is a glucagon -like
XX CC peptide 1 (GLP-1) compound and the second is a human albumin or its
XX CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
XX CC analogue or fragment, where the C-terminus of first polypeptide is fused
XX CC to the N-terminus of the second polypeptide. The invention is useful for
XX CC normalising blood glucose levels in mammal, for treating a patient with
XX CC non-insulin diabetes mellitus or obesity, or for the manufacture of
XX CC medicament for treating the above mentioned diseases. The present
XX CC sequence is a fusion protein of the invention
XX SQ Sequence 287 AA;
AAE30934 Length: 287 February 4, 2005 13:32 Type: P Check: 7029 ..
Found using 'seq5' (mohamed337.key)
1 HGEGTFTSDLSKQMEAEAVRLFIEWLKNKGPPSGGGGGGGGGGSAEPKSC
28
61 DKHTCPCPAPELLGGP
...
-----
1 match found in sequence:
aae30937 ; Human GLP/exendin peptide analogue #1.
(from "seq5ags pep")
TOIG of: aae30937 check: 7369 from: 1 to: 31

ID AAE30937 standard; peptide; 31 AA.
XX XX
XX AC AAE30937;
XX XX
XX DT 24-FEB-2003 (first entry)
XX XX
XX DE Human GLP/exendin peptide analogue #1.
XX XX
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
XX KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic.
XX OS Homo sapiens.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 31
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200246227-A2.
XX XX
XX PD 13-JUN-2002.
XX XX
XX PF 29-NOV-2001; 2001WO-US043165.
XX XX
XX PR 07-DEC-2000; 2000US-0251954P.

```

```

XX XX (ELIL ) LILLY & CO ELI.
XX PA Glaesner W, Micanovic R, Tschang SR;
XX XX
XX DR WPI; 2003-018534/01.
XX XX
XX PT Novel heterologous fusion protein, useful for treating non-insulin
XX PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX PT 1 compound fused to human albumin or to the Fc portion of an
XX PT immunoglobulin.
XX PS Example 6; Page 90; 200pp; English.
XX CC The invention relates to a heterologous fusion protein comprising a first
XX CC polypeptide fused to a second polypeptide, where the polypeptides has a N
XX CC -terminus and a C-terminus and the first polypeptide is a glucagon -like
XX CC peptide 1 (GLP-1) compound and the second is a human albumin or its
XX CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
XX CC analogue or fragment, where the C-terminus of first polypeptide is fused
XX CC to the N-terminus of the second polypeptide. The invention is useful for
XX CC normalising blood glucose levels in mammal, for treating a patient with
XX CC non-insulin diabetes mellitus or obesity, or for the manufacture of
XX CC medicament for treating the above mentioned diseases. The present
XX CC sequence is human GLP/exendin peptide analogue
XX SQ Sequence 31 AA;
AAE30937 Length: 31 February 4, 2005 13:32 Type: P Check: 7369 ..
Found using 'seq5' (mohamed337.key)
1 HGEGTFTSDLSKQMEAEAVRLFIEWLKNKGPP
28
-----
1 match found in sequence:
aae30938 ; Human GLP/exendin peptide analogue #2.
(from "seq5ags.pep")
TOIG of: aae30938 check: 9570 from: 1 to: 39

ID AAE30938 standard; peptide; 39 AA.
XX XX
XX AC AAE30938;
XX XX
XX DT 24-FEB-2003 (first entry)
XX XX
XX DE Human GLP/exendin peptide analogue #2.
XX XX
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
XX KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic.
XX OS Homo sapiens.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200246227-A2.
XX XX
XX PD 13-JUN-2002.
XX XX
XX PF 29-NOV-2001; 2001WO-US043165.
XX XX
XX PR 07-DEC-2000; 2000US-0251954P.
XX XX
XX PA (ELIL ) LILLY & CO ELI.
XX PI Glaesner W, Micanovic R, Tschang SR;
XX XX
XX DR WPI; 2003-018534/01.
XX PT Novel heterologous fusion protein, useful for treating non-insulin

```

```

KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
KW fusion protein.
XX
OS Homo sapiens.
OS Unidentified.
OS Chimeric.
XX
XX WO200246227-A2.
XX
XX 13-JUN-2002.
XX
XX 29-NOV-2001; 2001WO-US043165.
XX
XX 07-DEC-2000; 2000US-0251954P.
XX
XX (ELIL ) LILLY & CO ELI.
XX
XX Glaesner W, Micanovic R, Tschang SR;
XX
XX WPI; 2003-018534/01.
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
XX dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX Example 6; Page 84; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
XX polypeptide fused to a second polypeptide, where the polypeptides has a N
XX -terminus and a C-terminus and the first polypeptide is a glucagon-like
XX peptide 1 (GLP-1) compound and the second is a human albumin or its
XX analogue or fragment, where the C-terminus of an immunoglobulin (Ig) or its
XX analogue or fragment, where the C-terminus of first polypeptide is fused
XX to the N-terminus of the second polypeptide. The invention is useful for
XX normalising blood glucose levels in mammal, for treating a patient with
XX non-insulin diabetes mellitus or obesity, or for the manufacture of
XX medicament for treating the above mentioned diseases. The present
XX sequence is a fusion protein of the invention
XX
XX Sequence 272 AA;
XX
AAE30932 Length: 272 February 4, 2005 13:32 Type: P Check: 5210 ..
Found using 'seq5' (mohamed337.key)
|-----|
1 HGEFTFTDLSKQMEBAVRLFIWLKNGPSSGAPPSPAPPSAEKPKCDKTHTCPPCPAPELL
1
61 GGPSVFLFPPKPKDTLMI
...
1 match found in sequence:
aae30933 ; Exendin-4-C2-Immunoglobulin G1 (IgG1) fusion protein.
(from "seq5ags.pep")
TOIG of: aae30933 Check: 4385 from: 1 to: 272
ID AAE30933 standard; protein; 272 AA.
XX
AC AAE30933;
XX
XX 24-FEB-2003 (first entry)
XX
XX Exendin-4-C2-Immunoglobulin G1 (IgG1) fusion protein.
XX
XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
XX therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
XX fusion protein.
XX
XX Homo sapiens.
XX Unidentified.
XX
XX WO200246227-A2.
XX
XX 13-JUN-2002.
XX

```

```

OS Chimeric.
XX
XX WO200246227-A2.
XX
XX 13-JUN-2002.
XX
XX 29-NOV-2001; 2001WO-US043165.
XX
XX 07-DEC-2000; 2000US-0251954P.
XX
XX (ELIL ) LILLY & CO ELI.
XX
XX Glaesner W, Micanovic R, Tschang SR;
XX
XX WPI; 2003-018534/01.
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
XX dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX Example 6; Page 85; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
XX polypeptide fused to a second polypeptide, where the polypeptides has a N
XX -terminus and a C-terminus and the first polypeptide is a glucagon-like
XX peptide 1 (GLP-1) compound and the second is a human albumin or its
XX analogue or fragment, where the C-terminus of an immunoglobulin (Ig) or its
XX analogue or fragment, where the C-terminus of first polypeptide is fused
XX to the N-terminus of the second polypeptide. The invention is useful for
XX normalising blood glucose levels in mammal, for treating a patient with
XX non-insulin diabetes mellitus or obesity, or for the manufacture of
XX medicament for treating the above mentioned diseases. The present
XX sequence is a fusion protein of the invention
XX
XX Sequence 272 AA;
XX
AAE30933 Length: 272 February 4, 2005 13:32 Type: P Check: 4385 ..
Found using 'seq5' (mohamed337.key)
|-----|
1 HGEFTFTDLSKQMEBAVRLFIWLKNGPSSGASSGAAEPKSCDKTHTCPPCPAPELL
1
61 GGPSVFLFPPKPKDTLMI
...
1 match found in sequence:
aae30934 ; Exendin-4-linker-Immunoglobulin G1 (IgG1) fusion protein.
(from "seq5ags.pep")
TOIG of: aae30934 Check: 7029 from: 1 to: 287
ID AAE30934 standard; protein; 287 AA.
XX
AC AAE30934;
XX
XX 24-FEB-2003 (first entry)
XX
XX Exendin-4-linker-Immunoglobulin G1 (IgG1) fusion protein.
XX
XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
XX therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
XX fusion protein.
XX
XX Homo sapiens.
XX Unidentified.
XX
XX Chimeric.
XX
XX WO200246227-A2.
XX
XX 13-JUN-2002.
XX

```

```

-----
1 match found in sequence:
aae30913 ; Exendin-4 peptide (7-45).
  (from "seq5ags.pep")
TOIG of: aae30913 check: 9570 from: 1 to: 39

ID AAE30913 standard; peptide; 39 AA.
XX
XX AC AAE30913;
XX
XX DT 24-FEB-2003 (first entry)
XX
XX DE Exendin-4 peptide (7-45).
XX
XX KW Glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig; therapy;
XX non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
XX exendin-4.
XX
XX OS Unidentified.
XX
XX PN WO200246227-A2.
XX
XX PD 13-JUN-2002.
XX
XX PF 29-NOV-2001; 2001WO-US043165.
XX
XX PR 07-DEC-2000; 2000US-0251954P.
XX
XX PA (ELIL ) LILLY & CO ELI.
XX
XX PI Glaesner W, Micanovic R, Tschang SR;
XX
XX DR WFI; 2003-018534/01.
XX
XX PT Novel heterologous fusion protein, useful for treating non-insulin
XX dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX PS Disclosure; Page 32; 200pp; English.
XX
XX CC The invention relates to a heterologous fusion protein comprising a first
XX polypeptide fused to a second polypeptide, where the polypeptides has a N
XX -terminus and a C-terminus and the first polypeptide is a glucagon-like
XX peptide 1 (GLP-1) compound and the second is a human albumin or its
XX analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
XX analogue or fragment, where the C-terminus of first polypeptide is fused
XX to the N-terminus of the second polypeptide. The invention is useful for
XX normalising blood glucose levels in mammal, for treating a patient with
XX non-insulin diabetes mellitus or obesity, or for the manufacture of
XX medicament for treating the above mentioned diseases. The present
XX sequence is exendin-4 peptide used in the invention
XX
XX SQ Sequence 39 AA;
AAE30913 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

-----
1 HGEFTFTSDLSKQMEBAVRLFTLEWLNKGPPSGAPPSPS
  1 28
  (from "seq5ags.pep")
TOIG of: aae30920 check: 3586 from: 1 to: 640

-----
1 match found in sequence:
aae30920 ; Exendin-4-linker-human serum albumin (HSA) fusion protein.
  (from "seq5ags.pep")
TOIG of: aae30920 check: 3586 from: 1 to: 640

ID AAE30920 standard; protein; 640 AA.
XX
XX AC AAE30920;
XX
XX DT 24-FEB-2003 (first entry)
XX
XX DE Exendin-4-Immunoglobulin G1 (IgG1) fusion protein.
XX
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
  therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
  fusion protein.
  (from "seq5ags.pep")
  TOIG of: aae30932 check: 5210 from: 1 to: 272

-----
1 match found in sequence:
aae30932 ; Exendin-4-Immunoglobulin G1 (IgG1) fusion protein.
  (from "seq5ags.pep")
  TOIG of: aae30932 check: 5210 from: 1 to: 272

```

```

DT 24-FEB-2003 (first entry)
XX
XX DE Exendin-4-linker-human serum albumin (HSA) fusion protein.
XX
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
  therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
  fusion protein.
XX
XX OS Homo sapiens.
XX OS Unidentified.
XX OS Chimeric.
XX
XX PN WO200246227-A2.
XX
XX PD 13-JUN-2002.
XX
XX PF 29-NOV-2001; 2001WO-US043165.
XX
XX PR 07-DEC-2000; 2000US-0251954P.
XX
XX PA (ELIL ) LILLY & CO ELI.
XX
XX PI Glaesner W, Micanovic R, Tschang SR;
XX
XX DR WFI; 2003-018534/01.
XX
XX PT Novel heterologous fusion protein, useful for treating non-insulin
XX dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX PS Example 6; Page 81-82; 200pp; English.
XX
XX CC The invention relates to a heterologous fusion protein comprising a first
XX polypeptide fused to a second polypeptide, where the polypeptides has a N
XX -terminus and a C-terminus and the first polypeptide is a glucagon-like
XX peptide 1 (GLP-1) compound and the second is a human albumin or its
XX analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
XX analogue or fragment, where the C-terminus of first polypeptide is fused
XX to the N-terminus of the second polypeptide. The invention is useful for
XX normalising blood glucose levels in mammal, for treating a patient with
XX non-insulin diabetes mellitus or obesity, or for the manufacture of
XX medicament for treating the above mentioned diseases. The present
XX sequence is a fusion protein of the invention
XX
XX SQ Sequence 640 AA;
AAE30920 Length: 640 February 4, 2005 13:32 Type: P Check: 3586 ..
Found using 'seq5' (mohamed337.key)

-----
1 HGEFTFTSDLSKQMEBAVRLFTLEWLNKGPPSGAPPSPSGGGGGGGGGGGGSDAHKS
  1 28
  (from "seq5ags.pep")
  TOIG of: aae30932 check: 5210 from: 1 to: 272

-----
61 EVAHRFKDLGEENFKALV
...
-----
1 match found in sequence:
aae30932 ; Exendin-4-Immunoglobulin G1 (IgG1) fusion protein.
  (from "seq5ags.pep")
  TOIG of: aae30932 check: 5210 from: 1 to: 272

ID AAE30932 standard; protein; 272 AA.
XX
XX AC AAE30932;
XX
XX DT 24-FEB-2003 (first entry)
XX
XX DE Exendin-4-Immunoglobulin G1 (IgG1) fusion protein.
XX
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
  therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
  fusion protein.
  (from "seq5ags.pep")
  TOIG of: aae30932 check: 5210 from: 1 to: 272

```


XX DT 26-MAR-2002 (first entry)
XX DE
XX DE Gila monster extendin 4 peptide.
XX KW Acute coronary syndrome; ACS; Q-wave myocardial infarction; Q-wave MI;
XX KW angina; non-Q-wave cardiac necrosis; ischaemic heart disease;
XX KW congestive heart failure; heart murmur; troponin I; troponin T;
XX KW creatine kinase myocardial isoenzyme; CK-MB; ST-segment; chest pain;
XX KW nausea; palpitation; dizziness; angiodysplasia; pulmonary oedema;
XX KW peripheral oedema; extrasystole; arterial fibrillation; arrhythmia;
XX KW diabetes; hypertension; hypercholesterolaemia; hyperlipidaemia; obesity;
XX KW smoking; impaired glucose tolerance; blood glucose; thrombolytic therapy;
XX KW cardiac distress; glucagon-like peptide-1; GIP-1 homolog; Gila monster;
XX KW extendin 4.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39 /note= "C-terminal amide"
XX FT
XX PN WO200189554-A2.
XX PD 29-NOV-2001.
XX XX
XX PF 18-MAY-2001; 2001WO-US015996.
XX PN 19-MAY-2000; 2000US-0205239P.
XX XX
XX PA (BION-) BIONEERASKA INC.
XX XX
XX PI Coolidge TR, Ehlers M;
XX XX WPI; 2002-089892/12.
XX DR
XX PT New method of treating patients suffering from acute coronary syndrome,
XX PT but not suffering from Q-wave myocardial infarction involves the use of
XX PT glucagon-like peptide-1 derivatives.
XX XX
XX PS Disclosure; Page 15; 38pp; English.
XX XX
XX CC The invention relates to a novel method of treating patients suffering
XX CC from acute coronary syndrome (ACS) and not from Q-wave myocardial
XX CC infarction (Q-wave MI) that involves administering a glucagon-like
XX CC peptide-1 (GLP-1) molecule to the patients. The method is also useful for
XX CC treating patients suffering from stable/unstable angina, non-Q-wave
XX CC cardiac necrosis, ischaemic heart disease or at a risk of developing
XX CC ischaemic heart disease, cardiac abnormalities including congestive heart
XX CC failure, worsening heart murmur (due to mitral regurgitation and cardiac
XX CC conduction disturbances); for treating patients who have a blood troponin
XX CC I level of less than 0.4 ng/ml and blood troponin T level of no more than
XX CC 0.1 ng/ml; do not have elevated blood creatine kinase myocardial enzyme
XX CC and ST-segment elevation, do not exhibit a pathological Q-wave, exhibit
XX CC pain or symptoms such as chest pain greater than 15 minutes in duration,
XX CC chest pain at rest or chest pain following minimal exertion (that is
XX CC poorly responsive to sublingual nitrates), nausea, shortness of breath,
XX CC palpitation and dizziness and have not suffered from a Q-wave myocardial
XX CC infarction prior to the onset of the symptoms, and having normal ECG. The
XX CC GLP-1 compound is further useful in angioplasty, for treating patients
XX CC showing symptoms of pulmonary and peripheral oedema, atrial or
XX CC ventricular extrasystoles, arterial fibrillation and other arrhythmias;
XX CC and those suffering from diabetes, hypertension, hypercholesterolaemia,
XX CC hyperlipidaemia, obesity and smoking. The administration of GLP-1
XX CC following a Q-myocardial infarction (QMI) ameliorates the tissue damage
XX CC that results from the QMI and subsequent reperfusion-induced injury. An
XX CC advantage of using GLP-1 molecules is that high doses can be used without
XX CC consequent hypoglycaemia and hyperglycaemia. Thus doses up to 10 nmol/kg
XX CC can be used without adverse effects, as the action of the molecules are
XX CC ideal for optimising glucose metabolism in individuals including those
XX CC with impaired glucose tolerance and elevated or aberrant blood glucose
XX CC levels. The molecule increases the time during which thrombolytic therapy
XX CC becomes effective following the first symptom of cardiac distress. The

CC present sequence is Gila monster extendin 4 peptide which is homologous to
CC mammalian GLP-1 peptide
XX
SQ Sequence 39 AA;

AAE14427 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 HSGRTFTSDLSKQMBEAVRLFIETLKNKGPPSSGAPPPS
28

1 match found in sequence:
aae30912; Extendin-3 peptide (7-45).
(from "seq5ags.pep")
TOIG of: aae30912 check: 9591 from: 1 to: 39

ID AAE30912 standard; peptide; 39 AA.
XX
AC AAE30912;
XX
DT 24-FEB-2003 (first entry)
XX
DE Extendin-3 peptide (7-45).
XX
KW Glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig; therapy;
KW non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
KW extendin-3.
XX
OS Unidentified.
XX
PN WO200246227-A2.
XX
PD 13-JUN-2002.
XX
PF 29-NOV-2001; 2001WO-US043165.
XX
PR 07-DEC-2000; 2000US-0251954P.
XX
XX (BLIL) LILLY & CO ELI.
XX
PI Glaesner W, Micanovic R, Tschang SR;
XX
DR WPI; 2003-018534/01.
XX
PT Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
PT immunoglobulin.
XX
PS Disclosure; Page 31; 200pp; English.
XX
CC The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC -terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is extendin-3 peptide used in the invention
XX
SQ Sequence 39 AA;

AAE30912 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)

1 HSGRTFTSDLSKQMBEAVRLFIETLKNKGPPSSGAPPPS
28

```

OS Synthetic.
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 183; Page 146; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX Sequence 39 AA;
XX
AA08532 Length: 39 February 4, 2005 13:32 Type: P Check: 9112 ..
Found using 'seq5' (mohamed337.key)
1 AGAFTFTSDLSKQLEEEAVRLFIETLKNKGPPSGAPPPS
28
-----
1 match found in sequence:
aae14425 ; Gila monster exendin 3 peptide.
(from "seq5ags.pep")
TOIG of: aae14425 check: 9591 from: 1 to: 39
ID AAE14425 standard; peptide; 39 AA.
XX
XX AAE14425;
XX
XX 26-MAR-2002 (first entry)
XX
XX Gila monster exendin 3 peptide.
XX
XX Acute coronary syndrome; ACS; Q-wave myocardial infarction; Q-wave MI;
XX angina; non-Q-wave cardiac necrosis; ischaemic heart disease;
XX congestive heart failure; heart murmur; troponin I; troponin T;
XX creatine kinase myocardial isoenzyme; CK-MB; ST-segment; chest pain;
XX nausea; palpitation; dizziness; angiotensin; pulmonary oedema;
XX peripheral oedema; extrasystole; arterial fibrillation; arrhythmia;
XX diabetes; hypertension; hypercholesterolaemia; hyperlipidaemia; obesity;
XX smoking; impaired glucose tolerance; blood glucose; thrombolytic therapy;
XX cardiac distress; glucagon-like peptide-1; GLP-1 homolog; Gila monster;
XX exendin 3.
XX
XX Heloderma suspectum.
XX
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT

```

```

XX WO200189554-A2.
XX
XX 29-NOV-2001.
XX
XX 18-MAY-2001; 2001WO-US015996.
XX
XX 19-MAY-2000; 2000US-0205239P.
XX
XX (BION-) BIONEERASKA INC.
XX
XX Coolidge TR, Ehlers M;
XX
XX WPI; 2002-089892/12.
XX
XX New method of treating patients suffering from acute coronary syndrome,
XX but not suffering from Q-wave myocardial infarction involves the use of
XX glucagon-like peptide-1 derivatives.
XX
XX Disclosure; Page 15; 38pp; English.
XX
XX The invention relates to a novel method of treating patients suffering
XX from acute coronary syndrome (ACS) and not from Q-wave myocardial
XX infarction (Q-wave MI) that involves administering a glucagon-like
XX peptide-1 (GLP-1) molecule to the patients. The method is also useful for
XX treating patients suffering from stable/unstable angina, non-Q-wave
XX cardiac necrosis, ischaemic heart disease or at a risk of developing
XX ischaemic heart disease, cardiac abnormalities including congestive heart
XX failure, worsening heart murmur (due to mitral regurgitation and cardiac
XX conduction disturbances); for treating patients who have a blood troponin
XX I level of less than 0.4 ng/ml and blood troponin T level of no more than
XX 0.1 ng/ml; do not have elevated blood creatine kinase myocardial enzyme
XX and ST-segment elevation, do not exhibit a pathological Q-wave, exhibit
XX pain or symptoms such as chest pain greater than 15 minutes in duration,
XX chest pain at rest or chest pain following minimal exertion (that is
XX poorly responsive to sublingual nitrates), nausea, shortness of breath,
XX palpitation and dizziness and have not suffered from a Q-wave myocardial
XX infarction prior to the onset of the symptoms, and having normal ECG. The
XX GLP-1 compound is further useful in angioplasty, for treating patients
XX showing symptoms of pulmonary and peripheral oedema, atrial or
XX ventricular extrasystoles, arterial fibrillation and other arrhythmias;
XX and those suffering from diabetes, hypertension, hypercholesterolaemia,
XX hyperlipidaemia, obesity and smoking. The administration of GLP-1
XX following a Q-myocardial infarction (QMI) ameliorates the tissue damage
XX that results from the QMI and subsequent reperfusion-induced injury. An
XX advantage of using GLP-1 molecules is that high doses can be used without
XX consequent hypoglycaemia and hyperglycaemia. Thus doses up to 10 nmol/kg
XX can be used without adverse effects, as the action of the molecules are
XX ideal for optimising glucose metabolism in individuals including those
XX with impaired glucose tolerance and elevated or aberrant blood glucose
XX levels. The molecule increases the time during which thrombolytic therapy
XX becomes effective following the first symptom of cardiac distress. The
XX present sequence is Gila monster exendin 3 peptide which is homologous to
XX mammalian GLP-1 peptide
XX
XX Sequence 39 AA;
XX
AAE14425 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1 HSDGTFSTDSLKQLEEEAVRLFIETLKNKGPPSGAPPPS
28
-----
1 match found in sequence:
aae14427 ; Gila monster exendin 4 peptide.
(from "seq5ags.pep")
TOIG of: aae14427 check: 9570 from: 1 to: 39
ID AAE14427 standard; peptide; 39 AA.
XX
XX AAE14427;
XX

```

SQ Sequence 35 AA;

AAE08529 Length: 35 February 4, 2005 13:32 Type: P Check: 7441 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGAGTFTSDLSKQMEBAVRLFIWLNKGPFSSGA
28

1 match found in sequence:
aae08530 ; Exendin agonist peptide #175.
(from "seq5ags.pep")
TOIG of: aae08530 check: 4862 from: 1 to: 30

ID AAE08530 standard; peptide; 30 AA.
AC AAE08530;
XX
XX
DT 01-NOV-2001 (first entry)
XX
XX
DE Exendin agonist peptide #175.
XX
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 30 /note= "C-terminal amide"
FT
XX
XX
PN WO200151078-A1.
XX
XX
PD 19-JUL-2001.
XX
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
XX
PR 10-JAN-2000; 2000US-017536SP.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Kolterman OG, Young AA;
XX
XX
DR WPI; 2001-514422/56.
XX
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX
PS Example 181; Page 145; 161pp; English.
XX
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX
SQ Sequence 30 AA;

AAE08530 Length: 30 February 4, 2005 13:32 Type: P Check: 4862 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGAGTFTSDLSKQMEBAVRLFIWLNKG
28

1 match found in sequence:
aae08531 ; Exendin agonist peptide #176.
(from "seq5ags.pep")

TOIG of: aae08531 check: 9563 from: 1 to: 39

ID AAE08531 standard; peptide; 39 AA.
AC AAE08531;
XX
XX
DT 01-NOV-2001 (first entry)
XX
XX
DE Exendin agonist peptide #176.
XX
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 39 /note= "C-terminal amide"
FT
XX
XX
PN WO200151078-A1.
XX
XX
PD 19-JUL-2001.
XX
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
XX
PR 10-JAN-2000; 2000US-017536SP.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Kolterman OG, Young AA;
XX
XX
DR WPI; 2001-514422/56.
XX
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX
PS Example 182; Page 146; 161pp; English.
XX
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX
SQ Sequence 39 AA;

AAE08531 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGSGTFTSDLSKQMEBAVRLFIWLNKGPFSSGAPPPS
28

1 match found in sequence:
aae08532 ; Exendin agonist peptide #177.
(from "seq5ags.pep")
TOIG of: aae08532 check: 9112 from: 1 to: 39

ID AAE08532 standard; peptide; 39 AA.
AC AAE08532;
XX
XX
DT 01-NOV-2001 (first entry)
XX
XX
DE Exendin agonist peptide #177.
XX
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX

PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 178; Page 143; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 37 AA;

AAE08527 Length: 37 February 4, 2005 13:32 Type: P Check: 1706 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQMEEAARLFIWLNKGSGGAAA
28
-----|-----
1 match found in sequence:
aae08528 ; Exendin agonist peptide #173.
(from "seq5ag8.pap")
TOIG of: aae08528 check: 862 from: 1 to: 36

ID AAE08528 standard; peptide; 36 AA.
XX
AC AAE08528;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #173.
XX
KW Exendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "Homoproline"
FT Modified-site 36 /note= "Homoproline; C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.

PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 179; Page 144; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 36 AA;

AAE08528 Length: 36 February 4, 2005 13:32 Type: P Check: 862 ..
Found using 'seq5' (mohamed337.key)
1 AGEFTFTSLSKQMEEAARLFIWLNKGSGGAX
28
-----|-----
1 match found in sequence:
aae08529 ; Exendin agonist peptide #174.
(from "seq5ag8.pap")
TOIG of: aae08529 check: 7441 from: 1 to: 35

ID AAE08529 standard; peptide; 35 AA.
XX
AC AAE08529;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #174.
XX
KW Exendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 35 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 180; Page 145; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX

KW diuretic; coronary heart disease; dyslipidaemia.
 XX Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 31 /note= "Thioprolin"
 FT Modified-site 36 /note= "Thioprolin"
 FT Modified-site 37 /note= "Thioprolin"
 FT Modified-site 38 /note= "Thioprolin; C-terminal amide"
 FT
 XX WO200151078-A1.
 XX
 XX 19-JUL-2001.
 XX
 PF 09-JAN-2001; 2001WO-US000719.
 XX
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Kolterman OG, Young AA;
 PI
 XX WPI; 2001-514422/56.
 PD
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidaemia.
 XX
 XX Example 176; Page 142; 161pp; English.
 XX
 XX The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering exendin or an exendin agonist. Exendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Exendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of exendin
 XX
 XX Sequence 38 AA;
 SQ
 AAE08525 Length: 38 February 4, 2005 13:32 Type: P Check: 7457 ..
 Found using 'seq5' (mohamed337.key)
 1 HGAGTFTSLSKQMBEAVRLFIEWLKNGXSGAXXX
 1

 1 match found in sequence:
 aae08526 ; Exendin agonist peptide #171.
 (from "seq5ags.pep")
 TOIG of: aae08526 check: 7197 from: 1 to: 38
 ID AAE08526 standard; peptide; 38 AA.
 XX
 AC AAE08526;
 XX
 XX 01-NOV-2001 (first entry)
 DT
 XX Exendin agonist peptide #171.
 DE
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FT Modified-site 36 /note= "Thioprolin"
 FT

FT Modified-site 37 /note= "Thioprolin"
 FT Modified-site 38 /note= "Thioprolin; C-terminal amide"
 FT
 XX WO200151078-A1.
 XX
 XX 19-JUL-2001.
 XX
 XX 09-JAN-2001; 2001WO-US000719.
 XX
 XX 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Kolterman OG, Young AA;
 PI
 XX WPI; 2001-514422/56.
 DR
 XX
 XX Use of exendin and exendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidaemia.
 XX
 XX Example 177; Page 143; 161pp; English.
 XX
 XX The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering exendin or an exendin agonist. Exendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Exendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of exendin
 XX
 XX Sequence 38 AA;
 SQ
 AAE08526 Length: 38 February 4, 2005 13:32 Type: P Check: 7197 ..
 Found using 'seq5' (mohamed337.key)
 1 HGATFTSLSKQMBEAVRLFIEWLKNGSPSGAXXX
 1

 1 match found in sequence:
 aae08527 ; Exendin agonist peptide #172.
 (from "seq5ags.pep")
 TOIG of: aae08527 check: 1706 from: 1 to: 37
 ID AAE08527 standard; peptide; 37 AA.
 XX
 AC AAE08527;
 XX
 XX 01-NOV-2001 (first entry)
 DT
 XX Exendin agonist peptide #172.
 DE
 XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FT Modified-site 31 /note= "N-methyl alanine"
 FT Modified-site 36 /note= "N-methyl alanine"
 FT Modified-site 37 /note= "N-methyl alanine"
 FT
 XX WO200151078-A1.
 XX
 XX 19-JUL-2001.
 XX

CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 31 AA;

AAE08522 Length: 31 February 4, 2005 13:32 Type: P Check: 7345 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEATFTSDLSKQEEAVRLFIEWLKNGGP 28
1

1 match found in sequence:
aae08523; Exendin agonist peptide #168.
(from "seq5ags.pep")
TOIG of: aae08523 check: 4423 from: 1 to: 30

ID AAE08523 standard; peptide; 30 AA.

XX AAE08523;

AC 01-NOV-2001 (first entry)

XX Exendin agonist peptide #168.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 30

FT /note= "C-terminal amide"

FT WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.

XX Example 174; Page 141; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 30 AA;

AAE08523 Length: 30 February 4, 2005 13:32 Type: P Check: 4423 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEATFTSALSQLEAEAVRLFIEFLKNGG 28
1

1 match found in sequence:

aae08524; Exendin agonist peptide #169.
(from "seq5ags.pep")
TOIG of: aae08524 check: 2313 from: 1 to: 29

ID AAE08524 standard; peptide; 29 AA.

XX AAE08524;

AC 01-NOV-2001 (first entry)

XX Exendin agonist peptide #169.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 29

FT /note= "C-terminal amide"

FT WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.

XX Example 175; Page 141; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 29 AA;

AAE08524 Length: 29 February 4, 2005 13:32 Type: P Check: 2313 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGRGTTSDLSKQLEAEAVRLFIEFLKNG 28
1

1 match found in sequence:
aae08525; Exendin agonist peptide #170.
(from "seq5ags.pep")
TOIG of: aae08525 check: 7457 from: 1 to: 38

ID AAE08525 standard; peptide; 38 AA.

XX AAE08525;

XX 01-NOV-2001 (first entry)

XX Exendin agonist peptide #170.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

```

PN WO200151078-A1.
PD 19-JUL-2001.
PF 09-JAN-2001; 2001WO-US0000719.
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 171; Page 139; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 32 AA;
XX
AAE08520 Length: 32 February 4, 2005 13:32 Type: P Check: 18 ..
Found using 'seq5' (mohamed337.key)
1 ACGTFTSDLSKQLEEAVERLFIETLKNKGPS
  1 |-----|
  28
-----
1 match found in sequence:
aae08521; Exendin agonist peptide #166.
(from "seq5ags.pep")
TOIG of: aae08521 check: 9574 from: 1 to: 32

ID AAE08521 standard; peptide; 32 AA.
XX
XX AAE08521;
XX AC
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #166.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 32
FT /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 173; Page 140; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 32 AA;
XX
AAE08521 Length: 32 February 4, 2005 13:32 Type: P Check: 9574 ..
Found using 'seq5' (mohamed337.key)
1 HGAGTFTSDLSKQLEEAVERLFIETLKNKGPS
  1 |-----|
  28
-----
1 match found in sequence:
aae08522; Exendin agonist peptide #167.
(from "seq5ags.pep")
TOIG of: aae08522 check: 7345 from: 1 to: 31

ID AAE08522 standard; peptide; 31 AA.
XX
XX AAE08522;
XX AC
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #167.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 31
FT /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 173; Page 140; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 32 AA;
XX

```

```
1 HGAGTFTSLSKQLEEEAVRLFIETFLKNGPSSGA
1
-----
1 match found in sequence:
aae08518 ; Exendin agonist peptide #163.
(from "seq5ags.pep")
TOIG of: aae08518 check: 5154 from: 1 to: 34

ID AAE08518 standard; peptide; 34 AA.
XX
AC AAE08518;
XX
AC AAE08518;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #163.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 34
FT Modified-site 34 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
levels, and treating heart disease and dyslipidemia.
XX
PS Example 169; Page 138; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
triglyceride and other lipid levels by administering exendin or an
exendin agonist. Exendins have inotropic and diuretic effects. They
suppress the secretion of glucagon. Exendin and its agonists have a
significant effect on the reduction of blood serum triglyceride
concentrations. They are used to treat coronary heart disease and
dyslipidaemia, and for modifying postprandial triglyceride levels. The
present peptide sequence is an agonist of exendin
XX
SQ Sequence 34 AA;

AAE08518 Length: 34 February 4, 2005 13:32 Type: P Check: 5154 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSLSKQLEEEAVRLFIETFLKNGPSSG
1
-----
1 match found in sequence:
aae08519 ; Exendin agonist peptide #164.
(from "seq5ags.pep")
TOIG of: aae08519 check: 2737 from: 1 to: 33

ID AAE08519 standard; peptide; 33 AA.
XX
AC AAE08519;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #165.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 32
FT Modified-site 32 /note= "C-terminal amide"
XX
SQ Sequence 33 AA;

AAE08519 Length: 33 February 4, 2005 13:32 Type: P Check: 2737 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSLSKQLEEEAVRLFIETFLKNGPSS
1
-----
1 match found in sequence:
aae08520 ; Exendin agonist peptide #165.
(from "seq5ags.pep")
TOIG of: aae08520 check: 18 from: 1 to: 32

ID AAE08520 standard; peptide; 32 AA.
XX
AC AAE08520;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #165.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 32
FT Modified-site 32 /note= "C-terminal amide"
XX
SQ Sequence 33 AA;

AAE08519 Length: 33 February 4, 2005 13:32 Type: P Check: 2737 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSLSKQLEEEAVRLFIETFLKNGPSS
1
-----
1 match found in sequence:
aae08520 ; Exendin agonist peptide #165.
(from "seq5ags.pep")
TOIG of: aae08520 check: 18 from: 1 to: 32

ID AAE08520 standard; peptide; 32 AA.
XX
AC AAE08520;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #165.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 32
FT Modified-site 32 /note= "C-terminal amide"
XX
SQ Sequence 33 AA;
```


PA (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
PI WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX Example 166; Page 136; 161pp; English.
PS The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 36 AA;
SQ
AAE08515 Length: 36 February 4, 2005 13:32 Type: P Check: 9777 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
AGEGTFTSDASKQLEBEAVRLFIEFLKNGGPSSGAP 28

1 match found in sequence:
aae08516; Extendin agonist peptide #161.
(from "seq5ags.pep")
TOIG of: aae08516 check: 7446 from: 1 to: 35
ID AAE08516 standard; peptide; 35 AA.
XX
AC AAE08516;
XX
XX 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #161.
XX
XW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 35 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX Example 167; Page 137; 161pp; English.
PS The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 35 AA;
SQ
AAE08516 Length: 35 February 4, 2005 13:32 Type: P Check: 7446 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
AGEGTFTSDLSKQMEBEAVRLFIEFLKNGGPSSGA 28

1 match found in sequence:
aae08517; Extendin agonist peptide #162.
(from "seq5ags.pep")
TOIG of: aae08517 check: 7002 from: 1 to: 35
ID AAE08517 standard; peptide; 35 AA.
XX
AC AAE08517;
XX
XX 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #162.
XX
XW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 35 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX Example 168; Page 137; 161pp; English.
PS The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 35 AA;
SQ
AAE08517 Length: 35 February 4, 2005 13:32 Type: P Check: 7002 ..
Found using 'seq5' (mohamed337.key)
1 |-----|

XX Example 161; Page 133; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Extendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of extendin

XX Sequence 28 AA;

AAE08510 Length: 28 February 4, 2005 13:32 Type: P Check: 9887 ..

Found using 'seq5' (mohamed337.key)

1 |-----|

1 AGDGTFTDLSKQLEEEAVRLFIEFLKA 28

1 match found in sequence:

aae08511 ; Extendin agonist peptide #156.

(from "seq5ags.pep")

TOIG of: aae08511 check: 6326 from: 1 to: 38

ID AAE08511 standard; peptide; 38 AA.

XX AAE08511;

AC AAE08511;

XX 01-NOV-2001 (first entry)

DT Extendin agonist peptide #156.

DE Extendin agonist peptide #156.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

OS Key Location/Qualifiers

FH Modified-site 28

FT /note= "C-terminal amide"

PN WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PA Kolterman OG, Young AA;

PI WPI; 2001-514422/56.

DR Use of extendin and extendin agonist compounds for modulating triglyceride

XX levels, and treating heart disease and dyslipidaemia.

XX Example 162; Page 134; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Extendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of extendin

XX Sequence 38 AA;

AAE08512 Length: 38 February 4, 2005 13:32 Type: P Check: 5882 ..

Found using 'seq5' (mohamed337.key)

1 |-----|

1 AGEGFTDLSKQLEEEAVRLFIEFLKNGPSSGAPPP 28

1 match found in sequence:

aae08512 ; Extendin agonist peptide #157.

(from "seq5ags.pep")

TOIG of: aae08512 check: 5882 from: 1 to: 38

ID AAE08512 standard; peptide; 38 AA.

XX AAE08512;

AC AAE08512;

XX 01-NOV-2001 (first entry)

DT Extendin agonist peptide #157.

DE Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

OS Key Location/Qualifiers

FH Modified-site 28

FT /note= "C-terminal amide"

PN WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PA Kolterman OG, Young AA;

PI WPI; 2001-514422/56.

DR Use of extendin and extendin agonist compounds for modulating triglyceride

XX levels, and treating heart disease and dyslipidaemia.

XX Example 163; Page 134; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Extendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of extendin

XX Sequence 38 AA;

AAE08513 Length: 38 February 4, 2005 13:32 Type: P Check: 5882 ..

Found using 'seq5' (mohamed337.key)

1 |-----|

1 HCGTFTDLSKQLEEEAVRLFIEFLKNGPSSGNAPP 28

1 match found in sequence:

aae08513 ; Extendin agonist peptide #158.

(from "seq5ags.pep")

TOIG of: aae08513 check: 3269 from: 1 to: 37

```

XX 09-JAN-2001; 2001WO-US000719.
FF 10-JAN-2000; 2000US-0175365P.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 160; Page 133; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
XX
XX AAE08509 Length: 28 February 4, 2005 13:32 Type: P Check: 326 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX 1 |-----|
XX 1 AGDGTFTSDLSKQWEEAVRLFIEWLKA 28
XX
XX -----
XX 1 match found in sequence:
XX aae08510 ; Extendin agonist peptide #155.
XX (from "seq5ags.pep")
XX TOIG of: aae08510 check: 9887 from: 1 to: 28
XX
XX ID AAE08510 standard; peptide; 28 AA.
XX AC AAE08510;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #155.
XX
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

```

CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
SQ Sequence 28 AA;

AAE08505 Length: 28 February 4, 2005 13:32 Type: P Check: 404 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGDGTFTSDLSKQMEAEAVRLFIEWAKN 28

1 match found in sequence:
aae08506 ; Extendin agonist peptide #151.
(from "seq5ags.pep")
TOIG of: aae08506 check: 9965 from: 1 to: 28

ID AAE08506 standard; peptide; 28 AA.

XX AAE08506;

DT 01-NOV-2001 (first entry)

XX Extendin agonist peptide #151.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.

XX Example 157; Page 131; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

SQ Sequence 28 AA;

AAE08506 Length: 28 February 4, 2005 13:32 Type: P Check: 9965 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGDGTFTSDLSKQLEAEAVRLFIEPAKN 28

1 match found in sequence:
aae08507 ; Extendin agonist peptide #152.
(from "seq5ags.pep")
TOIG of: aae08507 check: 420 from: 1 to: 28

ID AAE08507 standard; peptide; 28 AA.

XX AAE08507;

DT 01-NOV-2001 (first entry)

XX Extendin agonist peptide #152.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.

XX Example 158; Page 131; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

SQ Sequence 28 AA;

AAE08507 Length: 28 February 4, 2005 13:32 Type: P Check: 420 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
AGDGTFTSDLSKQMEAEAVRLFIEWLAN 28

1 match found in sequence:
aae08508 ; Extendin agonist peptide #153.
(from "seq5ags.pep")
TOIG of: aae08508 check: 9981 from: 1 to: 28

ID AAE08508 standard; peptide; 28 AA.

XX AAE08508;

DT 01-NOV-2001 (first entry)

XX Extendin agonist peptide #153.

XX ID

PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX
XX Example 149; Page 126; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08498 Length: 28 February 4, 2005 13:32 Type: P Check: 550 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRLFEFLKN 28
-----|
1 match found in sequence:
aae08499 ; Extendin agonist peptide #144.
(from "seq5ags.pep")
TOIG of: aae08499 check: 1035 from: 1 to: 28
-----|
ID AAE08499 standard; peptide; 28 AA.
XX
XX AC AAE08499;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #144.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Misc-difference 23 /note= "Tertiary butyl glycine"
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 150; Page 127; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08499 Length: 28 February 4, 2005 13:32 Type: P Check: 1035 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRLFEFLKN 28
-----|
1 match found in sequence:
aae08500 ; Extendin agonist peptide #145.
(from "seq5ags.pep")
TOIG of: aae08500 check: 596 from: 1 to: 28
-----|
ID AAE08500 standard; peptide; 28 AA.
XX
XX AC AAE08500;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #145.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Misc-difference 23 /note= "Tertiary butyl glycine"
FT Modified-site 28 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 151; Page 127; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08500 Length: 28 February 4, 2005 13:32 Type: P Check: 596 ..
Found using 'seq5' (mohamed337.key)


```

FT Modified-site 28 /note= "C-terminal amide"
FT XX
FN WO200151078-A1.
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 148; Page 126; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride and
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08497 Length: 28 February 4, 2005 13:32 Type: P Check: 989 ..
Found using 'seq5' (mohamed337.ky)
1 |-----|
1 AGDGTFTSDLSKQMEEEAVRLFVEWLKN 28
-----
1 match found in sequence:
AAE08498 ; Extendin agonist peptide #143.
(from "seq5ags.pep")
TOIG of: aae08498 check: 550 from: 1 to: 28
ID AAE08498 standard; peptide; 28 AA.
XX
AC AAE08498;
XX
DT 01-NOV-2001 (first entry)
DE Extendin agonist peptide #143.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX

```

CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08493 Length: 28 February 4, 2005 13:32 Type: P Check: 459 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVRAFLIEFLKN 28

1 match found in sequence:
aae08494 ; Exendin agonist peptide #139.
(from "seq5ags.pep")
TOIG of: aae08494 check: 20 from: 1 to: 28

ID AAE08494 standard; peptide; 28 AA.
XX
AC AAE08494;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #139.
XX
KW Exendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 28
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 145; Page 124; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08494 Length: 28 February 4, 2005 13:32 Type: P Check: 20 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVRAFLIEFLKN 28

1 match found in sequence:
aae08494 ; Exendin agonist peptide #139.
(from "seq5ags.pep")
TOIG of: aae08494 check: 20 from: 1 to: 28

ID AAE08494 standard; peptide; 28 AA.
XX
AC AAE08494;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #139.
XX
KW Exendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 28
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 145; Page 124; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08494 Length: 28 February 4, 2005 13:32 Type: P Check: 20 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVRAFLIEFLKN 28

1 match found in sequence:
aae08496 ; Exendin agonist peptide #141.
(from "seq5ags.pep")
TOIG of: aae08496 check: 647 from: 1 to: 28

ID AAE08496 standard; peptide; 28 AA.
XX
AC AAE08496;
1 |-----|
1 AGDGTFTSDLSKQMEEEAVRAFLIEFLKN 28

1 match found in sequence:
aae08496 ; Exendin agonist peptide #141.
(from "seq5ags.pep")
TOIG of: aae08496 check: 647 from: 1 to: 28

ID AAE08496 standard; peptide; 28 AA.
XX
AC AAE08496;

1 28

1 match found in sequence:
aae08495 ; Exendin agonist peptide #140.
(from "seq5ags.pep")
TOIG of: aae08495 check: 1086 from: 1 to: 28

ID AAE08495 standard; peptide; 28 AA.
XX
AC AAE08495;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #140.
XX
KW Exendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Misc-difference 22 /note= "Naphthyl alanine"
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 146; Page 124; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08495 Length: 28 February 4, 2005 13:32 Type: P Check: 1086 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 AGDGTFTSDLSKQMEEEAVRLXIEFLKN 28

1 match found in sequence:
aae08496 ; Exendin agonist peptide #141.
(from "seq5ags.pep")
TOIG of: aae08496 check: 647 from: 1 to: 28

ID AAE08496 standard; peptide; 28 AA.
XX
AC AAE08496;

TOIG of: aae08490 check: 9852 from: 1 to: 28

```
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 137; Page 119; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

AAE08486 Length: 28 February 4, 2005 13:32 Type: P Check: 187 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSLSKQLEAAVRLFIKLN 28
-----|
1 match found in sequence:
aae08487; Extendin agonist peptide #132.
(from "seq5ags.pep")
TOIG of: aae08487 check: 622 from: 1 to: 28

ID AAE08487 standard; peptide; 28 AA.
XX
AC AAE08487;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #132.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 139; Page 120; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

AAE08487 Length: 28 February 4, 2005 13:32 Type: P Check: 622 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSLSKQMEAAVRLFIKLN 28
-----|
1 match found in sequence:
aae08488; Extendin agonist peptide #133.
(from "seq5ags.pep")
TOIG of: aae08488 check: 183 from: 1 to: 28

ID AAE08488 standard; peptide; 28 AA.
XX
AC AAE08488;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #133.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 139; Page 120; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ
```

```
1 match found in sequence:
aae08484 ; Exendin agonist peptide #129.
(from "seq5ags.pep")
TOIG of: aae08484 check: 191 from: 1 to: 28

ID AAE08484 standard; peptide; 28 AA.
XX
AC AAE08484;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #129.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PP 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Kolterman OG, Young AA;
XX PI
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 135; Page 118; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
SQ
AAE08485 Length: 28 February 4, 2005 13:32 Type: P Check: 191 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLAAEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aae08485 ; Exendin agonist peptide #130.
(from "seq5ags.pep")
TOIG of: aae08485 check: 626 from: 1 to: 28

ID AAE08485 standard; peptide; 28 AA.
XX
AC AAE08485;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #130.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PP 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Kolterman OG, Young AA;
XX PI
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 135; Page 118; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
SQ
AAE08484 Length: 28 February 4, 2005 13:32 Type: P Check: 626 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQMAEAVRLFIEWLKN 28
|-----|
1 match found in sequence:
aae08486 ; Exendin agonist peptide #131.
(from "seq5ags.pep")
TOIG of: aae08486 check: 187 from: 1 to: 28

ID AAE08486 standard; peptide; 28 AA.
XX
AC AAE08486;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #131.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
```

PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX
PS Example 132; Page 116; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08481 Length: 28 February 4, 2005 13:32 Type: P Check: 844 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQXEEAVRLFIETLKN 28

1 match found in sequence:
aae08482 ; Extendin agonist peptide #127.
(from "seq5ags.pep")
TOIG of: aae08482 check: 419 from: 1 to: 28
ID AAE08482 standard; peptide; 28 AA.
XX
XX AAE08482;
XX AC
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #127.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Misc-difference 14 /note= "Pentyl glycine"
XX Modified-site 28 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 133; Page 117; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08482 Length: 28 February 4, 2005 13:32 Type: P Check: 419 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQXEEAVRLFIETLKN 28

1 match found in sequence:
aae08483 ; Extendin agonist peptide #128.
(from "seq5ags.pep")
TOIG of: aae08483 check: 630 from: 1 to: 28
ID AAE08483 standard; peptide; 28 AA.
XX
XX AAE08483;
XX AC
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #128.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 134; Page 117; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08483 Length: 28 February 4, 2005 13:32 Type: P Check: 630 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQXEEAVRLFIETLKN 28

```
XX Extensin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX OS Key Location/Qualifiers
XX FH Modified-site 28
XX FT /note= "C-terminal amide"
XX FT
XX FN WO200151078-A1.
XX PD 19-JUL-2001.
XX PP 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX CC Use of extensin and extensin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX PS Example 130; Page 115; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extensin or an
XX extensin agonist. Extensins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extensin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extensin
XX SQ Sequence 28 AA;
AAE08479 Length: 28 February 4, 2005 13:32 Type: P Check: 522 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSLSKQAEAEVRLFIWLKN 28
-----
1 match found in sequence:
aae08480 ; Extensin agonist peptide #125.
(from "seq5ags.pep")
TOIG of: aae08480 check: 97 from: 1 to: 28
ID AAE08480 standard; peptide; 28 AA.
XX AC AAE08480;
XX DT 01-NOV-2001 (first entry)
XX DE Extensin agonist peptide #125.
XX KW Extensin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX FN WO200151078-A1.
XX PD 19-JUL-2001.
```

```
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extensin and extensin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX Example 131; Page 116; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extensin or an
XX extensin agonist. Extensins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extensin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extensin
XX SQ Sequence 28 AA;
AAE08480 Length: 28 February 4, 2005 13:32 Type: P Check: 97 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSLSKQAEAEVRLFIWLKN 28
-----
1 match found in sequence:
aae08481 ; Extensin agonist peptide #126.
(from "seq5ags.pep")
TOIG of: aae08481 check: 844 from: 1 to: 28
ID AAE08481 standard; peptide; 28 AA.
XX AC AAE08481;
XX DT 01-NOV-2001 (first entry)
XX DE Extensin agonist peptide #126.
XX KW Extensin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Misc-difference 14
XX FT /note= "Pentyl glycine"
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX FN WO200151078-A1.
XX PD 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
```


CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08476 Length: 28 February 4, 2005 13:32 Type: P Check: 131 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSAQLEEEAVRLFIEFLKN 28
|-----|

1 match found in sequence:
aae08477 ; Extendin agonist peptide #122.
(from "seq5ags.pep")
TOIG of: aae08477 check: 482 from: 1 to: 28

ID AAE08477 standard; peptide; 28 AA.

XX
AC AAE08477;

XX
DT 01-NOV-2001 (first entry)

XX
DE Extendin agonist peptide #122.

XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"

XX
PN WO200151078-A1.

XX
PD 19-JUL-2001.

XX
PF 09-JAN-2001; 2001WO-US000719.

XX
PR 10-JAN-2000; 2000US-0175365P.

XX
PA (AMYL-) AMYLIN PHARM INC.

XX
PI Kolterman OG, Young AA;

XX
DR WPI; 2001-514422/56.

XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.

XX
PS Example 128; Page 114; 161pp; English.

XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

XX
SQ Sequence 28 AA;

AAE08477 Length: 28 February 4, 2005 13:32 Type: P Check: 482 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKAMEEAVRLFIEFLKN 28
|-----|

1 match found in sequence:
aae08478 ; Extendin agonist peptide #123.
(from "seq5ags.pep")
TOIG of: aae08478 check: 43 from: 1 to: 28

ID AAE08478 standard; peptide; 28 AA.

XX
AC AAE08478;

XX
DT 01-NOV-2001 (first entry)

XX
DE Extendin agonist peptide #123.

XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"

XX
PN WO200151078-A1.

XX
PD 19-JUL-2001.

XX
PF 09-JAN-2001; 2001WO-US000719.

XX
PR 10-JAN-2000; 2000US-0175365P.

XX
PA (AMYL-) AMYLIN PHARM INC.

XX
PI Kolterman OG, Young AA;

XX
DR WPI; 2001-514422/56.

XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.

XX
PS Example 129; Page 115; 161pp; English.

XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

XX
SQ Sequence 28 AA;

AAE08478 Length: 28 February 4, 2005 13:32 Type: P Check: 43 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKALEEAVRLFIEFLKN 28
|-----|

1 match found in sequence:
aae08479 ; Extendin agonist peptide #124.
(from "seq5ags.pep")
TOIG of: aae08479 check: 522 from: 1 to: 28

ID AAE08479 standard; peptide; 28 AA.

XX
AC AAE08479;

XX
DT 01-NOV-2001 (first entry)

XX
DE Extendin agonist peptide #124.

FT XX /note= "C-terminal amide"
PN XX WO200151078-A1.
XX XX 19-JUL-2001.
PD XX
XX XX
XX XX 09-JAN-2001; 2001WO-US000719.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX XX levels, and treating heart disease and dyslipidemia.
XX XX Example 125; Page 112; 161pp; English.
XX XX The patent discloses a method for modulating plasma or postprandial
XX XX triglyceride and other lipid levels by administering extendin or an
XX XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX XX suppress the secretion of glucagon. Extendin and its agonists have a
XX XX significant effect on the reduction of blood serum triglyceride
XX XX concentrations. They are used to treat coronary heart disease and
XX XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX XX present peptide sequence is an agonist of extendin
XX XX Sequence 28 AA;
XX XX
XX XX AAE08474 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..
XX XX Found using 'seq5' (mohamed337.key)
XX XX
XX XX 1 AGDGTFTSLAKQLEEEAVRLFIEFLKN 28
XX XX

1 match found in sequence:
aae08475 ; Extendin agonist peptide #120.
(from "seq5ags.pep")
TOIG of: aae08475 check: 570 from: 1 to: 28
ID AAE08475 standard; peptide; 28 AA.
XX AC AAE08475;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Extendin agonist peptide #120.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200151078-A1.
XX XX 19-JUL-2001.
XX XX
XX XX 09-JAN-2001; 2001WO-US000719.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX XX levels, and treating heart disease and dyslipidemia.
XX XX Example 127; Page 113; 161pp; English.
XX XX The patent discloses a method for modulating plasma or postprandial
XX XX triglyceride and other lipid levels by administering extendin or an
XX XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX XX suppress the secretion of glucagon. Extendin and its agonists have a
XX XX significant effect on the reduction of blood serum triglyceride
XX XX concentrations. They are used to treat coronary heart disease and
XX XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX XX present peptide sequence is an agonist of extendin
XX XX Sequence 28 AA;
XX XX
XX XX AAE08474 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..
XX XX Found using 'seq5' (mohamed337.key)
XX XX
XX XX 1 AGDGTFTSLAKQLEEEAVRLFIEFLKN 28
XX XX

1 match found in sequence:
aae08475 ; Extendin agonist peptide #120.
(from "seq5ags.pep")
TOIG of: aae08475 check: 570 from: 1 to: 28
ID AAE08475 standard; peptide; 28 AA.
XX AC AAE08475;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Extendin agonist peptide #120.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200151078-A1.
XX XX 19-JUL-2001.
XX XX
XX XX 09-JAN-2001; 2001WO-US000719.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX XX levels, and treating heart disease and dyslipidemia.
XX XX Example 127; Page 113; 161pp; English.
XX XX The patent discloses a method for modulating plasma or postprandial
XX XX triglyceride and other lipid levels by administering extendin or an
XX XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX XX suppress the secretion of glucagon. Extendin and its agonists have a
XX XX significant effect on the reduction of blood serum triglyceride
XX XX concentrations. They are used to treat coronary heart disease and
XX XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX XX present peptide sequence is an agonist of extendin
XX XX Sequence 28 AA;
XX XX
XX XX AAE08475 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
XX XX Found using 'seq5' (mohamed337.key)
XX XX
XX XX 1 AGDGTFTSLAQMBEEAVRLFIEWLKN 28
XX XX

1 match found in sequence:
aae08476 ; Extendin agonist peptide #121.
(from "seq5ags.pep")
TOIG of: aae08476 check: 131 from: 1 to: 28
ID AAE08476 standard; peptide; 28 AA.
XX AC AAE08476;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Extendin agonist peptide #121.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200151078-A1.
XX XX 19-JUL-2001.
XX XX
XX XX 09-JAN-2001; 2001WO-US000719.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX XX levels, and treating heart disease and dyslipidemia.
XX XX Example 127; Page 113; 161pp; English.
XX XX The patent discloses a method for modulating plasma or postprandial
XX XX triglyceride and other lipid levels by administering extendin or an
XX XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX XX suppress the secretion of glucagon. Extendin and its agonists have a
XX XX significant effect on the reduction of blood serum triglyceride
XX XX concentrations. They are used to treat coronary heart disease and
XX XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX XX present peptide sequence is an agonist of extendin
XX XX Sequence 28 AA;
XX XX

XX WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX Example 126; Page 113; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
XX
XX AAE08475 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX 1 AGDGTFTSLAQMBEEAVRLFIEWLKN 28
XX

1 match found in sequence:
aae08476 ; Extendin agonist peptide #121.
(from "seq5ags.pep")
TOIG of: aae08476 check: 131 from: 1 to: 28
ID AAE08476 standard; peptide; 28 AA.
XX AC AAE08476;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE
XX DE Extendin agonist peptide #121.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX XX
XX PN WO200151078-A1.
XX XX 19-JUL-2001.
XX XX
XX XX 09-JAN-2001; 2001WO-US000719.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX Kolterman OG, Young AA;
XX XX WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX XX levels, and treating heart disease and dyslipidemia.
XX XX Example 127; Page 113; 161pp; English.
XX XX The patent discloses a method for modulating plasma or postprandial
XX XX triglyceride and other lipid levels by administering extendin or an
XX XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX XX suppress the secretion of glucagon. Extendin and its agonists have a
XX XX significant effect on the reduction of blood serum triglyceride
XX XX concentrations. They are used to treat coronary heart disease and
XX XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX XX present peptide sequence is an agonist of extendin
XX XX Sequence 28 AA;
XX XX


```

CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX
SQ Sequence 28 AA;

AAE08470 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
Found using 'seq5' (mohamed337.key)

1 1 -----|
   1 ACDGFTSDASKQLEERAVRLFIEFLKN 28
-----|
1 match found in sequence:
aae08471; Extendin agonist peptide #116.
(from "seq5ags.pep")
TOIG of: aae08471 check: 810 from: 1 to: 28

ID AAE08471 standard; peptide; 28 AA.
AC AAE08471;
XX
XX
DT 01-NOV-2001 (first entry)
XX
XX
DE Extendin agonist peptide #116.
XX
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Misc-difference 10 /note= "Pentyl glycine"
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX
PN WO200151078-A1.
XX
XX
PD 19-JUL-2001.
XX
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Kolterman OG, Young AA;
XX
XX
DR WPI; 2001-514422/56.
XX
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX
PS Example 122; Page 110; 161pp; English.
XX
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX
SQ Sequence 28 AA;

AAE08471 Length: 28 February 4, 2005 13:32 Type: P Check: 810 ..
Found using 'seq5' (mohamed337.key)
-----|

```

```

XX AAE08467;
AC 01-NOV-2001 (first entry)
DT
DE Exendin agonist peptide #112.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 118; Page 108; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
SQ
AAE08467 Length: 28 February 4, 2005 13:32 Type: P Check: 699 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSELKQEEBAVRLFIEWLKN 28
-----
1 match found in sequence:
aae08468 ; Exendin agonist peptide #113.
(from "seq5ags.pep")
TOIG of: aae08468 check: 260 from: 1 to: 28

ID AAE08468 standard; peptide; 28 AA.
XX
AC AAE08468;
XX
XX 01-NOV-2001 (first entry)
XX
XX Exendin agonist peptide #113.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 118; Page 108; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
SQ
AAE08467 Length: 28 February 4, 2005 13:32 Type: P Check: 699 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSELKQEEBAVRLFIEWLKN 28
-----
1 match found in sequence:
aae08468 ; Exendin agonist peptide #113.
(from "seq5ags.pep")
TOIG of: aae08468 check: 260 from: 1 to: 28

ID AAE08468 standard; peptide; 28 AA.
XX
AC AAE08468;
XX
XX 01-NOV-2001 (first entry)
XX
XX Exendin agonist peptide #113.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 118; Page 108; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
SQ

```

```

FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
PT
XX Example 119; Page 109; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
SQ
AAE08468 Length: 28 February 4, 2005 13:32 Type: P Check: 260 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSELKQEEBAVRLFIEWLKN 28
-----
1 match found in sequence:
aae08469 ; Exendin agonist peptide #114.
(from "seq5ags.pep")
TOIG of: aae08469 check: 580 from: 1 to: 28

ID AAE08469 standard; peptide; 28 AA.
XX
AC AAE08469;
XX
XX 01-NOV-2001 (first entry)
XX
XX Exendin agonist peptide #114.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX

```

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
SQ

AAE08464 Length: 28 February 4, 2005 13:32 Type: P Check: 107 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTADLSKQLEEEAVRLFIEFLKN 28
1

1 match found in sequence:
aae08465 ; Extendin agonist peptide #110.
(from "seq5ags.pep")
TOIG of: aae08465 check: 663 from: 1 to: 28

ID AAE08465 standard; peptide; 28 AA.
XX
AC AAE08465;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #110.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 116; Page 107; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
SQ

AAE08465 Length: 28 February 4, 2005 13:32 Type: P Check: 663 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTADLSKQLEEEAVRLFIEFLKN 28
1

1 match found in sequence:
aae08465 ; Extendin agonist peptide #110.
(from "seq5ags.pep")
TOIG of: aae08465 check: 663 from: 1 to: 28

ID AAE08465 standard; peptide; 28 AA.
XX
AC AAE08465;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #110.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 116; Page 107; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
SQ

Found using 'seq5' (mohamed337.key)

1 AGDGTFTSALSQKEEAVRLFIEFLKN 28
1

1 match found in sequence:
aae08466 ; Extendin agonist peptide #111.
(from "seq5ags.pep")
TOIG of: aae08466 check: 224 from: 1 to: 28

ID AAE08466 standard; peptide; 28 AA.
XX
AC AAE08466;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #111.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 117; Page 107; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
SQ

AAE08466 Length: 28 February 4, 2005 13:32 Type: P Check: 224 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSALSQKEEAVRLFIEFLKN 28
1

1 match found in sequence:
aae08467 ; Extendin agonist peptide #112.
(from "seq5ags.pep")
TOIG of: aae08467 check: 699 from: 1 to: 28

ID AAE08467 standard; peptide; 28 AA.
XX
AC AAE08467;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #112.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 117; Page 107; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX Sequence 28 AA;
SQ

```
KW diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX
XX Key Location/Qualifiers
PH Modified-site 28
FT /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
XX PN 19-JUL-2001.
XX
XX PD
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX PS Example 113; Page 105; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX SQ Sequence 28 AA;
XX
AAE08462 Length: 28 February 4, 2005 13:32 Type: P Check: 244 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTADLSKQLEERAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aae08463 ; Extendin agonist peptide #108.
(from "seq5ags.pep")
TOIG of: aae08463 check: 546 from: 1 to: 28
-----
ID AAE08463 standard; peptide; 28 AA.
XX
XX AC AAE08464;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #108.
XX
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX PH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX PS Example 115; Page 106; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX SQ Sequence 28 AA;
XX
AAE08463 Length: 28 February 4, 2005 13:32 Type: P Check: 546 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTADLSKQMBEERAVRLFIEWLKN 28
1
-----
1 match found in sequence:
aae08464 ; Extendin agonist peptide #109.
(from "seq5ags.pep")
TOIG of: aae08464 check: 107 from: 1 to: 28
-----
ID AAE08464 standard; peptide; 28 AA.
XX
XX AC AAE08464;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #109.
XX
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX PH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX PS Example 115; Page 106; 161pp; English.
XX
```

```
SQ Sequence 28 AA;
AAE08459 Length: 28 February 4, 2005 13:32 Type: P Check: 798
Found using 'seq5' (mohamed337.key)
-----|-----|
1 AGDGTXTSDLSKQMEEEAVRLFIEWLKN 28
-----|-----|
1 match found in sequence:
aee08460 ; Exendin agonist peptide #105.
(from "seq5ags.pep")
TOIG of: aae08460 check: 359 from: 1 to: 28

ID AAE08460 standard; peptide; 28 AA.
XX AC AAE08460;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #105.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 6 /note= "Naphthylalanine"
XX FT Modified-site 28
XX FT Modified-site /note= "C-terminal amide"
XX PN WO200151078-A1.
XX XX
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PT
XX DR WPI; 2001-514422/56.
XX XX
XX PN WO200151078-A1.
XX XX
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PT
XX DR WPI; 2001-514422/56.
XX XX
XX PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT
XX PS Example 111; Page 104; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
AAE08460 Length: 28 February 4, 2005 13:32 Type: P Check: 359
Found using 'seq5' (mohamed337.key)
-----|-----|
1 AGDGTXTSDLSKQLEEEAVRLFIEFLKN 28
-----|-----|
1 match found in sequence:
```

```
aae08461 ; Exendin agonist peptide #106.
(from "seq5ags.pep")
TOIG of: aae08461 check: 683 from: 1 to: 28

ID AAE08461 standard; peptide; 28 AA.
XX AC AAE08461;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #106.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX XX
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PT
XX DR WPI; 2001-514422/56.
XX XX
XX PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT
XX PS Example 112; Page 104; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
AAE08461 Length: 28 February 4, 2005 13:32 Type: P Check: 683
Found using 'seq5' (mohamed337.key)
-----|-----|
1 AGDGTFTSDLSKQMEEEAVRLFIEWLKN 28
-----|-----|
1 match found in sequence:
aee08462 ; Exendin agonist peptide #107.
(from "seq5ags.pep")
TOIG of: aae08462 check: 244 from: 1 to: 28

ID AAE08462 standard; peptide; 28 AA.
XX AC AAE08462;
XX XX
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #107.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX XX
```



```

PP 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 108; Page 102; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

AAE08457 Length: 28 February 4, 2005 13:32 Type: P Check: 595 ..
Found using 'seq5' (mohamed337.key)

1 AGDGAFSTDSLKQMBEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aee08458 ; Extendin agonist peptide #103.
(from "seq5ags.pep")
TOIG of: aae08458 check: 156 from: 1 to: 28

ID AAE08458 standard; peptide; 28 AA.
XX
XX AC AAE08458;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #103.
XX
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX FT Modified-site 28 /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 110; Page 103; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

AAE08457 Length: 28 February 4, 2005 13:32 Type: P Check: 595 ..
Found using 'seq5' (mohamed337.key)

1 AGDGAFSTDSLKQMBEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aee08458 ; Extendin agonist peptide #103.
(from "seq5ags.pep")
TOIG of: aae08458 check: 156 from: 1 to: 28

ID AAE08458 standard; peptide; 28 AA.
XX
XX AC AAE08458;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #103.
XX
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX FT Modified-site 28 /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 110; Page 103; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

```

```

PS Example 109; Page 103; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

AAE08458 Length: 28 February 4, 2005 13:32 Type: P Check: 156 ..
Found using 'seq5' (mohamed337.key)

1 AGDGAFSTDSLKQMBEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aee08459 ; Extendin agonist peptide #104.
(from "seq5ags.pep")
TOIG of: aae08459 check: 798 from: 1 to: 28

ID AAE08459 standard; peptide; 28 AA.
XX
XX AC AAE08459;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #104.
XX
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 6 /note= "Naphthylalanine"
XX FT Modified-site 28 /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 110; Page 103; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX Sequence 28 AA;
SQ

```

```
1 match found in sequence:
aae08455 ; Exendin agonist peptide #100.
(from "seq5ags.pep")
TOIG of: aae08455 check: 690 from: 1 to: 28

ID AAE08455 standard; peptide; 28 AA.
XX
AC AAE08455;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #100.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 106; Page 101; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08456 Length: 28 February 4, 2005 13:32 Type: P Check: 251 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAVRLFIEFLKN
1 28
-----
1 match found in sequence:
aae08457 ; Exendin agonist peptide #102.
(from "seq5ags.pep")
TOIG of: aae08457 check: 595 from: 1 to: 28

ID AAE08457 standard; peptide; 28 AA.
XX
AC AAE08457;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #102.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
```

```
1 match found in sequence:
aae08455 ; Exendin agonist peptide #100.
(from "seq5ags.pep")
TOIG of: aae08455 check: 690 from: 1 to: 28

ID AAE08455 standard; peptide; 28 AA.
XX
AC AAE08455;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #100.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
PS Example 106; Page 101; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08455 Length: 28 February 4, 2005 13:32 Type: P Check: 690 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAVRLFIEFLKN
1 28
-----
1 match found in sequence:
aae08456 ; Exendin agonist peptide #101.
(from "seq5ags.pep")
TOIG of: aae08456 check: 251 from: 1 to: 28

ID AAE08456 standard; peptide; 28 AA.
XX
AC AAE08456;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #101.
XX
```

DR WPI; 2001-514422/56.
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 103; Page 99; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX Sequence 28 AA;
SQ
AAE08452 Length: 28 February 4, 2005 13:32 Type: P Check: 590 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTSDASKQMBEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aae08453 ; Exendin agonist peptide #98.
(from "seq5ags.pep")
TOIG of: aae08453 check: 681 from: 1 to: 28

ID AAE08453 standard; peptide; 28 AA.
XX
AC AAE08453;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #98.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 104; Page 100; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX Sequence 28 AA;
SQ
AAE08453 Length: 28 February 4, 2005 13:32 Type: P Check: 681 ..
Found using 'seq5' (mohamed337.key)
1 AAEFTTSDLSKQMBEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aae08454 ; Exendin agonist peptide #99.
(from "seq5ags.pep")
TOIG of: aae08454 check: 242 from: 1 to: 28

ID AAE08454 standard; peptide; 28 AA.
XX
AC AAE08454;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #99.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
PN Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 105; Page 100; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX Sequence 28 AA;
SQ
AAE08454 Length: 28 February 4, 2005 13:32 Type: P Check: 242 ..
Found using 'seq5' (mohamed337.key)
1 AAEFTTSDLSKQMBEEAVRLFIEFLKN 28
-----|

CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of extendin
 XX
 SQ Sequence 28 AA;

AAE08447 Length: 28 February 4, 2005 13:32 Type: P Check: 234 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGTFTSALSKQEEAVRLFIEFLKN 28

 1 match found in sequence:
 aae08448 ; Extendin agonist peptide #93.
 (from "seq5ags.pep")
 TOIG of: aae08448 check: 693 from: 1 to: 28

ID AAE08448 standard; peptide; 28 AA.

XX
 AC AAE08448;

XX
 DT 01-NOV-2001 (first entry)

XX
 DE Extendin agonist peptide #93.

XX
 KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.

XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "C-terminal amide"

XX
 PN WO200151078-A1.

XX
 PD 19-JUL-2001.

XX
 PF 09-JAN-2001; 2001WO-US000719.

XX
 PR 10-JAN-2000; 2000US-0175365P.

XX
 PA (AMYL-) AMYLIN PHARM INC.

XX
 PI Kolterman OG, Young AA;

XX
 DR WPI; 2001-514422/56.

XX
 PT Use of extendin and extendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidaemia.

XX
 PS Example 99; Page 97; 161pp; English.

XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of extendin

XX
 SQ Sequence 28 AA;

AAE08448 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGEFTSLSKQEEAVRLFIEFLKN 28

 1 match found in sequence:
 aae08449 ; Extendin agonist peptide #94.
 (from "seq5ags.pep")
 TOIG of: aae08449 check: 688 from: 1 to: 28

ID AAE08449 standard; peptide; 28 AA.

XX
 AC AAE08449;

XX
 DT 01-NOV-2001 (first entry)

XX
 DE Extendin agonist peptide #94.

XX
 KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.

XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "C-terminal amide"

XX
 PN WO200151078-A1.

XX
 PD 19-JUL-2001.

XX
 PF 09-JAN-2001; 2001WO-US000719.

XX
 PR 10-JAN-2000; 2000US-0175365P.

XX
 PA (AMYL-) AMYLIN PHARM INC.

XX
 PI Kolterman OG, Young AA;

XX
 DR WPI; 2001-514422/56.

XX
 PT Use of extendin and extendin agonist compounds for modulating triglyceride
 PT levels, and treating heart disease and dyslipidaemia.

XX
 PS Example 100; Page 97; 161pp; English.

XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of extendin

XX
 SQ Sequence 28 AA;

AAE08449 Length: 28 February 4, 2005 13:32 Type: P Check: 688 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGGTFTSLSKQEEAVRLFIEFLKN 28

 1 match found in sequence:
 aae08450 ; Extendin agonist peptide #95.
 (from "seq5ags.pep")
 TOIG of: aae08450 check: 676 from: 1 to: 28

ID AAE08450 standard; peptide; 28 AA.

XX
 AC AAE08450;

```
OS Synthetic.
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT XX
XX WO200151078-A1.
XX PN
XX 19-JUL-2001.
XX PD
XX
XX PF
XX 09-JAN-2001; 2001WO-US000719.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT
XX Example 96; Page 95; 161pp; English.
XX PS
XX The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 28 AA;
XX
AAE08445 Length: 28 February 4, 2005 13:32 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGAGTFTSDLSKQLEBEAVRLFIEFLKN 28
-----
1 match found in sequence:
aae08446 ; Extendin agonist peptide #91.
(from "seq5ags.pep")
TOIG of: aae08446 check: 237 from: 1 to: 28
-----
ID AAE08446 standard; peptide; 28 AA.
XX AC
XX AAE08446;
XX AC
XX 01-NOV-2001 (first entry)
XX DT
XX Extendin agonist peptide #91.
XX DE
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX OS
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT XX
XX WO200151078-A1.
XX PN
XX 19-JUL-2001.
XX PD
XX
XX PF
XX 09-JAN-2001; 2001WO-US000719.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT
XX Example 96; Page 95; 161pp; English.
XX PS
XX The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 28 AA;
XX
AAE08446 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEATFTSDLSKQLEBEAVRLFIEFLKN 28
-----
1 match found in sequence:
aae08447 ; Extendin agonist peptide #92.
(from "seq5ags.pep")
TOIG of: aae08447 check: 234 from: 1 to: 28
-----
ID AAE08447 standard; peptide; 28 AA.
XX AC
XX AAE08447;
XX AC
XX 01-NOV-2001 (first entry)
XX DT
XX Extendin agonist peptide #92.
XX DE
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX OS
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT XX
XX WO200151078-A1.
XX PN
XX 19-JUL-2001.
XX PD
XX
XX PF
XX 09-JAN-2001; 2001WO-US000719.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT
XX Example 98; Page 96; 161pp; English.
XX PS
XX The patent discloses a method for modulating plasma or postprandial
XX CC
```

```
-----|
1  HGEGFTSDASKQMEBEAVRLFIEWLKNG
   1 28

-----|
1 match found in sequence:
aee08443 ; Exendin agonist peptide #88.
(from "seq5ags.pep")
TOIG of: aae08443 check: 4015 from: 1 to: 37

ID AAE08443 standard; peptide; 37 AA.
XX
AC AAE08443;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #88.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "Homoproline"
FT Modified-site 36 /note= "Homoproline"
FT Modified-site 37 /note= "Homoproline; C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
PT Example 92; Page 92; 161pp; English.
XX
PS The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
SQ Sequence 37 AA;

AAE08443 Length: 37 February 4, 2005 13:32 Type: P Check: 4015 ..
Found using 'seq5' (mohamed337.key)

-----|
1  HGEGFTSDASKQMEBEAVRLFIEWLKNGXSGSAXX
   1 28

-----|
1 match found in sequence:
aee08444 ; Exendin agonist peptide #89.
(from "seq5ags.pep")

ID AAE08444 standard; peptide; 28 AA.
XX
AC AAE08444;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #89.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PN Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
PT Example 95; Page 94; 161pp; English.
XX
PS The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08444 Length: 28 February 4, 2005 13:32 Type: P Check: 254 ..
Found using 'seq5' (mohamed337.key)

-----|
1  AGEGFTSDLSKQLEBEAVRLFIEFLKN
   1 28

-----|
1 match found in sequence:
aee08445 ; Exendin agonist peptide #90.
(from "seq5ags.pep")
TOIG of: aae08445 check: 249 from: 1 to: 28

ID AAE08445 standard; peptide; 28 AA.
XX
AC AAE08445;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #90.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
```

```

PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX PS Example 89; Page 90; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX SQ Sequence 28 AA;
XX
AAE08440 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)
1 1 HGGTFTSDLSKQLEEEAVRLFIIDFLKN 28
-----
1 match found in sequence:
aae08441 ; Extendin agonist peptide #86.
(from "seq5ags.pep")
TOIG of: aae08441 check: 2215 from: 1 to: 33
-----
ID AAE08441 standard; peptide; 33 AA.
XX
XX AC AAE08441;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #86.
XX
XX EX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 33 /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX PS Example 90; Page 91; 161pp; English.
XX

```

```

CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX SQ Sequence 33 AA;
XX
AAE08441 Length: 33 February 4, 2005 13:32 Type: P Check: 2215 ..
Found using 'seq5' (mohamed337.key)
1 1 HGGTFTSDASKQLEEEAVRLFIEFLKNGGPSS 28
-----
1 match found in sequence:
aae08442 ; Extendin agonist peptide #87.
(from "seq5ags.pep")
TOIG of: aae08442 check: 2649 from: 1 to: 29
-----
ID AAE08442 standard; peptide; 29 AA.
XX
XX AC AAE08442;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Extendin agonist peptide #87.
XX
XX EX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 29 /note= "C-terminal amide"
XX
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX PS Example 91; Page 91; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of extendin
XX
XX SQ Sequence 29 AA;
XX
AAE08442 Length: 29 February 4, 2005 13:32 Type: P Check: 2649 ..
Found using 'seq5' (mohamed337.key)

```



```
XX AAE08438;
XX AC
XX 01-NOV-2001 (first entry)
XX DT
XX DE Exendin agonist peptide #83.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS
XX Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 22 /note= "Naphthylalanine"
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PS 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 87; Page 89; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
XX AAE08438 Length: 28 February 4, 2005 13:32 Type: P Check: 657 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTSDLSKQLBEEAVRLXIEPLKN 28
-----
1 match found in sequence:
aae08439; Exendin agonist peptide #84.
(from "seq5ags.pep")
TOIG of: aae08439 check: 1045 from: 1 to: 28
ID AAE08439 standard; peptide; 28 AA.
XX AC
XX AAE08439;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #84.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS
XX Synthetic.
```

```
XX Key Location/Qualifiers
XX FT Modified-site 23 /note= "Tertiary-butylglycine"
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 88; Page 90; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
XX AAE08439 Length: 28 February 4, 2005 13:32 Type: P Check: 1045 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTSDLSKQMBEEAVRLFEXWLKN 28
-----
1 match found in sequence:
aae08440; Exendin agonist peptide #85.
(from "seq5ags.pep")
TOIG of: aae08440 check: 237 from: 1 to: 28
ID AAE08440 standard; peptide; 28 AA.
XX AC
XX AAE08440;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #85.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS
XX Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
```

CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of extendin
 XX Sequence 28 AA;
 SQ
 AAE08435 Length: 28 February 4, 2005 13:32 Type: P Check: 701 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSLSKQMEAEVRLFIWLKN 28
 1 match found in sequence:
 aae08436 ; Extendin agonist peptide #81.
 (from "seq5ags.pep")
 TOIG of: aae08436 check: 649 from: 1 to: 28 ..
 ID AAE08436 standard; peptide; 28 AA.
 XX
 AC AAE08436;
 XX
 DT 01-NOV-2001 (first entry)
 XX
 DE Extendin agonist peptide #81.
 XX
 KW Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT Modified-site /note= "C-terminal amide"
 FT
 FT
 XX WO200151078-A1.
 XX
 PD 19-JUL-2001.
 XX
 PF 09-JAN-2001; 2001WO-US000719.
 XX
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Kolterman OG, Young AA;
 XX WPI; 2001-514422/56.
 XX
 XX Use of extendin and extendin agonist compounds for modulating triglyceride
 XX levels, and treating heart disease and dyslipidaemia.
 XX Example 85; Page 88; 161pp; English.
 XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of extendin
 XX Sequence 28 AA;
 SQ
 AAE08436 Length: 28 February 4, 2005 13:32 Type: P Check: 649 ..
 Found using 'seq5' (mohamed337.key)

1 HEGGFTSLSKQMAEAEVRLFIWLKN 28
 1 match found in sequence:
 aae08437 ; Extendin agonist peptide #82.
 (from "seq5ags.pep")
 TOIG of: aae08437 check: 381 from: 1 to: 28
 ID AAE08437 standard; peptide; 28 AA.
 XX
 AC AAE08437;
 XX
 DT 01-NOV-2001 (first entry)
 XX
 DE Extendin agonist peptide #82.
 XX
 KW Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
 KW diuretic; coronary heart disease; dyslipidaemia.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 10
 FT Modified-site /note= "Pentylglycine"
 FT Modified-site 28
 FT Modified-site /note= "C-terminal amide"
 FT
 XX WO200151078-A1.
 XX
 PD 19-JUL-2001.
 XX
 PF 09-JAN-2001; 2001WO-US000719.
 XX
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Kolterman OG, Young AA;
 XX WPI; 2001-514422/56.
 XX
 XX Use of extendin and extendin agonist compounds for modulating triglyceride
 XX levels, and treating heart disease and dyslipidaemia.
 XX Example 86; Page 89; 161pp; English.
 XX
 CC The patent discloses a method for modulating plasma or postprandial
 CC triglyceride and other lipid levels by administering extendin or an
 CC extendin agonist. Extendins have inotropic and diuretic effects. They
 CC suppress the secretion of glucagon. Extendin and its agonists have a
 CC significant effect on the reduction of blood serum triglyceride
 CC concentrations. They are used to treat coronary heart disease and
 CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
 CC present peptide sequence is an agonist of extendin
 XX Sequence 28 AA;
 SQ
 AAE08437 Length: 28 February 4, 2005 13:32 Type: P Check: 381 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSLSKQMEAEVRLFIWLKN 28
 1 match found in sequence:
 aae08438 ; Extendin agonist peptide #83.
 (from "seq5ags.pep")
 TOIG of: aae08438 check: 657 from: 1 to: 28
 ID AAE08438 standard; peptide; 28 AA.

```
XX AC ADL66135;
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 15.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX PS WPI; 2004-042706/04.
XX KW Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 15; 173pp; English.
XX KW The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66135 Length: 39 February 4, 2005 13:32 Type: P Check: 9678 ..
Found using 'seq5' (mohamed337.key)
1 HGEGTYSDSLKQMEAEAVRLFIEWLKNGPSSGAPPPS
28
1 match found in sequence:
adl66136 ; Exendin agonist peptide, SEQ ID No 16.
(from "seq5ags.pep")
TOIG of: adl66136 check: 9563 from: 1 to: 39
ID ADL66136 standard; peptide; 39 AA.
XX AC ADL66136;
XX DT 20-MAY-2004 (first entry)
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
```

```
DE Exendin agonist peptide, SEQ ID No 16.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX PS WPI; 2004-042706/04.
XX KW Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 16; 173pp; English.
XX KW The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66136 Length: 39 February 4, 2005 13:33 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)
1 HGEGTSSDSLKQMEAEAVRLFIEWLKNGPSSGAPPPS
28
1 match found in sequence:
adl66137 ; Exendin agonist peptide, SEQ ID No 17.
(from "seq5ags.pep")
TOIG of: adl66137 check: 9571 from: 1 to: 39
ID ADL66137 standard; peptide; 39 AA.
XX AC ADL66137;
XX DT 20-MAY-2004 (first entry)
XX KW Exendin agonist peptide, SEQ ID No 17.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
```

1 YGEGTFTSDLSKQMEAEAVRLFIEWLKNGPSSGAPPPS
1
28

1 match found in sequence:

adl66133 ; Exendin agonist peptide, SEQ ID No 13.
(from "seq5ags.pep")
TOIG of: adl66133 check: 9804 from: 1 to: 39

ID ADL66133 standard; peptide; 39 AA.

XX AC ADL66133;

XX XX 20-MAY-2004 (first entry)

XX XX Exendin agonist peptide, SEQ ID No 13.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX XX WO2003099314-A1.

XX XX 04-DEC-2003.

XX XX 28-MAY-2003; 2003WO-US016699.

XX XX 28-MAY-2002; 2002US-00157224.

XX XX (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX XX WPI; 2004-042706/04.

XX XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 13; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipidemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66133 Length: 39 February 4, 2005 13:33 Type: P Check: 9804 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQMEAEAVRLFIEWLKNGPSSGAPPPY
1
28

1 match found in sequence:

adl66134 ; Exendin agonist peptide, SEQ ID No 14.
(from "seq5ags.pep")
TOIG of: adl66134 check: 9567 from: 1 to: 39

ID ADL66134 standard; peptide; 39 AA.

XX AC ADL66134;

XX XX 20-MAY-2004 (first entry)

XX XX Exendin agonist peptide, SEQ ID No 14.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX XX WO2003099314-A1.

XX XX 04-DEC-2003.

XX XX 28-MAY-2003; 2003WO-US016699.

XX XX 28-MAY-2002; 2002US-00157224.

XX XX (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX XX WPI; 2004-042706/04.

XX XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 14; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipidemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66134 Length: 39 February 4, 2005 13:33 Type: P Check: 9567 ..
Found using 'seq5' (mohamed337.key)

1 HGDGFTFTSDLSKQMEAEAVRLFIEWLKNGPSSGAPPPS
1
28

1 match found in sequence:

adl66135 ; Exendin agonist peptide, SEQ ID No 15.
(from "seq5ags.pep")
TOIG of: adl66135 check: 9678 from: 1 to: 39

ID ADL66135 standard; peptide; 39 AA.

CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66130 Length: 39 February 4, 2005 13:33 Type: P Check: 9556 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLSEAEAVRLFIEWLKNGGPGSSGAPPPS
1 28
-----|-----|

1 match found in sequence:
adl66131 ; Exendin agonist peptide, SEQ ID No 11.
(from "seq5agr.pep")
TOIG of: adl66131 check: 9145 from: 1 to: 39

ID ADL66131 standard; peptide; 39 AA.

XX AC ADL66131;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 11.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 11; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66131 Length: 39 February 4, 2005 13:33 Type: P Check: 9145 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMBEAEAVRLFIEFLKNGGPGSSGAPPPS
1 28
-----|-----|

1 match found in sequence:
adl66132 ; Exendin agonist peptide, SEQ ID No 12.
(from "seq5agr.pep")
TOIG of: adl66132 check: 9587 from: 1 to: 39

ID ADL66132 standard; peptide; 39 AA.

XX AC ADL66132;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 12.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 12; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66132 Length: 39 February 4, 2005 13:33 Type: P Check: 9587 ..
Found using 'seq5' (mohamed337.key)

CC The invention relates to a novel pharmaceutical composition comprising an
 CC exendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66128 Length: 28 February 4, 2005 13:33 Type: P Check: 151 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLAIEFLKN
 1
 28

 1 match found in sequence:
 adl66129 ; Exendin agonist peptide, SEQ ID No 9.
 (from "seqSags.pep")
 TOIG of: adl66129 check: 9131 from: 1 to: 39

ID ADL66129 standard; peptide; 39 AA.
 XX
 AC ADL66129;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Exendin agonist peptide, SEQ ID No 9.
 XX
 KW exendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
 FH Modified-site 39
 FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 9; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC exendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66129 Length: 39 February 4, 2005 13:32 Type: P Check: 9131 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGPSSGAPPPS
 1
 28

 1 match found in sequence:
 adl66130 ; Exendin agonist peptide, SEQ ID No 10.
 (from "seqSags.pep")
 TOIG of: adl66130 check: 9556 from: 1 to: 39

ID ADL66130 standard; peptide; 39 AA.

XX ADL66130;

XX 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 10.

XX exendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
 FH Modified-site 39
 FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose .
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 10; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC exendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or

PI Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 6; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX Sequence 30 AA;
 SQ
 ADL66126 Length: 30 February 4, 2005 13:32 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKG
 28
 -----|-----
 1 match found in sequence:
 adl66127; Extendin agonist peptide, SEQ ID No 7.
 (from "seq5ags.pep")
 TOIG of: adl66127 check: 4889 from: 1 to: 30
 ID ADL66127 standard; peptide; 30 AA.
 XX
 AC ADL66127;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 7.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 30
 FT /note= "C-terminal amide"
 XX
 PN WO2003099314-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 28-MAY-2003; 2003WO-US016699.
 XX
 PR 28-MAY-2002; 2002US-00157224.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young AA, Kolterman OG;
 XX
 DR WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 7; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX Sequence 30 AA;
 SQ
 ADL66127 Length: 30 February 4, 2005 13:33 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKG
 28
 -----|-----
 1 match found in sequence:
 adl66128; Extendin agonist peptide, SEQ ID No 8.
 (from "seq5ags.pep")
 TOIG of: adl66128 check: 151 from: 1 to: 28
 ID ADL66128 standard; peptide; 28 AA.
 XX
 AC ADL66128;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 8.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "C-terminal amide"
 XX
 PN WO2003099314-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 28-MAY-2003; 2003WO-US016699.
 XX
 PR 28-MAY-2002; 2002US-00157224.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young AA, Kolterman OG;
 XX
 DR WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 8; 173pp; English.
 XX

```

FH Key          Location/Qualifiers
FT Modified-site 39
FT FT           /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 1; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
XX
ADL66122 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)
1
1 HSDGTFSDLSKQMEAEAVRLFTEWLKNGGSPSGAPPPS
28
1 match found in sequence:
adl66123 ; Extendin agonist peptide, SEQ ID No 2.
(from "seq5ags.pep")
TOIG of: adl66123 check: 9570 from: 1 to: 39
-----
ID ADL66123 standard; peptide; 39 AA.
XX
XX ADL66123;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 2.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular; gila monster.
XX
XX Heloderma suspectum.
XX
XX Key          Location/Qualifiers
FH Modified-site 39
FT FT           /note= "C-terminal amide"
XX
XX WO2003099314-A1.

```

```

XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 2; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
XX
ADL66123 Length: 39 February 4, 2005 13:33 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
1
1 HSGGTFSDLSKQMEAEAVRLFTEWLKNGGSPSGAPPPS
28
1 match found in sequence:
adl66126 ; Extendin agonist peptide, SEQ ID No 6.
(from "seq5ags.pep")
TOIG of: adl66126 check: 4889 from: 1 to: 30
-----
ID ADL66126 standard; peptide; 30 AA.
XX
XX ADL66126;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 6.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX

```


CC The invention relates to a novel pharmacologically active peptide
 CC conjugate having a reduced tendency towards enzymatic cleavage comprises
 CC X and Z, where: (a) X is a pharmacologically active peptide sequence; and
 CC (b) Z is a stabilising peptide sequence of 4-20 amino acid units
 CC covalently bound to X, where each amino acid unit in the stabilizing
 CC peptide sequence, Z being selected from Ala, Leu, Ser, Thr, Tyr, Asn,
 CC Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of formula -
 CC NH-C(R1)(R2)-C(=O)- (I), where: R1 and R2 are H, 1-6C alkyl, phenyl, and
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenyl-methyl are optionally
 CC substituted with 1-3 substituents selected from 1-6C-alkyl, 2-6C-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy, or R1 and R2
 CC 2 together with the C atom to which they are bound form a cyclopentyl,
 CC cyclohexyl or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid; the ratio between the half-life of the peptide
 CC conjugate and the half-life of the corresponding active peptide sequence,
 CC X, when treated with carboxypeptidase A or leucine aminopeptidase in
 CC about 50 mM phosphate buffer solution at about pH 7.4 and about 37 deg C
 CC or in serum or plasma is at least about 2 (preferably at least about 10),
 CC or when the pharmacologically active peptide X is not orally absorbed,
 CC the conjugate is adsorbed, or a salt, with the proviso that the
 CC pharmacologically active peptide conjugate is not selected from sequences
 CC (ADI24837)-(ADI24841). The peptide conjugates can be used for treating
 CC e.g. pain, HIV, cancer, diabetes, incontinence, hypertension, amnesia,
 CC Alzheimer's disease, fever, depression, sex hormone regulation, eating
 CC disorders, schizophrenia, osteoporosis or insomnia. They can also be used
 CC for treating e.g. CNS disorders and as contraceptives. The conjugated
 CC peptides are less susceptible to degradation by proteases compared to the
 CC corresponding free pharmacologically active peptides. This sequence
 CC represents a pharmacologically active peptide as the X part of the
 CC peptide of the invention.

XX SQ Sequence 39 AA;

ADI24854 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 HGEFTFTSLSKQMEAEAVRLFIEWLKNGPSSGAPPPS
 1 28

 1 match found in sequence:
 adi24855 ; Exendin-3 as active moiety for pharmacologically active peptide.
 (from "seq5ags.pep")
 TOIG of: adi24855 check: 9591 from: 1 to: 39

ID ADI24855 standard; peptide; 39 AA.

XX AC ADI24855;

XX DT 15-APR-2004 (first entry)

XX DE Exendin-3 as active moiety for pharmacologically active peptide.

XX KW pharmacologically active peptide conjugate; enzymatic cleavage; pain;
 KW HIV; cancer; diabetes; incontinence; hypertension; amnesia;
 KW Alzheimer's disease; fever; depression; sex hormone regulation;
 KW eating disorder; schizophrenia; osteoporosis; insomnia;
 KW central nervous system disorder; contraceptive.

XX OS Synthetic.

XX PN WO9946283-A1.

XX PD 16-SEP-1999.

XX PF 09-MAR-1999; 99WO-DK000118.

XX PR 09-MAR-1998; 98DK-00000317.

XX PA (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD;

XX WPI; 1999-561659/47.

XX New peptide conjugates used for treating, e.g. pain, HIV, depression,
 PT schizophrenia, osteoporosis or insomnia.

XX Claim 24; Page 91; 113pp; English.

XX The invention relates to a novel pharmacologically active peptide
 CC conjugate having a reduced tendency towards enzymatic cleavage comprises
 CC X and Z, where: (a) X is a pharmacologically active peptide sequence; and
 CC (b) Z is a stabilising peptide sequence of 4-20 amino acid units
 CC covalently bound to X, where each amino acid unit in the stabilizing
 CC peptide sequence, Z being selected from Ala, Leu, Ser, Thr, Tyr, Asn,
 CC Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of formula -
 CC NH-C(R1)(R2)-C(=O)- (I), where: R1 and R2 are H, 1-6C alkyl, phenyl, and
 CC phenyl-methyl, where 1-6C-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenyl-methyl are optionally
 CC substituted with 1-3 substituents selected from 1-6C-alkyl, 2-6C-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy, or R1 and R2
 CC 2 together with the C atom to which they are bound form a cyclopentyl,
 CC cyclohexyl or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid; the ratio between the half-life of the peptide
 CC conjugate and the half-life of the corresponding active peptide sequence,
 CC X, when treated with carboxypeptidase A or leucine aminopeptidase in
 CC about 50 mM phosphate buffer solution at about pH 7.4 and about 37 deg C
 CC or in serum or plasma is at least about 2 (preferably at least about 10),
 CC or when the pharmacologically active peptide X is not orally absorbed,
 CC the conjugate is adsorbed, or a salt, with the proviso that the
 CC pharmacologically active peptide conjugate is not selected from sequences
 CC (ADI24837)-(ADI24841). The peptide conjugates can be used for treating
 CC e.g. pain, HIV, cancer, diabetes, incontinence, hypertension, amnesia,
 CC Alzheimer's disease, fever, depression, sex hormone regulation, eating
 CC disorders, schizophrenia, osteoporosis or insomnia. They can also be used
 CC for treating e.g. CNS disorders and as contraceptives. The conjugated
 CC peptides are less susceptible to degradation by proteases compared to the
 CC corresponding free pharmacologically active peptides. This sequence
 CC represents a pharmacologically active peptide as the X part of the
 CC peptide of the invention.

XX SQ Sequence 39 AA;

ADI24855 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 HSDGTFSTLSKQMEAEAVRLFIEWLKNGPSSGAPPPS
 1 28

 1 match found in sequence:

adl66122 ; Exendin agonist peptide, SEQ ID No 1.
 (from "seq5ags.pep")
 TOIG of: adl66122 check: 9591 from: 1 to: 39

ID ADL66122 standard; peptide; 39 AA.

XX AC ADL66122;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 1.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular; mexican beaded lizard.

XX OS Heloderma horridum.

Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMEBAVRLFTIEWLKNKGX
28

1 match found in sequence:
adh73029 ; Glucagon like peptide-1 related exendin peptide 1.

(from "seq5ags.pep")
TOIG of: adh73029 check: 7617 from: 1 to: 31

ID ADH73029 standard; peptide; 31 AA.

AC ADH73029;

DT 25-MAR-2004 (first entry)

DE Glucagon like peptide-1 related exendin peptide 1.

KW cardiac disease; cardiovascular disease; diabetic patient;
KW non-diabetic patient; glucagon like peptide-1; GLP 1; cardiant;
KW cardiovascular-gen; antiarrhythmic; antianginal; antiarteriosclerotic;
KW vasotropic; hypotensive; glucose metabolism;
KW cardiovascular haemodynamic regulator; left ventricular hypertrophy;
KW coronary artery disease; essential hypertension;
KW acute hypertensive emergency; cardiomyopathy; heart insufficiency;
KW exercise tolerance; chronic heart failure; arrhythmia;
KW cardiac dysrhythmia; syncope; atherosclerosis;
KW mild chronic heart failure; angina pectoris; cardiac bypass reocclusion;
KW intermittent claudication; atherosclerosis obliterans;
KW diastolic dysfunction; systolic dysfunction; brain natriuretic peptide;
KW BNP; myocardial infarction; acute coronary syndrome; unstable angina;
KW non-Q-wave cardiac necrosis; Q-wave myocardial infarct; stroke.

OS Unidentified.

XX Key Location/Qualifiers

FT Misc-difference 31 /label= Pro, Tyr

PN WO2003084563-A1.

XX 16-OCT-2003.

XX 02-APR-2003; 2003WO-DK000216.

XX 04-APR-2002; 2002DK-00000499.

PR 23-APR-2002; 2002US-0375255P.

XX (NOVO) NOVO NORDISK AS.

XX Knudsen LB, Rolin BC, Carr RD, Selmer J, Larsen J, Elbrond B;

PI Nielsen LB, Christoffersen C;

XX WPI; 2004-022543/02.

XX Use of a glucagon like peptide-1 agonist or its salt for the preparation
PT of a pharmaceutical composition for the treatment or prevention of an
PT early cardiac or early cardiovascular disease in a diabetic or non-
PT diabetic patient.

XX Disclosure; Page 7; 14pp; English.

XX This invention relates to a novel method for the treatment or prevention
CC of an early cardiac or early cardiovascular disease in a diabetic or non-
CC diabetic patient where a glucagon like peptide-1 (GLP 1) agonist or its
CC salt is used. The invention may be useful for the development of
CC compounds with a cardiant, cardiovascular-gen, antiarrhythmic,
CC antianginal, antiarteriosclerotic, vasotropic or hypotensive activity
CC through action as glucose metabolism regulators or cardiovascular
CC haemodynamics regulators. The invention may be used for the treatment or
CC prevention of an early cardiac or early cardiovascular disease (for

CC example left ventricular hypertrophy, coronary artery disease, essential
CC hypertension, acute hypertensive emergency, cardiomyopathy, heart
CC insufficiency, exercise tolerance, chronic heart failure, arrhythmia,
CC cardiac dysrhythmia, syncope, atherosclerosis, mild chronic heart
CC failure, angina pectoris, cardiac bypass reocclusion, intermittent
CC claudication (for example atherosclerosis obliterans), diastolic
CC dysfunction and systolic dysfunction) in a diabetic or non-diabetic
CC patient; for the preparation of a pharmaceutical composition for reducing
CC the level of brain natriuretic peptide (BNP) in plasma and/or heart
CC tissue in a diabetic or non-diabetic patient. The invention may also be
CC useful for the treatment of myocardial infarction, acute coronary
CC syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial
CC infarct and morbidity after stroke. The GLP-1 agonists are in the form of
CC stable derivatives and exhibit a protracted profile of action compared to
CC the corresponding other GLP-1 analogues. The GLP-1 analogues lower the
CC brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in
CC addition to lowering blood glucose and plasma lipids. The present
CC sequence is that of an exendin peptide which is related to the invention.
XX
XX Sequence 31 AA;

ADH73029 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMEBAVRLFTIEWLKNKGX
28

1 match found in sequence:
adi24854 ; Exendin-4 as active moiety for pharmacologically active peptide.

(from "seq5ags.pep")

TOIG of: adi24854 check: 9570 from: 1 to: 39

ID ADI24854 standard; peptide; 39 AA.

XX AC ADI24854;

DT 15-APR-2004 (first entry)

DE Exendin-4 as active moiety for pharmacologically active peptide.

XX pharmacologically active peptide conjugate; enzymatic cleavage; pain;
KW HIV; cancer; diabetes; incontinence; hypertension; amnesia;
KW Alzheimer's disease; fever; depression; sex hormone regulation;
KW eating disorder; schizophrenia; osteoporosis; insomnia;
KW Central nervous system disorder; contraceptive.

OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 39

FT /note= "amidated C-terminus"

XX WO9946283-A1.

XX 16-SEP-1999.

XX 09-MAR-1999; 99WO-DK000118.

PR 09-MAR-1998; 98DK-00000317.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD;

XX WPI; 1999-561659/47.

XX New peptide conjugates used for treating, e.g. pain, HIV, depression,
PT schizophrenia, osteoporosis or insomnia.

XX Claim 24; Page 91; 113pp; English.

```

1 1 HSGTFTSDLSKQMEEEAVRLFIEWLKNKGX
  1 28
-----
1 match found in sequence:
adf4966 ; H. horridum exendin-3 peptide fragment.
(from "seq5ags.pep")
TOIG of: adf4966 check: 9591 from: 1 to: 39

ID ADF4966 standard; peptide; 39 AA.
XX
AC ADF4966;
XX
DT 12-FEB-2004 (first entry)
XX
DE H. horridum exendin-3 peptide fragment.
XX
KW detection; EST; expressed sequence tag library; conserved structure;
KW pharmaceutical; drug target; mexican bearded lizard; natriuretic peptide;
KW bradykinin; angiotensin-converting enzyme; ss; exendin-3.
XX
OS Heloderma horridum.
XX
PN WO2003071268-A2.
XX
PD 28-AUG-2003.
XX
PF 20-FEB-2003; 2003WO-EP001765.
XX
PR 20-FEB-2002; 2002DE-01008187.
XX
PA (PAIO-) PAION GMBH.
XX
PI Schleuning W, Schulz T;
XX
DR WPI; 2003-697652/66.
XX
PT Identifying substances with a specific activity in target organisms,
PT useful for drug development, by detecting compounds with related activity
PT in reference organisms.
XX
PS Example 1; Page 28; 76pp; German.
XX
CC This invention describes a novel method for discovering a substance that
CC is pharmaceutically active in a target organism. The method comprises
CC generating an EST (expressed sequence tag) library from the reference
CC organism or tissue and identifying active compounds in the reference
CC material, particularly by structure/sequence comparison between the EST
CC library and sequence information on the target organism. Particularly at
CC least two reference organisms are used, to allow identification of
CC conserved structures, which are then used to identify orthologous
CC structures in the target. Optionally the orthologous structures are then
CC modified, e.g. by structure-based optimisation of the required
CC properties. The method is used to identify polypeptides which are then
CC used optionally after optimisation of properties, as pharmaceuticals, or
CC after validation as a drug target, for development of ligands, also
CC potential pharmaceuticals. Polypeptides and nucleic acids encoding them,
CC can also be used for identification and validation of drug targets and
CC for identifying lead structures for pharmaceutical development. The
CC method facilitates discovery of agents that are biologically active,
CC specifically in humans, and should reduce the time between discovery and
CC development of new drugs, since previous understanding of molecular
CC mechanisms of pathology or of the structures involved in drug design are
CC not necessary. The identified drugs will usually be very specific, with
CC reduced side effects. Sequencing of a cDNA bank from the mexican bearded
CC lizard Heloderma horridum indicated a 736 bp sequence that, by comparison
CC with sequences in published databases, encoded a 196 amino acid precursor
CC of natriuretic peptide. Analysis of corresponding sequences from other
CC reptiles showed that the N-terminal region of the new sequence probably
CC encodes peptides that potentiate the effect of bradykinin and inhibit
CC angiotensin-converting enzyme.

```

```

XX SQ Sequence 39 AA;
ADP4966 Length: 39 February 4, 2005 13:32 Type: P Check: 9591
Found using 'seq5' (mohamed337.key)
-----
1 1 HSDGFTSDLSKQMEEEAVRLFIEWLKNKGFPSSGAPPPS
  1 28
-----
1 match found in sequence:
adh22131 ; Exendin peptide, an insulinotropic GLP-1 compound.
(from "seq5ags.pep")
TOIG of: adh22131 check: 7617 from: 1 to: 31

ID ADH22131 standard; peptide; 31 AA.
XX
AC ADH22131;
XX
DT 11-MAR-2004 (first entry)
XX
DE Exendin peptide, an insulinotropic GLP-1 compound.
XX
KW Type 1 diabetes; Latent Autoimmune Diabetes in the Adult; LADA; CD3;
KW GLP-1; beta-cell; glycaemic control; exendin; insulinotropic;
KW immunosuppressive; antidiabetic.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Misc-difference 31 /label= Pro, Tyr
FT
XX WO2003105897-A1.
XX
PD 24-DEC-2003.
XX
PF 12-JUN-2003; 2003WO-DK000387.
XX
PR 14-JUN-2002; 2002DK-00000909.
XX
PA (NOVO ) NOVO NORDISK AS.
XX
PI Michelsen BK, Sturis J;
XX
DR WPI; 2004-090759/09.
XX
PT Preventing and intervening of Type 1 diabetes and latent autoimmune
PT diabetes in the adult, comprising administering a modulator of CD3 and a
PT GLP-1 compound to a patient.
XX
PS Disclosure; Page 8; 24pp; English.
XX
CC This invention relates to a novel method for the prevention and
CC intervention into Type 1 diabetes and Latent Autoimmune Diabetes in the
CC Adult (LADA). Specifically, it refers to the administration of a
CC modulator derived from a CD3 and GLP-1 compound. This combined treatment
CC provides a synergistic effect and can attenuate the further destruction
CC of beta-cells, hence improving glycaemic control in diabetic patients.
CC Furthermore, it can be used as a prophylactic for people at high risk for
CC the development of type 1 diabetes and can provide an improved prognosis
CC with respect to microvascular and macrovascular complications. The
CC present invention describes exendin, a GLP-1 compound that is
CC insulinotropic, as well as analogues and fragments derived thereof that
CC can be used to modulate beta cell function. Accordingly, the compositions
CC of this invention exhibit immunosuppressive and antidiabetic activities.
CC This peptide sequence is a GLP-1 compound, the exendin peptide of the
CC invention.
XX
SQ Sequence 31 AA;
ADH22131 Length: 31 February 4, 2005 13:32 Type: P Check: 7617

```

```

1 1 HGGTFTSDLSKQMEEAVALFIEWLKNGGPGSSGAPPPS
    28
-----
1 match found in sequence:
add02757 ; Exendin-4 amino acid sequence SEQ ID NO:4.
(from "seq5ags.pep")
TOIG of: add02757 check: 9570 from: 1 to: 39

ID ADD02757 standard; peptide; 39 AA.
XX
AC ADD02757;
XX
DT 01-JAN-2004 (first entry)
XX
DE Exendin derivative parent peptide #1.
XX
KW GLP-1; glucagon-like peptide-1; exendin; antidiabetic; anti-obesity;
KW insulinotropic; hypoglycaemic; insulin secretion; glucagon suppressor;
KW gastric emptying inhibitor; pancreatic secretion inhibitor;
KW non-insulin-dependent diabetes mellitus;
KW insulin-dependent diabetes mellitus; obesity; hyperglycaemia.
XX
OS Homo sapiens.
XX
PN WO2003078462-A2.
XX
PD 25-SEP-2003.
XX
PF 11-MAR-2003; 2003WO-US007210.
XX
PR 12-MAR-2002; 2002US-00097230.
XX
PA (CEDA-) CEDARS SINAI MEDICAL CENT.
XX
PI Perfetti R, Hui H;
XX
DR WPI; 2003-779115/73.
XX
PT New insulin-secreting cell comprising an insulin-secreting cell
PT transfected with a nucleotide sequence encoding a protein selected from
PT glucagons-like peptide-1 (GLP) and its analog, useful for treating
PT diabetes.
XX
PS Claim 7; SEQ ID NO 4; 45pp; English.
XX
CC The present invention describes an insulin-secreting cell comprising an
CC insulin-secreting cell transfected with a nucleotide sequence encoding a
CC protein selected from glucagon-like peptide-1 (GLP-1) and its analogue.
CC Also described: (1) constructing an insulin-dependent glucose-secreting
CC cell comprising: (a) providing an insulin-secreting cell; (b) isolating
CC from a proglucagon a minigene construct comprising a nucleotide sequence
CC comprising the coding region for a protein; (c) providing a plasmid; (d)
CC transfecting the plasmid with the minigene construct; and (e) including
CC the plasmid in the insulin-secreting cell; (2) determining the ability of
CC a drug to stimulate cells to secrete insulin comprising: (a) providing an
CC insulin by providing the insulin-secreting cell; (b) exposing the cell to
CC the drug; and (c) measuring the amount of insulin secreted by the cell;
CC and (3) supplying insulin to a mammal comprising: (a) providing the
CC insulin-secreting cells; (b) exposing the cells to a body fluid of the
CC mammal, the body fluid providing an indication of glucose level; and (c)
CC transferring to the mammal insulin secreted from the cells. The insulin-
CC secreting cell and methods are useful for treating diabetes. The cells
CC are also useful for investigating the development and function of the
CC pancreas, the cell that constitutes it, and the secretion it produces.
CC The present sequence represents exendin-4, which is a GLP-1 receptor
CC agonist used in the exemplification of the present invention.
XX
SQ Sequence 39 AA;

ADD02757 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)
-----
1 1 HGGTFTSDLSKQMEEAVALFIEWLKNGGPGSSGAPPPS
    28
-----
1 match found in sequence:
add12855 ; Exendin derivative parent peptide #1.
(from "seq5ags.pep")
TOIG of: add12855 check: 7617 from: 1 to: 31

ID ADD12855 standard; peptide; 31 AA.
XX
AC ADD12855;
XX
DT 01-JAN-2004 (first entry)
XX
DE Exendin derivative parent peptide #1.
XX
KW GLP-1; glucagon-like peptide-1; exendin; antidiabetic; anti-obesity;
KW insulinotropic; hypoglycaemic; insulin secretion; glucagon suppressor;
KW gastric emptying inhibitor; pancreatic secretion inhibitor;
KW non-insulin-dependent diabetes mellitus;
KW insulin-dependent diabetes mellitus; obesity; hyperglycaemia.
XX
OS Synthetic.
XX
Key Location/Qualifiers
FH Misc-difference 31
FT /label= Pro, Tyr
FT
XX WO9943708-A1.
XX
PD 02-SEP-1999.
XX
PF 25-FEB-1999; 99WO-DK000086.
XX
PR 27-FEB-1998; 98DX-00000274.
PR 05-MAY-1998; 98US-0084357P.
XX
PA (NOVO ) NOVO-NORDISK AS.
XX
PI Knudsen LB, Huusfeldt PO, Nielsen PF, Madsen K;
XX
DR WPI; 1999-540562/45.
XX
PT New derivatives of glucagon-like peptide-1 and exendin containing
PT lipophilic substituent, for treating diabetes and obesity.
XX
PS Claim 82; Page 61; 69pp; English.
XX
CC The present invention describes derivatives (A1) of GLP-1 (glucagon-like
CC peptide-1) (7-c) (with c = 35 or 36) having just one lipophilic
CC substituent (LS) attached to the C-terminal amino acid (aa) and
CC derivatives (A2) of exendin with LS attached to at least one aa of the
CC parent peptide. A1 excludes compounds Arg26, Arg34, Lys36-(N-
CC epsilon(omega-carboxyl)-GLP-1(7-36)-OH, where X = nonadecanoyl,
CC heptadecanoyl, undecanoyl or heptanoyl. Also described are compositions
CC containing A1 and A2 plus a vehicle or carrier. A1 and A2 have
CC antidiabetic, anti-obesity, insulinotropic and hypoglycaemic activities.
CC A1 stimulates secretion of insulin but suppresses that of glucagon. They
CC also inhibit gastric emptying and pancreatic secretion and may reduce
CC food intake. A1 and A2 are used to treat (non-)insulin-dependent diabetes
CC mellitus and obesity, and also to prevent hyperglycaemia. A1 and A2 have
CC a greater persistence in vivo than corresponding peptides without LS
CC (because of reduced sensitivity to dipeptidyl peptidases). When
CC formulated with other antidiabetic agents, they often produce a
CC synergistic effect. The present sequence represents an exendin derivative
CC parent peptide, which is used in the exemplification of the present
CC invention.
XX
SQ Sequence 31 AA;

ADD12855 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..
Found using 'seq5' (mohamed337.key)
-----

```

CC ovaries, abnormal uterine bleeding and spontaneous abortion, and for
 CC restoring regular menses, ovulation and fertility. A GLP-1 molecule
 CC reduces insulin resistance or increases insulin sensitivity. The present
 CC sequence represents a Gila monster venom peptide, extendin 4, which shows
 CC homology to GLP-1.
 XX
 SQ Sequence 39 AA;
 ADA4872 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)
 1 HSGTFTSDLSKQWEEAVRLFIEWLKNKGPPSGAPPPS
 28
 -----|-----
 1 match found in sequence:
 adb84203; Gila monster venom extendin 3.
 (from "seq5ags.pep")
 TOIG of: adb84203 check: 9591 from: 1 to: 39
 ID ADB84203 standard; peptide; 39 AA.
 XX
 AC ADB84203;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Gila monster venom extendin 3.
 XX
 KW vasotrophic; intermittent claudication; skeletal muscle injury; ischaemia;
 KW glucagon-like peptide-1; GLP-1; peripheral vascular disease;
 KW glucose oxidation; fatty acid oxidation reduction; Gila monster venom;
 KW extendin 3.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 39 /note= "C-terminal amide"
 FT
 XX
 XX US2003073626-A1.
 XX
 PD 17-APR-2003.
 XX
 XX 05-MAR-2002; 2002US-00091258.
 XX
 XX 30-APR-1999; 99US-00302596.
 XX
 XX 09-MAY-2001; 2001US-00851738.
 XX
 XX (HATH/) HATHWAY D R.
 XX (COOL/) COOLIDGE T R.
 XX
 XX Hathaway DR, Coolidge TR;
 XX
 XX WPI; 2003-677986/64.
 XX
 XX Method for the treatment or prevention of intermittent claudication or
 XX skeletal muscle injury caused by ischemia and/or reperfusion in a human
 XX subject, comprises administration of a glucagon-like peptide-1 molecule.
 XX
 XX Disclosure; Page 4; 12pp; English.
 XX
 XX The invention describes a method for the treatment or prevention of
 XX intermittent claudication or skeletal muscle injury caused by ischaemia
 XX and/or reperfusion in a human subject, comprising the administration of a
 XX glucagon-like peptide-1 (GLP-1) molecule. The method is useful for
 XX treating or preventing intermittent claudication or skeletal muscle
 XX injury caused by ischaemia and/or reperfusion in a human subject
 XX suffering from peripheral vascular disease (PVD). Administration of GLP-1
 XX in a subject improves skeletal muscle performance by promoting glucose
 XX oxidation and reducing fatty acid oxidation. This is the amino acid
 XX sequence of a mammalian glucagon-like peptide-1 (1-37) that
 XX can be used in the method of the invention.

XX
 SQ Sequence 39 AA;
 ADB84203 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)
 1 HSGTFTSDLSKQWEEAVRLFIEWLKNKGPPSGAPPPS
 28
 -----|-----
 1 match found in sequence:
 adb84205; Gila monster venom extendin 4.
 (from "seq5ags.pep")
 TOIG of: adb84205 check: 9570 from: 1 to: 39
 ID ADB84205 standard; peptide; 39 AA.
 XX
 AC ADB84205;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Gila monster venom extendin 4.
 XX
 KW vasotrophic; intermittent claudication; skeletal muscle injury; ischaemia;
 KW glucagon-like peptide-1; GLP-1; peripheral vascular disease;
 KW glucose oxidation; fatty acid oxidation reduction; Gila monster venom;
 KW extendin 4.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Misc-difference 39 /note= "C-terminal amide"
 FT
 XX
 XX US2003073626-A1.
 XX
 PD 17-APR-2003.
 XX
 XX 05-MAR-2002; 2002US-00091258.
 XX
 XX 30-APR-1999; 99US-00302596.
 XX
 XX 09-MAY-2001; 2001US-00851738.
 XX
 XX (HATH/) HATHWAY D R.
 XX (COOL/) COOLIDGE T R.
 XX
 XX Hathaway DR, Coolidge TR;
 XX
 XX WPI; 2003-677986/64.
 XX
 XX Method for the treatment or prevention of intermittent claudication or
 XX skeletal muscle injury caused by ischemia and/or reperfusion in a human
 XX subject, comprises administration of a glucagon-like peptide-1 molecule.
 XX
 XX Disclosure; Page 4; 12pp; English.
 XX
 XX The invention describes a method for the treatment or prevention of
 XX intermittent claudication or skeletal muscle injury caused by ischaemia
 XX and/or reperfusion in a human subject, comprising the administration of a
 XX glucagon-like peptide-1 (GLP-1) molecule. The method is useful for
 XX treating or preventing intermittent claudication or skeletal muscle
 XX injury caused by ischaemia and/or reperfusion in a human subject
 XX suffering from peripheral vascular disease (PVD). Administration of GLP-1
 XX in a subject improves skeletal muscle performance by promoting glucose
 XX oxidation and reducing fatty acid oxidation. This is the amino acid
 XX sequence of a mammalian glucagon-like peptide-1 (1-37) that
 XX can be used in the method of the invention.
 XX
 XX Sequence 39 AA;
 ADB84205 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

CC GLP-1, and/or GIP. The treatment may be combined with the administration
 CC of dipeptidyl peptidase IV (DPP-IV) inhibitors. ABU91969-ABU91975
 CC represent GLP-1, GLP-1 variant, exendin or GIP peptides
 XX
 SQ Sequence 39 AA;

ABU91974 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

1 HSEGTFTDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1 28

1 match found in sequence:
 ada44870 ; Gila monster exendin 3 peptide SEQ ID NO: 7.
 (from "seq5ags.pep")
 TOIG of: ada44870 check: 9591 from: 1 to: 39

ID ADA44870 standard; peptide; 39 AA.
 XX ADA44870;
 AC
 XX 20-NOV-2003 (first entry)
 XX
 DT Gila monster exendin 3 peptide SEQ ID NO: 7.
 XX
 DE polycystic ovary syndrome; PCOS; glucagon-like peptide-1; GLP-1;
 XX gynaecological; antidiabetic; anorectic; hypotensive; antilipaeamic;
 KW antinfertility; depilatory; andocrine-gen.; antiseborrheic;
 KW dermatological; plasma glucose regulator; insulin secretion stimulator;
 KW insulin resistance; hyperinsulinaemia; type-2 diabetes; obesity;
 KW hypertension; hyperlipidaemia; anovulation; irregular ovulation;
 KW infertility; hyperandrogenism; hirsutism; alopecia; acne;
 KW enlarged multifollicular ovaries; abnormal uterine bleeding;
 KW spontaneous abortion; insulin sensitivity; Gila monster; exendin 3.
 XX
 XX Heloderma suspectum.

Key Location/Qualifiers
 FH Modified-site 39
 FT /note= "C-terminal amide"

XX WO2003061362-A2.

XX 31-JUL-2003.

XX 14-JAN-2003; 2003WO-US001109.

XX 22-JAN-2002; 2002US-0350395P.

XX 11-DEC-2002; 2002US-00317126.

XX (REST-) RESTORAGEN INC.

XX Hathaway DR;

XX WPI; 2003-663337/62.

XX Treating polycystic ovary syndrome and associated symptoms e.g. insulin

XX resistance comprises administering glucagon-like peptide-1 molecule.

XX Disclosure; Page 9; 11pp; English.

XX The invention relates to a method for treating polycystic ovary syndrome
 CC (PCOS). The method comprises administering a glucagon-like peptide-1 (GLP
 CC -1) molecule. The method of the invention has gynecological,
 CC antidiabetic, anorectic, hypotensive, antilipaeamic, antinfertility,
 CC depilatory, andocrine-gen., antiseborrheic, and dermatological activity.
 CC A GLP-1 molecule of the invention acts as a plasma glucose regulator, or
 CC insulin secretion stimulator. The method is useful for treating
 CC polycystic ovary syndrome (PCOS) and its symptoms, particularly insulin
 CC resistance, hyperinsulinaemia, type-2 diabetes, obesity, hypertension,
 CC hyperlipidaemia, anovulation or irregular ovulation, infertility,

CC hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular
 CC ovaries, abnormal uterine bleeding and spontaneous abortion, and for
 CC restoring regular menses, ovulation and fertility. A GLP-1 molecule
 CC reduces insulin resistance or increases insulin sensitivity. The present
 CC sequence represents a Gila monster venom peptide, exendin 3, which shows
 XX homology to GLP-1.

SQ Sequence 39 AA;

ADA44870 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGTFTDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1 28

1 match found in sequence:
 ada44872 ; Gila monster exendin 4 peptide SEQ ID NO: 9.
 (from "seq5ags.pep")
 TOIG of: ada44872 check: 9570 from: 1 to: 39

ID ADA44872 standard; peptide; 39 AA.

XX ADA44872;

XX 20-NOV-2003 (first entry)

XX Gila monster exendin 4 peptide SEQ ID NO: 9.

XX polycystic ovary syndrome; PCOS; glucagon-like peptide-1; GLP-1;
 KW gynaecological; antidiabetic; anorectic; hypotensive; antilipaeamic;
 KW antinfertility; depilatory; andocrine-gen.; antiseborrheic;
 KW dermatological; plasma glucose regulator; insulin secretion stimulator;
 KW insulin resistance; hyperinsulinaemia; type-2 diabetes; obesity;
 KW hypertension; hyperlipidaemia; anovulation; irregular ovulation;
 KW infertility; hyperandrogenism; hirsutism; alopecia; acne;
 KW enlarged multifollicular ovaries; abnormal uterine bleeding;
 KW spontaneous abortion; insulin sensitivity; Gila monster; exendin 4.

XX Heloderma suspectum.

XX WO2003061362-A2.

XX 31-JUL-2003.

XX 14-JAN-2003; 2003WO-US001109.

XX 22-JAN-2002; 2002US-0350395P.

XX 11-DEC-2002; 2002US-00317126.

XX (REST-) RESTORAGEN INC.

XX Hathaway DR;

XX WPI; 2003-663337/62.

XX Treating polycystic ovary syndrome and associated symptoms e.g. insulin

XX resistance comprises administering glucagon-like peptide-1 molecule.

XX Disclosure; Page 9; 11pp; English.

XX The invention relates to a method for treating polycystic ovary syndrome
 CC (PCOS). The method comprises administering a glucagon-like peptide-1 (GLP
 CC -1) molecule. The method of the invention has gynecological,
 CC antidiabetic, anorectic, hypotensive, antilipaeamic, antinfertility,
 CC depilatory, andocrine-gen., antiseborrheic, and dermatological activity.
 CC A GLP-1 molecule of the invention acts as a plasma glucose regulator, or
 CC insulin secretion stimulator. The method is useful for treating
 CC polycystic ovary syndrome (PCOS) and its symptoms, particularly insulin
 CC resistance, hyperinsulinaemia, type-2 diabetes, obesity, hypertension,
 CC hyperlipidaemia, anovulation or irregular ovulation, infertility,
 CC hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular

protein metabolism. The polypeptides are useful for treating a subject with diabetes (particularly type 2 diabetes) or a neurodegenerative condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain injury, spinal chord injury or peripheral neuropathy), as well as for reducing the symptom(s) of neurodegenerative conditions in a subject. The polypeptides are also useful for treating a subject with neurotoxic injury or neurodegenerative condition, or for reducing the symptom(s) of neurotoxic injury or neurodegenerative condition in a subject. The present sequence is a Gila-monster lizard extendin-4 analogue

XX Sequence 30 AA;

ABU66238 Length: 30 February 4, 2005 13:32 Type: P Check: 5123 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMEEEAVRLPIAWLNKGR 28
1

1 match found in sequence:
abu66255 ; Gila monster extendin-4 analogue #14.
(from "seq5ags.pep")
TOIG of: abu66255 check: 333 from: 1 to: 36

ID ABU66255 standard; peptide; 36 AA.
XX
AC ABU66255;
XX
DT 20-MAY-2003 (first entry)
XX
DE Gila monster extendin-4 analogue #14.
XX
KW Glucagon-like peptide-1; GLP 1; extendin-4; antidiabetic; stroke;
KW nootropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO2003011892-A2.
XX
PD 13-FEB-2003.
XX
PF 30-JUL-2002; 2002WO-US024141.
XX
PR 31-JUL-2001; 2001US-0309076P.
XX
PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
XX
DR WPI; 2003-268106/26.
XX
PT New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).
XX
PS Example 9; Page 37; 119pp; English.
XX
CC The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Extendin-4 or an extendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal

processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
CC polypeptides are also useful for treating a subject with neurotoxic
CC injury or neurodegenerative condition, or for reducing the symptom(s) of
CC neurotoxic injury or neurodegenerative condition in a subject. The
CC present sequence is a Gila-monster lizard extendin-4 analogue

XX Sequence 36 AA;

ABU66255 Length: 36 February 4, 2005 13:32 Type: P Check: 333 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMEEEAVRLFIEWLNKGFSSGAP 28
1

1 match found in sequence:
abu91974 ; Gila monster extendin peptide.
(from "seq5ags.pep")
TOIG of: abu91974 check: 9570 from: 1 to: 39

ID ABU91974 standard; peptide; 39 AA.
XX
AC ABU91974;
XX
DT 14-JUL-2003 (first entry)
XX
DE Gila monster extendin peptide.
XX
KW Adenoviral vector; glucagon-like peptide 1; GLP-1; GIP; obesity;
KW glucose-dependent insulinotropic peptide; type II diabetes;
KW in vivo expression; dipeptidyl peptidase IV inhibitor; DPP-IV;
KW GLP-1 variant; extendin; antidiabetic; anorectic; gene therapy.
XX
OS Unidentified.
XX
PN WO2003030946-A1.
XX
PD 17-APR-2003.
XX
PF 09-OCT-2002; 2002WO-US032051.
XX
PR 09-OCT-2001; 2001US-0328116P.
XX
PA (NOVS) NOVARTIS AG.
XX
PI Connelly S, Golightly D, Hughes T, Kaleko M, Pattison S;
PI Sakhuja K;
XX
DR WPI; 2003-381685/36.
DR N-PSDB; ACA92262.
XX
PT New viral vectors comprising a sequence encoding glucagons-like peptide 1
PT or glucose-dependent insulinotropic peptide, a sequence encoding a signal
PT sequence, and a polyadenylation signal, for treating e.g. diabetes or
PT obesity.
XX
PS Disclosure; Page 17; 62pp; English.
XX
CC The present invention relates to an adenoviral vector comprising a
CC polynucleotide sequence encoding glucagon-like peptide 1 (GLP-1) or
CC glucose-dependent insulinotropic peptide (GIP), a polynucleotide sequence
CC encoding a signal sequence upstream of it, and a polyadenylation signal
CC downstream of it. The viral vector is useful in gene therapy for treating
CC type II diabetes, obesity and related conditions by in vivo expression of

CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard extendin-4 analogue
 XX
 SQ Sequence 28 AA;

ABU66221 Length: 28 February 4, 2005 13:32 Type: P Check: 700 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTTSDLSKQMEAEAVRLFIEWLK 28

1 match found in sequence:
 abu66237 ; Gila monster extendin-4 analogue #11.
 (from "seq5ags.pep")
 TOIG of: abu66237 check: 5219 from: 1 to: 30

ID ABU66237 standard; peptide; 30 AA.
 XX
 AC ABU66237;
 XX
 DT 20-MAY-2003 (first entry)
 XX
 XX Gila monster extendin-4 analogue #11.

Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
 norepinephrine; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 cerebrotrophic; neuronal death; neuronal differentiation; mutein;
 neuronal proliferation; neuronal process growth; amyloid protein;
 diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 Alzheimer's disease; Parkinson's disease; Huntington's disease;
 amytrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

XX Heloderma suspectum.
 OS Synthetic.
 OS

XX WO2003011892-A2.

XX 13-FEB-2003.

XX 30-JUL-2002; 2002WO-US024141.

XX 31-JUL-2001; 2001US-0309076P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).

XX Example 2; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Extendin-4 or an extendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's

CC disease, amytrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard extendin-4 analogue
 XX
 SQ Sequence 30 AA;

ABU66237 Length: 30 February 4, 2005 13:32 Type: P Check: 5219 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTTSDLSKQMEAEAVRLFIEWLKNGR 28

1 match found in sequence:
 abu66238 ; Gila monster extendin-4 analogue #12.
 (from "seq5ags.pep")
 TOIG of: abu66238 check: 5123 from: 1 to: 30

ID ABU66238 standard; peptide; 30 AA.

XX AC ABU66238;

XX 20-MAY-2003 (first entry)

XX Gila monster extendin-4 analogue #12.

Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
 norepinephrine; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 cerebrotrophic; neuronal death; neuronal differentiation; mutein;
 neuronal proliferation; neuronal process growth; amyloid protein;
 diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 Alzheimer's disease; Parkinson's disease; Huntington's disease;
 amytrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

XX Heloderma suspectum.

OS Synthetic.

XX WO2003011892-A2.

XX 13-FEB-2003.

XX 30-JUL-2002; 2002WO-US024141.

XX 31-JUL-2001; 2001US-0309076P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).

XX Example 2; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Extendin-4 or an extendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor

ABU66219 Length: 35 February 4, 2005 13:32 Type: P Check: 7453 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGPPSSG 28
1

1 match found in sequence:
abu66220 ; Gila monster extendin-4 analogue #4.
(from "seq5ags.pep")
TOIG of: abu66220 check: 2764 from: 1 to: 33

ID ABU66220 standard; peptide; 33 AA.

AC ABU66220;

DE 20-MAY-2003 (first entry)

XX Gila monster extendin-4 analogue #4.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
KW neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

XX Heloderma suspectum.

OS Synthetic.

XX WO2003011892-A2.

XX 13-FEB-2003.

XX 30-JUL-2002; 2002WO-US024141.

XX 31-JUL-2001; 2001US-0309076P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).

XX Claim 27; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Extendin-4 or an extendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal
CC processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
CC polypeptides are also useful for treating a subject with neurotoxic
CC injury or neurodegenerative condition, or for reducing the symptom(s) of
CC neurotoxic injury or neurodegenerative condition in a subject. The

CC present sequence is a Gila-monster lizard extendin-4 analogue

XX Sequence 33 AA;

ABU66220 Length: 33 February 4, 2005 13:32 Type: P Check: 2764 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGPPSS 28
1

1 match found in sequence:
abu66221 ; Gila monster extendin-4 analogue #5.
(from "seq5ags.pep")
TOIG of: abu66221 check: 700 from: 1 to: 28

ID ABU66221 standard; peptide; 28 AA.

AC ABU66221;

DE 20-MAY-2003 (first entry)

XX Gila monster extendin-4 analogue #5.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
KW neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

OS Heloderma suspectum.

OS Synthetic.

XX WO2003011892-A2.

XX 13-FEB-2003.

XX 30-JUL-2002; 2002WO-US024141.

XX 31-JUL-2001; 2001US-0309076P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).

XX Claim 27; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Extendin-4 or an extendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal
CC processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The

```
1
-----
1 match found in sequence:
abu6218 ; Gila monster extendin-4 analogue #2.
(from "seq5ags.pep")
TOIG of: abu6218 check: 3293 from: 1 to: 37

ID ABU6218 standard; peptide; 37 AA.
XX
AC ABU6218;
XX
DT 20-MAY-2003 (first entry)
XX
DE Gila monster extendin-4 analogue #2.
XX
KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
KW nootropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO2003011892-A2.
XX
PD 13-FEB-2003.
XX
PF 30-JUL-2002; 2002WO-US024141.
XX
PR 31-JUL-2001; 2001US-0309076P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
XX
DR WPI; 2003-268106/26.
XX
PT New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).
XX
PS Claim 27; Fig 1; 119pp; English.
XX
CC The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Extendin-4 or an extendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal
CC processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
CC polypeptides are also useful for treating a subject with neurotoxic
CC injury or neurodegenerative condition, or for reducing the symptom(s) of
CC neurotoxic injury or neurodegenerative condition in a subject. The
CC present sequence is a Gila-monster lizard extendin-4 analogue
XX
SQ Sequence 37 AA;

ABU6218 Length: 37 February 4, 2005 13:32 Type: P Check: 3293 ..
Found using 'seq5' (mohamed337.key)

-----
1 match found in sequence:
abu6219 ; Gila monster extendin-4 analogue #3.
(from "seq5ags.pep")
TOIG of: abu6219 check: 7453 from: 1 to: 35

ID ABU6219 standard; peptide; 35 AA.
XX
AC ABU6219;
XX
DT 20-MAY-2003 (first entry)
XX
DE Gila monster extendin-4 analogue #3.
XX
KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
KW nootropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO2003011892-A2.
XX
PD 13-FEB-2003.
XX
PF 30-JUL-2002; 2002WO-US024141.
XX
PR 31-JUL-2001; 2001US-0309076P.
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
XX
DR WPI; 2003-268106/26.
XX
PT New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).
XX
PS Claim 27; Fig 1; 119pp; English.
XX
CC The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Extendin-4 or an extendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal
CC processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
CC polypeptides are also useful for treating a subject with neurotoxic
CC injury or neurodegenerative condition, or for reducing the symptom(s) of
CC neurotoxic injury or neurodegenerative condition in a subject. The
CC present sequence is a Gila-monster lizard extendin-4 analogue
XX
SQ Sequence 35 AA;
```

AC ABU6216;
 XX 23-OCT-2003 (revised)
 DT 20-MAY-2003 (first entry)
 XX
 XX Glucagon-like peptide 1/exendin-4 analogue #1.
 XX
 XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; stroke; human;
 KW neotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutant;
 KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 XX
 XX Homo sapiens.
 OS Heloderma suspectum.
 OS Chimeric.
 XX
 XX WO2003011892-A2.
 XX
 XX 13-FEB-2003.
 XX
 XX 30-JUL-2002; 2002WO-US024141.
 XX
 XX 31-JUL-2001; 2001US-0309076P.
 XX
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
 DR WPI; 2003-268106/26.
 XX
 XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).
 XX
 XX Claim 27; Fig 1; 119pp; English.
 XX
 XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Exendin-4 or an exendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a human GLP-1/Gila-monster lizard exendin-4
 CC chimeric analogue peptide. (Updated on 23-OCT-2003 to standardise OS
 CC field)
 XX
 XX Sequence 39 AA;
 SQ
 ABU6216 Length: 39 February 4, 2005 13:32 Type: P Check: 9558 ..
 Found using 'seq5' (mohamed337.key)

1 HAEGTFTSDLSKQMEAEAVRLFIEWLKGPPSGAPPPS
 -----|
 28

1 match found in sequence:
 abu6217; Gila monster exendin-4 analogue #1.
 (from "seq5ags.pep")
 TOIG of: abu6217 check: 4877 from: 1 to: 30

ID ABU6217 standard; peptide; 30 AA.
 XX
 XX AC ABU6217;
 XX
 XX DT 20-MAY-2003 (first entry)
 XX
 XX DE Gila monster exendin-4 analogue #1.
 XX
 XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; stroke;
 KW neotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutant;
 KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 XX
 XX Heloderma suspectum.
 OS Synthetic.
 XX
 XX PN WO2003011892-A2.
 XX
 XX PD 13-FEB-2003.
 XX
 XX 30-JUL-2002; 2002WO-US024141.
 XX
 XX 31-JUL-2001; 2001US-0309076P.
 XX
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
 DR WPI; 2003-268106/26.
 XX
 XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).
 XX
 XX Claim 27; Fig 1; 119pp; English.
 XX
 XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Exendin-4 or an exendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard exendin-4 analogue
 XX
 XX Sequence 30 AA;
 SQ
 ABU6217 Length: 30 February 4, 2005 13:32 Type: P Check: 4877 ..
 Found using 'seq5' (mohamed337.key)

1 HAEGTFTSDLSKQMEAEAVRLFIEWLKGNG
 -----|

TOIG of: abp58578 check: 9570 from: 1 to: 39

ID ABP58578 standard; peptide; 39 AA.

XX AC ABP58578;

XX DT 28-MAR-2003 (first entry)

XX DE Mexican beaded lizard extendin-4.

XX KW Extendin-4; Mexican beaded lizard; extendin-4 analogue; antidiabetic; insulin secretagogue; type 2 diabetes.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

XX FT Modified-site 39

XX FT /note= "C-terminal amide"

XX PN WO200290388-A1.

XX PD 14-NOV-2002.

XX PF 08-MAY-2002; 2002WO-CN000316.

XX PR 10-MAY-2001; 2001CN-00112856.

XX PA (SHAN-) SHANGHAI HUAYI BIO LAB.

XX PI Sun Y, Wu D, Zhu Z, Yu G, Shen C, Zhao S, Zhou J;

XX WPI; 2003-120527/11.

XX Polypeptide extendin-4 derivatives, useful for promoting insulin secretion and reducing blood sugar, for treating diabetes type 2.

XX PS Disclosure; Page 2; 24pp; Chinese.

XX CC The invention relates to novel analogues of extendin-4 (ABP58572-ABP58576) or their pharmaceutically acceptable salts. The invention also encompasses a procedure for preparing the extendin-4 analogues. Extendin-4 (ABP58578) is a polypeptide obtained from the Mexican beaded lizard (Heloderma horridum) which acts as an agonist of glucagon-like peptide 1 (GLP-1; see ABP58577). Like extendin-4 itself, the extendin-4 analogues of the invention have antidiabetic activity, being able to promote the secretion of insulin and reduce blood sugar, and are thus applicable in treating type 2 diabetes. 0.1 micrograms of an extendin-4 analogue was demonstrated to be able to reduce blood sugar to approximately 20% of its former value after one hour, and its effects lasted 30 minutes longer than 4 micrograms of insulin. The extendin-4 analogues of the invention can be synthesised either chemically or by recombinant methods, thereby permitting large-scale production. The present sequence represents wild-type extendin-4 which is referred to in the disclosure of the invention

XX SQ Sequence 39 AA;

ABP58578 Length: 39 February 4, 2005 13:32 Type: P Check: 9570

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEEEAVRLFIWLKNGKPGSPGAPPPS 28

1 match found in sequence:

abu66208 ; Gila monster extendin-4.

(from "seq5ags.pep")

TOIG of: abu66208 check: 9570 from: 1 to: 39

ID ABU66208 standard; peptide; 39 AA.

XX AC ABU66208;

XX

DT 20-MAY-2003 (first entry)

XX Gila monster extendin-4.

XX KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke; nootropic; neuroprotective; antiparkinsonian; anticonvulsant; cerebroprotective; neuronal death; neuronal differentiation; neuronal proliferation; neuronal process growth; amyloid protein; diabetes; type 2 diabetes; neurodegenerative condition; brain injury; Alzheimer's disease; Parkinson's disease; Huntington's disease; amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury; peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

XX OS Heloderma suspectum.

XX PN WO2003011892-A2.

XX PD 13-FEB-2003.

XX PF 30-JUL-2002; 2002WO-US024141.

XX PR 31-JUL-2001; 2001US-0309076P.

XX PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their analogues, useful for treating a subject with diabetes or a neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple sclerosis or brain injury).

XX Claim 27; Fig 1; 119pp; English.

XX CC The invention relates to a purified polypeptide, which comprises the amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue, Extendin-4 or an extendin analogue with a spacer between the amino acid residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1. Also include are: (1) reducing neuronal death, promoting neuronal differentiation or proliferation, or promoting growth of neuronal processes, by contacting one or more neurons with the polypeptide; and (2) reducing formation or accumulation of amyloid protein by contacting one or more neurons with the polypeptide, which affects amyloid precursor protein metabolism. The polypeptides are useful for treating a subject with diabetes (particularly type 2 diabetes) or a neurodegenerative condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain injury, spinal chord injury or peripheral neuropathy), as well as for reducing the symptom(s) of neurodegenerative conditions in a subject. The polypeptides are also useful for treating a subject with neurotoxic injury or neurodegenerative condition, or for reducing the symptom(s) of neurotoxic injury or neurodegenerative condition in a subject. The present sequence is wild-type Gila-monster lizard extendin-4

XX SQ Sequence 39 AA;

ABU66208 Length: 39 February 4, 2005 13:32 Type: P Check: 9570

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEEEAVRLFIWLKNGKPGSPGAPPPS 28

1 match found in sequence:

abu66216 ; Glucagon-like peptide 1/extendin-4 analogue #1.

(from "seq5ags.pep")

TOIG of: abu66216 check: 9558 from: 1 to: 39

ID ABU66216 standard; peptide; 39 AA.

XX

CC digestive hormone disease, atherosclerosis, vascular disease, gestational
 CC diabetes, liver disease and cirrhosis, glucocorticoid excess, Cushing's
 CC disease, the presence of activated counter regulatory hormones that occur
 CC after trauma or a disease, hypertriglyceridemia, chronic pancreatitis,
 CC the need for parenteral feeding, and a catabolic state following surgery
 CC or injury. Sequences ABB07149-155 represent peptide fragments from gila
 CC monster venoms that are homologous to GLP-1 molecules and can be included
 CC in the composition
 XX
 XX Sequence 39 AA;

ABB07151 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

1 HSGDTFTSDLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
 1
 28

 1 match found in sequence:
 abb80100 ; Glucagon like peptide-1 (GLP-1) extendin 3.
 (from "seq5ags.pep")

TOIG of: abb80100 check: 9591 from: 1 to: 39

ID ABB80100 standard; peptide; 39 AA.

XX ABB80100;

XX AC ABB80100;

XX DT 02-OCT-2002 (first entry)

XX DE Glucagon like peptide-1 (GLP-1) extendin 3.

XX KW Glucagon like peptide-1; GLP-1; extendin 3; cardiant; antidiabetic;

XX KW vasotrophic; hibernating myocardium; congestive heart failure;

XX KW ischaemic cardiomyopathy; diabetic cardiomyopathy.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

XX FT Modified-site 39

XX FT /note= "C-terminal amide"

XX PN WO200234285-A2.

XX XX 02-MAY-2002.

XX PF 22-OCT-2001; 2001WO-US032559.

XX PR 20-OCT-2000; 2000US-0241834P.

XX PR 23-OCT-2000; 2000US-0242139P.

XX PR 03-NOV-2000; 2000US-0245234P.

XX PA (COOL/) COOLIDGE T R.

XX XX Ehlers M;

XX PI WPI; 2002-426545/45.

XX DR Treatment of hibernating myocardium involves administering GLP-1

XX PT molecule.

XX PS Disclosure; Page 13; 25pp; English.

XX The invention relates to the treatment of hibernating myocardium by
 CC administering a GLP-1 (glucagon like peptide-1) molecule. GLP-1 activity
 CC may be described as, cardiant, antidiabetic and vasotropic. GLP-1 may be
 CC used for treating, hibernating myocardium, congestive heart failure,
 CC ischaemic cardiomyopathy and diabetic cardiomyopathy. GLP-1 reduces
 CC plasma or heart norepinephrine level in a patient. The current sequence
 CC represents the glucagon like peptide-1 (GLP-1) known as extendin 3

XX Sequence 39 AA;

ABB80100 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGTFSTSDLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
 1
 28

 1 match found in sequence:
 abb83059 ; Glucagon like peptide-1 (GLP-1) extendin 4 #2.
 (from "seq5ags.pep")

TOIG of: abb83059 check: 9570 from: 1 to: 39

ID ABB83059 standard; peptide; 39 AA.

XX ABB83059;

XX AC 02-OCT-2002 (first entry)

XX DE Glucagon like peptide-1 (GLP-1) extendin 4 #2.

XX KW Glucagon like peptide-1; GLP-1; extendin 4; cardiant; antidiabetic;

XX KW vasotrophic; hibernating myocardium; congestive heart failure;

XX KW ischaemic cardiomyopathy; diabetic cardiomyopathy.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

XX FT Modified-site 39

XX FT /note= "C-terminal amide"

XX PN WO200234285-A2.

XX XX 02-MAY-2002.

XX PF 22-OCT-2001; 2001WO-US032559.

XX PR 20-OCT-2000; 2000US-0241834P.

XX PR 23-OCT-2000; 2000US-0242139P.

XX PR 03-NOV-2000; 2000US-0245234P.

XX PA (COOL/) COOLIDGE T R.

XX XX Ehlers M;

XX PI WPI; 2002-426545/45.

XX DR Treatment of hibernating myocardium involves administering GLP-1

XX PT molecule.

XX PS Disclosure; Page 13; 25pp; English.

XX The invention relates to the treatment of hibernating myocardium by
 CC administering a GLP-1 (glucagon like peptide-1) molecule. GLP-1 activity
 CC may be described as, cardiant, antidiabetic and vasotropic. GLP-1 may be
 CC used for treating, hibernating myocardium, congestive heart failure,
 CC ischaemic cardiomyopathy and diabetic cardiomyopathy. GLP-1 reduces
 CC plasma or heart norepinephrine level in a patient. The current sequence
 CC represents the glucagon like peptide-1 (GLP-1) known as extendin 4

XX Sequence 39 AA;

ABB83059 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
 Found using 'seq5' (mohamed337.key)

1 HSGDTFTSDLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
 1
 28

 1 match found in sequence:
 abb58578 ; Mexican beaded lizard extendin-4.
 (from "seq5ags.pep")

CC (IGT) or non-insulin requiring type II diabetes to insulin requiring type
 CC II diabetes. The invention also relates to the use of GLP-1, its
 CC analogues, derivatives and agonists for increasing the insulin synthesis
 CC capability of a subject. The GLP-1 derivative is Arg34,Lys26(N-epsilon-
 CC (gamma-Glu(N-alpha-hexadecanoyl))-GLP-1(7-37). The GLP-1 agonist is
 CC particularly GLP-1(7-37) and GLP-1(7-36)amide and the corresponding Thr8,
 CC Met8, Gly8 and Val8 analogues. The method is used for delaying
 CC progression of impaired glucose tolerance or non-insulin requiring type
 CC II diabetes to insulin requiring type II diabetes and for increasing
 CC insulin synthesis

XX Sequence 31 AA;

AA76998 Length: 31 February 4, 2005 13:32 Type: P Check: 7617 ..

Found using 'seq5' (mohamed337.key)

1 HEGGTFSDLKQMEEEAVRLFIEWLKNKGX 28
 1

1 match found in sequence:

abb07149 ; Gila monster venom extendin 3 fragment.
 (from "seq5ags.pep")

TOIG of: abb07149 check: 9591 from: 1 to: 39

ID ABB07149 standard; peptide; 39 AA.

XX AC

XX ABB07149;

XX DT 13-MAR-2002 (first entry)

XX DE Gila monster venom extendin 3 fragment.

XX GLP-1; glucagon-like-peptide-1; growth-hormone releasing factor; GRF;
 KW parathyroid hormone; PTH; antidiabetic; anorectic; cerebroprotective;
 KW vasotrophic; anti-inflammatory; antiarteriosclerotic; hepatotropic;
 KW tranquilizer; vulnery; osteopathic; gila monster; extendin.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

FT Modified-site 39
 FT /note= "C-terminal amide"

XX PN WO200187322-A2.

XX PD 22-NOV-2001.

XX PF 17-MAY-2001; 2001WO-US015872.

XX PR 17-MAY-2000; 2000US-0205377P.

XX PR 19-MAY-2000; 2000US-0205262P.

XX PA (BION-) BIONEBRASKA INC.

XX PI Holmquist B, Dormady DC;

XX DR WPI; 2002-082941/11.

XX PT New peptide formulation for treating disease e.g. diabetes, obesity,
 PT ischemia comprises peptides, an acid having a specified dissociation
 PT constant and an excipient.

XX PS Disclosure; Page 10; 34pp; English.

XX The invention provides a pharmaceutical composition that comprises a
 CC molecule selected from a glucagon-like-peptide-1 (GLP-1) molecule, growth
 CC -hormone releasing factor (GRF) molecule or a parathyroid hormone (PTH)
 CC molecule. The composition further includes a weak acid such as acetic
 CC acid. The pH of the composition is 3 - 5. The composition can be used for
 CC the treatment of a disease or condition selected from diabetes, excess
 CC appetite, obesity, stroke, ischemia, reperfusion injury, disturbed

CC glucose metabolism, surgery, coma, shock, gastrointestinal disease,
 CC digestive hormone disease, atherosclerosis, vascular disease, gestational
 CC diabetes, liver disease and cirrhosis, glucocorticoid excess, Cushing's
 CC disease, the presence of activated counter regulatory hormones that occur
 CC after trauma or a disease, hypertriglyceridemia, chronic pancreatitis,
 CC the need for parenteral feeding, and a catabolic state following surgery
 CC or injury. Sequences ABB07149-155 represent peptide fragments from gila
 CC monster venoms that are homologous to GLP-1 molecules and can be included
 CC in the composition

XX Sequence 39 AA;

ABB07149 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..

Found using 'seq5' (mohamed337.key)

1 HSDGTFSDLKQMEEEAVRLFIEWLKNKGSPSGAPPPS 28
 1

1 match found in sequence:

abb07151 ; Gila monster venom extendin 4 peptide (residues 1-39).
 (from "seq5ags.pep")

TOIG of: abb07151 check: 9570 from: 1 to: 39

ID ABB07151 standard; peptide; 39 AA.

XX AC

XX ABB07151;

XX DT 13-MAR-2002 (first entry)

XX DE Gila monster venom extendin 4 peptide (residues 1-39).

XX GLP-1; glucagon-like-peptide-1; growth-hormone releasing factor; GRF;
 KW parathyroid hormone; PTH; antidiabetic; anorectic; cerebroprotective;
 KW vasotrophic; anti-inflammatory; antiarteriosclerotic; hepatotropic;
 KW tranquilizer; vulnery; osteopathic; gila monster; extendin.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

FT Modified-site 39
 FT /note= "C-terminal amide"

XX PN WO200187322-A2.

XX PD 22-NOV-2001.

XX PF 17-MAY-2001; 2001WO-US015872.

XX PR 17-MAY-2000; 2000US-0205377P.

XX PR 19-MAY-2000; 2000US-0205262P.

XX PA (BION-) BIONEBRASKA INC.

XX PI Holmquist B, Dormady DC;

XX DR WPI; 2002-082941/11.

XX PT New peptide formulation for treating disease e.g. diabetes, obesity,
 PT ischemia comprises peptides, an acid having a specified dissociation
 PT constant and an excipient.

XX PS Disclosure; Page 11; 34pp; English.

XX The invention provides a pharmaceutical composition that comprises a
 CC molecule selected from a glucagon-like-peptide-1 (GLP-1) molecule, growth
 CC -hormone releasing factor (GRF) molecule or a parathyroid hormone (PTH)
 CC molecule. The composition further includes a weak acid such as acetic
 CC acid. The pH of the composition is 3 - 5. The composition can be used for
 CC the treatment of a disease or condition selected from diabetes, excess
 CC appetite, obesity, stroke, ischemia, reperfusion injury, disturbed
 CC glucose metabolism, surgery, coma, shock, gastrointestinal disease,

CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 29 AA;

AAY31564 Length: 29 February 4, 2005 13:32 Type: P Check: 2649 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDASKQMEERAVRLFIEWLKNG
 1
 28

1 match found in sequence:
 aay31565 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31565 check: 3183 from: 1 to: 37

ID AAY31565 standard; peptide; 37 AA.

XX AC AAY31565;

XX DT 08-NOV-1999 (first entry)

XX DE Extendin agonist peptide.

XX KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.

XX OS Heloderma sp.

XX FH Key Location/Qualifiers

XX FT Modified-site 36 /note= "hydroxyproline"

XX FT Modified-site 37 /note= "hydroxyproline; C-terminal amide"

XX FT

XX FN WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 65; Page 64; 94pp; English.

XX CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia

CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 37 AA;

AAY31565 Length: 37 February 4, 2005 13:32 Type: P Check: 3183 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDASKQMEERAVRLFIEWLKNGPSSGAPP
 1
 28

1 match found in sequence:
 aay76998 ; Extendin peptide.
 (from "seq5ags.pep")
 TOIG of: aay76998 check: 7617 from: 1 to: 31

ID AAY76998 standard; peptide; 31 AA.

XX AC AAY76998;

XX DT 01-JUN-2000 (first entry)

XX DE Extendin peptide.

XX KW Extendin; GLP-1; agonist; glucagon like peptide-1; insulin synthesis;
 KW impaired glucose tolerance; IGR; non-insulin requiring type II diabetes;
 KW insulin requiring type II diabetes.

XX OS Unidentified.

XX FH Key Location/Qualifiers

XX FT Misc-difference 31 /label= Pro, Tyr

XX FN WO200007617-A1.

XX PD 17-FEB-2000.

XX PF 29-JUL-1999; 99WO-DK000424.

XX PR 31-JUL-1998; 98DK-00000998.

XX PR 12-AUG-1998; 98DK-00001025.

XX PA (NOVO) NOVO-NORDISK AS.

XX PI Nielsen JH, Friedrichsen BN, Rugh S, Tromholt N, Bjorn S;

XX PI Knudsen LB, Sturis J;

XX DR WPI; 2000-2055569/18.

XX PT Use of GLP-1, its analogs, derivatives and agonists for increasing
 PT insulin synthesis, delaying progression of impaired glucose tolerance or
 PT non-insulin requiring type II diabetes to insulin requiring type II
 PT diabetes.

XX PS Disclosure; Page 4; 68pp; English.

XX CC This sequence represents an extendin peptide, and is a GLP-1 agonist. The
 CC invention relates to the use of a glucagon like peptide-1 (GLP-1), its
 CC analogue, derivative, or a GLP-1 agonist for the preparation of a
 CC medicament for delaying the progression of impaired glucose tolerance

CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 XX

SQ Sequence 28 AA;

AAY31562 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
 Found using 'seq5' (mohamed337.key)

```

1  HGEGTTSDLSKQLEEEAVRLFIDFLKN
  1  |-----|
  28

```

 1 match found in sequence:
 aay31563 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31563 check: 2215 from: 1 to: 33

ID AAY31563 standard; peptide; 33 AA.

XX AC AAY31563;
 XX DT 08-NOV-1999 (first entry)
 XX DE Extendin agonist peptide.

XX Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.
 OS Heloderma sp.
 XX Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"
 FT

XX WO9940788-A1.
 XX PN 19-AUG-1999.
 XX PD 05-FEB-1999; 99WO-US002554.
 XX PF 13-FEB-1998; 98US-0075122P.
 XX PR (AMYL-) AMYLIN PHARM INC.
 XX PA Young AA, Vine W, Beeley NRA, Prickett K;
 XX PI WPI; 1999-527332/44.
 XX DR Increasing urine flow by administering peptides or peptide agonists.
 XX PT Example 62; Page 62; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing

CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 XX

SQ Sequence 33 AA;

AAY31563 Length: 33 February 4, 2005 13:32 Type: P Check: 2215 ..
 Found using 'seq5' (mohamed337.key)

```

1  HGEGTTSDASKQLEEEAVRLFIEFLKNGPSS
  1  |-----|
  28

```

 1 match found in sequence:
 aay31564 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31564 check: 2649 from: 1 to: 29

ID AAY31564 standard; peptide; 29 AA.

XX AC AAY31564;
 XX DT 08-NOV-1999 (first entry)
 XX DE Extendin agonist peptide.

XX Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.
 OS Heloderma sp.
 XX Key Location/Qualifiers
 FT Modified-site 29 /note= "C-terminal amide"
 FT

XX WO9940788-A1.
 XX PN 19-AUG-1999.
 XX PD 05-FEB-1999; 99WO-US002554.
 XX PF 13-FEB-1998; 98US-0075122P.
 XX PR (AMYL-) AMYLIN PHARM INC.
 XX PA Young AA, Vine W, Beeley NRA, Prickett K;
 XX PI WPI; 1999-527332/44.
 XX DR Increasing urine flow by administering peptides or peptide agonists;
 XX PT Example 63; Page 63; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing

CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 28 AA;

AA31560 Length: 28 February 4, 2005 13:32 Type: P Check: 657
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQLEEEAVRLXIEFLKN 28
 |-----|

1 match found in sequence:
 aay31561 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31561 check: 1045 from: 1 to: 28

ID AAY31561 standard; peptide; 28 AA.

XX AC AAY31561;
 XX
 DT 08-NOV-1999 (first entry)
 XX
 DE Extendin agonist peptide.

XX Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.
 OS Heloderma sp.

XX Key Location/Qualifiers
 FH Modified-site 23
 FT Modified-site 28 /note= "tButylglycine"
 FT Modified-site 28 /note= "C-terminal amide"

XX WO9940788-A1.

XX 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

PT Increasing urine flow by administering peptides or peptide agonists.

XX Example 60; Page 61; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing

CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX

SQ Sequence 28 AA;

AA31561 Length: 28 February 4, 2005 13:32 Type: P Check: 1045
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQLEEEAVRLXIEFLKN 28
 |-----|

1 match found in sequence:
 aay31562 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31562 check: 237 from: 1 to: 28

ID AAY31562 standard; peptide; 28 AA.

XX AC AAY31562;

XX DT 08-NOV-1999 (first entry)

XX DE Extendin agonist peptide.

XX Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.
 OS Heloderma sp.

XX Key Location/Qualifiers
 FH Modified-site 28
 FT Modified-site 28 /note= "C-terminal amide"

XX WO9940788-A1.

XX 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

PT Increasing urine flow by administering peptides or peptide agonists.

XX Example 61; Page 62; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing

CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAV31558 Length: 28 February 4, 2005 13:32 Type: P Check: 649 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSELSKQMAEAVRLFIEWLKN 28
 1 |-----|

 1 match found in sequence:
 aay31559 ; Exendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31559 check: 211 from: 1 to: 28

ID AAY31559 standard; peptide; 28 AA.

XX AAY31559;

AC AAY31559;

DT 08-NOV-1999 (first entry)

DE Exendin agonist peptide.

XX Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

OS Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FH Modified-site 10

FT /note= "pentylglycine"

FT Modified-site 28

FT /note= "C-terminal amide"

XX WO9940788-A1.

XX 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.

XX Example 58; Page 60; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure.
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility

CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAV31559 Length: 28 February 4, 2005 13:32 Type: P Check: 211 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSDGSKQLEEAVALRLFIEFLKN 28
 1 |-----|

 1 match found in sequence:
 aay31560 ; Exendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31560 check: 657 from: 1 to: 28

ID AAY31560 standard; peptide; 28 AA.

AC AAY31560;

DT 08-NOV-1999 (first entry)

DE Exendin agonist peptide.

XX Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

OS Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FH Modified-site 22

FT /note= "Naphthyl alanine"

FT Modified-site 28

FT /note= "C-terminal amide"

XX WO9940788-A1.

XX 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.

XX Example 59; Page 61; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure.
 CC increasing renal plasma flow and glomerular filtration rate, treating pre

CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds
XX
XX
SQ Sequence 28 AA;

AAV31556 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
Found using 'seq5' (mohamed337.key)

1 HGECTPSSDLSKQMEEREAARLFIWLNK 28
|-----|

1 match found in sequence:
aay31557 : Exendin agonist peptide.
(from "seq5agg.pep")
TOIG of: aay31557 check: 701 from: 1 to: 28

ID AAY31557 standard; peptide; 28 AA.

XX
AC AAY31557;

DT 08-NOV-1999 (first entry)

DE Exendin agonist peptide.

KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.

OS Synthetic.

OS Heloderma sp.

PH Key Location/Qualifiers

FT Modified-site 28
FT /note= "C-terminal amide"

XX
XX WO9940788-A1.

XX
PD 19-AUG-1999.

XX
PF 05-FEB-1999; 99WO-US002554.

XX
PR 13-FEB-1998; 98US-0075122P.

XX
PA (AMYL-) AMYLIN PHARM INC.

XX
PI Young AA, Vine W, Beeley NRA, Prickett K;

XX
DR WPI; 1999-527332/44.

XX
PT Increasing urine flow by administering peptides or peptide agonists.

XX
PS Example 56; Page 59; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine

CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds
XX
XX
SQ Sequence 28 AA;

AAV31557 Length: 28 February 4, 2005 13:32 Type: P Check: 701 ..
Found using 'seq5' (mohamed337.key)

1 HGECTPSSDLSKQMEEREAARLFIWLNK 28
|-----|

1 match found in sequence:
aay31558 : Exendin agonist peptide.
(from "seq5agg.pep")
TOIG of: aay31558 check: 649 from: 1 to: 28

ID AAY31558 standard; peptide; 28 AA.

XX
AC AAY31558;

DT 08-NOV-1999 (first entry)

DE Exendin agonist peptide.

KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.

OS Synthetic.

OS Heloderma sp.

PH Key Location/Qualifiers

FT Modified-site 28
FT /note= "C-terminal amide"

XX
XX WO9940788-A1.

XX
PD 19-AUG-1999.

XX
PF 05-FEB-1999; 99WO-US002554.

XX
PR 13-FEB-1998; 98US-0075122P.

XX
PA (AMYL-) AMYLIN PHARM INC.

XX
PI Young AA, Vine W, Beeley NRA, Prickett K;

XX
DR WPI; 1999-527332/44.

XX
PT Increasing urine flow by administering peptides or peptide agonists.

XX
PS Example 57; Page 60; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 30 AA;

AAV31554 Length: 30 February 4, 2005 13:32 Type: P Check: 4886 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGDGTTSDLSKQMEBAVRLFIETFLKN 28

 1 match found in sequence:
 aay31555 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31555 check: 369 from: 1 to: 28

ID AAY31555 standard; peptide; 28 AA.

XX AC AAY31555;

XX DT 08-NOV-1999 (first entry)

XX DE Extendin agonist peptide.

XX EX Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.

XX OS Heloderma sp.

XX FH Key Location/Qualifiers

FT Modified-site 6 /note= "Naphthylalanine"

FT Modified-site 28 /note= "C-terminal amide"

FT /note= "C-terminal amide"

XX PN WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 54; Page 58; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine

CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds

XX SQ Sequence 28 AA;

AAV31555 Length: 28 February 4, 2005 13:32 Type: P Check: 369 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEGETXTSDLSKQLEBAVRLFIETFLKN 28

 1 match found in sequence:
 aay31556 ; Extendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31556 check: 693 from: 1 to: 28

ID AAY31556 standard; peptide; 28 AA.

XX AC AAY31556;

XX DT 08-NOV-1999 (first entry)

XX DE Extendin agonist peptide.

XX EX Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.

XX OS Heloderma sp.

XX FH Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT /note= "C-terminal amide"

XX PN WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 55; Page 59; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 36 AA;

AAY31552 Length: 36 February 4, 2005 13:32 Type: P Check: 333 ..
 Found using 'seq5' (mohamed337.key)

1 HGEGETTSDLSKQMBEAVRLFIEWLKNGQPSSGAP
 1 28

 1 match found in sequence:
 aay31553 ; Exendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31553 check: 7463 from: 1 to: 35

ID AAY31553 standard; peptide; 35 AA.

XX AC AAY31553;

XX DT 08-NOV-1999 (first entry)

XX DE Exendin agonist peptide.

XX KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.

XX OS Heloderma sp.

XX PH Key Location/Qualifiers

FT Modified-site 35 /note= "C-terminal amide"

FT XX WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 52; Page 57; 94pp; English.

XX CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 35 AA;

AAY31553 Length: 35 February 4, 2005 13:32 Type: P Check: 7463 ..
 Found using 'seq5' (mohamed337.key)

1 RGEGETTSDLSKQMBEAVRLFIEWLKNGQPSSGA
 1 28

 1 match found in sequence:
 aay31554 ; Exendin agonist peptide.
 (from "seq5ags.pep")
 TOIG of: aay31554 check: 4886 from: 1 to: 30

ID AAY31554 standard; peptide; 30 AA.

XX AC AAY31554;

XX DT 08-NOV-1999 (first entry)

XX DE Exendin agonist peptide.

XX KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.

XX OS Heloderma sp.

XX PH Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT XX WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 53; Page 58; 94pp; English.

XX CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,

Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNGXGSGAXX
1 28

1 match found in sequence:
aay31551; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31551 check: 3293 from: 1 to: 37

ID AAY31551 standard; peptide; 37 AA.
XX
AC AAY31551;
XX
DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
PH Key Location/Qualifiers
FT Modified-site 31 /note= "hydroxyproline"
FT Modified-site 36 /note= "hydroxyproline"
FT Modified-site 37 /note= "hydroxyproline; C-terminal amide"
XX
PN WO9940788-A1.
XX
PD 19-AUG-1999.
XX
PF 05-FEB-1999; 99WO-US002554.
XX
PR 13-FEB-1998; 98US-0075122P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Vine W, Beeley NRA, Prickett K;
XX
DR WPI; 1999-527332/44.
XX
PT Increasing urine flow by administering peptides or peptide agonists.
XX
PS Example 50; Page 56; 94pp; English.
XX
CC The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure.
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds

XX
SQ Sequence 37 AA;
AAY31551 Length: 37 February 4, 2005 13:32 Type: P Check: 3293
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQMEEEAVRLFIEWLKNGPSSGAPP
1 28
1 match found in sequence:
aay31552; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31552 check: 333 from: 1 to: 36

ID AAY31552 standard; peptide; 36 AA.
XX
AC AAY31552;
XX
DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
PH Key Location/Qualifiers
FT Modified-site 31 /note= "hydroxyproline"
FT Modified-site 36 /note= "hydroxyproline; C-terminal amide"
XX
PN WO9940788-A1.
XX
PD 19-AUG-1999.
XX
PF 05-FEB-1999; 99WO-US002554.
XX
PR 13-FEB-1998; 98US-0075122P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Vine W, Beeley NRA, Prickett K;
XX
DR WPI; 1999-527332/44.
XX
PT Increasing urine flow by administering peptides or peptide agonists.
XX
PS Example 51; Page 57; 94pp; English.
XX
CC The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,

```

-----
1 match found in sequence:
aay31549 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31549 check: 3541 from: 1 to: 37

ID AAY31549 standard; peptide; 37 AA.
XX
XX AAY31549;
AC
XX
DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
XX Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "N-methyl alanine"
FT Modified-site 37
FT Modified-site /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 48; Page 55; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
XX Sequence 37 AA;
SQ
AAY31549 Length: 37 February 4, 2005 13:32 Type: P Check: 3541
Found using 'seq5' (mohamed337.key)

```

```

-----
1 match found in sequence:
aay31550 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31550 check: 4125 from: 1 to: 37

ID AAY31550 standard; peptide; 37 AA.
XX
XX AAY31550;
AC
XX
DT 08-NOV-1999 (first entry)
XX
XX Exendin agonist peptide.
XX
XX Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "N-methyl alanine"
FT Modified-site 36
FT Modified-site /note= "N-methyl alanine"
FT Modified-site 37 /note= "N-methyl alanine; C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 49; Page 56; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
XX Sequence 37 AA;
SQ
AAY31550 Length: 37 February 4, 2005 13:32 Type: P Check: 4125

```

DT 08-NOV-1999 (first entry)
XX Extendin agonist peptide.
XX
XX
KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "thioprolin"
FT Modified-site 36 /note= "thioprolin"
FT Modified-site 37 /note= "thioprolin"
FT Modified-site 38 /note= "thioprolin; C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 46; Page 54; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
XX Sequence 38 AA;
SQ
AAY31547 Length: 38 February 4, 2005 13:32 Type: P Check: 7469 ..
Found using 'seq5' (mohamed337.key)
1

1 HGEGTFTSDLSKQMEBEAVRLFIEWLKNGXSGAXXX
28

1 match found in sequence:
aay31548; Extendin agonist peptide.
(from "seq5ags.pep")

TOIG of: aay31548 check: 7221 from: 1 to: 38
ID AAY31548 standard; peptide; 38 AA.
XX
XX AAY31548;
XX
DT 08-NOV-1999 (first entry)
XX Extendin agonist peptide.
XX
XX
KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 36 /note= "thioprolin"
FT Modified-site 37 /note= "thioprolin"
FT Modified-site 38 /note= "thioprolin; C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 47; Page 55; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
XX Sequence 38 AA;
SQ
AAY31548 Length: 38 February 4, 2005 13:32 Type: P Check: 7221 ..
Found using 'seq5' (mohamed337.key)
1

1 HGEGTFTSDLSKQMEBEAVRLFIEWLKNGGPGSGAXXX
28

1


```

DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 31
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 42; Page 52; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 31 AA;
AAY31543 Length: 31 February 4, 2005 13:32 Type: P Check: 6930 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIFLKNNGG
1 28
-----
1 match found in sequence:
aay31544 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31544 check: 4450 from: 1 to: 30
ID AAY31544 standard; peptide; 30 AA.
XX
AC AAY31544;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 43; Page 52-53; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 30 AA;
AAY31544 Length: 30 February 4, 2005 13:32 Type: P Check: 4450 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIFLKNNGG
1 28
-----
1 match found in sequence:
aay31545 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31545 check: 2759 from: 1 to: 29
ID AAY31545 standard; peptide; 29 AA.
XX
AC AAY31545;
XX

```

DT	08-NOV-1999	(first entry)
XX	Exendin agonist peptide.	
XX	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;	
XX	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;	
XX	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;	
XX	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;	
XX	hypertension; urine flow.	
XX	Synthetic.	
XX	Heloderma sp.	
XX	Key Location/Qualifiers	
XX	Modified-site 32	/note= "C-terminal amide"
XX	WO9940788-A1.	
XX	19-AUG-1999.	
XX	05-FEB-1999;	99WO-US002554.
XX	13-FEB-1998;	98US-0075122P.
XX	(AMYL-) AMYLIN PHARM INC.	
XX	Young AA, Vine W, Beeley NRA, Prickett K;	
XX	WPI; 1999-527332/44.	
XX	Increasing urine flow by administering peptides or peptide agonists.	
XX	Example 40; Page 51; 94pp; English.	
XX	The invention relates to new methods of increasing urine flow that	
XX	comprises administering an exendin or exendin agonist, or a GLP-1	
XX	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	
XX	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for	
XX	increasing urine flow, decreasing potassium concentration in urine,	
XX	preventing or alleviating a disorder associated with toxic hypervolemia	
XX	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	
XX	edema, cirrhosis, or hypertension). They can also be used for inducing	
XX	rapid diuresis, preparing an individual for surgical procedure,	
XX	increasing renal plasma flow and glomerular filtration rate, treating pre	
XX	-eclampsia or eclampsia of pregnancy, and increasing a condition/	
XX	disorder that can be alleviated by increasing cardiac contractility	
XX	(congestive heart failure, pulmonary edema, systemic edema or renal	
XX	failure). Unlike prior art diuretics, the new methods increase urine	
XX	excretion and sodium excretion without increasing potassium loss, and are	
XX	fast acting. They have a prolonged duration of action, are inotropic,	
XX	have a low toxicity, and are easily administered intravenously. Sequences	
XX	AA31505-560 represent examples of exendin agonists compounds	
XX	Sequence 32 AA;	
XX	AA31541 Length: 32 February 4, 2005 13:32 Type: P Check: 9586	
XX	Found using 'seq5' (mohamed337.key)	
XX	1 HGEGTFTSDLSKOLEEAVRLFIEFLKNGGPGS	28
XX	1 match found in sequence:	
XX	aay31542; Exendin agonist peptide.	
XX	(from "seq5ags.pep")	
XX	TOIG of: aay31542 check: 7369 from: 1 to: 31	
XX	ID AAY31542 standard; peptide; 31 AA.	
XX	AC AAY31542;	
XX		

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 39; Page 50; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 33 AA;
AAY31539 Length: 33 February 4, 2005 13:32 Type: P Check: 2325
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIETLNKGGPSS
1 |-----|
1 HGGTFTSDLSKQMEEEAVRLFIETLNKGGPS
1 |-----|
1 match found in sequence:
aay31540 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31540 check: 25 from: 1 to: 32
ID AAY31540 standard; peptide; 32 AA.
XX
XX AAY31540;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 32
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 39; Page 50; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 32 AA;
AAY31540 Length: 32 February 4, 2005 13:32 Type: P Check: 25
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIETLNKGGPS
1 |-----|
1 HGGTFTSDLSKQMEEEAVRLFIETLNKGGPS
1 |-----|
1 match found in sequence:
aay31541 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31541 check: 9586 from: 1 to: 32
ID AAY31541 standard; peptide; 32 AA.
XX
XX AAY31541;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
KW Extensin agonist peptide.
KW Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 36; Page 49; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extensin or extensin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extensin agonists compounds
XX
SQ Sequence 34 AA;
AAY31537 Length: 34 February 4, 2005 13:32 Type: P Check: 4739
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQLEEEAVRLFIEFLKNGGPFSS
1
-----|-----|
1 match found in sequence:
aay31538 ; Extensin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31538 check: 2764 from: 1 to: 33
ID AAY31538 standard; peptide; 33 AA.
XX
AC AAY31538;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
KW Extensin agonist peptide.
KW Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 37; Page 49; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extensin or extensin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extensin agonists compounds
XX
SQ Sequence 33 AA;
AAY31538 Length: 33 February 4, 2005 13:32 Type: P Check: 2764
Found using 'seq5' (mohamed337.key)
1 HGEFTFTDLSKQLEEEAVRLFIEFLKNGGPFSS
1
-----|-----|
1 match found in sequence:
aay31539 ; Extensin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31539 check: 2325 from: 1 to: 33
ID AAY31539 standard; peptide; 33 AA.
XX
AC AAY31539;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 35
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 34; Page 48; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
XX Sequence 35 AA;
XX
AAY31535 Length: 35 February 4, 2005 13:32 Type: P Check: 7014
Found using 'seq5' (mohamed337.key)
1 HGEFTTSLSKQLEEEAVRLFIETLKNKGPPSSGA
1 1
-----|-----|
1 match found in sequence:
aay31536 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31536 check: 5178 from: 1 to: 34

ID AAY31536 standard; peptide; 34 AA.
XX
AC AAY31536;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 35; Page 48; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
XX Sequence 34 AA;
XX
AAY31536 Length: 34 February 4, 2005 13:32 Type: P Check: 5178
Found using 'seq5' (mohamed337.key)
1 HGEFTTSLSKQLEEEAVRLFIETLKNKGPPSSG
1 1
-----|-----|
1 match found in sequence:
aay31537 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31537 check: 4739 from: 1 to: 34

ID AAY31537 standard; peptide; 34 AA.
XX
AC AAY31537;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extending agonist peptide.
KW Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 36
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 32; Page 47; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX preventing urine flow, decreasing potassium concentration in urine,
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 36 AA;
AAY31533 Length: 36 February 4, 2005 13:32 Type: P Check: 9894 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGSPGAP
1 28
-----
1 match found in sequence:
aay31534 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31534 check: 7453 from: 1 to: 35
ID AAY31534 standard; peptide; 35 AA.
XX
AC AAY31534;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extending agonist peptide.
KW Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 35
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 33; Page 47; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX preventing urine flow, decreasing potassium concentration in urine,
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 35 AA;
AAY31534 Length: 35 February 4, 2005 13:32 Type: P Check: 7453 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEFLKNGGSPSGA
1 28
-----
1 match found in sequence:
aay31535 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31535 check: 7014 from: 1 to: 35
ID AAY31535 standard; peptide; 35 AA.
XX
AC AAY31535;
XX

```

DT	08-NOV-1999	(first entry)
XX	Exendin agonist peptide.	
DE	Exendin agonist peptide.	
XX	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;	
KW	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;	
KW	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;	
KW	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;	
KW	hypertension; urine flow.	
XX	Synthetic.	
OS	Heloderma sp.	
XX	Key Location/Qualifiers	
FH	Modified-site 38	
FT	/note= "C-terminal amide"	
FT		
XX	WO9940788-A1.	
PN	19-AUG-1999.	
PD		
XX	05-FEB-1999; 99WO-US002554.	
PP		
XX	13-FEB-1998; 98US-0075122P.	
PR		
XX	(AMYL-) AMYLIN PHARM INC.	
PA		
XX	Young AA, Vine W, Beeley NRA, Prickett K;	
PI		
XX	WPI; 1999-527332/44.	
DR		
XX	Increasing urine flow by administering peptides or peptide agonists.	
PT		
XX	Example 31; Page 46; 94pp; English.	
PS		
XX	The invention relates to new methods of increasing urine flow that	
CC	comprises administering an exendin or exendin agonist, or a GLP-1	
CC	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	
CC	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for	
CC	increasing urine flow, decreasing potassium concentration in urine,	
CC	preventing or alleviating a disorder associated with toxic hypervolemia	
CC	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	
CC	edema, cirrhosis, or hypertension). They can also be used for inducing	
CC	rapid diuresis, preparing an individual for surgical procedure,	
CC	increasing renal plasma flow and glomerular filtration rate, treating pre	
CC	-eclampsia or eclampsia of pregnancy, and increasing a condition/	
CC	disorder that can be alleviated by increasing cardiac contractility	
CC	(congestive heart failure, pulmonary edema, systemic edema or renal	
CC	failure). Unlike prior art diuretics, the new methods increase urine	
CC	excretion and sodium excretion without increasing potassium loss, and are	
CC	fast acting. They have a prolonged duration of action, are isotropic,	
CC	have a low toxicity, and are easily administered intravenously. Sequences	
CC	AAAY31505-560 represent examples of exendin agonists compounds	
XX		
XX	Sequence 37 AA;	
SQ		
AAAY31531	Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..	
Found using 'seqs'	(mohamed337.key)	
1	HGEGTFTSDLSKQLEBEAVRLFIETFLKNKGPGSSGAPP ----- 1 28	
1 match found in sequence:		
aay31532 ; Exendin agonist peptide.		
(from "seqsags.pep")		
TOIG of: aay31532 check: 333 from: 1 to: 36		
ID AAY31532 standard; peptide; 36 AA.		
XX AC AAY31532;		
XX XY		

DT	08-NOV-1999	(first entry)
XX	Exendin agonist peptide.	
DE	Exendin agonist peptide.	
XX	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;	
KW	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;	
KW	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;	
KW	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;	
KW	hypertension; urine flow.	
XX	Synthetic.	
OS	Heloderma sp.	
XX	Key Location/Qualifiers	
FH	Modified-site 38	
FT	/note= "C-terminal amide"	
FT		
XX	WO9940788-A1.	
PN	19-AUG-1999.	
PD		
XX	05-FEB-1999; 99WO-US002554.	
PP		
XX	13-FEB-1998; 98US-0075122P.	
PR		
XX	(AMYL-) AMYLIN PHARM INC.	
PA		
XX	Young AA, Vine W, Beeley NRA, Prickett K;	
PI		
XX	WPI; 1999-527332/44.	
DR		
XX	Increasing urine flow by administering peptides or peptide agonists.	
PT		
XX	Example 30; Page 46; 94pp; English.	
PS		
XX	The invention relates to new methods of increasing urine flow that	
CC	comprises administering an exendin or exendin agonist, or a GLP-1	
CC	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	
CC	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for	
CC	increasing urine flow, decreasing potassium concentration in urine,	
CC	preventing or alleviating a disorder associated with toxic hypervolemia	
CC	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	
CC	edema, cirrhosis, or hypertension). They can also be used for inducing	
CC	rapid diuresis, preparing an individual for surgical procedure,	
CC	increasing renal plasma flow and glomerular filtration rate, treating pre	
CC	-eclampsia or eclampsia of pregnancy, and increasing a condition/	
CC	disorder that can be alleviated by increasing cardiac contractility	
CC	(congestive heart failure, pulmonary edema, systemic edema or renal	
CC	failure). Unlike prior art diuretics, the new methods increase urine	
CC	excretion and sodium excretion without increasing potassium loss, and are	
CC	fast acting. They have a prolonged duration of action, are isotropic,	
CC	have a low toxicity, and are easily administered intravenously. Sequences	
CC	AAAY31505-560 represent examples of exendin agonists compounds	
XX		
XX	Sequence 37 AA;	
SQ		
AAAY31531	Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..	
Found using 'seqs'	(mohamed337.key)	
1	HGEGTFTSDLSKQLEBEAVRLFIETFLKNKGPGSSGAPP ----- 1 28	
1 match found in sequence:		
aay31532 ; Exendin agonist peptide.		
(from "seqsags.pep")		
TOIG of: aay31532 check: 333 from: 1 to: 36		
ID AAY31532 standard; peptide; 36 AA.		
XX AC AAY31532;		
XX XY		

DT	08-NOV-1999	(first entry)
XX	DE	Exendin agonist peptide.
XX	KW	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
XX	KW	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
XX	KW	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
XX	KW	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX	KW	hypertension; urine flow.
OS	Synthetic.	
OS	Heloderma sp.	
XX	Key	Location/Qualifiers
FH	Modified-site	38
FT	/note= "C-terminal amide"	
XX	WO9940788-A1.	
PX	19-AUG-1999.	
XX	05-FEB-1999;	99WO-US002554.
XX	13-FEB-1998;	98US-0075122P.
XX	(AMYL-) AMYLIN PHARM INC.	
XX	Young AA, Vine W, Beeley NRA, Prickett K;	
XX	WPI; 1999-527332/44.	
XX	Increasing urine flow by administering peptides or peptide agonists.	
XX	Example 28; Page 45; 94pp; English.	
XX	The invention relates to new methods of increasing urine flow that	
CC	comprises administering an exendin or exendin agonist, or a GLP-1	
CC	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	
CC	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for	
CC	increasing urine flow, decreasing potassium concentration in urine,	
CC	preventing or alleviating a disorder associated with toxic hypervolemia	
CC	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	
CC	edema, cirrhosis, or hypertension). They can also be used for inducing	
CC	rapid diuresis, preparing an individual for surgical procedure,	
CC	increasing renal plasma flow and glomerular filtration rate, treating pre	
CC	-eclampsia or eclampsia of pregnancy, and increasing a condition/	
CC	disorder that can be alleviated by increasing cardiac contractility	
CC	(congestive heart failure, pulmonary edema, systemic edema or renal	
CC	failure). Unlike prior art diuretics, the new methods increase urine	
CC	excretion and sodium excretion without increasing potassium loss, and are	
CC	fast acting. They have a prolonged duration of action, are isotropic,	
CC	have a low toxicity, and are easily administered intravenously. Sequences	
CC	AAV31505-560 represent examples of exendin agonists compounds	
XX	Sequence 38 AA;	
SQ	Length: 38 February 4, 2005 13:32 Type: P Check: 5894	
Found using 'seq5' (mohamed337.key)		
1	HGEGTFTSDLSKOLEEAVRLFIETFLKNGSPSGAPP	28
1	-----	
1	match found in sequence:	
aay31530 ; Exendin agonist peptide.		
(from "seq5ags.pep")		
TOIG of: aay31530 check: 3293 from: 1 to: 37		
ID AAY31530 standard; peptide; 37 AA.		
XX AC AAY31530;		
XX		

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 26; Page 43; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31527 Length: 28 February 4, 2005 13:32 Type: P Check: 9897
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQLEEEAVRLFIETFLKA 28
|-----|
1 match found in sequence:
aay31528 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31528 check: 6333 from: 1 to: 38
ID AAY31528 standard; peptide; 38 AA.
XX
AC AAY31528;
XX

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 27; Page 44; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 38 AA;
AAY31528 Length: 38 February 4, 2005 13:32 Type: P Check: 6333
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQMEEEAVRLFIEWLKNGGPGSGAPPP 28
|-----|
1 match found in sequence:
aay31529 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31529 check: 5894 from: 1 to: 38
ID AAY31529 standard; peptide; 38 AA.
XX
AC AAY31529;
XX

```

DT	XX	08-NOV-1999	(first entry)
DT	XX	08-NOV-1999	(first entry)
DE	DE	Extendin agonist peptide.	
DE	DE	Extendin agonist peptide.	
KW	KW	Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;	
KW	KW	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;	
KW	KW	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;	
KW	KW	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;	
KW	KW	hypertension; urine flow.	
OS	OS	Synthetic.	
OS	OS	Heloderma sp.	
XX	XX	Key	Location/Qualifiers
FT	FT	Modified-site	28
FT	FT	/note= "C-terminal amide"	
XX	XX	W09940788-A1.	
XX	XX	19-AUG-1999.	
XX	XX	05-FEB-1999;	99WO-US002554.
XX	XX	13-FEB-1998;	98US-0075122P.
XX	XX	(AMYL-) AMYLIN PHARM INC.	
XX	XX	Young AA, Vine W, Beeley NRA, Prickett K;	
XX	XX	WPI; 1999-527332/44.	
XX	XX	Increasing urine flow by administering peptides or peptide agonists.	
XX	XX	Example 24; Page 42; 94pp; English.	
XX	XX	The invention relates to new methods of increasing urine flow that	
XX	XX	comprises administering an extendin or extendin agonist, or a GLP-1	
XX	XX	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	
XX	XX	extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for	
XX	XX	increasing urine flow, decreasing potassium concentration in urine,	
XX	XX	preventing or alleviating a disorder associated with toxic hypervolemia	
XX	XX	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	
XX	XX	edema, cirrhosis, or hypertension). They can also be used for inducing	
XX	XX	rapid diuresis, preparing an individual for surgical procedure,	
XX	XX	increasing renal plasma flow and glomerular filtration rate, treating pre	
XX	XX	eclampsia or eclampsia of pregnancy, and increasing a condition/	
XX	XX	disorder that can be alleviated by increasing cardiac contractility	
XX	XX	(congestive heart failure, pulmonary edema, systemic edema or renal	
XX	XX	failure). Unlike prior art diuretics, the new methods increase urine	
XX	XX	excretion and sodium excretion without increasing potassium loss, and are	
XX	XX	fast acting. They have a prolonged duration of action, are inotropic,	
XX	XX	have a low toxicity, and are easily administered intravenously. Sequences	
XX	XX	AA31505-560 represent examples of extendin agonists compounds	
XX	XX	Sequence 28 AA;	
XX	XX	AA31525 Length: 28 February 4, 2005 13:32 Type: P Check: 9975	
XX	XX	Found using 'seqs' (mohamed337.key)	
XX	XX	1 HGEFTTSDLSKQLEEEAVRLFIEFAN	28
XX	XX	1	
XX	XX	1 match found in sequence:	
XX	XX	aa31526 ; Extendin agonist peptide.	
XX	XX	(from "seq5ags.pep")	
XX	XX	TOIG of: aa31526 check: 9991 from: 1 to: 28	
XX	XX	ID AA31526 standard; peptide; 28 AA.	
XX	XX	AA31526;	
XX	XX		

08-NOV-1999 (first entry)
Exendin agonist peptide.
Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
hypertension; urine flow.
Synthetic.
Heloderma sp.
Key Location/Qualifiers
Modified-site 28 /note= "C-terminal amide"
WO9940788-A1.
19-AUG-1999.
05-FEB-1999; 99WO-US002554.
13-FEB-1998; 98US-0075122P.
(AMYL-) AMYLIN PHARM INC.
Young AA, Vine W, Beeley NRA, Prickett K;
WPI; 1999-527332/44.
Increasing urine flow by administering peptides or peptide agonists.
Example 23; Page 42; 94pp; English.
The invention relates to new methods of increasing urine flow that
comprises administering an exendin or exendin agonist, or a GLP-1
(glucagon-like peptide) or GLP-1 agonist. The new methods using an
exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
increasing urine flow, decreasing potassium concentration in urine,
preventing or alleviating a disorder associated with toxic hypervolemia
(renal failure, congestive heart failure, nephrotic syndrome, pulmonary
edema, cirrhosis, or hypertension). They can also be used for inducing
rapid diuresis, preparing an individual for surgical procedure,
increasing renal plasma flow and glomerular filtration rate, treating pre
-eclampsia or eclampsia of pregnancy, and increasing a condition/
disorder that can be alleviated by increasing cardiac contractility
(congestive heart failure, pulmonary edema, systemic edema or renal
failure). Unlike prior art diuretics, the new methods increase urine
excretion and sodium excretion without increasing potassium loss, and are
fast acting. They have a prolonged duration of action, are inotropic,
have a low toxicity, and are easily administered intravenously. Sequences
AAV31505-560 represent examples of exendin agonists compounds
Sequence 28 AA;
AAV31524 Length: 28 February 4, 2005 13:32 Type: P Check: 136
Found using 'seq5' (mohamed337.key)
1 HEGGTFSDLSKQLEEEAVRLFIAFLKN 28
1 match found in sequence:
aay31525; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31525 check: 9975 from: 1 to: 28
ID AAY31525 standard; peptide; 28 AA.
XX
AC AAY31525;
XX

08-NOV-1999 (first entry)
Exendin agonist peptide.
Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
hypertension; urine flow.
Synthetic.
Heloderma sp.
Key Location/Qualifiers
Modified-site 28 /note= "C-terminal amide"
WO9940788-A1.
19-AUG-1999.
05-FEB-1999; 99WO-US002554.
13-FEB-1998; 98US-0075122P.
(AMYL-) AMYLIN PHARM INC.
Young AA, Vine W, Beeley NRA, Prickett K;
WPI; 1999-527332/44.
Increasing urine flow by administering peptides or peptide agonists.
Example 22; Page 41; 94pp; English.
The invention relates to new methods of increasing urine flow that
comprises administering an exendin or exendin agonist, or a GLP-1
(glucagon-like peptide) or GLP-1 agonist. The new methods using an
exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
increasing urine flow, decreasing potassium concentration in urine,
preventing or alleviating a disorder associated with toxic hypervolemia
(renal failure, congestive heart failure, nephrotic syndrome, pulmonary
edema, cirrhosis, or hypertension). They can also be used for inducing
rapid diuresis, preparing an individual for surgical procedure,
increasing renal plasma flow and glomerular filtration rate, treating pre
-eclampsia or eclampsia of pregnancy, and increasing a condition/
disorder that can be alleviated by increasing cardiac contractility
(congestive heart failure, pulmonary edema, systemic edema or renal
failure). Unlike prior art diuretics, the new methods increase urine
excretion and sodium excretion without increasing potassium loss, and are
fast acting. They have a prolonged duration of action, are inotropic,
have a low toxicity, and are easily administered intravenously. Sequences
AAV31505-560 represent examples of exendin agonists compounds
Sequence 28 AA;
AAV31523 Length: 28 February 4, 2005 13:32 Type: P Check: 165
Found using 'seq5' (mohamed337.key)
1 HEGGTFSDLSKQLEEEAVRLFIAFLKN 28
1 match found in sequence:
aay31524; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31524 check: 136 from: 1 to: 28
ID AAY31524 standard; peptide; 28 AA.
XX
AC AAY31524;
XX

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
KW Exendin agonist peptide.
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 20; Page 40; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;

AAY31521 Length: 28 February 4, 2005 13:32 Type: P Check: 9921
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEENAVLFIFLKN 28
1 |-----|
1 match found in sequence:
aay31522 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31522 check: 30 from: 1 to: 28

ID AAY31522 standard; peptide; 28 AA.
XX
AC AAY31522;
XX

DT 08-NOV-1999 (first entry)
XX
DE
XX
KW Exendin agonist peptide.
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 20; Page 40; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;

AAY31522 Length: 28 February 4, 2005 13:32 Type: P Check: 9921
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEENAVLFIFLKN 28
1 |-----|
1 match found in sequence:
aay31522 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31522 check: 30 from: 1 to: 28

ID AAY31522 standard; peptide; 28 AA.
XX
AC AAY31522;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
DE
XX
XX
KW Extending agonist peptide.
KW Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 18; Page 39; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31519 Length: 28 February 4, 2005 13:32 Type: P Check: 193
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSDLSKQLEAAVRLEFLKN
1 28
-----
1 match found in sequence:
aay31520 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31520 check: 9862 from: 1 to: 28
ID AAY31520 standard; peptide; 28 AA.
XX
AC AAY31520;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
DE
XX
XX
KW Extending agonist peptide.
KW Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 19; Page 40; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31520 Length: 28 February 4, 2005 13:32 Type: P Check: 9862
Found using 'seq5' (mohamed337.key)
1 HGEFTFTSDLSKQLEAAARLFIEFLKN
1 28
-----
1 match found in sequence:
aay31521 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31521 check: 9921 from: 1 to: 28
ID AAY31521 standard; peptide; 28 AA.
XX
AC AAY31521;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
KW Extensin agonist peptide.
KW Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 16; Page 38; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extensin or extensin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extensin agonists compounds
XX
SQ Sequence 28 AA;
AAY31517 Length: 28 February 4, 2005 13:32 Type: P Check: 201
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay31518 ; Extensin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31518 check: 197 from: 1 to: 28
ID AAY31518 standard; peptide; 28 AA.
XX
AC AAY31518;
XX

DT 08-NOV-1999 (first entry)
XX
DE
XX
KW Extensin agonist peptide.
KW Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 16; Page 38; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extensin or extensin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extensin agonists compounds
XX
SQ Sequence 28 AA;
AAY31518 Length: 28 February 4, 2005 13:32 Type: P Check: 197
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay31519 ; Extensin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31519 check: 193 from: 1 to: 28
ID AAY31519 standard; peptide; 28 AA.
XX
AC AAY31519;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extensin agonist peptide.
KW Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 14; Page 37; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extensin or extensin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extensin agonists compounds
XX
SQ Sequence 28 AA;
AAY31515 Length: 28 February 4, 2005 13:32 Type: P Check: 53
Found using 'seq5' (mohamed337.key)
1 HEGGTFTSLSKALEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aay31516 ; Extensin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31516 check: 107 from: 1 to: 28
ID AAY31516 standard; peptide; 28 AA.
XX
AC AAY31516;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 15; Page 38; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extensin or extensin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extensin agonists compounds
XX
SQ Sequence 28 AA;
AAY31516 Length: 28 February 4, 2005 13:32 Type: P Check: 107
Found using 'seq5' (mohamed337.key)
1 HEGGTFTSLSKQAEAEAVRLFIEFLKN 28
-----|
1 match found in sequence:
aay31517 ; Extensin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31517 check: 201 from: 1 to: 28
ID AAY31517 standard; peptide; 28 AA.
XX
AC AAY31517;
XX

```



```

DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 12; Page 36; 94pp; English.
XX
CC The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;

AAY31513 Length: 28 February 4, 2005 13:32 Type: P Check: 63
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDLAQLEEEAVRLFIFLKN 28
|-----|
1 match found in sequence:
aay31514 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31514 check: 141 from: 1 to: 28

ID AAY31514 standard; peptide; 28 AA.
XX
AC AAY31514;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 13; Page 37; 94pp; English.
XX
CC The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;

AAY31514 Length: 28 February 4, 2005 13:32 Type: P Check: 141
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDLAQLEEEAVRLFIFLKN 28
|-----|
1 match found in sequence:
aay31515 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31515 check: 53 from: 1 to: 28

ID AAY31515 standard; peptide; 28 AA.
XX
AC AAY31515;
XX

```

```
DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 10; Page 35; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31511 Length: 28 February 4, 2005 13:32 Type: P Check: 117 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTADLSKQLEEAVALRFLFELKN 28
-----|-----
1 match found in sequence:
aay31512 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31512 check: 151 from: 1 to: 28
ID AAY31512 standard; peptide; 28 AA.
XX
AC AAY31512;
XX
```

```
DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 11; Page 36; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31512 Length: 28 February 4, 2005 13:32 Type: P Check: 151 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTTSDASKQLEEAVALRFLFELKN 28
-----|-----
1 match found in sequence:
aay31513 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31513 check: 63 from: 1 to: 28
ID AAY31513 standard; peptide; 28 AA.
XX
AC AAY31513;
XX
```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 8; Page 34; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31509 Length: 28 February 4, 2005 13:32 Type: P Check: 166
Found using 'seq5' (mohamed337.key)
1 HEGGATSDLSKQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay31510 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31510 check: 231 from: 1 to: 28
ID AAY31510 standard; peptide; 28 AA.
XX
XX AAY31510;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 9; Page 35; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31510 Length: 28 February 4, 2005 13:32 Type: P Check: 231
Found using 'seq5' (mohamed337.key)
1 HEGGTATSDLSKQLEEEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
aay31511 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31511 check: 117 from: 1 to: 28
ID AAY31511 standard; peptide; 28 AA.
XX
XX AAY31511;
XX

```

```

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extendin agonist peptide.
KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 6; Page 33; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31507 Length: 28 February 4, 2005 13:32 Type: P Check: 261
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRLFIEFLKN 28
-----|-----
1 match found in sequence:
aay31508 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31508 check: 249 from: 1 to: 28
ID AAY31508 standard; peptide; 28 AA.
XX
AC AAY31508;
XX

DT 08-NOV-1999 (first entry)
XX
DE
XX
XX
KW Extendin agonist peptide.
KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Example 7; Page 34; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an extendin or extendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are inotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of extendin agonists compounds
XX
SQ Sequence 28 AA;
AAY31507 Length: 28 February 4, 2005 13:32 Type: P Check: 249
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRLFIEFLKN 28
-----|-----
1 match found in sequence:
aay31509 ; Extendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31509 check: 166 from: 1 to: 28
ID AAY31509 standard; peptide; 28 AA.
XX
AC AAY31509;
XX

```

DT	08-NOV-1999	(first entry)
XX	Exendin agonist peptide.	
XX	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;	
XX	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;	
XX	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;	
XX	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;	
XX	hypertension; urine flow.	
XX	Synthetic.	
XX	Heloderma sp.	
XX	Key Location/Qualifiers	
XX	Modified-site 30	
XX	/note= "C-terminal amide"	
XX	WO9940788-A1.	
XX	19-AUG-1999.	
XX	05-FEB-1999; 99WO-US002554.	
XX	13-FEB-1998; 98US-0075122P.	
XX	(AMYL-) AMYLIN PHARM INC.	
XX	Young AA, Vine W, Beeley NRA, Prickett K;	
XX	WPI; 1999-527332/44.	
XX	Increasing urine flow by administering peptides or peptide agonists.	
XX	Example 4; Page 32; 94pp; English.	
XX	The invention relates to new methods of increasing urine flow that	
XX	comprises administering an exendin or exendin agonist, or a GLP-1	
XX	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	
XX	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for	
XX	increasing urine flow, decreasing potassium concentration in urine,	
XX	preventing or alleviating a disorder associated with toxic hypervolemia	
XX	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	
XX	edema, cirrhosis, or hypertension). They can also be used for inducing	
XX	rapid diuresis, preparing an individual for surgical procedure,	
XX	increasing renal plasma flow and glomerular filtration rate, treating pre	
XX	-eclampsia or eclampsia of pregnancy, and increasing a condition/	
XX	disorder that can be alleviated by increasing cardiac contractility	
XX	(congestive heart failure, pulmonary edema, systemic edema or renal	
XX	failure). Unlike prior art diuretics, the new methods increase urine	
XX	excretion and sodium excretion without increasing potassium loss, and are	
XX	fast acting. They have a prolonged duration of action, are inotropic,	
XX	have a low toxicity, and are easily administered intravenously. Sequences	
XX	AA31505-560 represent examples of exendin agonists compounds	
XX	Sequence 30 AA;	
XX	AA31505 Length: 30 February 4, 2005 13:32 Type: P Check: 4889	
XX	Found using 'seq5' (mohamed337.key)	
XX	1 HGGGTFTSDLSKQMEEEAVRLFIEWLKNGG	
XX	1	
XX	-----	
XX	1 match found in sequence:	
XX	aay31506 ; Exendin agonist peptide.	
XX	(from "seq5ags.pep")	
XX	TOIG of: aay31506 check: 700 from: 1 to: 28	
XX	ID AAY31506 standard; peptide; 28 AA.	
XX	AC AAY31506;	
XX	XX	

DE Exendin-3 peptide sequence.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma horridum.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 39 /note= "C-terminal amide"
FT
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Claim 14; Page 7; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing cardiac contractility
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. The
CC present sequence represents an exendin-3 peptide which can be used in the
CC methods of the invention
XX
SQ Sequence 39 AA;
AAY31501 Length: 39 February 4, 2005 13:32 Type: P Check: 9591 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HSDGFTSLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aay31502 ; Exendin-4 peptide sequence.
(from "seq5ags.pep")
TOIG of: aay31502 check: 9570 from: 1 to: 39

ID AAY31502 standard; peptide; 39 AA.
XX
AC AAY31502;
XX
DT 08-NOV-1999 (first entry)

XX Exendin-4 peptide sequence.
DE
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma suspectum.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 39 /note= "C-terminal amide"
FT
XX
XX WO9940788-A1.
XX
XX 19-AUG-1999.
XX
XX 05-FEB-1999; 99WO-US002554.
XX
XX 13-FEB-1998; 98US-0075122P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX Increasing urine flow by administering peptides or peptide agonists.
XX
XX Claim 15; Page 7; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing cardiac contractility
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. The
CC present sequence represents an exendin-4 peptide which can be used in the
CC methods of the invention
XX
SQ Sequence 39 AA;
AAY31502 Length: 39 February 4, 2005 13:32 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
HGEGTFTSLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aay31505 ; Exendin agonist peptide.
(from "seq5ags.pep")
TOIG of: aay31505 check: 4889 from: 1 to: 30

ID AAY31505 standard; peptide; 30 AA.
XX
AC AAY31505;
XX

CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 33 AA;

AAV24867 Length: 33 February 4, 2005 13:32 Type: P Check: 2215 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTTSDASKQLEEEAVRLFIIFLKNKGSPSS
 28

 1 match found in sequence:

ayay24868 ; Exendin agonist peptide #60.
 (from "seq5aggs.pep")

TOIG of: aay24868 check: 2649 from: 1 to: 29

ID AAY24868 standard; peptide; 29 AA.

XX AC AAY24868;

XX AC AAY24868;

DT 24-AUG-1999 (first entry)

XX DE Exendin agonist peptide #60.

XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX OS Synthetic.

OS Heloderma sp.

XX PN WO9925727-A2.

XX PD 27-MAY-1999.

XX PP 13-NOV-1998; 98WO-US024210.

XX PR 14-NOV-1997; 97US-0065442P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-394773/33.

XX PT New exendin agonist peptides - can regulate gastric motility and slow

PT gastric emptying, used for treating, e.g. diabetes.

XX PS Claim 18; Fig 4; 108pp; English.

XX CC AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying

XX SQ Sequence 29 AA;

AAV24868 Length: 29 February 4, 2005 13:32 Type: P Check: 2649 ..

Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTTSDASKQMEEEAVRLFIIFLKNKG
 28

 1 match found in sequence:

ayay24869 ; Exendin agonist peptide #61.
 (from "seq5aggs.pep")

TOIG of: aay24869 check: 4015 from: 1 to: 37

ID AAY24869 standard; peptide; 37 AA.

XX AC AAY24869;

XX DT 24-AUG-1999 (first entry)

XX DE Exendin agonist peptide #61.

XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX OS Synthetic.

OS Heloderma sp.

XX PN WO9925727-A2.

XX PD 27-MAY-1999.

XX PF 13-NOV-1998; 98WO-US024210.

XX PR 14-NOV-1997; 97US-0065442P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-394773/33.

XX PT New exendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.

XX PS Claim 18; Fig 4; 108pp; English.

XX CC AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying

XX SQ Sequence 37 AA;

AAV24869 Length: 37 February 4, 2005 13:32 Type: P Check: 4015 ..

Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEFTTSDASKQMEEEAVRLFIIFLKNKGXSGAXX
 28

 1 match found in sequence:

ayay31501 ; Exendin-3 peptide sequence.
 (from "seq5aggs.pep")

TOIG of: aay31501 check: 9591 from: 1 to: 39

ID AAY31501 standard; peptide; 39 AA.

XX AC AAY31501;

XX DT 08-NOV-1999 (first entry)

XX

```

PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 28 AA;

AAY24864 Length: 28 February 4, 2005 13:32 Type: P Check: 657 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HEGGFTSDLSKQLEEEAVRLXIEFLKN 28

-----
1 match found in sequence:
aay24865 ; Extendin agonist peptide #57.
(from "seq5ags.pep")
TOIG of: aay24865 check: 1045 from: 1 to: 28

ID AAY24865 standard; peptide; 28 AA.
XX
AC AAY24865;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #57.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.

```

```

XX Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 28 AA;

AAY24865 Length: 28 February 4, 2005 13:32 Type: P Check: 1045 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HEGGFTSDLSKQLEEEAVRLXIEFLKN 28

-----
1 match found in sequence:
aay24867 ; Extendin agonist peptide #59.
(from "seq5ags.pep")
TOIG of: aay24867 check: 2215 from: 1 to: 33

ID AAY24867 standard; peptide; 33 AA.
XX
AC AAY24867;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #59.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying

```



```

KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
OS Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New exendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX Claim 18; Fig 4; 108pp; English.
XX AAY24809 to AAY24877 represent exendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are exendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 35 AA;
XX AAY24857 Length: 35 February 4, 2005 13:32 Type: P Check: 7463 ..
XX Found using 'seq5' (mohamed337.key)
1 |-----|
1 RGEFTFTSDLSKQMEAEAVRLFIEWLKNKGFSSGA
28
-----
1 match found in sequence:
aay24858 ; Exendin agonist peptide #50.
(from "seq5ags.pep")
TOIG of: aay24858 check: 4886 from: 1 to: 30
ID AAY24858 standard; peptide; 30 AA.
XX AC AAY24858;
XX DT 24-AUG-1999 (first entry)
XX DE Exendin agonist peptide #50.
XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
OS Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
OS Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.

```

```

XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New exendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX Claim 18; Fig 4; 108pp; English.
XX AAY24809 to AAY24877 represent exendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are exendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 30 AA;
XX AAY24858 Length: 30 February 4, 2005 13:32 Type: P Check: 4886 ..
XX Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGDTFTSDLSKQMEAEAVRLFIEWLKNKG
28
-----
1 match found in sequence:
aay24859 ; Exendin agonist peptide #51.
(from "seq5ags.pep")
TOIG of: aay24859 check: 383 from: 1 to: 28
ID AAY24859 standard; peptide; 28 AA.
XX AC AAY24859;
XX DT 24-AUG-1999 (first entry)
XX DE Exendin agonist peptide #51.
XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
OS Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New exendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX PT
XX

```

```

XX SQ Sequence 37 AA;
AAV24854 Length: 37 February 4, 2005 13:32 Type: P Check: 1733
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGSSGAA
  1 28
-----
1 match found in sequence:
aay24855 ; Exendin agonist peptide #47.
(from "seq5ags.pep")
TOIG of: aay24855 check: 4125 from: 1 to: 37

ID AAY24855 standard; peptide; 37 AA.
XX
AC AAY24855;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #47.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 37 AA;

AAY24855 Length: 37 February 4, 2005 13:32 Type: P Check: 4125
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGSSGAXX
  1 28
-----
1 match found in sequence:

```

```

aay24856 ; Exendin agonist peptide #48.
(from "seq5ags.pep")
TOIG of: aay24856 check: 869 from: 1 to: 36

ID AAY24856 standard; peptide; 36 AA.
XX
AC AAY24856;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #48.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 36 AA;

AAY24856 Length: 36 February 4, 2005 13:32 Type: P Check: 869
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGSSGAX
  1 28
-----
1 match found in sequence:
aay24857 ; Exendin agonist peptide #49.
(from "seq5ags.pep")
TOIG of: aay24857 check: 7463 from: 1 to: 35

ID AAY24857 standard; peptide; 35 AA.
XX
AC AAY24857;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #49.
XX

```

```

PR 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-394773/33.
XX
XX New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 38 AA;
XX
AAY24852 Length: 38 February 4, 2005 13:32 Type: P Check: 7221 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGTFTSDLSKQMBEEAVRLFIETWLNKGSPSGAXXX
28
-----
1 match found in sequence:
aay24853 ; Extendin agonist peptide #45.
(from "seq5ags.pep")
TOIG of: aay24853 check: 2828 from: 1 to: 37

ID AAY24853 standard; peptide; 37 AA.
XX
XX AC AAY24853;
XX
XX DT 24-AUG-1999 (first entry)
XX
XX DE Extendin agonist peptide #45.
XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925727-A2.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024210.
XX
XX PR 14-NOV-1997; 97US-0065442P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX PS WPI; 1999-394773/33.
XX
XX New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX

```

```

XX
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 37 AA;
XX
AAY24853 Length: 37 February 4, 2005 13:32 Type: P Check: 2828 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGTFTSDLSKQMBEEAVRLFIETWLNKGSGAGPP
28
-----
1 match found in sequence:
aay24854 ; Extendin agonist peptide #46.
(from "seq5ags.pep")
TOIG of: aay24854 check: 1733 from: 1 to: 37

ID AAY24854 standard; peptide; 37 AA.
XX
XX AC AAY24854;
XX
XX DT 24-AUG-1999 (first entry)
XX
XX DE Extendin agonist peptide #46.
XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925727-A2.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024210.
XX
XX PR 14-NOV-1997; 97US-0065442P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX PS WPI; 1999-394773/33.
XX
XX New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX

```

(from "seq5ags.pep")
TOIG of: aay24850 check: 2320 from: 1 to: 29

ID AAY24850 standard; peptide; 29 AA.

AC AAY24850;

DT 24-AUG-1999 (first entry)

DE Extendin agonist peptide #42.

XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

OS Synthetic.

OS Heloderma sp.

PN WO9925727-A2.

XX 27-MAY-1999.

PF 13-NOV-1998; 98WO-US024210.

XX 14-NOV-1997; 97US-0065442P.

PA (AMYL-) AMYLIN PHARM INC.

PI Beeley NRA, Prickett KS;

XX WPI; 1999-394773/33.

XX New extendin agonist peptides - can regulate gastric motility and slow gastric emptying, used for treating, e.g. diabetes.

PS Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent extendin agonist peptides which can regulate gastric motility and slow gastric emptying. The peptides can be used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic conditions. The peptides are extendin agonists which have activity as agents to regulate gastric motility and to slow gastric emptying, as evidenced by the ability to reduce post-prandial glucose levels in mammals. They can be used for the treatment of Type I and II diabetes and hyperglycaemic or hypoglycaemic conditions. They can also be used for the treatment of disorders which would be benefited by agents which lower plasma glucose levels and in treatment of disorders which would be benefited with agents useful in delaying and/or slowing gastric emptying

SQ Sequence 29 AA;

AAY24850 Length: 29 February 4, 2005 13:32 Type: P Check: 2320 ..
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKNG
1 28

1 match found in sequence:
aay24851 ; Extendin agonist peptide #43.
(from "seq5ags.pep")
TOIG of: aay24851 check: 7469 from: 1 to: 38

ID AAY24851 standard; peptide; 38 AA.

AC AAY24851;

DT 24-AUG-1999 (first entry)

DE Extendin agonist peptide #43.

XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW

XX

OS

OS Heloderma sp.

PN WO9925727-A2.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024210.

XX 14-NOV-1997; 97US-0065442P.

XX (AMYL-) AMYLIN PHARM INC.

PA Beeley NRA, Prickett KS;

XX WPI; 1999-394773/33.

XX New extendin agonist peptides - can regulate gastric motility and slow gastric emptying, used for treating, e.g. diabetes.

PS Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent extendin agonist peptides which can regulate gastric motility and slow gastric emptying. The peptides can be used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic conditions. The peptides are extendin agonists which have activity as agents to regulate gastric motility and to slow gastric emptying, as evidenced by the ability to reduce post-prandial glucose levels in mammals. They can be used for the treatment of Type I and II diabetes and hyperglycaemic or hypoglycaemic conditions. They can also be used for the treatment of disorders which would be benefited by agents which lower plasma glucose levels and in treatment of disorders which would be benefited with agents useful in delaying and/or slowing gastric emptying

SQ Sequence 38 AA;

AAY24851 Length: 38 February 4, 2005 13:32 Type: P Check: 7469 ..
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKNGXSGAXXX
1 28

1 match found in sequence:
aay24852 ; Extendin agonist peptide #44.
(from "seq5ags.pep")
TOIG of: aay24852 check: 7221 from: 1 to: 38

ID AAY24852 standard; peptide; 38 AA.

AC AAY24852;

DT 24-AUG-1999 (first entry)

DE Extendin agonist peptide #44.

XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

OS Synthetic.

OS Heloderma sp.

PN WO9925727-A2.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024210.

XX

CC AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 31 AA;
 AAY24847 Length: 31 February 4, 2005 13:32 Type: P Check: 6930 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSDLSKQLEEAARVLFIEFLKNGG
 1

 1 match found in sequence:
 aay24848 ; Exendin agonist peptide #40.
 (from "seq5ags.pep")
 TOIG of: aay24848 check: 4450 from: 1 to: 30
 ID AAY24848 standard; peptide; 30 AA.
 AC AAY24848;
 XX
 DT 24-AUG-1999 (first entry)
 DE Exendin agonist peptide #40.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 New exendin agonist peptides - can regulate gastric motility and slow
 gastric emptying, used for treating, e.g. diabetes.
 XX
 Claim 18; Fig 4; 108pp; English.
 XX
 AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX

SQ Sequence 30 AA;
 AAY24848 Length: 30 February 4, 2005 13:32 Type: P Check: 4450 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSDLSKQLEEAARVLFIEFLKNGG
 1

 1 match found in sequence:
 aay24849 ; Exendin agonist peptide #41.
 (from "seq5ags.pep")
 TOIG of: aay24849 check: 2759 from: 1 to: 29
 ID AAY24849 standard; peptide; 29 AA.
 XX
 AC AAY24849;
 XX
 DT 24-AUG-1999 (first entry)
 DE Exendin agonist peptide #41.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 New exendin agonist peptides - can regulate gastric motility and slow
 gastric emptying, used for treating, e.g. diabetes.
 XX
 Claim 18; Fig 4; 108pp; English.
 XX
 AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 29 AA;
 AAY24849 Length: 29 February 4, 2005 13:32 Type: P Check: 2759 ..
 Found using 'seq5' (mohamed337.key)
 1 HGGTFTSDLSKQLEEAARVLFIEFLKNGG
 1

 1 match found in sequence:
 aay24850 ; Exendin agonist peptide #42.
 aay24850 ; Exendin agonist peptide #42.

KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925727-A2.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 32 AA;
 SQ AAY24845 Length: 32 February 4, 2005 13:32 Type: P Check: 9586 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HGEGFTSDLSKQEEAAVRLFIKNGGSPS
 28

 1 match found in sequence:
 aay24846 ; Extendin agonist peptide #38.
 (from "seq5ags.pep")
 TOIG of: aay24846 check: 7369 from: 1 to: 31
 ID AAY24846 standard; peptide; 31 AA.
 XX AC AAY24846;
 XX 24-AUG-1999 . (first entry)
 XX Extendin agonist peptide #38.
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925727-A2.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX Claim 18; Fig 4; 108pp; English.

XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 31 AA;
 SQ AAY24846 Length: 31 February 4, 2005 13:32 Type: P Check: 7369 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HGEGFTSDLSKQEEAAVRLFIWLKNGGP
 28

 1 match found in sequence:
 aay24847 ; Extendin agonist peptide #39.
 (from "seq5ags.pep")
 TOIG of: aay24847 check: 6930 from: 1 to: 31
 ID AAY24847 standard; peptide; 31 AA.
 XX AC AAY24847;
 XX 24-AUG-1999 (first entry)
 XX Extendin agonist peptide #39.
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925727-A2.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX Claim 18; Fig 4; 108pp; English.

AAV24842 Length: 33 February 4, 2005 13:32 Type: P Check: 2764 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNGGPSS
28

1 match found in sequence:
aay24843 ; Exendin agonist peptide #35.
(from "seq5aggs.pep")
TOIG of: aay24843 check: 2325 from: 1 to: 33

ID AAY24843 standard; peptide; 33 AA.
XX
AC AAY24843;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #35.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 33 AA;

AAV24843 Length: 33 February 4, 2005 13:32 Type: P Check: 2325 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNGGPSS
28

1 match found in sequence:
aay24844 ; Exendin agonist peptide #36.
(from "seq5aggs.pep")
TOIG of: aay24844 check: 9586 from: 1 to: 32

ID AAY24844 standard; peptide; 32 AA.
XX
AC AAY24844;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #36.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 32 AA;

AAV24844 Length: 32 February 4, 2005 13:32 Type: P Check: 25 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNGGPSS
28

1 match found in sequence:
aay24845 ; Exendin agonist peptide #37.
(from "seq5aggs.pep")
TOIG of: aay24845 check: 9586 from: 1 to: 32

ID AAY24845 standard; peptide; 32 AA.
XX
AC AAY24845;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #37.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 XX WPI; 1999-394773/33.
 DR
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 XX Claim 18; Fig 4; 108pp; English.
 PS
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 CC
 XX Sequence 34 AA;
 SQ
 AAY24840 Length: 34 February 4, 2005 13:32 Type: P Check: 5178 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGFTTSDLSKQMEEAVALRFLIEFLKNGGPSSG
 1
 -----|-----
 1 match found in sequence:
 aay24841; Extendin agonist peptide #33.
 (from "seq5ags.pep")
 TOIG of: aay24841 check: 4739 from: 1 to: 34
 ID AAY24841 standard; peptide; 34 AA.
 XX
 AC AAY24841;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #33.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 XX WPI; 1999-394773/33.
 DR
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 XX Claim 18; Fig 4; 108pp; English.
 PS
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can

CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 XX Sequence 34 AA;
 SQ
 AAY24841 Length: 34 February 4, 2005 13:32 Type: P Check: 4739 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGFTTSDLSKQMEEAVALRFLIEFLKNGGPSSG
 1
 -----|-----
 1 match found in sequence:
 aay24842; Extendin agonist peptide #34.
 (from "seq5ags.pep")
 TOIG of: aay24842 check: 2764 from: 1 to: 33
 ID AAY24842 standard; peptide; 33 AA.
 XX
 AC AAY24842;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #34.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 XX WPI; 1999-394773/33.
 DR
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 XX Claim 18; Fig 4; 108pp; English.
 PS
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 XX Sequence 33 AA;
 SQ

```

ID AAY24838 standard; peptide; 35 AA.
XX
AC AAY24838;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #30.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 35 AA;
XX
AAY24838 Length: 35 February 4, 2005 13:32 Type: P Check: 7453 ..
Found using 'seq5' (mohamed337.key)
1 |-----|-----|-----|-----|-----|
1 HEGTFTSLSKQMEEEAVRLFIEFLKNGPSSGA
28
-----
1 match found in sequence:
aay24839 ; Exendin agonist peptide #31.
(from "seq5ags.pep")
TOIG of: aay24839 check: 7014 from: 1 to: 35
ID AAY24839 standard; peptide; 35 AA.
XX
AC AAY24839;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #31.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

```

```

XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 35 AA;
XX
AAY24839 Length: 35 February 4, 2005 13:32 Type: P Check: 7014 ..
Found using 'seq5' (mohamed337.key)
1 |-----|-----|-----|-----|-----|
1 HEGTFTSLSKQLEEEAVRLFIEFLKNGPSSGA
28
-----
1 match found in sequence:
aay24840 ; Exendin agonist peptide #32.
(from "seq5ags.pep")
TOIG of: aay24840 check: 5178 from: 1 to: 34
ID AAY24840 standard; peptide; 34 AA.
XX
AC AAY24840;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #32.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX

```

CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 37 AA;

AA24835 Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..
 Found using 'seq5' (mohamed337.key)

1 HGGFTFTSDLSKQLEEEAVRLFIETLKNKGPPSSGAP
 1
 28

 1 match found in sequence:
 aay24836 ; Extendin agonist peptide #28.
 (from "seq5ags.pep")
 TOIG of: aay24836 check: 333 from: 1 to: 36

ID AAY24836 standard; peptide; 36 AA.
 XX
 AC AAY24836;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #28.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 PT New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 36 AA;

AA24835 Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..
 Found using 'seq5' (mohamed337.key)

Sequence 36 AA;

AA24836 Length: 36 February 4, 2005 13:32 Type: P Check: 333 ..
 Found using 'seq5' (mohamed337.key)

1 HGGFTFTSDLSKQLEEEAVRLFIETLKNKGPPSSGAP
 1
 28

 1 match found in sequence:
 aay24837 ; Extendin agonist peptide #29.
 (from "seq5ags.pep")
 TOIG of: aay24837 check: 9894 from: 1 to: 36

ID AAY24837 standard; peptide; 36 AA.
 XX
 AC AAY24837;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #29.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 PT New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 36 AA;

AA24837 Length: 36 February 4, 2005 13:32 Type: P Check: 9894 ..
 Found using 'seq5' (mohamed337.key)

1 HGGFTFTSDLSKQLEEEAVRLFIETLKNKGPPSSGAP
 1
 28

 1 match found in sequence:
 aay24838 ; Extendin agonist peptide #30.
 (from "seq5ags.pep")
 TOIG of: aay24838 check: 7453 from: 1 to: 35

```

OS Synthetic.
OS Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX Claim 18; Fig 4; 108pp; English.
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are extendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 38 AA;
XX AAY24833 Length: 38 February 4, 2005 13:32 Type: P Check: 5894 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQLEEAVALFIEPLKNGPSSGAPPP
1 28
-----
1 match found in sequence:
aay24834 ; Extendin agonist peptide #26.
(from "seq5ags.pep")
TOIG of: aay24834 check: 6333 from: 1 to: 38
ID AAY24834 standard; peptide; 38 AA.
XX AC AAY24834;
XX 24-AUG-1999 (first entry)
XX Extendin agonist peptide #26.
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
XX Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX Claim 18; Fig 4; 108pp; English.
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are extendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 38 AA;
XX AAY24833 Length: 38 February 4, 2005 13:32 Type: P Check: 5894 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQLEEAVALFIEPLKNGPSSGAPPP
1 28
-----
1 match found in sequence:
aay24834 ; Extendin agonist peptide #26.
(from "seq5ags.pep")
TOIG of: aay24834 check: 6333 from: 1 to: 38
ID AAY24834 standard; peptide; 38 AA.
XX AC AAY24834;
XX 24-AUG-1999 (first entry)
XX Extendin agonist peptide #26.
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
XX Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.

```

```

XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX Claim 18; Fig 4; 108pp; English.
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are extendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 38 AA;
XX AAY24834 Length: 38 February 4, 2005 13:32 Type: P Check: 6333 ..
XX Found using 'seq5' (mohamed337.key)
1 HGEFTFTSLSKQLEEAVALFIEPLKNGPSSGAPPP
1 28
-----
1 match found in sequence:
aay24835 ; Extendin agonist peptide #27.
(from "seq5ags.pep")
TOIG of: aay24835 check: 2854 from: 1 to: 37
ID AAY24835 standard; peptide; 37 AA.
XX AC AAY24835;
XX 24-AUG-1999 (first entry)
XX Extendin agonist peptide #27.
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
XX Heloderma sp.
XX WO9925727-A2.
XX 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX Claim 18; Fig 4; 108pp; English.
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be

```

Found using 'seq5' (mohamed337.key)

```
1 1-----|
  HGEGTFTSDLSKQLEEEAVRLFIEFLAN 28
  1
```

1 match found in sequence:
 aay24831 ; Exendin agonist peptide #23.
 (from "seq5ags.pep")
 TOIG of: aay24831 check: 261 from: 1 to: 28

```
ID AAY24831 standard; peptide; 28 AA.
XX
AC AAY24831;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #23.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 28 AA;
```

AAY24831 Length: 28 February 4, 2005 13:32 Type: P Check: 261 ..
 Found using 'seq5' (mohamed337.key)

```
1 1-----|
  HGEGTFTSDLSKQLEEEAVRLFIEFLKN 28
  1
```

1 match found in sequence:
 aay24832 ; Exendin agonist peptide #24.
 (from "seq5ags.pep")
 TOIG of: aay24832 check: 6333 from: 1 to: 38

```
ID AAY24832 standard; peptide; 38 AA.
XX
AC AAY24832;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #24.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 38 AA;
```

AAY24832 Length: 38 February 4, 2005 13:32 Type: P Check: 6333 ..
 Found using 'seq5' (mohamed337.key)

```
1 1-----|
  HGEGTFTSDLSKQLEEEAVRLFIEWLKNGGPGSSGAPPP 28
  1
```

1 match found in sequence:
 aay24833 ; Exendin agonist peptide #25.
 (from "seq5ags.pep")
 TOIG of: aay24833 check: 5894 from: 1 to: 38

```
ID AAY24833 standard; peptide; 38 AA.
XX
AC AAY24833;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #25.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
```

PI Beley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX PS Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX SQ Sequence 28 AA;
 AAY24828 Length: 28 February 4, 2005 13:32 Type: P Check: 136 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSDLSKQLEEAVALRFLFIEALKN 28
 |-----|
 1 match found in sequence:
 aay24829 ; Extendin agonist peptide #21.
 (from "seq5ags.pep")
 TOIG of: aay24829 check: 9975 from: 1 to: 28
 ID AAY24829 standard; peptide; 28 AA.
 XX AC AAY24829;
 XX DT 24-AUG-1999 (first entry)
 XX DE Extendin agonist peptide #21.
 XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX OS Synthetic.
 OS Heloderma sp.
 XX FN WO9925727-A2.
 XX PD 27-MAY-1999.
 XX PF 13-NOV-1998; 98WO-US024210.
 XX PR 14-NOV-1997; 97US-0065442P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Beley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX PS Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic

CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX SQ Sequence 28 AA;
 AAY24829 Length: 28 February 4, 2005 13:32 Type: P Check: 9975 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGGFTSDLSKQLEEAVALRFLFIEAFKN 28
 |-----|
 1 match found in sequence:
 aay24830 ; Extendin agonist peptide #22.
 (from "seq5ags.pep")
 TOIG of: aay24830 check: 9991 from: 1 to: 28
 ID AAY24830 standard; peptide; 28 AA.
 XX AC AAY24830;
 XX DT 24-AUG-1999 (first entry)
 XX DE Extendin agonist peptide #22.
 XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX OS Synthetic.
 OS Heloderma sp.
 XX FN WO9925727-A2.
 XX PD 27-MAY-1999.
 XX PF 13-NOV-1998; 98WO-US024210.
 XX PR 14-NOV-1997; 97US-0065442P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Beley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX PS Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX SQ Sequence 28 AA;
 AAY24830 Length: 28 February 4, 2005 13:32 Type: P Check: 9991 ..

```

XX AAY24826;
AC 24-AUG-1999 (first entry)
DT
XX
DE Extendin agonist peptide #18.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PP 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying.
XX
SQ Sequence 28 AA;
AAY24826 Length: 28 February 4, 2005 13:32 Type: P Check: 30 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRAFIKFN 28
|-----|
1 match found in sequence:
aay24827 ; Extendin agonist peptide #19.
(from "seq5ags.pep")
TOIG of: aay24827 check: 261 from: 1 to: 28

ID AAY24827 standard; peptide; 28 AA.
XX
AC AAY24827;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #19.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.

```

```

OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PP 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying.
XX
SQ Sequence 28 AA;
AAY24827 Length: 28 February 4, 2005 13:32 Type: P Check: 261 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQLEEEAVRLFIFLKN 28
|-----|
1 match found in sequence:
aay24828 ; Extendin agonist peptide #20.
(from "seq5ags.pep")
TOIG of: aay24828 check: 136 from: 1 to: 28

ID AAY24828 standard; peptide; 28 AA.
XX
AC AAY24828;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #20.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PP 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX

```


CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;

AAV24823 Length: 28 February 4, 2005 13:32 Type: P Check: 193 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEAARLFIEFLKN 28
 1

1 match found in sequence:
 aay24824 ; Exendin agonist peptide #16.
 (from "seq5ags.pep")
 TOIG of: aay24824 check: 9862 from: 1 to: 28

ID AAY24824 standard; peptide; 28 AA.

XX
 AC AAY24824;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #16.

XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.
 OS Heloderma sp.
 OS
 XX WO9925727-A2.
 XX
 XX 27-MAY-1999.

XX
 XX 13-NOV-1998; 98WO-US024210.
 XX
 XX 14-NOV-1997; 97US-0065442P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beesley NRA, Prickett KS;

XX WPI; 1999-394773/33.

XX New exendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.

XX Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;

AAV24824 Length: 28 February 4, 2005 13:32 Type: P Check: 9862 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEAARLFIEFLKN 28
 1

1 match found in sequence:
 aay24825 ; Exendin agonist peptide #17.
 (from "seq5ags.pep")
 TOIG of: aay24825 check: 9921 from: 1 to: 28

ID AAY24825 standard; peptide; 28 AA.

XX
 AC AAY24825;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #17.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.
 OS Heloderma sp.
 OS
 XX WO9925727-A2.
 XX
 XX 27-MAY-1999.

XX
 XX 13-NOV-1998; 98WO-US024210.
 XX
 XX 14-NOV-1997; 97US-0065442P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beesley NRA, Prickett KS;

XX WPI; 1999-394773/33.

XX New exendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.

XX Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;

AAV24825 Length: 28 February 4, 2005 13:32 Type: P Check: 9921 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEAARLFIEFLKN 28
 1

1 match found in sequence:
 aay24826 ; Exendin agonist peptide #18.
 (from "seq5ags.pep")
 TOIG of: aay24826 check: 30 from: 1 to: 28

ID AAY24826 standard; peptide; 28 AA.

```

XX WPI; 1999-394773/33.
XX DR
XX PT
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS
XX Claim 18; Fig 4; 108pp; English.
XX CC
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower the
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying.
XX SQ Sequence 28 AA;
AAY24822 Length: 28 February 4, 2005 13:32 Type: P Check: 197 ..
Found using 'seq5' (mohamed337.key)
|-----|
1 HSGGTFTSLSKQLAEAAVRLFIETLKN
28
-----
1 match found in sequence:
aay24823 ; Extendin agonist peptide #15.
(from "seq5ags.pep")
TOIG of: aay24823 Check: 193 from: 1 to: 28
ID AAY24823 standard; peptide; 28 AA.
XX AC AAY24823;
XX DT
XX DE 24-AUG-1999 (first entry)
XX EX Extendin agonist peptide #15.
XX KW Extendin; agonist; Heloderma sp.; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX PS
XX PS WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS
XX PS Claim 18; Fig 4; 108pp; English.
XX CC
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as

```


DR WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT
 XX Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 28 AA;
 SQ
 AAY24816 Length: 28 February 4, 2005 13:32 Type: P Check: 151 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HEGTFTSDASKOLEEAVRLFIFLKN 28

 1 match found in sequence:
 aay24817; Extendin agonist peptide #9.
 (from "seq5ags.pep")
 TOIG of: aay24817 check: 63 from: 1 to: 28
 ID AAY24817 standard; peptide; 28 AA.
 XX
 AC AAY24817;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #9.
 XX
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 XX WO9925727-A2.
 XX
 XX 27-MAY-1999.
 XX
 XX 13-NOV-1998; 98WO-US024210.
 XX
 XX 14-NOV-1997; 97US-0065442P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Beeley NRA, Prickett KS;
 FI
 FI WPI; 1999-394773/33.
 XX
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT
 XX Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 28 AA;
 SQ

CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 28 AA;
 SQ
 AAY24817 Length: 28 February 4, 2005 13:32 Type: P Check: 63 ..
 Found using 'seq5' (mohamed337.key)
 1 |-----|
 1 HEGTFTSDAKOLEEAVRLFIFLKN 28

 1 match found in sequence:
 aay24818; Extendin agonist peptide #10.
 (from "seq5ags.pep")
 TOIG of: aay24818 check: 141 from: 1 to: 28
 ID AAY24818 standard; peptide; 28 AA.
 XX
 AC AAY24818;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #10.
 XX
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 XX WO9925727-A2.
 XX
 XX 27-MAY-1999.
 XX
 XX 13-NOV-1998; 98WO-US024210.
 XX
 XX 14-NOV-1997; 97US-0065442P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Beeley NRA, Prickett KS;
 FI
 FI WPI; 1999-394773/33.
 XX
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT
 XX Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 28 AA;
 SQ
 AAY24818 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
 Found using 'seq5' (mohamed337.key)

```

XX 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #6.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are extendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX SQ Sequence 28 AA;

AAY24814 Length: 28 February 4, 2005 13:32 Type: P Check: 231
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGGTATSDLSKQLEEAARLFIIEFLKN 28

-----
1 match found in sequence:
aay24815 ; Extendin agonist peptide #7.
(from "seq5ags.pep")
TOIG of: aay24815 check: 117 from: 1 to: 28

ID AAY24815 standard; peptide; 28 AA.
XX AC AAY24815;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #7.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.

```

```

PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are extendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX SQ Sequence 28 AA;

AAY24815 Length: 28 February 4, 2005 13:32 Type: P Check: 117
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 HGGTFTADLSKQLEEAARLFIIEFLKN 28

-----
1 match found in sequence:
aay24816 ; Extendin agonist peptide #8.
(from "seq5ags.pep")
TOIG of: aay24816 check: 151 from: 1 to: 28

ID AAY24816 standard; peptide; 28 AA.
XX AC AAY24816;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #8.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX

```



XX


```

XX      SQ      Sequence 28 AA;
AAV17633 Length: 28 February 4, 2005 13:32 Type: P Check: 254 ..
Found using 'seq5' (mohamed337.key)

1      |-----|
      1  AGEFTTSDLSKQLEEEAVRLFIEFLKN
      28
-----
1 match found in sequence:
aay17634 ; Exendin agonist peptide #100.
(from "seq5ags.pep")
TOIG of: aay17634 check: 4882 from: 1 to: 30

ID      AAY17634 standard; peptide; 30 AA.
XX
AC      AAY17634;
XX
DT      09-AUG-1999 (first entry)
XX
DE      Exendin agonist peptide #100.
XX
KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
PN      WO9925728-A1.
XX
PD      27-MAY-1999.
XX
PF      13-NOV-1998; 98WO-US024273.
XX
PR      14-NOV-1997; 97US-0066029P.
XX
PA      (AMYL-) AMYLIN PHARM INC.
XX
PI      Beeley NRA, Prickett KS;
XX
DR      WPI; 1999-347456/29.
XX
PT      Peptide agonists of exendin - delay stomach emptying, for treating
PT      diabetes and hypo- or hyper-glycemia.
XX
PS      Claim 71; Fig 7; 144pp; English.
XX
CC      AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC      peptides that are found in the venom of the Gila-monster, a lizard
CC      endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC      to treat diabetes mellitus (types I or II), hyperglycaemia or
CC      hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC      exendins and their agonists. They regulate gastric motility and slow
CC      gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ      Sequence 30 AA;

AAV17635 Length: 30 February 4, 2005 13:32 Type: P Check: 4443 ..
Found using 'seq5' (mohamed337.key)

1      |-----|
      1  AGEFTTSDLSKQLEEEAVRLFIEFLKN
      28
-----
1 match found in sequence:
aay24809 ; Exendin agonist peptide #1.
(from "seq5ags.pep")
TOIG of: aay24809 check: 4889 from: 1 to: 30

ID      AAY24809 standard; peptide; 30 AA.
XX
AC      AAY24809;
XX
DT      24-AUG-1999 (first entry)
XX
DE      Exendin agonist peptide #1.
XX
KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
PN      WO9925727-A2.

```

```

ID      AAY17635 standard; peptide; 30 AA.
XX
AC      AAY17635;
XX
DT      09-AUG-1999 (first entry)
XX
DE      Exendin agonist peptide #101.
XX
KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
PN      WO9925728-A1.
XX
PD      27-MAY-1999.
XX
PF      13-NOV-1998; 98WO-US024273.
XX
PR      14-NOV-1997; 97US-0066029P.
XX
PA      (AMYL-) AMYLIN PHARM INC.
XX
PI      Beeley NRA, Prickett KS;
XX
DR      WPI; 1999-347456/29.
XX
PT      Peptide agonists of exendin - delay stomach emptying, for treating
PT      diabetes and hypo- or hyper-glycemia.
XX
PS      Claim 71; Fig 7; 144pp; English.
XX
CC      AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC      peptides that are found in the venom of the Gila-monster, a lizard
CC      endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC      to treat diabetes mellitus (types I or II), hyperglycaemia or
CC      hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC      exendins and their agonists. They regulate gastric motility and slow
CC      gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ      Sequence 30 AA;

AAV17635 Length: 30 February 4, 2005 13:32 Type: P Check: 4443 ..
Found using 'seq5' (mohamed337.key)

1      |-----|
      1  AGEFTTSDLSKQLEEEAVRLFIEFLKN
      28
-----
1 match found in sequence:
aay24809 ; Exendin agonist peptide #1.
(from "seq5ags.pep")
TOIG of: aay24809 check: 4889 from: 1 to: 30

ID      AAY24809 standard; peptide; 30 AA.
XX
AC      AAY24809;
XX
DT      24-AUG-1999 (first entry)
XX
DE      Exendin agonist peptide #1.
XX
KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
PN      WO9925727-A2.

```


KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 OS Synthetic.
 OS Heloderma sp.
 XX WO9925728-A1.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024273.
 XX 14-NOV-1997; 97US-0066029P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-347456/29.
 XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX Claim 28; Fig 4; 144pp; English.
 XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 39 AA;
 SQ

AAY17623 Length: 39 February 4, 2005 13:32 Type: P Check: 9112 ..
 Found using 'seq5' (mohamed337.key)

1 AGAGTFTSDLSKQLEEEAVRLFIETLKN 28
 1 AGAGTFTSDLSKQLEEEAVRLFIETLKN 28

 1 match found in sequence:
 aay17632 ; Exendin agonist peptide #98.
 (from "seq5ags.pep")
 TOIG of: aay17632 check: 693 from: 1 to: 28

ID AAY17632 standard; peptide; 28 AA.
 XX
 AC AAY17632;
 XX
 DT 09-AUG-1999. (first entry)
 XX
 DE Exendin agonist peptide #98.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925728-A1.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024273.
 XX 14-NOV-1997; 97US-0066029P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-347456/29.
 XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX Claim 71; Fig 7; 144pp; English.
 XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 39 AA;
 SQ

AAY17623 Length: 39 February 4, 2005 13:32 Type: P Check: 9112 ..
 Found using 'seq5' (mohamed337.key)

1 AGAGTFTSDLSKQLEEEAVRLFIETLKN 28
 1 AGAGTFTSDLSKQLEEEAVRLFIETLKN 28

 1 match found in sequence:
 aay17632 ; Exendin agonist peptide #98.
 (from "seq5ags.pep")
 TOIG of: aay17632 check: 693 from: 1 to: 28

ID AAY17632 standard; peptide; 28 AA.
 XX
 AC AAY17632;
 XX
 DT 09-AUG-1999. (first entry)
 XX
 DE Exendin agonist peptide #98.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925728-A1.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024273.
 XX 14-NOV-1997; 97US-0066029P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-347456/29.
 XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX Claim 71; Fig 7; 144pp; English.
 XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 39 AA;
 SQ

PI Beeley NRA, Prickett KS;
 XX WPI; 1999-347456/29.
 XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX Claim 71; Fig 7; 144pp; English.
 XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;
 SQ

AAY17632 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
 Found using 'seq5' (mohamed337.key)

1 AGAGTFTSDLSKQLEEEAVRLFIETLKN 28
 1 AGAGTFTSDLSKQLEEEAVRLFIETLKN 28

 1 match found in sequence:
 aay17633 ; Exendin agonist peptide #99.
 (from "seq5ags.pep")
 TOIG of: aay17633 check: 254 from: 1 to: 28

ID AAY17633 standard; peptide; 28 AA.
 XX
 AC AAY17633;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #99.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925728-A1.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024273.
 XX 14-NOV-1997; 97US-0066029P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-347456/29.
 XX Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX Claim 71; Fig 7; 144pp; English.
 XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC exendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;
 SQ

CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX
 SQ Sequence 35 AA;

AAY17620 Length: 35 February 4, 2005 13:32 Type: P Check: 7441 ..
 Found using 'seq5' (mohamed337.key)

1 HGAGTFTSDLSKQMEEEAVRLFIEWLKNKGPSSGA
 1 28

 1 match found in sequence:
 aay17621 ; Extendin agonist peptide #87.
 (from "seq5ags.pep")
 TOIG of: aay17621 check: 4862 from: 1 to: 30

ID AAY17621 standard; peptide; 30 AA.

XX
 AC AAY17621;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #87.

XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.

OS Heloderma sp.
 XX
 FN WO9925728-A1.
 XX
 PD 27-MAY-1999.

XX
 PF 13-NOV-1998; 98WO-US024273.
 XX
 PR 14-NOV-1997; 97US-0066029P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-347456/29.

XX Peptide agonists of extendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX
 SQ Sequence 30 AA;

AAY17621 Length: 30 February 4, 2005 13:32 Type: P Check: 4862 ..
 Found using 'seq5' (mohamed337.key)

1 HGAGTFTSDLSKQMEEEAVRLFIEWLKNKG
 1 28

 1 match found in sequence:
 aay17622 ; Extendin agonist peptide #88.
 (from "seq5ags.pep")
 TOIG of: aay17622 check: 9563 from: 1 to: 39

ID AAY17622 standard; peptide; 39 AA.

XX
 AC AAY17622;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #88.

XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.
 OS Heloderma sp.
 XX
 FN WO9925728-A1.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.

XX 14-NOV-1997; 97US-0066029P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-347456/29.

XX Peptide agonists of extendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX
 SQ Sequence 39 AA;

AAY17622 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
 Found using 'seq5' (mohamed337.key)

1 AGEGTFTSDLSKQMEEEAVRLFIEWLKNKGPSSGAPPPS
 1 28

 1 match found in sequence:
 aay17623 ; Extendin agonist peptide #89.
 (from "seq5ags.pep")
 TOIG of: aay17623 check: 9112 from: 1 to: 39

ID AAY17623 standard; peptide; 39 AA.

XX
 AC AAY17623;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #89.

XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;

```

AC  AAY17619;
XX
XX  09-AUG-1999 (first entry)
XX
XX  Extendin agonist peptide #84.
XX
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX  Synthetic.
OS  Heloderma sp.
OS  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC  peptides that are found in the venom of the Gila-monster, a lizard
CC  endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC  to treat diabetes mellitus (types I or II), hyperglycaemia or
CC  hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC  extendins and their agonists. They regulate gastric motility and slow
CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX  Sequence 37 AA;
XX
XX  AAY17618 Length: 37 February 4, 2005 13:32 Type: P Check: 1706
XX  Found using 'seq5' (mohamed337.key)
XX
XX  1 HGGTFTSLSKQMEERAVRLFIEWLKNKGSSGAAA
XX  28
XX
XX  1 match found in sequence:
XX  aay17619 ; Extendin agonist peptide #85.
XX  (from "seq5ags.pap")
XX  TOIG of: aay17619 check: 862 from: 1 to: 36
XX
XX  ID AAY17619 standard; peptide; 36 AA.
XX
XX  AC AAY17619;
XX
XX  DT 09-AUG-1999 (first entry)
XX
XX  DE Extendin agonist peptide #85.
XX
XX  KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX  OS Synthetic.
XX  OS Heloderma sp.
XX  WO9925728-A1.
XX
XX  PD 27-MAY-1999.
XX

```

```

XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC  peptides that are found in the venom of the Gila-monster, a lizard
CC  endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC  to treat diabetes mellitus (types I or II), hyperglycaemia or
CC  hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC  extendins and their agonists. They regulate gastric motility and slow
CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX  Sequence 36 AA;
XX
XX  AAY17619 Length: 36 February 4, 2005 13:32 Type: P Check: 862
XX  Found using 'seq5' (mohamed337.key)
XX
XX  1 AGSGTFTSLSKQMEERAVRLFIEWLKNKGSSGAX
XX  28
XX
XX  1 match found in sequence:
XX  aay17620 ; Extendin agonist peptide #86.
XX  (from "seq5ags.pap")
XX  TOIG of: aay17620 check: 7441 from: 1 to: 35
XX
XX  ID AAY17620 standard; peptide; 35 AA.
XX
XX  AC AAY17620;
XX
XX  DT 09-AUG-1999 (first entry)
XX
XX  DE Extendin agonist peptide #86.
XX
XX  KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX  OS Synthetic.
XX  OS Heloderma sp.
XX  WO9925728-A1.
XX
XX  PD 27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX

```

```

DR WPI; 1999-347456/29.
XX Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX Sequence 29 AA;
SQ
AAY17615 Length: 29 February 4, 2005 13:32 Type: P Check: 2313 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 AGEFTFTSLSKQLEEEAVRLFIEFLKNG
    28
-----
1 match found in sequence:
aay17616 ; Exendin agonist peptide #82.
(from "seq5ags.pep")
TOIG of: aay17616 check: 7457 from: 1 to: 38
ID AAY17616 standard; peptide; 38 AA.
XX
AC AAY17616;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #82.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
OS Heloderma sp.
XX WO9925728-A1.
XX PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
OS Synthetic.
OS Heloderma sp.
XX WO9925728-A1.
XX PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX Sequence 38 AA;
SQ

```

```

AAY17616 Length: 38 February 4, 2005 13:32 Type: P Check: 7457 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGAGTFTSLSKQMEEEAVRLFIEWLKNGXSGAXXX
    28
-----
1 match found in sequence:
aay17617 ; Exendin agonist peptide #83.
(from "seq5ags.pep")
TOIG of: aay17617 check: 7197 from: 1 to: 38
ID AAY17617 standard; peptide; 38 AA.
XX
AC AAY17617;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #83.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX Synthetic.
OS Heloderma sp.
XX WO9925728-A1.
XX PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX Sequence 38 AA;
SQ
AAY17617 Length: 38 February 4, 2005 13:32 Type: P Check: 7197 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGAGTFTSLSKQMEEEAVRLFIEWLKNGGPGSSGAXXX
    28
-----
1 match found in sequence:
aay17618 ; Exendin agonist peptide #84.
(from "seq5ags.pep")
TOIG of: aay17618 check: 1706 from: 1 to: 37
ID AAY17618 standard; peptide; 37 AA.
XX

```

```

1 match found in sequence:
aay17613 ; Exendin agonist peptide #79.
(from "seq5ags.pep")
TOIG of: aay17613 check: 7345 from: 1 to: 31

ID AAY17613 standard; peptide; 31 AA.
XX
AC AAY17613;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #79.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 31 AA;

AAY17613 Length: 31 February 4, 2005 13:32 Type: P Check: 7345 ..
Found using 'seq5' (mohamed337.key)

1 HGEATFTSDLSKQMEEEAVRLFIEWLKNGGP
1 28
-----|-----
1 match found in sequence:
aay17614 ; Exendin agonist peptide #80.
(from "seq5ags.pep")
TOIG of: aay17614 check: 4423 from: 1 to: 30

ID AAY17614 standard; peptide; 30 AA.
XX
AC AAY17614;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #80.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX

1 match found in sequence:
aay17615 ; Exendin agonist peptide #81.
(from "seq5ags.pep")
TOIG of: aay17615 check: 2313 from: 1 to: 29

ID AAY17615 standard; peptide; 29 AA.
XX
AC AAY17615;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #81.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 30 AA;

AAY17614 Length: 30 February 4, 2005 13:32 Type: P Check: 4423 ..
Found using 'seq5' (mohamed337.key)

1 HGEATFTSALSQLEEEAVRLFIEFLKNGG
1 28
-----|-----
1 match found in sequence:
aay17615 ; Exendin agonist peptide #81.
(from "seq5ags.pep")
TOIG of: aay17615 check: 2313 from: 1 to: 29

ID AAY17615 standard; peptide; 29 AA.
XX
AC AAY17615;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #81.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 30 AA;

```

```

CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 32 AA;
SQ
AAV17611 Length: 32 February 4, 2005 13:32 Type: P Check: 18 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  | AEGGFTSDLSKQLEEAARVLFIEFLKNGGPS
  | 28
  |
1 |-----|
  | aay17612; Extendin agonist peptide #78.
  | (from "seq5ags.pep")
  | TOIG of: aay17612 check: 9574 from: 1 to: 32
  |
  |-----|
  | 1 match found in sequence:
  | aay17612; Extendin agonist peptide #78.
  | (from "seq5ags.pep")
  | TOIG of: aay17612 check: 9574 from: 1 to: 32
  |
  |-----|
  | ID AAV17612 standard; peptide; 32 AA.
  | AC AAV17612;
  |
  |-----|
  | 09-AUG-1999 (first entry)
  | Extendin agonist peptide #78.
  |
  |-----|
  | Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
  | diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
  | hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
  |
  |-----|
  | Synthetic.
  | OS Heloderma sp.
  |
  |-----|
  | WO9925728-A1.
  | PN
  |
  |-----|
  | 27-MAY-1999.
  |
  |-----|
  | 13-NOV-1998; 98WO-US024273.
  |
  |-----|
  | 14-NOV-1997; 97US-0066029P.
  |
  |-----|
  | (AMYL-) AMYLIN PHARM INC.
  |
  |-----|
  | Beeley NRA, Prickett KS;
  |
  |-----|
  | WPI; 1999-347456/29.
  |
  |-----|
  | Peptide agonists of extendin - delay stomach emptying, for treating
  | diabetes and hypo- or hyper-glycemia.
  |
  |-----|
  | Claim 28; Fig 4; 144pp; English.
  |
  |-----|
  | AAV17535 to AAV17624 represent extendin peptide agonists. Extendins are
  | peptides that are found in the venom of the Gila-monster, a lizard
  | endogenous to Arizona and Northern Mexico. The peptide agonists are used
  | to treat diabetes mellitus (types I or II), hyperglycaemia or
  | hypoglycaemia. They can also be used for in vitro and in vivo studies on
  | extendins and their agonists. They regulate gastric motility and slow
  | gastric emptying (resulting in lower post-prandial glucose levels)
  |
  |-----|
  | SQ Sequence 32 AA;
  |
  |-----|
  | AAV17612 Length: 32 February 4, 2005 13:32 Type: P Check: 9574 ..
  | Found using 'seq5' (mohamed337.key)

1 |-----|
  | HGAGFTTSDLSKQLEEAARVLFIEFLKNGGPS
  | 28
  |
1 |-----|
  |
  |-----|

```



```

OS Heloderma sp.
XX WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 36 AA;

AAY17605 Length: 36 February 4, 2005 13:32 Type: P Check: 306 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSALSKQMEEEAVRLFIEFLKNGGPGSSGAP
1 28
-----
1 match found in sequence:
aay17606 ; Exendin agonist peptide #72.
(from "seq5ags.pep")
TOIG of: aay17606 check: 9777 from: 1 to: 36

ID AAY17606 standard; peptide; 36 AA.
XX AC AAY17606;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #72.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 36 AA;

AAY17607 Length: 35 February 4, 2005 13:32 Type: P Check: 7446 ..
Found using 'seq5' (mohamed337.key)

1 AGEFTTSDASKQLEEEAVRLFIEFLKNGGPGSSGAP
1 28
-----
1 match found in sequence:
aay17607 ; Exendin agonist peptide #73.
(from "seq5ags.pep")
TOIG of: aay17607 check: 7446 from: 1 to: 35

ID AAY17607 standard; peptide; 35 AA.
XX AC AAY17607;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #73.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 35 AA;

AAY17607 Length: 35 February 4, 2005 13:32 Type: P Check: 7446 ..

```

```

PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 36 AA;

AAY17606 Length: 36 February 4, 2005 13:32 Type: P Check: 9777 ..
Found using 'seq5' (mohamed337.key)

1 AGEFTTSDASKQLEEEAVRLFIEFLKNGGPGSSGAP
1 28
-----
1 match found in sequence:
aay17607 ; Exendin agonist peptide #73.
(from "seq5ags.pep")
TOIG of: aay17607 check: 7446 from: 1 to: 35

ID AAY17607 standard; peptide; 35 AA.
XX AC AAY17607;
XX DT 09-AUG-1999 (first entry)
XX DE Exendin agonist peptide #73.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024273.
XX PR 14-NOV-1997; 97US-0066029P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX WPI; 1999-347456/29.
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX SQ Sequence 35 AA;

AAY17607 Length: 35 February 4, 2005 13:32 Type: P Check: 7446 ..

```


CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX
 SQ Sequence 38 AA;

AAV17602 Length: 38 February 4, 2005 13:32 Type: P Check: 6326 ..
 Found using 'seq5' (mohamed337.key)

1 AGGATFTSDLSKQMEEEAVRLFIEWLKNGGPPSGAPP
 1
 28

 1 match found in sequence:
 aay17603 ; Exendin agonist peptide #69.
 (from "seq5ags.pep")
 TOIG of: aay17603 check: 5882 from: 1 to: 38

ID AAY17603 standard; peptide; 38 AA.

XX AAY17603;

AC AAY17603;

XX 09-AUG-1999 (first entry)

DT Exendin agonist peptide #69.

DE Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925728-A1.

PN 27-MAY-1999.

FD 13-NOV-1998; 98WO-US024273.

XX 14-NOV-1997; 97US-0066029P.

PR (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-347456/29.

DR Peptide agonists of exendin - delay stomach emptying, for treating

XX diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

PS AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are

XX peptides that are found in the venom of the Gila monster, a lizard

CC endogenous to Arizona and Northern Mexico. The peptide agonists are used

CC to treat diabetes mellitus (types I or II), hyperglycaemia or

CC hypoglycaemia. They can also be used for in vitro and in vivo studies on

CC extendins and their agonists. They regulate gastric motility and slow

CC gastric emptying (resulting in lower post-prandial glucose levels)

XX Sequence 38 AA;

SQ AAY17603 Length: 38 February 4, 2005 13:32 Type: P Check: 5882 ..

Found using 'seq5' (mohamed337.key)

1 HGAGTFTSDLSKQMEEEAVRLFIEFLKNGGPPSGAPP
 1
 28

 1 match found in sequence:
 aay17604 ; Exendin agonist peptide #70.

(from "seq5ags.pep")
 TOIG of: aay17604 check: 3269 from: 1 to: 37
 ID AAY17604 standard; peptide; 37 AA.

XX AAY17604;

AC AAY17604;

XX 09-AUG-1999 (first entry)

DT Exendin agonist peptide #70.

DE Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925728-A1.

PN 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.

XX 14-NOV-1997; 97US-0066029P.

PR (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-347456/29.

DR Peptide agonists of exendin - delay stomach emptying, for treating

XX diabetes and hypo- or hyper-glycemia.

XX Claim 28; Fig 4; 144pp; English.

PS AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are

XX peptides that are found in the venom of the Gila monster, a lizard

CC endogenous to Arizona and Northern Mexico. The peptide agonists are used

CC to treat diabetes mellitus (types I or II), hyperglycaemia or

CC hypoglycaemia. They can also be used for in vitro and in vivo studies on

CC extendins and their agonists. They regulate gastric motility and slow

CC gastric emptying (resulting in lower post-prandial glucose levels)

XX Sequence 37 AA;

SQ AAY17604 Length: 37 February 4, 2005 13:32 Type: P Check: 3269 ..

Found using 'seq5' (mohamed337.key)

1 HGATFTSDLSKQMEEEAVRLFIEWLKNGGPPSGAPP
 1
 28

 1 match found in sequence:
 aay17605 ; Exendin agonist peptide #71.
 (from "seq5ags.pep")
 TOIG of: aay17605 check: 306 from: 1 to: 36

ID AAY17605 standard; peptide; 36 AA.

XX AAY17605;

AC AAY17605;

XX 09-AUG-1999 (first entry)

DT Exendin agonist peptide #71.

DE Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

```

DE  Extendin agonist peptide #66.
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS  Synthetic.
OS  Heloderma sp.
XX  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycaemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC  peptides that are found in the venom of the Gila-monster, a lizard
CC  endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC  to treat diabetes mellitus (types I or II), hyperglycaemia or
CC  hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC  extendins and their agonists. They regulate gastric motility and slow
CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX  Sequence 28 AA;
SQ
AAY17600 Length: 28 February 4, 2005 13:32 Type: P Check: 326 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  AGDGTFTSDLSKQLEEEAVRLFIEWLKA 28
-----
1 match found in sequence:
aay17601 ; Extendin agonist peptide #67.
(from "seq5ags.pep")
TOIG of: aay17601 check: 9887 from: 1 to: 28

ID  AAY17601 standard; peptide; 28 AA.
XX
AC  AAY17601;
XX
XX  09-AUG-1999 (first entry)
XX
DE  Extendin agonist peptide #67.
XX
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS  Synthetic.
OS  Heloderma sp.
XX  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycaemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC  peptides that are found in the venom of the Gila-monster, a lizard
CC  endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC  to treat diabetes mellitus (types I or II), hyperglycaemia or
CC  hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC  extendins and their agonists. They regulate gastric motility and slow
CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX  Sequence 28 AA;
SQ
AAY17600 Length: 28 February 4, 2005 13:32 Type: P Check: 326 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  AGDGTFTSDLSKQLEEEAVRLFIEWLKA 28
-----
1 match found in sequence:
aay17601 ; Extendin agonist peptide #67.
(from "seq5ags.pep")
TOIG of: aay17601 check: 9887 from: 1 to: 28

ID  AAY17601 standard; peptide; 28 AA.
XX
AC  AAY17601;
XX
XX  09-AUG-1999 (first entry)
XX
DE  Extendin agonist peptide #67.
XX
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS  Synthetic.
OS  Heloderma sp.
XX  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX

```

```

XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycaemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC  peptides that are found in the venom of the Gila-monster, a lizard
CC  endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC  to treat diabetes mellitus (types I or II), hyperglycaemia or
CC  hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC  extendins and their agonists. They regulate gastric motility and slow
CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX  Sequence 28 AA;
SQ
AAY17601 Length: 28 February 4, 2005 13:32 Type: P Check: 9887 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  AGDGTFTSDLSKQLEEEAVRLFIEFLKA 28
-----
1 match found in sequence:
aay17602 ; Extendin agonist peptide #68.
(from "seq5ags.pep")
TOIG of: aay17602 check: 6326 from: 1 to: 38

ID  AAY17602 standard; peptide; 38 AA.
XX
XX  AAY17602;
XX
XX  09-AUG-1999 (first entry)
XX
DE  Extendin agonist peptide #68.
XX
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS  Synthetic.
OS  Heloderma sp.
XX  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycaemia.
XX
XX  Claim 28; Fig 4; 144pp; English.
XX
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC  peptides that are found in the venom of the Gila-monster, a lizard
CC  endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC  to treat diabetes mellitus (types I or II), hyperglycaemia or
CC  hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC  extendins and their agonists. They regulate gastric motility and slow
CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX

```

```

XX Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17597 Length: 28 February 4, 2005 13:32 Type: P Check: 9965 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEEEAVRLFIETFLAN 28
1
-----|
1 match found in sequence:
aay17598 ; Extendin agonist peptide #64.
(from "seq5ags.pep")
TOIG of: aay17598 check: 420 from: 1 to: 28

ID AAY17598 standard; peptide; 28 AA.
XX
XX AC AAY17598;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Extendin agonist peptide #64.
XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-Al.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX OS Peptide agonists of extendin - delay stomach emptying, for treating
XX OS diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC extendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17598 Length: 28 February 4, 2005 13:32 Type: P Check: 420 ..
Found using 'seq5' (mohamed337.key)

```

```

1 AGDGTFTSDLSKQLEEEAVRLFIETFLAN 28
1
-----|
1 match found in sequence:
aay17599 ; Extendin agonist peptide #65.
(from "seq5ags.pep")
TOIG of: aay17599 check: 9981 from: 1 to: 28

ID AAY17599 standard; peptide; 28 AA.
XX
XX AC AAY17599;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Extendin agonist peptide #65.
XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-Al.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX OS Peptide agonists of extendin - delay stomach emptying, for treating
XX OS diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC extendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17599 Length: 28 February 4, 2005 13:32 Type: P Check: 9981 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEEEAVRLFIETFLAN 28
1
-----|
1 match found in sequence:
aay17600 ; Extendin agonist peptide #66.
(from "seq5ags.pep")
TOIG of: aay17600 check: 326 from: 1 to: 28

ID AAY17600 standard; peptide; 28 AA.
XX
XX AC AAY17600;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX

```

```

ID AAY17595 standard; peptide; 28 AA.
AC AAY17595;
XX
XX
DT 09-AUG-1999 (first entry)
XX
XX
XX Extendin agonist peptide #61.
XX
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO9925728-A1.
PN
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
SQ

AAY17595 Length: 28 February 4, 2005 13:32 Type: P Check: 126 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSLSKQLEEEAVRLFIEALKN 28

-----
1 match found in sequence:
aay17596 ; Extendin agonist peptide #62.
(from "seq5ags.pep")
TOIG of: aay17596 check: 404 from: 1 to: 28

ID AAY17596 standard; peptide; 28 AA.
XX
AC AAY17596;
XX
XX 09-AUG-1999 (first entry)
XX
XX Extendin agonist peptide #62.
XX
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO9925728-A1.
PN
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
SQ

AAY17595 Length: 28 February 4, 2005 13:32 Type: P Check: 126 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSLSKQLEEEAVRLFIEALKN 28

-----
1 match found in sequence:
aay17596 ; Extendin agonist peptide #62.
(from "seq5ags.pep")
TOIG of: aay17596 check: 404 from: 1 to: 28

ID AAY17596 standard; peptide; 28 AA.
XX
AC AAY17596;
XX
XX 09-AUG-1999 (first entry)
XX
XX Extendin agonist peptide #62.
XX
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO9925728-A1.
PN
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
SQ

```

```

PN WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
SQ

AAY17596 Length: 28 February 4, 2005 13:32 Type: P Check: 404 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSLSKQLEEEAVRLFIEALKN 28

-----
1 match found in sequence:
aay17597 ; Extendin agonist peptide #63.
(from "seq5ags.pep")
TOIG of: aay17597 check: 9965 from: 1 to: 28

ID AAY17597 standard; peptide; 28 AA.
XX
AC AAY17597;
XX
XX 09-AUG-1999 (first entry)
XX
XX Extendin agonist peptide #63.
XX
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO9925728-A1.
PN
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.

```

```

XX  Beeley NRA, Prickett KS;
XX  WPI; 1999-347456/29.
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyperglycaemia.
XX  Claim 28; Fig 4; 144pp; English.
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX  peptides that are found in the venom of the Gila-monster, a lizard
XX  endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX  to treat diabetes mellitus (types I or II), hyperglycaemia or
XX  hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX  extendins and their agonists. They regulate gastric motility and slow
XX  gastric emptying (resulting in lower post-prandial glucose levels)
XX  Sequence 28 AA;
AC  AAY17593 Length: 28 February 4, 2005 13:32 Type: P Check: 666
Found using 'seq5' (mohamed337.key)
1  AGDGTFTSDLSKQMEEEAVRLFDLWLN 28
-----|-----
1 match found in sequence:
aay17593 ; Extendin agonist peptide #59.
(from "seq5ags.pep")
TOIG of: aay17593 check: 227 from: 1 to: 28

ID  AAY17593 standard; peptide; 28 AA.
XX
XX  AAY17593;
AC  AAY17593;
XX
XX  09-AUG-1999 (first entry)
XX
XX  Extendin agonist peptide #59.
XX
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX  Synthetic.
XX  Heloderma sp.
XX  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycaemia.
XX  Claim 28; Fig 4; 144pp; English.
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX  peptides that are found in the venom of the Gila-monster, a lizard
XX  endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX  to treat diabetes mellitus (types I or II), hyperglycaemia or
XX  hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX  extendins and their agonists. They regulate gastric motility and slow
XX  gastric emptying (resulting in lower post-prandial glucose levels)

```

```

CC  gastric emptying (resulting in lower post-prandial glucose levels)
XX  Sequence 28 AA;
XX  AAY17593 Length: 28 February 4, 2005 13:32 Type: P Check: 227
Found using 'seq5' (mohamed337.key)
1  AGDGTFTSDLSKQMEEEAVRLFDLWLN 28
-----|-----
1 match found in sequence:
aay17594 ; Extendin agonist peptide #60.
(from "seq5ags.pep")
TOIG of: aay17594 check: 140 from: 1 to: 28

ID  AAY17594 standard; peptide; 28 AA.
XX
XX  AAY17594;
AC  AAY17594;
XX
XX  09-AUG-1999 (first entry)
XX
XX  Extendin agonist peptide #60.
XX
XX  Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX  diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX  hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX  Synthetic.
XX  Heloderma sp.
XX  WO9925728-A1.
XX
XX  27-MAY-1999.
XX
XX  13-NOV-1998; 98WO-US024273.
XX
XX  14-NOV-1997; 97US-0066029P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Beeley NRA, Prickett KS;
XX  WPI; 1999-347456/29.
XX
XX  Peptide agonists of extendin - delay stomach emptying, for treating
XX  diabetes and hypo- or hyper-glycaemia.
XX  Claim 28; Fig 4; 144pp; English.
XX  AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX  peptides that are found in the venom of the Gila-monster, a lizard
XX  endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX  to treat diabetes mellitus (types I or II), hyperglycaemia or
XX  hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX  extendins and their agonists. They regulate gastric motility and slow
XX  gastric emptying (resulting in lower post-prandial glucose levels)
XX  Sequence 28 AA;
XX  AAY17594 Length: 28 February 4, 2005 13:32 Type: P Check: 140
Found using 'seq5' (mohamed337.key)
1  AGDGTFTSDLSKQMEEEAVRLFDLWLN 28
-----|-----
1 match found in sequence:
aay17595 ; Extendin agonist peptide #61.
(from "seq5ags.pep")
TOIG of: aay17595 check: 126 from: 1 to: 28

```

```
1
-----
1 match found in sequence:
aay17590 ; Exendin agonist peptide #56.
(from "seq5ags.pep")
TOIG of: aay17590 check: 1035 from: 1 to: 28

ID AAY17590 standard; peptide; 28 AA.
XX
AC AAY17590;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #56.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17590 Length: 28 February 4, 2005 13:32 Type: P Check: 1035 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSDLSKQLEEEAVRLFEXEFLKN 28

-----
1 match found in sequence:
aay17591 ; Exendin agonist peptide #57.
(from "seq5ags.pep")
TOIG of: aay17591 check: 596 from: 1 to: 28

ID AAY17591 standard; peptide; 28 AA.
XX
AC AAY17591;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #57.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17591 Length: 28 February 4, 2005 13:32 Type: P Check: 596 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTSDLSKQLEEEAVRLFEXEFLKN 28

-----
1 match found in sequence:
aay17592 ; Exendin agonist peptide #58.
(from "seq5ags.pep")
TOIG of: aay17592 check: 666 from: 1 to: 28

ID AAY17592 standard; peptide; 28 AA.
XX
AC AAY17592;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #58.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
```

```

PD 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels).
XX
XX Sequence 28 AA;
XX
XX AAY17587 Length: 28 February 4, 2005 13:32 Type: P Check: 647 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX 1 AGDGTFTSDLSKQLEEEAVRLXIEFLKN 28
XX |-----|
XX -----
XX 1 match found in sequence:
XX aay17588 ; Exendin agonist peptide #54.
XX (from "seq5ags.pep")
XX TOIG of: aay17588 check: 989 from: 1 to: 28
XX
XX ID AAY17588 standard; peptide; 28 AA.
XX
XX AC AAY17588;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #54.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.

```

```

XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels).
XX
XX Sequence 28 AA;
XX
XX AAY17588 Length: 28 February 4, 2005 13:32 Type: P Check: 989 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX 1 AGDGTFTSDLSKQLEEEAVRLFVEFLKN 28
XX |-----|
XX -----
XX 1 match found in sequence:
XX aay17589 ; Exendin agonist peptide #55.
XX (from "seq5ags.pep")
XX TOIG of: aay17589 check: 550 from: 1 to: 28
XX
XX ID AAY17589 standard; peptide; 28 AA.
XX
XX AC AAY17589;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #55.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels).
XX
XX Sequence 28 AA;
XX
XX AAY17589 Length: 28 February 4, 2005 13:32 Type: P Check: 550 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX 1 AGDGTFTSDLSKQLEEEAVRLFVEFLKN 28
XX |-----|
XX -----

```


CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;

AAV17579 Length: 28 February 4, 2005 13:32 Type: P Check: 183 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDLSKQLEEAARLVFIEFLKN 28

 1 match found in sequence:
 aay17580 ; Exendin agonist peptide #46.
 (from "seq5ags.pep")
 TOIG of: aay17580 check: 291 from: 1 to: 28

ID AAY17580 standard; peptide; 28 AA.
 XX
 AC AAY17580;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #46.
 XX

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

OS Synthetic.
 OS Heloderma sp.
 XX WO9925728-A1.
 XX
 PD 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.
 XX
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.

XX Beesley NRA, Prickett KS;
 XX
 DR WPI; 1999-347456/29.

XX Peptide agonists of exendin - delay stomach emptying, for treating
 XX diabetes and hypo- or hyper-glycemia.
 XX Claim 28; Fig 4; 144pp; English.

XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are

CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;

AAV17580 Length: 28 February 4, 2005 13:32 Type: P Check: 291 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDLSKQLEEAARLVFIEFLKN 28

 1 match found in sequence:
 aay17581 ; Exendin agonist peptide #47.
 (from "seq5ags.pep")
 TOIG of: aay17581 check: 9852 from: 1 to: 28

ID AAY17581 standard; peptide; 28 AA.

XX
 AC AAY17581;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #47.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.
 OS Heloderma sp.
 XX WO9925728-A1.
 XX
 PD 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024273.
 XX
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.

XX Beesley NRA, Prickett KS;
 XX
 DR WPI; 1999-347456/29.

XX Peptide agonists of exendin - delay stomach emptying, for treating
 XX diabetes and hypo- or hyper-glycemia.
 XX Claim 28; Fig 4; 144pp; English.

XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;

AAV17581 Length: 28 February 4, 2005 13:32 Type: P Check: 9852 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 AGDGTFTSDLSKQLEEAARLVFIEFLKN 28

 1 match found in sequence:
 aay17582 ; Exendin agonist peptide #48.
 (from "seq5ags.pep")
 TOIG of: aay17582 check: 350 from: 1 to: 28

ID AAY17582 standard; peptide; 28 AA.
 XX
 AC AAY17582;

XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #48.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

```

XX 09-AUG-1999 (first entry)
XX Extensin agonist peptide #43.
XX
XX Extensin; agonist; Heloderma sp.; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
XX Heloderma sp.
XX WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17577 Length: 28 February 4, 2005 13:32 Type: P Check: 187 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEAAVRLFIIEFLKN 28
1
-----|
1 match found in sequence:
aay17578 ; Exendin agonist peptide #44.
(from "seq5ags.pep")
TOIG of: aay17578 check: 622 from: 1 to: 28

ID AAY17578 standard; peptide; 28 AA.
XX
XX AC AAY17578;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Extensin agonist peptide #44.
XX
XX KW Extensin; agonist; Heloderma sp.; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
XX Heloderma sp.
XX WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17577 Length: 28 February 4, 2005 13:32 Type: P Check: 187 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEAAVRLFIIEFLKN 28
1
-----|
1 match found in sequence:
aay17578 ; Exendin agonist peptide #44.
(from "seq5ags.pep")
TOIG of: aay17578 check: 622 from: 1 to: 28

ID AAY17578 standard; peptide; 28 AA.
XX
XX AC AAY17578;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Extensin agonist peptide #44.
XX
XX KW Extensin; agonist; Heloderma sp.; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
XX Heloderma sp.
XX WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17578 Length: 28 February 4, 2005 13:32 Type: P Check: 622 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEAAVRLFIIEFLKN 28
1
-----|
1 match found in sequence:
aay17579 ; Exendin agonist peptide #45.
(from "seq5ags.pep")
TOIG of: aay17579 check: 183 from: 1 to: 28

ID AAY17579 standard; peptide; 28 AA.
XX
XX AC AAY17579;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Extensin agonist peptide #45.
XX
XX KW Extensin; agonist; Heloderma sp.; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
XX Heloderma sp.
XX WO9925728-A1.
XX
XX 27-MAY-1999.
XX
XX 13-NOV-1998; 98WO-US024273.
XX
XX 14-NOV-1997; 97US-0066029P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
XX AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX

```

```

XX Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
XX Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17574 Length: 28 February 4, 2005 13:32 Type: P Check: 630 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMAEAVRLFIETWLNK 28
1
-----
1 match found in sequence:
aay17575 ; Exendin agonist peptide #41.
(from "seq5ags.pep")
TOIG of: aay17575 check: 191 from: 1 to: 28

ID AAY17575 standard; peptide; 28 AA.
XX
AC AAY17575;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #41.
XX
EX Endin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
OS Peptide agonists of exendin - delay stomach emptying, for treating
OS diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;

```

```

AAY17575 Length: 28 February 4, 2005 13:32 Type: P Check: 191 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMAEAVRLFIETWLNK 28
1
-----
1 match found in sequence:
aay17576 ; Exendin agonist peptide #42.
(from "seq5ags.pep")
TOIG of: aay17576 check: 626 from: 1 to: 28

ID AAY17576 standard; peptide; 28 AA.
XX
AC AAY17576;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #42.
XX
EX Endin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-347456/29.
XX
OS Peptide agonists of exendin - delay stomach emptying, for treating
OS diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX Sequence 28 AA;
XX
AAY17576 Length: 28 February 4, 2005 13:32 Type: P Check: 626 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMAEAVRLFIETWLNK 28
1
-----
1 match found in sequence:
aay17577 ; Exendin agonist peptide #43.
(from "seq5ags.pep")
TOIG of: aay17577 check: 187 from: 1 to: 28

ID AAY17577 standard; peptide; 28 AA.
XX
AC AAY17577;

```

```

aay17572 ; Exendin agonist peptide #38.
(from "seq5ags.pep")
TOIG of: aay17572 check: 606 from: 1 to: 28

ID AAY17572 standard; peptide; 28 AA.
XX
AC AAY17572;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #38.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17572 Length: 28 February 4, 2005 13:32 Type: P Check: 181 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQGEAEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aay17574 ; Exendin agonist peptide #40.
(from "seq5ags.pep")
TOIG of: aay17574 check: 630 from: 1 to: 28

ID AAY17574 standard; peptide; 28 AA.
XX
AC AAY17574;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #40.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-347456/29.
XX

```

```

aay17572 ; Exendin agonist peptide #38.
(from "seq5ags.pep")
TOIG of: aay17572 check: 606 from: 1 to: 28

ID AAY17572 standard; peptide; 28 AA.
XX
AC AAY17572;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #38.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925728-A1.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024273.
XX
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-347456/29.
XX
PT Peptide agonists of exendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX
PS Claim 28; Fig 4; 144pp; English.
XX
CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
CC peptides that are found in the venom of the Gila monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC exendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX
SQ Sequence 28 AA;

AAY17572 Length: 28 February 4, 2005 13:32 Type: P Check: 606 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQGEAEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aay17573 ; Exendin agonist peptide #39.
(from "seq5ags.pep")
TOIG of: aay17573 check: 181 from: 1 to: 28

ID AAY17573 standard; peptide; 28 AA.
XX
AC AAY17573;
XX
DT 09-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #39.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX

```

```

PR 14-NOV-1997; 97US-0066029P.
XX (AMYL-) AMYLIN PHARM INC.
XX Bealey NRA, Prickett KS;
XX WPI; 1999-347456/29.
XX Peptide agonists of extendin - delay stomach emptying, for treating
PT diabetes and hypo- or hyper-glycemia.
XX Claim 28; Fig 4; 144pp; English.
XX AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
CC peptides that are found in the venom of the Gila-monster, a lizard
CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
CC to treat diabetes mellitus (types I or II), hyperglycaemia or
CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
CC extendins and their agonists. They regulate gastric motility and slow
CC gastric emptying (resulting in lower post-prandial glucose levels)
XX Sequence 28 AA;
SQ

AAY17569 Length: 28 February 4, 2005 13:32 Type: P Check: 43 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQAEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aay17570 ; Extendin agonist peptide #36.
(from "seq5ags.pep")
TOIG of: aay17570 check: 522 from: 1 to: 28

ID AAY17570 standard; peptide; 28 AA.
XX
XX AC AAY17571;
XX 09-AUG-1999 (first entry)
XX
XX DE Extendin agonist peptide #37.
XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Bealey NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX OS Peptide agonists of extendin - delay stomach emptying, for treating
XX OS diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC extendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX Sequence 28 AA;
SQ

AAY17571 Length: 28 February 4, 2005 13:32 Type: P Check: 97 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQAEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aay17571 ; Extendin agonist peptide #37.
(from "seq5ags.pep")
TOIG of: aay17571 check: 97 from: 1 to: 28

ID AAY17571 standard; peptide; 28 AA.
XX
XX AC AAY17571;
XX 09-AUG-1999 (first entry)
XX
XX DE Extendin agonist peptide #37.
XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925728-A1.
XX 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Bealey NRA, Prickett KS;
XX
XX DR WPI; 1999-347456/29.
XX
XX OS Peptide agonists of extendin - delay stomach emptying, for treating
XX OS diabetes and hypo- or hyper-glycemia.
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC extendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)
XX Sequence 28 AA;
SQ

AAY17571 Length: 28 February 4, 2005 13:32 Type: P Check: 97 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQAEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:

```

```
RX PubMed=11683627; DOI=10.1021/bi010902s;
RA Neldigh J.W., Fesim Meyer R.M., Prickett K.S., Andersen N.H.;
RT "Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in
RL the solution and micelle-associated states.";
RL Biochemistry 40:13188-13200(2001).
CC -!- FUNCTION: Has a VIP/secretin-like biological activity. Interacts
CC with the exendin receptor.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC -!- SIMILARITY: Belongs to the glucagon family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U77613; AAB51130.1; -.
CC PIR; A42486; HWGH4G.
CC PDB; 1JRJ; NMR; A=48-86.
CC DR InterPro; IPR000532; Glucagon.
CC Pfam; PF00123; Hormone_2; 1.
CC SMART; SM00070; GLUCA; 1.
CC PROSITE; PS00260; GLUCAGON; 1.
CC 3D-structure; Amidation; Direct protein sequencing; Glucagon family;
CC Signal; Toxin. 1 23 Potential.
CC SIGNAL 1 23 Potential.
CC FT PROPEP 24 47
CC FT PEPTIDE 48 86 Exendin-4.
CC FT MOD RES 86 86 Serine amide (G-87 provides amide group).
CC FT TURN 52 53
CC FT HELIX 54 74
CC FT TURN 75 76
CC FT HELIX 77 79
CC SQ SEQUENCE 87 AA; 9479 MW; 656BA6E3D87454A2 CRC64;
EXE4 HELSU Length: 87 February 4, 2005 13:47 Type: P Check: 973 ..
Found using 'seq5' (mohamed337.key)

1 MKIILWLCVFLFLATLPIISWQMPVSGLSSEDSASSESPASKIKRHSDGCTFTSDLSKQ
-----|-----
61 MEEAVRLFIEWLKNGGPPSGNPPSG 75
Times: CPU 00:00:00.00 Total Elapsed 00:00:00.00
-- Search Statistics --
Number of sequences searched: 3
Number of sequence hits: 3
Number of separate matches: 3
Number of sequence hits saved: 0
```

```
DR HSPSP; P26349; 1JRJ.
DR GO; GO:0005576; C:extracellular; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; Hormone_2; 1.
DR SMART; SM00070; GLUCA; 1.
DR PROSITE; PS00260; GLUCAGON; 1.
CC SIGNAL 1 21 Potential.
CC FT CHAIN 48 86 exendin 3.
CC SQ SEQUENCE 87 AA; 9481 MW; E66FA6F15AE5F127 CRC64;
Q7SZU6 Length: 87 February 4, 2005 13:47 Type: P Check: 1771 ..
Found using 'seq5' (mohamed337.key)

1 MKIILWLCVFLFLATLPIISWQMPVSGLSSEDSASSESPASKIKRHSDGCTFTSDLSKQ
-----|-----
61 MEEAVRLFIEWLKNGGPPSGNPPSG 75
Times: CPU 00:00:00.00 Total Elapsed 00:00:00.00
-- Search Statistics --
Number of sequences searched: 3
Number of sequence hits: 3
Number of separate matches: 3
Number of sequence hits saved: 0
```

> O <
O|O Inteligenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq5_uni" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.

Selected sequence key from "mohamed337.key":
seq5 (AA) ID seq5 AA preliminary pattern

followed by

- 1 any character
- 2 s or g or a or t
- 2 a or d or e
- 2 any character
- 2 a or t
- 2 any character
- 2 t or s
- 2 a or s or t
- 2 any character
- 2 any character
- 2 a or s
- 2 a or k
- 2 a or q
- 2 any character
- 2 a or e
- 2 a or e
- 2 a or e
- 2 a or v
- 2 a or i
- 2 any character
- 2 any character
- 2 a or e or d
- 2 any character
- 2 a or l
- 2 a or k
- 2 a or n

Selected files:

File : seq5uni.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file No
Find non-matching hits only No Sequence or key file No
Report key used Yes List of hits Yes
Note position of hit Yes Hit display Yes
Display full annotations Yes Name and annotations Yes
Sequence context 50

-- Run Parameters --

Run mode Batch
Time to start comparison now
Notify at end of run No

1 match found in sequence:

exe3helho ; Exendin-3.
(from "seq5uni.pep")

TOIG of: exe3_helho check: 9591 from: 1 to: 39

ID EXE3 HELHO STANDARD; PRT; 39 AA.
AC P20394;
DT 01-FEB-1991 (Rel. 17, Created)

DT 01-FEB-1991 (Rel. 17, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Exendin-3.
OS Heloderma horridum horridum (Mexican beaded lizard).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scieroglossa; Anguimorpha; Helodermatidae;
OC Heloderma.
OX NCBI_TaxID=8552;
RN [1]
RP SEQUENCE.
RC TISSUE=Venom;
RX MEDLINE=91056067; PubMed=1700785;
RA Eng J., Andrew P.C., Kleinman W.A., Singh L., Raufman J.-P.;
RT "Purification and structure of exendin-3, a new pancreatic
secretagogue isolated from Heloderma horridum venom.";
RL J. Biol. Chem. 265:20259-20262(1990).
CC -|- FUNCTION: Has a VIP/secretin-like biological activity. Interacts
with the exendin receptor.
CC -|- SUBCELLULAR LOCATION: Secreted.
CC -|- TISSUE SPECIFICITY: Expressed by the venom gland.
CC -|- SIMILARITY: Belongs to the glucagon family.
DR PIR; A23674; HWGH32.
DR KSSP; P26349; LJRJ.
DR InterPro; IPR000532; Glucagon.
DR Pfam; PF00123; Hormone_2; 1.
DR SMART; SM00070; GLUCA; 1.
DR PROSITE; PS00260; GLUCAGON; 1.
KW Amidation; Direct protein sequencing; Glucagon family; Toxin.
FT MOD_RES 39 39 Serine amide.
SQ SEQUENCE 39 AA; 4204 MW; A44251D3A4B1D1B9 CRC64;

EXE3 HELHO Length: 39 February 4, 2005 13:47 Type: P Check: 9591
Found using 'seq5' (mohamed337.key)

1 HSDGFTSDLSKQMEAEAVLFIEWLKNGPSSGAPPPS

1
28

1 match found in sequence:
exe4helho ; Exendin-4 precursor.
(from "seq5uni.pep")
TOIG of: exe4_helso check: 973 from: 1 to: 87

ID EXE4 HELSU STANDARD; PRT; 87 AA.

AC P26349;
DT 01-MAY-1992 (Rel. 22, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Exendin-4 precursor.
OS Heloderma suspectum (Gila monster).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scieroglossa; Anguimorpha; Helodermatidae;
OC Heloderma.
OX NCBI_TaxID=8554;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97172477; PubMed=9020121; DOI=10.1074/jbc.272.7.4335;
RA Chen Y.E., Drucker D.J.;
RT "Tissue-specific expression of unique mRNAs that encode proglucagon-
derived peptides or exendin 4 in the lizard.";
RL J. Biol. Chem. 272:4108-4115(1997).
RN [2]
RP SEQUENCE OF 48-86.
RC TISSUE=Venom;
RX MEDLINE=92218391; PubMed=1313797;
RA Eng J., Kleinman W.A., Singh L., Raufman J.-P.;
RT "Isolation and characterization of exendin-4, an exendin-3 analogue,
from Heloderma suspectum venom. Further evidence for an exendin
receptor on dispersed acini from guinea pig pancreas.";
RL J. Biol. Chem. 267:7402-7405(1992).
RN [3]
RP STRUCTURE BY NMR OF 48-86.


```

> O <
O | O IntelliGenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq5_pir" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.
Selected sequence key from "mohamed337.key":
seq5 (AA) ID seq5 AA preliminary pattern
followed by
1 any character
2 s or g or a or t
2 a or d or e
2 any character
2 a or t
2 any character
2 t or s
2 a or s or t
2 any character
2 any character
2 a or s
2 a or k
2 a or q
2 any character
2 a or e
2 a or e
2 a or e
2 a
2 a or v
2 a or r
2 a or l
2 any character
2 any character
2 a or e or d
2 any character
2 a or l
2 a or k
2 a or n

Selected files:
File : seq5pir.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact No
Find non-matching hits only No
Report key used Yes
List of hits Yes
Hit display Yes
Note position of hit Yes
Display full annotations Yes
Sequence context 50

File Options:
Indirect file No
Sequence or key file No
List of hits Yes
Hit display Yes
Name and annotations Yes

-- Run Parameters --

Run mode Batch
Time to start comparison now
Notify at end of run No

-----
1 match found in sequence:
hwgh3z ; TOIG of: hwgh3z check: 9591 from: 1 to: 39
(from "seq5pir.pir")
TOIG of: hwgh3z check: 9591 from: 1 to: 39

P1;HWGH3Z - extendin-3 - Mexican beaded lizard
C:Species: Heloderma horridum (Mexican beaded lizard)
C>Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004

P1;HWGH4G - extendin-4 - Gila monster
C:Species: Heloderma suspectum (Gila monster)
C>Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
C:Accession: A42486
R:Eng, J.; Kleinman, W.A.; Singh, L.; Singh, G.; Raufman, J.P.
J. Biol. Chem. 267, 7402-7405, 1992
A>Title: Isolation and characterization of extendin-4, an extendin-3 analogue,
from Heloderma suspectum venom. Further evidence for an extendin receptor on
dispersed acini from guinea pig pancreas.
A:Reference number: A42486; MUID:92218391; PMID:1313797
A:Accession: A42486
A:Molecule type: protein
A:Residues: 1-39 <ENG>
A:CROSS-references: UNIPROT:P26349
C:Comment: Extendin-4 does not stimulate amylase secretion by pancreatic acinar
cells.
C:Superfamily: Glucagon
C:Keywords: amidated carboxyl end; duplication; venom
F;39/Modified site: amidated carboxyl end (Ser) #status experimental

HWGH4G Length: 39 February 4, 2005 13:46 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

-----
1 HSGGTFTSDLSKQMEAEAVRLFIEWLKNQGPSSGAPPPS
28
-----
1 match found in sequence:
hwgh4g ; TOIG of: hwgh4g check: 9570 from: 1 to: 39
(from "seq5pir.pir")
TOIG of: hwgh4g check: 9570 from: 1 to: 39

P1;HWGH4G - extendin-4 - Gila monster
C:Species: Heloderma suspectum (Gila monster)
C>Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
C:Accession: A42486
R:Eng, J.; Kleinman, W.A.; Singh, L.; Singh, G.; Raufman, J.P.
J. Biol. Chem. 267, 7402-7405, 1992
A>Title: Isolation and characterization of extendin-4, an extendin-3 analogue,
from Heloderma suspectum venom. Further evidence for an extendin receptor on
dispersed acini from guinea pig pancreas.
A:Reference number: A42486; MUID:92218391; PMID:1313797
A:Accession: A42486
A:Molecule type: protein
A:Residues: 1-39 <ENG>
A:CROSS-references: UNIPROT:P26349
C:Comment: Extendin-4 does not stimulate amylase secretion by pancreatic acinar
cells.
C:Superfamily: Glucagon
C:Keywords: amidated carboxyl end; duplication; venom
F;39/Modified site: amidated carboxyl end (Ser) #status experimental

HWGH4G Length: 39 February 4, 2005 13:46 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

-----
1 HSGGTFTSDLSKQMEAEAVRLFIEWLKNQGPSSGAPPPS
28
-----

Times: CPU Total Elapsed
00:00:00.00 00:00:00.00

Number of sequences searched: 2
Number of sequence hits: 2
Number of separate matches: 2
Number of sequence hits saved: 0

-- Search Statistics --

```

This Page Blank (uspto)

```

XX 17-DEC-2002; 2002US-0434508P.
PR 19-DEC-2002; 2002US-0434888P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hathaway DR, Baron AD;
XX
XX WPI; 2004-507584/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
PT cardiac arrhythmias by metabolic intervention.
XX
XX Disclosure; SEQ ID NO 23; 49pp; English.
XX
XX The present sequence is that of 14Leu,25Phe exendin-4 (1-28) amide
CC derived from Heloderma suspectum exendin-4 ADQ28643. It is an example of
CC exendin analogues of the invention. The present invention provides
CC methods and compositions for preventing and treating cardiac arrhythmias.
CC The compositions comprise exendin, GLP-1, an incretin, a compound that
CC binds to a receptor for GLP-1, or an agonist, analogue, derivative or
CC variant of these compounds or their biologically active fragments. These
CC compounds enhance peripheral glucose uptake by potentiating insulin
CC secretion without inducing dangerous hypoglycaemia. They are effective at
CC maintaining the electrochemical gradient across cardiac cellular
CC membranes, thereby reducing the likelihood of arrhythmias developing.
CC They also strongly suppress glucagon secretion, independent of its
CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
CC levels substantially more than can be accomplished with insulin. High FFA
CC levels have been implicated as a major toxic mechanism during myocardial
CC ischaemia. The compounds can be administered by injection following an
CC ischaemic event or a cardiac intervention such as angioplasty, coronary
CC bypass grafting or placement of an intracoronary stent, and can be used
CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
CC cardiac ischaemia-reperfusion and congestive heart failure.
XX
XX Sequence 28 AA;
ADQ28652 Length: 28 February 4, 2005 13:33 Type: P Check: 261 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGFTFTSDLSKQLEEEAVRLAIEFLKN 28
-----
1 match found in sequence:
adq28653 ; 14Leu,22Ala,25Phe exendin-4 (1-28) amide, useful as antiarrhythmic.
(from "seq5ags.pep")
TOIG of: adq28653 check: 151 from: 1 to: 28

ID ADQ28653 standard; peptide; 28 AA.
XX
XX AC ADQ28653;
XX
XX DT 23-SEP-2004 (first entry)
XX
XX 14Leu,22Ala,25Phe exendin-4 (1-28) amide, useful as antiarrhythmic.
XX
XX Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
XX Heloderma suspectum.
XX
XX Key Location/Qualifiers
FT Misc-difference 14 /note= "Wild-type Met substituted by Leu"
FT Misc-difference 22 /note= "Wild-type Phe substituted by Ala"
FT Misc-difference 25 /note= "Wild-type Trp substituted by Phe"
FT Modified-site 28 /note= "C-terminal amide"

```

```

XX WO2004056313-A2.
XX
XX 08-JUL-2004.
XX
XX 17-DEC-2003; 2003WO-US040504.
XX
XX 17-DEC-2002; 2002US-0434508P.
PR 19-DEC-2002; 2002US-0434888P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hathaway DR, Baron AD;
XX
XX WPI; 2004-507584/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
PT cardiac arrhythmias by metabolic intervention.
XX
XX Disclosure; SEQ ID NO 24; 49pp; English.
XX
XX The present sequence is that of 14Leu,22Ala,25Phe exendin-4 (1-28) amide
CC derived from Heloderma suspectum exendin-4 ADQ28643. It is an example of
CC exendin analogues of the invention. The present invention provides
CC methods and compositions for preventing and treating cardiac arrhythmias.
CC The compositions comprise exendin, GLP-1, an incretin, a compound that
CC binds to a receptor for GLP-1, or an agonist, analogue, derivative or
CC variant of these compounds or their biologically active fragments. These
CC compounds enhance peripheral glucose uptake by potentiating insulin
CC secretion without inducing dangerous hypoglycaemia. They are effective at
CC maintaining the electrochemical gradient across cardiac cellular
CC membranes, thereby reducing the likelihood of arrhythmias developing.
CC They also strongly suppress glucagon secretion, independent of its
CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
CC levels substantially more than can be accomplished with insulin. High FFA
CC levels have been implicated as a major toxic mechanism during myocardial
CC ischaemia. The compounds can be administered by injection following an
CC ischaemic event or a cardiac intervention such as angioplasty, coronary
CC bypass grafting or placement of an intracoronary stent, and can be used
CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
CC cardiac ischaemia-reperfusion and congestive heart failure.
XX
XX Sequence 28 AA;
ADQ28653 Length: 28 February 4, 2005 13:33 Type: P Check: 151 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGFTFTSDLSKQLEEEAVRLAIEFLKN 28
-----

```

-- Search Statistics --

Times: CPU 00:00:02.02 Total Elapsed 00:00:22.00

Number of sequences searched: 1153
 Number of sequence hits: 1153
 Number of separate matches: 1153
 Number of sequence hits saved: 0

```
DR WPI; 2004-507584/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
PT cardiac arrhythmias by metabolic intervention.
XX
XX Disclosure; SEQ ID NO 21; 49pp; English.
XX
XX The present sequence is that of exendin-4 (1-28) amide derived from
CC Heloderma suspectum exendin-4 ADQ28643. It is an example of exendin
CC analogues of the invention. The present invention provides methods and
CC compositions for preventing and treating cardiac arrhythmias. The
CC compositions comprise exendin, GLP-1, an incertin, a compound that binds
CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
CC of these compounds or their biologically active fragments. These
CC compounds enhance peripheral glucose uptake by potentiating insulin
CC secretion without inducing dangerous hypoglycaemia. They are effective at
CC maintaining the electrochemical gradient across cardiac cellular
CC membranes, thereby reducing the likelihood of arrhythmias developing.
CC They also strongly suppress glucagon secretion, independent of its
CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
CC levels substantially more than can be accomplished with insulin. High FFA
CC levels have been implicated as a major toxic mechanism during myocardial
CC ischaemia. The compounds can be administered by injection following an
CC ischaemic event or a cardiac intervention such as angioplasty, coronary
CC bypass grafting or placement of an intracoronary stent, and can be used
CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
CC cardiac ischaemia-reperfusion and congestive heart failure.
XX
XX Sequence 28 AA;
SQ
ADQ28650 Length: 28 February 4, 2005 13:33 Type: P Check: 700
Found using 'seq5' (mohamed337.key)
1
1 HGEFTFTSLSKQLEEBEAVRLFIEFLKNGGPGSGAPPPS
1
1 match found in sequence:
adq28651 ; 14Leu,25Phe exendin-4 amide, useful as antiarrhythmic.
(from "seq5ags.pep")
TOIG of: adq28651 check: 9131 from: 1 to: 39
ID ADQ28651 standard; peptide; 39 AA.
XX
XX ADQ28651;
AC
XX
XX 23-SEP-2004 (first entry)
XX
XX 14Leu,25Phe exendin-4 amide, useful as antiarrhythmic.
XX
XX Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
XX Heloderma suspectum.
XX
XX Key Location/Qualifiers
XX Misc-difference 14 /note= "Wild-type Met substituted by Leu"
XX Misc-difference 25 /note= "Wild-type Trp substituted by Phe"
XX Modified-site 39 /note= "C-terminal amide"
XX
XX WO2004056313-A2.
XX
XX 08-JUL-2004.
XX
XX 17-DEC-2003; 2003WO-US040504.
XX
XX 17-DEC-2002; 2002US-0434508P.
XX
XX 19-DEC-2002; 2002US-0434888P.
XX

(PMYL-) AMYLIN PHARM INC.
Hathaway DR, Baron AD;
WPI; 2004-507584/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
PT cardiac arrhythmias by metabolic intervention.
XX
XX Disclosure; SEQ ID NO 22; 49pp; English.
XX
XX The present sequence is that of 14Leu,25Phe exendin-4 amide derived from
CC Heloderma suspectum exendin-4 ADQ28643. It is an example of exendin
CC analogues of the invention. The present invention provides methods and
CC compositions for preventing and treating cardiac arrhythmias. The
CC compositions comprise exendin, GLP-1, an incertin, a compound that binds
CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
CC of these compounds or their biologically active fragments. These
CC compounds enhance peripheral glucose uptake by potentiating insulin
CC secretion without inducing dangerous hypoglycaemia. They are effective at
CC maintaining the electrochemical gradient across cardiac cellular
CC membranes, thereby reducing the likelihood of arrhythmias developing.
CC They also strongly suppress glucagon secretion, independent of its
CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
CC levels substantially more than can be accomplished with insulin. High FFA
CC levels have been implicated as a major toxic mechanism during myocardial
CC ischaemia. The compounds can be administered by injection following an
CC ischaemic event or a cardiac intervention such as angioplasty, coronary
CC bypass grafting or placement of an intracoronary stent, and can be used
CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
CC cardiac ischaemia-reperfusion and congestive heart failure.
XX
XX Sequence 39 AA;
SQ
ADQ28651 Length: 39 February 4, 2005 13:33 Type: P Check: 9131
Found using 'seq5' (mohamed337.key)
1
1 HGEFTFTSLSKQLEEBEAVRLFIEFLKNGGPGSGAPPPS
1
1 match found in sequence:
adq28652 ; 14Leu,25Phe exendin-4 (1-28) amide, useful as antiarrhythmic.
(from "seq5ags.pep")
TOIG of: adq28652 check: 261 from: 1 to: 28
ID ADQ28652 standard; peptide; 28 AA.
XX
XX ADQ28652;
AC
XX
XX 23-SEP-2004 (first entry)
XX
XX 14Leu,25Phe exendin-4 (1-28) amide, useful as antiarrhythmic.
XX
XX Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
XX Heloderma suspectum.
XX
XX Key Location/Qualifiers
XX Misc-difference 14 /note= "Wild-type Met substituted by Leu"
XX Misc-difference 25 /note= "Wild-type Trp substituted by Phe"
XX Modified-site 28 /note= "C-terminal amide"
XX
XX WO2004056313-A2.
XX
XX 08-JUL-2004.
XX
XX 17-DEC-2003; 2003WO-US040504.
XX
XX 17-DEC-2002; 2002US-0434508P.
XX
XX 19-DEC-2002; 2002US-0434888P.
XX
```

DR WPI; 2004-507584/48.
 XX Use of an incertin, a glucagon-like peptide-1, an extendin, or a compound
 PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
 PT cardiac arrhythmias by metabolic intervention.
 XX
 XX Disclosure; SEQ ID NO 19; 49pp; English.
 XX
 CC The present sequence is that of extendin-4 (1-30) peptide derived from
 CC Heloderma suspectum extendin-4 ADQ28643. It is an example of extendin
 CC analogues of the invention. The present invention provides methods and
 CC compositions for preventing and treating cardiac arrhythmias. The
 CC compositions comprise extendin, GLP-1, an incretin, a compound that binds
 CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
 CC of these compounds or their biologically active fragments. These
 CC compounds enhance peripheral glucose uptake by potentiating insulin
 CC secretion without inducing dangerous hypoglycaemia. They are effective at
 CC maintaining the electrochemical gradient across cardiac cellular
 CC membranes, thereby reducing the likelihood of arrhythmias developing.
 CC They also strongly suppress glucagon secretion, independent of its
 CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
 CC levels substantially more than can be accomplished with insulin. High FFA
 CC levels have been implicated as a major toxic mechanism during myocardial
 CC ischaemia. The compounds can be administered by injection following an
 CC ischaemic event or a cardiac intervention such as angioplasty, coronary
 CC bypass grafting or placement of an intracoronary stent, and can be used
 CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
 CC cardiac ischaemia-reperfusion and congestive heart failure.
 XX
 SQ Sequence 30 AA;

ADQ28648 Length: 30 February 4, 2005 13:33 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNKG 28
 1

 1 match found in sequence:
 adq28649 ; Extendin-4 (1-30) amide, useful as antiarrhythmic.
 (from "seq5ags.pep")

TOIG of: adq28649 check: 4889 from: 1 to: 30

ID ADQ28649 standard; peptide; 30 AA.
 XX
 AC ADQ28649;
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE Extendin-4 (1-30) amide, useful as antiarrhythmic.
 XX
 KW Extendin-4 (1-30); antiarrhythmic; cardiovascular-gen.; vasotropic.
 XX
 OS Heloderma suspectum.

Key	Location/Qualifiers
Modified-site	30
	/note= "C-terminal amide"

WO2004056313-A2.

08-JUL-2004.

17-DEC-2003; 2003WO-US040504.

17-DEC-2002; 2002US-0434508P.

19-DEC-2002; 2002US-0434888P.

(AMYL-) AMYLIN PHARM INC.

Hathaway DR, Baron AD;

XX

DR WPI; 2004-507584/48.
 XX
 PT Use of an incertin, a glucagon-like peptide-1, an extendin, or a compound
 PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
 PT cardiac arrhythmias by metabolic intervention.
 XX
 XX Disclosure; SEQ ID NO 20; 49pp; English.
 XX

CC The present sequence is that of extendin-4 (1-30) amide derived from
 CC Heloderma suspectum extendin-4 ADQ28643. It is an example of extendin
 CC analogues of the invention. The present invention provides methods and
 CC compositions for preventing and treating cardiac arrhythmias. The
 CC compositions comprise extendin, GLP-1, an incretin, a compound that binds
 CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
 CC of these compounds or their biologically active fragments. These
 CC compounds enhance peripheral glucose uptake by potentiating insulin
 CC secretion without inducing dangerous hypoglycaemia. They are effective at
 CC maintaining the electrochemical gradient across cardiac cellular
 CC membranes, thereby reducing the likelihood of arrhythmias developing.
 CC They also strongly suppress glucagon secretion, independent of its
 CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
 CC levels substantially more than can be accomplished with insulin. High FFA
 CC levels have been implicated as a major toxic mechanism during myocardial
 CC ischaemia. The compounds can be administered by injection following an
 CC ischaemic event or a cardiac intervention such as angioplasty, coronary
 CC bypass grafting or placement of an intracoronary stent, and can be used
 CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
 CC cardiac ischaemia-reperfusion and congestive heart failure.
 XX
 SQ Sequence 30 AA;

ADQ28649 Length: 30 February 4, 2005 13:33 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNKG 28
 1

 1 match found in sequence:
 adq28650 ; Extendin-4 (1-28) amide, useful as antiarrhythmic.
 (from "seq5ags.pep")

TOIG of: adq28650 check: 700 from: 1 to: 28

ID ADQ28650 standard; peptide; 28 AA.
 XX
 AC ADQ28650;
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE Extendin-4 (1-28) amide, useful as antiarrhythmic.
 XX
 KW Extendin-4 (1-28); antiarrhythmic; cardiovascular-gen.; vasotropic.
 XX
 OS Heloderma suspectum.

Key	Location/Qualifiers
Modified-site	28
	/note= "C-terminal amide"

WO2004056313-A2.

08-JUL-2004.

17-DEC-2003; 2003WO-US040504.

17-DEC-2002; 2002US-0434508P.

19-DEC-2002; 2002US-0434888P.

(AMYL-) AMYLIN PHARM INC.

Hathaway DR, Baron AD;

XX

```

PI Hathaway DR, Baron AD;
XX WPI; 2004-507584/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
XX PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
XX PT cardiac arrhythmias by metabolic intervention.
XX
XX Disclosure; SEQ ID NO 12; 49pp; English.
XX
XX The present sequence is that of the exendin-3 peptide of Heloderma
XX CC harridum. This is a glucose-dependent insulinotropic peptide that
XX CC enhances peripheral glucose uptake without inducing dangerous
XX CC hyperglycaemia. The present invention provides methods and compositions
XX CC for preventing and treating cardiac arrhythmias. The compositions
XX CC comprise exendin, GLP-1, an incretin, a compound that binds to a receptor
XX CC for GLP-1, or an agonist, derivative or variant of these
XX CC compounds or their biologically active fragments. These compounds enhance
XX CC peripheral glucose uptake by potentiating insulin secretion without
XX CC inducing dangerous hypoglycaemia. They are effective at maintaining the
XX CC electrochemical gradient across cardiac cellular membranes, thereby
XX CC reducing the likelihood of arrhythmias developing. They also strongly
XX CC suppress glucagon secretion, independent of its insulinotropic action,
XX CC and thereby reduce plasma free fatty acid (FFA) levels substantially more
XX CC than can be accomplished with insulin. High FFA levels have been
XX CC implicated as a major toxic mechanism during myocardial ischaemia. The
XX CC compounds can be administered by injection following an ischaemic event
XX CC or a cardiac intervention such as angioplasty, coronary bypass grafting
XX CC or placement of an intracoronary stent, and can be used to treat or
XX CC prevent ventricular arrhythmias such as cardiac ischaemia, cardiac
XX CC ischaemia-reperfusion and congestive heart failure.
XX
XX SQ Sequence 39 AA;
ADQ28641 Length: 39 February 4, 2005 13:33 Type: P Check: 9591
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HSDGFTSDLSKQMEAEAVRLFIEWLKNKGSPSGAPPPS 28
-----
1 match found in sequence:
adq28643 ; Exendin-4, useful as antiarrhythmic.
(from "seq5ags.pep")
TOIG of: adq28643 check: 9570 from: 1 to: 39
ID ADQ28643 standard; peptide; 39 AA.
XX
XX AC ADQ28643;
XX
XX DT 23-SEP-2004 (first entry)
XX
XX DE Exendin-4, useful as antiarrhythmic.
XX
XX KW Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
XX OS Heloderma suspectum.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX
XX PN WO2004056313-A2.
XX
XX PD 08-JUL-2004.
XX
XX PF 17-DEC-2003; 2003WO-US040504.
XX
XX PR 17-DEC-2002; 2002US-0434508P.
XX
XX PR 19-DEC-2002; 2002US-0434888P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Hathaway DR, Baron AD;
XX
XX Hathaway DR, Baron AD;
XX WPI; 2004-507584/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
XX PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
XX PT cardiac arrhythmias by metabolic intervention.
XX
XX Disclosure; SEQ ID NO 14; 49pp; English.
XX
XX The present sequence is that of exendin-4 of Heloderma suspectum. This is
XX CC a glucose-dependent insulinotropic peptide that enhances peripheral
XX CC glucose uptake without inducing dangerous hyperglycaemia. The present
XX CC invention provides methods and compositions for preventing and treating
XX CC cardiac arrhythmias. The compositions comprise exendin, GLP-1, an
XX CC incretin, a compound that binds to a receptor for GLP-1, or an agonist,
XX CC analogue, derivative or variant of these compounds or their biologically
XX CC active fragments. These compounds enhance peripheral glucose uptake by
XX CC potentiating insulin secretion without inducing dangerous hypoglycaemia.
XX CC They are effective at maintaining the electrochemical gradient across
XX CC cardiac cellular membranes, thereby reducing the likelihood of
XX CC arrhythmias developing. They also strongly suppress glucagon secretion,
XX CC independent of its insulinotropic action, and thereby reduce plasma free
XX CC fatty acid (FFA) levels substantially more than can be accomplished with
XX CC insulin. High FFA levels have been implicated as a major toxic mechanism
XX CC during myocardial ischaemia. The compounds can be administered by
XX CC injection following an ischaemic event or a cardiac intervention such as
XX CC angioplasty, coronary bypass grafting or placement of an intracoronary
XX CC stent, and can be used to treat or prevent ventricular arrhythmias such
XX CC as cardiac ischaemia, cardiac ischaemia-reperfusion and congestive heart
XX CC failure.
XX
XX SQ Sequence 39 AA;
ADQ28643 Length: 39 February 4, 2005 13:33 Type: P Check: 9570
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEFTFSDLSKQMEAEAVRLFIEWLKNKGSPSGAPPPS 28
-----
1 match found in sequence:
adq28648 ; Exendin-4 (1-30) peptide, useful as antiarrhythmic.
(from "seq5ags.pep")
TOIG of: adq28648 check: 4889 from: 1 to: 30
ID ADQ28648 standard; peptide; 30 AA.
XX
XX AC ADQ28648;
XX
XX DT 23-SEP-2004 (first entry)
XX
XX DE Exendin-4 (1-30) peptide, useful as antiarrhythmic.
XX
XX KW Exendin-4 (1-30); antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
XX OS Heloderma suspectum.
XX
XX PN WO2004056313-A2.
XX
XX PD 08-JUL-2004.
XX
XX PF 17-DEC-2003; 2003WO-US040504.
XX
XX PR 17-DEC-2002; 2002US-0434508P.
XX
XX PR 19-DEC-2002; 2002US-0434888P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Hathaway DR, Baron AD;
XX

```


PI Baron AD, Hathaway DR, Mistry M, Roman RJ;
XX WPI; 2004-507586/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
PT of a medicament for the prevention or treatment of nephropathy.
XX
XX Disclosure; SEQ ID NO 21; 50pp; English.
XX
XX The present invention describes an incertin, a glucagon-like peptide-1
CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
CC their agonist, analogue, derivative or variant or fragment (I), that is
CC used in the manufacture of a medicament for the prevention or treatment
CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
CC activities. (I) can be used in the manufacture of a medicament for the
CC prevention or treatment of nephropathy; preventing progression of
CC nephropathy to end stage renal disease (ESRD); improving endothelial
CC function in the treatment of reduced vasodilatory capacity; reducing
CC proteinuria; and preventing or slowing progression of glomerulosclerosis
CC associated with insulin resistance, diabetes and hypertension. The
CC compounds act in part by improving insulin resistance, cation balance,
CC hypertension and/or by facilitating glucose oxidation; including that by
CC endothelial cells in the kidney and by other cells, rather by oxidation
CC of free fatty acids; and so leads to an enhanced production of ATP for
CC use by the cells and reduces oxidative stress on the affected tissue. The
CC present sequence represents an extendin analogue peptide, which is given
CC in the exemplification of the present invention.
XX
XX Sequence 28 AA;
SQ
ADP86548 Length: 28 February 4, 2005 13:33 Type: P Check: 700 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQEBEAVRLFIEWLKN 28

1 match found in sequence:
adp86549 ; Extendin-4 analogue peptide SEQ ID NO:22.
(from "seq5ags.pep")
TOIG of: adp86549 check: 9131 from: 1 to: 39
ID ADP86549 standard; peptide; 39 AA.
XX
XX ADP86549;
AC
XX
XX 23-SEP-2004 (first entry)
DT
XX
XX Extendin-4 analogue peptide SEQ ID NO:22.
DE
XX
XX incertin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
KW hypertension.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Key 39
FT Modified-site /note= "amidated"
FT
XX
XX WO2004056317-A2.
FN
XX
XX 08-JUL-2004.
PD
XX
XX 19-DEC-2003; 2003WO-US040713.
PF
XX
XX 19-DEC-2002; 2002US-00741534.
PR
XX
XX 17-DEC-2003; 2003US-00740146.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX

PI Baron AD, Hathaway DR, Mistry M, Roman RJ;
XX WPI; 2004-507586/48.
XX
XX Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
PT of a medicament for the prevention or treatment of nephropathy.
XX
XX Disclosure; SEQ ID NO 22; 50pp; English.
XX
XX The present invention describes an incertin, a glucagon-like peptide-1
CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
CC their agonist, analogue, derivative or variant or fragment (I), that is
CC used in the manufacture of a medicament for the prevention or treatment
CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
CC activities. (I) can be used in the manufacture of a medicament for the
CC prevention or treatment of nephropathy; preventing progression of
CC nephropathy to end stage renal disease (ESRD); improving endothelial
CC function in the treatment of reduced vasodilatory capacity; reducing
CC proteinuria; and preventing or slowing progression of glomerulosclerosis
CC associated with insulin resistance, diabetes and hypertension. The
CC compounds act in part by improving insulin resistance, cation balance,
CC hypertension and/or by facilitating glucose oxidation; including that by
CC endothelial cells in the kidney and by other cells, rather by oxidation
CC of free fatty acids; and so leads to an enhanced production of ATP for
CC use by the cells and reduces oxidative stress on the affected tissue. The
CC present sequence represents an extendin analogue peptide, which is given
CC in the exemplification of the present invention.
XX
XX Sequence 39 AA;
SQ
ADP86549 Length: 39 February 4, 2005 13:33 Type: P Check: 9131 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQEBEAVRLFIEWLKN 28

1 match found in sequence:
adp86550 ; Extendin-4 analogue peptide SEQ ID NO:23.
(from "seq5ags.pep")
TOIG of: adp86550 check: 261 from: 1 to: 28
ID ADP86550 standard; peptide; 28 AA.
XX
XX ADP86550;
AC
XX
XX 23-SEP-2004 (first entry)
DT
XX
XX Extendin-4 analogue peptide SEQ ID NO:23.
DE
XX
XX incertin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
KW hypertension.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Key 28
FT Modified-site /note= "amidated"
FT
XX
XX WO2004056317-A2.
FN
XX
XX 08-JUL-2004.
PD
XX
XX 19-DEC-2003; 2003WO-US040713.
PF
XX
XX 19-DEC-2002; 2002US-00741534.
PR
XX
XX 17-DEC-2003; 2003US-00740146.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX


```

XX
PT Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
PT of a medicament for the prevention or treatment of nephropathy.
XX
PS Disclosure; SEQ ID NO 19; 50pp; English.
XX
CC The present invention describes an incertin, a glucagon-like peptide-1
CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
CC their agonist, analogue, derivative or variant or fragment (I), that is
CC used in the manufacture of a medicament for the prevention or treatment
CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
CC activities. (I) can be used in the manufacture of a medicament for the
CC prevention or treatment of nephropathy; preventing progression of
CC nephropathy to end stage renal disease (ESRD); improving endothelial
CC function in the treatment of reduced vasodilatory capacity; reducing
CC proteinuria; and preventing or slowing progression of glomerulosclerosis
CC associated with insulin resistance, diabetes and hypertension. The
CC compounds act in part by improving insulin resistance, cation balance,
CC hypertension and/or by facilitating glucose oxidation; including that by
CC endothelial cells in the kidney and by other cells, rather by oxidation
CC of free fatty acids; and so leads to an enhanced production of ATP for
CC use by the cells and reduces oxidative stress on the affected tissue. The
CC present sequence represents an extendin analogue peptide, which is given
CC in the exemplification of the present invention.
XX
SQ Sequence 30 AA;
ADP86546 Length: 30 February 4, 2005 13:33 Type: P Check: 4889
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQMEERAVRLFIEWLKNKG 28
1 -----|
1 match found in sequence:
adp86547 ; Extendin-4 analogue peptide SEQ ID NO:20.
(from "seq5ags.pep")
TOIG of: adp86547 check: 4889 from: 1 to: 30

ID ADP86547 standard; peptide; 30 AA.
XX
AC ADP86547;
XX
DT 23-SEP-2004 (first entry)
XX
DE Extendin-4 analogue peptide SEQ ID NO:20.
XX
KW incertin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
KW hypertension.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 30 /note= "amidated"
FT
XX WO2004056317-A2.
XX
PD 08-JUL-2004.
XX
PF 19-DEC-2003; 2003WO-US040713.
XX
PR 19-DEC-2002; 2002US-00741534.
XX
PR 17-DEC-2003; 2003US-00740146.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
FI Baron AD, Hathaway DR, Mistry M, Roman RJ;
XX

```

```

DR WPI; 2004-507586/48.
XX
PT Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
PT of a medicament for the prevention or treatment of nephropathy.
XX
PS Disclosure; SEQ ID NO 20; 50pp; English.
XX
CC The present invention describes an incertin, a glucagon-like peptide-1
CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
CC their agonist, analogue, derivative or variant or fragment (I), that is
CC used in the manufacture of a medicament for the prevention or treatment
CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
CC activities. (I) can be used in the manufacture of a medicament for the
CC prevention or treatment of nephropathy; preventing progression of
CC nephropathy to end stage renal disease (ESRD); improving endothelial
CC function in the treatment of reduced vasodilatory capacity; reducing
CC proteinuria; and preventing or slowing progression of glomerulosclerosis
CC associated with insulin resistance, diabetes and hypertension. The
CC compounds act in part by improving insulin resistance, cation balance,
CC hypertension and/or by facilitating glucose oxidation; including that by
CC endothelial cells in the kidney and by other cells, rather by oxidation
CC of free fatty acids; and so leads to an enhanced production of ATP for
CC use by the cells and reduces oxidative stress on the affected tissue. The
CC present sequence represents an extendin analogue peptide, which is given
CC in the exemplification of the present invention.
XX
SQ Sequence 30 AA;
ADP86547 Length: 30 February 4, 2005 13:33 Type: P Check: 4889
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQMEERAVRLFIEWLKNKG 28
1 -----|
1 match found in sequence:
adp86548 ; Extendin-4 analogue peptide SEQ ID NO:21.
(from "seq5ags.pep")
TOIG of: adp86548 check: 700 from: 1 to: 28

ID ADP86548 standard; peptide; 28 AA.
XX
AC ADP86548;
XX
DT 23-SEP-2004 (first entry)
XX
DE Extendin-4 analogue peptide SEQ ID NO:21.
XX
KW incertin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
KW hypertension.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "amidated"
FT
XX WO2004056317-A2.
XX
PD 08-JUL-2004.
XX
PF 19-DEC-2003; 2003WO-US040713.
XX
PR 19-DEC-2002; 2002US-00741534.
XX
PR 17-DEC-2003; 2003US-00740146.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
FI Baron AD, Hathaway DR, Mistry M, Roman RJ;
XX

```


CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of extendin, or its agonists or analogues, having a
 CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject
 CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
 CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous
 CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.

XX Sequence 28 AA;

ADP48990 Length: 28 February 4, 2005 13:33 Type: P Check: 261 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEGTFTSDLSKQLEEEAVRLAIEFLKN 28

 1 match found in sequence:

adp48990 ; Gila monster amidated 14-Leu, 22-Ala, 25-Phe extendin-4 (1-28) pepti
 (from "seq5ags.pep")
 TOIG of: adp48990 check: 151 from: 1 to: 28

ID ADP48990 standard; peptide; 28 AA.

AC ADP48990;

XX 09-SEP-2004 (first entry)

XX Gila monster amidated 14-Leu, 22-Ala, 25-Phe extendin-4 (1-28) peptide.
 XX polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
 XX fertility; spontaneous abortion; gene therapy; insulin resistance;
 XX menses; Gila monster; extendin-4; mutant; mutein.

XX Heloderma suspectum.

OS Synthetic.

XX Key Location/Qualifiers

FT Misc-difference 14 /note= "The wild-type residue has been substituted by
 Leu"

FT Misc-difference 22 /note= "The wild-type residue has been substituted by
 Ala"

FT Misc-difference 25

FT /note= "The wild-type residue has been substituted by
 Phe"

FT Modified-site 28 /note= "C-terminal amide"

FT

XX WO2004052390-A1.

XX 24-JUN-2004.

XX 30-JUL-2003; 2003WO-US023715.

XX 11-DEC-2002; 2002US-00317126.

XX 14-JAN-2003; 2003WO-US001109.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett K, Young A, Hathaway DR;

XX

DR WPI; 2004-468706/44.

XX Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 PT reducing insulin resistance, restoring fertility or preventing
 PT spontaneous abortion by administering a compound consisting of extendin or
 PT its agonist or analog.

XX Claim 1; SEQ ID NO 19; 65pp; English.

XX The invention relates to a novel method for treating a subject suffering
 CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of extendin, or its agonists or analogues, having a
 CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject
 CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
 CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous
 CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.

XX Sequence 28 AA;

ADP48990 Length: 28 February 4, 2005 13:33 Type: P Check: 151 ..
 Found using 'seq5' (mohamed337.key)

1 |-----|
 1 HGEGTFTSDLSKQLEEEAVRLAIEFLKN 28

 1 match found in sequence:

adp86539 ; Extendin-3 peptide SEQ ID NO:12.
 (from "seq5ags.pep")
 TOIG of: adp86539 check: 9591 from: 1 to: 39

ID ADP86539 standard; peptide; 39 AA.

XX ADP86539;

XX 23-SEP-2004 (first entry)

XX Extendin-3 peptide SEQ ID NO:12.

XX incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 XX nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 XX proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 XX hypertension.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 39 /note= "amidated"

FT

XX WO2004056317-A2.

XX 08-JUL-2004.

XX 19-DEC-2003; 2003WO-US040713.

XX 19-DEC-2002; 2002US-00741534.

XX 17-DEC-2003; 2003US-00740146.

XX (AMYL-) AMYLIN PHARM INC.

XX Baron AD, Hathaway DR, Mistry M, Roman RJ;

XX

CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.

XX SQ Sequence 28 AA;

ADP48987 Length: 28 February 4, 2005 13:33 Type: P Check: 700 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSDLSKQMEEEAVRLFIEWLKN 28
 1 -----|

 1 match found in sequence:

adp48988 ; Gila monster amidated 14-Leu, 25-Phe extendin-4 peptide.
 (from "seq5ags.pep")
 TOIG of: adp48988 check: 9131 from: 1 to: 39

ID ADP48988 standard; peptide; 39 AA.

XX AC ADP48988;

XX DT 09-SEP-2004 (first entry)

XX DE Gila monster amidated 14-Leu, 25-Phe extendin-4 peptide.

XX KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
 XX fertility; spontaneous abortion; gene therapy; insulin resistance;
 XX menses; Gila monster; extendin-4; mutant; mutein.

XX OS Heloderma suspectum.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT FT Misc-difference 14 /note= "The wild-type residue has been substituted by
 FT Leu"

FT FT Misc-difference 25

FT FT /note= "The wild-type residue has been substituted by
 FT Phe"

FT FT Modified-site 39 /note= "C-terminal amide"

XX PN WO2004052390-A1.

XX XX 24-JUN-2004.

XX PF 30-JUL-2003; 2003WO-US023715.

XX PR 11-DEC-2002; 2002US-00317126.

XX PR 14-JAN-2003; 2003WO-US001109.

XX XX (AMYL-) AMYLIN PHARM INC.

XX XX Beeley NRA, Prickett K, Young A, Hathaway DR;

XX PI WPI; 2004-468706/44.

XX DR Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 XX reducing insulin resistance, restoring fertility or preventing
 XX spontaneous abortion by administering a compound consisting of extendin or
 XX its agonist or analog.

XX PS Claim 1; SEQ ID NO 17; 65pp; English.

XX CC The invention relates to a novel method for treating a subject suffering
 CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of extendin, or its agonists or analogues, having a
 CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject

CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
 CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous
 CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.

XX SQ Sequence 39 AA;

ADP48988 Length: 39 February 4, 2005 13:33 Type: P Check: 9131 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSDLSKQLEEEAVRLFIEFLKNGPSSGAPPPS 28
 1 -----|

 1 match found in sequence:

adp48989 ; Gila monster amidated 14-Leu, 25-Phe extendin-4 (1-28) peptide.
 (from "seq5ags.pep")
 TOIG of: adp48989 check: 261 from: 1 to: 28

ID ADP48989 standard; peptide; 28 AA.

XX AC ADP48989;

XX DT 09-SEP-2004 (first entry)

XX DE Gila monster amidated 14-Leu, 25-Phe extendin-4 (1-28) peptide.

XX KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
 XX fertility; spontaneous abortion; gene therapy; insulin resistance;
 XX menses; Gila monster; extendin-4; mutant; mutein.

XX OS Heloderma suspectum.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT FT Misc-difference 14 /note= "The wild-type residue has been substituted by
 FT Leu"

FT FT Misc-difference 25 /note= "The wild-type residue has been substituted by
 FT Phe"

FT FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2004052390-A1.

XX XX 24-JUN-2004.

XX PF 30-JUL-2003; 2003WO-US023715.

XX PR 11-DEC-2002; 2002US-00317126.

XX PR 14-JAN-2003; 2003WO-US001109.

XX XX (AMYL-) AMYLIN PHARM INC.

XX XX Beeley NRA, Prickett K, Young A, Hathaway DR;

XX PI WPI; 2004-468706/44.

XX DR Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 XX reducing insulin resistance, restoring fertility or preventing
 XX spontaneous abortion by administering a compound consisting of extendin or
 XX its agonist or analog.

XX PS Claim 1; SEQ ID NO 18; 65pp; English.

XX CC The invention relates to a novel method for treating a subject suffering

CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.

SQ Sequence 30 AA;

ADP48985 Length: 30 February 4, 2005 13:33 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNGG
 1 28

 1 match found in sequence:

adp48986 ; Gila monster amidated extendin-4 peptide (1-30).
 (from "seq5ags.pep")

TOIG of: adp48986 check: 4889 from: 1 to: 30

ID ADP48986 standard; peptide; 30 AA.

XX AC ADP48986;

XX DT 09-SEP-2004 (first entry)

XX DE Gila monster amidated extendin-4 peptide (1-30).

XX KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
 KW fertility; spontaneous abortion; gene therapy; insulin resistance;
 KW menses; Gila monster; extendin-4.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

XX FN WO2004052390-A1.

XX PD 24-JUN-2004.

XX PF 30-JUL-2003; 2003WO-US023715.

XX PR 11-DEC-2002; 2002US-00317126.

XX PR 14-JAN-2003; 2003WO-US001109.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett K, Young A, Hathaway DR;

XX DR WPI; 2004-468706/44.

XX PT Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 PT reducing insulin resistance, restoring fertility or preventing
 PT spontaneous abortion by administering a compound consisting of extendin or
 PT its agonist or analog.

XX PS Claim 1; SEQ ID NO 15; 65pp; English.

XX CC The invention relates to a novel method for treating a subject suffering
 CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of extendin, or its agonists or analogues, having a
 CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject
 CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
 CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous

CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.

SQ Sequence 30 AA;

ADP48986 Length: 30 February 4, 2005 13:33 Type: P Check: 4889 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQMEEEAVRLFIEWLKNGG
 1 28

 1 match found in sequence:

adp48987 ; Gila monster amidated extendin-4 peptide (1-28).
 (from "seq5ags.pep")

TOIG of: adp48987 check: 700 from: 1 to: 28

ID ADP48987 standard; peptide; 28 AA.

XX AC ADP48987;

XX DT 09-SEP-2004 (first entry)

XX DE Gila monster amidated extendin-4 peptide (1-28).

XX KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
 KW fertility; spontaneous abortion; gene therapy; insulin resistance;
 KW menses; Gila monster; extendin-4.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

XX FN WO2004052390-A1.

XX PD 24-JUN-2004.

XX PF 30-JUL-2003; 2003WO-US023715.

XX PR 11-DEC-2002; 2002US-00317126.

XX PR 14-JAN-2003; 2003WO-US001109.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett K, Young A, Hathaway DR;

XX DR WPI; 2004-468706/44.

XX PT Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 PT reducing insulin resistance, restoring fertility or preventing
 PT spontaneous abortion by administering a compound consisting of extendin or
 PT its agonist or analog.

XX PS Claim 1; SEQ ID NO 16; 65pp; English.

XX CC The invention relates to a novel method for treating a subject suffering
 CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of extendin, or its agonists or analogues, having a
 CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject
 CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
 CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous

[illegible]

```

1 1 HGEFTTDLKQMEEAVALFIEWLKNGPSSGAPPPS
  1 28
-----
1 match found in sequence:
adp20988 ; Gila monster lizard venom isolated 39 amino acid extendin-4 peptide.
(from "seqSags.pep")
TOIG of: adp20988 check: 9570 from: 1 to: 39

ID ADP20988 standard; peptide; 39 AA.
XX
AC ADP20988;
XX
DT 09-SEP-2004 (first entry)
XX
DE Gila monster lizard venom isolated 39 amino acid extendin-4 peptide.
XX
KW diabetes; extendin-4; thiazolidinedione; insulin sensitizer; antidiabetic;
KW immunosuppressive; cytostatic; anorectic; antilipaeamic; hypotensive;
KW antiarteriosclerotic; ophthalmological; nephrotropic; neuroprotective;
KW type 1 diabetes; type 2; hyperglycaemia; latent autoimmune;
KW maturity onset; polycystic ovarian syndrome; gestational; obesity;
KW dyslipidaemia; hyperlipidaemia; hypertriglyceridaemia;
KW hyperlipoproteinaemia; hypercholesterolaemia; hypertension;
KW arteriosclerosis; atherosclerosis; cardiovascular disease;
KW diabetic retinopathy; background retinopathy; proliferative retinopathy;
KW diabetic nephropathy; neuropathy; beta-cell; venom; Gila monster lizard;
KW GLP-1 receptor agonist.
XX
OS Heloderma suspectum.
XX
PN WO2004050115-A2.
XX
PD 17-JUN-2004.
XX
PF 01-DEC-2003; 2003WO-DK000824.
XX
PR 03-DEC-2002; 2002DK-00001864.
PR 09-DEC-2002; 2002US-0431999P.
XX
PA (NOVO ) NOVO NORDISK AS.
XX
PI Knudsen LB;
XX
DR WPI; 2004-480530/45.
XX
PT Treating or preventing diabetes or diabetes-related disease by
PT administering extendin-4 compound and thiazolidinedione insulin sensitizer
PT to patient.
XX
PS Claim 7; SEQ ID NO 1; 31pp; English.
XX
CC The invention relates to a novel method for treating or preventing
CC diabetes or a diabetes-related disease, which involves administering an
CC extendin-4 compound and thiazolidinedione insulin sensitizer to the
CC patient. The invention further comprises the use of extendin-4 compound
CC and thiazolidinedione insulin sensitizer for the preparation of one or
CC more medicaments for carrying out the method; and a pharmaceutical
CC composition comprising extendin-4 compound and thiazolidinedione
CC preservative. The compositions and method have the following activities:
CC antidiabetic, immunosuppressive, cytostatic, anorectic, antilipaeamic,
CC hypotensive, antiarteriosclerotic, ophthalmological, nephrotropic, and
CC neuroprotective. The method is useful for treating or preventing diabetes
CC or a diabetes related disease chosen from type 1 diabetes, type 2
CC diabetes, hyperglycaemia, latent autoimmune diabetes in adults, maturity
CC onset diabetes, polycystic ovarian syndrome, gestational diabetes,
CC obesity, dyslipidaemia, hyperlipidaemia, hypertriglyceridaemia,
CC hyperlipoproteinaemia, hypercholesterolaemia, hypertension,
CC arteriosclerosis, atherosclerosis, cardiovascular disease, diabetic
CC retinopathy, background retinopathy, proliferative retinopathy, diabetic
CC nephropathy, neuropathy and diabetic neuropathy, where the patient is
CC human. The method is useful for increasing the number of beta-cells in a

```

```

CC patient. The insulin sensitizer is useful for the preparation of one or
CC more medicaments for carrying out the method. This sequence represents a
CC 39 amino acid extendin-4 peptide isolated from the venom of the Gila
CC monster lizard, Heloderma suspectum. This peptide is used to act as a
CC potent GLP-1 receptor agonist for stimulating insulin release relating to
CC the method of the invention.
XX
SQ Sequence 39 AA;
ADP20988 Length: 39 February 4, 2005 13:33 Type: P Check: 9570
Found using 'seq5' (mohamed337.key)
1 HGEFTTDLKQMEEAVALFIEWLKNGPSSGAPPPS
  1 28
-----
1 match found in sequence:
adp48978 ; Gila monster amidated extendin-3 peptide.
(from "seqSags.pep")
TOIG of: adp48978 check: 9591 from: 1 to: 39

ID ADP48978 standard; peptide; 39 AA.
XX
AC ADP48978;
XX
DT 09-SEP-2004 (first entry)
XX
DE Gila monster amidated extendin-3 peptide.
XX
KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
KW fertility; spontaneous abortion; gene therapy; insulin resistance;
KW menses; Gila monster; extendin-3.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT /note= "C-terminal amide"
XX
PN WO2004052390-A1.
XX
PD 24-JUN-2004.
XX
PF 30-JUL-2003; 2003WO-US023715.
XX
PR 11-DEC-2002; 2002US-00317126.
PR 14-JAN-2003; 2003WO-US001109.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett K, Young A, Hathaway DR;
XX
DR WPI; 2004-468706/44.
XX
PT Treating a subject suffering from polycystic ovary syndrome (PCOS) for
PT reducing insulin resistance, restoring fertility or preventing
PT spontaneous abortion by administering a compound consisting of extendin or
PT its agonist or analog.
XX
PS Disclosure; SEQ ID NO 7; 65pp; English.
XX
CC The invention relates to a novel method for treating a subject suffering
CC from polycystic ovary syndrome (PCOS). The method comprises administering
CC a compound consisting of extendin, or its agonists or analogues, having a
CC sequence given in the specification, where the subject exhibits at least
CC one symptom of PCOS. The invention further relates to: reducing insulin
CC resistance in a subject suffering from PCOS; preventing the onset of type
CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
CC a subject suffering from PCOS; restoring regular ovulation in a subject
CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
CC novel compounds of the invention may be used in gene therapy to treat

```

CC glycol (PEG) polymer having a molecular weight of greater than 30 kDa.
CC Modified GLP-1 receptor agonists are useful for treating type 1 diabetes,
CC type 2 diabetes, maturity onset diabetes of the young, latent autoimmune
CC diabetes adult, gestational diabetes and Syndrome X (all claimed). They
CC can also be used to treat hyperglycaemia, impaired glucose tolerance,
CC impaired fasting glucose and obesity caused by inducing glucose-dependent
CC insulin secretion. They may also be effective in the treatment of
CC obesity, atherosclerotic disease, hyperlipidaemia, hypercholesterolaemia,
CC low high density lipoprotein levels, hypertension, cardiovascular disease
CC (including atherosclerosis, coronary heart disease and hypertension),
CC cerebrovascular disease, peripheral vessel disease, physiological
CC disorders and the secondary causes of diabetes. The modified GLP-1
CC receptor agonists can be prepared by synthetic or recombinant methods.
CC They induce glucose-dependent insulin secretion without reducing
CC gastrointestinal motility, thereby lessening the gastrointestinal side-
CC effects associated with previous GLP-1 receptor agonists.

XX Sequence 40 AA;

ADN16852 Length: 40 February 4, 2005 13:33 Type: P Check: 2250 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTFTSLSKQWEEAVRLFIEWLKNKGPPSGAPPSC
28

1 match found in sequence:
adn16852 ; Fermentation-derived product exendin-4 analogue ZP10 peptide.
(from "seq5ags.pep")
TOIG of: adn16852 check: 5122 from: 1 to: 44

ID ADN16852 standard; peptide; 44 AA.

XX AC ADN16852;

XX DT 01-JUL-2004 (first entry)

XX DE Fermentation-derived product exendin-4 analogue ZP10 peptide.

XX KW fermentation-derived product; microfiltration; fermentation broth;
XX exendin-4 analogue; ZP10 peptide.

XX OS Unidentified.

XX PH Key Location/Qualifiers

XX FT Misc-difference 44 /note= "C-terminal amide"

XX PN WO2004029076-A2.

XX PD 08-APR-2004.

XX PF 25-SEP-2003; 2003WO-DK000627.

XX PR 25-SEP-2002; 2002DK-00001422.

XX PA (NOVO) NOVO NORDISK AS.

XX PT Christensen LH, Nielsen TK;

XX DR WPI; 2004-375439/35.

XX PT Purifying fermentation-derived product such as interleukins, insulin,
XX albumin, involves microfiltration of fermentation broth containing
XX fermentation-derived product at specific microfiltration temperature and
XX isolating final product.

XX PS Claim 25; Page 17; 20pp; English.

XX CC This invention relates to a novel method of purifying a fermentation-
XX derived product, which involves microfiltration of a fermentation broth
XX containing the fermentation-derived product at a microfiltration

CC temperature within the range from 66-90 degrees C and isolating the final
CC product. The method of the invention is efficient in purifying a
CC fermentation-derived product with an improved microfiltration process
CC comprising elevated temperatures. The present sequence is that of an
CC exendin-4 analogue ZP10 peptide which is a fermentation-derived product
CC to which the method of the invention may be applied.

XX Sequence 44 AA;

ADN16852 Length: 44 February 4, 2005 13:33 Type: P Check: 5122 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEFTFTSLSKQWEEAVRLFIEWLKNKGPPSGAPPSCPKKKKK
28

1 match found in sequence:
ado55979 ; Human exendin-4 peptide related to diabetes treatment.
(from "seq5ags.pep")
TOIG of: ado55979 check: 9570 from: 1 to: 39

ID ADO55979 standard; peptide; 39 AA.

XX AC ADO55979;

XX DT 15-JUL-2004 (first entry)

XX DE Human exendin-4 peptide related to diabetes treatment.

XX KW diabetes; beta-cell proliferation; beta-cell apoptosis; antidiabetic;
XX immunosuppressive; protein kinase; Akt1; p44MAPK; caspase-3; exendin-4;
XX human.

XX OS Homo sapiens.

XX PN CA2389462-A1.

XX PD 21-DEC-2003.

XX PF 21-JUN-2002; 2002CA-02389462.

XX PR 21-JUN-2002; 2002US-00111111.

XX PA (WANG/) WANG Q Q.

XX PT (BRUB/) BRUBAKER P L.

XX PI Wang QQ, Brubaker PL;

XX WPI; 2004-099536/11.

XX PT Preventing and/or delaying diabetes in a subject in need, involves
XX administering to subject a compound that increases beta-cell
XX proliferation and/or reduces beta cell apoptosis in subject.

XX PS Disclosure; SEQ ID NO 2; 43pp; English.

XX CC This invention relates to a novel method of preventing and/or delaying
XX diabetes in a subject in need, which involves administering to the
XX subject an effective amount of a compound that increases beta-cell
XX proliferation and/or reduces beta-cell apoptosis in the subject. The
XX invention may be useful for the production of compounds with an
XX antidiabetic or immunosuppressive activity by increasing expression of
XX protein kinase (Akt1 and/or p44MAPK) in the beta-cells and decreasing
XX caspase-3 activation. The method is useful for preventing and/or delaying
XX diabetes in a subject. The present sequence is that of a human exendin-4
XX peptide which is related to the method of the invention.

XX Sequence 39 AA;

ADO55979 Length: 39 February 4, 2005 13:33 Type: P Check: 9570 ..
Found using 'seq5' (mohamed337.key)

DR WPI; 2004-042770/04.
 XX Harvesting a desired polypeptide produced by a recombinant host cell, for
 PT producing pharmaceuticals, comprises selecting a recombinant nucleic acid
 PT comprising nucleic acid fragments encoding a leader peptide and the
 PT polypeptide.
 XX Claim 4; Page 49; 109pp; English.
 XX The invention relates to a novel method for harvesting a (poly)peptide
 CC produced by a recombinant host cell. The novel method involves selecting
 CC a cell comprising a first nucleic acid encoding a leader peptide and a
 CC second nucleic acid fragment encoding the desired (poly)peptide. The
 CC first and second fragments are within the same open reading frame of the
 CC first nucleic acid and the leader peptide is functionally equivalent to
 CC an N-terminal leader peptide found with the pre-peptide of a lantibiotic.
 CC The host cells and nucleic acids are useful for producing, harvesting and
 CC post-translational modification of polypeptides. The polypeptides may be
 CC used in the production of pharmaceuticals, e.g. as antigen for vaccine or
 CC immunogenic composition. This sequence represents a polypeptide relating
 CC to the novel method of the invention.
 XX SQ Sequence 39 AA;

ADL92031 Length: 39 February 4, 2005 13:33 Type: P Check: 9661 ..
 Found using 'seq5' (mohamed337.key)

1 HSDGFTTSLSKQMEERAVRLFIEWLKNGPSSGCPPPS
 1
 28

 1 match found in sequence:
 adl92153 ; Exendin-4 protein sequence.
 (from "seq5ags.pep")
 TOIG of: adl92153 check: 7609 from: 1 to: 64

ID ADL92153 standard; protein; 64 AA.
 XX AC ADL92153;
 XX DT 20-MAY-2004 (first entry)
 XX DE Exendin-4 protein sequence.
 XX KW harvesting; recombinant; host cell; N-terminal leader peptide;
 KW pre-peptide; lantibiotic; post-translational modification;
 KW pharmaceuticals; vaccine; immunogenic.
 XX OS Unidentified.
 XX PN WO2003099862-A1.
 XX PD 04-DEC-2003.
 XX PF 26-MAY-2003; 2003WO-NL000389.
 XX PR 24-MAY-2002; 2002EP-00077060.
 XX PR 07-FEB-2003; 2003US-00360101.
 XX PA (NANO-) APPLIED NANOSYSTEMS BV.
 XX PI Moll GN, Leenhouts CJ, Kuipers OP, Driessen AJM;
 XX WPI; 2004-042770/04.
 XX Harvesting a desired polypeptide produced by a recombinant host cell, for
 PT producing pharmaceuticals, comprises selecting a recombinant nucleic acid
 PT comprising nucleic acid fragments encoding a leader peptide and the
 PT polypeptide.
 XX Claim 4; Page 68; 109pp; English.

CC The invention relates to a novel method for harvesting a (poly)peptide
 CC produced by a recombinant host cell. The novel method involves selecting
 CC a cell comprising a first nucleic acid encoding a leader peptide and a
 CC second nucleic acid fragment encoding the desired (poly)peptide. The
 CC first and second fragments are within the same open reading frame of the
 CC first nucleic acid and the leader peptide is functionally equivalent to
 CC an N-terminal leader peptide found with the pre-peptide of a lantibiotic.
 CC The host cells and nucleic acids are useful for producing, harvesting and
 CC post-translational modification of polypeptides. The polypeptides may be
 CC used in the production of pharmaceuticals, e.g. as antigen for vaccine or
 CC immunogenic composition. This sequence represents a polypeptide relating
 CC to the novel method of the invention.
 XX SQ Sequence 64 AA;
 ADL92153 Length: 64 February 4, 2005 13:33 Type: P Check: 7609 ..
 Found using 'seq5' (mohamed337.key)

1 MPVESGLSSDSASSEFASKIKRHGSGTFTSLSKQMEERAVRLFIEWLKNGPSSGAP
 25
 52

61 PPSG

 1 match found in sequence:
 adm41384 ; Exendin-4, glucagon-like peptide 1 receptor agonist (antidiabetic).
 (from "seq5ags.pep")
 TOIG of: adm41384 check: 2250 from: 1 to: 40

ID ADM41384 standard; peptide; 40 AA.
 XX AC ADM41384;
 XX DT 03-JUN-2004 (first entry)
 XX DE Exendin-4, glucagon-like peptide 1 receptor agonist (antidiabetic).
 XX KW Glucagon-like peptide 1; GLP-1; human; receptor; agonist; antidiabetic;
 KW immunosuppressive; anorectic; antiarteriosclerotic; hypotensive;
 KW antilipaemic; exendin-4.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT Modified-site 40
 FT /note= "PEGylated amino acid residue"

WO2004022004-A2.
 XX 18-MAR-2004.
 XX 04-SEP-2003; 2003WO-US028093.
 XX 06-SEP-2002; 2002US-0408696P.
 XX 09-JAN-2003; 2003US-0439369P.
 XX (FARB) BAYER PHARM CORP.
 XX Pan C, Whelan JP;
 XX WPI; 2004-282764/26.
 XX Novel glucagon-like peptide-1 receptor agonist or modified GLP-1 receptor
 PT agonist, useful for treating diabetes, impaired glucose tolerance,
 PT metabolic syndrome or pre-diabetic state.
 XX Claim 1; SEQ ID NO 31; 56pp; English.

The present sequence is that of an exendin-4 peptide modified to include
 CC a PEGylated C-terminal Cys residue. This is an example of a modified
 CC glucagon-like peptide 1 (GLP-1) receptor agonist of the invention
 CC comprising a GLP-1 receptor agonist peptide linked to a polyethylene

```

PR 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPT; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 187; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
SQ
ADL66307 Length: 39 February 4, 2005 13:32 Type: P Check: 9563 ..
Found using 'seq5' (mohamed337.key)
1 AGEGTFTSDLSKQEEAVRLFIEFLKNGGPGSSGAPPPS
1 28
-----
1 match found in sequence:
adl66308 ; Extendin agonist peptide, SEQ ID No 188.
(from "seq5ags.pep")
TOIG of: adl66308 check: 9112 from: 1 to: 39
-----
ID ADL66308 standard; peptide; 39 AA.
XX
XX AC ADL66308;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 188.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX Modified-site 39 /note= "C-terminal amide"
XX FT
XX FT
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX XX 28-MAY-2003; 2003WO-US016699.
XX
XX XX 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;

```

```

XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 188; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
SQ
ADL66308 Length: 39 February 4, 2005 13:33 Type: P Check: 9112 ..
Found using 'seq5' (mohamed337.key)
1 AGAGTFTSDLSKQEEAVRLFIEFLKNGGPGSSGAPPPS
1 28
-----
1 match found in sequence:
adl92031 ; Extendin-3 C35-sequence.
(from "seq5ags.pep")
TOIG of: adl92031 check: 9661 from: 1 to: 39
-----
ID ADL92031 standard; peptide; 39 AA.
XX
XX AC ADL92031;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin-3 C35-sequence.
XX
XX KW harvesting; recombinant; host cell; N-terminal leader peptide;
XX KW pre-peptide; lantibiotic; post-translational modification;
XX KW pharmaceuticals; vaccine; immunogenic.
XX
XX OS Unidentified.
XX
XX FH Key Location/Qualifiers
XX Modified-site 32 /note= "This residue forms a thioether bond with residue
XX FT 35 to form a lanthionine ring"
XX FT Modified-site 35 /note= "This residue forms a thioether bond with residue
XX FT 32 to form a lanthionine ring"
XX FT
XX PN WO2003099862-A1.
XX
XX PD 04-DEC-2003.
XX
XX XX 26-MAY-2003; 2003WO-NL000389.
XX
XX XX 24-MAY-2002; 2002EP-00077060.
XX
XX XX 07-FEB-2003; 2003US-00360101.
XX
XX PA (NANO-) APPLIED NANOSYSTEMS BV.
XX
XX PI Moll GN, Leenhouts CJ, Kuipers OP, Driessen AJM;
XX

```

```

FH Key      Location/Qualifiers
FT Modified-site 35
  /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 185; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 35 AA;
SQ
ADL66305 Length: 35 February 4, 2005 13:32 Type: P Check: 7441 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGATFTSDLSKQMEERAVRLFIEWLKNKGPSGA
    28
-----
1 match found in sequence:
  adl66306 ; Extendin agonist peptide, SEQ ID No 186.
  (from "seq5ags.pep")
  TOIG of: adl66306 check: 4862 from: 1 to: 30
-----
ID ADL66306 standard; peptide; 30 AA.
XX
XX ADL66306;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Extendin agonist peptide, SEQ ID No 186.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
OS
XX
XX Key      Location/Qualifiers
FH Modified-site 30
  /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
PN
```

```

XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 186; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 30 AA;
SQ
ADL66306 Length: 30 February 4, 2005 13:32 Type: P Check: 4862 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  1 HGATFTSDLSKQMEERAVRLFIEWLKNKG
    28
-----
1 match found in sequence:
  adl66307 ; Extendin agonist peptide, SEQ ID No 187.
  (from "seq5ags.pep")
  TOIG of: adl66307 check: 9563 from: 1 to: 39
-----
ID ADL66307 standard; peptide; 39 AA.
XX
XX ADL66307;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Extendin agonist peptide, SEQ ID No 187.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
OS
XX
XX Key      Location/Qualifiers
FH Modified-site 39
  /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
PN
XX
XX 04-DEC-2003.
PD
XX
XX 28-MAY-2003; 2003WO-US016699.
PF
XX
```

[illegible]

```

XX  extendin; extended-release formulation; plasma level; antidiabetic;
KW  anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW  inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW  dyslipidaemia; cardiovascular.
XX  Synthetic.
XX  Key      Location/Qualifiers
FH  Modified-site 31
FT  /note= "Thioprolin"
FT  Modified-site 36..38
FT  /note= "Thioprolin"
FT  Modified-site 38
FT  /note= "C-terminal amide"
XX  WO2003099314-A1.
XX  04-DEC-2003.
XX  28-MAY-2003; 2003WO-US016699.
XX  28-MAY-2002; 2002US-00157224.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Young AA, Kolterman OG;
XX  WPI; 2004-042706/04.
XX  Pharmaceutical composition for treating diabetes, impaired glucose
PT  tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT  extendin or an extendin agonist peptide in an extended-release formulation.
XX  Disclosure; SEQ ID NO 181; 173pp; English.
XX  The invention relates to a novel pharmaceutical composition comprising an
CC  extendin (agonist) peptide in an extended-release formulation. The
CC  formulation is capable of releasing the peptide over a predetermined
CC  release period, the period being at least one hour, and in an amount such
CC  that, when the composition is administered to a human, an average
CC  sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC  of the predetermined release period. The composition has antidiabetic,
CC  anorectic, and antilipaeamic activities. The novel composition and method
CC  are useful in treating diabetes and conditions that would be benefited by
CC  lowering plasma glucose or delaying and/or slowing gastric emptying or
CC  inhibiting food intake, such as impaired glucose tolerance, obesity,
CC  hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC  represents an extendin agonist peptide of the invention.
XX  Sequence 38 AA;
SQ
ADL66301 Length: 38 February 4, 2005 13:33 Type: P Check: 7457 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  HGAGTFTSLKQMEAEAVRLFIEWLKNGXSSGAXXX
28
-----
1 match found in sequence:
adl66302 ; Extendin agonist peptide, SEQ ID No 182.
(from "seq5ags.pep")
TOIG of: adl66302 check: 7197 from: 1 to: 38
ID ADL66302 standard; peptide; 38 AA.
XX
AC ADL66302;
XX
DT 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 182.
XX

```

```

KW  extendin; extended-release formulation; plasma level; antidiabetic;
KW  anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW  inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW  dyslipidaemia; cardiovascular.
XX  Synthetic.
XX  Key      Location/Qualifiers
FH  Modified-site 36..38
FT  /note= "Thioprolin"
FT  Modified-site 38
FT  /note= "C-terminal amide"
XX  WO2003099314-A1.
XX  04-DEC-2003.
XX  28-MAY-2003; 2003WO-US016699.
XX  28-MAY-2002; 2002US-00157224.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Young AA, Kolterman OG;
XX  WPI; 2004-042706/04.
XX  Pharmaceutical composition for treating diabetes, impaired glucose
PT  tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT  extendin or an extendin agonist peptide in an extended-release formulation.
XX  Disclosure; SEQ ID NO 182; 173pp; English.
XX  The invention relates to a novel pharmaceutical composition comprising an
CC  extendin (agonist) peptide in an extended-release formulation. The
CC  formulation is capable of releasing the peptide over a predetermined
CC  release period, the period being at least one hour, and in an amount such
CC  that, when the composition is administered to a human, an average
CC  sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC  of the predetermined release period. The composition has antidiabetic,
CC  anorectic, and antilipaeamic activities. The novel composition and method
CC  are useful in treating diabetes and conditions that would be benefited by
CC  lowering plasma glucose or delaying and/or slowing gastric emptying or
CC  inhibiting food intake, such as impaired glucose tolerance, obesity,
CC  hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC  represents an extendin agonist peptide of the invention.
XX  Sequence 38 AA;
SQ
ADL66302 Length: 38 February 4, 2005 13:33 Type: P Check: 7197 ..
Found using 'seq5' (mohamed337.key)
1  |-----|
1  HGAGTFTSLKQMEAEAVRLFIEWLKNGXSSGAXXX
28
-----
1 match found in sequence:
adl66303 ; Extendin agonist peptide, SEQ ID No 183.
(from "seq5ags.pep")
TOIG of: adl66303 check: 4098 from: 1 to: 37
ID ADL66303 standard; peptide; 37 AA.
XX
AC ADL66303;
XX
DT 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 183.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW  anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW  inhibiting food intake; tolerance; obesity; hyperglycaemia;

```

(from "seq5ags.pep")
TOIG of: adl66299 check: 4423 from: 1 to: 30

ID ADL66299 standard; peptide; 30 AA.

XX ADL66299;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 179.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 30
FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
PS Disclosure; SEQ ID NO 179; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 30 AA;

ADL66299 Length: 30 February 4, 2005 13:33 Type: P Check: 4423 ..

Found using 'seq5' (mohamed337.key)

1 HGEFTTSALSQLEEEAVRLFIEFLKNG
1 28

1 match found in sequence:

adl66300 ; Extendin agonist peptide, SEQ ID No 180.
(from "seq5ags.pep")
TOIG of: adl66300 check: 2313 from: 1 to: 29

ID ADL66300 standard; peptide; 29 AA.

XX

AC

ADL66300;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 180.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 29
FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 180; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 29 AA;

ADL66300 Length: 29 February 4, 2005 13:33 Type: P Check: 2313 ..

Found using 'seq5' (mohamed337.key)

1 AGEFTTSDLSKQLEEEAVRLFIEFLKNG
1 28

1 match found in sequence:

adl66301 ; Extendin agonist peptide, SEQ ID No 181.
(from "seq5ags.pep")
TOIG of: adl66301 check: 7457 from: 1 to: 38

ID ADL66301 standard; peptide; 38 AA.

XX

AC ADL66301;

XX

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 181.

ADL66296 Length: 32 February 4, 2005 13:33 Type: P Check: 18 ..
Found using 'seq5' (mohamed337.key)

1 AGEGTFTSDLSKQMEERAVRLFIEWLKNGGPS
28

1 match found in sequence:
adl66297 ; Exendin agonist peptide, SEQ ID No 177.
(from "seq5agr.pap")
TOIG of: adl66297 check: 9574 from: 1 to: 32

ID ADL66297 standard; peptide; 32 AA.
XX
AC ADL66297;
XX
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 177.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 32 /note= "C-terminal amide"
FT
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID No 177; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 32 AA;

ADL66297 Length: 32 February 4, 2005 13:33 Type: P Check: 9574 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSDLSKQMEERAVRLFIEWLKNGGPS

28

1 match found in sequence:
adl66298 ; Exendin agonist peptide, SEQ ID No 178.
(from "seq5agr.pap")
TOIG of: adl66298 check: 7345 from: 1 to: 31

ID ADL66298 standard; peptide; 31 AA.
XX
AC ADL66298;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 178.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "C-terminal amide"
FT
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID No 178; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 31 AA;

ADL66298 Length: 31 February 4, 2005 13:33 Type: P Check: 7345 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSDLSKQMEERAVRLFIEWLKNGGP
28

1 match found in sequence:
adl66299 ; Exendin agonist peptide, SEQ ID No 179.

CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 34 AA;

ADL66294 Length: 34 February 4, 2005 13:33 Type: P Check: 5154 ..
Found using 'seq5', (mohamed337.key)

1 HGEFTFTDLSKQMEERAVRLFIEWLKNKGPPSS
-----|-----|
1 28

1 match found in sequence:

adl66295 ; Extendin agonist peptide, SEQ ID No 175.
(from "seq5ags.pep")
TOIG of: adl66295 check: 2737 from: 1 to: 33

ID ADL66295 standard; peptide; 33 AA.

XX ADL66295;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 175.

XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
XX Modified-site 33 /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 175; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,

CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 33 AA;

ADL66295 Length: 33 February 4, 2005 13:33 Type: P Check: 2737 ..
Found using 'seq5', (mohamed337.key)

1 HGEFTFTSALSQMEERAVRLFIEWLKNKGPPSS
-----|-----|
1 28

1 match found in sequence:

adl66296 ; Extendin agonist peptide, SEQ ID No 176.
(from "seq5ags.pep")
TOIG of: adl66296 check: 18 from: 1 to: 32

ID ADL66296 standard; peptide; 32 AA.

XX ADL66296;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 176.

XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
XX Modified-site 32 /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 176; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.

XX Sequence 32 AA;

PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 172; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 35 AA;

ADL66292 Length: 35 February 4, 2005 13:33 Type: P Check: 7446 ..
Found using 'seq5' (mohamed337.key)

1 AGEGTFTSDLSKQMEEAVALRFLFIEFLKNGPSSGA
1 28

1 match found in sequence:
adl66293 ; Extendin agonist peptide, SEQ ID No 173.
(from "seq5ags.pep")
TOIG of: adl66293 check: 7002 from: 1 to: 35

ID ADL66293 standard; peptide; 35 AA.

XX AC ADL66293;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 173.

XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipemic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 35

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 173; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 35 AA;

ADL66293 Length: 35 February 4, 2005 13:32 Type: P Check: 7002 ..
Found using 'seq5' (mohamed337.key)

1 HGAGTFTSDLSKQLEEAVALRFLFIEFLKNGPSSGA
1 28

1 match found in sequence:
adl66294 ; Extendin agonist peptide, SEQ ID No 174.
(from "seq5ags.pep")
TOIG of: adl66294 check: 5154 from: 1 to: 34

ID ADL66294 standard; peptide; 34 AA.

XX AC ADL66294;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 174.

XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipemic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 34

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 174; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%

PR 28-MAY-2002; 2002US-00157224.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 XX Disclosure; SEQ ID NO 170; 173pp; English.
 XX
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 XX Sequence 36 AA;
 SQ

ADL66290 Length: 36 February 4, 2005 13:33 Type: P Check: 306
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSALSKQMEAEAVRLFIEFLKNGPSSGAP
 1
 28

1 match found in sequence:
 adl66291; Extendin agonist peptide, SEQ ID No 171.
 (from "seq5ags.pep")
 TOIG of: adl66291 check: 9777 from: 1 to: 36

ID ADL66291 standard; peptide; 36 AA.
 XX
 AC ADL66291;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 171.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT Modified-site 36 /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 XX Disclosure; SEQ ID NO 171; 173pp; English.
 XX
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 XX Sequence 36 AA;
 SQ

ADL66291 Length: 36 February 4, 2005 13:33 Type: P Check: 9777
 Found using 'seq5' (mohamed337.key)

1 AGEGTFTSDASKQLEAEAVRLFIEFLKNGPSSGAP
 1
 28

1 match found in sequence:
 adl66292; Extendin agonist peptide, SEQ ID No 172.
 (from "seq5ags.pep")
 TOIG of: adl66292 check: 7446 from: 1 to: 35

ID ADL66292 standard; peptide; 35 AA.
 XX
 AC ADL66292;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 172.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT Modified-site 35 /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

```

FH Key                               Location/Qualifiers
FT Modified-site                     /note= "C-terminal amide"
XX                                     38
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 168; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 38 AA;
SQ
ADL66288 Length: 38 February 4, 2005 13:33 Type: P Check: 5882 ..
Found using 'seq5' (mohamed337.key)
1
1 HGAGTFTSLSKQLEBAVRLFIETLKNKGPPSGAPPP
28
-----
1 match found in sequence:
adl66289 ; Extendin agonist peptide, SEQ ID No 169.
(from "seq5ags.pep")
TOIG of: adl66289 check: 3269 from: 1 to: 37
-----
ID ADL66289 standard; peptide; 37 AA.
XX
XX ADL66289;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 169.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key                               Location/Qualifiers
XX Modified-site                     /note= "C-terminal amide"
XX                                     37
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 169; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 37 AA;
SQ
ADL66289 Length: 37 February 4, 2005 13:33 Type: P Check: 3269 ..
Found using 'seq5' (mohamed337.key)
1
1 HGATFTSLSKQLEBAVRLFIETLKNKGPPSGAPP
28
-----
1 match found in sequence:
adl66290 ; Extendin agonist peptide, SEQ ID No 170.
(from "seq5ags.pep")
TOIG of: adl66290 check: 306 from: 1 to: 36
-----
ID ADL66290 standard; peptide; 36 AA.
XX
XX ADL66290;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 170.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key                               Location/Qualifiers
XX Modified-site                     /note= "C-terminal amide"
XX                                     36
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX

```

```

XX DE      Exendin agonist peptide, SEQ ID No 166.
XX KW      exendin; extended-release formulation; plasma level; antidiabetic;
XX KW      anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW      inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW      dyslipidaemia; cardiovascular.
XX OS      Synthetic.
XX FH      Key      Location/Qualifiers
XX FT      Modified-site 28
XX FT      /note= "C-terminal amide"
XX PN      WO2003099314-A1.
XX PD      04-DEC-2003.
XX PF      28-MAY-2003; 2003WO-US016699.
XX PR      28-MAY-2002; 2002US-00157224.
XX XX      (AMYL-) AMYLIN PHARM INC.
XX PI      Young AA, Kolterman OG;
XX PI      WPI; 2004-042706/04.
XX DR      Pharmaceutical composition for treating diabetes, impaired glucose
XX PT      tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT      exendin or an exendin agonist peptide in an extended-release formulation.
XX PS      Disclosure; SEQ ID NO 166; 173pp; English.
XX CC      The invention relates to a novel pharmaceutical composition comprising an
XX CC      exendin (agonist) peptide in an extended-release formulation. The
XX CC      formulation is capable of releasing the peptide over a predetermined
XX CC      release period, the period being at least one hour, and in an amount such
XX CC      that, when the composition is administered to a human, an average
XX CC      sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC      of the predetermined release period. The composition has antidiabetic,
XX CC      anorectic, and antilipemic activities. The novel composition and method
XX CC      are useful in treating diabetes and conditions that would be benefited by
XX CC      lowering plasma glucose and/or slowing gastric emptying or
XX CC      inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC      hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC      represents an exendin agonist peptide of the invention.
XX SQ      Sequence 28 AA;
ADL66286 Length: 28 February 4, 2005 13:33 Type: P Check: 9887 ..
Found using 'seq5' (mohamed337.key)
1 1 AGDGTFTDLSKQLEEAARVLFIEFLKA
1 28
-----
1 match found in sequence:
adl66287 ; Exendin agonist peptide, SEQ ID No 167.
(from "seq5ags.pep")
TOIG of: adl66287 check: 6326 from: 1 to: 38
-----
ID ADL66287 standard; peptide; 38 AA.
XX AC ADL66287;
XX XX
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 167.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipemic; diabetes; glucose; gastric emptying;

```

```

KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX Synthetic.
XX OS
XX FH      Key      Location/Qualifiers
XX FT      Modified-site 38
XX FT      /note= "C-terminal amide"
XX PN      WO2003099314-A1.
XX PD      04-DEC-2003.
XX PF      28-MAY-2003; 2003WO-US016699.
XX PR      28-MAY-2002; 2002US-00157224.
XX XX      (AMYL-) AMYLIN PHARM INC.
XX PI      Young AA, Kolterman OG;
XX PI      WPI; 2004-042706/04.
XX DR      Pharmaceutical composition for treating diabetes, impaired glucose
XX PT      tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT      exendin or an exendin agonist peptide in an extended-release formulation.
XX PS      Disclosure; SEQ ID NO 167; 173pp; English.
XX CC      The invention relates to a novel pharmaceutical composition comprising an
XX CC      exendin (agonist) peptide in an extended-release formulation. The
XX CC      formulation is capable of releasing the peptide over a predetermined
XX CC      release period, the period being at least one hour, and in an amount such
XX CC      that, when the composition is administered to a human, an average
XX CC      sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC      of the predetermined release period. The composition has antidiabetic,
XX CC      anorectic, and antilipemic activities. The novel composition and method
XX CC      are useful in treating diabetes and conditions that would be benefited by
XX CC      lowering plasma glucose and/or slowing gastric emptying or
XX CC      inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC      hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC      represents an exendin agonist peptide of the invention.
XX SQ      Sequence 38 AA;
ADL66287 Length: 38 February 4, 2005 13:33 Type: P Check: 6326 ..
Found using 'seq5' (mohamed337.key)
1 1 AGDGTFTDLSKQLEEAARVLFIEFLKNGPSSGAPPP
1 28
-----
1 match found in sequence:
adl66288 ; Exendin agonist peptide, SEQ ID No 168.
(from "seq5ags.pep")
TOIG of: adl66288 check: 5882 from: 1 to: 38
-----
ID ADL66288 standard; peptide; 38 AA.
XX AC ADL66288;
XX XX
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 168.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX OS

```

1 match found in sequence:
adl66284 ; Exendin agonist peptide, SEQ ID No 164.
(from "seq5ags.pep")
TOIG of: adl66284 check: 9981 from: 1 to: 28

ID ADL66284 standard; peptide; 28 AA.
XX AC ADL66284;
XX AC
DT 20-MAY-2004 (first entry)
XX XX
DE Exendin agonist peptide, SEQ ID No 165.
XX XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX OS
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT FT
XX WO2003099314-A1.
XX XX
XX 04-DEC-2003.
XX XX
XX 28-MAY-2003; 2003WO-US016699.
XX PF
XX 28-MAY-2002; 2002US-00157224.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young AA, Kolterman OG;
XX PI
XX WPI; 2004-042706/04.
XX DR
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 165; 173pp; English.
XX PS
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipidemic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66285 Length: 28 February 4, 2005 13:33 Type: P Check: 326 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEEEAVRLFIEWLKA 28
1
-----|
1 match found in sequence:
adl66286 ; Exendin agonist peptide, SEQ ID No 166.
(from "seq5ags.pep")
TOIG of: adl66286 check: 9887 from: 1 to: 28

ID ADL66286 standard; peptide; 28 AA.
XX AC ADL66286;
XX AC
DT 20-MAY-2004 (first entry)
XX XX

1 match found in sequence:
adl66284 ; Exendin agonist peptide, SEQ ID No 164.
(from "seq5ags.pep")
TOIG of: adl66284 check: 9981 from: 1 to: 28

ID ADL66284 standard; peptide; 28 AA.
XX AC ADL66284;
XX AC
DT 20-MAY-2004 (first entry)
XX XX
DE Exendin agonist peptide, SEQ ID No 164.
XX XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX OS
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT FT
XX WO2003099314-A1.
XX XX
XX 04-DEC-2003.
XX XX
XX 28-MAY-2003; 2003WO-US016699.
XX PF
XX 28-MAY-2002; 2002US-00157224.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young AA, Kolterman OG;
XX PI
XX WPI; 2004-042706/04.
XX DR
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 164; 173pp; English.
XX PS
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipidemic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66284 Length: 28 February 4, 2005 13:33 Type: P Check: 9981 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEEEAVRLFIEWLKA 28
1
-----|
1 match found in sequence:
adl66285 ; Exendin agonist peptide, SEQ ID No 165.
(from "seq5ags.pep")
TOIG of: adl66285 check: 326 from: 1 to: 28

SQ Sequence 28 AA;

ADL66281 Length: 28 February 4, 2005 13:33 Type: P Check: 404
Found using 'seq5' (mohamed337.key)-----
1 AGDGTFTSLSKQEEAEAVRLFIEWAKN 28
11 match found in sequence:
adl66282 ; Exendin agonist peptide, SEQ ID No 162.
(from "seq5ags.pep")
TOIG of: adl66282 check: 9965 from: 1 to: 28

ID ADL66282 standard; peptide; 28 AA.

XX AC ADL66282;

XX XX 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 162.

XX XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX XX Key Location/Qualifiers

XX FH Modified-site 28 /note= "C-terminal amide"

XX FT
XX PN WO2003099314-A1.

XX XX 04-DEC-2003.

XX XX 28-MAY-2003; 2003WO-US016699.

XX XX 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX XX
XX Pharmacutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 162; 173pp; English.

XX XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66282 Length: 28 February 4, 2005 13:33 Type: P Check: 9965

Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQEEAEAVRLFIEFAKN 28
11 match found in sequence:
adl66283 ; Exendin agonist peptide, SEQ ID No 163.
(from "seq5ags.pep")
TOIG of: adl66283 check: 420 from: 1 to: 28

ID ADL66283 standard; peptide; 28 AA.

XX AC ADL66283;

XX XX 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 163.

XX XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX XX Key Location/Qualifiers

XX FH Modified-site 28 /note= "C-terminal amide"

XX FT
XX PN WO2003099314-A1.

XX XX 04-DEC-2003.

XX XX 28-MAY-2003; 2003WO-US016699.

XX XX 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX XX
XX Pharmacutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 163; 173pp; English.

XX XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66283 Length: 28 February 4, 2005 13:32 Type: P Check: 420

Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQEEAEAVRLFIEWLAN 28
1

CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66279 Length: 28 February 4, 2005 13:32 Type: P Check: 140 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEAEAVRLFIEALKN 28
|-----|

1 match found in sequence:

adl66280 : Extendin agonist peptide, SEQ ID No 160.
(from "seq5ags.pep")

TOIG of: adl66280 check: 126 from: 1 to: 28

ID ADL66280 standard; peptide; 28 AA.

XX AC ADL66280;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 160.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX PH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX PS WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 160; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66280 Length: 28 February 4, 2005 13:33 Type: P Check: 126 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEAEAVRLFIEALKN 28
|-----|

1 match found in sequence:

adl66281 : Extendin agonist peptide, SEQ ID No 161.
(from "seq5ags.pep")

TOIG of: adl66281 check: 404 from: 1 to: 28

ID ADL66281 standard; peptide; 28 AA.

XX AC ADL66281;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 161.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX PH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX PS WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 161; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.

PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID NO 157; 173pp; English.

CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66277 Length: 28 February 4, 2005 13:32 Type: P Check: 666 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEEEAVRLFDLFLKN 28
 1

 1 match found in sequence:
 adl66278 ; Extendin agonist peptide, SEQ ID No 159.
 (from "seq5ags.pep")
 TOIG of: adl66278 check: 227 from: 1 to: 28

ID ADL66278 standard; peptide; 28 AA.
 AC ADL66278;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 DE Extendin agonist peptide, SEQ ID No 158.
 XX
 XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.

XX Key Location/Qualifiers
 XX Modified-site 28 /note= "C-terminal amide"
 FT
 FT

PN WO2003099314-A1.

PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID NO 158; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66278 Length: 28 February 4, 2005 13:33 Type: P Check: 227 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEEEAVRLFDLFLKN 28
 1

 1 match found in sequence:
 adl66279 ; Extendin agonist peptide, SEQ ID No 159.
 (from "seq5ags.pep")
 TOIG of: adl66279 check: 140 from: 1 to: 28

ID ADL66279 standard; peptide; 28 AA.

AC ADL66279;

XX 20-MAY-2004 (first entry)

DT Extendin agonist peptide, SEQ ID No 159.

DE extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

XX Modified-site 28 /note= "C-terminal amide"

FT

FT

PN WO2003099314-A1.

PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID No 159; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such


```
PR 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 155; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX Sequence 28 AA;
SQ
ADL66275 Length: 28 February 4, 2005 13:33 Type: P Check: 1035 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSLSKQMEEAVALRFXEWLKN 28
-----|
1 match found in sequence:
adl66276 ; Extendin agonist peptide, SRQ ID No 156.
(from "seq5ags.pep")
TOIG of: adl66276 check: 596 from: 1 to: 28
ID ADL66276 standard; peptide; 28 AA.
XX
AC ADL66276;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 156.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 23 /note= "Tertiary-butylglycine"
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PR 28-MAY-2003; 2003WO-US016699.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX (AMYL-) AMYLIN PHARM INC.
```

```
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 156; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX Sequence 28 AA;
SQ
ADL66276 Length: 28 February 4, 2005 13:32 Type: P Check: 596 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSLSKQLEEAVALRFXEFLKN 28
-----|
1 match found in sequence:
adl66277 ; Extendin agonist peptide, SEQ ID No 157.
(from "seq5ags.pep")
TOIG of: adl66277 check: 666 from: 1 to: 28
ID ADL66277 standard; peptide; 28 AA.
XX
AC ADL66277;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 157.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PR 28-MAY-2003; 2003WO-US016699.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
```

```

FT XX                               /note= "C-terminal amide"
FN XX WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 153; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66273 Length: 28 February 4, 2005 13:33 Type: P Check: 989 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSDLSKQLEEAARLVEFLKN 28
-----
1 match found in sequence:
adl66274 ; Exendin agonist peptide, SEQ ID No 154.
(from "seq5ags.pep")
TOIG of: adl66274 check: 550 from: 1 to: 28
-----
ID ADL66274 standard; peptide; 28 AA.
XX
XX AC ADL66274;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Exendin agonist peptide, SEQ ID No 154.
XX
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX PD 04-DEC-2003.

```

```

XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 154; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66274 Length: 28 February 4, 2005 13:33 Type: P Check: 550 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSDLSKQLEEAARLVEFLKN 28
-----
1 match found in sequence:
adl66275 ; Exendin agonist peptide, SEQ ID No 155.
(from "seq5ags.pep")
TOIG of: adl66275 check: 1035 from: 1 to: 28
-----
ID ADL66275 standard; peptide; 28 AA.
XX
XX AC ADL66275;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Exendin agonist peptide, SEQ ID No 155.
XX
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 23 /note= "Tertiary-butylglycine"
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX

```

```

KW dyslipidaemia; cardiovascular.
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
XX Modified-site 22
XX Modified-site 28 /note= "Naphthylalanine"
XX Modified-site 28 /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 151; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66271 Length: 28 February 4, 2005 13:33 Type: P Check: 1086 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEEEAVRLXIEWLKN 28
-----
1 match found in sequence:
adl66272 ; Extendin agonist peptide, SEQ ID No 152.
(from "seq5ags.pep")
TOIG of: adl66272 check: 647 from: 1 to: 28

ID ADL66272 standard; peptide; 28 AA.
XX
XX ADL66272;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 152.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
OS

```

```

XX Key Location/Qualifiers
XX Modified-site 22
XX Modified-site 28 /note= "Naphthylalanine"
XX Modified-site 28 /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 152; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66272 Length: 28 February 4, 2005 13:33 Type: P Check: 647 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRLXIEFLKN 28
-----
1 match found in sequence:
adl66273 ; Extendin agonist peptide, SEQ ID No 153.
(from "seq5ags.pep")
TOIG of: adl66273 check: 989 from: 1 to: 28

ID ADL66273 standard; peptide; 28 AA.
XX
XX ADL66273;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 153.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28

```

```

XX AC ADL66269;
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 149.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 149; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;
ADL66269 Length: 28 February 4, 2005 13:32 Type: P Check: 459 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRAFIEMLNK 28
1 match found in sequence:
adl66270; Exendin agonist peptide, SEQ ID No 150.
(from "seq5ags.pep")
TOIG of: adl66270 check: 20 from: 1 to: 28
-----
ID ADL66270 standard; peptide; 28 AA.
XX AC ADL66270;
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 151.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 149; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;
ADL66269 Length: 28 February 4, 2005 13:32 Type: P Check: 459 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRAFIEMLNK 28
1 match found in sequence:
adl66270; Exendin agonist peptide, SEQ ID No 150.
(from "seq5ags.pep")
TOIG of: adl66270 check: 20 from: 1 to: 28
-----
ID ADL66270 standard; peptide; 28 AA.
XX AC ADL66270;
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 151.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 150; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;
ADL66270 Length: 28 February 4, 2005 13:33 Type: P Check: 20 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLEEEAVRAFIEMLNK 28
1 match found in sequence:
adl66271; Exendin agonist peptide, SEQ ID No 151.
(from "seq5ags.pep")
TOIG of: adl66271 check: 1086 from: 1 to: 28
-----
ID ADL66271 standard; peptide; 28 AA.
XX AC ADL66271;
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 151.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 150; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;

```

1 AGDGTFTSLSKQLEEEAARLFIEFLKN 28

1 match found in sequence:

adl66267 ; Exendin agonist peptide, SEQ ID No 147.
(from "seq5ags.pep")
TOIG of: adl66267 check: 350 from: 1 to: 28

ID ADL66267 standard; peptide; 28 AA.

XX AC ADL66267;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 147.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 147; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66267 Length: 28 February 4, 2005 13:33 Type: P Check: 350

Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAARLFIEFLKN 28

1 match found in sequence:

adl66268 ; Exendin agonist peptide, SEQ ID No 148.
(from "seq5ags.pep")
TOIG of: adl66268 check: 9911 from: 1 to: 28

ID ADL66268 standard; peptide; 28 AA.

XX AC ADL66268;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 148.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 148; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66268 Length: 28 February 4, 2005 13:33 Type: P Check: 9911

Found using 'seq5' (mohamed337.key)

1 AGDGTFTSLSKQLEEEAARLFIEFLKN 28

1 match found in sequence:
adl66269 ; Exendin agonist peptide, SEQ ID No 149.
(from "seq5ags.pep")
TOIG of: adl66269 check: 459 from: 1 to: 28

ID ADL66269 standard; peptide; 28 AA.

CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66264 Length: 28 February 4, 2005 13:32 Type: P Check: 183 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEEAARLFIETLKN 28
 1

1 match found in sequence:
 adl66265 ; Extendin agonist peptide, SEQ ID No 145.
 (from "seq5ags.pep")
 TOIG of: adl66265 check: 291 from: 1 to: 28

ID ADL66265 standard; peptide; 28 AA.

XX AC ADL66265;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 145.

KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"

PN WO2003099314-A1.

PD 04-DEC-2003.

PF 28-MAY-2003; 2003WO-US016699.

PR 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 145; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipidemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66265 Length: 28 February 4, 2005 13:32 Type: P Check: 291 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEERARLFIETLKN 28
 1

1 match found in sequence:
 adl66266 ; Extendin agonist peptide, SEQ ID No 146.
 (from "seq5ags.pep")
 TOIG of: adl66266 check: 9852 from: 1 to: 28

ID ADL66266 standard; peptide; 28 AA.

XX AC ADL66266;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 146.

KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"

PN WO2003099314-A1.

PD 04-DEC-2003.

PF 28-MAY-2003; 2003WO-US016699.

PR 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 146; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipidemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66266 Length: 28 February 4, 2005 13:33 Type: P Check: 9852 ..
 Found using 'seq5' (mohamed337.key)

CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66262 Length: 28 February 4, 2005 13:33 Type: P Check: 187 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQLEAEAVRLFIFLKN 28
|-----|
1 AGDGTFTSDLSKQLEAEAVRLFIFLKN 28

1 match found in sequence:
adl66263 ; Extendin agonist peptide, SEQ ID No 143.
(from "seq5ags.pep")
TOIG of: adl66263 check: 622 from: 1 to: 28

ID ADL66263 standard; peptide; 28 AA.

XX AC ADL66263;

XX AC ADL66263;

DT 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 143.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 143; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66263 Length: 28 February 4, 2005 13:32 Type: P Check: 622 ..
Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDLSKQMEAEAVRLFTEWLKN 28
|-----|
1 AGDGTFTSDLSKQMEAEAVRLFTEWLKN 28

1 match found in sequence:
adl66264 ; Extendin agonist peptide, SEQ ID No 144.
(from "seq5ags.pep")
TOIG of: adl66264 check: 183 from: 1 to: 28

ID ADL66264 standard; peptide; 28 AA.

XX AC ADL66264;

XX AC ADL66264;

DT 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 144.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 144; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or

PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 140; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66260 Length: 28 February 4, 2005 13:33 Type: P Check: 191
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQLAEAVRLFIFLKN 28

1 match found in sequence:
adl66261 ; Extendin agonist peptide, SEQ ID No 141.
(from "seq5ags.pep")
TOIG of: adl66261 check: 626 from: 1 to: 28
ID ADL66261 standard; peptide; 28 AA.
XX
AC ADL66261;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 141.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
FN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 141; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66261 Length: 28 February 4, 2005 13:32 Type: P Check: 626
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQMEAEAVRLFIEWLKN 28

1 match found in sequence:
adl66262 ; Extendin agonist peptide, SEQ ID No 142.
(from "seq5ags.pep")
TOIG of: adl66262 check: 187 from: 1 to: 28
ID ADL66262 standard; peptide; 28 AA.
XX
AC ADL66262;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 142.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
FN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 142; 173pp; English.
XX

PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
PI Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
DR
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 138; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66258 Length: 28 February 4, 2005 13:33 Type: P Check: 419 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQXEEAVRLFIIFLNK 28
|-----|
1 match found in sequence:
adl66259 ; Extendin agonist peptide, SEQ ID No 139.
(from "seq5aggs.pep")
TOIG of: adl66259 check: 630 from: 1 to: 28
ID ADL66259 standard; peptide; 28 AA.
XX
AC ADL66259;
XX
XX 20-MAY-2004 (first entry)
DT
DE Extendin agonist peptide, SEQ ID No 139.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
PH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
PD
XX 28-MAY-2003; 2003WO-US016699.
PF
XX

XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
DR
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 139; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66259 Length: 28 February 4, 2005 13:33 Type: P Check: 630 ..
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSDLSKQXEEAVRLFIIFLNK 28
|-----|
1 match found in sequence:
adl66260 ; Extendin agonist peptide, SEQ ID No 140.
(from "seq5aggs.pep")
TOIG of: adl66260 check: 191 from: 1 to: 28
ID ADL66260 standard; peptide; 28 AA.
XX
AC ADL66260;
XX
XX 20-MAY-2004 (first entry)
DT
DE Extendin agonist peptide, SEQ ID No 140.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
PH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
PD
XX 28-MAY-2003; 2003WO-US016699.
PF
XX
XX 28-MAY-2002; 2002US-00157224.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX

```

OS Synthetic.
XX Key Location/Qualifiers
FH Modified-site 28 /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 136; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL6256 Length: 28 February 4, 2005 13:33 Type: P Check: 97 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSLSKQAEAEAVRLFIEFLKV 28
-----
1 match found in sequence:
adl66257 ; Extendin agonist peptide, SEQ ID No 137.
(from "seq5ags.pep")
TOIG of: adl66257 check: 844 from: 1 to: 28
ID ADL66257 standard; peptide; 28 AA.
XX
XX ADL66257;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 137.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipemic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 14 /note= "Pentylglycine"
FT
FT

```

```

FT Modified-site 28 /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 137; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66257 Length: 28 February 4, 2005 13:33 Type: P Check: 844 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGDGTFTSLSKQAEAEAVRLFIEFLKV 28
-----
1 match found in sequence:
adl66258 ; Extendin agonist peptide, SEQ ID No 138.
(from "seq5ags.pep")
TOIG of: adl66258 check: 419 from: 1 to: 28
ID ADL66258 standard; peptide; 28 AA.
XX
XX ADL66258;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 138.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipemic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 14 /note= "Pentylglycine"
FT
FT Modified-site 28 /note= "C-terminal amide"
XX
XX

```

```

XX 20-MAY-2004 (first entry)
XX Exendin agonist peptide, SEQ ID No 134.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 134; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL6254 Length: 28 February 4, 2005 13:32 Type: P Check: 43
Found using 'seq5' (mohamed337.key)
1
1 AGDGTFTSLKALEEAEVRLFIETLKN 28
1
1 match found in sequence:
adl6255 ; Exendin agonist peptide, SEQ ID No 135.
(from "seq5ags.pep")
TOIG of: adl6255 check: 522 from: 1 to: 28
-----
ID ADL6255 standard; peptide; 28 AA.
XX
XX ADL6255;
XX
XX 20-MAY-2004 (first entry)
XX
XX Exendin agonist peptide, SEQ ID No 135.
XX

```

```

KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 135; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL6255 Length: 28 February 4, 2005 13:32 Type: P Check: 522
Found using 'seq5' (mohamed337.key)
1
1 AGDGTFTSLKQAEAEVRLFIETLKN 28
1
1 match found in sequence:
adl6256 ; Exendin agonist peptide, SEQ ID No 136.
(from "seq5ags.pep")
TOIG of: adl6256 check: 97 from: 1 to: 28
-----
ID ADL6256 standard; peptide; 28 AA.
XX
XX ADL6256;
XX
XX 20-MAY-2004 (first entry)
XX
XX Exendin agonist peptide, SEQ ID No 136.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX

```

```
-----
1 match found in sequence:
adl66252 ; Exendin agonist peptide, SEQ ID No 132.
(from "seq5ags.pep")
TOIG of: adl66252 check: 131 from: 1 to: 28

ID ADL66252 standard; peptide; 28 AA.
XX
AC ADL66252;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 132.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
PI WPI; 2004-042706/04.
XX
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 132; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66252 Length: 28 February 4, 2005 13:33 Type: P Check: 131
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTDLSAQLEEEAVRLFIEPLKN 28
-----
1 match found in sequence:
adl66253 ; Exendin agonist peptide, SEQ ID No 133.
(from "seq5ags.pep")
TOIG of: adl66253 check: 131 from: 1 to: 28

ID ADL66253 standard; peptide; 28 AA.
XX
AC ADL66253;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 133.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
PI WPI; 2004-042706/04.
XX
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 133; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66253 Length: 28 February 4, 2005 13:32 Type: P Check: 482
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTDLSKAMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
adl66254 ; Exendin agonist peptide, SEQ ID No 134.
(from "seq5ags.pep")
TOIG of: adl66254 check: 43 from: 1 to: 28

ID ADL66254 standard; peptide; 28 AA.
XX
AC ADL66254;
XX
```

CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66249 Length: 28 February 4, 2005 13:33 Type: P Check: 492 ..

Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTFTSLAKQEEAEAVRLFIEFLKN
  1                               28

```

1 match found in sequence:

adl66250 ; Extendin agonist peptide, SEQ ID No 130.
(from "seq5ags.pep")
TOIG of: adl66250 check: 53 from: 1 to: 28

ID ADL66250 standard; peptide; 28 AA.

XX AC ADL66250;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 130.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PP 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 130; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66250 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..

Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTFTSLAKQEEAEAVRLFIEFLKN
  1                               28

```

1 match found in sequence:

adl66251 ; Extendin agonist peptide, SEQ ID No 131.
(from "seq5ags.pep")
TOIG of: adl66251 check: 570 from: 1 to: 28

ID ADL66251 standard; peptide; 28 AA.

XX AC ADL66251;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 131.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PP 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 131; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66251 Length: 28 February 4, 2005 13:32 Type: P Check: 570 ..
Found using 'seq5' (mohamed337.key)

```

1 |-----|
  AGDGTFTSLAKQEEAEAVRLFIEFLKN
  1                               28

```

CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 XX Sequence 28 AA;

ADL66247 Length: 28 February 4, 2005 13:33 Type: P Check: 810 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDXSKQMEEEAVRLFIEFLKN 28
 |-----|

1 match found in sequence:
 adl66248 ; Extendin agonist peptide, SEQ ID No 128.
 (from "seq5ags.pep")
 TOIG of: adl66248 check: 371 from: 1 to: 28

ID ADL66248 standard; peptide; 28 AA.
 XX
 AC ADL66248;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 128.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.

Key Location/Qualifiers
 FT Modified-site 10 /note= "Pentylglycine"
 FT Modified-site 28 /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.

XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX
 XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 FT extendin or an extendin agonist peptide in an extended-release formulation.
 XX

PS Disclosure; SEQ ID No 128; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 XX Sequence 28 AA;

ADL66248 Length: 28 February 4, 2005 13:33 Type: P Check: 371 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTSDXSKQMEEEAVRLFIEFLKN 28
 |-----|

1 match found in sequence:
 adl66249 ; Extendin agonist peptide, SEQ ID No 129.
 (from "seq5ags.pep")
 TOIG of: adl66249 check: 492 from: 1 to: 28

ID ADL66249 standard; peptide; 28 AA.
 XX
 AC ADL66249;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 129.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.

Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.

XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX
 XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 FT extendin or an extendin agonist peptide in an extended-release formulation.
 XX

PS Disclosure; SEQ ID No 129; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 125; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 28 AA;
 ADL66245 Length: 28 February 4, 2005 13:33 Type: P Check: 580 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDASKQMBEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 adl66246 ; Extendin agonist peptide, SEQ ID No 126.
 (from "seq5ags.pep")
 TOIG of: adl66246 Check: 141 from: 1 to: 28

 ID ADL66246 standard; peptide; 28 AA.
 XX
 AC ADL66246;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 126.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "C-terminal amide"
 FT
 FT
 FT
 XX WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 XX extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 XX Disclosure; SEQ ID NO 126; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 28 AA;
 ADL66246 Length: 28 February 4, 2005 13:33 Type: P Check: 141 ..
 Found using 'seq5' (mohamed337.key)
 1 AGDGTFTSDASKQLEEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 adl66247 ; Extendin agonist peptide, SEQ ID No 127.
 (from "seq5ags.pep")
 TOIG of: adl66247 Check: 810 from: 1 to: 28

 ID ADL66247 standard; peptide; 28 AA.
 XX
 AC ADL66247;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 127.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 10
 FT /note= "Pentylglycine"
 FT 28
 FT Modified-site /note= "C-terminal amide"
 FT
 FT
 XX WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 XX extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 XX Disclosure; SEQ ID NO 127; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such

```
PR 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 123; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66243 Length: 28 February 4, 2005 13:33 Type: P Check: 699
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSELSKQLEEEAVRLFIETLKN
1 28
-----
1 match found in sequence:
adl66244 ; Extendin agonist peptide, SEQ ID No 124.
(from "seq5ags.pep")
TOIG of: adl66244 check: 260 from: 1 to: 28
-----
ID ADL66244 standard; peptide; 28 AA.
XX
XX AC ADL66244;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 124.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
```

```
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 124; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66244 Length: 28 February 4, 2005 13:33 Type: P Check: 260
Found using 'seq5' (mohamed337.key)
1 AGDGTFTSELSKQLEEEAVRLFIETLKN
1 28
-----
1 match found in sequence:
adl66245 ; Extendin agonist peptide, SEQ ID No 125.
(from "seq5ags.pep")
TOIG of: adl66245 check: 580 from: 1 to: 28
-----
ID ADL66245 standard; peptide; 28 AA.
XX
XX AC ADL66245;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 125.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
```



```

XX DE Exendin agonist peptide, SEQ ID No 119.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 119; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The novel composition has antidiabetic,
XX anorectic, and antilipidemic activities. The composition has antidiabetic,
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66239 Length: 28 February 4, 2005 13:33 Type: P Check: 546 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTADLSKQLEEBEAVRLFIEFLKN 28

-----
1 match found in sequence:
adl66240 ; Exendin agonist peptide, SEQ ID No 120.
(from "seq5ags.pep")
TOIG of: adl66240 check: 107 from: 1 to: 28

ID ADL66240 standard; peptide; 28 AA.
XX
AC ADL66240;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 120.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;

```

```

KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 120; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The novel composition has antidiabetic,
XX anorectic, and antilipidemic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66240 Length: 28 February 4, 2005 13:33 Type: P Check: 107 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
  1 AGDGTFTADLSKQLEEBEAVRLFIEFLKN 28

-----
1 match found in sequence:
adl66241 ; Exendin agonist peptide, SEQ ID No 121.
(from "seq5ags.pep")
TOIG of: adl66241 check: 663 from: 1 to: 28

ID ADL66241 standard; peptide; 28 AA.
XX
AC ADL66241;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 121.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX

```

```
1 match found in sequence:
adl66237 ; Exendin agonist peptide, SEQ ID No 117.
(from "seq5ags.pep")
TOIG of: adl66237 check: 683 from: 1 to: 28

ID ADL66237 standard; peptide; 28 AA.
XX AC
XX ADL66237;
XX DT
XX DE
XX EXendin agonist peptide, SEQ ID No 117.
XX KW
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD
XX PD 04-DEC-2003.
XX PF
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID No 117; 173pp; English.
XX CC
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ
SQ Sequence 28 AA;

ADL66237 Length: 28 February 4, 2005 13:33 Type: P Check: 683
Found using 'seq5' (mohamed337.key)

1 AGDGTFFSSDLSKQLEEEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
adl66237 ; Exendin agonist peptide, SEQ ID No 117.
(from "seq5ags.pep")
TOIG of: adl66237 check: 683 from: 1 to: 28

ID ADL66237 standard; peptide; 28 AA.
XX AC
XX ADL66237;
XX DT
XX DE
XX EXendin agonist peptide, SEQ ID No 117.
XX KW
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD
XX PD 04-DEC-2003.
XX PF
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID No 117; 173pp; English.
XX CC
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ
SQ Sequence 28 AA;

ADL66237 Length: 28 February 4, 2005 13:33 Type: P Check: 683
Found using 'seq5' (mohamed337.key)

1 AGDGTFFSSDLSKQLEEEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
adl66237 ; Exendin agonist peptide, SEQ ID No 117.
(from "seq5ags.pep")
TOIG of: adl66237 check: 683 from: 1 to: 28

ID ADL66237 standard; peptide; 28 AA.
XX AC
XX ADL66237;
XX DT
XX DE
XX EXendin agonist peptide, SEQ ID No 117.
XX KW
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD
XX PD 04-DEC-2003.
XX PF
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PT
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID No 118; 173pp; English.
XX CC
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ
SQ Sequence 28 AA;

ADL66238 Length: 28 February 4, 2005 13:33 Type: P Check: 244
Found using 'seq5' (mohamed337.key)

1 AGDGTFFSSDLSKQLEEEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
adl66239 ; Exendin agonist peptide, SEQ ID No 119.
(from "seq5ags.pep")
TOIG of: adl66239 check: 546 from: 1 to: 28

ID ADL66239 standard; peptide; 28 AA.
XX AC
XX ADL66239;
XX DT
XX DT 20-MAY-2004 (first entry)
```

```

1 1 -----
  AGDGAFTSDLSKQLEEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
adl66235 ; Exendin agonist peptide, SEQ ID No 115.
(from "seq5ags.pep")
TOIG of: adl66235 check: 798 from: 1 to: 28

ID ADL66235 standard; peptide; 28 AA.
XX
AC ADL66235;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 115.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 6 /note= "Naphthylalanine"
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
FN WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 115; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;

ADL66235 Length: 28 February 4, 2005 13:33 Type: P Check: 798
Found using 'seq5' (mohamed337.key)

1 1 -----
  AGDGTXTDLSKQLEEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
adl66235 ; Exendin agonist peptide, SEQ ID No 115.
(from "seq5ags.pep")
TOIG of: adl66235 check: 798 from: 1 to: 28

ID ADL66235 standard; peptide; 28 AA.
XX
AC ADL66235;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 115.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 6 /note= "Naphthylalanine"
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
FN WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 115; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;

ADL66235 Length: 28 February 4, 2005 13:33 Type: P Check: 798
Found using 'seq5' (mohamed337.key)

1 1 -----
  AGDGTXTDLSKQLEEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
adl66236 ; Exendin agonist peptide, SEQ ID No 116.
(from "seq5ags.pep")
TOIG of: adl66236 check: 359 from: 1 to: 28

ID ADL66236 standard; peptide; 28 AA.
XX
AC ADL66236;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 116.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 6 /note= "Naphthylalanine"
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
FN WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 116; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;

ADL66236 Length: 28 February 4, 2005 13:32 Type: P Check: 359
Found using 'seq5' (mohamed337.key)

1 1 -----
  AGDGTXTDLSKQLEEEAVRLFIEFLKN 28
  1
-----

```

CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66232 Length: 28 February 4, 2005 13:32 Type: P Check: 251 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTDLSKQLEEEAVRLFIFLKN
 1 28

1 match found in sequence:

adl66233 ; Extendin agonist peptide, SEQ ID No 113.
 (from "seq5ags.pep")
 TOIG of: adl66233 check: 595 from: 1 to: 28

ID ADL66233 standard; peptide; 28 AA.

XX AC ADL66233;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 113.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 XX Modified-site 28

XX FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 113; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66233 Length: 28 February 4, 2005 13:32 Type: P Check: 595 ..
 Found using 'seq5' (mohamed337.key)

1 AGDGTFTDLSKQMEEEAVRLFIEWLKN
 1 28

1 match found in sequence:

adl66234 ; Extendin agonist peptide, SEQ ID No 114.
 (from "seq5ags.pep")
 TOIG of: adl66234 check: 156 from: 1 to: 28

ID ADL66234 standard; peptide; 28 AA.

XX AC ADL66234;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 114.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 XX Modified-site 28

XX FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 114; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66234 Length: 28 February 4, 2005 13:33 Type: P Check: 156 ..
 Found using 'seq5' (mohamed337.key)

```

PS  Disclosure; SEQ ID NO 110; 173pp; English.
CC  The invention relates to a novel pharmaceutical composition comprising an
CC  extendin (agonist) peptide in an extended-release formulation. The
CC  formulation is capable of releasing the peptide over a predetermined
CC  release period, the period being at least one hour, and in an amount such
CC  that, when the composition is administered to a human, an average
CC  sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC  of the predetermined release period. The composition has antidiabetic,
CC  anorectic, and antilipemic activities. The novel composition and method
CC  are useful in treating diabetes and conditions that would be benefited by
CC  lowering plasma glucose or delaying and/or slowing gastric emptying or
CC  inhibiting food intake, such as impaired glucose tolerance, obesity,
CC  hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC  represents an extendin agonist peptide of the invention.
XX  Sequence 28 AA;
SQ

ADL66230 Length: 28 February 4, 2005 13:33 Type: P Check: 242 ..
Found using 'seq5' (mohamed337.key)

1  |-----|
1  | AAEGTFTSDLSKQLEEEAVRLFIETLKN 28
1  |-----|

-----
1 match found in sequence:
adl66231; Extendin agonist peptide, SEQ ID NO 111.
(from "seq5ags.pep")
TOIG of: adl66231 check: 690 from: 1 to: 28

ID  ADL66231 standard; peptide; 28 AA.
XX
AC  ADL66231;
XX
DT  20-MAY-2004 (first entry)
XX
DE  Extendin agonist peptide, SEQ ID NO 111.
XX
KW  extendin; extended-release formulation; plasma level; antidiabetic;
KW  anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW  inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW  dyslipidaemia; cardiovascular.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28 /note= "C-terminal amide"
FT
FT
XX  WO2003099314-A1.
XX
PD  04-DEC-2003.
XX
PF  28-MAY-2003; 2003WO-US016699.
XX
PR  28-MAY-2002; 2002US-00157224.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Young AA, Kolterman OG;
XX
DR  WPI; 2004-042706/04.
XX
PT  Pharmaceutical composition for treating diabetes, impaired glucose
PT  tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT  extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS  Disclosure; SEQ ID NO 111; 173pp; English.
XX
CC  The invention relates to a novel pharmaceutical composition comprising an
CC  extendin (agonist) peptide in an extended-release formulation. The
CC  formulation is capable of releasing the peptide over a predetermined
CC  release period, the period being at least one hour, and in an amount such
CC  that, when the composition is administered to a human, an average
CC  sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC  of the predetermined release period. The composition has antidiabetic,
CC  anorectic, and antilipemic activities. The novel composition and method
CC  are useful in treating diabetes and conditions that would be benefited by
CC  lowering plasma glucose or delaying and/or slowing gastric emptying or
CC  inhibiting food intake, such as impaired glucose tolerance, obesity,
CC  hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC  represents an extendin agonist peptide of the invention.
XX  Sequence 28 AA;
SQ

ADL66231 Length: 28 February 4, 2005 13:33 Type: P Check: 690 ..
Found using 'seq5' (mohamed337.key)

1  |-----|
1  | AGDGTFTSDLSKQWEEAVRLFIETLKN 28
1  |-----|

-----
1 match found in sequence:
adl66232; Extendin agonist peptide, SEQ ID NO 112.
(from "seq5ags.pep")
TOIG of: adl66232 check: 251 from: 1 to: 28

ID  ADL66232 standard; peptide; 28 AA.
XX
AC  ADL66232;
XX
DT  20-MAY-2004 (first entry)
XX
DE  Extendin agonist peptide, SEQ ID NO 112.
XX
KW  extendin; extended-release formulation; plasma level; antidiabetic;
KW  anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW  inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW  dyslipidaemia; cardiovascular.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28 /note= "C-terminal amide"
FT
FT
XX  WO2003099314-A1.
XX
PD  04-DEC-2003.
XX
PF  28-MAY-2003; 2003WO-US016699.
XX
PR  28-MAY-2002; 2002US-00157224.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Young AA, Kolterman OG;
XX
DR  WPI; 2004-042706/04.
XX
PT  Pharmaceutical composition for treating diabetes, impaired glucose
PT  tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT  extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS  Disclosure; SEQ ID NO 112; 173pp; English.
XX
CC  The invention relates to a novel pharmaceutical composition comprising an
CC  extendin (agonist) peptide in an extended-release formulation. The
CC  formulation is capable of releasing the peptide over a predetermined
CC  release period, the period being at least one hour, and in an amount such
CC  that, when the composition is administered to a human, an average
CC  sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC  of the predetermined release period. The composition has antidiabetic,
CC  anorectic, and antilipemic activities. The novel composition and method

```

PA (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 XX Disclosure; SEQ ID NO 108; 173pp; English.
 XX
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 XX Sequence 28 AA;
 SQ
 ADL66228 Length: 28 February 4, 2005 13:33 Type: P Check: 590
 Found using 'seq5' (mohamed337.key)
 1 HGEFTTSDASKQMEEEAVRLFIEWLKN 28
 |-----|
 1 match found in sequence:
 adl66229 ; Extendin agonist peptide, SEQ ID No 109.
 (from "seq5ags.pep")
 TOIG of: adl66229 check: 681 from: 1 to: 28

 ID ADL66229 standard; peptide; 28 AA.
 XX
 AC ADL66229;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 109.
 XX
 XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH Modified-site 28
 FT /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX

XX
 PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 XX Disclosure; SEQ ID NO 109; 173pp; English.
 XX
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 XX Sequence 28 AA;
 SQ
 ADL66229 Length: 28 February 4, 2005 13:33 Type: P Check: 681
 Found using 'seq5' (mohamed337.key)
 1 AEGTFTSDLSKQMEEEAVRLFIEWLKN 28
 |-----|
 1 match found in sequence:
 adl66230 ; Extendin agonist peptide, SEQ ID No 110.
 (from "seq5ags.pep")
 TOIG of: adl66230 check: 242 from: 1 to: 28

 ID ADL66230 standard; peptide; 28 AA.
 XX
 AC ADL66230;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 110.
 XX
 XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH Modified-site 28
 FT /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX

```

FT XX /note= "C-terminal amide"
PN XX WO2003099314-A1.
XX XX
PD 04-DEC-2003.
XX XX
PF 28-MAY-2003; 2003WO-US016699.
XX XX
PR 28-MAY-2002; 2002US-00157224.
XX XX
PA (AMYL-) AMYLIN PHARM INC.
PI Young AA, Kolterman OG;
PT WPI; 2004-042706/04.
DR XX
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 106; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66226 Length: 28 February 4, 2005 13:32 Type: P Check: 676
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEATFTSDLSKQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
adl66227 ; Extendin agonist peptide, SEQ ID No 107.
(from "seq5ags.pep")
TOIG of: adl66227 check: 673 from: 1 to: 28
-----
ID ADL66227 standard; peptide; 28 AA.
XX
AC ADL66227;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 107.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
PD 04-DEC-2003.

```

```

XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 107; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66227 Length: 28 February 4, 2005 13:33 Type: P Check: 673
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGECTFTSALSQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
adl66228 ; Extendin agonist peptide, SEQ ID No 108.
(from "seq5ags.pep")
TOIG of: adl66228 check: 590 from: 1 to: 28
-----
ID ADL66228 standard; peptide; 28 AA.
XX
AC ADL66228;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 108.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX

```



```
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 104; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66224 Length: 28 February 4, 2005 13:33 Type: P Check: 693 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 AGEGFTTSDLSKQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
adl66225 ; Extendin agonist peptide, SEQ ID No 105.
(from "seq5ags.pep")
TOIG of: adl66225 check: 688 from: 1 to: 28
-----
ID ADL66225 standard; peptide; 28 AA.
XX
XX ADL66225;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 105.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
```

```
XX Synthetic.
OS
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 105; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66225 Length: 28 February 4, 2005 13:33 Type: P Check: 688 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGAGFTTSDLSKQMEEEAVRLFIEWLKN 28
-----
1 match found in sequence:
adl66226 ; Extendin agonist peptide, SEQ ID No 106.
(from "seq5ags.pep")
TOIG of: adl66226 check: 676 from: 1 to: 28
-----
ID ADL66226 standard; peptide; 28 AA.
XX
XX ADL66226;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 106.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
```

```
(from "seq5ags.pep")
TOIG of: adl66222 check: 237 from: 1 to: 28

ID ADL66222 standard; peptide; 28 AA.
XX
AC ADL66222;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 102.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID No 102; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66222 Length: 28 February 4, 2005 13:33 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEATFTSDLSKQLEEAARLFIETFLKN 28
-----
1 match found in sequence:
adl66222 ; Extendin agonist peptide, SEQ ID No 103.
(from "seq5ags.pep")
TOIG of: adl66222 check: 234 from: 1 to: 28

ID ADL66223 standard; peptide; 28 AA.
XX
AC ADL66223;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 103.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID No 103; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66223 Length: 28 February 4, 2005 13:33 Type: P Check: 234 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HGEATFTSALSQLEEAARLFIETFLKN 28
-----
1 match found in sequence:
adl66224 ; Extendin agonist peptide, SEQ ID No 104.
(from "seq5ags.pep")
TOIG of: adl66224 check: 693 from: 1 to: 28

ID ADL66224 standard; peptide; 28 AA.
XX
AC ADL66224;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 104.
```

```
ADL66219 Length: 37 February 4, 2005 13:33 Type: P Check: 4015 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDASKQMEAEAVRLFIEWLKNGGSGCAXX
  1
-----|-----|
1 match found in sequence:
adl66220 ; Exendin agonist peptide, SEQ ID No 100.
(from "seq5ags.pep")
TOIG of: adl66220 check: 254 from: 1 to: 28

ID ADL66220 standard; peptide; 28 AA.
XX
AC ADL66220;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 100.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 100; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66220 Length: 28 February 4, 2005 13:33 Type: P Check: 254 ..
Found using 'seq5' (mohamed337.key)

1 AGEFTFTSDLSKQLEEAARLFIETFLKN
  1
-----|-----|
1 match found in sequence:
adl66222 ; Exendin agonist peptide, SEQ ID No 102.
```

```
1
-----|-----|
1 match found in sequence:
adl66221 ; Exendin agonist peptide, SEQ ID No 101.
(from "seq5ags.pep")
TOIG of: adl66221 check: 249 from: 1 to: 28

ID ADL66221 standard; peptide; 28 AA.
XX
AC ADL66221;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 101.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 101; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66221 Length: 28 February 4, 2005 13:33 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQLEEAARLFIETFLKN
  1
-----|-----|
1 match found in sequence:
adl66222 ; Exendin agonist peptide, SEQ ID No 102.
```

CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX
SQ Sequence 33 AA;

ADL66217 Length: 33 February 4, 2005 13:33 Type: P Check: 2215
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDASKQLEEEAVRLFIEFLKNGGPS
1 28

1 match found in sequence:
adl66218 ; Extendin agonist peptide, SEQ ID No 98.
(from "seq5ags.pep")
TOIG of: adl66218 check: 2649 from: 1 to: 29

ID ADL66218 standard; peptide; 29 AA.

XX AC ADL66218;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 98.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 29 /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 98; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 29 AA;

ADL66218 Length: 29 February 4, 2005 13:33 Type: P Check: 2649
Found using 'seq5' (mohamed337.key)

1 HEGGFTSDASKQMBEEAVRLFIEWLKNG
1 28

1 match found in sequence:
adl66219 ; Extendin agonist peptide, SEQ ID No 99.
(from "seq5ags.pep")
TOIG of: adl66219 check: 4015 from: 1 to: 37

ID ADL66219 standard; peptide; 37 AA.

XX AC ADL66219;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 99.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 31 /note= "Homoproline"
XX FT Modified-site 36..37 /note= "Homoproline"
XX FT Modified-site 37 /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 99; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 37 AA;

CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66215 Length: 28 February 4, 2005 13:33 Type: P Check: 1045 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQEEAEAVRLFEXWLKN 28
 |-----|
 1

1 match found in sequence:
 adl66216 ; Extendin agonist peptide, SEQ ID No 96.
 (from "seq5ags.pep")
 TOIG of: adl66216 check: 237 from: 1 to: 28

ID ADL66216 standard; peptide; 28 AA.

XX AC ADL66216;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 96.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX FT WO2003099314-A1.

XX PN 04-DEC-2003.

XX PD 28-MAY-2003; 2003WO-US016699.

XX PF 28-MAY-2002; 2002US-00157224.

XX PR (AMYL-) AMYLIN PHARM INC.

XX PA Young AA, Kolterman OG;

XX PI WPI; 2004-042706/04.

XX DR Pharmaceutical composition for treating diabetes, impaired glucose
 XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 XX extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 96; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66216 Length: 28 February 4, 2005 13:33 Type: P Check: 237 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQEEAEAVRLFIDFLKN 28
 |-----|
 1

1 match found in sequence:
 adl66217 ; Extendin agonist peptide, SEQ ID No 97.
 (from "seq5ags.pep")
 TOIG of: adl66217 check: 2215 from: 1 to: 33

ID ADL66217 standard; peptide; 33 AA.

XX AC ADL66217;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 97.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 33 /note= "C-terminal amide"

XX FT WO2003099314-A1.

XX PN 04-DEC-2003.

XX PD 28-MAY-2003; 2003WO-US016699.

XX PF 28-MAY-2002; 2002US-00157224.

XX PR (AMYL-) AMYLIN PHARM INC.

XX PA Young AA, Kolterman OG;

XX PI WPI; 2004-042706/04.

XX DR Pharmaceutical composition for treating diabetes, impaired glucose
 XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 XX extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 97; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 93; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;

ADL66213 Length: 28 February 4, 2005 13:33 Type: P Check: 381 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDXSKQLEEEAVRLFTIEFLKN
1 28

1 match found in sequence:
adl66214 ; Extendin agonist peptide, SEQ ID No 94.
(from "seq5ags.pep")
TOIG of: adl66214 check: 657 from: 1 to: 28

ID ADL66214 standard; peptide; 28 AA.

XX AC ADL66214;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 94.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 22 /note= "Naphthylalanine"

FT Modified-site 28 /note= "C-terminal amide"

FT WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
PT

XX

PS Disclosure; SEQ ID NO 94; 173pp; English.

XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;

ADL66214 Length: 28 February 4, 2005 13:33 Type: P Check: 657 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQLEEEAVRLXIEFLKN
1 28

1 match found in sequence:
adl66215 ; Extendin agonist peptide, SEQ ID No 95.
(from "seq5ags.pep")
TOIG of: adl66215 check: 1045 from: 1 to: 28

ID ADL66215 standard; peptide; 28 AA.

XX AC ADL66215;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 95.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 23 /note= "Tertiary-butylglycine"

FT Modified-site 28 /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
PS Disclosure; SEQ ID No 95; 173pp; English.
XX

```
PR 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 91; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66211 Length: 28 February 4, 2005 13:33 Type: P Check: 701
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGTFTSLSKQMAEEAVRLFIEWLKN 28
-----|
1 match found in sequence:
adl66212; Extendin agonist peptide, SEQ ID No 92.
(from "seq5ags.pep")
TOIG of: adl66212 Check: 649 from: 1 to: 28
ID ADL66212 standard; peptide; 28 AA.
XX
XX AC ADL66212;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 92.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28 /note= "C-terminal amide"
FT
FT
FT
XX WO200309314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
```

```
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 92; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66212 Length: 28 February 4, 2005 13:33 Type: P Check: 649
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGTFTSLSKQMAEEAVRLFIEWLKN 28
-----|
1 match found in sequence:
adl66213; Extendin agonist peptide, SEQ ID No 93.
(from "seq5ags.pep")
TOIG of: adl66213 check: 381 from: 1 to: 28
ID ADL66213 standard; peptide; 28 AA.
XX
XX AC ADL66213;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 93.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 10 /note= "Pentylglycine"
FT Modified-site 28 /note= "C-terminal amide"
FT
FT
XX WO200309314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
```

```

FT Modified-site /note= "Naphthylalanine"
FT 28
FT /note= "C-terminal amide"
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 89; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX Sequence 28 AA;
SQ
ADL66209 Length: 28 February 4, 2005 13:33 Type: P Check: 369 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGXTSDLSKQLEEEAVRLFIEFLKN 28
-----|
1 match found in sequence:
adl66210 ; Extendin agonist peptide, SEQ ID No 90.
(from "seq5ags.pep")
TOIG of: adl66210 check: 593 from: 1 to: 28

ID ADL66210 standard; peptide; 28 AA.
XX AC ADL66210;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 90.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 89; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX Sequence 28 AA;
SQ
ADL66210 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGTFSSDLKQMEEEAVRLFIEWLKN 28
-----|
1 match found in sequence:
adl66211 ; Extendin agonist peptide, SEQ ID No 91.
(from "seq5ags.pep")
TOIG of: adl66211 check: 701 from: 1 to: 28

ID ADL66211 standard; peptide; 28 AA.
XX AC ADL66211;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 91.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX

```



```

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 35 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PP 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX FH Pharmaceutical composition for treating diabetes, impaired glucose
XX FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 87; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 35 AA;
ADL66207 Length: 35 February 4, 2005 13:33 Type: P Check: 7463 ..
Found using 'seq5' (mohamed337.key)
1 RGEGTFTSDLSKQMEEEAVRLFIEWLKNQSPSSGA
1 |-----|
1 match found in sequence:
adl66208 : Extendin agonist peptide, SEQ ID No 88.
(from "seq5ags.pep")
TOIG of: adl66208 check: 4886 from: 1 to: 30
ID ADL66208 standard; peptide; 30 AA.
XX AC ADL66208;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 88.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

```

```

XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PP 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX FH Pharmaceutical composition for treating diabetes, impaired glucose
XX FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 88; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 30 AA;
ADL66208 Length: 30 February 4, 2005 13:33 Type: P Check: 4886 ..
Found using 'seq5' (mohamed337.key)
1 HGDCGTFSTSDLSKQMEEEAVRLFIEWLKNKG
1 |-----|
1 match found in sequence:
adl66209 : Extendin agonist peptide, SEQ ID No 89.
(from "seq5ags.pep")
TOIG of: adl66209 check: 369 from: 1 to: 28
ID ADL66209 standard; peptide; 28 AA.
XX AC ADL66209;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 89.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 6

```


ID ADL66203 standard; peptide; 37 AA.
XX AC
XX ADL66203;
XX DE
XX 20-MAY-2004 (first entry)
XX DE
XX Extendin agonist peptide, SEQ ID No 83.
XX DE
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX Synthetic.
XX OS
XX Key Location/Qualifiers
XX FT Modified-site 31 /note= "N-methylalanine"
XX FT Modified-site 37
XX FT Modified-site 37 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX XX
XX 04-DEC-2003.
XX PD
XX 28-MAY-2003; 2003WO-US016699.
XX PF
XX 28-MAY-2002; 2002US-00157224.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young AA, Kolterman OG;
XX PI
XX WPI; 2004-042706/04.
XX DR
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS
XX Disclosure; SEQ ID NO 83; 173pp; English.
XX XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX XX
XX Sequence 37 AA;
SQ
ADL66203 Length: 37 February 4, 2005 13:33 Type: P Check: 3541 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMEEA VRLFI EWLNKGXSSGAPP 28
|-----|
1

1 match found in sequence:
adl66204 ; Extendin agonist peptide, SEQ ID No 84.
(from "seq5ags.pep")
TOIG of: adl66204 check: 4125 from: 1 to: 37

ID ADL66204 standard; peptide; 37 AA.
XX

AC ADL66204;
XX XX
XX 20-MAY-2004 (first entry)
XX DE
XX Extendin agonist peptide, SEQ ID No 84.
XX DE
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX Synthetic.
XX OS
XX Key Location/Qualifiers
XX FT Modified-site 31 /note= "N-methylalanine"
XX FT Modified-site 36..37
XX FT Modified-site 37 /note= "N-methylalanine"
XX FT Modified-site 37 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX XX
XX 04-DEC-2003.
XX PD
XX 28-MAY-2003; 2003WO-US016699.
XX PF
XX 28-MAY-2002; 2002US-00157224.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young AA, Kolterman OG;
XX PI
XX WPI; 2004-042706/04.
XX DR
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS
XX Disclosure; SEQ ID NO 84; 173pp; English.
XX XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX XX
XX Sequence 37 AA;
SQ
ADL66204 Length: 37 February 4, 2005 13:33 Type: P Check: 4125 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMEEA VRLFI EWLNKGXSSGAXX 28
|-----|
1

1 match found in sequence:
adl66205 ; Extendin agonist peptide, SEQ ID No 85.
(from "seq5ags.pep")
TOIG of: adl66205 check: 4125 from: 1 to: 37

ID ADL66205 standard; peptide; 37 AA.
XX
AC ADL66205;

1 match found in sequence:
adl66201 ; Exendin agonist peptide, SEQ ID No 81.
(from "seq5ags.pep")
TOIG of: adl66201 check: 7469 from: 1 to: 38

ID ADL66201 standard; peptide; 38 AA.

XX ADL66201;

XX 20-MAY-2004 (first entry)

DE Exendin agonist peptide, SEQ ID No 81.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 31 /note= "Thioprolin"

FT Modified-site 36..38 /note= "Thioprolin"

FT Modified-site 38 /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID No 81; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 38 AA;

ADL66201 Length: 38 February 4, 2005 13:33 Type: P Check: 7469 ..

Found using 'seq5' (mohamed337.key)

1 HEGTFTDLSKQMEEAARLFTWLNKNGXSSGAXXX
1 28

1 match found in sequence:

adl66202 ; Exendin agonist peptide, SEQ ID No 82.
(from "seq5ags.pep")
TOIG of: adl66202 check: 7221 from: 1 to: 38

ID ADL66202 standard; peptide; 38 AA.

XX ADL66202;

XX 20-MAY-2004 (first entry)

DE Exendin agonist peptide, SEQ ID No 82.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 36..38 /note= "Thioprolin"

FT Modified-site 38 /note= "C-terminal amide"

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID No 82; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 38 AA;

ADL66202 Length: 38 February 4, 2005 13:32 Type: P Check: 7221 ..

Found using 'seq5' (mohamed337.key)

1 HEGTFTDLSKQMEEAARLFTWLNKNGPSSGAXXX
1 28

1 match found in sequence:
adl66203 ; Exendin agonist peptide, SEQ ID No 83.
(from "seq5ags.pep")
TOIG of: adl66203 check: 3541 from: 1 to: 37

SQ Sequence 30 AA;

ADL66198 Length: 30 February 4, 2005 13:32 Type: P Check: 4450 ..
Found using 'seq5' (mohamed337.key)1 HGGTFTSDLSKQLEEAVALRFLFKNGG
1 28

-----1 match found in sequence:

adl66199 ; Exendin agonist peptide, SEQ ID No 79.
(from "seq5ags.pep")
TOIG of: adl66199 check: 2759 from: 1 to: 29

ID ADL66199 standard; peptide; 29 AA.

XX AC ADL66199;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 79.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 29 /note= "C-terminal amide"XX PN WO2003099314-A1.
XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 79; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

SQ Sequence 29 AA;

ADL66199 Length: 29 February 4, 2005 13:32 Type: P Check: 2759 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEAVALRFLFKNGG
1 28

-----1 match found in sequence:

adl66200 ; Exendin agonist peptide, SEQ ID No 80.
(from "seq5ags.pep")
TOIG of: adl66200 check: 2320 from: 1 to: 29

ID ADL66200 standard; peptide; 29 AA.

XX AC ADL66200;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 80.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 29 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 80; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

SQ Sequence 29 AA;

ADL66200 Length: 29 February 4, 2005 13:33 Type: P Check: 2320 ..

Found using 'seq5' (mohamed337.key)

CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 31 AA;

ADL66196 Length: 31 February 4, 2005 13:33 Type: P Check: 7369 ..
 Found using 'seq5' (mohamed337.key)

1 HEGGTFSDLSKQMEEEAVRLFIEWLKNGGP
 28

 1 match found in sequence:
 adl66197 ; Extendin agonist peptide, SEQ ID No 77.
 (from "seq5ags.pep")
 TOIG of: adl66197 check: 6930 from: 1 to: 31

ID ADL66197 standard; peptide; 31 AA.

XX AC ADL66197;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 77.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 31 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 77; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 31 AA;

ADL66197 Length: 31 February 4, 2005 13:32 Type: P Check: 6930 ..
 Found using 'seq5' (mohamed337.key)

1 HEGGTFSDLSKOLEEEAVRLFIEFLKNGGP
 28

 1 match found in sequence:
 adl66198 ; Extendin agonist peptide, SEQ ID No 78.
 (from "seq5ags.pep")
 TOIG of: adl66198 check: 4450 from: 1 to: 30

ID ADL66198 standard; peptide; 30 AA.

XX AC ADL66198;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 78.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 78; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX
PS Disclosure; SEQ ID NO 74; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 32 AA;

ADL66194 Length: 32 February 4, 2005 13:33 Type: P Check: 25 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMBEAVRLFIEFLKNGGPS
1
-----|-----|
28

1 match found in sequence:

adl66195 ; Extendin agonist peptide, SEQ ID No 75.
(from "seq5ags.pep")
TOIG of: adl66195 check: 9586 from: 1 to: 32

ID ADL66195 standard; peptide; 32 AA.

XX AC ADL66195;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 75.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 32 /note= "C-terminal amide"

XX FN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PP 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 75; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 32 AA;

ADL66195 Length: 32 February 4, 2005 13:33 Type: P Check: 9586 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQMBEAVRLFIEFLKNGGPS
1
-----|-----|
28

1 match found in sequence:

adl66196 ; Extendin agonist peptide, SEQ ID No 76.
(from "seq5ags.pep")
TOIG of: adl66196 check: 7369 from: 1 to: 31

ID ADL66196 standard; peptide; 31 AA.

XX AC ADL66196;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 76.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 31 /note= "C-terminal amide"

XX FN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PP 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 76; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such

```
PF 28-MAY-2003; 2003WO-US016699.
XX
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 72; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 33 AA;
SQ
ADL66192 Length: 33 February 4, 2005 13:33 Type: P Check: 2764 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HEGTFTSDLSKQLEEEAVRLFIEFLKNGPSS 28
-----
1 match found in sequence:
adl66193 ; Extendin agonist peptide, SEQ ID No 73.
(from "seq5ags.pep")
TOIG of: adl66193 check: 2325 from: 1 to: 33
-----
ID ADL66193 standard; peptide; 33 AA.
XX
XX AC ADL66193;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 73.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX Modified-site 33 /note= "C-terminal amide"
XX
XX FT
XX
XX FN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
```

```
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 73; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 33 AA;
SQ
ADL66193 Length: 33 February 4, 2005 13:33 Type: P Check: 2325 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HEGTFTSDLSKQLEEEAVRLFIEFLKNGPSS 28
-----
1 match found in sequence:
adl66194 ; Extendin agonist peptide, SEQ ID No 74.
(from "seq5ags.pep")
TOIG of: adl66194 check: 25 from: 1 to: 32
-----
ID ADL66194 standard; peptide; 32 AA.
XX
XX AC ADL66194;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 74.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX Modified-site 32 /note= "C-terminal amide"
XX
XX FT
XX
XX FN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
```



```
OS Synthetic.
XX Key Location/Qualifiers
XX Modified-site 34
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 70; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 34 AA;
XX
ADL66190 Length: 34 February 4, 2005 13:33 Type: P Check: 5178 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGETFTSDLSKQEEAEVRLFIETLKNKGPPSSG
28
-----
1 match found in sequence:
adl66191 ; Extendin agonist peptide, SEQ ID NO 71.
(from "seq5ags.pep")
TOIG of: adl66191 check: 4739 from: 1 to: 34
-----
ID ADL66191 standard; peptide; 34 AA.
XX
XX ADL66191;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 71.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 34
XX /note= "C-terminal amide"
XX
XX
```

```
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 71; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 34 AA;
XX
ADL66191 Length: 34 February 4, 2005 13:33 Type: P Check: 4739 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGEGETFTSDLSKQEEAEVRLFIETLKNKGPPSSG
28
-----
1 match found in sequence:
adl66192 ; Extendin agonist peptide, SEQ ID No 72.
(from "seq5ags.pep")
TOIG of: adl66192 check: 2764 from: 1 to: 33
-----
ID ADL66192 standard; peptide; 33 AA.
XX
XX ADL66192;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 72.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 33
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
```

```

XX 20-MAY-2004 (first entry)
XX Extendin agonist peptide, SEQ ID No 68.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 35
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 68; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipidemic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 35 AA;
XX
ADL66188 Length: 35 February 4, 2005 13:33 Type: P Check: 7453 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HEGGFTSDLSKQMEAEAVRLFIEFLKNGGPPSSGA
1 28

-----
1 match found in sequence:
adl66189 ; Extendin agonist peptide, SEQ ID No 69.
(from "seq5ags.pap")
TOIG of: adl66189 check: 7014 from: 1 to: 35

ID ADL66189 standard; peptide; 35 AA.
XX
XX ADL66189;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 69.
XX

```

```

KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 35
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 69; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipidemic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 35 AA;
XX
ADL66189 Length: 35 February 4, 2005 13:32 Type: P Check: 7014 ..
Found using 'seq5' (mohamed337.key)

1 |-----|
1 HEGGFTSDLSKQLEAEAVRLFIEFLKNGGPPSSGA
1 28

-----
1 match found in sequence:
adl66190 ; Extendin agonist peptide, SEQ ID No 70.
(from "seq5ags.pap")
TOIG of: adl66190 check: 5178 from: 1 to: 34

ID ADL66190 standard; peptide; 34 AA.
XX
XX ADL66190;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 70.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX

```

1 match found in sequence:
adl66187 ; Exendin agonist peptide, SEQ ID No 67.
(from "seq5ags.pep")

ADL66188;

CC represents an extendin agonist peptide of the invention.

XX Sequence 38 AA;

ADL66183 Length: 38 February 4, 2005 13:33 Type: P Check: 5894 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGFGSSGAPP
28

1 match found in sequence:

adl66184 ; Extendin agonist peptide, SEQ ID No 64.
(from "seq5ags.pep")

TOIG of: adl66184 check: 3293 from: 1 to: 37

ID ADL66184 standard; peptide; 37 AA.

XX AC ADL66184;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 64.

KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

OS Synthetic.

FH Key Location/Qualifiers

FT Modified-site 37 /note= "C-terminal amide"

PN WO2003099314-A1.

PD 04-DEC-2003.

PF 28-MAY-2003; 2003WO-US016699.

PR 28-MAY-2002; 2002US-00157224.

PA (AMYL-) AMYLIN PHARM INC.

PI Young AA, Kolterman OG;

DR WPI; 2004-042706/04.

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 64; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 37 AA;

ADL66184 Length: 37 February 4, 2005 13:33 Type: P Check: 3293 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGFGSSGAPP
28

1 match found in sequence:

adl66185 ; Extendin agonist peptide, SEQ ID No 65.
(from "seq5ags.pep")

TOIG of: adl66185 check: 2854 from: 1 to: 37

ID ADL66185 standard; peptide; 37 AA.

XX AC ADL66185;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 65.

KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

OS Synthetic.

FH Key Location/Qualifiers

FT Modified-site 37 /note= "C-terminal amide"

PN WO2003099314-A1.

PD 04-DEC-2003.

PF 28-MAY-2003; 2003WO-US016699.

PR 28-MAY-2002; 2002US-00157224.

PA (AMYL-) AMYLIN PHARM INC.

PI Young AA, Kolterman OG;

DR WPI; 2004-042706/04.

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 65; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 37 AA;

ADL66185 Length: 37 February 4, 2005 13:33 Type: P Check: 2854 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGFGSSGAPP
28

CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66181 Length: 28 February 4, 2005 13:33 Type: P Check: 9897 ..
 Found using 'seq5' (mohamed337.key)

1 HGBGTFTSDLSKQLEEAVERLFIETFLKA
 1 28

1 match found in sequence:
 adl66182 ; Extendin agonist peptide, SEQ ID No 62.
 (from "seq5ags.pep")
 TOIG of: adl66182 check: 6333 from: 1 to: 38

ID ADL66182 standard; peptide; 38 AA.

AC ADL66182;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 62.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

OS Synthetic.

XX Key Location/Qualifiers

FH Modified-site 38

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose

XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

XX extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 62; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 38 AA;

ADL66182 Length: 38 February 4, 2005 13:33 Type: P Check: 6333 ..
 Found using 'seq5' (mohamed337.key)

1 HGBGTFTSDLSKQLEEAVERLFIETFLKNGSPSSGAPPP
 1 28

1 match found in sequence:
 adl66183 ; Extendin agonist peptide, SEQ ID No 63.
 (from "seq5ags.pep")
 TOIG of: adl66183 check: 5894 from: 1 to: 38

ID ADL66183 standard; peptide; 38 AA.

AC ADL66183;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 63.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

OS Synthetic.

XX Key Location/Qualifiers

FH Modified-site 38

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose

XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

XX extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 63; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence

DR WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 59; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66179 Length: 28 February 4, 2005 13:33 Type: P Check: 9975 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HEGGFTSDLSKQLEEEAVRLFIEPAKN 28

1 match found in sequence:
adl66180 ; Extendin agonist peptide, SEQ ID No 60.
(from "seq5ags.pep")
TOIG of: adl66180 check: 9991 from: 1 to: 28

ID ADL66180 standard; peptide; 28 AA.
XX
AC ADL66180;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 60.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 60; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66180 Length: 28 February 4, 2005 13:33 Type: P Check: 9991 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HEGGFTSDLSKQLEEEAVRLFIEFLAN 28

1 match found in sequence:
adl66181 ; Extendin agonist peptide, SEQ ID No 61.
(from "seq5ags.pep")
TOIG of: adl66181 check: 9997 from: 1 to: 28

ID ADL66181 standard; peptide; 28 AA.
XX
AC ADL66181;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 61.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 61; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The

PD 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 57; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66177 Length: 28 February 4, 2005 13:33 Type: P Check: 165
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HEGTFTSDLSKQLEEEAVRLFIATLKN 28

1 match found in sequence:
adl66178 ; Extendin agonist peptide, SEQ ID No 58.
(from "seq5ags.pep")
TOIG of: adl66178 check: 136 from: 1 to: 28

ID ADL66178 standard; peptide; 28 AA.
XX
XX ADL66178;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 58.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Key 28
FT Modified-site /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX 28-MAY-2002; 2002US-00157224.
XX

XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 58; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66178 Length: 28 February 4, 2005 13:33 Type: P Check: 136
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HEGTFTSDLSKQLEEEAVRLFIATLKN 28

1 match found in sequence:
adl66179 ; Extendin agonist peptide, SEQ ID No 59.
(from "seq5ags.pep")
TOIG of: adl66179 check: 9975 from: 1 to: 28

ID ADL66179 standard; peptide; 28 AA.
XX
XX ADL66179;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 59.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Key 28
FT Modified-site /note= "C-terminal amide"
FT
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX

```
KW 1 1 match found in sequence:
XX adl66176 ; Exendin agonist peptide, SEQ ID No 56.
OS (from "seq5ags.pep")
XX TOIG of: adl66176 check: 30 from: 1 to: 28
XX
XX ADL66176 standard; peptide; 28 AA.
XX ADL66176;
XX 20-MAY-2004 (first entry)
XX Exendin agonist peptide, SEQ ID No 56.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX Synthetic.
XX Key Location/Qualifiers
XX FH Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PS WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 55; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66175 Length: 28 February 4, 2005 13:33 Type: P Check: 9921
Found using 'seq5' (mohamed337.key)
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 match found in sequence:
XX adl66176 ; Exendin agonist peptide, SEQ ID No 56.
XX (from "seq5ags.pep")
XX TOIG of: adl66176 check: 30 from: 1 to: 28
XX
XX ADL66176 standard; peptide; 28 AA.
XX ADL66176;
XX 20-MAY-2004 (first entry)
XX Exendin agonist peptide, SEQ ID No 56.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX Synthetic.
XX Key Location/Qualifiers
XX FH Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PS WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 55; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66176 Length: 28 February 4, 2005 13:32 Type: P Check: 30
Found using 'seq5' (mohamed337.key)
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 match found in sequence:
XX adl66177 ; Exendin agonist peptide, SEQ ID No 57.
XX (from "seq5ags.pep")
XX TOIG of: adl66177 check: 165 from: 1 to: 28
XX
XX ADL66177 standard; peptide; 28 AA.
XX ADL66177;
XX 20-MAY-2004 (first entry)
XX Exendin agonist peptide, SEQ ID No 57.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX Synthetic.
XX Key Location/Qualifiers
XX FH Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX
```

```
FT Modified-site 28 /note= "C-terminal amide"
XX WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PS WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 56; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX exendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an exendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66176 Length: 28 February 4, 2005 13:32 Type: P Check: 30
Found using 'seq5' (mohamed337.key)
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 1 HEGGFTSDLSKQLEEAVALFIEFLKN 28
1 match found in sequence:
XX adl66177 ; Exendin agonist peptide, SEQ ID No 57.
XX (from "seq5ags.pep")
XX TOIG of: adl66177 check: 165 from: 1 to: 28
XX
XX ADL66177 standard; peptide; 28 AA.
XX ADL66177;
XX 20-MAY-2004 (first entry)
XX Exendin agonist peptide, SEQ ID No 57.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX Synthetic.
XX Key Location/Qualifiers
XX FH Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX
```



```

XX AC ADL66173;
XX DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 53.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 53; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;
ADL66173 Length: 28 February 4, 2005 13:33 Type: P Check: 193 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQLEAAVRLFIETFLKN 28
1 -----|
1 match found in sequence:
adl66174 ; Exendin agonist peptide, SEQ ID No 54.
(from "seq5ags.pap")
TOIG of: adl66174 check: 9862 from: 1 to: 28
-----
ID ADL66174 standard; peptide; 28 AA.
XX AC ADL66174;
XX DT 20-MAY-2004 (first entry)
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 54; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;
ADL66174 Length: 28 February 4, 2005 13:33 Type: P Check: 9862 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQLEEAARLFIEFLKN 28
1 -----|
1 match found in sequence:
adl66175 ; Exendin agonist peptide, SEQ ID No 55.
(from "seq5ags.pap")
TOIG of: adl66175 check: 9921 from: 1 to: 28
-----
ID ADL66175 standard; peptide; 28 AA.
XX AC ADL66175;
XX DT 20-MAY-2004 (first entry)
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 54; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;
ADL66174 Length: 28 February 4, 2005 13:33 Type: P Check: 9862 ..
Found using 'seq5' (mohamed337.key)
1 HGEFTTSDLSKQLEEAARLFIEFLKN 28
1 -----|
1 match found in sequence:
adl66175 ; Exendin agonist peptide, SEQ ID No 55.
(from "seq5ags.pap")
TOIG of: adl66175 check: 9921 from: 1 to: 28
-----
ID ADL66175 standard; peptide; 28 AA.
XX AC ADL66175;
XX DT 20-MAY-2004 (first entry)
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX DR WPI; 2004-042706/04.
XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 54; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 28 AA;

```

```
1 HEGTFTSDLSKQAEAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
adl66171 ; Exendin agonist peptide, SEQ ID No 51.
(from "seq5ags.pep")
TOIG of: adl66171 check: 201 from: 1 to: 28

ID ADL66171 standard; peptide; 28 AA.
XX
AC ADL66171;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 51.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidaemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID No 51; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66171 Length: 28 February 4, 2005 13:33 Type: P Check: 201 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQAEAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
adl66171 ; Exendin agonist peptide, SEQ ID No 53.
(from "seq5ags.pep")
TOIG of: adl66173 check: 193 from: 1 to: 28

ID ADL66173 standard; peptide; 28 AA.
adl66172 ; Exendin agonist peptide, SEQ ID No 52.
(from "seq5ags.pep")
TOIG of: adl66172 check: 197 from: 1 to: 28

ID ADL66172 standard; peptide; 28 AA.
XX
AC ADL66172;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 52.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipidaemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID No 52; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66172 Length: 28 February 4, 2005 13:33 Type: P Check: 197 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTSDLSKQAEAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
adl66173 ; Exendin agonist peptide, SEQ ID No 53.
(from "seq5ags.pep")
TOIG of: adl66173 check: 193 from: 1 to: 28

ID ADL66173 standard; peptide; 28 AA.
```

CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66168 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSDLSAQLEEAERVLFIEFLKN 28
1

1 match found in sequence:
adl66169 ; Exendin agonist peptide, SEQ ID No 49.
(from "seq5agr.pap")
TOIG of: adl66169 check: 53 from: 1 to: 28

ID ADL66169 standard; peptide; 28 AA.

XX AC ADL66169;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 49.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX PH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PH Pharmaceutical composition for treating diabetes, impaired glucose
XX FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX FT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 49; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66169 Length: 28 February 4, 2005 13:33 Type: P Check: 53 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSDLSKALEEAERVLFIEFLKN 28
1

1 match found in sequence:
adl66170 ; Exendin agonist peptide, SEQ ID No 50.
(from "seq5agr.pap")
TOIG of: adl66170 check: 107 from: 1 to: 28

ID ADL66170 standard; peptide; 28 AA.

XX AC ADL66170;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 50.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX PH Key Location/Qualifiers

XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PH Pharmaceutical composition for treating diabetes, impaired glucose
XX FT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX FT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 50; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66170 Length: 28 February 4, 2005 13:33 Type: P Check: 107 ..
Found using 'seq5' (mohamed337.key)

CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66166 Length: 28 February 4, 2005 13:33 Type: P Check: 151 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDASKQLEEEAVRLFIEFLKN 28
 |-----|

1 match found in sequence:
 adl66167 : Extendin agonist peptide, SEQ ID No 47.
 (from "seq5ags.pap")
 TOIG of: adl66167 check: 63 from: 1 to: 28

ID ADL66167 standard; peptide; 28 AA.

AC ADL66167;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 47.

KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

OS Synthetic.

FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"

WO2003099314-A1.

PD 04-DEC-2003.

PF 28-MAY-2003; 2003WO-US016699.

PR 28-MAY-2002; 2002US-00157224.

PA (AMYL-) AMYLIN PHARM INC.

PI Young AA, Kolterman OG;

DR WPI; 2004-042706/04.

PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 47; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66167 Length: 28 February 4, 2005 13:33 Type: P Check: 63 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDAKQLEEEAVRLFIEFLKN 28
 |-----|

1 match found in sequence:
 adl66168 : Extendin agonist peptide, SEQ ID No 48.
 (from "seq5ags.pap")
 TOIG of: adl66168 check: 141 from: 1 to: 28

ID ADL66168 standard; peptide; 28 AA.

AC ADL66168;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 48.

KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

OS Synthetic.

FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"

WO2003099314-A1.

PD 04-DEC-2003.

PF 28-MAY-2003; 2003WO-US016699.

PR 28-MAY-2002; 2002US-00157224.

PA (AMYL-) AMYLIN PHARM INC.

PI Young AA, Kolterman OG;

DR WPI; 2004-042706/04.

PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 48; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or

PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 44; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66164 Length: 28 February 4, 2005 13:33 Type: P Check: 231 ..
Found using 'seq5' (mohamed337.key)
-----|-----
1 HEGTATSDLSKQLEEAVALRIFLKN 28
-----|-----
1 match found in sequence:
adl66165 ; Extendin agonist peptide, SEQ ID No 45.
(from "seq5ags.pep")
TOIG of: adl66165 check: 117 from: 1 to: 28

ID ADL66165 standard; peptide; 28 AA.
XX
AC ADL66165;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 45.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 45; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipemic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
ADL66165 Length: 28 February 4, 2005 13:33 Type: P Check: 117 ..
Found using 'seq5' (mohamed337.key)
-----|-----
1 HEGTFTADLSKQLEEAVALRIFLKN 28
-----|-----
1 match found in sequence:
adl66166 ; Extendin agonist peptide, SEQ ID No 46.
(from "seq5ags.pep")
TOIG of: adl66166 check: 151 from: 1 to: 28

ID ADL66166 standard; peptide; 28 AA.
XX
AC ADL66166;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 46.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID No 46; 173pp; English.
XX

```

PN XX WO2003099314-A1.
PD XX
XX XX 04-DEC-2003.
XX XX
PF XX 28-MAY-2003; 2003WO-US016699.
XX XX
PR XX 28-MAY-2002; 2002US-00157224.
XX XX
PA (AMYL-) AMYLIN PHARM INC.
XX XX
PI Young AA, Kolterman OG;
XX XX
DR WPI; 2004-042706/04.
XX XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX XX
PS Disclosure; SEQ ID NO 42; 173pp; English.
XX XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX XX
SQ Sequence 28 AA;
ADL66162 Length: 28 February 4, 2005 13:33 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HAEGTFTDLSKQLEEAARLFIIFLN 28
-----
1 match found in sequence:
adl66163 ; Extendin agonist peptide, SEQ ID No 43.
(from "seq5ags.pep")
TOIG of: adl66163 check: 166 from: 1 to: 28

ID ADL66163 standard; peptide; 28 AA.
XX AC ADL66163;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 43.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX XX

```

```

XX XX 28-MAY-2002; 2002US-00157224.
XX XX
PA (AMYL-) AMYLIN PHARM INC.
XX XX
PI Young AA, Kolterman OG;
XX XX
DR WPI; 2004-042706/04.
XX XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX XX
PS Disclosure; SEQ ID NO 43; 173pp; English.
XX XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX XX
SQ Sequence 28 AA;
ADL66163 Length: 28 February 4, 2005 13:33 Type: P Check: 166 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HGGAFTSDLSKQLEEAARLFIIFLN 28
-----
1 match found in sequence:
adl66164 ; Extendin agonist peptide, SEQ ID No 44.
(from "seq5ags.pep")
TOIG of: adl66164 check: 231 from: 1 to: 28

ID ADL66164 standard; peptide; 28 AA.
XX AC ADL66164;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 44.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX XX

```

KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX Synthetic.

XX Key Location/Qualifiers
 FH Modified-site 28
 FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WFI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidemia or cardiovascular disease comprises an extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 40; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an extendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66160 Length: 28 February 4, 2005 13:33 Type: P Check: 700
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQEEAEVRLFIWLNK 28
 1

1 match found in sequence:

adl66161 ; Extendin agonist peptide, SEQ ID No 41.
 (from "seq5ags.pep")
 TOIG of: adl66161 check: 261 from: 1 to: 28

ID ADL66161 standard; peptide; 28 AA.

XX ADL66161;

XX 20-MAY-2004 (first entry).

XX Extendin agonist peptide, SEQ ID No 41.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
 FH Modified-site 28
 FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WFI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidemia or cardiovascular disease comprises an extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 41; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an extendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66161 Length: 28 February 4, 2005 13:32 Type: P Check: 261
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQEEAEVRLFIWLNK 28
 1

1 match found in sequence:

adl66162 ; Extendin agonist peptide, SEQ ID No 42.
 (from "seq5ags.pep")
 TOIG of: adl66162 check: 249 from: 1 to: 28

ID ADL66162 standard; peptide; 28 AA.

XX ADL66162;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 42.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

XX Modified-site 28
 FT /note= "C-terminal amide"

XX

DT	20-MAY-2004	(first entry)	
XX	Exendin agonist peptide, SEQ ID NO 37.		
XX	Exendin; extended-release formulation; plasma level; antidiabetic;		
XX	anorectic; antilipemic; diabetes; glucose; gastric emptying;		
KW	inhibiting food intake; tolerance; obesity; hyperglycaemia;		
KW	dyslipidaemia; cardiovascular.		
XX	Synthetic.		
OS			
XX	Key	Location/Qualifiers	
XX	Modified-site	31	
FT		/note= "N-methylalanine"	
FT	Modified-site	36..38	
FT		/note= "N-methylalanine"	
FT	Modified-site	39	
FT		/note= "C-terminal amide"	
XX	WO2003099314-A1.		
PN			
XX			
PD	04-DEC-2003.		
XX			
PF	28-MAY-2003; 2003WO-US016699.		
XX			
PR	28-MAY-2002; 2002US-00157224.		
XX			
PA	(AMYL-) AMYLIN PHARM INC.		
XX	Young AA, Kolterman OG;		
PI	WPI; 2004-042706/04.		
XX			
DR			
XX	Pharmaceutical composition for treating diabetes, impaired glucose		
PT	tolerance, obesity, dyslipidemia or cardiovascular disease comprises an		
PT	exendin or an exendin agonist peptide in an extended-release formulation.		
XX			
PS	Disclosure; SEQ ID NO 37; 173pp; English.		
XX			
CC	The invention relates to a novel pharmaceutical composition comprising an		
CC	exendin (agonist) peptide in an extended-release formulation. The		
CC	formulation is capable of releasing the peptide over a predetermined		
CC	release period, the period being at least one hour, and in an amount such		
CC	that, when the composition is administered to a human, an average		
CC	sustained plasma level of at least 5 pg/ml is achieved for at least 25%		
CC	of the predetermined release period. The composition has antidiabetic,		
CC	anorectic, and antilipemic activities. The composition has antidiabetic,		
CC	are useful in treating diabetes and conditions that would be benefited by		
CC	lowering plasma glucose or delaying and/or slowing gastric emptying or		
CC	inhibiting food intake, such as impaired glucose tolerance, obesity,		
CC	hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence		
CC	represents an exendin agonist peptide of the invention.		
XX			
SQ	Sequence 39 AA;		

ADL66157 Length: 39 February 4, 2005 13:33 Type: P Check: 706 ..

Found using 'seq5' (mohamed337.key)

SQ Sequence 39 AA;
ADJ66157 Length: 39 February 4, 2005 13:33 Type: P Check: 706 ..
Found using 'seq5' (mohamed337.key)

1 1 |-----| HGEFTSDLSQMEEEAVRLFIEWLKGXSSGAXXXS 28

```
-----
1 match found in sequence:
adl66158 ; Exendin agonist peptide, SEQ ID No 38.
      (from "seq5ags pep")
      :TOIG of: adl66158 check: 458 from: 1 to: 39
      ID ADI66158 standard; peptide; 39 AA.
```

ID ADL66158 standard; peptide; 39 AA.

AC ADL66158;

20-MAY-2004 (first entry)

```

XX
SQ      Sequence 39 AA;
ADL66156 Length: 39 February 4, 2005 13:32 Type: P Check: 267 ..
Found using 'seq5' (mohamed337.key)

```

```

round using seqs (named seqs.ref)
|-----|
HGETFTSDLSKOLEEEAVRLFIEFLNGGXSSGAXXXS

```

1 match found in sequence:
adl66157 ; Exendin agonist peptide, SEQ ID No 37.
(from "seqsage.pep")
TOIG of: adl66157 check: 706 from: 1 to: 39

TOIG OF: 4416613/ CHECK: 706 FROM: 1 TO: 35

XX
XX
1 / CT00074 DTXX
AC : ADL66157;

ID	ADL66154 standard; peptide; 39 AA.
XX	
AC	ADL66154;
XX	
DT	20-MAY-2004 (first entry)
XX	
DE	Exendin agonist peptide, SEQ ID No 34.
XX	
KW	exendin; extended-release formulation; plasma level; antidiabetic;
KW	anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW	inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW	dyslipidaemia; cardiovascular.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	Modified-site 31 /note= "Thioprolin"
FT	Modified-site 36..38
FT	Modified-site /note= "Homoprolin"
FT	Modified-site 39
FT	/note= "C-terminal amide"
XX	
PN	WO2003099314-A1.
XX	
XX	04-DEC-2003.
PD	
XX	
PF	28-MAY-2003; 2003WO-US016699.
XX	
PR	28-MAY-2002; 2002US-00157224.
XX	
PA	(AMYL-) AMYLIN PHARM INC.
XX	
PI	Young AA, Kolterman OG;
XX	
DR	WPI; 2004-042706/04.
XX	
PT	Pharmaceutical composition for treating diabetes, impaired glucose
PT	tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT	exendin or an exendin agonist peptide in an extended-release formulation.
XX	
PS	Disclosure; SEQ ID NO 34; 173pp; English.
XX	
CC	The invention relates to a novel pharmaceutical composition comprising an
CC	exendin (agonist) peptide in an extended-release formulation. The
CC	formulation is capable of releasing the peptide over a predetermined
CC	release period, the period being at least one hour, and in an amount such
CC	that, when the composition is administered to a human, an average
CC	sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC	of the predetermined release period. The composition has antidiabetic,
CC	anorectic, and antilipemic activities. The novel composition and method
CC	are useful in treating diabetes and conditions that would be benefited by
CC	lowering plasma glucose or delaying and/or slowing gastric emptying or
CC	inhibiting food intake, such as impaired glucose tolerance, obesity,
CC	hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC	represents an exendin agonist peptide of the invention.
XX	
SQ	Sequence 39 AA;
ADL66154	Length: 39 February 4, 2005 13:33 Type: P Check: 458 ..
Found using 'seq5'	(mohamed337.key)
1	HGEGTFTSDLSKQWEAEAVRLFIETFLNKGPPSSGAXXKS 28

1	match found in sequence:
adl66155 ; Exendin agonist peptide, SEQ ID No 35.	
(from "seq5ags.pep")	
TOIG of: adl66155 check: 267 from: 1 to: 39	
ID ADL66155 standard; peptide; 39 AA.	
XX	
AC	ADL66155;
XX	
DT	20-MAY-2004 (first entry)
XX	
DE	Exendin agonist peptide, SEQ ID No 35.
XX	
KW	exendin; extended-release formulation; plasma level; antidiabetic;
KW	anorectic; antilipemic; diabetes; glucose; gastric emptying;
KW	inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW	dyslipidaemia; cardiovascular.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	Modified-site 36..38
FT	Modified-site /note= "Homoprolin"
FT	Modified-site 39
FT	/note= "C-terminal amide"
XX	
PN	WO2003099314-A1.
XX	
XX	04-DEC-2003.
PD	
XX	
PF	28-MAY-2003; 2003WO-US016699.
XX	
PR	28-MAY-2002; 2002US-00157224.
XX	
PA	(AMYL-) AMYLIN PHARM INC.
XX	
PI	Young AA, Kolterman OG;
XX	
DR	WPI; 2004-042706/04.
XX	
PT	Pharmaceutical composition for treating diabetes, impaired glucose
PT	tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT	exendin or an exendin agonist peptide in an extended-release formulation.
XX	
PS	Disclosure; SEQ ID NO 35; 173pp; English.
XX	
CC	The invention relates to a novel pharmaceutical composition comprising an
CC	exendin (agonist) peptide in an extended-release formulation. The
CC	formulation is capable of releasing the peptide over a predetermined
CC	release period, the period being at least one hour, and in an amount such
CC	that, when the composition is administered to a human, an average
CC	sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC	of the predetermined release period. The composition has antidiabetic,
CC	anorectic, and antilipemic activities. The novel composition and method
CC	are useful in treating diabetes and conditions that would be benefited by
CC	lowering plasma glucose or delaying and/or slowing gastric emptying or
CC	inhibiting food intake, such as impaired glucose tolerance, obesity,
CC	hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC	represents an exendin agonist peptide of the invention.
XX	
SQ	Sequence 39 AA;
ADL66155	Length: 39 February 4, 2005 13:33 Type: P Check: 267 ..
Found using 'seq5'	(mohamed337.key)
1	HGEGTFTSDLSKQLEEAERVLFIETFLNKGSGSAGAXXS 28

1	match found in sequence:
adl66156 ; Exendin agonist peptide, SEQ ID No 36.	
(from "seq5ags.pep")	
TOIG of: adl66156 check: 267 from: 1 to: 39	
ID ADL66156 standard; peptide; 39 AA.	
XX	
AC	ADL66156;

1 match found in sequence:

adl66152 ; Exendin agonist peptide, SEQ ID No 32.
(from "seq5ags.pep")

TOIG of: adl66152 Check: 458 from: 1 to: 39

ID ADL66152 standard; peptide; 39 AA.

XX AC ADL66152;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 32.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 36..38

FT /note= "Thioprolin"

FT Modified-site 39

FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 32; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66152 Length: 39 February 4, 2005 13:33 Type: P Check: 458 ..

Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGPPSGAXXXS

28

1 match found in sequence:

adl66153 ; Exendin agonist peptide, SEQ ID No 33.
(from "seq5ags.pep")

TOIG of: adl66153 Check: 706 from: 1 to: 39

ID ADL66153 standard; peptide; 39 AA.

XX AC ADL66153;

XX XX 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 33.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipidemic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 31

FT /note= "Homoprolin"

FT Modified-site 36..38

FT /note= "Homoprolin"

FT Modified-site 39

FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 33; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC exendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipidemic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66153 Length: 39 February 4, 2005 13:32 Type: P Check: 706 ..

Found using 'seq5' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGXSSGAXXXS

28

1 match found in sequence:

adl66154 ; Exendin agonist peptide, SEQ ID No 34.
(from "seq5ags.pep")

TOIG of: adl66154 Check: 458 from: 1 to: 39

1 HAEGTFTSDLSKLEEEAVRLFIEFLKNG 28

CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66147 Length: 39 February 4, 2005 13:33 Type: P Check: 9915 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQEEBAVRLFXEWLKNKGPPSGAPPPS
28
-----|-----|

1 match found in sequence:
adl66148 ; Exendin agonist peptide, SEQ ID No 28.
(from "seq5ags.pep")
TOIG of: adl66148 check: 9476 from: 1 to: 39

ID ADL66148 standard; peptide; 39 AA.

XX AC

XX ADL66148;

XX DT 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 28.

DE exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 23 /note= "Tertiary-butylglycine"

FT Modified-site 39

FT /note= "C-terminal amide"

XX WO200309314-A1.

XX PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 28; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;
SQ

ADL66148 Length: 39 February 4, 2005 13:33 Type: P Check: 9476 ..
Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQEEBAVRLFXEFLKNKGPPSGAPPPS
28
-----|-----|

1 match found in sequence:
adl66149 ; Exendin agonist peptide, SEQ ID No 29.
(from "seq5ags.pep")
TOIG of: adl66149 check: 9546 from: 1 to: 39

ID ADL66149 standard; peptide; 39 AA.

XX AC

XX ADL66149;

XX DT 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 29.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 39

FT /note= "C-terminal amide"

XX WO200309314-A1.

XX PD 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 29; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66149 Length: 39 February 4, 2005 13:33 Type: P Check: 9546 ..
Found using 'seq5' (mohamed337.key)

CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66145 Length: 39 February 4, 2005 13:33 Type: P Check: 9869 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQEEAVRLFVFLKNGPSSGAPPPS
 1
 28

1 match found in sequence:
 adl66146 ; Extendin agonist peptide, SEQ ID No 26.
 (from "seq5ags.pep")
 TOIG of: adl66146 check: 9430 from: 1 to: 39

ID ADL66146 standard; peptide; 39 AA.

XX AC ADL66146;

XX XX 20-MAY-2004 (first entry)

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 26.
 XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 39
 FT /note= "C-terminal amide"

XX FN WO2003099314-A1.

XX XX 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX XX 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX XX WPI; 2004-042706/04.

XX DR Pharmaceutical composition for treating diabetes, impaired glucose
 XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 XX extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 26; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66146 Length: 39 February 4, 2005 13:33 Type: P Check: 9430 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTTSDLSKQEEAVRLFVFLKNGPSSGAPPPS
 1
 28

1 match found in sequence:
 adl66147 ; Extendin agonist peptide, SEQ ID No 27.
 (from "seq5ags.pep")
 TOIG of: adl66147 check: 9915 from: 1 to: 39

ID ADL66147 standard; peptide; 39 AA.

XX AC ADL66147;

XX XX 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 27.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 23
 FT /note= "Tertiary-butylglycine"

FT Modified-site 39
 FT /note= "C-terminal amide"

XX XX WO2003099314-A1.

XX XX 04-DEC-2003.

XX XX 28-MAY-2003; 2003WO-US016699.

XX XX 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX XX WPI; 2004-042706/04.

XX DR Pharmaceutical composition for treating diabetes, impaired glucose
 XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 XX extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 27; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 23; 173pp; English.
XX

CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 39 AA;

ADL66143 Length: 39 February 4, 2005 13:33 Type: P Check: 9299 ..
Found using 'seqs' (mohamed337.key)

1 HGEFTTSDLSKQEEAEAVRLFTEFLKNGPSSGAPPPS
|-----|
28

1 match found in sequence:

adl66144 ; Exendin agonist peptide, SEQ ID No 24.
(from "seq5ags.pep")
TOIG of: adl66144 check: 9966 from: 1 to: 39

ID ADL66144 standard; peptide; 39 AA.

XX
AC ADL66144;

XX 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 24.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

XX Modified-site 22 /note= "Naphthylalanine"

XX Modified-site 39

XX /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 24; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 39 AA;

ADL66144 Length: 39 February 4, 2005 13:33 Type: P Check: 9966 ..
Found using 'seqs' (mohamed337.key)

1 HGEFTTSDLSKQEEAEAVRLFTEFLKNGPSSGAPPPS
|-----|
28

1 match found in sequence:

adl66145 ; Exendin agonist peptide, SEQ ID No 25.
(from "seq5ags.pep")
TOIG of: adl66145 check: 9869 from: 1 to: 39

ID ADL66145 standard; peptide; 39 AA.

XX
AC ADL66145;

XX 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 25.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

XX Modified-site 39 /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 25; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The

PA (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 21; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;
 ADL66141 Length: 39 February 4, 2005 13:33 Type: P Check: 9251 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSDXSKQEEAVRLFIEFLKNGPSSGAPPPS
 1
 -----|-----|
 28

1 match found in sequence:
 adl66142 ; Extendin agonist peptide, SEQ ID No 22.
 (from "seq5ags.pep")
 TOIG of: adl66142 check: 9724 from: 1 to: 39

ID ADL66142 standard; peptide; 39 AA.
 XX
 AC ADL66142;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 22.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH Modified-site 14 /note= "Pentylglycine"
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 FT WO2003099314-A1.
 XX
 XX PD 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX

XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 22; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;
 ADL66142 Length: 39 February 4, 2005 13:32 Type: P Check: 9724 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSDXSKQEEAVRLFIEFLKNGPSSGAPPPS
 1
 -----|-----|
 28

1 match found in sequence:
 adl66143 ; Extendin agonist peptide, SEQ ID No 23.
 (from "seq5ags.pep")
 TOIG of: adl66143 check: 9299 from: 1 to: 39

ID ADL66143 standard; peptide; 39 AA.
 XX
 AC ADL66143;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 23.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH Modified-site 14 /note= "Pentylglycine"
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 FT WO2003099314-A1.
 XX
 XX PD 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX

PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX PS Disclosure; SEQ ID NO 19; 173pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The novel composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 39 AA;
ADL66139 Length: 39 February 4, 2005 13:33 Type: P Check: 9579 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSELSKQMBEAVRLFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
adl66140 ; Extendin agonist peptide, SEQ ID No 20.
(from "seq5ags.pep")
TOIG of: adl66140 check: 9690 from: 1 to: 39
ID ADL66140 standard; peptide; 39 AA.
XX
XX AC ADL66140;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 20.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX PH Key Location/Qualifiers
XX FT Modified-site 10
XX FT Modified-site 39 /note= "Pentylglycine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PP

XX 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX PS Disclosure; SEQ ID NO 20; 173pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 39 AA;
ADL66140 Length: 39 February 4, 2005 13:33 Type: P Check: 9690 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDXSKQMBEAVRLFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
adl66141 ; Extendin agonist peptide, SEQ ID No 21.
(from "seq5ags.pep")
TOIG of: adl66141 check: 9251 from: 1 to: 39
ID ADL66141 standard; peptide; 39 AA.
XX
XX AC ADL66141;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 21.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX PH Key Location/Qualifiers
XX FT Modified-site 10
XX FT Modified-site 39 /note= "Pentylglycine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX

KW dyslipidaemia; cardiovascular.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 XX WO2003099314-A1.
 FN 04-DEC-2003.
 PD
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 PF
 XX 28-MAY-2002; 2002US-00157224.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young AA, Kolterman OG;
 PI WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 PT
 XX Disclosure; SEQ ID NO 17; 173pp; English.
 PS
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;
 ADL66137 Length: 39 February 4, 2005 13:33 Type: P Check: 9571 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1 28
 |-----|
 1 match found in sequence:
 adl66138 ; Extendin agonist peptide, SEQ ID No 18.
 (from "seq5ags.pep")
 TOIG of: adl66138 check: 9578 from: 1 to: 39

ID ADL66138 standard; peptide; 39 AA.
 XX
 AC ADL66138;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX Extendin agonist peptide, SEQ ID No 18.
 DE
 XX
 XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers

FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 XX WO2003099314-A1.
 PN 04-DEC-2003.
 PD
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 PF
 XX 28-MAY-2002; 2002US-00157224.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young AA, Kolterman OG;
 PI WPI; 2004-042706/04.
 XX
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 PT
 XX Disclosure; SEQ ID NO 18; 173pp; English.
 PS
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;
 ADL66138 Length: 39 February 4, 2005 13:32 Type: P Check: 9578 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
 1 28
 |-----|
 1 match found in sequence:
 adl66139 ; Extendin agonist peptide, SEQ ID No 19.
 (from "seq5ags.pep")
 TOIG of: adl66139 check: 9579 from: 1 to: 39

ID ADL66139 standard; peptide; 39 AA.
 XX
 AC ADL66139;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX Extendin agonist peptide, SEQ ID No 19.
 DE
 XX
 XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 XX WO2003099314-A1.
 PN